
<html lang="en"     class="pb-page"  data-request-id="e3322888-66bf-4394-9600-99ed5c5ff46e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c01640;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2021.64.issue-6;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities" /></meta><meta name="dc.Creator" content="Rao  Song" /></meta><meta name="dc.Creator" content="Wenliang  Qiao" /></meta><meta name="dc.Creator" content="Jun  He" /></meta><meta name="dc.Creator" content="Jiasheng  Huang" /></meta><meta name="dc.Creator" content="Youfu  Luo" /></meta><meta name="dc.Creator" content="Tao  Yang" /></meta><meta name="dc.Description" content="Proteostasis is the process of regulating intracellular proteins to maintain the balance of the cell proteome, which is crucial for cancer cell survival. Several proteases located in the cytoplasm,..." /></meta><meta name="Description" content="Proteostasis is the process of regulating intracellular proteins to maintain the balance of the cell proteome, which is crucial for cancer cell survival. Several proteases located in the cytoplasm,..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 3, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01640" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01640" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01640" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01640" /></link>
        
    
    

<title>Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01640" /></meta><meta property="og:title" content="Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0025.jpeg" /></meta><meta property="og:description" content="Proteostasis is the process of regulating intracellular proteins to maintain the balance of the cell proteome, which is crucial for cancer cell survival. Several proteases located in the cytoplasm, mitochondria, lysosome, and extracellular environment have been identified as potential antitumor targets because of their involvement in proteostasis. Although the discovery of small-molecule inhibitors targeting proteases faces particular challenges, rapid advances in chemical biology and structural biology, and the new technology of drug discovery have facilitated the development of promising protease modulators. In this review, the protein structure and function of important tumor-related proteases and their inhibitors are presented. We also provide a prospective on advances and the outlook of new drug strategies that target these proteases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01640"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01640">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01640&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01640&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01640&amp;href=/doi/10.1021/acs.jmedchem.0c01640" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2851-2877</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01851" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rao Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rao Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rao++Song">Rao Song</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenliang Qiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenliang Qiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lung Cancer Center, Laboratory of Lung Cancer, West China Medical School, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenliang++Qiao">Wenliang Qiao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++He">Jun He</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiasheng Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiasheng Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiasheng++Huang">Jiasheng Huang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Youfu Luo</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Youfu Luo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1579607a4a6c7a607360556676603b7071603b767b"><span class="__cf_email__" data-cfemail="5b372e340422342e3d2e1b28382e753e3f2e753835">[email protected]</span></a> (Y.L.)</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Youfu++Luo">Youfu Luo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7327-0368" title="Orcid link">http://orcid.org/0000-0001-7327-0368</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Tao Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</div><div class="loa-info-affiliations-info">Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f188909f9685909eb1869299829284df929f"><span class="__cf_email__" data-cfemail="344d555a5340555b7443575c4757411a575a">[email protected]</span></a> (T.Y.)</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Yang">Tao Yang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01640&amp;href=/doi/10.1021%2Facs.jmedchem.0c01640" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2851–2877</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 September 2020</li><li><span class="item_label"><b>Published</b> online</span>3 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01640</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2851%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRao%2BSong%252C%2BWenliang%2BQiao%252C%2BJun%2BHe%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D6%26contentID%3Dacs.jmedchem.0c01640%26title%3DProteases%2Band%2BTheir%2BModulators%2Bin%2BCancer%2BTherapy%253A%2BChallenges%2Band%2BOpportunities%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2877%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01640"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1913</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01640" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rao&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Wenliang&quot;,&quot;last_name&quot;:&quot;Qiao&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Jiasheng&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Youfu&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2851-2877&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01640&quot;},&quot;abstract&quot;:&quot;Proteostasis is the process of regulating intracellular proteins to maintain the balance of the cell proteome, which is crucial for cancer cell survival. Several proteases located in the cytoplasm, mitochondria, lysosome, and extracellular environment have been identified as potential antitumor targets because of their involvement in proteostasis. Although the discovery of small-molecule inhibitors targeting proteases faces particular challenges, rapid advances in chemical biology and structural biology, and the new technology of drug discovery have facilitated the development of promising protease modulators. In this review, the protein structure and function of important tumor-related proteases and their inhibitors are presented. We also provide a prospective on advances and the outlook of new drug strategies that target these proteases.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01640&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01640" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01640&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01640" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01640&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01640" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01640&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01640&amp;href=/doi/10.1021/acs.jmedchem.0c01640" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01640" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01640" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01640%26sid%3Dliteratum%253Aachs%26pmid%3D33656892%26genre%3Darticle%26aulast%3DSong%26date%3D2021%26atitle%3DProteases%2Band%2BTheir%2BModulators%2Bin%2BCancer%2BTherapy%253A%2BChallenges%2Band%2BOpportunities%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D6%26spage%3D2851%26epage%3D2877%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/jmcmar.2021.64.issue-6/20210325/jmcmar.2021.64.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Proteostasis is the process of regulating intracellular proteins to maintain the balance of the cell proteome, which is crucial for cancer cell survival. Several proteases located in the cytoplasm, mitochondria, lysosome, and extracellular environment have been identified as potential antitumor targets because of their involvement in proteostasis. Although the discovery of small-molecule inhibitors targeting proteases faces particular challenges, rapid advances in chemical biology and structural biology, and the new technology of drug discovery have facilitated the development of promising protease modulators. In this review, the protein structure and function of important tumor-related proteases and their inhibitors are presented. We also provide a prospective on advances and the outlook of new drug strategies that target these proteases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In a mammalian cell, the folded three-dimensional (3D) structure and the abundance of the thousands of different proteins are carefully controlled to keep the proteome in a balanced state, which is referred to as proteostasis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Proteolytic machineries play a crucial role in complex networks in maintaining proteostasis. Protein degradation, one of the proteolytic machineries, is a key biological event, which removes superfluous and unfolded/misfolded proteins to maintain proteostasis by a protease-mediated hydrolysis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">However, dysregulation of protease-mediated protein degradation may cause cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Consequently, several important proteases related to protein degradation have been identified as promising antitumor drug targets, including proteasome, human caseinolytic protease p (hClpP), cathepsin B, and metallopeptidases (MMPs), which are, respectively, located in the cytoplasma, mitochondria, lysosome, and extracellular environment (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In cytoplasma, the proteasome plays a crucial role in the protein degradation by being involved in the ubiquitin-proteasome system (UPS), a major pathway of intracellular protein degradation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> As a promising target, its inhibitor Bortezomib has been approved as a therapy for multiple myeloma and mantle cell lymphoma.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In the lysosome of cancer cells, the lysosomal hydrolases in the autophagy lysosomal system (ALS) are crucial for the intracellular proteostasis. Among them, cathepsin B, a cysteine cathepsin, participates in many pathological processes and is the most investigated target for cancer treatment.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In mitochondria, it was demonstrated that the hClpP-mediated proteostasis regulation is associated with tumor cell invasion and metastasis.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Thus, currently, several modulators of hClpP have been explored for the treatment of acute myeloid leukemia.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> As important as the proteostasis in these organelles is in maintaining extracellular proteostasis, the extracellular matrix (ECM) is a structural framework composed of proteins and polysaccharides, which affects cancer cell migration.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The MMP family is the most important proteolytic family of proteins for ECM degradation, based on which plenty of inhibitors have been discovered with antitumor activity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative proteases for proteostasis. The proteasomes are distributed in the cytoplasm and nucleus and participate in the UPS. hClpP located in the mitochondrial matrix maintains the mitochondria proteostasis. Cathepsin B participates in the ALS. MMPs mainly degrade ECM in the extracellular environment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Numerous small molecules targeting the proteasome, hClpP, MMPs, and cathepsin B have been developed to bind to their active site and function as protease inhibitors. However, these active-site-based inhibitors have disadvantages that may hinder their clinical development. For example, in solid tumors, proteasome inhibitors have been found to be largely ineffective, even when combined with other antitumor agents.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition, almost none of hClpP covalent inhibitors that are effective in an in vitro assay were promoted to a clinical investigation, which was credited to their poor druggability.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Also a large number of MMP inhibitors have been discovered at the preclinical stage with potent antitumor activity; however, many of them failed in clinical trials.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Recent rapid advances in chemical biology and structural biology have facilitated a resolution of the aforementioned challenges. For instance, a targeted protein degradation strategy, proteolysis targeted chimera (PROTAC) technology, has been developed by taking advantage of the hydrolysis function of proteasome in UPS, which is now widely used as a promising way for drug discovery, especially for undruggable targets.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Beyond inhibiting proteolytic activity, enhancing the cellular ability to dispose of toxic protein species by upregulating proteolytic activity is another way for cancer treatment. Several agonists of hClpP, such as ONC201 and its derivatives that have been revealed to replace the chaperone protein hClpX, have been identified and are currently in clinical trials for cancer treatment.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> With advances in biological functions and structural information on MMPs, subtype-selective inhibitors have been identified, and several are in clinical trials.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p last">Thus, in this perspective, we provide an overview of the protein structure and function of several proteases related to proteostasis of the cytoplasma, mitochondria, lysosome, and extracellular environment. We also focus on the protease inhibitors that are in a clinic and in developing. Notably, the advances and outlook of new strategies on important tumor-related proteases that offer opportunities in overcoming issues of selectivity, resistance, and even undruggable targets in this field are also prospected.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Proteasome</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15453" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15453" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The UPS is an important protein degradation pathway that is involved in many biological processes, such as cell differentiation, apoptosis, and protein regulation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This system consists of 26S proteasome and some enzymes such as the E3 ligase.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Structure of the Proteasome</h3><div class="NLM_p">The 26S proteasome is a complex 2.5 MDa protein degradation machine that is composed of a proteolytic core particle (CP) and one or two terminal regulatory particles (RPs). The RP (19S proteasome) is responsible for recognizing the substrate and transferring it to the cavity of the CP for hydrolysis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The CP (20S proteasome), composed of α 1–7 subunits and β 1–7 subunits, is arranged into four rings and a hollow stacked heptamer structure.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The two outer rings and the two inner rings are composed of α subunits and β subunits, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The α subunits are structural, forming barriers with their N-terminal tails, which hinder the movement of the proteasome. The active centers of the proteasome are located in β1, β2, and β5 subunits that are responsible for caspase-like, trypsin-like, and chymotrypsin-like proteolytic activities, respectively.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The three active β subunits are encoded by multiple genes. In certain cells, one or more alternative subunits are incorporated into the catalytic domain of the 20S proteasome, thereby modulating the catalytic performance of the proteasome.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The composition of the two β-rings is independent with different subunits (β1 or β1i, β2 or β2i, β3, β4, β5, β5i or β5t, β6 and β7), forming a mixed proteasome. All catalytic subunits are threonine proteases that undergo protein degradation through the UPS. Apart from the 26S proteasome, three enzymes involved in ubiquitination, namely, ubiquitin activating enzyme (E1), ubiquitin binding enzyme (E2), and ubiquitin ligase (E3), are important components of the UPS. Under the action of E1, E2, and E3, the protein to be hydrolyzed is tagged by the ubiquitination process, which is then specifically recognized and eventually degraded into small peptide fragments by the proteasome (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) The proteasome structure consists of four rings, with each ring containing seven different subunits, and is capped by regulatory particles (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RYP">1RYP</a>). (B) Schematic of the UPS. The substrate protein is ubiquitinated through the activity of E1, E2, and E3 and subsequently hydrolyzed by the proteasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Proteasome in Cancer</h3><div class="NLM_p last">The 26S proteasome is a critical complex of the UPS, which coordinates the regulation and degradation of intracellular proteins. This multienzyme protease is responsible for degrading redundant, unwanted, and misfolded protein. Many substrates of the proteasome are regulatory proteins critical to cell growth, which regulate cell cycle progress, signaling pathways, and pro-apoptotic and antiapoptotic proteins.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> An abnormal regulation of any of these processes may lead to a malignant transformation and tumorigenesis. Thus, the proteasome is considered an important antitumor target. Theoretically, proteasome inhibitors (PIs) could inhibit protein turnover and produce cytotoxicity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> PI-mediated cell cytotoxicity is caused mainly by elevating apoptosis by switching on the apoptotic mitochondrial pathway, switching off the death-receptor pathway, and increasing the endoplasmic reticulum stress.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> The UPS is specifically dysregulated in a variety of tumors. Upregulating the activity of the proteasome leads to an excessive degradation of specific tumor suppressor substrates, including the tumor suppressor p53 and nuclear factor κB (NF-κB).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Many physiological and pathological processes related to tumor progression are regulated by proteasomes, such as cell cycle control mechanisms, carcinogenic transformation; proinflammatory cytokine signaling pathways; tumor necrosis factor and IL-6; cell adhesion signaling through molecular ICAM-1 and VCAM-1 transmission; the stress response pathway; antiapoptotic signaling through Bcl-2, IAP and TRAIL; pro-angiogenic signaling through VEGF and GRO-α.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Caused by PIs toward the proteasome, multiple downstream effects, including the inhibition of NF-κB signaling and the accumulation of misfolded and unfolded proteins, lead to endoplasmic reticulum stress and an unfolded protein response. These differences inhibit growth factor receptors, adhesion molecules, and angiogenesis. Tumor cells are more sensitive to PIs than normal cells.<a onclick="showRef(event, 'ref23 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref26">(23,26)</a> Thus, PIs can prevent tumor cell proliferation and selectively induce tumor cell apoptosis, which increases sensitivity to radiotherapy and chemotherapy.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.3.  Proteasome Inhibitors</h3><div class="NLM_p">Research has demonstrated that PIs with significant therapeutic activity against multiple myeloma and mantle cell lymphoma because of the high protein turnover in myeloma cells results in the preferential susceptibility of PIs toward malignant cells over normal cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This is also a reason for the limited clinical indications of PIs.</div><div class="NLM_p">The number of proteasome inhibitors in clinical development is increasing. The first phase I data on bortezomib were published in 2002, and it was approved by the Food & Drug Administration (FDA) in 2003. In the past 10 years, there has been a flurry of approvals for carfizomib and ixazomib in 2012 and 2015, respectively, with pivotal investigations ongoing for both agents. Apart from these three inhibitors, there were many open clinical trials of other PIs. Currently, there are two types of PIs, peptide PIs with N-terminal peptide fragments and a C-terminal pharmacophore, and nonpeptide PIs of natural products or natural product metabolites. Peptide PIs include peptide aldehydes, peptide boric acids, and peptide epoxy ketones.</div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">2.3.1.  Peptide Aldehydes</h4><div class="NLM_p">MG132 (<b>1</b>) and Ac-Leu-Leu-norlecucinal (ALLN1, <b>2</b>), the representatives of peptide aldehydes, were the first class of PIs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Their structures were characterized by the introduction of an aldehyde group at the C-terminus of a di- or tripeptide. The aldehyde group interacted with catalytic Thr-1 to form a hemiacetal, which was responsible for protease inhibition (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> These compounds were used often as positive controls in PI-discovery research. However, some drawbacks, such as a fast dissociation rate, drug resistance, and low selectivity, have limited their application.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition mechanisms of proteasome inhibitors featuring different warheads. (A) Aldehydes. (B) Boronic acids. (C) Epoxyketones. (D) β-lactone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.3.2.  Peptide Boronic Acids</h4><div class="NLM_p">Peptide boronic acids were the most extensively explored PIs. The covalent binding of the high electrophilic boric acid group with Thr-OH at the β active site along with the hydrogen bonding account for the high inhibition activity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Bortezomib (<b>3</b>) was the representative drug of effective polypeptide borate PIs (β5 IC<sub>50</sub> = 2.4–7 nM, β1 IC<sub>50</sub> = 24–74 nM), which showed good antitumor activity in vivo, and was the first approved proteasome inhibitor (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>)<named-content content-type="anchor" rid="fig4" type="simple"></named-content>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Bortezomib exhibited strong binding affinities to the active site (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a><named-content content-type="anchor" rid="fig5" type="simple"></named-content>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> A phase II study of bortezomib with 202 patients focusing on a relapsed multiple myeloma showed that 35% of the patients responded.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Importantly, bortezomib prolonged progression-free survival. Compared with peptide aldehydes, peptide boronic acids had a stronger potency and selectivity to proteasomes because they tightly bound to threonine. Currently, as a single agent or in multiple drug combinations, bortezomib was used for the first-line treatment of multiple myeloma and mantle cell lymphoma.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of some proteasome inhibitors and the β active site of the proteasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative proteasome inhibitors covalently bind at the active site of the proteasome: (A) MG132 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FGH">5FGH</a>); (B) Bortezomib (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16">2F16</a>); (C) Carfilzomib (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R67">4R67</a>); (D) Salinosporamide A (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FAK">2FAK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ixazomib (<b>4</b>) was the first oral proteasome inhibitor approved by the FDA in 2015 for the treatment of multiple myeloma (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Ixazomib was originally discovered from a large number of proteasome inhibitors featuring a boron element with physicochemical properties different from those of bortezomib.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Ixazomib preferentially bound to and inhibited the β5 subunit and also inhibited β1 and β2 subunits at higher concentrations.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Patients who were resistant to bortezomib were often effectively treated with ixazomib. Thus, ixazomib had good application prospects.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p last">Delanzomib (<b>5</b>) (β5 half-maximal inhibitory concentration (IC<sub>50</sub>) = 3.4 nM) was an orally active P2 threonine boronic acid proteasome inhibitor related to bortezomib that showed a favorable safety profile with no neurotoxicity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Delanzomib monotherapy was tolerated adequately but showed a limited efficacy in patients with relapsed/refractory multiple myeloma.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a></div></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">2.3.3.  Peptide Epoxyketones</h4><div class="NLM_p">Carfilzomib (<b>6</b>) was a peptide epoxyketone proteasome inhibitor approved by the FDA in 2012 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Carfilzomib took epoxyketone as its electrophilic warhead to form a morpholine ring with threonine at the active site of the proteasome, which prolonged the duration of proteasome inhibition (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> The epoxyketone moiety in carfilzomib was derived from epoxomicin, a selective proteasome inhibitor exhibiting in vivo anti-inflammatory activity.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Compared with bortezomib, it had the advantages of a higher selectivity and lower incidence of neurological side effects, which had become a new trend in the clinical treatment of multiple myeloma.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> However, other side effects existed such as cardiovascular complications.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p last">Oprozomib (<b>7</b>) was a tripeptide proteasome inhibitor with an epoxyketone warhead derived from carflzomib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Oprozomib selectively and irreversibly bound to and inhibited the β5 subunit,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and it had an antitumor activity in xenograft models of various cancers.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec2_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">2.3.4.  Nonpeptides</h4><div class="NLM_p">In recent years, many small-molecule proteasome inhibitors that were structurally different from bortezomib have been discovered. These nonpeptide inhibitors are capable of overcoming resistance issues and are more potent toward different malignancies.</div><div class="NLM_p">Among the nonpeptide PIs, omuralide (<b>8</b>), salinosporamide A (<b>9</b>), and salinosporamide B (<b>10</b>) contained a highly active β-lactone moiety (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which was responsible for inhibition.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The carbonyl of the β-lactone was attacked by the hydroxyl group of the Thr residue at the catalyzed N-terminus to form a new ester bond (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p last">Omuralide, derived from lactacystin, was the first natural β-lactone to display proteasome inhibitory activity. Salinosporamide A was isolated from <i>Salinispora</i> in marine sediments and is currently in clinical phase III trials. Omuralide was an irreversible inhibitor that contained a dicyclic β-lactone-lactam.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Hyperactivation of the β1 and β2 proteolytic sites compensated for inhibition at the β5 subunit when using first-generation PIs. However, salinosporamide A irreversibly bound to all three proteolytic sites to prevent this compensatory activation of the β1 and β2 subunits.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Apart from clinical investigations on multiple myeloma, several studies were conducted to test salinosporamide A for the treatment of glioblastomas because of its good permeability of the blood–brain barrier.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.4.  Proteolysis Targeted Chimeras (PROTACs)</h3><div class="NLM_p">During the development of PIs as anticancer agents, drug resistance and poor specificity are the most important issues. As mentioned above, three active site-based PIs are approved for cancer treatment. However, they have some drawbacks, such as severe side effects and limited indications. Beyond blocking the function of targeted proteins with small-molecule inhibitors, in 2001, the Crews group developed a targeted protein degradation (TPD) technique—PROTAC based on the UPS pathway. Recently, several PROTAC molecules developed for the treatment of various diseases have been promoted in clinical trials. In this system, the proteasome is responsible for the degradation of target proteins.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> PROTAC provides an attractive mechanism to modulate proteins independent of enzymatic or signaling activity. The PROTAC strategy has several advantages, including targeting undruggable proteins, directly eliminating the accumulation of target proteins, solving drug resistance, and sub-stoichiometric catalytic activity.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.4.1.  PROTAC Technology</h4><div class="NLM_p">PROTACs are bifunctional hybrid molecules that simultaneously bind to E3 ubiquitin ligase and the target protein. Interaction causes the ubiquitination of exposed lysines on the target protein by the E3 ubiquitin ligase complex. The ubiquitinated protein is then recognized by the proteasome through the UPS pathway and catalytically degraded (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The PROTAC molecule does not inhibit the biological function of the target protein but eliminates the target protein through degradation. Currently, hundreds of PROTACs have been developed, two of which have been approved by the FDA for phase I clinical trials in 2019. ARV-110 (AR) and ARV-471 (ER) have been used for treating patients with metastatic castration-resistant prostate cancer (MCRPC) or ER<sup>+</sup>/HER2<sup>–</sup> locally advanced or metastatic breast cancer (MBC).<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic of the PROTAC technology. A PROTAC molecule connects the target protein and an E3 ubiquitin ligase complex. The E3 ubiquitin ligase is recruited to the target protein by the PROTAC, and subsequently the ubiquitinated protein is recognized and degraded by the proteasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">However, there are some drawbacks to PROTACs. PROTACs are limited to intracellular target proteins by engaging the native intracellular protein degradation machinery. In addition, PROTACs face the problem of poor druggability, such as poor oral absorption and the risk of oxidative metabolism.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">2.4.2.  The E3 Ubiquitin Ligase Ligand</h4><div class="NLM_p">PROTACs are commonly composed of three chemical elements: a ligand of the target protein, a ligand of the E3 ubiquitin ligase, and a linker connecting these two ligands.</div><div class="NLM_p">Among the more than 700 kinds of E3 ubiquitin ligases identified, only several E3 ubiquitin ligases have been developed for the PROTAC strategy, including mouse double minute 2 homologue (MDM2), cellular inhibitor of apoptosis protein 1 (cIAP1), Von Hippel-Lindau (VHL) and Cereblon (CRBN).<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> Nutlin-3a, beatatin, VHL ligand 1, and thalidomide are representative ligands for MDM2, cIAP1, VHL, and CRBN, respectively, which have no effect on the activity of the corresponding E3 ubiquitin ligase (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative E3 ubiquitin ligase ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">2.4.3.  Small-Molecule PROTACs</h4><div id="sec2_4_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15">2.4.3.1.  MDM2-Based PROTAC</h5><div class="NLM_p">Functioning as an E3 ligase, MDM2 bound to and ubiquitinated p53, resulting in an efficient p53 degradation.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The first PROTAC molecule (<b>11</b>), based on the MDM2 ligand nutlin, conjugated nutlin-3a (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) and the nonsteroidal androgen receptor (AR) ligand through a poly(ethylene glycol) (PEG) linker. This chimera degraded the AR in Hela cells efficiently with a 50% degradation concentration (DC<sub>50</sub>) value of 10 mmol/L (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A).<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Structures of MDM2-based PROTAC (<b>11</b> and <b>12</b>). (B) Structures of cIAP1-based PROTAC (<b>13</b> and <b>14</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition, PROTAC A1874 (<b>12</b>), by connecting bromodomain and extraterminal (BET) inhibitors and MDM2 inhibitors with PEG, achieved a dose-dependent degradation of BRD4 in HCT116 cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div></div><div id="sec2_4_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16">2.4.3.2.  cIAP1-Based PROTAC</h5><div class="NLM_p">Bestatin (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) could selectively downregulate cIAP1, which led to the degradation of cIAP1 by the proteasome with autoubiquitination. In 2010, the first cIAP1-based PROTAC (<b>13</b>) was constructed by conjugating beatatin-methyl eater (MEBS) with all-trans retinoic acid (ATRA) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> In this molecule, ATRT was an endogenous ligand of the retinoic acid receptor (RAS).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> This chimera has been demonstrated to inhibit the migration of neuroblastoma IMR-32.</div><div class="NLM_p last">SNIPER (ABL)-062 (<b>14</b>) (DC<sub>50</sub> = 30–100 nmol/L, <i>D</i><sub>max</sub> > 70%) could significantly reduce BCR-ABL at a concentration of 30 nmol/L (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B), in which imatinib was set as the E3 ligase ligand, resulting in a higher degradation activity.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Notably, this molecule bound to the allosteric site of BCR-ABL, indicating the potential use of ligands that bind to non-orthosteric sites of target proteins.</div></div><div id="sec2_4_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17">2.4.3.3.  VHL-Based PROTAC</h5><div class="NLM_p">VHL is a tumor suppressor, and its major substrate is hypoxia inducible factor-1α (HIF-1α).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In 2012, PROTAC <b>15</b> was developed as a drug against the interaction between VHL and HIF1α (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The VHL ligand (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) could be coupled to the recognition site of HIF1α in VHL. Fifty percent of ERRα was degraded at a concentration of 100 nM. Importantly, after a treatment with compound <b>15</b>, the levels of ERRα in the mouse heart, kidney, and MDA-MB-231 xenograft tumors were reduced by ∼44%, 44%, and 39%, respectively.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of VHL-based PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">AR signaling is crucial for the growth and survival of prostate cancer cells. Although suppression of AR transcriptional activity is a common strategy in the treatment of prostate cancer, a castration-resistant form of the disease eventually develops. Some evidence suggested that AR degradation mediated by PROTAC can potentially address AR-dependent mechanisms of drug resistance. ARCC-4 (<b>16</b>) derived from enzalutamide induced AR degradation, with a ratio of ∼95%, at low nanomolar concentrations (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In addition, compared with enzalutamide, ARCC-4 inhibited the proliferation of prostate tumor cells and retained antiproliferative effects on tumor cells in a high androgen environment.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Therefore, ARCC-4 had the potential to solve the drug resistance issue caused by small-molecule inhibitors in clinical treatments. Arvinas also developed an AR-targeted PROTAC molecule called ARV-110 (undisclosed structure) as an oral therapy, which showed potent activity in degrading AR and mutated AR specifically and achieved antitumor activity in ENV-naive and -resistant prostate cancer xenograft models.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> A Phase I study of AVR-110 showed that it has an acceptable safety profile.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p">The strategy for the treatment of prostate cancer includes not only androgen deprivation for final remission, but also inhibiting the BET family of proteins. AVR-771 (<b>17</b>) was a hetero-bifunctional compound that had a small-molecule BET-binding moiety (JQ1) conjugated to the E3 ligase VHL ligand through a short alkyl linker (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The ternary complex facilitated proteasomal degradation by presenting BETs in a spatially favorable position, leading to the prolonged and profound degradation of BETs.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> AVR-771 was assessed to degrade BRD2/3/4 proteins at concentrations below 5 nmol/L in several prostate cancer cell lines (DC<sub>50</sub> < 1 nmol/L, <i>D</i><sub>max</sub> > 90%), which also reduced the tumor regression of resistant prostate cancer (CRPC) in a mouse xenograft model.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> AVR-771 showed efficacy and advantages in the treatment of CRPC when compared with that of traditional inhibitors.</div><div class="NLM_p last">The Kirsten rat sarcoma (KRAS) viral oncogene homologue is a sought-after drug target, despite being considered undruggable because of its frequent mutation in human cancers.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The Crews group reported the development of LC-2 (<b>18</b>), the first PROTAC with ability of degrading endogenous KRAS<sup>G12C</sup> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> LC-2 covalently combined KRAS<sup>G12C</sup> with a MRTX849 warhead to recruit the E3 ligase VHL and induce a rapid and sustained degradation of KRAS<sup>G12C</sup> with DC<sub>50</sub> values ranging from 0.25 to 0.76 μM. LC-2 suppressed mitogen-activated protein kinase (MAPK) signaling in both homozygous and heterozygous KRAS<sup>G12C</sup> cell lines. LC-2 demonstrated that a PROTAC-mediated degradation was a viable alternative for attenuating oncogenic KRAS levels and downstream signaling transduction in cancer cells.</div></div><div id="sec2_4_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18">2.4.3.4.  CRBN-Based PROTAC</h5><div class="NLM_p">CRBN ligase is the most widely used E3 ubiquitin ligase (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The first CRBN-based PROTAC ARV-825 (<b>19</b>) was discovered by conjugating the BRD4 ligand OTX015 and the CRBN ligand pomalidomide with a PEG linker. ARV-825 completely degraded BRD4 (DC<sub>50</sub> < 1 nmol/L) within 6 h at 10 nmol/L, with an inhibition of the C-myc expression and an induction of cell apoptosis (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of CRBN-based PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">BTK is a nonreceptor cytoplasmic tyrosine kinase participating in the B-cell receptor (BCR) signaling pathway, which is a vital signal transduction pathway for B cells.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> The first covalent BTK inhibitor, ibrutinib, has been approved for the treatment of a variety of B-cell malignancies by the FDA. However, patients developed drug resistance after the treatment of ibrutinib because of the C481S missense BTK mutation.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> PROTAC L18I (<b>20</b>), constructed on the basis of ibrutinib, was capable of resolving the issue of ibrutinib drug resistance (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> The PEG linker afforded L18I good solubility in water and phosphate buffered saline. L18I degraded the C481S BTK mutant with a DC<sub>50</sub> of less than 50 nM and also effectively controlled ibrutinib-resistant B-cell tumors induced by the BTK C481S mutant.</div><div class="NLM_p">PROTAC <b>21</b>, recruiting CRBN by wogonin, showed good CDK9 degradation activity and selectively downregulated the level of CDK9 in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Notably, a triazole linker was used in this chimera by click chemistry, which endowed a higher efficiency than other compounds bearing alkane chains as linkers.</div><div class="NLM_p">Because of its high potency and selectivity for anaplastic lymphoma kinase (ALK), ceritinib has been approved by the FDA for the treatment of patients with ALK-positive nonsmall cell lung cancer. With the PROTAC technology, MS4078 (<b>22</b>) was constructed based on ceritinib, which significantly reduces ALK levels in SU-DHL-1 and NCI-H2228 cell lines, thereby reducing tumorigenic activity (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> More importantly, MS4078 had good stability in mouse plasma.</div><div class="NLM_p">The signal transducer and activator of transcription 3 (STAT3) is an attractive therapeutic target for cancer treatment.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> However, targeting STAT3 with small molecules is challenging, which makes it an undruggable target. Recently, by conjugating CRBN with the developed STAT3 SH2 domain inhibitor, SD-36 (<b>23</b>) has been discovered as a promising and selective PROTAC STAT3 degrader, which induced STAT3 degradation at low concentrations in cells and in tissues (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Thus, PROTAC SD-36 can target a difficult-to-drug protein.</div><div class="NLM_p last">In addition to the aforementioned PROTACS, several other CRBN-based PROTACs that degrade casein kinase 2 (CK2), histone deacetylase 6 (HDAC6), CDK4/6, PCAF/GCN5, and fusion protein BCR-ABL have been developed.<a onclick="showRef(event, 'ref58 ref87 ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref58 ref87 ref88 ref89 ref90">(58,87−90)</a></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">3.  Human Caseinolytic Protease P (hClpP)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">hClpP is found in the mitochondrial matrix and recognizes proteins participating in metabolism, transcriptional regulation, cell division, and damage repair. hClpP also participates in the proteolysis of unfolded and misfolded proteins, ribosomal arrest proteins, and regulatory proteins. In the mitochondrial matrix, hClpP maintains protein homeostasis and participates in the degradation and proteolysis of several enzymes in the electron transport chain and other cellular metabolic pathways.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.1.  Cellular Functions of hClpP</h3><div class="NLM_p">hClpP is a highly conserved serine protease encoded by nuclear genes and translated in the cytoplasm and transferred into the mitochondrial matrix. hClpP is composed of 14 hClpP subunits forming two heptacyclic cylinders that is capped by six hClpX subunits. The symmetrical bicyclic 14-mer structure forms an internal chamber where protein hydrolysis occurs.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The function of hClpX is to recognize specific proteins and transport them into the pores of hClpP for degradation.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Although the structure of the hClpXP complex at high resolution remains unknown, the translocation of hexameric hClpX and heptameric hClpP has been characterized (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) The structure of hClpXP. hClpP is assembled into a double-ringed tetradecameric structure with its chaperone hClpX on each end. (B) Graphical representation of the hClpXP proteolytic process. The substrate protein binds to the hClpX, and subsequently hClpX unfolds the substrate and transfers it to the cavity of hClpP for proteolysis by an ATP-dependent pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Some hypotheses about a substrate protein degradation by the hClpXP complex have been developed. First hClpX recognizes the certain substrate protein, and unfolds substrate protein in an adenosine triphosphate (ATP)-dependent manner. The unfolded protein is then transported through the axle hole of hClpX to hClpP. Finally, the unfolded substrate enters the cavity of hClpP and is catalytically degraded into small peptides, which are subsequently released through the lateral hole of hClpP (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B).<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a></div><div class="NLM_p last">The intracellular function of hClpP promotes the hydrolysis of misfolded or damaged proteins to maintain protein homeostasis, thereby preventing these proteins from forming protein aggregates and impairing normal cell function.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Mitochondrial DNA mutations lead to an increase in the number of mitochondrial unfolded proteins, misfolded mitochondrial proteins, mitochondrial sibling protein loss, and accumulation of respiratory defects, which all stimulate the hClpP expression.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Knocking down hClpP is associated with misfolded SDHB and the loss of complex II activity, and it increases the respiratory chain deficit and the oxidative stress state.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.2.  Role of hClpP in Cancer</h3><div class="NLM_p">Uncontrolled cell growth and the proliferation of tumor cells relies on a rapid energy metabolism, which stimulates cellular stress by increasing reactive oxygen species (ROS). The increase of ROS produces different oxidative damage and increases the risk of protein misfolding and accumulation in mitochondria, resulting in mitochondrial dysfunction.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> To counteract or reduce this damage, hClpP expression is upregulated to maintain the mitochondrial function.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p last">Although the exact role of hClpP in cancer is unresolved, hClpP is highly expressed in various tumor tissues and organs, such as prostate, liver, myeloid leukemia, thyroid, lung, gastric, and breast cancer.<a onclick="showRef(event, 'ref7 ref97'); return false;" href="javascript:void(0);" class="ref ref7 ref97">(7,97)</a> Current evidence suggests that an increase in the expression of hClpP is not a direct cause of tumorigenesis but essential for the proliferation and metastasis of certain cancers. Moreover, hClpP expression in cancer is highly dependent on cell type. For example, the knockdown of hClpP has little effect on proliferation in MCF-7 cells, whereas inhibiting hClpP in PC3, K562, and OCI-AML2 cells reduces tumor cell viability.<a onclick="showRef(event, 'ref6 ref97'); return false;" href="javascript:void(0);" class="ref ref6 ref97">(6,97)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.3.  Inhibitors of hClpP</h3><div class="NLM_p">Chemically inhibiting the hClpP proteolytic activity may be the direct therapeutic strategy against cancer cells. In general, many inhibitors have been identified and inhibit hClpP activity by covalently binding to Ser153 located within its cavity (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). These reported molecules, which were previously designed as potential antibacterial agents to sterilize various bacterial species, lack chemical diversity.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Although there are several drugs targeting the active site of hClpP, no such compounds have reached the clinic.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Biological function of hClpP impaired by hClpP inhibitors. The hClpP inhibitors bind to the active site of hClpP to inhibit substrate protein hydrolysis (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TG6">1TG6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.3.1.  β-Lactones</h4><div class="NLM_p">β-Lactones were developed originally as potential antibiotics that inhibited <i>Staphylococcus aureus</i> ClpP (<i>Sa</i>ClpP).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Subsequently, the analogue A2-32-01 (<b>24</b>) showed therapeutic potential for treating acute myeloid leukemia and was the earliest discovered hClpP inhibitor (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Although the mechanism of action remained unresolved, it was hypothesized that the mechanism was similar to that of β-lactone covalent inhibitors. The hydroxyl group of Ser153 attacked the lactone as a nucleophilic group, and the ring opened to form a covalent product (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B). A3-32-01 displayed moderate cytotoxicity toward myeloid leukemia cells OCI-AML2 and K562. For example, A2-32-01 exhibited toxicity toward the osteosarcoma cell line 143B, whereas no toxicity toward mitochondria-depleted 143B Rho (0) cells was observed.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, A2-32-01 did not exert good antitumor activity in vivo, because the lactone was unstable and easily hydrolyzed.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) Structure of β-lactone hClpP inhibitor A3-32-01. (B) Inhibition mechanism of β-lactone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">3.3.2.  Phenyl Esters</h4><div class="NLM_p">Phenyl esters were developed to improve the efficacy and chemical stability of β-lactones. AV-167 (<b>25</b>) was screened from a library of bacterial ClpP inhibitors, which also displayed inhibitory activity against hClpP (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> The mechanism of action of AV-167 was revealed by mass spectrometry; the hydroxyl group of hClpP Ser153, a nucleophilic group, attacked the carboxyl group of the phenyl ester to form a covalent bond (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> AV-167 exhibited inhibitory activity against hClpP, which is similar to <i>Sa</i>ClpP. Modification based on the AV-167 scaffold has been performed to improve selectivity. A series of analogues carrying a phenyl ester element and a substituent functional moiety at the 2-position bearing a characteristic curved naphthofuran group has been synthesized, among which TG42 (<b>26</b>), TG53 (<b>27</b>), and TG43 (<b>28</b>) performed better than AV-167 in a hClpP peptidase assay but were unable to inhibit the activity of <i>Sa</i>ClpP (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The proliferation and migration of Huh-7 cells were inhibited after a treatment with TG42 for 16 h.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Gel-free quantitative activity-based protein profiling (ABPP) in Jurkat cells depicted that TG42 significantly bound with hClpP; however, many other prominent target proteins were additionally obtained, which may reveal the low selectivity of TG42 in human proteomes or have limited access to the compound in the mitochondrial matrix.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Phenyl ester hClpP inhibitors. (B) Inhibition mechanism of phenyl ester.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">3.3.3.  Boronic Acids</h4><div class="NLM_p">Boronic acids were selective for serine residues, whose empty p orbital can interact with the hydroxy of Ser153 in hClpP, forming a tetracoordinate complex (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) Inhibition mechanism of boronic acid inhibitors. (B) Boronic acid hClpP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Different from known peptidic α-amino boronic acids, WLS6a (<b>29</b>) was an N-terminal peptidic α-amino boronic acid that is a selective inhibitor of hClpXP with protease Lon (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Moreover, Tan et al. identified a series of α-amino boronic acids with the inhibition of the hClpXP complex through a de novo design and a virtual screening platform modified for covalent ligands.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> One α-amino boronic acid, compound <b>30</b>, was a potent inhibitor of the hClpXP complex with an IC<sub>50</sub> of 0.8 μM (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B).</div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">3.4.  Agonists of hClpP</h3><div class="NLM_p">Currently, most targeted small molecules covalently bind to the active site of proteases, which may lead to a low selectivity and adverse side effects. To solve these problems, identification of noncovalent agonists with new mechanisms are considered as an ideal alternative choice. The binding sites of hClpP and hClpX provide an opportunity to chemically activate the degradation by hClpXP. Small agonists, such as activators of self-compartmentalized proteases (ACPs), acyldepsipeptides (ADEPs), and their derivatives, have been developed to cause the dysfunction of homologous bacterial ClpXP complexes by physically replacing ClpX from the ClpXP complex (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104,105)</a> Importantly, these compounds that disrupt bacterial ClpXP complexes induce effective bactericidal actions against various pathogenic microorganisms when compared with the inhibition of virulence factors by inhibitors.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The mechanism of hClpP agonists is by interrupting the binding of hClpP and hClpX to indistinguishably hydrolyze mitochondrial proteins. In addition, the major advantage of hClpP agonists is that cells will die so long as hClpP is expressed, regardless of the cell’s requirement of this protease for survival. Thus, hClpP agonists are potent modulators for cancer treatment.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Biological function of hClpP is dysregulated by hClpP agonists. The hClpP agonists physically displacing hClpX from hClpP cause dysregulation of substrate degradation (PDB ID:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TG6">1TG6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">3.4.1.  ADEP</h4><div class="NLM_p">Analogues of ADEP specifically targeting hClpP have been identified, which exhibited a high potency to induce apoptotic cell death in human cancer cell lines. Analysis of the cocrystal structure of ADEP-28 (<b>31</b>) with hClpP revealed that ADEP-28 was buried in a highly hydrophobic pocket of hClpP, and this site was where hClpX interacted with hClpP. Since the ADEP-28 had a higher affinity toward hClpP than hClpX, ADEP out-competes the IGF loops of hClpX in binding to hClpP. The binding of ADEP-28 enlarged the size of the cavity and forced hClpP to maintain its activated state, which promoted an indiscriminate hydrolysis of mitochondrial proteins and disrupted the protein homeostasis and cell death (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of hClpP agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">ADEP-28 and ADEP-41 (<b>32</b>) had strong activities in a fluorescein isothiocyanate (FITC)-casein degradation assay and induced the dissociation of hClpXP at low concentrations (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Both compounds induced cytotoxicity in HEK293 T-Rex cells expressing endogenous hClpP with sub-micromolar IC<sub>50</sub> values. Additionally, the two compounds showed greater sensitivity as the expression level of hClpP increased, which was demonstrated by the high tolerance of HEK293 T-Rex CLPP<sup><i>–/–</i></sup> toward ADEPs.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> ADEP-41 also exhibited good cytotoxicity toward Hela, U2OS, and SH-SY5Y cells with sub-micromolar IC<sub>50</sub> values. Moreover, increased DNA strand breaks, mitochondrial fragmentation, OXPHOS loss, and activation of caspase-3 and caspase-9 occurred after treatment with ADEP-41.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div></div><div id="sec3_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">3.4.2.  D9</h4><div class="NLM_p last">Besides ADEP, the small molecule D9 (<b>33</b>) was discovered to activate hClpP (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). A high-throughput screening of ∼140 000 small molecules revealed that D9 was the only candidate molecule that activates hClpP.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Importantly, D9 exhibited species selectivity with a preferential activation of hClpP. By cocrystallizing with the Y118A hClpP mutant, the mechanism of D9 was demonstrated to be similar to that of ADEP, which adopts a compact conformation.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> D9 replaced hClpX in a noncovalent manner and induced the expansion of the hClpP inner chamber to initiate activation.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> A structural modification of the terminal groups of D9 almost invariably decreased the effectiveness of D9.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> However, the biological activity of D9 in cell assays or in an animal model have not been reported.</div></div><div id="sec3_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">3.4.3.  Imipridones</h4><div class="NLM_p">ONC201 (<b>34</b>) and its derivatives ONC212 (<b>35</b>) and TRs (<b>36</b>–<b>40</b>) featuring the imipridone scaffold have been developed as hClpP activators (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows their biological activities.<a onclick="showRef(event, 'ref13 ref110'); return false;" href="javascript:void(0);" class="ref ref13 ref110">(13,110)</a> ONC201 was initially identified from 747 compounds and was under clinical research for the treatment of various cancers, although its mechanism of action has not been fully elucidated. The discovery of ONC201 was significant to the development of drugs that target hClpP for cancer treatment. This was the first hClpP-targeted compound with great potential for cancer treatment. Meanwhile, ONC201 and its derivatives represented a new scaffold for antibiotic development by activating bacterial ClpP.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Imipridone hClpP agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Activities of Imipridone hClpP Agonists</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">hClpP peptidase activity</th><th class="colsep0 rowsep0" align="center">in vitro activities</th><th class="colsep0 rowsep0" align="center">in vivo activities</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ONC201</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 12.5 μM</td><td class="colsep0 rowsep0" align="left">• TEX cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> = 700 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• OCI-AML2 cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> = 2400 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• OCI-AML3 cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> = 1200 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• Z138 cells<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> IC<sub>50</sub> = 1000 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• ∼10% cell viability with 5 μM of drug treatment for 72 h in human primary AML cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50</sub> = 1700 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• Completely inhibited the growth of SUM-159 cells by crystal violet colony formation assays at 10 μM for 48h</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ONC212</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• TEX cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> = 71 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• OCI-AML2 cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> = 76 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• OCI-AML3 cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> = 60 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• Z138 cells<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> IC<sub>50</sub> = 49 nM</td><td class="colsep0 rowsep0" align="left">• Significantly reduced tumor burden after drug treatment at 50 mg/kg/d every 2 d</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• Prolonged animal survival after drug treatment at 50 mg/kg/d every 2 d</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50</sub> = 77 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• Cell viability of human primary AML cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> decreased less 10% with 200 nM of drug treatment for 72 h</td><td class="colsep0 rowsep0" align="left">• Prolonged median survival of mice with 250 nM of drug treatment for 72 h</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TR27</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 800 nM</td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50</sub> = 100 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TR66</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 120 nM</td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50=</sub>11 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TR65</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 120 nM</td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50=</sub>7.4 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TR57</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 135 nM</td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50</sub> = 14 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">• Completely inhibited the growth of SUM-159 cells by crystal violet colony formation assays at 30 nM for 48 h</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TR79</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 120 nM</td><td class="colsep0 rowsep0" align="left">• SUM159 cells<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50</sub> = 57 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Cells from acute myeloid leukemia.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Cells from mantle cell lymphoma.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Cells from breast carcinoma.</p></div></div></div><div class="NLM_p">Isothermal titration calorimetry (ITC) and the cell thermal transfer method (CESTA) were used to determine the direct binding activity between ONC201 and hClpP in cells. Similar to ADEP and D9, ONC201 bound to the hydrophobic pocket of hClpP to enlarge the axial hole. A generous overlap of the hClpP binding site was found among these three activators. Compared with ONC201, ONC212 introduced a strong hydrophobic trifluoromethyl group that increased the hydrophobic effect and affinity to hClpP. ONC201 and ONC212 displayed cytotoxicity toward leukemia and lymphoma cells and were less toxic to normal cells. Oral ONC212 had a certain tumor suppressive effect on the mice of xenografted luciferase-labeled Z-138 cells overexpressing hClpP. In addition, before the original AML cells were transplanted into NOD-SCID gamma (NSG) mice, ex vivo ONC212 treatment can effectively inhibit their transplantation ability and significantly extend the survival time of the recipient mice. TR compounds also had cytotoxicity toward triple negative breast cancer (TNBC) cells SΜM159.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Cytotoxicity against tumor cells caused by imipridones was related to the respiratory chain. ONC201 significantly reduced the expression of complexes I, II, and IV, which caused a decrease in the basal oxygen consumption rate and an increase in mitochondrial ROS.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p last">Author: Overall, ADEP-28, D9, and ONC201 contain two similar terminal hydrophobic elements (i.e., the difluorophenyl group and the hydrophobic tail of ADEP-28; the two hydrophobic benzene rings of D9 and ONC201), which are buried in hClpP by strong hydrophobic interactions. Moreover, the skeleton of these agonists (i.e., ADEP-28’s cyclic peptidyl ring; the linker with seven atoms of D9 and ONC2010) are exposed on the surface of hClpP.</div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">4.  MMPs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">MMPs are zinc-dependent endopeptidases that collectively degrade the ECM. The ECM is a structural framework composed of collagen, elastin, proteoglycan, glycosaminoglycan, and other proteins that affect biological functions such as cell differentiation, proliferation, and adhesion.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition to degrading the ECM and influencing cancer cell migration, MMPs also regulate cell growth, inflammation, and angiogenesis.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Thus, MMPs are important proteases that regulate tumor proliferation and invasion, metastasis, differentiation, and cell death and therefore are potentially suitable targets for treating cancer.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.1.  Classification and Structure of MMPs</h3><div class="NLM_p">MMPs are secreted by fibroblasts, vascular smooth muscle, and white blood cells. Currently, 26 types of MMPs have been identified and are classified into six categories: collagenases (MMP-1, MMP-8, MMP-13); gelatinases (MMP-2, MMP-9); stromelysins (MMP-3, MMP-10, MMP-11); membrane-type (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, MMP-25); matrilysins (MMP-7, MMP-26); and others.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Most MMPs have a propeptide domain, a zinc-catalyzed domain, and a flexible hinge region.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Different MMPs have specific structural characteristics. For example, MMP-9 contains fibronectin domains that are not present in other MMPs (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref9 ref115'); return false;" href="javascript:void(0);" class="ref ref9 ref115">(9,115)</a> In addition, the interaction between the sulfhydryl group of the propeptide and the zinc ion of the catalytic domain keeps the zymogen of MMPs inactive. The zymogen is usually activated by other proteolytic enzymes that mediate the hydrolysis of the propeptide, such as serine proteases, intracellular peptidases, furan, plasmin, and active MMPs.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Different structural domains of the MMP family members.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.2.  MMPs in Cancer</h3><div class="NLM_p last">MMPs are overexpressed in a variety of cancer cells and are involved in each stage of carcinogenesis. The death rate of cancer is largely related to the metastasis and invasion of the original lesion. The overexpression of MMPs during the early stage of carcinogenesis was conducive to the reconstruction of the ECM, which is critical for tumorigenesis. The proteolysis of the basement membrane and other tissues by MMPs is a prerequisite for tumor invasion and metastasis.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Then, during metastasis, MMP-9 activity significantly increases the amount of VEGF to promote angiogenesis.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> In addition, MMPs can promote the migration of cancer cells by the destruction of ECM’s physical barriers. MMP roles in metastasis are not confined to only the localized ECM. It has been proved that the regulation of endothelial permeability and transendothelial migration through MMP-1 can support a tumor cell invasion into the circulation. A tumor growth can be promoted by an MMP-mediated inhibition of a signal transduction of receptors related to apoptosis or lymphocyte-mediated apoptosis. MMPs distribution varies throughout the tumor. MMP-2 shows the greatest abundance at the invasive front, while MMP-7 and MMP-14 were most expressed in the tumor center.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> MMP-9 is most commonly found at the periphery in primary tumors but located at the tumor core in metastasis.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> In general, MMPs are critical for tumor cell invasion and metastasis, tumor cell transformation, tumor angiogenesis, antiapoptosis, and immune regulation.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.3.  MMP Inhibitors in Clinical Trials</h3><div class="NLM_p">Most MMP inhibitors (MMPIs) are composed of a peptidomimetic skeleton, zinc binding group, and side chain. The first generation of MMPIs commonly contains a hydroxamate warhead, which has a high stability for chelation with a zinc ion. Many MMPIs kill cancer cells at very low concentrations (nanomolar) in vitro and in vivo and are undergoing clinical trials.</div><div class="NLM_p">Batimastat (<b>41</b>) (MMP-1, -2, -3, -7, and -9) was the first peptide hydroxamate inhibitor and showed good activities on a variety of tumor cell lines such as melanoma and colorectal cancer (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> The collagen-like backbone that mimics the peptide structure of natural substrates facilitated a chelation of the zinc ion in the active site of the MMPs.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Also, it exhibited a good anticancer effect in a large number of xenotransplantation and metastasis models. However, some drawbacks, such as poor solubility and slight systemic toxicity, have impeded its further development.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures of MMP inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another peptide hydroxamate inhibitor, marimastat (<b>42</b>), was a broad-spectrum MMP inhibitor (MMP-1, -2, -3, -7, and -9) with a high oral bioavailability because soluble α-hydroxyl and <i>t</i>-butyl groups are introduced (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> Marimastat reduced tumor markers significantly in a variety of malignant tumors in a dose-dependent manner. In a phase III study, the treatment effect of marimastat was unclear, whereas a significant therapeutic effect on patients with advanced gastric cancer was observed when combined with chemotherapy. Marimastat also had some major adverse side effects that affect the gastrointestinal tract and cause weight loss and inflammation.</div><div class="NLM_p">CGS-27023A (<b>43</b>), a sulphonamide derivative, inhibited major MMPs (MMP-1, -2, -3, -9, and -13) (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref125 ref126">(125,126)</a> CGS-27023A was a nonpeptidomimetic MMPI that prevented or slowed the formation of lung metastases in a preclinical model. The early inhibition of neoangiogenesis may be essential, which recommended the efficacy of a postoperative adjuvant therapy using CGS-27023A through an inhibition of angiogenesis.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> However, this compound failed in clinical trial because of its side effects of joint and muscle pain.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div><div class="NLM_p">Rebimastat (<b>44</b>) was a broad-spectrum MMPI with a sulfhydryl group introduced to chelate zinc ions (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Rebimastat strongly inhibited MMP-9, which led to the release of tumor necrosis factor-α, tumor necrosis factor-α receptor, interleukin-6 receptor, and L-selectin.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Phase I/II trials suggested that rebimastat was well-tolerated in patients and not dose-related with joint and muscle toxicities. The phase III clinical trial of the combination of rebimastat with carboplatin and paclitaxel for the treatment of lung cancer has been completed.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">Prinomastat (<b>45</b>), featuring hydroxamate, an optimized compound of CGS-27023A (<b>3</b>), showed an inhibitory activity against certain MMPs (MMP-2, -3, -9, -13, and -14) (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref126 ref131'); return false;" href="javascript:void(0);" class="ref ref126 ref131">(126,131)</a> Prinomastat showed effective antiproliferation efficacy against several tumor models after oral and intraperitoneal administrations. Treatment with prinomastat promoted apoptosis to inhibit tumor growth and angiogenesis in xenograft models. Prinomastat in combination with paclitaxel and carboplatin yielded a synergistic effect against nonsmall cell lung cancer (NSCLC) by inhibiting tumor growth and angiogenesis. Prinomastat combined with other drugs has been investigated in phase III trials among hormone-refractory prostate cancer patients and advance nonsmall cell lung cancer patients. However, it was terminated from clinical trials because of its poor efficacy and primary toxicities of dose and time-dependent joint and muscle-related symptoms.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p last">Tanomastat (<b>46</b>) featuring carboxylic acid instead of hydroxamates inhibited many MMPs (MMP-2, -3, and -9) (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Notably, no obvious arthralgia after treatment with tanomastat has been reported, suggesting that tanomastat has an enzyme specificity, which is different from hydroxamates.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> In phase III clinical trials with tanomastat, a poor curative effect of patients with advanced pancreatic cancer led to the suspension of the trials.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.4.  Selective MMP-2/9 Inhibitors</h3><div class="NLM_p">As mentioned, many MMP inhibitors have been developed with potent antitumor activity at the preclinical stage. However, these compounds failed to reach the clinic because of severe side effects and druggability issues, such as poor solubility, poor oral bioavailability, and musculoskeletal muscle syndrome (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Several aspects explain why these compounds failed in clinical trials. First, MMPs are a complex family with various subtypes that have different functions at different stages of cancer development. Certain MMPs may even have protective functions against cancer. Second, the serious side effects of MMPIs, such as musculoskeletal syndromes, have limited the maximum-tolerated doses of MMPIs, thereby restricting the efficacies of the drugs. For these reasons, the development of inhibitors that selectively target certain MMPs is critical for the development of anticancer drugs in the future.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selected MMP Inhibitors in Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">specificity</th><th class="colsep0 rowsep0" align="center">administration route</th><th class="colsep0 rowsep0" align="center">highest phase</th><th class="colsep0 rowsep0" align="center">reasons of discontinued</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Batimastat</td><td class="colsep0 rowsep0" align="left">MMP-1/2/3/7/9</td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="left">Failed</td><td class="colsep0 rowsep0" align="left">Mild systemic toxicity</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Marimastat</td><td class="colsep0 rowsep0" align="left">MMP-1, -2, -3, -7, and -9</td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">Failed</td><td class="colsep0 rowsep0" align="left">Poor curative effect</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CGS-27023A</td><td class="colsep0 rowsep0" align="left">MMP-1, -2, -3, -9, and -13</td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">Failed</td><td class="colsep0 rowsep0" align="left">Joint and muscle pain</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rebimastat</td><td class="colsep0 rowsep0" align="left">MMP-1, -2, -9, and -14</td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">Phase III</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Prinomastat</td><td class="colsep0 rowsep0" align="left">MMP-2, -3, -9, and -13</td><td class="colsep0 rowsep0" align="left">p.o. and i.p.</td><td class="colsep0 rowsep0" align="left">Failed</td><td class="colsep0 rowsep0" align="left">Lack of efficacy and severe toxicities</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tanomastat</td><td class="colsep0 rowsep0" align="left">MMP-2, -3, and -9</td><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">Failed</td><td class="colsep0 rowsep0" align="left">Lack of efficacy</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></td></tr></tbody></table></div></div><div class="NLM_p">Among all the MMPs, MMP-2/9 were demonstrated more druggable targets because the specifically inhibition did not induce a musculoskeletal syndrome in a rat model. Nowadays, many types of inhibitors have been explored, including natural inhibitors, monoclonal antibodies, hydroxamates, and nonhydroxamates.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37">4.4.1.  Natural Inhibitors</h4><div class="NLM_p">Natural products were considered as the most important resource for lead compound discovery. Several natural compounds have been discovered as MMP-2/9 inhibitors.</div><div class="NLM_p">Doxycycline (<b>47</b>), a chemically modified tetracycline antibiotic approved by the FDA for the treatment of periodontitis, has been repurposed as an antitumor agent by targeting MMP-9 (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Doxycycline exhibited cytotoxicity toward MDA-MB-435, U2OS, and PC-3 cells in a concentration-dependent manner.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Doxycycline was composed of a four-ring core with an attached dimethyl amino group that chelates Zn<sup>2+</sup> ions within MMPs.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Doxycycline, a prophylactic chemotherapeutic agent, was found to improve the overall survival in patients with osteosarcoma.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of MMP-2/9 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38">4.4.2.  Monoclonal Antibodies</h4><div class="NLM_p">Antibodies inhibiting MMP-9, such as REGA-3G12 and Andecaliximab, have also been successfully developed. REGA-3G12 was a mouse monoclonal antibody prepared by hybridoma technology, which had a high selectivity and mainly inhibited the catalytic site of MMP-9.<a onclick="showRef(event, 'ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref136 ref137">(136,137)</a></div><div class="NLM_p last">Andecaliximab was a selective MMP-9 inhibitor that prevented the extracellular matrix from releasing cytokines and growth factors, thereby inhibiting cancer.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Andecaliximab with mFOLFOX6 showed a potential therapeutic activity without additional toxicity in patients with HER2-negative gastric/GEJ adenocarcinoma. A phase III study evaluating the combined use of andecaliximab and mFOLFOX6 in this setting was ongoing.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39">4.4.3.  Hydroxamates</h4><div class="NLM_p">Several MMP-9 inhibitors with high selectivity have been explored, most of which contain sulfonamide groups or related moieties. For example, compound <b>48</b> was a γ-fluorinated sulfonamide hydroxamate derived from CGS-27030A, whose affinity for MMP-9 (IC<sub>50</sub> = 3 nM) was 10-fold higher when compared with that of MMP-2 (IC<sub>50</sub> = 32.8 nM) (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Compound <b>49</b> featuring <i>N</i>-isopropoxy-arylsulfonamido hydroxamates was a potent and selective inhibitor of MMP-2 (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Compound <b>49</b> significantly reduced the invasion and migration of human umbilical vein endothelial cells at low concentrations in vivo and also showed a potential proliferation inhibition without exerting toxicity.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><div class="NLM_p last">Compound <b>50</b> with arylsulfonyl hydroxamates exhibited good inhibition potency against MMP-2/9 over MMP-1 and MMP-3 and exerted potent in vivo activity in a cancer model (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Compound <b>50</b> showed 40% inhibition in the B16F10 melanoma of the xenograft model, which was comparable to that of marimastat.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">4.4.4.  Nonhydroxamates</h4><div class="NLM_p">Because hydroxamates may cause toxicity and low selectivity, developing new zinc binding groups to maintain the activity and reduce side effects has received significant attention. Consequently, a series of zinc binding groups has been identified and used in MMP inhibitor development, such as carboxyl, thiirane, imidazole and 2,3,4-triketone pyrimidine.</div><div class="NLM_p">Compound <b>51</b>, an arylamido carboxylic acid, showed good inhibitory activity against MMP-2 and MMP-9 (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Derivative <b>52</b> featuring carboxylic acid displayed an inhibitory activity toward MMP-2 and MMP-9 with excellent selectivity (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). More importantly, it was orally available with little or no adverse side effects.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p">Thiirane, a new zinc binding group, has been discovered and applied to construct new types of MMPIs. SB-3CT (<b>53</b>) was a selective, slow-binding MMP-2/MMP-9 inhibitor and was the first competitive MMPI (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The mechanism of action of SB-3CT was an enzyme-mediated opening of the thioether ring resulting in a stable formation of a zinc-thiolate species. In a mouse model, SB-3CT was demonstrated to inhibit liver metastasis and improve the survival rate.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><div class="NLM_p last">Pyrimidine-2,4,6-triketone compounds have been explored widely because of their good biological metabolism and bioavailability. For example, compound <b>54</b>, a C-5 double-substituted barbiturate, showed a potential MMP-9 effective inhibitory efficiency (IC<sub>50</sub> = 1 nM) and 26-fold selectivity for MMP-2 (IC<sub>50</sub> = 26 nM) (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">5.  Cathepsin B</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The ALS is a major intracellular protein degradation system, in which the lysosomal hydrolases play a crucial role. Among the ∼50 known lysosomal hydrolases, of particular importance are the cysteine proteases.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Cathepsin B, a cysteine cathepsin, participates in many pathological processes, including the degradation of ECM, promotion of tumor cell invasion, and metastasis and tumor angiogenesis.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Among all cysteine proteases, cathepsin B was first identified to be related to breast cancer. Since then, cathepsin B has been closely demonstrated to be associated with many other cancers.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a> In addition, the expression of cathepsins in different tumor cells increases significantly, especially cathepsin B.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">5.1.  Synthesis and Regulation of Cathepsin B</h3><div class="NLM_p last">Inactive preprocathepsin B is synthesized by the ribosome and enters the Golgi apparatus after passing through the endoplasmic reticulum via transport by transferrin. Glycosylation and phosphorylation are completed in the Golgi apparatus.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Cathepsin B is modified with mannose-6-phosphate, which is recognized by specific receptors on lysosomes and transported into lysosomes through vesicles. Preprocathepsin is an effective inhibitor of mature enzymes by blocking active sites upon binding in the opposite direction to the substrate.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The optimal pH value for the carboxylpeptidase activity of cathepsin B is 5.0, whereas that of an endopeptidase is above 7.0.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> In lysosomes, cathepsin B functions as a carboxylpeptidase, whereas in endosomes, plasma membranes, and colloidal solutions cathepsin B functions as an endopeptidase.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Endopeptidase activity is a typical feature of the pathological degradation of proteins in the ECM.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">5.2.  Cathepsin B in Cancer</h3><div class="NLM_p">Cathepsin B plays different roles in various stages of malignant tumors, and it is overexpressed in a variety of tumor cells, such as gastric, lung, oral squamous cell, esophagus, prostate, and endometrial cells.<a onclick="showRef(event, 'ref147 ref148 ref153'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref153">(147,148,153)</a> In liver and prostate cancer, the expression level and activity of cathepsin B are 3 to 9 times higher than those of surrounding normal cell tissues.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> In addition, cathepsin B is involved in the invasion and metastasis of tumors. Cathepsin B can degrade the ECM through its endopeptidase activity, directly promoting tumor invasion and metastasis.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Malignant cells are prone to an invasion in low pH conditions. The acidic extracellular environment can induce lysosomes to move to the inner membrane of the cell membrane and enhance dissolution. The lysosome secretes a large amount of cathepsin B outside the cell by exocytosis. The activity of cathepsin B is enhanced in an acidic environment, acting on the ECM, which promotes the degradation of type IV collagen and laminin in the matrix, thereby promoting the invasion and metastasis of malignant tumor cells.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> In addition, cathepsin B promotes tumor angiogenesis by degrading tissue inhibitors of MMPs (TIMP-1 and TIMP-2).<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p last">Cathepsin B is also involved in apoptosis, in which it controls the balance of the environment by removal of damaged or aging cells. Cathepsin B exerts antiapoptotic effects by inactivating Bak, Mcl-1, and the caspase inhibitor XIAP. Cathepsin B can also promote apoptosis by activating Bid, which induces the release of cytochrome c from mitochondria into the cytoplasm to activate caspase 9 and effect caspases 3, 6, and 7.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Overall, since cathepsin B plays crucial roles in different stages of tumorigenesis and progression, developing small molecules targeting cathepsin B for cancer treatment is a promising strategy.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44">5.3.  Inhibitors of Cathepsin B</h3><div class="NLM_p">Many cathepsin B inhibitors with a strong inhibitory activity have been developed. The mechanism of action involves the formation of a covalent bond through the reaction of the thiol group at Cys29 with the electrophilic warhead of the inhibitors (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> According to their molecular chemical structures, cathepsin B inhibitors can be categorized into aziridines, β-lactams, aldehydes, nitriles, cyclopropenones, epoxysuccinic acids, and active ketones. Although there are many inhibitors currently in the preclinical research stage, drug development has been hampered because of their low selectivity or poor stability.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Inhibition mechanism of cathepsin B inhibitors bearing various warheads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45">5.3.1.  Aziridine Inhibitors</h4><div class="NLM_p">The aziridine compounds work through the reaction of aziridine-2.3-dicarboxylic acid with Cys29 of cathepsin B (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Also, it was demonstrated that the N atom of the aziridine group accounts for their enhanced selectivity.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The carboxylic acid enhanced the activity to cathepsin B significantly.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> These compounds were often sensitive to pH and were most potent when the pH is 4, which limited their application. Compound <b>55</b> showed weak activity toward cathepsin B (cathepsin L <i>K</i><sub>i</sub> = 13 nmol/L, cathepsin B <i>K</i><sub>i</sub> = 9.4 μmol/L) (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Miraziridine (<b>56</b>) was a natural product extracted from marine sponges with an IC<sub>50</sub> value of 2.1 μmol/L. The azaoxyethane and α,β-unsaturated carboxylic acid of miraziridine acted as electrophilic groups during formation of a covalent bond (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of cathepsin B inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">5.3.2.  β-Lactam and β-Lactone Inhibitors</h4><div class="NLM_p last">β-Lactams and β-lactones acted on both serine and threonine residues. Similarly, several β-lactam and β-lactone compounds, such as compounds <b>57</b> and <b>58</b>, have been also identified as cathepsin B inhibitors. These compounds functioned by forming a covalent bond through the reaction of the thiol of cysteine residues with β-lactams or β-lactones (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a> and <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a>).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47">5.3.3.  Aldehyde Inhibitors</h4><div class="NLM_p last">Aldehydes can react with the active cysteine residue of cathepsin B to form a tetrahedral structure (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Compound <b>59</b> was developed as an active and selective aldehyde inhibitor (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). However, it formed a reversible Schiff base with cathepsin B that yielded an unsatisfactory stability and bioavailability, thereby limiting its application.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48">5.3.4.  Cyclopropenone Inhibitors</h4><div class="NLM_p last">Cyclopropenone compound <b>60</b> (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), an amphoteric compound, existed in two forms, a protonated form and a deprotonated form, under different pH conditions. Under acidic conditions compound <b>60</b> was protonated with a strong nucleophilicity and reacts with the cysteine of cathepsin B.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49">5.3.5.  Nitrile Inhibitors</h4><div class="NLM_p last">Because of their good inhibitory activity, reversibility, and stability, nitriles had a better druggability over the other inhibitors mentioned above. Nitriles were capable of forming thiourea intermediated at the active site of cathepsin B.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a><i>N</i>-Cyanonitrile compound <b>61</b>, due to its high activity and electrophilicity, was developed as a reversible inhibitor of cathepsin K, L, and B with IC<sub>50</sub> values of 5, 6, and 150 nmol/L, respectively (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50">5.3.6.  Epoxysuccinic Acid Inhibitors</h4><div class="NLM_p">As the most-explored type of inhibitors against proteases, epoxysuccinic acids had good inhibitory activities against a variety of cathepsins, including cathepsin B.</div><div class="NLM_p">The mechanism of epoxysuccinic acids was involved in the formation of a covalent bond through the reaction of the ethylene oxide with the thiol of Cys29 (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a> The peptidomimetic fragment of epoxysuccinic acids enhanced their binding activity, selectivity, and potency to inhibit cathepsin B. The <i>SS</i> configuration of epoxysuccinic acids was superior to the <i>RR</i> configuration. E-64d (<b>62</b>), a typical representative of epoxysuccinic acids, had good stability and cell permeability (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> CA-074 (<b>63</b>) inhibited cathepsin B exopeptidase activity with a high selectivity, thereby reducing tumor invasion, angiogenesis, and bone metastasis (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref168 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref170">(168,170)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Representative proteasome inhibitors covalently bind with Cys-29 of cathepsin B. (A) E-64c (an analogue of E-64d PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ITO">1ITO</a>) and (B) CA-074 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QDQ">1QDQ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51">5.3.7.  Active Ketone Inhibitors</h4><div class="NLM_p last">An active ketone was considered as a good leaving group that can react with a nucleophilic group, such as hydroxyls and sulfhydryls of serine and cysteine, respectively, to form a covalent bond. For example, diazomethyl ketone compounds (<b>64</b>, <b>65</b>) were irreversible inhibitors of papain (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> In both compounds, the diazomethyl ketone group had a cell permeability and sufficient stability in the presence of thiol-containing reducing agents such as dithiothreitol (DTT) and mercaptoethanol. Fluoromethyl ketone (<b>66</b>) was also an inhibitor of cathepsin B but metabolized to fluoroacetate, hindering a clinical development because of its poor safety profile (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref171 ref172">(171,172)</a></div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">5.3.8.  Other Inhibitors</h4><div class="NLM_p last">The compound 1,2,4-thiadiazole (<b>67</b>) bearing a thiophile warhead inhibited cathepsin B with a <i>K</i><sub>i</sub> = 2 μmol/L, and it selectively inhibits noncysteine protease family members (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">6.  Summary and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protease-mediated proteostasis regulation in organelles and the extracellular matrix has been demonstrated to be associated with tumor cell growth, tumor cell invasion, and metastasis. Several proteases, such as proteasome, hClpP, cathepsin B, and MMPs, have been believed as potential antitumor targets and received widespread concern in recent years. Thus, the development of protease inhibitors has attracted great interest in the scientific and industrial communities.</div><div class="NLM_p">Currently, numerous small-molecule protease inhibitors are in clinical practice or in the preclinical stage. For instance, bortezomib, a representative peptide boric acid of proteasome covalent inhibitor, has been approved by the FDA for multiple myeloma and mantle cell lymphoma treatment. Similarly to the covalent binding, several electrophilic warheads, such as β-lactones, β-lactams, phenyl esters, boric acids, aziridines, aldehydes, nitriles, cyclopropenones, and epoxysuccinic acids have been used to construct a covalent inhibitor of hClpP, MMPs, and cathepsin B. Through a tremendous amount of medicinal chemistry work, several inhibitors have been promoted to clinical investigation, such as rebimastat, tanomastat, and doxycycline.</div><div class="NLM_p">As stated above, most of the inhibitors developed against proteases undergo a covalent irreversible inhibition and have made important contributions to cancer treatment. However, a covalent inhibition may enhance the toxicity of off-targets and have additional risks. Reversible binding inhibitors or agonists may be an ideal alternative to address the safety issues raised from covalent inhibitors. As noncovalent agonists, ADEPs, D9, and imipridones target hClpP to interrupt (chemically) the degradation of the hClpXP complex, resulting in cancer cell death by indiscriminately hydrolyzing mitochondrial proteins. Among them, ONC201 featuring an imipridone scaffold exhibited a potent efficacy for cancer treatment in vitro and in vivo and is now in clinical trials.</div><div class="NLM_p">Benefiting from the hydrolysis activity of proteasome in UPS, the PROTAC technology was developed. Beyond inhibiting a proteolytic activity, PROTACs do not inhibit the biological function of the target protein but degrade the target protein. Currently, two PROTACs, ARV-110 (AR) and ARV-471 (ER), have been approved by the FDA for phase I clinical trials in 2019. Notably, PROTAC technology is being applied to a search solution of undruggable targets, such as STAT3 and KRAS. Thus, we believe that this technology will be an important way of an antitumor.</div><div class="NLM_p last">In summary, proteases located in organelles or extracellular matrix are promising antitumor drug targets. Great efforts have been made to create their inhibitors to fight against cancers. However, safety and selectivity are the issues confronting us. With the development of chemical biology, new strategies such as PROTACs and molecular glues are the ideal alternative way that will lead to the discovery of new antitumor agents with a novel mechanism to treat cancer. Advances in the structural biology of proteases provide opportunities to design next-generation protease modulators with good safety profiles. Also, a more informative structural analysis of proteases that reveals allosteric sites will facilitate the development of allosteric modulators. Thus, these powerful tools and strategies in drug discovery bring great hopes for the development of potent and safe protease modulators to treat cancers.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01640" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youfu Luo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation
Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7327-0368" title="Orcid link">http://orcid.org/0000-0001-7327-0368</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#402c352f1f392f352635003323356e2524356e232e"><span class="__cf_email__" data-cfemail="81edf4eedef8eef4e7f4c1f2e2f4afe4e5f4afe2ef">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation
Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="hlFld-Affiliation affiliation">Laboratory
of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b425a555c4f5a547b4c585348584e155855"><span class="__cf_email__" data-cfemail="fc859d929b889d93bc8b9f948f9f89d29f92">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rao Song</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation
Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenliang Qiao</span> - <span class="hlFld-Affiliation affiliation">Lung
Cancer Center, Laboratory of Lung Cancer, West China Medical School, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun He</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation
Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiasheng Huang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation
Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.S., W.Q., and J.H. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath3" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Jun He</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=BIO-d7e2813-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rao Song</b> received her Bachelor’s degree in Pharmacy at Harbin Medical University in 2018 from China. She is currently pursuing a Master’s degree in Luo’s lab at State Key Laboratory of Biotherapy, Sichuan University, from China. She is working on the design, synthesis, and mechanism study of antitumor small molecules.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Jiasheng Huang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=BIO-d7e2818-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wenliang Qiao</b> received his Ph.D. in thoracic surgery from the Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University in 2016; subsequently, he is working and being employed as a lecturer at the Department of Lung Cancer Center of West China Hospital. His research interests are focused on the molecular diagnosis and molecular subtype of individualized treatment for Early Lung Cancer and the study of clinical new drugs based on the neoantigen tumor vaccine for individualized immunotherapy of Lung Cancer.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Youfu Luo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=BIO-d7e2823-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jun He</b>, a Research Associate, received his Ph.D. in Pharmacy from Sichuan University in 2011 and now works at the State Key Laboratory of Biotherapy of Sichuan University in China. His research focuses on small-molecule drug discovery and computer-aided drug design for the treatment of diseases.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Tao Yang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=BIO-d7e2828-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jiasheng Huang</b> completed his B.S. in Pharmacy at Southwest Jiaotong University. He is currently a Ph.D. student in Luo’s lab at the State Key Laboratory of Biotherapy, Sichuan University. He is currently focusing on the development of a novel lead compound mainly targeting ClpP protease in humans.</p></figure></div><div class="bio" rid="ath1"><figure id="ath1" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Rao Song</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=BIO-d7e2833-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Youfu Luo</b>, professor of the State Key lab of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan. He obtained his Ph.D. from Sichuan University in 2009. He is mainly engaged in the research on small-molecule drug design and synthesis, especially antibacterial and antitumor agents, and structural biology and molecular pharmacology. His research interests cover structure-based drug discovery and development of new strategies for high-throughput screening.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Wenliang Qiao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=BIO-d7e2838-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tao Yang</b> received his Ph.D. in Medicinal Chemistry from the State Key Laboratory of Biotherapy, Sichuan University, in 2015, subsequently becoming a research assistant at the West China Hospital. He started his independent research in 2018 and is currently an Associate Professor in West China Hospital. His research interests are focused on small-molecule drug discovery, especially antibacterial agents and antitumor agents. He is also interested in drug discovery from natural sources.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was financially supported by grants from the National Natural Science Foundation of China (Grant No. 81973368) and National Mega-project for Innovative Drugs (2019ZX09721001-001-001).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin-proteasome system</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">autophagy-lysosomal system</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metallopeptidase</p></td></tr><tr><td class="NLM_term">CP</td><td class="NLM_def"><p class="first last">core particle</p></td></tr><tr><td class="NLM_term">RP</td><td class="NLM_def"><p class="first last">regulatory particles</p></td></tr><tr><td class="NLM_term">E1</td><td class="NLM_def"><p class="first last">ubiquitin activating enzyme</p></td></tr><tr><td class="NLM_term">E2</td><td class="NLM_def"><p class="first last">ubiquitin binding enzyme</p></td></tr><tr><td class="NLM_term">E3</td><td class="NLM_def"><p class="first last">ubiquitin ligase</p></td></tr><tr><td class="NLM_term">PIs</td><td class="NLM_def"><p class="first last">proteasome inhibitors</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor-κB</p></td></tr><tr><td class="NLM_term">TPD</td><td class="NLM_def"><p class="first last">targeted protein degradation</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeted chimera</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">kirsten rat sarcoma</p></td></tr><tr><td class="NLM_term">MCRPC</td><td class="NLM_def"><p class="first last">metastatic castration-resistant prostate cancer</p></td></tr><tr><td class="NLM_term">MBC</td><td class="NLM_def"><p class="first last">metastatic breast cancer</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">Von Hippel-Lindau</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">Cereblon</p></td></tr><tr><td class="NLM_term">hClpP</td><td class="NLM_def"><p class="first last">hμman caseinolytic protease P</p></td></tr><tr><td class="NLM_term">CK2</td><td class="NLM_def"><p class="first last">casein kinase 2</p></td></tr><tr><td class="NLM_term">HDAC6</td><td class="NLM_def"><p class="first last">histone deacetylase 6</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia inducible factor-1α</p></td></tr><tr><td class="NLM_term">MEBS</td><td class="NLM_def"><p class="first last">Methyl bestatin</p></td></tr><tr><td class="NLM_term">ATRA</td><td class="NLM_def"><p class="first last">all-trans retinoic acid</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">retinoic acid receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term"><i>Sa</i>ClpP</td><td class="NLM_def"><p class="first last"><i>Staphylococcus aureus</i> ClpP</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species. ADEPs, acyldepsipeptides</p></td></tr><tr><td class="NLM_term">ACPs</td><td class="NLM_def"><p class="first last">activators of self-compartmentalized proteases</p></td></tr><tr><td class="NLM_term">ITC</td><td class="NLM_def"><p class="first last">isothermal titration calorimetry</p></td></tr><tr><td class="NLM_term">CETSA</td><td class="NLM_def"><p class="first last">cell thermal transfer method</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 172 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthiesen, R.</span></span> <span> </span><span class="NLM_article-title">Review and literature mining on proteostasis factors and cancer</span>. <i>Methods Mol. Biol. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1449</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-3756-1_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2F978-1-4939-3756-1_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVChtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1449&publication_year=2016&pages=71-84&author=A.+Carvalhoauthor=M.+Rodr%C3%ADguezauthor=R.+Matthiesen&title=Review+and+literature+mining+on+proteostasis+factors+and+cancer&doi=10.1007%2F978-1-4939-3756-1_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Review and literature mining on proteostasis factors and cancer</span></div><div class="casAuthors">Carvalho, Ana Sofia; Rodriguez, Manuel S.; Matthiesen, Rune</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1449</span>
        (<span class="NLM_cas:issue">Proteostasis</span>),
    <span class="NLM_cas:pages">71-84</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Automatic anal. of increasingly growing literature repositories including data integration to other databases is a powerful tool to propose hypothesis that can be used to plan expts. to validate or disprove the hypothesis.  Furthermore, it provides means to evaluate the redundancy of research line in comparison to the published literature.  This is potentially beneficial for those developing research in a specific disease which are interested in exploring a particular pathway or set of genes/proteins.  In the scope of the integrating book a case will be made addressing proteostasis factors in cancer.  The maintenance of proteome homeostasis, known as proteostasis, is a process by which cells regulate protein translation, degrdn., subcellular localization, and protein folding and consists of an integrated network of proteins.  The ubiquitin-proteasome system plays a key role in essential biol. processes such as cell cycle, DNA damage repair, membrane trafficking, and maintaining protein homeostasis.  Cells maintain proteostasis by regulating protein translation, degrdn., subcellular localization, and protein folding.  Aberrant proteostasis leads to loss-of-function diseases (cystic fibrosis) and gain-of-toxic-function diseases (Alzheimer's, Parkinson's, and Huntington's disease).  Cancer therapy on the other hand explores inhibition of proteostasis factors to trigger endoplasmic reticulum stress with subsequent apoptosis.  Alternatively therapies target deubiquitinases and thereby regulate tumor promoters or suppressors.  Furthermore, mutations in specific proteostasis factors are assocd. with higher risk for specific cancers, e.g., BRCA mutations in breast cancer.  This chapter discusses proteostasis protein factors' assocn. with cancer from a literature mining perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplumLjf9-unbVg90H21EOLACvtfcHk0liay0lG8_w41g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVChtL%252FK&md5=f5c167f8079272f34ed12d1dfc29e6a9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3756-1_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3756-1_2%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DA.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%26aulast%3DMatthiesen%26aufirst%3DR.%26atitle%3DReview%2520and%2520literature%2520mining%2520on%2520proteostasis%2520factors%2520and%2520cancer%26jtitle%3DMethods%2520Mol.%2520Biol.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2016%26volume%3D1449%26spage%3D71%26epage%3D84%26doi%3D10.1007%2F978-1-4939-3756-1_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hipp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasturi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, F.</span></span> <span> </span><span class="NLM_article-title">The proteostasis network and its decline in ageing</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/s41580-019-0101-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fs41580-019-0101-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30733602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlWlt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=421-435&author=M.+Hippauthor=P.+Kasturiauthor=F.+Hartl&title=The+proteostasis+network+and+its+decline+in+ageing&doi=10.1038%2Fs41580-019-0101-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The proteostasis network and its decline in ageing</span></div><div class="casAuthors">Hipp, Mark S.; Kasturi, Prasad; Hartl, F. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">421-435</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Ageing is a major risk factor for the development of many diseases, prominently including neurodegenerative disorders such as Alzheimer disease and Parkinson disease.  A hallmark of many age-related diseases is the dysfunction in protein homeostasis (proteostasis), leading to the accumulation of protein aggregates.  In healthy cells, a complex proteostasis network, comprising mol. chaperones and proteolytic machineries and their regulators, operates to ensure the maintenance of proteostasis.  These factors coordinate protein synthesis with polypeptide folding, the conservation of protein conformation and protein degrdn.  However, sustaining proteome balance is a challenging task in the face of various external and endogenous stresses that accumulate during ageing.  These stresses lead to the decline of proteostasis network capacity and proteome integrity.  The resulting accumulation of misfolded and aggregated proteins affects, in particular, postmitotic cell types such as neurons, manifesting in disease.  Recent analyses of proteome-wide changes that occur during ageing inform strategies to improve proteostasis.  The possibilities of pharmacol. augmentation of the capacity of proteostasis networks hold great promise for delaying the onset of age-related pathologies assocd. with proteome deterioration and for extending healthspan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvfOtsme2IxLVg90H21EOLACvtfcHk0liay0lG8_w41g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlWlt70%253D&md5=55132b34d115ea5ccaf9fd29ecff6b36</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41580-019-0101-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-019-0101-y%26sid%3Dliteratum%253Aachs%26aulast%3DHipp%26aufirst%3DM.%26aulast%3DKasturi%26aufirst%3DP.%26aulast%3DHartl%26aufirst%3DF.%26atitle%3DThe%2520proteostasis%2520network%2520and%2520its%2520decline%2520in%2520ageing%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26spage%3D421%26epage%3D435%26doi%3D10.1038%2Fs41580-019-0101-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span> <span> </span><span class="NLM_article-title">The autophagy-lysosomal pathways and their emerging roles in modulating proteostasis in tumors</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4</span>, <span class="refDoi"> DOI: 10.3390/cells8010004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3390%2Fcells8010004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKhtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=4&author=Z.+Dongauthor=H.+Cui&title=The+autophagy-lysosomal+pathways+and+their+emerging+roles+in+modulating+proteostasis+in+tumors&doi=10.3390%2Fcells8010004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The autophagy-lysosomal pathways and their emerging roles in modulating proteostasis in tumors</span></div><div class="casAuthors">Dong, Zhen; Cui, Hongjuan</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In normal physiol. condition, the maintenance of cellular proteostasis is a prerequisite for cell growth, functioning, adapting to changing micro-environments, and responding to extracellular stress.  Cellular proteostasis is maintained by specific proteostasis networks (PNs) to prevent protein misfolding, aggregating, and accumulating in subcellular compartments.  Commonly, the PNs are composed of protein synthesis, mol. chaperones, endoplasmic reticulum (ER), unfolded protein response (UPR), stress response pathways (SRPs), secretions, ubiquitin proteasome system (UPS), and autophagy-lysosomal pathways (ALPs).  Although great efforts have been made to explore the underlying detailed mechanisms of proteostasis, there are many questions remain to explore, esp. in proteostasis regulated by the ALPs.  Proteostasis out-off-balance is correlated with various human diseases such as diabetes, stroke, inflammation, hypertension, pulmonary fibrosis, and Alzheimer's disease.  Enhanced regulation of PNs is obsd. in tumors, thereby indicating that proteostasis may play a pivotal role in tumorigenesis and cancer development.  Recently, inhibitors targeting the UPS have shown to be failed in solid tumor treatment.  However, there is growing evidence showing that the ALPs play important roles in regulation of proteostasis alone or with a crosstalk with other PNs in tumors.  In this review, we provide insights into the proteostatic process and how it is regulated by the ALPs, such as macroautophagy, aggrephagy, chaperone-mediated autophagy, microautophagy, as well as mitophagy during tumor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFptUCsoPP7Vg90H21EOLACvtfcHk0ljoDSDNYDvLZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKhtLfJ&md5=fb0d358d25e000a6e9bb5717dc21fb8b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fcells8010004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8010004%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DH.%26atitle%3DThe%2520autophagy-lysosomal%2520pathways%2520and%2520their%2520emerging%2520roles%2520in%2520modulating%2520proteostasis%2520in%2520tumors%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D4%26doi%3D10.3390%2Fcells8010004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskowitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzzy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor-Cortelli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubblefield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portlock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumetrescu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trehu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A.</span></span> <span> </span><span class="NLM_article-title">Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2005.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15613699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVKisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=676-684&author=O.+O%E2%80%99Connorauthor=J.+Wrightauthor=C.+Moskowitzauthor=J.+Muzzyauthor=B.+MacGregor-Cortelliauthor=M.+Stubblefieldauthor=D.+Strausauthor=C.+Portlockauthor=P.+Hamlinauthor=E.+Choiauthor=O.+Dumetrescuauthor=D.+Esseltineauthor=E.+Trehuauthor=J.+Adamsauthor=D.+Schenkeinauthor=A.+Zelenetz&title=Phase+II+clinical+experience+with+the+novel+proteasome+inhibitor+bortezomib+in+patients+with+indolent+non-Hodgkin%E2%80%99s+lymphoma+and+mantle+cell+lymphoma&doi=10.1200%2FJCO.2005.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma</span></div><div class="casAuthors">O'Connor, Owen; Wright, John; Moskowitz, Craig; Muzzy, Jamie; MacGregor-Cortelli, Barbara; Stubblefield, Michael; Straus, David; Portlock, Carol; Hamlin, Paul; Choi, Elizabeth; Dumetrescu, Otila; Esseltine, Dixie; Trehu, Elizabeth; Adams, Julian; Schenkein, David; Zelenetz, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">676-684</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose was to det. the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL).  Patients with indolent and MCL were eligible.  Bortezomib was given at a dose of 1.5 mg/m2 on days 1, 4, 8, and 11.  Patients were required to have received no more than three prior chemotherapy regimens, with at least 1 mo since the prior treatment, 3 mo from prior rituximab, and 7 days from prior corticosteroids; abs. neutrophil count more than 1,500/μL (500/μL if documented bone marrow involvement); and platelet count more than 50,000/μL.  Twenty-six patients were registered, of whom 24 were assessable.  Ten patients had follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had marginal zone lymphoma.  The overall response rate was 58%, with one complete remission (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular non-Hodgkin's lymphoma (NHL).  All responses were durable, lasting from 3 to 24+ months.  One patient with MCL achieved a CRu, four achieved a PR, and four had stable disease.  One patient with MCL maintained his remission for 19 mo.  Both patients with marginal zone lymphoma achieved PR lasting 8+ and 11+ months, resp.  Patients with SLL or CLL have yet to respond.  Overall, the drug was well tolerated, with only one grade 4 toxicity (hyponatremia).  The most common grade 3 toxicities were lymphopenia (n = 14) and thrombocytopenia (n = 7).  These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvJzC-Q3QCWrVg90H21EOLACvtfcHk0ljoDSDNYDvLZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVKisLg%253D&md5=9f60fb4da20f17036c070708f4cdf402</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DMoskowitz%26aufirst%3DC.%26aulast%3DMuzzy%26aufirst%3DJ.%26aulast%3DMacGregor-Cortelli%26aufirst%3DB.%26aulast%3DStubblefield%26aufirst%3DM.%26aulast%3DStraus%26aufirst%3DD.%26aulast%3DPortlock%26aufirst%3DC.%26aulast%3DHamlin%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DE.%26aulast%3DDumetrescu%26aufirst%3DO.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DTrehu%26aufirst%3DE.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DZelenetz%26aufirst%3DA.%26atitle%3DPhase%2520II%2520clinical%2520experience%2520with%2520the%2520novel%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520patients%2520with%2520indolent%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520and%2520mantle%2520cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D676%26epage%3D684%26doi%3D10.1200%2FJCO.2005.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiljeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span> <span> </span><span class="NLM_article-title">Cysteine cathepsins: from structure, function and regulation to new frontiers</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1824</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bbapap.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22024571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1824&publication_year=2012&pages=68-88&author=V.+Turkauthor=V.+Stokaauthor=O.+Vasiljevaauthor=M.+Renkoauthor=T.+Sunauthor=B.+Turkauthor=D.+Turk&title=Cysteine+cathepsins%3A+from+structure%2C+function+and+regulation+to+new+frontiers&doi=10.1016%2Fj.bbapap.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine cathepsins: From structure, function and regulation to new frontiers</span></div><div class="casAuthors">Turk, Vito; Stoka, Veronika; Vasiljeva, Olga; Renko, Miha; Sun, Tao; Turk, Boris; Turk, Dusan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1824</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-88</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  It is more than 50 years since the lysosome was discovered.  Since then its hydrolytic machinery, including proteases and other hydrolases, has been fairly well identified and characterized.  Among these are the cysteine cathepsins, members of the family of papain-like cysteine proteases.  They have unique reactive-site properties and an uneven tissue-specific expression pattern.  In living organisms, their activity is a delicate balance of expression, targeting, zymogen activation, inhibition by protein inhibitors and degrdn.  The specificity of their substrate binding sites, small-mol. inhibitor repertoire and crystal structures are providing new tools for research and development.  Their unique reactive-site properties have made it possible to confine the targets simply by the use of appropriate reactive groups.  The epoxysuccinyls still dominate the field, but now nitriles seem to be the most appropriate "warhead".  The view of cysteine cathepsins as lysosomal proteases is changing as there is now clear evidence of their localization in other cellular compartments.  Besides being involved in protein turnover, they build an important part of endosomal antigen presentation.  Together with the growing no. of non-endosomal roles of cysteine cathepsins is growing also the knowledge of their involvement in diseases such as cancer and rheumatoid arthritis, among others.  Finally, cysteine cathepsins are important regulators and signaling mols. of an unimaginable no. of biol. processes.  The current challenge is to identify their endogenous substrates, in order to gain an insight into the mechanisms of substrate degrdn. and processing.  In this review, some of the remarkable advances that have taken place in the past decade are presented.  This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEZ0u2P21D7Vg90H21EOLACvtfcHk0liAxN453PX8fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI&md5=8615c1f0205d66b0fad932d6ff874390</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DStoka%26aufirst%3DV.%26aulast%3DVasiljeva%26aufirst%3DO.%26aulast%3DRenko%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26atitle%3DCysteine%2520cathepsins%253A%2520from%2520structure%252C%2520function%2520and%2520regulation%2520to%2520new%2520frontiers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2012%26volume%3D1824%26spage%3D68%26epage%3D88%26doi%3D10.1016%2Fj.bbapap.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabanglo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W. A.</span></span> <span> </span><span class="NLM_article-title">The role of ClpP protease in bacterial pathogenesis and human diseases</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1413</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00124</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00124" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps12lt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1413-1425&author=V.+Bhandariauthor=K.+S.+Wongauthor=J.+L.+Zhouauthor=M.+F.+Mabangloauthor=R.+A.+Bateyauthor=W.+A.+Houry&title=The+role+of+ClpP+protease+in+bacterial+pathogenesis+and+human+diseases&doi=10.1021%2Facschembio.8b00124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of ClpP Protease in Bacterial Pathogenesis and Human Diseases</span></div><div class="casAuthors">Bhandari, Vaibhav; Wong, Keith S.; Zhou, Jin Lin; Mabanglo, Mark F.; Batey, Robert A.; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1413-1425</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In prokaryotic cells and eukaryotic organelles, the ClpP protease plays an important role in proteostasis.  The disruption of ClpP function has been shown to influence the infectivity and virulence of a no. of bacterial pathogens.  More recently, ClpP has been found to be involved in various forms of carcinomas and in Perrault syndrome, which is an inherited condition characterized by hearing loss in males and females and by ovarian abnormalities in females.  Hence, targeting ClpP is a potentially viable, attractive option for the treatment of different ailments.  Herein, the biochem. and cellular activities of ClpP are discussed along with the mechanisms by which ClpP affects bacterial pathogenesis and various human diseases.  In addn., a comprehensive overview is given of the new classes of compds. in development that target ClpP.  Many of these compds. are currently primarily aimed at treating bacterial infections.  Some of these compds. inhibit ClpP activity, while others activate the protease and lead to its dysregulation.  The ClpP activators are remarkable examples of small mols. that inhibit protein-protein interactions but also result in a gain of function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiUm3tuolaabVg90H21EOLACvtfcHk0liAxN453PX8fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps12lt7w%253D&md5=b7e2729aa3da2049740c7249a5f53d30</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00124%26sid%3Dliteratum%253Aachs%26aulast%3DBhandari%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BS.%26aulast%3DZhou%26aufirst%3DJ.%2BL.%26aulast%3DMabanglo%26aufirst%3DM.%2BF.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DHoury%26aufirst%3DW.%2BA.%26atitle%3DThe%2520role%2520of%2520ClpP%2520protease%2520in%2520bacterial%2520pathogenesis%2520and%2520human%2520diseases%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D1413%26epage%3D1425%26doi%3D10.1021%2Facschembio.8b00124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyaud, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraju, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qia, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketela, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienholds, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornblau, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human ccute myeloid leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccell.2015.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26058080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVejurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=864-876&author=A.+Coleauthor=Z.+Wangauthor=E.+Coyaudauthor=V.+Voisinauthor=M.+Grondaauthor=Y.+Jitkovaauthor=R.+Mattsonauthor=R.+Hurrenauthor=S.+Babovicauthor=N.+Macleanauthor=I.+Restallauthor=X.+Wangauthor=D.+V.+Jeyarajuauthor=M.+A.+Sukhaiauthor=S.+Prabhaauthor=S.+Bashirauthor=A.+Ramakrishnanauthor=E.+Leungauthor=Y.+H.+Qiaauthor=N.+Zhangauthor=K.+R.+Combesauthor=T.+Ketelaauthor=F.+Linauthor=W.+A.+Houryauthor=A.+Amanauthor=R.+Al-Awarauthor=W.+Zhengauthor=E.+Wienholdsauthor=C.+J.+Xuauthor=J.+Dickauthor=J.+C.+Wangauthor=J.+Moffatauthor=M.+D.+Mindenauthor=C.+J.+Eavesauthor=G.+D.+Baderauthor=Z.+Haoauthor=S.+M.+Kornblauauthor=B.+Raughtauthor=A.+D.+Schimmer&title=Inhibition+of+the+mitochondrial+protease+ClpP+as+a+therapeutic+strategy+for+human+ccute+myeloid+leukemia&doi=10.1016%2Fj.ccell.2015.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia</span></div><div class="casAuthors">Cole, Alicia; Wang, Zezhou; Coyaud, Etienne; Voisin, Veronique; Gronda, Marcela; Jitkova, Yulia; Mattson, Rachel; Hurren, Rose; Babovic, Sonja; MacLean, Neil; Restall, Ian; Wang, Xiaoming; Jeyaraju, Danny V.; Sukhai, Mahadeo A.; Prabha, Swayam; Bashir, Shaheena; Ramakrishnan, Ashwin; Leung, Elisa; Qia, Yi Hua; Zhang, Nianxian; Combes, Kevin R.; Ketela, Troy; Lin, Fengshu; Houry, Walid A.; Aman, Ahmed; Al-Awar, Rima; Zheng, Wei; Wienholds, Erno; Xu, Chang Jiang; Dick, John; Wang, Jean C. Y.; Moffat, Jason; Minden, Mark D.; Eaves, Connie J.; Bader, Gary D.; Hao, Zhenyue; Kornblau, Steven M.; Raught, Brian; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">864-876</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">From an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown reduced the viability of K562 leukemic cells.  Expression of this mitochondrial protease that has structural similarity to the cytoplasmic proteosome is increased in leukemic cells from approx. half of all patients with AML.  Genetic or chem. inhibition of ClpP killed cells from both human AML cell lines and primary samples in which the cells showed elevated ClpP expression but did not affect their normal counterparts.  Importantly, Clpp knockout mice were viable with normal hematopoiesis.  Mechanistically, we found that ClpP interacts with mitochondrial respiratory chain proteins and metabolic enzymes, and knockdown of ClpP in leukemic cells inhibited oxidative phosphorylation and mitochondrial metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PQElwRijsLVg90H21EOLACvtfcHk0liNIWWrgr2U6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVejurnJ&md5=37380b21ff34c266a30288bb3915bf90</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCoyaud%26aufirst%3DE.%26aulast%3DVoisin%26aufirst%3DV.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DMattson%26aufirst%3DR.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DBabovic%26aufirst%3DS.%26aulast%3DMaclean%26aufirst%3DN.%26aulast%3DRestall%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJeyaraju%26aufirst%3DD.%2BV.%26aulast%3DSukhai%26aufirst%3DM.%2BA.%26aulast%3DPrabha%26aufirst%3DS.%26aulast%3DBashir%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DQia%26aufirst%3DY.%2BH.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DCombes%26aufirst%3DK.%2BR.%26aulast%3DKetela%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DHoury%26aufirst%3DW.%2BA.%26aulast%3DAman%26aufirst%3DA.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DWienholds%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DC.%2BJ.%26aulast%3DDick%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DEaves%26aufirst%3DC.%2BJ.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DKornblau%26aufirst%3DS.%2BM.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DInhibition%2520of%2520the%2520mitochondrial%2520protease%2520ClpP%2520as%2520a%2520therapeutic%2520strategy%2520for%2520human%2520ccute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D864%26epage%3D876%26doi%3D10.1016%2Fj.ccell.2015.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">Remodelling the extracellular matrix in development and disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1038/nrm3904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrm3904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25415508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=786-801&author=C.+Bonnansauthor=J.+Chouauthor=Z.+Werb&title=Remodelling+the+extracellular+matrix+in+development+and+disease&doi=10.1038%2Fnrm3904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Remodelling the extracellular matrix in development and disease</span></div><div class="casAuthors">Bonnans, Caroline; Chou, Jonathan; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">786-801</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The extracellular matrix (ECM) is a highly dynamic structure that is present in all tissues and continuously undergoes controlled remodelling.  This process involves quant. and qual. changes in the ECM, mediated by specific enzymes that are responsible for ECM degrdn., such as metalloproteinases.  The ECM interacts with cells to regulate diverse functions, including proliferation, migration and differentiation.  ECM remodelling is crucial for regulating the morphogenesis of the intestine and lungs, as well as of the mammary and submandibular glands.  Dysregulation of ECM compn., structure, stiffness and abundance contributes to several pathol. conditions, such as fibrosis and invasive cancer.  A better understanding of how the ECM regulates organ structure and function and of how ECM remodelling affects disease progression will contribute to the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgvNjm5IvLgLVg90H21EOLACvtfcHk0liNIWWrgr2U6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtbbF&md5=623492080876fee0ffa62b9f0dc1937c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrm3904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3904%26sid%3Dliteratum%253Aachs%26aulast%3DBonnans%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DJ.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DRemodelling%2520the%2520extracellular%2520matrix%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D786%26epage%3D801%26doi%3D10.1038%2Fnrm3904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. I.</span></span> <span> </span><span class="NLM_article-title">Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1002/path.5225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fpath.5225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30582157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3cnlt1OgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=2019&pages=629-640&author=G.+A.+Conlonauthor=G.+I.+Murray&title=Recent+advances+in+understanding+the+roles+of+matrix+metalloproteinases+in+tumour+invasion+and+metastasis&doi=10.1002%2Fpath.5225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis</span></div><div class="casAuthors">Conlon Guy A; Murray Graeme I</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-640</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review aims to provide an overview of recent developments regarding the roles of MMPs in tumour invasion and metastasis.  Much of the mortality burden belonging to cancer relates to its ability to invade adjacent tissue and form metastases at distant sites.  This would not be possible without remodelling of the ECM, a process which is enabled by the functions of MMPs.  Recent studies provide a better understanding of the importance of the biophysical nature of the ECM, how this influences cancer cell motility, and how MMPs act to modify matrix stiffness.  The regulation of MMPs and the role of immune cell generated MMPs has also become better understood.  All of this provides a framework for the therapeutic targeting of MMPs and recent advances in the development of selective MMPs inhibitors are also reviewed.  Copyright © 2018 Pathological Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiGXnJU5dcZrBItaL1WaVAfW6udTcc2eYmwA3Am9T1Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnlt1OgsA%253D%253D&md5=1780b99718cb6b8c031f18439b4b4096</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fpath.5225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5225%26sid%3Dliteratum%253Aachs%26aulast%3DConlon%26aufirst%3DG.%2BA.%26aulast%3DMurray%26aufirst%3DG.%2BI.%26atitle%3DRecent%2520advances%2520in%2520understanding%2520the%2520roles%2520of%2520matrix%2520metalloproteinases%2520in%2520tumour%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Pathol.%26date%3D2019%26volume%3D247%26spage%3D629%26epage%3D640%26doi%3D10.1002%2Fpath.5225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perantoni, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the ubiquitin-proteasome system for cancer therapy</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2008.01013.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1111%2Fj.1349-7006.2008.01013.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=19037995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2009&pages=24-28&author=Y.+Yangauthor=J.+Kitagakiauthor=H.+Wangauthor=D.+Houauthor=A.+Perantoni&title=Targeting+the+ubiquitin-proteasome+system+for+cancer+therapy&doi=10.1111%2Fj.1349-7006.2008.01013.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the ubiquitin-proteasome system for cancer therapy</span></div><div class="casAuthors">Yang, Yili; Kitagaki, Jirouta; Wang, Honghe; Hou, De-Xing; Perantoni, Alan O.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-28</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system plays a crit. role in controlling the level, activity, and location of various cellular proteins.  Significant progress was made in investigating the mol. mechanisms of ubiquitination, particularly in understanding the structure of the ubiquitination machinery and identifying ubiquitin protein ligases, the primary specificity-detg. enzymes.  Therefore, it is now possible to target specific mols. involved in ubiquitination and proteasomal degrdn. to regulate many cellular processes such as signal transduction, proliferation, and apoptosis.  In particular, alterations in ubiquitination are obsd. in most, if not all, cancer cells.  This is manifested by destabilization of tumor suppressors, such as p53, and overexpression of oncogenes such as c-Myc and c-Jun.  In addn. to the development and clin. validation of proteasome inhibitor, bortezomib, in myeloma therapy, recent studies have demonstrated that it is possible to develop inhibitors for specific ubiquitination and deubiquitination enzymes.  With the help of structural studies, rational design, and chem. synthesis, it is conceivable that we will be able to use 'druggable' inhibitors of the ubiquitin system to evaluate their effects in animal tumor models in the not-so-distant future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_KciRHFSGhLVg90H21EOLACvtfcHk0lig2crks1brvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgurk%253D&md5=1e6fcbd11647d1bd370ea68a3cac96c7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.01013.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.01013.x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKitagaki%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DD.%26aulast%3DPerantoni%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520ubiquitin-proteasome%2520system%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Sci.%26date%3D2009%26volume%3D100%26spage%3D24%26epage%3D28%26doi%3D10.1111%2Fj.1349-7006.2008.01013.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">112260</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejmech.2020.112260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32224379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtVKgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2020&pages=112260&author=S.+Mondalauthor=N.+Adhikariauthor=S.+Banerjeeauthor=S.+A.+Aminauthor=T.+Jha&title=Matrix+metalloproteinase-9+%28MMP-9%29+and+its+inhibitors+in+cancer%3A+A+minireview&doi=10.1016%2Fj.ejmech.2020.112260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview</span></div><div class="casAuthors">Mondal, Subha; Adhikari, Nilanjan; Banerjee, Suvankar; Abdul Amin, Sk; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112260</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme.  MMP-9 is one of the most complex forms of matrix metalloproteinases.  MMP-9 has the ability to degrade the extracellular matrix (ECM) components and has important role in the pathophysiol. functions.  Overexpression and dysregulation of MMP-9 is assocd. with various diseases.  Thus, regulation and inhibition of MMP-9 is an important therapeutic approach for combating various diseases including cancer.  Inhibitors of MMP-9 can be used as anticancer agents.  Till date no selective MMP-9 inhibitors passed the clin. trials.  In this review the structure, activation, function and inhibitors of MMP-9 are mainly focused.  Some highly active and/or selective MMP-9 inhibitors have been discussed which may be helpful to explore the structural significance of MMP-9 inhibitors.  This study may be useful to design new potent and selective MMP-9 inhibitors against cancer in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKSwmQcbuNmbVg90H21EOLACvtfcHk0lig2crks1brvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtVKgs70%253D&md5=250e10deaacc265aa0a9af2b940d4e76</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112260%26sid%3Dliteratum%253Aachs%26aulast%3DMondal%26aufirst%3DS.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DMatrix%2520metalloproteinase-9%2520%2528MMP-9%2529%2520and%2520its%2520inhibitors%2520in%2520cancer%253A%2520A%2520minireview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D194%26spage%3D112260%26doi%3D10.1016%2Fj.ejmech.2020.112260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PROTACs: A novel strategy for cancer therapy</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2020.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.semcancer.2020.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32058059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2020&pages=171&author=J.+Liuauthor=J.+Maauthor=Y.+Liuauthor=J.+Xiaauthor=Y.+Liauthor=Z.+P.+Wangauthor=W.+Wei&title=PROTACs%3A+A+novel+strategy+for+cancer+therapy&doi=10.1016%2Fj.semcancer.2020.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: A novel strategy for cancer therapy</span></div><div class="casAuthors">Liu, Jing; Ma, Jia; Liu, Yi; Xia, Jun; Li, Yuyun; Wang, Z. Peter; Wei, Wenyi</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">Part_2</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time.  From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins.  The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chem. stability issues restrict their clin. application.  The second generation of small mol.-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied.  To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCR-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs.  The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role.  To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs.  The degrdn. of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKjhYqcuOobVg90H21EOLACvtfcHk0lig2crks1brvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D&md5=857bf22e06e986d57ad70fdd4a518953</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2020.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2020.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%2BP.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPROTACs%253A%2520A%2520novel%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D67%26spage%3D171%26doi%3D10.1016%2Fj.semcancer.2020.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graves, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aponte-Collazo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, E. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicheva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, T. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashamalla, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmuhamedov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1020</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1SntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1020-1029&author=P.+R.+Gravesauthor=L.+J.+Aponte-Collazoauthor=E.+M.+J.+Fennellauthor=A.+C.+Gravesauthor=A.+E.+Haleauthor=N.+Dichevaauthor=L.+E.+Herringauthor=T.+S.+K.+Gilbertauthor=M.+P.+Eastauthor=I.+M.+McDonaldauthor=M.+R.+Lockettauthor=H.+Ashamallaauthor=N.+J.+Moormanauthor=D.+S.+Karanewskyauthor=E.+J.+Iwanowiczauthor=E.+Holmuhamedovauthor=L.+M.+Graves&title=Mitochondrial+protease+ClpP+is+a+target+for+the+anticancer+compounds+ONC201+and+related+analogues&doi=10.1021%2Facschembio.9b00222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues</span></div><div class="casAuthors">Graves, Paul R.; Aponte-Collazo, Lucas J.; Fennell, Emily M. J.; Graves, Adam C.; Hale, Andrew E.; Dicheva, Nedyalka; Herring, Laura E.; Gilbert, Thomas S. K.; East, Michael P.; McDonald, Ian M.; Lockett, Matthew R.; Ashamalla, Hani; Moorman, Nathaniel J.; Karanewsky, Donald S.; Iwanowicz, Edwin J.; Holmuhamedov, Ekhson; Graves, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1020-1029</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ONC201 is a first-in-class imipridone mol. currently in clin. trials for the treatment of multiple cancers.  Despite enormous clin. potential, the mechanism of action is controversial.  To investigate the mechanism of ONC201 and identify compds. with improved potency, we tested a series of novel ONC201 analogs (TR compds.) for effects on cell viability and stress responses in breast and other cancer models.  The TR compds. were found to be ∼50-100 times more potent at inhibiting cell proliferation and inducing the integrated stress response protein ATF4 than ONC201.  Using immobilized TR compds., we identified the human mitochondrial caseinolytic protease P (ClpP) as a specific binding protein by mass spectrometry.  Affinity chromatog./drug competition assays showed that the TR compds. bound ClpP with ∼10-fold higher affinity compared to ONC201.  Importantly, we found that the peptidase activity of recombinant ClpP was strongly activated by ONC201 and the TR compds. in a dose- and time-dependent manner with the TR compds. displaying a ∼10-100 fold increase in potency over ONC201.  Finally, siRNA knockdown of ClpP in SUM159 cells reduced the response to ONC201 and the TR compds., including induction of CHOP, loss of the mitochondrial proteins (TFAM, TUFM), and the cytostatic effects of these compds.  Thus, we report that ClpP directly binds ONC201 and the related TR compds. and is an important biol. target for this class of mols.  Moreover, these studies provide, for the first time, a biochem. basis for the difference in efficacy between ONC201 and the TR compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ9b0PMFyCPbVg90H21EOLACvtfcHk0ligI2x6QdkZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1SntLw%253D&md5=9291bc01f382a0b53ce059e30ecadfce</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00222%26sid%3Dliteratum%253Aachs%26aulast%3DGraves%26aufirst%3DP.%2BR.%26aulast%3DAponte-Collazo%26aufirst%3DL.%2BJ.%26aulast%3DFennell%26aufirst%3DE.%2BM.%2BJ.%26aulast%3DGraves%26aufirst%3DA.%2BC.%26aulast%3DHale%26aufirst%3DA.%2BE.%26aulast%3DDicheva%26aufirst%3DN.%26aulast%3DHerring%26aufirst%3DL.%2BE.%26aulast%3DGilbert%26aufirst%3DT.%2BS.%2BK.%26aulast%3DEast%26aufirst%3DM.%2BP.%26aulast%3DMcDonald%26aufirst%3DI.%2BM.%26aulast%3DLockett%26aufirst%3DM.%2BR.%26aulast%3DAshamalla%26aufirst%3DH.%26aulast%3DMoorman%26aufirst%3DN.%2BJ.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DIwanowicz%26aufirst%3DE.%2BJ.%26aulast%3DHolmuhamedov%26aufirst%3DE.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26atitle%3DMitochondrial%2520protease%2520ClpP%2520is%2520a%2520target%2520for%2520the%2520anticancer%2520compounds%2520ONC201%2520and%2520related%2520analogues%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D1020%26epage%3D1029%26doi%3D10.1021%2Facschembio.9b00222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span> <span> </span><span class="NLM_article-title">The proteasome: overview of structure and functions</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.2183/pjab.85.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2183%2Fpjab.85.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVyhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=12-36&author=K.+Tanaka&title=The+proteasome%3A+overview+of+structure+and+functions&doi=10.2183%2Fpjab.85.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: Overview of structure and functions</span></div><div class="casAuthors">Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-36</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  The proteasome is a highly sophisticated protease complex designed to carry out selective, efficient and processive hydrolysis of client proteins.  It is known to collaborate with ubiquitin, which polymerizes to form a marker for regulated proteolysis in eukaryotic cells.  The highly organized proteasome plays a prominent role in the control of a diverse array of basic cellular activities by rapidly and unidirectionally catalyzing biol. reactions.  Studies of the proteasome during the past quarter of a century have provided profound insights into its structure and functions, which has appreciably contributed to our understanding of cellular life.  Many questions, however, remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa5tUP87L9fLVg90H21EOLACvtfcHk0ligI2x6QdkZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVyhu7o%253D&md5=e88b6a3d37c1fef34cdf9dce1657e88a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2183%2Fpjab.85.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.85.12%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DThe%2520proteasome%253A%2520overview%2520of%2520structure%2520and%2520functions%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2009%26volume%3D85%26spage%3D12%26epage%3D36%26doi%3D10.2183%2Fpjab.85.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, Y.</span></span> <span> </span><span class="NLM_article-title">The proteasome: molecular machinery and pathophysiological roles</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1515/hsz-2011-0285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1515%2Fhsz-2011-0285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23029643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFyrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2012&pages=217-234&author=K.+Tanakaauthor=T.+Mizushimaauthor=Y.+Saeki&title=The+proteasome%3A+molecular+machinery+and+pathophysiological+roles&doi=10.1515%2Fhsz-2011-0285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: molecular machinery and pathophysiological roles</span></div><div class="casAuthors">Tanaka, Keiji; Mizushima, Tsunehiro; Saeki, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-234</span>CODEN:
                <span class="NLM_cas:coden">BICHF3</span>;
        ISSN:<span class="NLM_cas:issn">1431-6730</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">A review.  The 26S proteasome, in collaboration with ubiquitin, operates the energy-dependent regulated proteolysis process in eukaryotic cells.  Over the past 30 years, several studies have comprehensively characterized the structure and mol./physiol. functions of the 26S proteasome.  It is a sophisticated 2.5-MDa protein degrdn. machine comprising a proteolytic core particle (CP) and one or two terminal regulatory particle(s) (RP).  The CP consists of two outer α rings and two inner β rings, which are made up of seven structurally similar α and β subunits, resp.  The CP contains catalytic threonine residues (β1, β2, and β5; caspase-like, trypsin-like, and chymotrypsin-like activities, resp.) on the inner surface of the chamber formed by two abutting β rings.  Intriguingly, the immunotype proteasomes, named "immunoproteasome" and "thymoproteasome", whose catalytic subunits are replaced by the related counterparts, were discovered lately.  Both unique isoenzymes essentially contribute to the acquisition of adaptive immunity in vertebrates.  The RP, which serves to recognize polyubiquitylated substrate proteins and plays a role in their deubiquitylating, unfolding, and translocation into the interior of the CP for destruction, forms two subcomplexes: the base and the lid.  On another front, the PA28 and PA200, alternative CP activator proteins discovered biochem., both play independent roles in proteolysis of the 26S proteasome.  Several studies have highlighted the importance of the proteasome in various intractable diseases that have been increasing in the aged society of the 21st century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9jQRtA_v8LbVg90H21EOLACvtfcHk0ligI2x6QdkZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFyrsb8%253D&md5=ce2dac842b8a99205b517f660e26996e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1515%2Fhsz-2011-0285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhsz-2011-0285%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DMizushima%26aufirst%3DT.%26aulast%3DSaeki%26aufirst%3DY.%26atitle%3DThe%2520proteasome%253A%2520molecular%2520machinery%2520and%2520pathophysiological%2520roles%26jtitle%3DBiol.%2520Chem.%26date%3D2012%26volume%3D393%26spage%3D217%26epage%3D234%26doi%3D10.1515%2Fhsz-2011-0285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, L. D.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitor drugs</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010919-023603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1146%2Fannurev-pharmtox-010919-023603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=31479618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12qsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=457-476&author=L.+D.+Fricker&title=Proteasome+inhibitor+drugs&doi=10.1146%2Fannurev-pharmtox-010919-023603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibitor Drugs</span></div><div class="casAuthors">Fricker, Lloyd D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">457-476</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Proteasomes are large, multicatalytic protein complexes that cleave cellular proteins into peptides.  There are many distinct forms of proteasomes that differ in catalytically active subunits, regulatory subunits, and assocd. proteins.  Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and mantle cell lymphoma, and they are being investigated for other diseases.  Bortezomib (Velcade) was the first proteasome inhibitor to be approved by the US Food and Drug Administration.  Carfilzomib (Kyprolis) and ixazomib (Ninlaro) have recently been approved, and more drugs are in development.  While the primary mechanism of action is inhibition of the proteasome, the downstream events that lead to selective cell death are not entirely clear.  Proteasome inhibitors have been found to affect protein turnover but at concns. that are much higher than those achieved clin., raising the possibility that some of the effects of proteasome inhibitors are mediated by other mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlN6sX0x7nUrVg90H21EOLACvtfcHk0lito8QgbnSXCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12qsrbK&md5=4c1413b510396792ca6a62b2b36cfaa5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010919-023603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010919-023603%26sid%3Dliteratum%253Aachs%26aulast%3DFricker%26aufirst%3DL.%2BD.%26atitle%3DProteasome%2520inhibitor%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2020%26volume%3D60%26spage%3D457%26epage%3D476%26doi%3D10.1146%2Fannurev-pharmtox-010919-023603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandolfi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span> <span> </span><span class="NLM_article-title">The proteasome and proteasome inhibitors in multiple myeloma</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1007/s10555-017-9707-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs10555-017-9707-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29196868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWmu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=561-584&author=S.+Gandolfiauthor=J.+P.+Laubachauthor=T.+Hideshimaauthor=D.+Chauhanauthor=K.+C.+Andersonauthor=P.+G.+Richardson&title=The+proteasome+and+proteasome+inhibitors+in+multiple+myeloma&doi=10.1007%2Fs10555-017-9707-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome and proteasome inhibitors in multiple myeloma</span></div><div class="casAuthors">Gandolfi, Sara; Laubach, Jacob P.; Hideshima, Teru; Chauhan, Dharminder; Anderson, Kenneth C.; Richardson, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">561-584</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Proteasome inhibitors are one of the most important classes of agents to have emerged for the treatment of multiple myeloma in the past two decades, and now form one of the backbones of treatment.  Three agents in this class have been approved by the United States Food and Drug Administration-the first-in-class compd. bortezomib, the second-generation agent carfilzomib, and the first oral proteasome inhibitor, ixazomib.  The success of this class of agents is due to the exquisite sensitivity of myeloma cells to the inhibition of the 26S proteasome, which plays a crit. role in the pathogenesis and proliferation of the disease.  Proteasome inhibition results in multiple downstream effects, including the inhibition of NF-κB signaling, the accumulation of misfolded and unfolded proteins, resulting in endoplasmic reticulum stress and leading to the unfolded protein response, the downregulation of growth factor receptors, suppression of adhesion mol. expression, and inhibition of angiogenesis; resistance to proteasome inhibition may arise through cellular responses mediating these downstream effects.  These multiple biol. consequences of proteasome inhibition result in synergistic or additive activity with other chemotherapeutic and targeted agents for myeloma, and proteasome inhibitor-based combination regimens have become established as a cornerstone of therapy throughout the myeloma treatment algorithm, incorporating agents from the other key classes of antimyeloma agents, including the immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors.  This review gives an overview of the crit. role of the proteasome in myeloma and the characteristics of the different proteasome inhibitors and provides a comprehensive summary of key clin. efficacy and safety data with the currently approved proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3y59EW8PTy7Vg90H21EOLACvtfcHk0lito8QgbnSXCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWmu7nM&md5=9d2da9fe3c3571fb4c94c7a4886ddef3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs10555-017-9707-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-017-9707-8%26sid%3Dliteratum%253Aachs%26aulast%3DGandolfi%26aufirst%3DS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DThe%2520proteasome%2520and%2520proteasome%2520inhibitors%2520in%2520multiple%2520myeloma%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2017%26volume%3D36%26spage%3D561%26epage%3D584%26doi%3D10.1007%2Fs10555-017-9707-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borissenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">20S proteasome and its inhibitors: Crystallographic knowledge for drug development</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1021/cr0502504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0502504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=687-717&author=L.+Borissenkoauthor=M.+Groll&title=20S+proteasome+and+its+inhibitors%3A+Crystallographic+knowledge+for+drug+development&doi=10.1021%2Fcr0502504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development</span></div><div class="casAuthors">Borissenko, Ljudmila; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">687-717</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The aim of this review is to discuss the latest insights on the structure and function of the proteasome, highlighting the structural features that det. its activity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwElwBj8JBKrVg90H21EOLACvtfcHk0lito8QgbnSXCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D&md5=af2e998e5443f598a46ffef71118a119</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fcr0502504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0502504%26sid%3Dliteratum%253Aachs%26aulast%3DBorissenko%26aufirst%3DL.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3D20S%2520proteasome%2520and%2520its%2520inhibitors%253A%2520Crystallographic%2520knowledge%2520for%2520drug%2520development%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26spage%3D687%26epage%3D717%26doi%3D10.1021%2Fcr0502504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturegli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span> <span> </span><span class="NLM_article-title">New insights into the function of the immunoproteasome in immune and nonimmune cells</span>. <i>Journal of immunology research</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">541984</span>, <span class="refDoi"> DOI: 10.1155/2015/541984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1155%2F2015%2F541984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26636107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC28vnvFCgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=541984&author=H.+Kimuraauthor=P.+Caturegliauthor=M.+Takahashiauthor=K.+Suzuki&title=New+insights+into+the+function+of+the+immunoproteasome+in+immune+and+nonimmune+cells&doi=10.1155%2F2015%2F541984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells</span></div><div class="casAuthors">Kimura Hiroaki; Takahashi Masafumi; Caturegli Patrizio; Suzuki Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">541984</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The immunoproteasome is a highly efficient proteolytic machinery derived from the constitutive proteasome and is abundantly expressed in immune cells.  The immunoproteasome plays a critical role in the immune system because it degrades intracellular proteins, for example, those of viral origin, into small proteins.  They are further digested into short peptides to be presented by major histocompatibility complex (MHC) class I molecules.  In addition, the immunoproteasome influences inflammatory disease pathogenesis through its ability to regulate T cell polarization.  The immunoproteasome is also expressed in nonimmune cell types during inflammation or neoplastic transformation, supporting a role in the pathogenesis of autoimmune diseases and neoplasms.  Following the success of inhibitors of the constitutive proteasome, which is now an established treatment modality for multiple myeloma, compounds that selectively inhibit the immunoproteasome are currently under active investigation.  This paper will review the functions of the immunoproteasome, highlighting areas where novel pharmacological treatments that regulate immunoproteasome activity could be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0syW_7fxhz2LFM_lbR1VmfW6udTcc2eaEo__KnssWWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vnvFCgtw%253D%253D&md5=2908f35ddb6ce2386f1524c73c43d30f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1155%2F2015%2F541984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F541984%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DCaturegli%26aufirst%3DP.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DNew%2520insights%2520into%2520the%2520function%2520of%2520the%2520immunoproteasome%2520in%2520immune%2520and%2520nonimmune%2520cells%26jtitle%3DJournal%2520of%2520immunology%2520research%26date%3D2015%26volume%3D2015%26spage%3D541984%26doi%3D10.1155%2F2015%2F541984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Szanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K.</span></span> <span> </span><span class="NLM_article-title">Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2866</span>– <span class="NLM_lpage">2875</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1535-7163.MCT-08-0391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18790767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2866-2875&author=M.+Lioniauthor=K.+Nomaauthor=A.+Snyderauthor=A.+Klein-Szantoauthor=J.+Diehlauthor=A.+Rustgiauthor=M.+Herlynauthor=K.+Smalley&title=Bortezomib+induces+apoptosis+in+esophageal+squamous+cell+carcinoma+cells+through+activation+of+the+p38+mitogen-activated+protein+kinase+pathway&doi=10.1158%2F1535-7163.MCT-08-0391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway</span></div><div class="casAuthors">Lioni, Mercedes; Noma, Kazuhiro; Snyder, Andrew; Klein-Szanto, Andres; Diehl, J. Alan; Rustgi, Anil K.; Herlyn, Meenhard; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2866-2875</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Esophageal squamous cell carcinoma (ESCC) is an exceptionally drug-resistant tumor with a 5-yr survival rate <5%.  From an initial drug screen, we identified bortezomib as having robust activity in ESCC lines.  Mechanistically, bortezomib induced a G2-M-phase cell cycle arrest and p53-independent apoptosis assocd. with caspase cleavage and Noxa induction.  Bortezomib also showed excellent activity in organotypic culture and in vivo models of ESCC.  Biochem., bortezomib treatment activated the p38 and c-Jun NH2-terminal kinase stress-activated mitogen-activated protein kinase (MAPK) pathways and induced phospho-H2AX activity.  Although H2AX is known to cooperate with c-Jun NH2-terminal kinase to induce apoptosis following UV irradn., knockdown of H2AX did not abrogate bortezomib-induced apoptosis.  Instead, blockade of p38 MAPK signaling, using either small interfering RNA or a pharmacol. inhibitor, reversed bortezomib-induced apoptosis and the up-regulation of Noxa.  Radiation therapy is known to activate the p38 MAPK pathway and is a mainstay of ESCC treatment strategies.  In a final series of studies, we showed that the coadministration of bortezomib with irradn. led to enhanced p38 MAPK activity and a significant redn. in colony formation.  We therefore suggest that p38 MAPK pathway activation is an excellent potential therapeutic strategy in ESCC.  It is further suggested that bortezomib could be added to existing ESCC therapeutic regimens. [Mol Cancer Ther 2008;7(9):2866-75].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNLct8sjAx97Vg90H21EOLACvtfcHk0ljAba5bjPI5jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7fP&md5=91c2a0fec8ebe9b7ccf505e68228f485</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0391%26sid%3Dliteratum%253Aachs%26aulast%3DLioni%26aufirst%3DM.%26aulast%3DNoma%26aufirst%3DK.%26aulast%3DSnyder%26aufirst%3DA.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DDiehl%26aufirst%3DJ.%26aulast%3DRustgi%26aufirst%3DA.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DSmalley%26aufirst%3DK.%26atitle%3DBortezomib%2520induces%2520apoptosis%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%2520cells%2520through%2520activation%2520of%2520the%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2866%26epage%3D2875%26doi%3D10.1158%2F1535-7163.MCT-08-0391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy-Thandavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaddar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenlein, P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.4161/auto.6.1.10323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.4161%2Fauto.6.1.10323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20110775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslCqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=19-35&author=S.+Periyasamy-Thandavanauthor=W.+Jacksonauthor=J.+Samaddarauthor=B.+Ericksonauthor=J.+Barrettauthor=L.+Raneyauthor=E.+Gopalauthor=V.+Ganapathyauthor=W.+Hillauthor=K.+Bhallaauthor=P.+Schoenlein&title=Bortezomib+blocks+the+catabolic+process+of+autophagy+via+a+cathepsin-dependent+mechanism%2C+affects+endoplasmic+reticulum+stress+and+induces+caspase-dependent+cell+death+in+antiestrogen-sensitive+and+resistant+ER%2B+breast+cancer+cells&doi=10.4161%2Fauto.6.1.10323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells</span></div><div class="casAuthors">Periyasamy-Thandavan, Sudharsan; Jackson, William H.; Samaddar, Julia S.; Erickson, Brian; Barrett, John R.; Raney, Lauren; Gopal, Elangovan; Ganapathy, Vadivel; Hill, William D.; Bhalla, Kapil N.; Schoenlein, Patricia V.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-35</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">In recent studies, we and others showed that autophagy is crit. to estrogen receptor pos. (ER+) breast cancer cell survival and the development of antiestrogen resistance.  Consequently, new approaches are warranted for targeting autophagy in breast cancer cells undergoing antiestrogen therapy.  Because crosstalk has been demonstrated between the autophagy- and proteasome-mediated pathways of protein degrdn., this study investigated how the proteasome inhibitor bortezomib affects autophagy and cell survival in antiestrogen-treated ER+ breast cancer cells.  Bortezomib, at clin. achievable doses, induced a robust death response in ER+, antiestrogen-sensitive and antiestrogen-resistant breast cancer cells undergoing hormonal therapy.  Cleavage of PARP and lamin A was detectable as a read-out of cell death, following bortezomib-induced mitochondrial dysfunction.  Prior to induction of cell death, bortezomib-treated cells showed high levels of light chain 3 (LC3) and p62, two protein markers for autophagy.  The accumulation of these proteins was due to bortezomib-mediated blockade of long-lived protein turnover during macroautophagy.  This novel action of bortezomib was linked to its blockade of cathepsin-L activity, which is required for autolysosomal-mediated protein turnover in ER+ breast cancer cells.  Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CHOP and GRP78.  Bortezomib also induced high levels of the pro-apoptotic protein BNIP3.  Knockdown of CHOP and/or BNIP3 expression via RNAi targeting significantly attenuated the death-promoting effects of bortezomib.  Thus, bortezomib inhibits prosurvival autophagy, in addn. to its known function in blocking the proteasome, and is cytotoxic to hormonally treated ER+ breast cancer cells.  These findings indicate that combining a proteasome inhibitor like bortezomib with antiestrogen therapy may have therapeutic advantage in the management of early-stage breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ0op4wl9kLLVg90H21EOLACvtfcHk0ljAba5bjPI5jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslCqu7Y%253D&md5=98fb9a4a9685c593dcdc279f175dbf32</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4161%2Fauto.6.1.10323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.6.1.10323%26sid%3Dliteratum%253Aachs%26aulast%3DPeriyasamy-Thandavan%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DSamaddar%26aufirst%3DJ.%26aulast%3DErickson%26aufirst%3DB.%26aulast%3DBarrett%26aufirst%3DJ.%26aulast%3DRaney%26aufirst%3DL.%26aulast%3DGopal%26aufirst%3DE.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DHill%26aufirst%3DW.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DSchoenlein%26aufirst%3DP.%26atitle%3DBortezomib%2520blocks%2520the%2520catabolic%2520process%2520of%2520autophagy%2520via%2520a%2520cathepsin-dependent%2520mechanism%252C%2520affects%2520endoplasmic%2520reticulum%2520stress%2520and%2520induces%2520caspase-dependent%2520cell%2520death%2520in%2520antiestrogen-sensitive%2520and%2520resistant%2520ER%252B%2520breast%2520cancer%2520cells%26jtitle%3DAutophagy%26date%3D2010%26volume%3D6%26spage%3D19%26epage%3D35%26doi%3D10.4161%2Fauto.6.1.10323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velankar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuteboom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccr.2005.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16286248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=407-419&author=D.+Chauhanauthor=L.+Catleyauthor=G.+Liauthor=K.+Podarauthor=T.+Hideshimaauthor=M.+Velankarauthor=C.+Mitsiadesauthor=N.+Mitsiadesauthor=H.+Yasuiauthor=A.+Letaiauthor=H.+Ovaaauthor=C.+Berkersauthor=B.+Nicholsonauthor=T.+Chaoauthor=S.+Neuteboomauthor=P.+Richardsonauthor=M.+Palladinoauthor=K.+Anderson&title=A+novel+orally+active+proteasome+inhibitor+induces+apoptosis+in+multiple+myeloma+cells+with+mechanisms+distinct+from+Bortezomib&doi=10.1016%2Fj.ccr.2005.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib</span></div><div class="casAuthors">Chauhan, Dharminder; Catley, Laurence; Li, Guilan; Podar, Klaus; Hideshima, Teru; Velankar, Mugdha; Mitsiades, Constantine; Mitsiades, Nicolas; Yasui, Hiroshi; Letai, Anthony; Ovaa, Huib; Berkers, Celia; Nicholson, Benjamin; Chao, Ta-Hsiang; Neuteboom, Saskia T. C.; Richardson, Paul; Palladino, Michael A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); however, prolonged treatment is assocd. with toxicity and development of drug resistance.  Here, the authors show that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  NPI-0052 is distinct from bortezomib in its chem. structure, effects on proteasome activities, mechanisms of action, and toxicity profile against normal cells.  Moreover, NPI-0052 is orally bioactive.  In animal tumor model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumor recurrence.  Combining NPI-0052 and bortezomib induces synergistic anti-MM activity.  Our study therefore provides the rationale for clin. protocols evaluating NPI-0052, alone and together with bortezomib, to improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaYeiXJugULVg90H21EOLACvtfcHk0lhZYEo_MZEyyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF&md5=7bce23ea2891fe8863835c589294b213</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DVelankar%26aufirst%3DM.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBerkers%26aufirst%3DC.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DT.%26aulast%3DNeuteboom%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DA%2520novel%2520orally%2520active%2520proteasome%2520inhibitor%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520with%2520mechanisms%2520distinct%2520from%2520Bortezomib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D407%26epage%3D419%26doi%3D10.1016%2Fj.ccr.2005.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">The proteasome: a suitable antineoplastic target</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1038/nrc1361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrc1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15122206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=349-360&author=J.+Adams&title=The+proteasome%3A+a+suitable+antineoplastic+target&doi=10.1038%2Fnrc1361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: a suitable antineoplastic target</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-360</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The proteasome is an abundant multi-enzyme complex that provides the main pathway for degrdn. of intracellular proteins in eukaryotic cells.  As such, it controls the levels of proteins that are important for cell-cycle progression and apoptosis in normal and malignant cells; for example, cyclins, caspases, BCL2, and nuclear factor of κB.  A proteasome inhibitor - bortezomib - was developed that has shown efficacy as an anticancer agent in the clinic.  How can targeting such a universal, broadly active cellular component provide the selectivity and specificity that are required for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdI0j9dL6efrVg90H21EOLACvtfcHk0lhZYEo_MZEyyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D&md5=eeb2566e017e4aa1223b7bc8adb3b419</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1361%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520proteasome%253A%2520a%2520suitable%2520antineoplastic%2520target%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D349%26epage%3D360%26doi%3D10.1038%2Fnrc1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">The development of proteasome inhibitors as anticancer drugs</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(04)00120-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS1535-6108%2804%2900120-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15144949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=417-421&author=J.+Adams&title=The+development+of+proteasome+inhibitors+as+anticancer+drugs&doi=10.1016%2FS1535-6108%2804%2900120-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The development of proteasome inhibitors as anticancer drugs</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">417-421</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins.  Because these pathways are crit. for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy.  Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clin. trials.  Efficacy and safety results from a phase 2 clin. trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozXYZQ-zxJdbVg90H21EOLACvtfcHk0lgEXntY2zhaJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D&md5=9a070d342533a3b6108150c40852834e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900120-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900120-5%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520development%2520of%2520proteasome%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D417%26epage%3D421%26doi%3D10.1016%2FS1535-6108%2804%2900120-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, A. K.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2217</span>– <span class="NLM_lpage">2229</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2004.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejca.2004.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15454246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2004&pages=2217-2229&author=A.+M.+Burgerauthor=A.+K.+Seth&title=The+ubiquitin-mediated+protein+degradation+pathway+in+cancer%3A+Therapeutic+implications&doi=10.1016%2Fj.ejca.2004.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications</span></div><div class="casAuthors">Burger, Angelika M.; Seth, Arun K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2217-2229</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The highly conserved eukaryotic ubiquitin-proteasome system (UP-S) plays a pivotal role in protein homeostasis and is crit. in regulating normal and cancer-related cellular processes.  The hierarchical nature of the UP-S provides a rich source of mol. targets for specific intervention and has therefore arisen as a promising approach to innovative anticancer therapies.  The first in class proteasome inhibitory agent Bortezomib (Velcade) has recently obtained regulatory approval for the treatment of multiple myeloma.  Ubiquitin-mediated degrdn. is a complex process that is comprised of well defined steps involving ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s).  Although a single E1 activates the ubiquitin conjugation machinery, a large no. of E2 conjugating enzymes and E3 ligases are now known to exist.  Proteins tagged with ubiquitin are subsequently recognized by the proteasome for digestion and fragmentation.  The enzymic nature, multitude of E3s and their specific substrate recognition predestines them as therapeutic targets.  This article will review known inhibitors of the proteasome and their mol. mechanisms as well as ongoing developments and promising avenues for targeting substrate-specific E3 ligases that are likely to yield a new class of therapeutics that will serve and complement the armamentarium of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE8GHAAD6JRbVg90H21EOLACvtfcHk0lgEXntY2zhaJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFWltL8%253D&md5=8303c779002b441396ebc3cd4c77b711</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2004.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2004.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DSeth%26aufirst%3DA.%2BK.%26atitle%3DThe%2520ubiquitin-mediated%2520protein%2520degradation%2520pathway%2520in%2520cancer%253A%2520Therapeutic%2520implications%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2004%26volume%3D40%26spage%3D2217%26epage%3D2229%26doi%3D10.1016%2Fj.ejca.2004.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiziltepe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">5228</span>– <span class="NLM_lpage">5236</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-06-161505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1182%2Fblood-2008-06-161505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=19270264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslalu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=5228-5236&author=T.+Hideshimaauthor=D.+Chauhanauthor=T.+Kiziltepeauthor=H.+Ikedaauthor=Y.+Okawaauthor=K.+Podarauthor=N.+Rajeauthor=A.+Protopopovauthor=N.+C.+Munshiauthor=P.+G.+Richardsonauthor=R.+D.+Carrascoauthor=K.+C.+Anderson&title=Biologic+sequelae+of+I%7Bkappa%7DB+kinase+%28IKK%29+inhibition+in+multiple+myeloma%3A+therapeutic+implications&doi=10.1182%2Fblood-2008-06-161505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications</span></div><div class="casAuthors">Hideshima, Teru; Chauhan, Dharminder; Kiziltepe, Tanyel; Ikeda, Hiroshi; Okawa, Yutaka; Podar, Klaus; Raje, Noopur; Protopopov, Alexei; Munshi, Nikhil C.; Richardson, Paul G.; Carrasco, Ruben D.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5228-5236</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Nuclear factor-κB (NF-κB) has an important role in multiple myeloma (MM) cell pathogenesis in the context of the bone marrow (BM) microenvironment.  In NF-κB signaling cascades, IκB kinase α (IKKα) and IKKβ are key mols. that predominantly mediate noncanonical and canonical pathways, resp.  In this study, we examd. the biol. sequelae of the inhibition of IKKα vs. IKKβ in MM cell lines.  All MM cell lines have constitutive canonical NF-κB activity, and a subset of MM cell lines shows noncanonical NF-κB activity.  Adhesion to BM stromal cells further activates both canonical and noncanonical NF-κB activity.  IKKβ inhibitor MLN120B blocks canonical pathway and growth of MM cell lines but does not inhibit the noncanonical NF-κB pathway.  Although IKKα knockdown induces significant growth inhibition in the cell lines with both canonical and noncanonical pathways, it does not inhibit NF-κB activation.  Importantly, IKKα down-regulation decreases expression of β-catenin and aurora-A, which are known to mediate MM cell growth and survival.  Finally, IKKβ inhibitor enhances the growth inhibition triggered by IKKα down-regulation in MM cells with both canonical and noncanonical NF-κB activity.  Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEvXZgJQso1rVg90H21EOLACvtfcHk0lin29xIFzXJrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslalu78%253D&md5=4ab46ccabdf5852ee3a66eea1e5f6431</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-06-161505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-06-161505%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DProtopopov%26aufirst%3DA.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DBiologic%2520sequelae%2520of%2520I%257Bkappa%257DB%2520kinase%2520%2528IKK%2529%2520inhibition%2520in%2520multiple%2520myeloma%253A%2520therapeutic%2520implications%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D5228%26epage%3D5236%26doi%3D10.1182%2Fblood-2008-06-161505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manasanch, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitors in cancer therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrclinonc.2016.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28117417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=417-433&author=E.+E.+Manasanchauthor=R.+Z.+Orlowski&title=Proteasome+inhibitors+in+cancer+therapy&doi=10.1038%2Fnrclinonc.2016.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors in cancer therapy</span></div><div class="casAuthors">Manasanch, Elisabet E.; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degrdn. machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins.  Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit mechanisms of cell death.  This notion set the stage for preclin. testing of proteasome inhibitors as a means to shift this fine equil. towards cell death.  Since the late 1990s, clin. trials have been conducted for a variety of malignancies, leading to regulatory approvals of proteasome inhibitors to treat multiple myeloma and mantle-cell lymphoma.  First-generation and second-generation proteasome inhibitors can elicit deep initial responses in patients with myeloma, for whom these drugs have dramatically improved outcomes, but relapses are frequent and acquired resistance to treatment eventually emerges.  In addn., promising preclin. data obtained with proteasome inhibitors in models of solid tumors have not been confirmed in the clinic, indicating the importance of primary resistance.  Investigation of the mechanisms of resistance is, therefore, essential to further maximize the utility of this class of drugs in the era of personalized medicine.  Herein, we discuss the advances and challenges resulting from the introduction of proteasome inhibitors into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwd7_v_RFD8bVg90H21EOLACvtfcHk0lin29xIFzXJrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGlsbg%253D&md5=7246069f357a4cc9449f822c57767811</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.206%26sid%3Dliteratum%253Aachs%26aulast%3DManasanch%26aufirst%3DE.%2BE.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DProteasome%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D417%26epage%3D433%26doi%3D10.1038%2Fnrclinonc.2016.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciechanover, A.</span></span> <span> </span><span class="NLM_article-title">Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1159/000334283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1159%2F000334283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22327508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVOnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=7-22&author=A.+Ciechanover&title=Intracellular+protein+degradation%3A+from+a+vague+idea+through+the+lysosome+and+the+ubiquitin-proteasome+system+and+onto+human+diseases+and+drug+targeting&doi=10.1159%2F000334283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting</span></div><div class="casAuthors">Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">7-22</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Between the 1950s and 1980s, scientists were focusing mostly on how the genetic code was transcribed to RNA and translated to proteins, but how proteins were degraded had remained a neglected research area.  With the discovery of the lysosome by Christian de Duve it was assumed that cellular proteins are degraded within this organelle.  Yet, several independent lines of exptl. evidence strongly suggested that intracellular proteolysis was largely nonlysosomal, but the mechanisms involved have remained obscure.  The discovery of the ubiquitin-proteasome system resolved the enigma.  We now recognize that degrdn. of intracellular proteins is involved in the regulation of a broad array of cellular processes, such as cell cycle and division, regulation of transcription factors, and assurance of the cellular quality control.  Not surprisingly, aberrations in the system have been implicated in the pathogenesis of human disease, such as malignancies and neurodegenerative disorders, which subsequently led to an increasing effort to develop mechanism-based drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFok37A034LVg90H21EOLACvtfcHk0lin29xIFzXJrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVOnu7Y%253D&md5=6c9c3fd3fd2ece46f673d810569c0d16</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1159%2F000334283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000334283%26sid%3Dliteratum%253Aachs%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DIntracellular%2520protein%2520degradation%253A%2520from%2520a%2520vague%2520idea%2520through%2520the%2520lysosome%2520and%2520the%2520ubiquitin-proteasome%2520system%2520and%2520onto%2520human%2520diseases%2520and%2520drug%2520targeting%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2012%26volume%3D10%26spage%3D7%26epage%3D22%26doi%3D10.1159%2F000334283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1039/c3np20126k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1039%2Fc3np20126k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23575525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=600-604&author=K.+B.+Kimauthor=C.+M.+Crews&title=From+epoxomicin+to+carfilzomib%3A+chemistry%2C+biology%2C+and+medical+outcomes&doi=10.1039%2Fc3np20126k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span></div><div class="casAuthors">Kim, Kyung Bo; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">600-604</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: 1992 to 2012The initial enthusiasm following the discovery of a pharmacol. active natural product is often fleeting due to the poor prospects for its ultimate clin. application.  Despite this, the ever-changing landscape of modern biol. has a const. need for mol. probes that can aid in our understanding of biol. processes.  After its initial discovery by Bristol-Myers Squibb as a microbial anti-tumor natural product, epoxomicin was deemed unfit for development due to its peptide structure and potentially labile epoxyketone pharmacophore.  Despite its drawbacks, epoxomicin's pharmacophore was found to provide unprecedented selectivity for the proteasome.  Epoxomicin also served as a scaffold for the generation of a synthetic tetrapeptide epoxyketone with improved activity, YU-101, which became the parent lead compd. of carfilzomib (Kyprolis®), the recently approved therapeutic agent for multiple myeloma.  In this era of rational drug design and high-throughput screening, the prospects for turning an active natural product into an approved therapy are often slim.  However, by understanding the journey that began with the discovery of epoxomicin and ended with the successful use of carfilzomib in the clinic, we may find new insights into the keys for success in natural product-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ZmojYh4VybVg90H21EOLACvtfcHk0lin29xIFzXJrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D&md5=fa9d90ac327e5383f6d80512ecec8db4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2Fc3np20126k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np20126k%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DFrom%2520epoxomicin%2520to%2520carfilzomib%253A%2520chemistry%252C%2520biology%252C%2520and%2520medical%2520outcomes%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2013%26volume%3D30%26spage%3D600%26epage%3D604%26doi%3D10.1039%2Fc3np20126k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10900</span>, <span class="refDoi"> DOI: 10.1038/ncomms10900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fncomms10900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26964885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFGru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10900&author=E.+M.+Huberauthor=W.+Heinemeyerauthor=X.+Liauthor=C.+S.+Arendtauthor=M.+Hochstrasserauthor=M.+Groll&title=A+unified+mechanism+for+proteolysis+and+autocatalytic+activation+in+the+20S+proteasome&doi=10.1038%2Fncomms10900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome</span></div><div class="casAuthors">Huber, Eva M.; Heinemeyer, Wolfgang; Li, Xia; Arendt, Cassandra S.; Hochstrasser, Mark; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10900</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biogenesis of the 20S proteasome is tightly regulated.  The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly.  However, the trigger for the self-activation and the reason for the strict conservation of threonine as the active site nucleophile remain enigmatic.  Here we use mutagenesis, X-ray crystallog. and biochem. assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.  Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.  Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavorable orientation of Ser1 towards incoming substrates.  This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy1w69NIOuAbVg90H21EOLACvtfcHk0lg8OpfbIrl1Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFGru74%253D&md5=aa01e2449bf910aa488b50477bd6f0a3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fncomms10900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10900%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DArendt%26aufirst%3DC.%2BS.%26aulast%3DHochstrasser%26aufirst%3DM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DA%2520unified%2520mechanism%2520for%2520proteolysis%2520and%2520autocatalytic%2520activation%2520in%2520the%252020S%2520proteasome%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10900%26doi%3D10.1038%2Fncomms10900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">CCR 20th anniversary commentary: In the beginning, there was PS-341</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-14-2549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25733705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsF2iurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=939-941&author=B.+A.+Teicherauthor=K.+C.+Anderson&title=CCR+20th+anniversary+commentary%3A+In+the+beginning%2C+there+was+PS-341&doi=10.1158%2F1078-0432.CCR-14-2549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341</span></div><div class="casAuthors">Teicher, Beverly A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">939-941</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Proteasome inhibitors have a 20-yr history in cancer therapy.  The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003.  Clin. Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708).  Clin Cancer Res; 21(5); 939-41. cpr2015 AACR.  See related article by Teicher et al., Clin Cancer Res 1999;5(9) Sept. 1999;2638-45.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoInDXnaUN_FbVg90H21EOLACvtfcHk0lg8OpfbIrl1Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsF2iurk%253D&md5=ad2d2441f819a54925c7166d38443ffd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2549%26sid%3Dliteratum%253Aachs%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DCCR%252020th%2520anniversary%2520commentary%253A%2520In%2520the%2520beginning%252C%2520there%2520was%2520PS-341%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D939%26epage%3D941%26doi%3D10.1158%2F1078-0432.CCR-14-2549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the boronic acid-based proteasome inhibitor Bortezomib in complex with the yeast 20S proteasome</span>. <i>Structure (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/j.str.2005.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+structure+of+the+boronic+acid-based+proteasome+inhibitor+Bortezomib+in+complex+with+the+yeast+20S+proteasome&doi=10.1016%2Fj.str.2005.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lg8OpfbIrl1Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520boronic%2520acid-based%2520proteasome%2520inhibitor%2520Bortezomib%2520in%2520complex%2520with%2520the%2520yeast%252020S%2520proteasome%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456%26doi%3D10.1016%2Fj.str.2005.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlogie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srkalovic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limentani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of bortezomib in relapsed, refractory myeloma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">2609</span>– <span class="NLM_lpage">2617</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa030288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1056%2FNEJMoa030288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12826635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2609-2617&author=P.+Richardsonauthor=B.+Barlogieauthor=J.+Berensonauthor=S.+Singhalauthor=S.+Jagannathauthor=D.+Irwinauthor=S.+Rajkumarauthor=G.+Srkalovicauthor=M.+Alsinaauthor=R.+Alexanianauthor=D.+Siegelauthor=R.+Orlowskiauthor=D.+Kuterauthor=S.+Limentaniauthor=S.+Leeauthor=T.+Hideshimaauthor=D.+Esseltineauthor=M.+Kauffmanauthor=J.+Adamsauthor=D.+Schenkeinauthor=K.+Anderson&title=A+phase+2+study+of+bortezomib+in+relapsed%2C+refractory+myeloma&doi=10.1056%2FNEJMoa030288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of bortezomib in relapsed, refractory myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Barlogie, Bart; Berenson, James; Singhal, Seema; Jagannath, Sundar; Irwin, David; Rajkumar, S. Vincent; Srkalovic, Gordan; Alsina, Melissa; Alexanian, Raymond; Siegel, David; Orlowski, Robert Z.; Kuter, David; Limentani, Steven A.; Lee, Stephanie; Hideshima, Teru; Esseltine, Dixie-Lee; Kauffman, Michael; Adams, Julian; Schenkein, David P.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2609-2617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclin. and phase 1 studies to have antimyeloma activity.  Methods: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently.  Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 wk, followed by 1 wk without treatment, for up to eight cycles (24 wk).  In patients with a suboptimal response, oral dexamethasone (20 mg daily, on the day of and the day after bortezomib administration) was added to the regimen.  The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee.  Results: Of 193 patients who could be evaluated, 92 % had been treated with three or more of the major classes of agents for myeloma, and in 91 %, the myeloma was refractory to the therapy received most recently.  The rate of response to bortezomib was 35 %, and those with a response included 7 patients in whom myeloma protein became undetectable and 12 in whom myeloma protein was detectable only by immunofixation.  The median overall survival was 16 mo, with a median duration of response of 12 mo.  Grade 3 adverse events included thrombocytopenia (in 28 % of patients), fatigue (in 12 %), peripheral neuropathy (in 12 %), and neutropenia (in 11 %).  Grade 4 events occurred in 14 % of patients.  Conclusions: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvlvB12o1xbVg90H21EOLACvtfcHk0lixMMBU2JqqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D&md5=7d7ef72077f270a421a538557b3bf9ca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030288%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DBarlogie%26aufirst%3DB.%26aulast%3DBerenson%26aufirst%3DJ.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DRajkumar%26aufirst%3DS.%26aulast%3DSrkalovic%26aufirst%3DG.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlexanian%26aufirst%3DR.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DKuter%26aufirst%3DD.%26aulast%3DLimentani%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DKauffman%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DA%2520phase%25202%2520study%2520of%2520bortezomib%2520in%2520relapsed%252C%2520refractory%2520myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2609%26epage%3D2617%26doi%3D10.1056%2FNEJMoa030288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rechsteiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. P.</span></span> <span> </span><span class="NLM_article-title">Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2004.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.tcb.2004.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15653075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=27-33&author=M.+Rechsteinerauthor=C.+P.+Hill&title=Mobilizing+the+proteolytic+machine%3A+cell+biological+roles+of+proteasome+activators+and+inhibitors&doi=10.1016%2Fj.tcb.2004.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors</span></div><div class="casAuthors">Rechsteiner, Martin; Hill, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-33</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Proteasomes perform the majority of proteolysis that occurs in the cytosol and nucleus of eukaryotic cells and, thereby, perform crucial roles in cellular regulation and homeostasis.  Isolated proteasomes are inactive because substrates cannot access the proteolytic sites.  PA28 and PA200 are activators that bind to proteasomes and stimulate the hydrolysis of peptides.  Several protein inhibitors of the proteasome have also been identified, and the properties of these activators and inhibitors have been characterized biochem.  By contrast, their physiol. roles, which have been reported to include prodn. of antigenic peptides, proteasome assembly and DNA repair, are controversial.  In this article, we briefly review the biochem. data and discuss the possible biol. roles of PA28, PA200 and proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg9BxR7OGV5LVg90H21EOLACvtfcHk0lixMMBU2JqqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOrtw%253D%253D&md5=e6abdf92be6c0860cb852f98e3dcc81c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DRechsteiner%26aufirst%3DM.%26aulast%3DHill%26aufirst%3DC.%2BP.%26atitle%3DMobilizing%2520the%2520proteolytic%2520machine%253A%2520cell%2520biological%2520roles%2520of%2520proteasome%2520activators%2520and%2520inhibitors%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D27%26epage%3D33%26doi%3D10.1016%2Fj.tcb.2004.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Ixazomib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0548-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs40265-016-0548-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26846321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=405-411&author=M.+Shirley&title=Ixazomib%3A+first+global+approval&doi=10.1007%2Fs40265-016-0548-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ixazomib: First Global Approval</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ixazomib (Ninlaro) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now Takeda Oncol.).  Ixazomib acts by binding to and inhibiting the β5 subunit of the 20S proteasome.  In Nov. 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.  Ixazomib is under regulatory review for this indication in the EU.  Phase III development of ixazomib is underway worldwide for newly-diagnosed multiple myeloma (in patients who are not eligible for stem cell transplant, or as maintenance therapy) and for relapsed or refractory systemic light chain (AL) amyloidosis.  Ixazomib is also under phase I-II development for the treatment of several other haematol. and non-haematol. malignancies, graft-vs.-host disease and lupus nephritis.  This article summarizes the milestones in the development of ixazomib leading to this first approval for multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMK0Ud8_wMNrVg90H21EOLACvtfcHk0lixMMBU2JqqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D&md5=a31e66cf68dce72be96fe8e8843919ac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0548-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0548-5%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DIxazomib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D405%26epage%3D411%26doi%3D10.1007%2Fs40265-016-0548-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kupperman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-09-2766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20160034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1970-1980&author=E.+Kuppermanauthor=E.+Leeauthor=Y.+Caoauthor=B.+Bannermanauthor=M.+Fitzgeraldauthor=A.+Bergerauthor=J.+Yuauthor=Y.+Yangauthor=P.+Halesauthor=F.+Bruzzeseauthor=J.+Liuauthor=J.+Blankauthor=K.+Garciaauthor=C.+Tsuauthor=L.+Dickauthor=P.+Flemingauthor=L.+Yuauthor=M.+Manfrediauthor=M.+Rolfeauthor=J.+Bolen&title=Evaluation+of+the+proteasome+inhibitor+MLN9708+in+preclinical+models+of+human+cancer&doi=10.1158%2F0008-5472.CAN-09-2766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span></div><div class="casAuthors">Kupperman, Erik; Lee, Edmund C.; Cao, Yueying; Bannerman, Bret; Fitzgerald, Michael; Berger, Allison; Yu, Jie; Yang, Yu; Bruzzese, Frank; Liu, Jane; Blank, Jonathan; Garcia, Khristofer; Tsu, Christopher; Dick, Larry; Fleming, Paul; Yu, Li; Manfredi, Mark; Rolfe, Mark; Bolen, Joe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1970-1980</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The proteasome was validated as an oncol. target following the clin. success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma.  Consequently, several groups are pursuing the development of addnl. small-mol. proteasome inhibitors for both hematol. and solid tumor indications.  Here, we describe MLN9708, a selective, orally bioavailable, second-generation proteasome inhibitor that is in phase I clin. development.  MLN9708 has a shorter proteasome dissocn. half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  MLN9708 has a larger blood vol. distribution at steady state, and anal. of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib.  MLN9708 showed activity in both solid tumor and hematol. preclin. xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity.  Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage.  Taken together, these data support the clin. development of MLN9708 for both hematol. and solid tumor indications.  Cancer Res; 70(5); 1970-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjauqAFEgDA7Vg90H21EOLACvtfcHk0lhq_JA2twA_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D&md5=45636404582fc0eb66581c6c19420458</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2766%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DBannerman%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520proteasome%2520inhibitor%2520MLN9708%2520in%2520preclinical%2520models%2520of%2520human%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1970%26epage%3D1980%26doi%3D10.1158%2F0008-5472.CAN-09-2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbiera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurlbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassnacht, M.</span></span> <span> </span><span class="NLM_article-title">Drug synergism of proteasome inhibitors and mitotane by complementary activation of ER Stress in adrenocortical carcinoma cells</span>. <i>Horm. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1007/s12672-016-0273-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs12672-016-0273-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27631436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSgtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=345-355&author=M.+Kroissauthor=S.+Sbieraauthor=S.+Kendlauthor=M.+Kurlbaumauthor=M.+Fassnacht&title=Drug+synergism+of+proteasome+inhibitors+and+mitotane+by+complementary+activation+of+ER+Stress+in+adrenocortical+carcinoma+cells&doi=10.1007%2Fs12672-016-0273-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells</span></div><div class="casAuthors">Kroiss, Matthias; Sbiera, Silviu; Kendl, Sabine; Kurlbaum, Max; Fassnacht, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Hormones & Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">345-355</span>CODEN:
                <span class="NLM_cas:coden">HCOABS</span>;
        ISSN:<span class="NLM_cas:issn">1868-8497</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clin. used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids.  Since mitotane has limited clin. activity as monotherapy, we here study the potential of activating ER-stress through alternative pathways.  The single reliable NCI-H295 cell culture model for ACC was used to study the impact MG132, bortezomib (BTZ) and carfilzomib (CFZ) on mRNA and protein expression of ER-stress markers, cell viability and steroid hormone secretion.  We found all proteasome inhibitors alone to trigger expression of mRNA (spliced X-box protein 1, XBP1) and protein markers indicative of the inositol-requiring enzyme 1 (IRE1) dependent pathway of ER-stress but not phosphorylation of eukaryotic initiation factor 2α (eIF2α), a marker of the PRKR-like endoplasmic reticulum kinase (PERK)-dependent pathway.  Whereas mitotane alone activated both pathways, combination of BTZ and CFZ with low-dose mitotane blocked mitotane-induced eIF2α phosphorylation but increased XBP1-mRNA splicing indicating that proteasome inhibitors can commit signalling towards a single ER-stress pathway in ACC cells.  By applying the median effect model of drug combinations using cell viability as a read out, we detd. significant drug synergism between mitotane and both BTZ and CFZ.  In conclusion, combination of mitotane with activators of ER-stress through the unfolded protein response is synergistic in an ACC cell culture model.  Since proteasome inhibitors are readily available clin., they are attractive candidates to study for ACC treatment in clin. trials in combination with mitotane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPLhlU503cLVg90H21EOLACvtfcHk0lhq_JA2twA_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSgtbvO&md5=b4db6d47e008073c5e9f05da0860acc1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs12672-016-0273-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12672-016-0273-2%26sid%3Dliteratum%253Aachs%26aulast%3DKroiss%26aufirst%3DM.%26aulast%3DSbiera%26aufirst%3DS.%26aulast%3DKendl%26aufirst%3DS.%26aulast%3DKurlbaum%26aufirst%3DM.%26aulast%3DFassnacht%26aufirst%3DM.%26atitle%3DDrug%2520synergism%2520of%2520proteasome%2520inhibitors%2520and%2520mitotane%2520by%2520complementary%2520activation%2520of%2520ER%2520Stress%2520in%2520adrenocortical%2520carcinoma%2520cells%26jtitle%3DHorm.%2520Cancer%26date%3D2016%26volume%3D7%26spage%3D345%26epage%3D355%26doi%3D10.1007%2Fs12672-016-0273-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallerani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberasco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cereda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span> <span> </span><span class="NLM_article-title">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2012.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejca.2012.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23058787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=290-296&author=E.+Galleraniauthor=M.+Zucchettiauthor=D.+Brunelliauthor=E.+Marangonauthor=C.+Noberascoauthor=D.+Hessauthor=A.+Delmonteauthor=G.+Martinelliauthor=S.+B%C3%B6hmauthor=C.+Driessenauthor=F.+De+Braudauthor=S.+Marsoniauthor=R.+Ceredaauthor=F.+Salaauthor=M.+D%E2%80%99Incalciauthor=C.+Sessa&title=A+first+in+human+phase+I+study+of+the+proteasome+inhibitor+CEP-18770+in+patients+with+advanced+solid+tumours+and+multiple+myeloma&doi=10.1016%2Fj.ejca.2012.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span></div><div class="casAuthors">Gallerani, Elisa; Zucchetti, Massimo; Brunelli, Dario; Marangon, Elena; Noberasco, Cristina; Hess, Dagmar; Delmonte, Angelo; Martinelli, Giovanni; Bohm, Steffen; Driessen, Christopher; De Braud, Filippo; Marsoni, Silvia; Cereda, Roberta; Sala, Federica; D'Incalci, Maurizio; Sessa, Cristiana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">290-296</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The safety, pharmacokinetics (PK) and pharmacodynamics of CEP-18770, a new peptide boronic acid proteasome inhibitor, have been investigated after i.v. administration on days 1, 4, 8 and 11 of every 21 d cycle in patients with solid tumors and multiple myeloma (MM).Thirty-eight patients were treated with CEP-18770 at escalating doses from 0.1 to 1.8 mg/m2 where 2 out of 5 patients showed dose limiting toxicities.  The max. tolerated/recommended dose (MTD/RD) of 1.5 mg/m2 was tested in 12 addnl. patients.  Skin rash was dose-limiting and occurred in 53% of patients; other frequent toxicities were asthenia (29%), stomatitis (21%) and pyrexia (16%).  No significant peripheral neuropathy was obsd.  PK in plasma was linear with a half-life of the elimination phase of 62.0 ± 43.5 h.  Proteasome inhibition in peripheral blood mononuclear cells was dose related in MM patients; it was of 45.4 ± 11.5% at the RD.CEP-18770 showed a favorable safety profile with lack of neurotoxicity and linear plasma PK.  The definition of the optimal biol. dose and schedule of treatment is actively pursued because of the high incidence of skin toxicity of the twice a week schedule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI8KtW1FW2LrVg90H21EOLACvtfcHk0lhq_JA2twA_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK&md5=29f393ac09aebfb7c0a4758fc9436af7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2012.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2012.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DGallerani%26aufirst%3DE.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DBrunelli%26aufirst%3DD.%26aulast%3DMarangon%26aufirst%3DE.%26aulast%3DNoberasco%26aufirst%3DC.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DB%25C3%25B6hm%26aufirst%3DS.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DMarsoni%26aufirst%3DS.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DSala%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DA%2520first%2520in%2520human%2520phase%2520I%2520study%2520of%2520the%2520proteasome%2520inhibitor%2520CEP-18770%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%2520and%2520multiple%2520myeloma%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D290%26epage%3D296%26doi%3D10.1016%2Fj.ejca.2012.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernareggi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassarà, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arasmo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Munari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allievi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strepponi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallamo, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1072</span>, <span class="refDoi"> DOI: 10.1021/jm7010589</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7010589" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1068-1072&author=B.+D.+Dorseyauthor=M.+Iqbalauthor=S.+Chatterjeeauthor=E.+Mentaauthor=R.+Bernardiniauthor=A.+Bernareggiauthor=P.+G.+Cassar%C3%A0author=G.+D%E2%80%99Arasmoauthor=E.+Ferrettiauthor=S.+De+Munariauthor=A.+Olivaauthor=G.+Pezzoniauthor=C.+Allieviauthor=I.+Strepponiauthor=B.+Ruggeriauthor=M.+A.+Atorauthor=M.+Williamsauthor=J.+P.+Mallamo&title=Discovery+of+a+potent%2C+selective%2C+and+orally+active+proteasome+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm7010589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Dorsey, Bruce D.; Iqbal, Mohamed; Chatterjee, Sankar; Menta, Ernesto; Bernardini, Raffaella; Bernareggi, Alberto; Cassara, Paolo G.; D'Arasmo, Germano; Ferretti, Edmondo; De Munari, Sergio; Oliva, Ambrogio; Pezzoni, Gabriella; Allievi, Cecilia; Strepponi, Ivan; Ruggeri, Bruce; Ator, Mark A.; Williams, Michael; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1068-1072</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome pathway plays a central role in regulation of the prodn. and destruction of cellular proteins.  These pathways mediate proliferation and cell survival, particularly in malignant cells.  The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy.  Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclin. development, [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid 20 (CEP-18770), is disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkNeu3d81vbVg90H21EOLACvtfcHk0ljXo9ozsrmuXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D&md5=cfc22ee09c2a4f4d9c695010187c4693</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm7010589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010589%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DMenta%26aufirst%3DE.%26aulast%3DBernardini%26aufirst%3DR.%26aulast%3DBernareggi%26aufirst%3DA.%26aulast%3DCassar%25C3%25A0%26aufirst%3DP.%2BG.%26aulast%3DD%25E2%2580%2599Arasmo%26aufirst%3DG.%26aulast%3DFerretti%26aufirst%3DE.%26aulast%3DDe%2BMunari%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DA.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DAllievi%26aufirst%3DC.%26aulast%3DStrepponi%26aufirst%3DI.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520proteasome%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1068%26epage%3D1072%26doi%3D10.1021%2Fjm7010589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harshbarger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human 20S proteasome in complex with carfilzomib</span>. <i>Structure (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.str.2014.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25599644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=418-424&author=W.+Harshbargerauthor=C.+Millerauthor=C.+Diedrichauthor=J.+Sacchettini&title=Crystal+structure+of+the+human+20S+proteasome+in+complex+with+carfilzomib&doi=10.1016%2Fj.str.2014.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib</span></div><div class="casAuthors">Harshbarger, Wayne; Miller, Chase; Diedrich, Chandler; Sacchettini, James</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, resp.  Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites.  Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes.  In addn., comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes.  Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQfIgWQjhexbVg90H21EOLACvtfcHk0lgupFq9M0qKpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D&md5=0249966770dad6c25b7844fb1cea59b1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DHarshbarger%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DDiedrich%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%252020S%2520proteasome%2520in%2520complex%2520with%2520carfilzomib%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D23%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.str.2014.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delforge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparetto, C.</span></span> <span> </span><span class="NLM_article-title">Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1872</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1263842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1080%2F10428194.2016.1263842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28140719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1872-1879&author=D.+Voglauthor=T.+Martinauthor=R.+Vijauthor=P.+Hariauthor=J.+Mikhaelauthor=D.+Siegelauthor=K.+Wuauthor=M.+Delforgeauthor=C.+Gasparetto&title=Phase+I%2FII+study+of+the+novel+proteasome+inhibitor+delanzomib+%28CEP-18770%29+for+relapsed+and+refractory+multiple+myeloma&doi=10.1080%2F10428194.2016.1263842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma</span></div><div class="casAuthors">Vogl, Dan T.; Martin, Thomas G.; Vij, Ravi; Hari, Parameswaran; Mikhael, Joseph R.; Siegel, David; Wu, Ka Lung; Delforge, Michel; Gasparetto, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1872-1879</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Delanzomib (CEP-18770), a reversible P2 threonine boronic acid proteasome (β5/β1 subunits) inhibitor that showed promising anti-myeloma effects in preclin. studies, was investigated in a single-agent multicenter phase I/II study in patients with relapsed/refractory myeloma.  Sixty-one patients (17 during dose escalation; 44 in the expansion cohort) received delanzomib on days 1, 8, and 15 in 28-d cycles; 47 received the max. tolerated dose (MTD), 2.1 mg/m2.  Dose-limiting toxicities (DLTs) at 2.4 mg/m2 were rash and thrombocytopenia.  At the MTD, the most prominent adverse events were nausea, vomiting, anorexia, fatigue, and pyrexia; grade 3/4 thrombocytopenia and neutropenia occurred in 53 and 23% of patients, resp.  Peripheral neuropathy (21%) was limited to grades 1/2.  At the MTD, 26 patients (55%) had stable disease and four (9%) had a partial response (PR).  Median time to progression (TTP) was 2.5 mo across the cohort.  Based upon the efficacy results, development of delanzomib for myeloma was discontinued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrogIPOb5BLBLVg90H21EOLACvtfcHk0lgupFq9M0qKpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gt7k%253D&md5=a1abbcc8ecd992e0e63256302d6d3eb1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1263842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1263842%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DMikhael%26aufirst%3DJ.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DDelforge%26aufirst%3DM.%26aulast%3DGasparetto%26aufirst%3DC.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520the%2520novel%2520proteasome%2520inhibitor%2520delanzomib%2520%2528CEP-18770%2529%2520for%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1872%26epage%3D1879%26doi%3D10.1080%2F10428194.2016.1263842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harshbarger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human 20S proteasome in complex with carfilzomib</span>. <i>Structure (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.str.2014.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25599644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=418-424&author=W.+Harshbargerauthor=C.+Millerauthor=C.+Diedrichauthor=J.+Sacchettini&title=Crystal+structure+of+the+human+20S+proteasome+in+complex+with+carfilzomib&doi=10.1016%2Fj.str.2014.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib</span></div><div class="casAuthors">Harshbarger, Wayne; Miller, Chase; Diedrich, Chandler; Sacchettini, James</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, resp.  Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites.  Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes.  In addn., comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes.  Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQfIgWQjhexbVg90H21EOLACvtfcHk0lgupFq9M0qKpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D&md5=0249966770dad6c25b7844fb1cea59b1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DHarshbarger%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DDiedrich%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%252020S%2520proteasome%2520in%2520complex%2520with%2520carfilzomib%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D23%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.str.2014.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comenzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molineaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span> <span> </span><span class="NLM_article-title">A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4830</span>– <span class="NLM_lpage">4840</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-11-3007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22761464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4830-4840&author=M.+Alsinaauthor=S.+Trudelauthor=R.+Furmanauthor=P.+Rosenauthor=O.+O%E2%80%99Connorauthor=R.+Comenzoauthor=A.+Wongauthor=L.+Kunkelauthor=C.+Molineauxauthor=A.+Goy&title=A+phase+I+single-agent+study+of+twice-weekly+consecutive-day+dosing+of+the+proteasome+inhibitor+carfilzomib+in+patients+with+relapsed+or+refractory+multiple+myeloma+or+lymphoma&doi=10.1158%2F1078-0432.CCR-11-3007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma</span></div><div class="casAuthors">Alsina, Melissa; Trudel, Suzanne; Furman, Richard R.; Rosen, Peter J.; O'Connor, Owen A.; Comenzo, Raymond L.; Wong, Alvin; Kunkel, Lori A.; Molineaux, Christopher J.; Goy, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4830-4840</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Carfilzomib is a next-generation, selective, proteasome inhibitor with clin. activity in relapsed and/or refractory multiple myeloma.  The objectives of this phase I study were to establish the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of escalating doses of carfilzomib in patients with relapsed or refractory hematol. malignancies.  Exptl. design: Carfilzomib (doses ranging from 1.2-27 mg/m2) was administered i.v. on 2 consecutive days for 3 wk of a 4-wk cycle.  Single-agent dose escalation (n = 37) was followed by a dose-expansion phase (n = 11) that comprised 2 cohorts (carfilzomib or carfilzomib + dexamethasone).  During dose expansion, carfilzomib was administered starting with 20 mg/m2 during the first week (days 1, 2) and then escalated to 27 mg/m2 thereafter.  Results: A max. tolerated dose (MTD) was not reached during dose escalation.  Dosing in the expansion cohort was well tolerated.  Adverse events were manageable and primarily of grade I or II.  The main hematol. adverse events of ≥ grade III were anemia and thrombocytopenia.  Notably, there were no observations of grade III or more peripheral neuropathy.  Carfilzomib was cleared rapidly with an elimination half-life of less than 30 min but still induced dose-dependent inhibition of the 20S chymotrypsin-like proteasome activity.  At doses of 15 to 27 mg/m2, there was evidence of activity among patients with multiple myeloma and with non-Hodgkin lymphoma.  Conclusions: Escalated dosing of carfilzomib on a schedule of 2 consecutive days for 3 wk of a 4-wk cycle was tolerable and showed promising activity.  This dose regimen has been selected for ongoing and future clin. studies, including PX-171-003A1 and the pivotal trial ASPIRE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_a1xG-rD-LVg90H21EOLACvtfcHk0lgEGYmcVsSdBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzE&md5=cb6a2086f5c90d9af01fb71884004762</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3007%26sid%3Dliteratum%253Aachs%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%26aulast%3DComenzo%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DKunkel%26aufirst%3DL.%26aulast%3DMolineaux%26aufirst%3DC.%26aulast%3DGoy%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%2520single-agent%2520study%2520of%2520twice-weekly%2520consecutive-day%2520dosing%2520of%2520the%2520proteasome%2520inhibitor%2520carfilzomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%2520or%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4830%26epage%3D4840%26doi%3D10.1158%2F1078-0432.CCR-11-3007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elofsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">10403</span>– <span class="NLM_lpage">10408</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.18.10403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1073%2Fpnas.96.18.10403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10468620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10403-10408&author=L.+Mengauthor=R.+Mohanauthor=B.+Kwokauthor=M.+Elofssonauthor=N.+Sinauthor=C.+Crews&title=Epoxomicin%2C+a+potent+and+selective+proteasome+inhibitor%2C+exhibits+in+vivo+antiinflammatory+activity&doi=10.1073%2Fpnas.96.18.10403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span></div><div class="casAuthors">Meng, Lihao; Mohan, Royce; Kwok, Benjamin H. B.; Elofsson, Mikael; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10403-10408</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The proteasome (multicatalytic protease) regulates cellular processes as diverse as cell cycle progression and NF-κB activation.  The potent antitumor natural product epoxomicin specifically targets the proteasome.  Using biotinylated epoxomicin as a mol. probe showed that epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome.  Enzymic analyses with purified bovine erythrocyte proteasome revealed that epoxomicin potently inhibited primarily the chymotrypsin-like activity.  The trypsin-like and peptidyl-glutamyl peptide hydrolyzing catalytic activities were also inhibited at 100- and 1000-fold slower rates, resp.  In contrast to peptide aldehyde proteasome inhibitors, epoxomicin did not inhibit the nonproteasomal proteases, such as trypsin, chymotrypsin, papain, calpain, and cathepsin B, at concns. up to 50 μM.  Epoxomicin was a more potent inhibitor of the chymotrypsin-like activity than lactacystin and the peptide vinyl sulfone NLVS.  Epoxomicin also effectively inhibited the NF-κB activation in vitro and potently blocked the in vivo inflammation in the murine ear edema assay.  The results define epoxomicin as a novel proteasome inhibitor that may be useful in exploring the role of proteasome in various in vivo and in vitro systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXsPAKuQJ_LVg90H21EOLACvtfcHk0lgEGYmcVsSdBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D&md5=df0b5cdcccf546d60dc4e01d885d554b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.10403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.10403%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKwok%26aufirst%3DB.%26aulast%3DElofsson%26aufirst%3DM.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DEpoxomicin%252C%2520a%2520potent%2520and%2520selective%2520proteasome%2520inhibitor%252C%2520exhibits%2520in%2520vivo%2520antiinflammatory%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D10403%26epage%3D10408%26doi%3D10.1073%2Fpnas.96.18.10403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strader, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanan-Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3281</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-01-065888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1182%2Fblood-2007-01-065888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17591945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yqur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3281-3290&author=D.+J.+Kuhnauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=J.+S.+Straderauthor=K.+D.+Shenkauthor=C.+M.+Sunauthor=S.+D.+Demoauthor=M.+K.+Bennettauthor=F.+W.+van+Leeuwenauthor=A.+A.+Chanan-Khanauthor=R.+Z.+Orlowski&title=Potent+activity+of+carfilzomib%2C+a+novel%2C+irreversible+inhibitor+of+the+ubiquitin-proteasome+pathway%2C+against+preclinical+models+of+multiple+myeloma&doi=10.1182%2Fblood-2007-01-065888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</span></div><div class="casAuthors">Kuhn, Deborah J.; Chen, Qing; Voorhees, Peter M.; Strader, John S.; Shenk, Kevin D.; Sun, Congcong M.; Demo, Susan D.; Bennett, Mark K.; van Leeuwen, Fijs W. B.; Chanan-Khan, Asher A.; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3281-3290</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a 1st-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM).  However, many patients have disease that does not respond to bortezomib, whereas others develop resistance, suggesting the need for other inhibitors with enhanced activity.  We therefore evaluated a novel, irreversible, epoxomicin-related proteasome inhibitor, carfilzomib.  In models of MM, this agent potently bound and specifically inhibited the chymotrypsin-like proteasome and immunoproteasome activities, resulting in accumulation of ubiquitinated substrates.  Carfilzomib induced a dose- and time-dependent inhibition of proliferation, ultimately leading to apoptosis.  Programmed cell death was assocd. with activation of c-Jun-N-terminal kinase, mitochondrial membrane depolarization, release of cytochrome c, and activation of both intrinsic and extrinsic caspase pathways.  This agent also inhibited proliferation and activated apoptosis in patient-derived MM cells and neoplastic cells from patients with other hematol. malignancies.  Importantly, carfilzomib showed increased efficacy compared with bortezomib and was active against bortezomib-resistant MM cell lines and samples from patients with clin. bortezomib resistance.  Carfilzomib also overcame resistance to other conventional agents and acted synergistically with dexamethasone to enhance cell death.  Taken together, these data provide a rationale for the clin. evaluation of carfilzomib in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96EI0UpzMFrVg90H21EOLACvtfcHk0lgEGYmcVsSdBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yqur3L&md5=e8b3c1eff57c7613bebb921bdef8f87d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-01-065888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-01-065888%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DStrader%26aufirst%3DJ.%2BS.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DPotent%2520activity%2520of%2520carfilzomib%252C%2520a%2520novel%252C%2520irreversible%2520inhibitor%2520of%2520the%2520ubiquitin-proteasome%2520pathway%252C%2520against%2520preclinical%2520models%2520of%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3281%26epage%3D3290%26doi%3D10.1182%2Fblood-2007-01-065888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roschewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manasanch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tageja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazandjian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailankody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulquin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuchlinski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamping, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounden, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braylan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdziel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choyke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landgren, O.</span></span> <span> </span><span class="NLM_article-title">Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma</span>. <i>JAMA oncology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1001%2Fjamaoncol.2015.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26181891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=746-754&author=N.+Kordeauthor=M.+Roschewskiauthor=A.+Zingoneauthor=M.+Kwokauthor=E.+Manasanchauthor=M.+Bhutaniauthor=N.+Tagejaauthor=D.+Kazandjianauthor=S.+Mailankodyauthor=P.+Wuauthor=C.+Morrisonauthor=R.+Costelloauthor=Y.+Zhangauthor=D.+Burtonauthor=M.+Mulquinauthor=D.+Zuchlinskiauthor=L.+Lampingauthor=A.+Carpenterauthor=Y.+Wallauthor=G.+Carterauthor=S.+Cunninghamauthor=V.+Goundenauthor=T.+Sissungauthor=C.+Peerauthor=I.+Maricauthor=K.+Calvoauthor=R.+Braylanauthor=C.+Yuanauthor=M.+Stetler-Stevensonauthor=D.+Arthurauthor=K.+Kongauthor=L.+Wengauthor=M.+Fahamauthor=L.+Lindenbergauthor=K.+Kurdzielauthor=P.+Choykeauthor=S.+Steinbergauthor=W.+Figgauthor=O.+Landgren&title=Treatment+with+carfilzomib-lenalidomide-dexamethasone+with+lenalidomide+extension+in+patients+with+smoldering+or+newly+diagnosed+multiple+myeloma&doi=10.1001%2Fjamaoncol.2015.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma</span></div><div class="casAuthors">Korde Neha; Landgren Ola; Roschewski Mark; Zingone Adriana; Kwok Mary; Kazandjian Dickran; Wu Peter; Morrison Candis; Costello Rene; Zhang Yong; Burton Debra; Mulquin Marcia; Zuchlinski Diamond; Lamping Liz; Carpenter Ashley; Wall Yvonne; Carter George; Cunningham Schuyler C; Manasanch Elisabet E; Bhutani Manisha; Tageja Nishant; Mailankody Sham; Gounden Verena; Maric Irina; Calvo Katherine R; Braylan Raul; Sissung Tristan M; Peer Cody; Figg William; Yuan Constance; Stetler-Stevenson Maryalice; Arthur Diane C; Kong Katherine A; Weng Li; Faham Malek; Lindenberg Liza; Kurdziel Karen; Choyke Peter; Steinberg Seth M</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">746-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM).  It is important to gain an understanding of this combination's tolerability and impact on minimal residual disease (MRD) negativity because this end point has been associated with improved survival.  OBJECTIVE:  To assess the safety and efficacy of carfilzomib-lenalidomide-dexamethasone therapy in NDMM and high-risk smoldering multiple myeloma (SMM).  DESIGN, SETTING, AND PARTICIPANTS:  Clinical and correlative pilot study at the National Institutes of Health Clinical Center.  Patients with NDMM or high-risk SMM were enrolled between July 11, 2011, and October 9, 2013.  Median follow-up was 17.3 (NDMM) and 15.9 months (SMM).  INTERVENTIONS:  Eight 28-day cycles were composed of carfilzomib 20/36 mg/m2 on days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on days 1 through 21; and dexamethasone 20/10 mg (cycles 1-4/5-8) on days 1, 2, 8, 9, 15, 16, 22, and 23.  Patients who achieved at least stable disease subsequently received 24 cycles of lenalidomide extended dosing.  MAIN OUTCOMES AND MEASURES:  Primary end points were neuropathy of grade 3 or greater (NDMM) and at least very good partial response rates (SMM).  Minimal residual disease was also assessed.  RESULTS:  Of 45 patients with NDMM, none had neuropathy of grade 3 or greater.  Of 12 patients with high-risk SMM, the most common of any-grade adverse events were lymphopenia (12 [100%]) and gastrointestinal disorders (11 [92%]).  All patients with SMM achieved at least a very good partial response during the study period.  Among the 28 patients with NDMM and the 12 with SMM achieving at least a near-complete response, MRD negativity was found in 28 of 28 (100% [95% CI, 88%-100%]), 11 of 12 (92% [95% CI, 62%-100%]) (multiparametric flow cytometry), 14 of 21 (67% [95% CI, 43%-85%]), and 9 of 12 (75% [95% CI, 43%-94%]) (next-generation sequencing), respectively.  In patients with NDMM, 12-month progression-free survival for MRD-negative vs MRD-positive status by flow cytometry and next-generation sequencing was 100% vs 79% (95% CI, 47%-94%; P < .001) and 100% vs 95% (95% CI, 75%-99%; P = .02), respectively.  CONCLUSIONS AND RELEVANCE:  Carfilzomib-lenalidomide-dexamethasone therapy is tolerable and demonstrates high rates of MRD negativity in NDMM, translating into longer progression-free survival in patients achieving MRD negativity.  Carfilzomib-lenalidomide-dexamethasone therapy also demonstrates efficacy in high-risk SMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIQnEjFT74UmGmni0r9GoKfW6udTcc2eZFVYGO-Xn7zLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVygtg%253D%253D&md5=f4c70f4a9eeaaccf7da444031d4a4479</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.2010%26sid%3Dliteratum%253Aachs%26aulast%3DKorde%26aufirst%3DN.%26aulast%3DRoschewski%26aufirst%3DM.%26aulast%3DZingone%26aufirst%3DA.%26aulast%3DKwok%26aufirst%3DM.%26aulast%3DManasanch%26aufirst%3DE.%26aulast%3DBhutani%26aufirst%3DM.%26aulast%3DTageja%26aufirst%3DN.%26aulast%3DKazandjian%26aufirst%3DD.%26aulast%3DMailankody%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMorrison%26aufirst%3DC.%26aulast%3DCostello%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DD.%26aulast%3DMulquin%26aufirst%3DM.%26aulast%3DZuchlinski%26aufirst%3DD.%26aulast%3DLamping%26aufirst%3DL.%26aulast%3DCarpenter%26aufirst%3DA.%26aulast%3DWall%26aufirst%3DY.%26aulast%3DCarter%26aufirst%3DG.%26aulast%3DCunningham%26aufirst%3DS.%26aulast%3DGounden%26aufirst%3DV.%26aulast%3DSissung%26aufirst%3DT.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DMaric%26aufirst%3DI.%26aulast%3DCalvo%26aufirst%3DK.%26aulast%3DBraylan%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DArthur%26aufirst%3DD.%26aulast%3DKong%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DL.%26aulast%3DFaham%26aufirst%3DM.%26aulast%3DLindenberg%26aufirst%3DL.%26aulast%3DKurdziel%26aufirst%3DK.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DFigg%26aufirst%3DW.%26aulast%3DLandgren%26aufirst%3DO.%26atitle%3DTreatment%2520with%2520carfilzomib-lenalidomide-dexamethasone%2520with%2520lenalidomide%2520extension%2520in%2520patients%2520with%2520smoldering%2520or%2520newly%2520diagnosed%2520multiple%2520myeloma%26jtitle%3DJAMA%2520oncology%26date%3D2015%26volume%3D1%26spage%3D746%26epage%3D754%26doi%3D10.1001%2Fjamaoncol.2015.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dajee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3038</span>, <span class="refDoi"> DOI: 10.1021/jm801329v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801329v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3028-3038&author=H.+Zhouauthor=M.+Aujayauthor=M.+Bennettauthor=M.+Dajeeauthor=S.+Demoauthor=Y.+Fangauthor=M.+Hoauthor=J.+Jiangauthor=C.+Kirkauthor=G.+Laidigauthor=E.+Lewisauthor=Y.+Luauthor=T.+Muchamuelauthor=F.+Parlatiauthor=E.+Ringauthor=K.+Shenkauthor=J.+Shieldsauthor=P.+Shwonekauthor=T.+Stantonauthor=C.+Sunauthor=C.+Sylvainauthor=T.+Wooauthor=J.+Yang&title=Design+and+synthesis+of+an+orally+bioavailable+and+selective+peptide+epoxyketone+proteasome+inhibitor+%28PR-047%29&doi=10.1021%2Fjm801329v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)</span></div><div class="casAuthors">Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; Lewis, Evan R.; Lu, Yan; Muchamuel, Tony; Parlati, Francesco; Ring, Eileen; Shenk, Kevin D.; Shields, Jamie; Shwonek, Peter J.; Stanton, Timothy; Sun, Congcong M.; Sylvain, Catherine; Woo, Tina M.; Yang, Jinfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epoxypeptides such as I are prepd. as carfilzomib analogs and proteasome inhibitors for use as antitumor agents; the inhibition of human 20S proteasomes and of the growth of multidrug-resistant and nonresistant cancer cells by selected compds. and their stabilities in simulated gastric and intestinal fluids and in liver microsomes are detd.  I selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrated an abs. bioavailability of up to 39% in rodents and dogs.  I is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equiv. to i.v. administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models.  I is prepd. in eight steps (longest linear sequence) from Cbz-L-phenylalanine, Boc-O-methyl-L-serine, 2-methyl-5-thiazolecarboxylic acid, and isopropenylmagnesium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNBIBwb8w47Vg90H21EOLACvtfcHk0lgQtpKJbJPAiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D&md5=688c8d0942539bab2e50617d083bf89a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm801329v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801329v%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DLaidig%26aufirst%3DG.%26aulast%3DLewis%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRing%26aufirst%3DE.%26aulast%3DShenk%26aufirst%3DK.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DStanton%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520and%2520selective%2520peptide%2520epoxyketone%2520proteasome%2520inhibitor%2520%2528PR-047%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3028%26epage%3D3038%26doi%3D10.1021%2Fjm801329v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurchla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Gomez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica-Worms, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandiella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garayoa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weilbaecher, K.</span></span> <span> </span><span class="NLM_article-title">The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fleu.2012.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22763387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Gnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=430-440&author=M.+Hurchlaauthor=A.+Garcia-Gomezauthor=M.+Hornickauthor=E.+Ocioauthor=A.+Liauthor=J.+Blancoauthor=L.+Collinsauthor=C.+Kirkauthor=D.+Piwnica-Wormsauthor=R.+Vijauthor=M.+Tomassonauthor=A.+Pandiellaauthor=J.+San+Miguelauthor=M.+Garayoaauthor=K.+Weilbaecher&title=The+epoxyketone-based+proteasome+inhibitors+carfilzomib+and+orally+bioavailable+oprozomib+have+anti-resorptive+and+bone-anabolic+activity+in+addition+to+anti-myeloma+effects&doi=10.1038%2Fleu.2012.183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects</span></div><div class="casAuthors">Hurchla, M. A.; Garcia-Gomez, A.; Hornick, M. C.; Ocio, E. M.; Li, A.; Blanco, J. F.; Collins, L.; Kirk, C. J.; Piwnica-Worms, D.; Vij, R.; Tomasson, M. H.; Pandiella, A.; San Miguel, J. F.; Garayoa, M.; Weilbaecher, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting pathol. bone destruction.  In clin. trials, carfilzomib, a next generation epoxyketone-based irreversible PI, has exhibited potent anti-myeloma efficacy and decreased side effects compared with bortezomib.  Carfilzomib and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following continual or transient treatment mimicking in vivo pharmacokinetics.  Interactions between myeloma cells and the bone marrow (BM) microenvironment augment the no. and activity of bone-resorbing osteoclasts (OCs) while inhibiting bone-forming osteoblasts (OBs), resulting in increased tumor growth and osteolytic lesions.  At clin. relevant concns., carfilzomib and oprozomib directly inhibited OC formation and bone resorption in vitro, while enhancing osteogenic differentiation and matrix mineralization.  Accordingly, carfilzomib and oprozomib increased trabecular bone vol., decreased bone resorption and enhanced bone formation in non-tumor bearing mice.  Finally, in mouse models of disseminated MM, the epoxyketone-based PIs decreased murine 5TGM1 and human RPMI-8226 tumor burden and prevented bone loss.  These data demonstrate that, in addn. to anti-myeloma properties, carfilzomib and oprozomib effectively shift the bone microenvironment from a catabolic to an anabolic state and, similar to bortezomib, may decrease skeletal complications of MM.  Leukemia (2013) 27, 430-440; doi:10.1038/leu.2012.183; published online 27 July 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVyg3b1Z0_G7Vg90H21EOLACvtfcHk0liIJlRfEyMjQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Gnu7Y%253D&md5=00a1f6b061368a1e0c9b0ca3e6942ab3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.183%26sid%3Dliteratum%253Aachs%26aulast%3DHurchla%26aufirst%3DM.%26aulast%3DGarcia-Gomez%26aufirst%3DA.%26aulast%3DHornick%26aufirst%3DM.%26aulast%3DOcio%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DBlanco%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DL.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DPiwnica-Worms%26aufirst%3DD.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DTomasson%26aufirst%3DM.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%26aulast%3DGarayoa%26aufirst%3DM.%26aulast%3DWeilbaecher%26aufirst%3DK.%26atitle%3DThe%2520epoxyketone-based%2520proteasome%2520inhibitors%2520carfilzomib%2520and%2520orally%2520bioavailable%2520oprozomib%2520have%2520anti-resorptive%2520and%2520bone-anabolic%2520activity%2520in%2520addition%2520to%2520anti-myeloma%2520effects%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fleu.2012.183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillenwater, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1007/s10637-016-0327-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs10637-016-0327-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26924128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=216-224&author=J.+R.+Infanteauthor=D.+S.+Mendelsonauthor=H.+A.+Burrisauthor=J.+C.+Bendellauthor=A.+W.+Tolcherauthor=M.+S.+Gordonauthor=H.+H.+Gillenwaterauthor=S.+Arastu-Kapurauthor=H.+L.+Wongauthor=K.+P.+Papadopoulos&title=A+first-in-human+dose-escalation+study+of+the+oral+proteasome+inhibitor+oprozomib+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-016-0327-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span></div><div class="casAuthors">Infante, Jeffrey R.; Mendelson, David S.; Burris, Howard A., III; Bendell, Johanna C.; Tolcher, Anthony W.; Gordon, Michael S.; Gillenwater, Heidi H.; Arastu-Kapur, Shirin; Wong, Hansen L.; Papadopoulos, Kyriakos P.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To det. the dose-limiting toxicities (DLTs), max. tolerated dose (MTD), safety, and pharmacokinetic and pharmacodynamic profiles of the tripeptide epoxyketone proteasome inhibitor oprozomib in patients with advanced refractory or recurrent solid tumors.  Patients received escalating once daily (QD) or split doses of oprozomib on days 1-5 of 14-day cycles (C).  The split-dose arm was implemented and compared in fasted (C1) and fed (C2) states.  Pharmacokinetic samples were collected during C1 and C2.  Proteasome inhibition was evaluated in red blood cells and peripheral blood mononuclear cells.  Forty-four patients (QD, n = 25; split dose, n = 19) were enrolled.  The most common primary tumor types were non-small cell lung cancer (18 %) and colorectal cancer (16%).  In the 180-mg QD cohort, two patients experienced DLTs: grade 3 vomiting and dehydration; grade 3 hypophosphatemia (n = 1 each).  In the split-dose group, three DLTs were obsd. 180-mg cohort: grade 3 hypophosphatemia; 210-mg cohort: grade 5 gastrointestinal hemorrhage and grade 3 hallucinations (n = 1 each).  In the QD and split-dose groups, the MTD was 150 and 180 mg, resp.  Common adverse events (all grades) included nausea (91%), vomiting (86%), and diarrhea (61%).  Peak concns. and total exposure of oprozomib generally increased with the increasing dose.  Oprozomib induced dose-dependent proteasome inhibition.  Best response was stable disease.  While generally low-grade, clin. relevant gastrointestinal toxicities occurred frequently with this oprozomib formulation.  Despite dose-dependent increases in pharmacokinetics and pharmacodynamics, single-agent oprozomib had minimal antitumor activity in this patient population with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW2c034hrkubVg90H21EOLACvtfcHk0liIJlRfEyMjQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D&md5=e54838bb160c0886d08c5d0b8cb81a6a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0327-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0327-x%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMendelson%26aufirst%3DD.%2BS.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DGillenwater%26aufirst%3DH.%2BH.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%2BL.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26atitle%3DA%2520first-in-human%2520dose-escalation%2520study%2520of%2520the%2520oral%2520proteasome%2520inhibitor%2520oprozomib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26spage%3D216%26epage%3D224%26doi%3D10.1007%2Fs10637-016-0327-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funakoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, T.</span></span> <span> </span><span class="NLM_article-title">A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2003.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bcp.2003.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=14698035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvF2qs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2004&pages=227-234&author=A.+Asaiauthor=T.+Tsujitaauthor=S.+V.+Sharmaauthor=Y.+Yamashitaauthor=S.+Akinagaauthor=M.+Funakoshiauthor=H.+Kobayashiauthor=T.+Mizukami&title=A+new+structural+class+of+proteasome+inhibitors+identified+by+microbial+screening+using+yeast-based+assay&doi=10.1016%2Fj.bcp.2003.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay</span></div><div class="casAuthors">Asai, Akira; Tsujita, Tetsuya; Sharma, Sreenath V.; Yamashita, Yoshinori; Akinaga, Shiro; Funakoshi, Minoru; Kobayashi, Hideki; Mizukami, Tamio</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">227-234</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A yeast-based growth interference assay was developed utilizing a yeast strain in which expression of Xenopus cyclin A1 was induced to elevate cell division cycle 28 (Cdc28) kinase activity.  Since the hyperactivation of Cdc28 kinase in yeast results in a growth-arrest phenotype, compds. which could rescue the cyclin A1-induced growth arrest might be potential new, antitumor drug candidates acting on the cyclin-dependent, kinase-mediated, cell cycle regulation pathway.  In the course of our microbial screening program, the new Streptomyces metabolites, belactosins, were identified.  As reported previously, belactosin A induced cell cycle arrest at G2/M phase in human cancer cells.  However, the mol. mechanism of action was unknown.  We herein demonstrate the proteasome inhibition by belactosin A.  Belactosin A did not inhibit yeast Cdc28 kinase and human cyclin-dependent kinase in vitro.  On the other hand, it inhibited the chymotrypsin-like activity of the rabbit 20S proteasome.  From the initial SAR studies, we identified a hydrophobic belactosin A deriv., KF33955, which exhibited a 100-fold greater growth-inhibitory activity against HeLa S3 cells than belactosin A, presumably due to its higher cell permeability.  The biochem. anal. using KF33955 suggested that the proteasome inhibitory activity of KF33955 were irreversible and required the β-lactone moiety to inhibit the proteasome.  KF33955 increased the intracellular levels of protein ubiquitination in NIH3T3 cells.  In addn., KF33955 treatment resulted in the accumulation of known proteasome substrates in HeLa S3 cells.  These results identify belactosin A as a useful lead compd. to target proteasome for the treatment of disease whose etiol. is dependent on the unregulated ubiquitin-proteasome pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfEKiU4_45bVg90H21EOLACvtfcHk0li7hHtsAEYq1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvF2qs7c%253D&md5=54982fb9e94876de45d1cc2d6a8888a7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2003.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2003.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DTsujita%26aufirst%3DT.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DFunakoshi%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DMizukami%26aufirst%3DT.%26atitle%3DA%2520new%2520structural%2520class%2520of%2520proteasome%2520inhibitors%2520identified%2520by%2520microbial%2520screening%2520using%2520yeast-based%2520assay%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D67%26spage%3D227%26epage%3D234%26doi%3D10.1016%2Fj.bcp.2003.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, B. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">5136</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1021/ja058320b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja058320b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28XislOgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=5136-5141&author=M.+Grollauthor=R.+Huberauthor=B.+C.+Potts&title=Crystal+structures+of+salinosporamide+A+%28NPI-0052%29+and+B+%28NPI-0047%29+in+complex+with+the+20S+proteasome+reveal+important+consequences+of+beta-lactone+ring+opening+and+a+mechanism+for+irreversible+binding&doi=10.1021%2Fja058320b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of β-Lactone Ring Opening and a Mechanism for Irreversible Binding</span></div><div class="casAuthors">Groll, Michael; Huber, Robert; Potts, Barbara C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5136-5141</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The crystal structures of the yeast 20S proteasome core particle (CP) in complex with Salinosporamides A (NPI-0052; 1) and B (4) were solved at <3 Å resoln.  Each ligand is covalently bound to Thr1Oγ via an ester linkage to the carbonyl derived from the β-lactone ring of the inhibitor.  In the case of 1, nucleophilic addn. to the β-lactone ring is followed by addn. of C-3O to the chloroethyl group, giving rise to a cyclic ether.  The crystal structures were compared to that of the omuralide/CP structure solved previously, and the collective data provide new insights into the mechanism of inhibition and irreversible binding of 1.  Upon opening of the β-lactone ring, C-3O assumes the position occupied by a water mol. in the unligated enzyme and hinders deacylation of the enzyme-ligand complex.  Furthermore, the resulting protonation state of Thr1NH2 deactivates the catalytic N-terminus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbVM4Pd5jUeLVg90H21EOLACvtfcHk0li7hHtsAEYq1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislOgu70%253D&md5=66d24b5c6af2e0542b1682fe5c493253</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fja058320b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja058320b%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DPotts%26aufirst%3DB.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520salinosporamide%2520A%2520%2528NPI-0052%2529%2520and%2520B%2520%2528NPI-0047%2529%2520in%2520complex%2520with%2520the%252020S%2520proteasome%2520reveal%2520important%2520consequences%2520of%2520beta-lactone%2520ring%2520opening%2520and%2520a%2520mechanism%2520for%2520irreversible%2520binding%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D5136%26epage%3D5141%26doi%3D10.1021%2Fja058320b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainwaring, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underhill, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannell, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span> <span> </span><span class="NLM_article-title">Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052–102 final results</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4566</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-15-2616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27117181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCkurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4559-4566&author=S.+J.+Harrisonauthor=P.+Mainwaringauthor=T.+Priceauthor=M.+J.+Millwardauthor=P.+Padrikauthor=C.+R.+Underhillauthor=P.+K.+Cannellauthor=S.+D.+Reichauthor=M.+Trikhaauthor=A.+Spencer&title=Phase+I+clinical+trial+of+marizomib+%28NPI-0052%29+in+patients+with+advanced+malignancies+including+multiple+myeloma%3A+study+NPI-0052%E2%80%93102+final+results&doi=10.1158%2F1078-0432.CCR-15-2616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results</span></div><div class="casAuthors">Harrison, Simon J.; Mainwaring, Paul; Price, Timothy; Millward, Michael J.; Padrik, Peeter; Underhill, Craig R.; Cannell, Paul K.; Reich, Steven D.; Trikha, Mohit; Spencer, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4559-4566</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors.  Exptl. Design: Phase I study (NPI-0052-102) evaluated the MTD, pharmacokinetics, and pharmacodynamics of marizomib i.v. on two dosing schedules.  Results: Forty-two patients with advanced malignancies received Schedule A (0.1-0.9 mg/m2 over 1-10 min on days 1, 8, 15 in 4-wk cycles); 44 patients with relapsed and/or refractory multiple myeloma (RRMM) and other hematol. malignancies received Schedule B (0.075-0.6 mg/m2 over 1 min to 2 h on days 1, 4, 8, 11, in 3-wk cycles).  The Schedule A recommended phase II dose was 0.7 mg/m2 over 10 min; Schedule B was 0.5 mg/m2 over 2 h.  The most common (>25% of patients) related adverse events were fatigue, nausea, diarrhea, and infusion site pain (Schedule A); and fatigue (Schedule B).  Overall response rate of 11% was seen in 27 efficacy-evaluable RRMM Schedule B patients (1 very good partial response, 3 partial responses, 4 minimal responses, and 12 stable disease).  One Schedule A patient with transformed marginal zone lymphoma had complete response.  Marizomib has a short half-life (<30 min), with high vol. of distribution (∼15-416 L) and clearance (∼0.9-22 L/min).  Conclusions: Marizomib does not exhibit the severe peripheral neuropathy or hematol. toxicity obsd. with other proteasome inhibitors.  Marizomib was generally well tolerated with low-dose dexamethasone, demonstrated activity in heavily pretreated RRMM patients, and warrants further evaluation.  Clin Cancer Res; 22(18); 4559-66. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGIG3zJzG8qrVg90H21EOLACvtfcHk0lhdOnRAzvkedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCkurrN&md5=728da81129d49246b6d42e5aa7b2adfb</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2616%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DS.%2BJ.%26aulast%3DMainwaring%26aufirst%3DP.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DMillward%26aufirst%3DM.%2BJ.%26aulast%3DPadrik%26aufirst%3DP.%26aulast%3DUnderhill%26aufirst%3DC.%2BR.%26aulast%3DCannell%26aufirst%3DP.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BD.%26aulast%3DTrikha%26aufirst%3DM.%26aulast%3DSpencer%26aufirst%3DA.%26atitle%3DPhase%2520I%2520clinical%2520trial%2520of%2520marizomib%2520%2528NPI-0052%2529%2520in%2520patients%2520with%2520advanced%2520malignancies%2520including%2520multiple%2520myeloma%253A%2520study%2520NPI-0052%25E2%2580%2593102%2520final%2520results%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D4559%26epage%3D4566%26doi%3D10.1158%2F1078-0432.CCR-15-2616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span> <span> </span><span class="NLM_article-title">Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.1111/bjh.14113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1111%2Fbjh.14113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27161872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=711-720&author=N.+Levinauthor=A.+Spencerauthor=S.+Harrisonauthor=D.+Chauhanauthor=F.+Burrowsauthor=K.+Andersonauthor=S.+Reichauthor=P.+Richardsonauthor=M.+Trikha&title=Marizomib+irreversibly+inhibits+proteasome+to+overcome+compensatory+hyperactivation+in+multiple+myeloma+and+solid+tumour+patients&doi=10.1111%2Fbjh.14113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients</span></div><div class="casAuthors">Levin, Nancy; Spencer, Andrew; Harrison, Simon J.; Chauhan, Dharminder; Burrows, Francis J.; Anderson, Kenneth C.; Reich, Steven D.; Richardson, Paul G.; Trikha, Mohit</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">711-720</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly obsd.  All clin. stage PIs effectively inhibit chymotrypsin-like (CT-L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase-like (C-L) and trypsin-like (T-L) subunits, in response to CT-L blockade.  Marizomib (MRZ), an irreversible PI that potently inhibits all three 20S proteasome subunits with a specificity distinct from other PIs, is currently in development for treatment of MM and malignant glioma.  The pan-proteasome pharmacodynamic activity in packed whole blood and peripheral blood mononuclear cells was measured in two studies in patients with advanced solid tumors and haematol. malignancies.  Functional inhibition of all proteasome subunits was achieved with once- or twice-weekly MRZ dosing; 100% inhibition of CT-L was frequently achieved within one cycle at therapeutic doses.  Concomitantly, C-L and T-L activities were either unaffected or increased, suggesting compensatory hyperactivation of these subunits.  Importantly, this response was overcome by continued administration of MRZ, with robust inhibition of T-L and C-L (up to 80% and 50%, resp.) by the end of Cycle 2 and maintained thereafter.  This enhanced proteasome inhibition was independent of tumor type and may underlie the clin. activity of MRZ in patients resistant to other PIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGGdyJ_2yUYbVg90H21EOLACvtfcHk0lhdOnRAzvkedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrvL&md5=fc63e2622217b316eddf1245eabcac11</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14113%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DN.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DReich%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DTrikha%26aufirst%3DM.%26atitle%3DMarizomib%2520irreversibly%2520inhibits%2520proteasome%2520to%2520overcome%2520compensatory%2520hyperactivation%2520in%2520multiple%2520myeloma%2520and%2520solid%2520tumour%2520patients%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2016%26volume%3D174%26spage%3D711%26epage%3D720%26doi%3D10.1111%2Fbjh.14113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchier-Hayes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, J.</span></span> <span> </span><span class="NLM_article-title">Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">18953</span>, <span class="refDoi"> DOI: 10.1038/srep18953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fsrep18953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26804704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=18953&author=C.+Mantonauthor=B.+Johnsonauthor=M.+Singhauthor=C.+Baileyauthor=L.+Bouchier-Hayesauthor=J.+Chandra&title=Induction+of+cell+death+by+the+novel+proteasome+inhibitor+marizomib+in+glioblastoma+in+vitro+and+in+vivo&doi=10.1038%2Fsrep18953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo</span></div><div class="casAuthors">Manton, Christa A.; Johnson, Blake; Singh, Melissa; Bailey, Cavan P.; Bouchier-Hayes, Lisa; Chandra, Joya</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18953</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New therapies for glioblastoma (GBM) are needed, as five-year survival is <10%.  The proteasome inhibitor marizomib (MRZ) has inhibitory and death-inducing properties unique from previous inhibitors such as bortezomib (BTZ), and has not been well examd. in GBM.  We evaluated the mechanism of death and in vivo properties of MRZ in GBM.  The activation kinetics of initiator caspases 2, 8, and 9 were assessed using chem. and knockdown strategies to det. their contribution to cell death.  Blood brain barrier permeance and proteasome inhibition by MRZ and BTZ were examd. in an orthotopic GBM model.  Blockade of caspase 9, relative to other caspases, was most protective against both MRZ and BTZ.  Only MRZ increased the proteasome substrate p27 in orthotopic brain tumors after a single injection, while both MRZ and BTZ increased p21 levels after multiple treatments.  Cleavage of caspase substrate lamin A was increased in orthotopic brain tumors from mice treated with MRZ or BTZ and the histone deacetylase inhibitor vorinostat.  Our data indicate that MRZ induces caspase 9-dependent death in GBM, suggesting drug efficacy biomarkers and possible resistance mechanisms.  MRZ reaches orthotopic brain tumors where it inhibits proteasome function and increases death in combination with vorinostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_5LjCLYtgLVg90H21EOLACvtfcHk0lg3sgwyt_RWuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsbg%253D&md5=984760631c99714aad04805689eaac16</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fsrep18953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18953%26sid%3Dliteratum%253Aachs%26aulast%3DManton%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DBouchier-Hayes%26aufirst%3DL.%26aulast%3DChandra%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520cell%2520death%2520by%2520the%2520novel%2520proteasome%2520inhibitor%2520marizomib%2520in%2520glioblastoma%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D18953%26doi%3D10.1038%2Fsrep18953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLaren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bota, D.</span></span> <span> </span><span class="NLM_article-title">Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier</span>. <i>Neuro-oncology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nov299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1093%2Fneuonc%2Fnov299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26681765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=840-848&author=K.+Diauthor=G.+Lloydauthor=V.+Abrahamauthor=A.+MacLarenauthor=F.+Burrowsauthor=A.+Desjardinsauthor=M.+Trikhaauthor=D.+Bota&title=Marizomib+activity+as+a+single+agent+in+malignant+gliomas%3A+ability+to+cross+the+blood-brain+barrier&doi=10.1093%2Fneuonc%2Fnov299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier</span></div><div class="casAuthors">Di, Kaijun; Lloyd, G. Kenneth; Abraham, Vivek; MacLaren, Ann; Burrows, Francis J.; Desjardins, Annick; Trikha, Mohit; Bota, Daniela A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">840-848</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: The proteasome plays a vital role in the physiol. of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM.  Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential for penetrating the blood-brain barrier.  While bortezomib and carfilzomib, the 2 proteasome inhibitors approved for treatment of multiple myeloma, have little activity against malignant gliomas in vivo, marizomib could be a novel therapeutic strategy for primary brain tumors.  Methods: The in-vitro antitumor activity of marizomib was studied in glioma cell lines U-251 and D-54.  The ability of marizomib to cross the blood-brain barrier and regulate proteasome activities was evaluated in cynomolgus monkeys and rats.  The antitumor effect of marizomib in vivo was tested in an orthotopic xenograft model of human GBM.  Results: Marizomib inhibited the proteasome activity, proliferation, and invasion of glioma cells.  Meanwhile, free radical prodn. and apoptosis induced by marizomib could be blocked by antioxidant N-acetyl cysteine.  In animal studies, marizomib distributed into the brain at 30% of blood levels in rats and significantly inhibited (>30%) baseline chymotrypsin-like proteasome activity in brain tissue of monkeys.  Encouragingly, the immunocompromised mice, intracranially implanted with glioma xenografts, survived significantly longer than the control animals (P < .05) when treated with marizomib.  Conclusions: These preclin. studies demonstrated that marizomib can cross the blood-brain barrier and inhibit proteasome activity in rodent and nonhuman primate brain and elicit a significant antitumor effect in a rodent intracranial model of malignant glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ1xNVIW5NBbVg90H21EOLACvtfcHk0lg3sgwyt_RWuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFKnsg%253D%253D&md5=f65e8dec9a154fe5f3b9faff3163c49a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnov299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnov299%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DK.%26aulast%3DLloyd%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DV.%26aulast%3DMacLaren%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DTrikha%26aufirst%3DM.%26aulast%3DBota%26aufirst%3DD.%26atitle%3DMarizomib%2520activity%2520as%2520a%2520single%2520agent%2520in%2520malignant%2520gliomas%253A%2520ability%2520to%2520cross%2520the%2520blood-brain%2520barrier%26jtitle%3DNeuro-oncology%26date%3D2016%26volume%3D18%26spage%3D840%26epage%3D848%26doi%3D10.1093%2Fneuonc%2Fnov299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Prime time for PROTACs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnchembio.1887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26284668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKntrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=634-635&author=R.+J.+Deshaies&title=Prime+time+for+PROTACs&doi=10.1038%2Fnchembio.1887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Protein degradation. Prime time for PROTACs</span></div><div class="casAuthors">Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">634-635</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PROTACs (proteolysis-targeting chimeric mols.) are heterobifunctional small mols. that simultaneously bind a target protein and a ubiquitin ligase, enabling ubiquitination and degrdn. of the target.  Major progress in developing potent and specific PROTACs has recently been reported, invigorating prospects for novel PROTAC-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMM05VgBV07Vg90H21EOLACvtfcHk0ljdA22rbGadpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKntrvF&md5=cea6459c9e7a6911b8368c544af23a1f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1887%26sid%3Dliteratum%253Aachs%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DPrime%2520time%2520for%2520PROTACs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D634%26epage%3D635%26doi%3D10.1038%2Fnchembio.1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Degradation of proteins by PROTACs and other strategies</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.apsb.2019.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32082969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=207-238&author=Y.+Wangauthor=X.+Jiangauthor=F.+Fengauthor=W.+Liuauthor=H.+Sun&title=Degradation+of+proteins+by+PROTACs+and+other+strategies&doi=10.1016%2Fj.apsb.2019.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of proteins by PROTACs and other strategies</span></div><div class="casAuthors">Wang, Yang; Jiang, Xueyang; Feng, Feng; Liu, Wenyuan; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-238</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Abnormal protein expression or activities are assocd. with many diseases, esp. cancer.  Therefore, down-regulating the proteins involved in cancer cell survival proved to be an effective strategy for cancer treatment-a no. of drugs based on proteolysis-targeting chimaera (PROTAC) mechanism have demonstrated clin. efficacy.  Recent progress in the PROTAC strategy includes identification of the structure of the first ternary eutectic complex, extra-terminal domain-4-PROTAC-Von-Hippel-Lindau (BRD4-PROTAC-VHL), and PROTAC ARV-110 has entered clin. trials for the treatment of prostate cancer in 2019.  These discoveries strongly proved the value of the PROTAC strategy.  In this review, we summarize recent meaningful research of PROTACs, including the mol. design and optimization strategy as well as clin. application of candidate mols.  We hope to provide useful insights for rational design of PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqERwPjLbNodLVg90H21EOLACvtfcHk0ljdA22rbGadpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnslaisA%253D%253D&md5=5a7f617407bdd143a37cfac1e11201f1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DDegradation%2520of%2520proteins%2520by%2520PROTACs%2520and%2520other%2520strategies%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D207%26epage%3D238%26doi%3D10.1016%2Fj.apsb.2019.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC design for the degradation of oncogenic BCR-ABL</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1002/anie.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fanie.201507634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=807-810&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+design+for+the+degradation+of+oncogenic+BCR-ABL&doi=10.1002%2Fanie.201507634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span></div><div class="casAuthors">Lai, Ashton C.; Toure, Momar; Hellerschmied, Doris; Salami, Jemilat; Jaime-Figueroa, Saul; Ko, Eunhwa; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">807-810</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol. is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.  PROTAC technol. employs small mols. that recruit target proteins for ubiquitination and removal by the proteasome.  The synthesis of PROTAC compds. that mediate the degrdn. of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported.  During the course of their development, the authors discovered that the capacity of a PROTAC to induce degrdn. involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely det. the degrdn. profiles of the compds.; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degrdn. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcSTHt5WfILVg90H21EOLACvtfcHk0ljdA22rbGadpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN&md5=58a5d78f32bc8a21fd1a6e0c38b8979c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520design%2520for%2520the%2520degradation%2520of%2520oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D807%26epage%3D810%26doi%3D10.1002%2Fanie.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span> <span> </span><span class="NLM_article-title">Light-induced protein degradation with photocaged PROTACs</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">18370</span>– <span class="NLM_lpage">18374</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b06422</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b06422" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOmurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=18370-18374&author=G.+Xueauthor=K.+Wangauthor=D.+Zhouauthor=H.+Zhongauthor=Z.+Pan&title=Light-induced+protein+degradation+with+photocaged+PROTACs&doi=10.1021%2Fjacs.9b06422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Light-Induced Protein Degradation with Photocaged PROTACs</span></div><div class="casAuthors">Xue, Gang; Wang, Kun; Zhou, Danli; Zhong, Hanbing; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">18370-18374</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Induction of protein degrdn. is emerging as a powerful strategy to modulate protein functions and alter cellular signaling pathways.  Proteolysis-targeting chimeras (PROTACs) have been used to degrade a range of diverse proteins in vitro and in vivo.  Here we present a type of photo-caged PROTACs (pc-PROTACs) to induce degrdn. activity with light.  Photo-removable blocking groups were added to a degrader of Brd4, and the resulting mol. pc-PROTAC1 showed potent degrdn. activity in live cells only after light irradn.  Furthermore, this mol. efficiently degraded Brd4 and induced expected phenotypic changes in zebrafish.  Addnl., this approach was successfully applied to construct pc-PROTAC3 of BTK.  Thus, a general strategy to induce protein degrdn. with light was established to augment the chemists' toolbox to study disease-relevant protein targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYGnlMSsz2ubVg90H21EOLACvtfcHk0ljP7k1DcMENWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOmurvJ&md5=75920669e7228755cfefb5650e4af6b0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b06422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b06422%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DLight-induced%2520protein%2520degradation%2520with%2520photocaged%2520PROTACs%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D18370%26epage%3D18374%26doi%3D10.1021%2Fjacs.9b06422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiters, A.</span></span> <span> </span><span class="NLM_article-title">Optical control of small molecule-induced protein degradation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">2193</span>– <span class="NLM_lpage">2197</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b12718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b12718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=2193-2197&author=Y.+Naroauthor=K.+Darrahauthor=A.+Deiters&title=Optical+control+of+small+molecule-induced+protein+degradation&doi=10.1021%2Fjacs.9b12718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Optical Control of Small Molecule-Induced Protein Degradation</span></div><div class="casAuthors">Naro, Yuta; Darrah, Kristie; Deiters, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2193-2197</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As an emerging approach to protein perturbation, small mol.-induced protein degrdn. has gained significant attention as both a chem. tool and a potential therapeutic.  To enable discrete control over its function, we have developed a broadly applicable approach for the optical activation of small mol.-induced protein degrdn.  By installing two different photolabile protecting groups, so-called caging groups, onto two different ligands recruiting Von Hippel-Lindau (VHL) and cereblon (CRBN) E3 ubiquitin ligases, our strategy enables light-triggered protein degrdn. for any small mol. warhead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7kp9dSOD7EbVg90H21EOLACvtfcHk0ljP7k1DcMENWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslOhsw%253D%253D&md5=ea8a4bfe78a8acd5fcb8d0bba85b2c02</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b12718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b12718%26sid%3Dliteratum%253Aachs%26aulast%3DNaro%26aufirst%3DY.%26aulast%3DDarrah%26aufirst%3DK.%26aulast%3DDeiters%26aufirst%3DA.%26atitle%3DOptical%2520control%2520of%2520small%2520molecule-induced%2520protein%2520degradation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D2193%26epage%3D2197%26doi%3D10.1021%2Fjacs.9b12718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinn, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faelth-Savitski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic in vivo protein knockdown by small-molecule PROTACs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnchembio.1858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26075522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=611-617&author=D.+P.+Bondesonauthor=A.+Maresauthor=I.+E.+D.+Smithauthor=E.+Koauthor=S.+Camposauthor=A.+H.+Miahauthor=K.+E.+Mulhollandauthor=N.+Routlyauthor=D.+L.+Buckleyauthor=J.+L.+Gustafsonauthor=N.+Zinnauthor=P.+Grandiauthor=S.+Shimamuraauthor=G.+Bergaminiauthor=M.+Faelth-Savitskiauthor=M.+Bantscheffauthor=C.+Coxauthor=D.+A.+Gordonauthor=R.+R.+Willardauthor=J.+J.+Flanaganauthor=L.+N.+Casillasauthor=B.+J.+Vottaauthor=W.+den+Bestenauthor=K.+Fammauthor=L.+Kruidenierauthor=P.+S.+Carterauthor=J.+D.+Harlingauthor=I.+Churcherauthor=C.+M.+Crews&title=Catalytic+in+vivo+protein+knockdown+by+small-molecule+PROTACs&doi=10.1038%2Fnchembio.1858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic in vivo protein knockdown by small-molecule PROTACs</span></div><div class="casAuthors">Bondeson, Daniel P.; Mares, Alina; Smith, Ian E. D.; Ko, Eunhwa; Campos, Sebastien; Miah, Afjal H.; Mulholland, Katie E.; Routly, Natasha; Buckley, Dennis L.; Gustafson, Jeffrey L.; Zinn, Nico; Grandi, Paola; Shimamura, Satoko; Bergamini, Giovanna; Faelth-Savitski, Maria; Bantscheff, Marcus; Cox, Carly; Gordon, Deborah A.; Willard, Ryan R.; Flanagan, John J.; Casillas, Linda N.; Votta, Bartholomew J.; den Besten, Willem; Famm, Kristoffer; Kruidenier, Laurens; Carter, Paul S.; Harling, John D.; Churcher, Ian; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">611-617</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clin. benefit.  This strategy, however, generally requires excessive drug concns. to ensure sufficient occupancy, often leading to adverse side effects.  Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chem. knockdown strategy in which a heterobifunctional mol. recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degrdn.  These compds. behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equil. occupancy.  We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concns.  In addn., mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts.  Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-mol. agents with the potent protein knockdown of RNAi and CRISPR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonhnajD3CxS7Vg90H21EOLACvtfcHk0lgCfWELZgLPQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP&md5=31eb8756c5661f78ab4527a50dc1e251</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1858%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DMares%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMulholland%26aufirst%3DK.%2BE.%26aulast%3DRoutly%26aufirst%3DN.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26aulast%3DZinn%26aufirst%3DN.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DShimamura%26aufirst%3DS.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DFaelth-Savitski%26aufirst%3DM.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DWillard%26aufirst%3DR.%2BR.%26aulast%3DFlanagan%26aufirst%3DJ.%2BJ.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DFamm%26aufirst%3DK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BS.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DCatalytic%2520in%2520vivo%2520protein%2520knockdown%2520by%2520small-molecule%2520PROTACs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D611%26epage%3D617%26doi%3D10.1038%2Fnchembio.1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ottis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2570</span>– <span class="NLM_lpage">2578</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Kisr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2570-2578&author=P.+Ottisauthor=M.+Toureauthor=P.+Crommauthor=E.+Koauthor=J.+Gustafsonauthor=C.+Crews&title=Assessing+different+E3+ligases+for+small+molecule+induced+protein+ubiquitination+and+degradation&doi=10.1021%2Facschembio.7b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation</span></div><div class="casAuthors">Ottis, Philipp; Toure, Momar; Cromm, Philipp M.; Ko, Eunhwa; Gustafson, Jeffrey L.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2570-2578</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol., the recruitment of E3 ubiquitin ligases to induce the degrdn. of a protein target, is rapidly impacting chem. biol., as well as modern drug development.  Here, we explore the breadth of this approach by evaluating different E3 ubiquitin ligases engineered in their substrate binding domains to accept a recruiting ligand.  Five out of six E3 ligases were found to be amenable to recruitment for target degrdn.  Taking advantage of the tight spatio-temporal control of inducing ubiquitination on a pre-selected target in living cells, we focused on two of the engineered E3 ligases, βTRCP and parkin, to characterize their ability to induce ubiquitination in comparison with the PROTAC-recruited endogenous E3 ligases VHL and cereblon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhBU1NFnjNbVg90H21EOLACvtfcHk0lgCfWELZgLPQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Kisr3O&md5=b643d34cb33b330a7658b8b7feb2c6cc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00485%26sid%3Dliteratum%253Aachs%26aulast%3DOttis%26aufirst%3DP.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DCromm%26aufirst%3DP.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DGustafson%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DAssessing%2520different%2520E3%2520ligases%2520for%2520small%2520molecule%2520induced%2520protein%2520ubiquitination%2520and%2520degradation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D2570%26epage%3D2578%26doi%3D10.1021%2Facschembio.7b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucheault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5904</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2008.07.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18752944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5904-5908&author=A.+Schneeklothauthor=M.+Pucheaultauthor=H.+Taeauthor=C.+Crews&title=Targeted+intracellular+protein+degradation+induced+by+a+small+molecule%3A+En+route+to+chemical+proteomics&doi=10.1016%2Fj.bmcl.2008.07.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span></div><div class="casAuthors">Schneekloth, Ashley R.; Pucheault, Mathieu; Tae, Hyun Seop; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5904-5908</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We have developed a heterobifunctional all-small mol. PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degrdn. of the androgen receptor.  This cell permeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker.  The SARM-nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase.  This leads to the ubiquitination of the androgen receptor, and its subsequent degrdn. by the proteasome.  Upon treatment of HeLa cells with 10 μM PROTAC for 7 h, we were able to observe a decrease in androgen receptor levels.  This degrdn. is proteasome dependent, as it is mitigated in cells pre-treated with 10 μM epoxomicin, a specific proteasome inhibitor.  These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZh1309EM47LVg90H21EOLACvtfcHk0lh9cOuLMzRpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL&md5=49f32203efc4b2f6f2cbc900df398a1a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.114%26sid%3Dliteratum%253Aachs%26aulast%3DSchneekloth%26aufirst%3DA.%26aulast%3DPucheault%26aufirst%3DM.%26aulast%3DTae%26aufirst%3DH.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DTargeted%2520intracellular%2520protein%2520degradation%2520induced%2520by%2520a%2520small%2520molecule%253A%2520En%2520route%2520to%2520chemical%2520proteomics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5904%26epage%3D5908%26doi%3D10.1016%2Fj.bmcl.2008.07.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernassola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciechanover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melino, G.</span></span> <span> </span><span class="NLM_article-title">The HECT family of E3 ubiquitin ligases: multiple players in cancer development</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccr.2008.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18598940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1ekt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=10-21&author=F.+Bernassolaauthor=M.+Karinauthor=A.+Ciechanoverauthor=G.+Melino&title=The+HECT+family+of+E3+ubiquitin+ligases%3A+multiple+players+in+cancer+development&doi=10.1016%2Fj.ccr.2008.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The HECT family of E3 ubiquitin ligases: multiple players in cancer development</span></div><div class="casAuthors">Bernassola, Francesca; Karin, Michael; Ciechanover, Aaron; Melino, Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-21</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest.  This review highlights recent discoveries on the ubiquitin-mediated degrdn. of crucial tumor suppressor mols. catalyzed by the HECT-type E3s.  By providing a portrait of their protein targets, we intend to link the substrate specificity of HECT-type E3s with their contribution to tumorigenesis.  Moreover, we discuss the relevance of targeting the HECT E3s, through the development of small-mol. inhibitors, as an anticancer therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS6JmekCvBZrVg90H21EOLACvtfcHk0lh9cOuLMzRpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1ekt7g%253D&md5=5322ca40bee58ac15c95ceec9beaeb0c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBernassola%26aufirst%3DF.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DCiechanover%26aufirst%3DA.%26aulast%3DMelino%26aufirst%3DG.%26atitle%3DThe%2520HECT%2520family%2520of%2520E3%2520ubiquitin%2520ligases%253A%2520multiple%2520players%2520in%2520cancer%2520development%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D14%26spage%3D10%26epage%3D21%26doi%3D10.1016%2Fj.ccr.2008.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, Y. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhanji, V.</span></span> <span> </span><span class="NLM_article-title">p53 inhibition by MDM2 in human pterygium</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2018.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.exer.2018.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29932882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2lu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=142-147&author=D.+Caoauthor=T.+K.+Ngauthor=Y.+W.+Y.+Yipauthor=A.+L.+Youngauthor=C.+P.+Pangauthor=W.+K.+Chuauthor=V.+Jhanji&title=p53+inhibition+by+MDM2+in+human+pterygium&doi=10.1016%2Fj.exer.2018.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">p53 inhibition by MDM2 in human pterygium</span></div><div class="casAuthors">Cao, Di; Ng, Tsz Kin; Yip, Yolanda W. Y.; Young, Alvin L.; Pang, Chi Pui; Chu, Wai Kit; Jhanji, Vishal</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">142-147</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To confirm that mouse double minute 2 (MDM2) could inhibit p53 activity in human pterygium.  And to show the disruption of MDM2-p53 interaction could reactive the functions of p53 in pterygium.  Pterygium and corresponding conjunctiva tissues were collected for establishment of primary cell lines.  Expression patterns of MDM2 and p53 were detected by immunofluorescence.  Protein localization of p53 and MDM2, and transcriptional activity of p53 in both untreated and MDM2 antagonist (Nutlin) treated pterygium cells were quantified.  In pterygium, p53 was highly expressed in cytoplasm and slightly expressed in the nuclei.  MDM2 was localized in the nuclei.  A p53 transcriptional regulated target gene, p21, was not expressed in pterygium tissues, suggesting the p53 transcriptional activity was not active in pterygium.  After treatment with Nutlin, increased nuclear localization of p53 (4.05%-80.56%) was obsd. in pterygium cells along with increasing Nutlin dosages (from 0 to 50 μM, p < 0.001).  The expression of p21 was increased after Nutlin treatments in pterygium cells (2.49 folds in 20 μM Nutlin treated cells compared to control treated cells, p = 0.012).  We discovered a novel mechanism in pterygium whereby MDM2 suppresses p53 transcriptional activity despite abundant p53 in pterygium.  Disruption of MDM2-p53 interaction by Nutlin could be a potential treatment for pterygium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTrKcuSDmAIrVg90H21EOLACvtfcHk0lhy-NNjpqW3Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2lu7%252FN&md5=183bcb9a77f4ff97db7cefc19943c541</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2018.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2018.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DD.%26aulast%3DNg%26aufirst%3DT.%2BK.%26aulast%3DYip%26aufirst%3DY.%2BW.%2BY.%26aulast%3DYoung%26aufirst%3DA.%2BL.%26aulast%3DPang%26aufirst%3DC.%2BP.%26aulast%3DChu%26aufirst%3DW.%2BK.%26aulast%3DJhanji%26aufirst%3DV.%26atitle%3Dp53%2520inhibition%2520by%2520MDM2%2520in%2520human%2520pterygium%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2018%26volume%3D175%26spage%3D142%26epage%3D147%26doi%3D10.1016%2Fj.exer.2018.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucheault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5904</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2008.07.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18752944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5904-5908&author=A.+R.+Schneeklothauthor=M.+Pucheaultauthor=H.+S.+Taeauthor=C.+M.+Crews&title=Targeted+intracellular+protein+degradation+induced+by+a+small+molecule%3A+En+route+to+chemical+proteomics&doi=10.1016%2Fj.bmcl.2008.07.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span></div><div class="casAuthors">Schneekloth, Ashley R.; Pucheault, Mathieu; Tae, Hyun Seop; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5904-5908</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We have developed a heterobifunctional all-small mol. PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degrdn. of the androgen receptor.  This cell permeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker.  The SARM-nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase.  This leads to the ubiquitination of the androgen receptor, and its subsequent degrdn. by the proteasome.  Upon treatment of HeLa cells with 10 μM PROTAC for 7 h, we were able to observe a decrease in androgen receptor levels.  This degrdn. is proteasome dependent, as it is mitigated in cells pre-treated with 10 μM epoxomicin, a specific proteasome inhibitor.  These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZh1309EM47LVg90H21EOLACvtfcHk0lhy-NNjpqW3Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL&md5=49f32203efc4b2f6f2cbc900df398a1a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.114%26sid%3Dliteratum%253Aachs%26aulast%3DSchneekloth%26aufirst%3DA.%2BR.%26aulast%3DPucheault%26aufirst%3DM.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520intracellular%2520protein%2520degradation%2520induced%2520by%2520a%2520small%2520molecule%253A%2520En%2520route%2520to%2520chemical%2520proteomics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5904%26epage%3D5908%26doi%3D10.1016%2Fj.bmcl.2008.07.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podlaski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammlott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span> <span> </span><span class="NLM_article-title">In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1126/science.1092472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1126%2Fscience.1092472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=14704432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2004&pages=844-848&author=L.+T.+Vassilevauthor=B.+T.+Vuauthor=B.+Gravesauthor=D.+Carvajalauthor=F.+Podlaskiauthor=Z.+Filipovicauthor=N.+Kongauthor=U.+Kammlottauthor=C.+Lukacsauthor=C.+Klein&title=In+vivo+activation+of+the+p53+pathway+by+small-molecule+antagonists+of+MDM2&doi=10.1126%2Fscience.1092472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2</span></div><div class="casAuthors">Vassilev, Lyubomir T.; Vu, Binh T.; Graves, Bradford; Carvajal, Daisy; Podlaski, Frank; Filipovic, Zoran; Kong, Norman; Kammlott, Ursula; Lukacs, Christine; Klein, Christian; Fotouhi, Nader; Liu, Emily A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">5659</span>),
    <span class="NLM_cas:pages">844-848</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">MDM2 binds the p53 tumor suppressor protein with high affinity and neg. modulates its transcriptional activity and stability.  Overexpression of MDM2, found in many human tumors, effectively impairs p53 function.  Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy.  Here, we identify potent and selective small-mol. antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes.  These compds. bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzumitGD6V4bVg90H21EOLACvtfcHk0lgDu0Epqwvz4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKmtA%253D%253D&md5=cf80c399e8eca8766be1023cda438df3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1126%2Fscience.1092472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1092472%26sid%3Dliteratum%253Aachs%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26aulast%3DVu%26aufirst%3DB.%2BT.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DCarvajal%26aufirst%3DD.%26aulast%3DPodlaski%26aufirst%3DF.%26aulast%3DFilipovic%26aufirst%3DZ.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DKammlott%26aufirst%3DU.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DKlein%26aufirst%3DC.%26atitle%3DIn%2520vivo%2520activation%2520of%2520the%2520p53%2520pathway%2520by%2520small-molecule%2520antagonists%2520of%2520MDM2%26jtitle%3DScience%26date%3D2004%26volume%3D303%26spage%3D844%26epage%3D848%26doi%3D10.1126%2Fscience.1092472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lartigue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">251</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-18-2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=251&author=J.+Hinesauthor=S.+Lartigueauthor=H.+Dongauthor=Y.+Qianauthor=C.+M.+Crews&title=MDM2-recruiting+PROTAC+offers+superior%2C+synergistic+antiproliferative+activity+via+simultaneous+degradation+of+BRD4+and+stabilization+of+p53&doi=10.1158%2F0008-5472.CAN-18-2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span></div><div class="casAuthors">Hines, John; Lartigue, Schan; Dong, Hanqing; Qian, Yimin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Although the no. of proteins effectively targeted for posttranslational degrdn. by PROTAC has grown steadily, the no. of E3 ligases successfully exploited to accomplish this has been limited to the few for which small-mol. ligands have been discovered.  Although the E3 ligase MDM2 is bound by the nutlin class of small-mol. ligands, there are few nutlin-based PROTAC.  Because a nutlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53, we examd. the ability of such a PROTAC to decrease cancer cell viability.  A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency.  Given the complementary ability of A1874 to stabilize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of many cancer cell lines with wild-type p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4.  This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhead combine to exert a synergistic antiproliferative effect.  Our study highlights the untapped potential that may be unlocked by expanding the repertoire of E3 ligases that can be recruited by PROTAC.  Significance: These findings present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic biol. activities assocd. with both ends of this heterobifunctional mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UdOVtfCjPLVg90H21EOLACvtfcHk0lgDu0Epqwvz4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D&md5=e5dbf80505bb32c232bce66b0445a1a9</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-2918%26sid%3Dliteratum%253Aachs%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DLartigue%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DMDM2-recruiting%2520PROTAC%2520offers%2520superior%252C%2520synergistic%2520antiproliferative%2520activity%2520via%2520simultaneous%2520degradation%2520of%2520BRD4%2520and%2520stabilization%2520of%2520p53%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D251%26doi%3D10.1158%2F0008-5472.CAN-18-2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">5820</span>– <span class="NLM_lpage">5826</span>, <span class="refDoi"> DOI: 10.1021/ja100691p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja100691p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1Gktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=5820-5826&author=Y.+Itohauthor=M.+Ishikawaauthor=M.+Naitoauthor=Y.+Hashimoto&title=Protein+knockdown+using+methyl+bestatin-ligand+hybrid+molecules%3A+design+and+synthesis+of+inducers+of+ubiquitination-mediated+degradation+of+cellular+retinoic+acid-binding+proteins&doi=10.1021%2Fja100691p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Knockdown Using Methyl Bestatin-Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins</span></div><div class="casAuthors">Itoh, Yukihiro; Ishikawa, Minoru; Naito, Mikihiko; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5820-5826</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Induction of selective degrdn. of target proteins by small mols. (protein knockdown) would be useful for biol. research and treatment of various diseases.  To achieve protein knockdown, we utilized the ubiquitin ligase activity of cellular inhibitor of apoptosis protein 1 (cIAP1), which is activated by Me bestatin (MeBS, 2).  We speculated that formation of an artificial (nonphysiol.) complex of cIAP1 and a target protein would be induced by a hybrid mol. consisting of MeBS (2) linked to a ligand of the target protein, and this would lead to cIAP1-mediated ubiquitination and subsequent proteasomal degrdn. of the target protein.  To verify this hypothesis, we focused on cellular retinoic acid-binding proteins (CRABP-I and -II) and designed hybrid mols. (compds. 4) consisting of MeBS (2) coupled via spacers of various lengths to all-trans retinoic acid (ATRA, 3), a ligand of CRABPs.  Compds. 4 induced selective loss of CRABP-I and -II proteins in cells.  We confirmed that 4b induced formation of a complex of cIAP1 and CRABP-II in vitro and induced proteasomal degrdn. of CRABP-II in cells.  When neuroblastoma IMR-32 cells were treated with 4b, the level of CRABP-II was reduced and cell migration was inhibited, suggesting potential value of CRABP-II-targeting therapy for controlling tumor metastasis.  Our results indicate that 4b possesses sufficient activity, permeability, and stability in cells to be employed in cellular assays.  Hybrid mols. such as 4 should be useful not only as chem. tools for studying the biol./physiol. functions of CRABPs but also as candidate therapeutic agents targeting CRABPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUZurgNT02VLVg90H21EOLACvtfcHk0lhJ5LkKEOOJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1Gktb0%253D&md5=96c56bb081695a00b6fa6c269aaeef1b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fja100691p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja100691p%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DProtein%2520knockdown%2520using%2520methyl%2520bestatin-ligand%2520hybrid%2520molecules%253A%2520design%2520and%2520synthesis%2520of%2520inducers%2520of%2520ubiquitination-mediated%2520degradation%2520of%2520cellular%2520retinoic%2520acid-binding%2520proteins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D5820%26epage%3D5826%26doi%3D10.1021%2Fja100691p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitaguchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4453</span>– <span class="NLM_lpage">4457</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2012.04.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22658364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVeksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4453-4457&author=Y.+Itohauthor=M.+Ishikawaauthor=R.+Kitaguchiauthor=K.+Okuhiraauthor=M.+Naitoauthor=Y.+Hashimoto&title=Double+protein+knockdown+of+cIAP1+and+CRABP-II+using+a+hybrid+molecule+consisting+of+ATRA+and+IAPs+antagonist&doi=10.1016%2Fj.bmcl.2012.04.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist</span></div><div class="casAuthors">Itoh, Yukihiro; Ishikawa, Minoru; Kitaguchi, Risa; Okuhira, Keiichiro; Naito, Mikihiko; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4453-4457</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein knockdown can be achieved by the use of a small mol. that possesses affinity for both the target protein and ubiquitin ligase.  We have designed such a degrdn.-inducing mol. targeting cIAP1 and CRABP-II, which are involved in proliferation of several cancer cell lines and in neuroblastoma growth, resp.  As a CRABP-II-recognizing moiety, all-trans retinoic acid (ATRA, 3), a physiol. ligand of CRABP, was chosen.  As a cIAP1-recognizing moiety, MV1 (5), which is a cIAP1/cIAP2/XIAP pan-ligand, was chosen.  Although cIAP1 itself possesses ubiquitin ligase activity, we expected that its decompn. would be efficiently mediated by related mols., including cIAP2 and XIAP, which also possess ubiquitin ligase activity.  The designed degrdn. inducer 6, in which ATRA (3) and MV1 (5) moieties are connected via a linker, was synthesized and confirmed to induce efficient degrdn. of both cIAP1 and CRABP-II.  It showed potently inhibited the proliferation of IMR32 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5r5ZhuMqcy7Vg90H21EOLACvtfcHk0lhJ5LkKEOOJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVeksrk%253D&md5=80ae0bc8df5b583ae01d7113558dc266</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.134%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DKitaguchi%26aufirst%3DR.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DDouble%2520protein%2520knockdown%2520of%2520cIAP1%2520and%2520CRABP-II%2520using%2520a%2520hybrid%2520molecule%2520consisting%2520of%2520ATRA%2520and%2520IAPs%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4453%26epage%3D4457%26doi%3D10.1016%2Fj.bmcl.2012.04.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sameshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohoka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1042</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2js7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1042-1047&author=K.+Shimokawaauthor=N.+Shibataauthor=T.+Sameshimaauthor=N.+Miyamotoauthor=O.+Ujikawaauthor=H.+Naraauthor=N.+Ohokaauthor=T.+Hattoriauthor=N.+Choauthor=M.+Naito&title=Targeting+the+allosteric+site+of+oncoprotein+BCR-ABL+as+an+alternative+strategy+for+effective+target+protein+degradation&doi=10.1021%2Facsmedchemlett.7b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation</span></div><div class="casAuthors">Shimokawa, Kenichiro; Shibata, Norihito; Sameshima, Tomoya; Miyamoto, Naoki; Ujikawa, Osamu; Nara, Hiroshi; Ohoka, Nobumichi; Hattori, Takayuki; Cho, Nobuo; Naito, Mikihiko</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1042-1047</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein degrdn. technol. based on hybrid small mols. is an emerging drug modality that has significant potential in drug discovery and as a unique method of post-translational protein knockdown in the field of chem. biol.  Here, we report the first example of a novel and potent protein degrdn. inducer that binds to an allosteric site of the oncogenic BCR-ABL protein.  BCR-ABL allosteric ligands were incorporated into the SNIPER (Specific and Nongenetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers) platform, and a series of in vitro biol. assays of binding affinity, target protein modulation, signal transduction, and growth inhibition were carried out.  One of the designed compds., I (SNIPER(ABL)-062), showed desirable binding affinities against ABL1, cIAP1/2, and XIAP and consequently caused potent BCR-ABL degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-F9T_RIbVbVg90H21EOLACvtfcHk0lisMA7UfkhcrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2js7fI&md5=2500e7d9129934033f969721141a8c1b</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00247%26sid%3Dliteratum%253Aachs%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DN.%26aulast%3DSameshima%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DUjikawa%26aufirst%3DO.%26aulast%3DNara%26aufirst%3DH.%26aulast%3DOhoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DT.%26aulast%3DCho%26aufirst%3DN.%26aulast%3DNaito%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520allosteric%2520site%2520of%2520oncoprotein%2520BCR-ABL%2520as%2520an%2520alternative%2520strategy%2520for%2520effective%2520target%2520protein%2520degradation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1042%26epage%3D1047%26doi%3D10.1021%2Facsmedchemlett.7b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span> <span> </span><span class="NLM_article-title">The expression of VHL (Von Hippel-Lindau) after traumatic spinal cord injury and its role in neuronal apoptosis</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2400</span>, <span class="refDoi"> DOI: 10.1007/s11064-016-1952-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs11064-016-1952-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27324785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCmtr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=2391-2400&author=J.+Haoauthor=X.+Chenauthor=T.+Fuauthor=J.+Liuauthor=M.+Yuauthor=W.+Hanauthor=S.+Heauthor=R.+Qianauthor=F.+Zhang&title=The+expression+of+VHL+%28Von+Hippel-Lindau%29+after+traumatic+spinal+cord+injury+and+its+role+in+neuronal+apoptosis&doi=10.1007%2Fs11064-016-1952-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The Expression of VHL (Von Hippel-Lindau) After Traumatic Spinal Cord Injury and Its Role in Neuronal Apoptosis</span></div><div class="casAuthors">Hao, Jie; Chen, Xiaoqing; Fu, Ting; Liu, Jie; Yu, Mingchen; Han, Wei; He, Shuang; Qian, Rong; Zhang, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2391-2400</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The VHL (Von Hippel-Lindau) gene is a tumor suppressor gene, which is best known as an E3 ubiquitin ligase that neg. regulates the hypoxia inducible factor.  The inactivation of VHL gene could result in the abnormal synthesis of VHL protein, which is in contact with the development and occurrence of renal clear cell carcinoma.  However, the expression and possible function of VHL in central nervous system (CNS) is still unclear.  To examine the function of VHL in CNS injury and repair, we used an acute spinal cord injury (SCI) model in adult rats.  Western blot anal. showed an important upregulation of VHL protein, reaching a peak at day 3 and then declined during the following days.  Double immunofluorescence staining showed that VHL was co-expressed with neurons, but not with astrocytes and microglia.  Moreover, we detected that active caspase-3 had co-localized with VHL in neurons after SCI.  Addnl. in vitro, VHL depletion, by short interfering RNA, significantly reduced neuronal apoptosis.  In conclusion, these data suggested that the change of VHL protein expression was related to neuronal apoptosis after SCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJzWNQks1A3LVg90H21EOLACvtfcHk0lisMA7UfkhcrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCmtr3E&md5=4b26d50baf1618df1a43f12f8079c4e0</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs11064-016-1952-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-016-1952-7%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DF.%26atitle%3DThe%2520expression%2520of%2520VHL%2520%2528Von%2520Hippel-Lindau%2529%2520after%2520traumatic%2520spinal%2520cord%2520injury%2520and%2520its%2520role%2520in%2520neuronal%2520apoptosis%26jtitle%3DNeurochem.%2520Res.%26date%3D2016%26volume%3D41%26spage%3D2391%26epage%3D2400%26doi%3D10.1007%2Fs11064-016-1952-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alabi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance</span>. <i>Communications biology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.1038/s42003-018-0105-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fs42003-018-0105-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30271980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3czksVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=100&author=J.+Salamiauthor=S.+Alabiauthor=R.+R.+Willardauthor=N.+J.+Vitaleauthor=J.+Wangauthor=H.+Dongauthor=M.+Jinauthor=D.+P.+McDonnellauthor=A.+P.+Crewauthor=T.+K.+Neklesaauthor=C.+M.+Crews&title=Androgen+receptor+degradation+by+the+proteolysis-targeting+chimera+ARCC-4+outperforms+enzalutamide+in+cellular+models+of+prostate+cancer+drug+resistance&doi=10.1038%2Fs42003-018-0105-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance</span></div><div class="casAuthors">Salami Jemilat; Crews Craig M; Alabi Shanique; Crews Craig M; Willard Ryan R; Vitale Nick J; Wang Jing; Dong Hanqing; Jin Meizhong; Crew Andrew P; Neklesa Taavi K; McDonnell Donald P; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The androgen receptor is a major driver of prostate cancer and inhibition of its transcriptional activity using competitive antagonists, such as enzalutamide remains a frontline therapy for prostate cancer management.  However, the majority of patients eventually develop drug resistance.  We propose that targeting the androgen receptor for degradation via Proteolysis Targeting Chimeras (PROTACs) will be a better therapeutic strategy for targeting androgen receptor signaling in prostate cancer cells.  Here we perform a head-to-head comparison between a currently approved androgen receptor antagonist enzalutamide, and its PROTAC derivative, ARCC-4, across different cellular models of prostate cancer drug resistance.  ARCC-4 is a low-nanomolar androgen receptor degrader able to degrade about 95% of cellular androgen receptors.  ARCC-4 inhibits prostate tumor cell proliferation, degrades clinically relevant androgen receptor point mutants and unlike enzalutamide, retains antiproliferative effect in a high androgen environment.  Thus, ARCC-4 exemplifies how protein degradation can address the drug resistance hurdles of enzalutamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQilKiHIro9_JI8NvIb08rbfW6udTcc2eZW1GmRhbAbmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czksVCksA%253D%253D&md5=b8b7a81226dcf37d9ff430244b21f952</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fs42003-018-0105-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-018-0105-8%26sid%3Dliteratum%253Aachs%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DAlabi%26aufirst%3DS.%26aulast%3DWillard%26aufirst%3DR.%2BR.%26aulast%3DVitale%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DAndrogen%2520receptor%2520degradation%2520by%2520the%2520proteolysis-targeting%2520chimera%2520ARCC-4%2520outperforms%2520enzalutamide%2520in%2520cellular%2520models%2520of%2520prostate%2520cancer%2520drug%2520resistance%26jtitle%3DCommunications%2520biology%26date%3D2018%26volume%3D1%26spage%3D100%26doi%3D10.1038%2Fs42003-018-0105-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs as potential therapeutic agents for cancer drug resistance</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00848</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00848" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=240-249&author=X.+Sunauthor=Y.+Rao&title=PROTACs+as+potential+therapeutic+agents+for+cancer+drug+resistance&doi=10.1021%2Facs.biochem.9b00848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance</span></div><div class="casAuthors">Sun, Xiuyun; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Cancer drug resistance has become the major problem facing current clin. treatment via different kinds of therapies.  Proteolysis targeting chimeras (PROTACs) as a novel and powerful strategy have attracted a great deal of attention both from academia and from industry for their sensitivity to drug-resistant targets relying on their unique characteristics compared to those of traditional inhibitors.  PROTACs exert their function by degrading the target protein instead of inhibiting targets.  Thus, different kinds of resistance could be conquered by PROTACs such as target mutation or overexpression.  Various resistant targets have been overcome by PROTACs, including AR, ER, BTK, BET, and BCR-ABL.  Though PROTACs have achieved some significant advances in combating drug resistance, more cases are needed to prove the efficiency of PROTACs in addressing the hurdle of resistance in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_hi9ENDVPLVg90H21EOLACvtfcHk0ljGHf7EOsKQCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP&md5=bb7d34974dcb22f73ce9ce60665c391f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00848%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%2520as%2520potential%2520therapeutic%2520agents%2520for%2520cancer%2520drug%2520resistance%26jtitle%3DBiochemistry%26date%3D2020%26volume%3D59%26spage%3D240%26epage%3D249%26doi%3D10.1021%2Facs.biochem.9b00848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelzang, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan Moore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3500</span>– <span class="NLM_lpage">3500</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.3500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2020.38.15_suppl.3500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=3500-3500&author=D.+P.+Petrylakauthor=X.+Gaoauthor=N.+J.+Vogelzangauthor=M.+H.+Garfieldauthor=I.+Taylorauthor=M.+Dougan+Mooreauthor=R.+A.+Peckauthor=H.+A.+Burris&title=First-in-human+phase+I+study+of+ARV-110%2C+an+androgen+receptor+%28AR%29+PROTAC+degrader+in+patients+%28pts%29+with+metastatic+castrate-resistant+prostate+cancer+%28mCRPC%29+following+enzalutamide+%28ENZ%29+and%2For+abiraterone+%28ABI%29&doi=10.1200%2FJCO.2020.38.15_suppl.3500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.3500%26sid%3Dliteratum%253Aachs%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DVogelzang%26aufirst%3DN.%2BJ.%26aulast%3DGarfield%26aufirst%3DM.%2BH.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DDougan%2BMoore%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DR.%2BA.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520ARV-110%252C%2520an%2520androgen%2520receptor%2520%2528AR%2529%2520PROTAC%2520degrader%2520in%2520patients%2520%2528pts%2529%2520with%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528mCRPC%2529%2520following%2520enzalutamide%2520%2528ENZ%2529%2520and%252For%2520abiraterone%2520%2528ABI%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D3500%26epage%3D3500%26doi%3D10.1200%2FJCO.2020.38.15_suppl.3500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span> <span> </span><span class="NLM_article-title">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">7124</span>– <span class="NLM_lpage">7129</span>, <span class="refDoi"> DOI: 10.1073/pnas.1521738113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1073%2Fpnas.1521738113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27274052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7124-7129&author=K.+Rainaauthor=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=D.+Gordonauthor=A.+Rossiauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=K.+Siuauthor=J.+Winklerauthor=A.+Crewauthor=C.+Crewsauthor=K.+Coleman&title=PROTAC-induced+BET+protein+degradation+as+a+therapy+for+castration-resistant+prostate+cancer&doi=10.1073%2Fpnas.1521738113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Raina, Kanak; Lu, Jing; Qian, Yimin; Altieri, Martha; Gordon, Deborah; Rossi, Ann Marie K.; Wang, Jing; Chen, Xin; Dong, Hanqing; Siu, Kam; Winkler, James D.; Crew, Andrew P.; Crews, Craig M.; Coleman, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States.  Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is assocd. with a poor prognosis.  Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed.  Recently, inhibitors of bromodomain and extra-terminal (BET) family proteins have shown growth-inhibitory activity in preclin. models of CRPC.  Here, we demonstrate that ARV-771, a small-mol. pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technol., demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.  Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.  This study is, to our knowledge, the first to demonstrate efficacy with a small-mol. BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7QtYgZVig7Vg90H21EOLACvtfcHk0linBQE_Pyahxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D&md5=34218e685ad72950f3eb85586110c43d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1521738113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1521738113%26sid%3Dliteratum%253Aachs%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DCrew%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DK.%26atitle%3DPROTAC-induced%2520BET%2520protein%2520degradation%2520as%2520a%2520therapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D7124%26epage%3D7129%26doi%3D10.1073%2Fpnas.1521738113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapakshe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coarfa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fleu.2017.207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28663582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=343-352&author=B.+Sunauthor=W.+Fiskusauthor=Y.+Qianauthor=K.+Rajapaksheauthor=K.+Rainaauthor=K.+Colemanauthor=A.+Crewauthor=A.+Shenauthor=D.+Saenzauthor=C.+Millauthor=A.+Nowakauthor=N.+Jainauthor=L.+Zhangauthor=M.+Wangauthor=J.+Khouryauthor=C.+Coarfaauthor=C.+Crewsauthor=K.+Bhalla&title=BET+protein+proteolysis+targeting+chimera+%28PROTAC%29+exerts+potent+lethal+activity+against+mantle+cell+lymphoma+cells&doi=10.1038%2Fleu.2017.207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Bet protein proteolysis targeting chimera (protac) exerts potent lethal activity against mantle cell lymphoma cells</span></div><div class="casAuthors">Sun, B.; Fiskus, W.; Qian, Y.; Rajapakshe, K.; Raina, K.; Coleman, K. G.; Crew, A. P.; Shen, A.; Saenz, D. T.; Mill, C. P.; Nowak, A. J.; Jain, N.; Zhang, L.; Wang, M.; Khoury, J. D.; Coarfa, C.; Crews, C. M.; Bhalla, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-352</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Bromodomain extraterminal protein (BETP) inhibitors transcriptionally repress oncoproteins and nuclear factor-κB (NF-κB) target genes that undermines the growth and survival of mantle cell lymphoma (MCL) cells.  However, BET bromodomain inhibitor (BETi) treatment causes accumulation of BETPs, assocd. with reversible binding and incomplete inhibition of BRD4 that potentially compromises the activity of BETi in MCL cells.  Unlike BETi, BET-PROTACs (proteolysis-targeting chimera) ARV-825 and ARV-771 (Arvinas, Inc.) recruit and utilize an E3-ubiquitin ligase to effectively degrade BETPs in MCL cells.  BET-PROTACs induce more apoptosis than BETi of MCL cells, including those resistant to ibrutinib.  BET-PROTAC treatment induced more perturbations in the mRNA and protein expressions than BETi, with depletion of c-Myc, CDK4, cyclin D1 and the NF-κB transcriptional targets Bcl-xL, XIAP and BTK, while inducing the levels of HEXIM1, NOXA and CDKN1A/p21.  Treatment with ARV-771, which possesses superior pharmacol. properties compared with ARV-825, inhibited the in vivo growth and induced greater survival improvement than the BETi OTX015 of immune-depleted mice engrafted with MCL cells.  Cotreatment of ARV-771 with ibrutinib or the BCL2 antagonist venetoclax or CDK4/6 inhibitor palbociclib synergistically induced apoptosis of MCL cells.  These studies highlight promising and superior preclin. activity of BET-PROTAC than BETi, requiring further in vivo evaluation of BET-PROTAC as a therapy for ibrutinib-sensitive or -resistant MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAZxihoDZILrVg90H21EOLACvtfcHk0ljTfJqiG-ZL8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77J&md5=f771eee574daf11546b93866ea314381</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.207%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DRajapakshe%26aufirst%3DK.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrew%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DSaenz%26aufirst%3DD.%26aulast%3DMill%26aufirst%3DC.%26aulast%3DNowak%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DKhoury%26aufirst%3DJ.%26aulast%3DCoarfa%26aufirst%3DC.%26aulast%3DCrews%26aufirst%3DC.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DBET%2520protein%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520exerts%2520potent%2520lethal%2520activity%2520against%2520mantle%2520cell%2520lymphoma%2520cells%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D343%26epage%3D352%26doi%3D10.1038%2Fleu.2017.207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span> <span> </span><span class="NLM_article-title">Small molecule KRAS agonist for mutant KRAS cancer therapy</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-1012-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs12943-019-1012-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30971271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FktVKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=85&author=K.+Xuauthor=D.+Parkauthor=A.+T.+Magisauthor=J.+Zhangauthor=W.+Zhouauthor=G.+L.+Sicaauthor=S.+S.+Ramalingamauthor=W.+J.+Curranauthor=X.+Deng&title=Small+molecule+KRAS+agonist+for+mutant+KRAS+cancer+therapy&doi=10.1186%2Fs12943-019-1012-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy</span></div><div class="casAuthors">Xu Ke; Park Dongkyoo; Curran Walter J; Deng Xingming; Magis Andrew T; Zhang Jun; Zhou Wei; Ramalingam Suresh S; Sica Gabriel L</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions.  Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatment of KRAS-mutant lung cancer.  RESULTS:  Here we identified a small molecule KRAS agonist, KRA-533, that binds the GTP/GDP-binding pocket of KRAS.  In vitro GDP/GTP exchange assay reveals that KRA-533 activates KRAS by preventing the cleavage of GTP into GDP, leading to the accumulation of GTP-KRAS, an active form of KRAS.  Treatment of human lung cancer cells with KRA-533 resulted in increased KRAS activity and suppression of cell growth.  Lung cancer cell lines with KRAS mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation.  Mutating one of the hydrogen-bonds among the KRA-533 binding amino acids in KRAS (mutant K117A) resulted in failure of KRAS to bind KRA-533.  KRA-533 had no effect on the activity of K117A mutant KRAS, suggesting that KRA-533 binding to K117 is required for KRA-533 to enhance KRAS activity.  Intriguingly, KRA-533-mediated KRAS activation not only promoted apoptosis but also autophagic cell death.  In mutant KRAS lung cancer xenografts and genetically engineered mutant KRAS-driven lung cancer models, KRA-533 suppressed malignant growth without significant toxicity to normal tissues.  CONCLUSIONS:  The development of this KRAS agonist as a new class of anticancer drug offers a potentially effective strategy for the treatment of lung cancer with KRAS mutation and/or mutant KRAS-driven lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQdRmF3d0rzcULxIEhxUjPfW6udTcc2ebV2qfwPttMZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FktVKlug%253D%253D&md5=78831531111b46153564c1c9ad23d6e8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1012-4%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DD.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSica%26aufirst%3DG.%2BL.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DCurran%26aufirst%3DW.%2BJ.%26aulast%3DDeng%26aufirst%3DX.%26atitle%3DSmall%2520molecule%2520KRAS%2520agonist%2520for%2520mutant%2520KRAS%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%26date%3D2019%26volume%3D18%26spage%3D85%26doi%3D10.1186%2Fs12943-019-1012-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bond, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalawansha, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1375</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.0c00411</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.0c00411" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlans7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=1367-1375&author=M.+J.+Bondauthor=L.+Chuauthor=D.+A.+Nalawanshaauthor=K.+Liauthor=C.+M.+Crews&title=Targeted+degradation+of+oncogenic+KRASG12C+by+VHL-recruiting+PROTACs&doi=10.1021%2Facscentsci.0c00411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs</span></div><div class="casAuthors">Bond, Michael J.; Chu, Ling; Nalawansha, Dhanusha A.; Li, Ke; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1367-1375</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRAS is mutated in ~ 20% of human cancers and is one of the most sought-after targets for pharmacol. modulation, despite having historically been considered "undruggable." The discovery of potent covalent inhibitors of the KRASG12C mutant in recent years has sparked a new wave of interest in small mols. targeting KRAS.  While these inhibitors have shown promise in the clinic, we wanted to explore PROTAC-mediated degrdn. as a complementary strategy to modulate mutant KRAS.  Herein, we report the development of LC-2(I), the first PROTAC capable of degrading endogenous KRASG12C.  LC-2 covalently binds KRASG12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRASG12C degrdn. leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines.  LC-2 demonstrates that PROTAC-mediated degrdn. is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.  KRAS is one of the most sought-after targets for cancer therapy.  Herein, we report the development of LC-2, the first PROTAC capable of inducing endogenous KRASG12C degrdn. by recruiting VHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra8EvL_8O3_rVg90H21EOLACvtfcHk0liXXsVrTRcIqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlans7zM&md5=09dc3d55acd5ecd3e8e0e18740830263</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.0c00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.0c00411%26sid%3Dliteratum%253Aachs%26aulast%3DBond%26aufirst%3DM.%2BJ.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DNalawansha%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520degradation%2520of%2520oncogenic%2520KRASG12C%2520by%2520VHL-recruiting%2520PROTACs%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2020%26volume%3D6%26spage%3D1367%26epage%3D1375%26doi%3D10.1021%2Facscentsci.0c00411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase in B cell malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&author=R.+Hendriksauthor=S.+Yuvarajauthor=L.+Kil&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0liXXsVrTRcIqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Targeting the C481S Ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3564</span>– <span class="NLM_lpage">3575</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3564-3575&author=A.+Buhimschiauthor=H.+Armstrongauthor=M.+Toureauthor=S.+Jaime-Figueroaauthor=T.+Chenauthor=A.+Lehmanauthor=J.+Woyachauthor=A.+Johnsonauthor=J.+Byrdauthor=C.+Crews&title=Targeting+the+C481S+Ibrutinib-resistance+mutation+in+Bruton%E2%80%99s+tyrosine+kinase+using+PROTAC-mediated+degradation&doi=10.1021%2Facs.biochem.8b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation</span></div><div class="casAuthors">Buhimschi, Alexandru D.; Armstrong, Haley A.; Toure, Momar; Jaime-Figueroa, Saul; Chen, Timothy L.; Lehman, Amy M.; Woyach, Jennifer A.; Johnson, Amy J.; Byrd, John C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3564-3575</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies.  Yet, more than 80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S).  Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist and these patients have poor outcomes.  To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degrdn. of both wild-type and C481S mutant BTK.  We selected a lead PROTAC, MT-802, from several candidates based on its potency to induce BTK knockdown.  MT-802 recruits BTK to the cereblon (CRBN) E3 ubiquitin ligase complex to trigger BTK ubiquitination and degrdn. via the proteasome.  MT-802 binds fewer off-target kinases than ibrutinib and retains equiv. potency (>99% degrdn. at nanomolar concns.) against wild-type and C481S BTK.  In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot.  Collectively, these data provide basis for further preclin. study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-ls5ps9FaLVg90H21EOLACvtfcHk0lhpJWQWFsSoTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO&md5=bd27f09d041413c7bacb6d61fcb9a327</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00391%26sid%3Dliteratum%253Aachs%26aulast%3DBuhimschi%26aufirst%3DA.%26aulast%3DArmstrong%26aufirst%3DH.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DByrd%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DTargeting%2520the%2520C481S%2520Ibrutinib-resistance%2520mutation%2520in%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520using%2520PROTAC-mediated%2520degradation%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3564%26epage%3D3575%26doi%3D10.1021%2Facs.biochem.8b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2105</span>– <span class="NLM_lpage">2110</span>, <span class="refDoi"> DOI: 10.1038/s41375-019-0440-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fs41375-019-0440-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30858551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=2105-2110&author=Y.+Sunauthor=N.+Dingauthor=Y.+Songauthor=Z.+Yangauthor=W.+Liuauthor=J.+Zhuauthor=Y.+Rao&title=Degradation+of+Bruton%E2%80%99s+tyrosine+kinase+mutants+by+PROTACs+for+potential+treatment+of+ibrutinib-resistant+non-Hodgkin+lymphomas&doi=10.1038%2Fs41375-019-0440-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas</span></div><div class="casAuthors">Sun Yonghui; Yang Zimo; Rao Yu; Ding Ning; Song Yuqin; Zhu Jun; Liu Wanli</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2105-2110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF-dfST00W0BcfW6udTcc2eZ9ARV5eWJHLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D&md5=9d58ea99a2e3c695ee226e78431fce91</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fs41375-019-0440-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-019-0440-x%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDegradation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520mutants%2520by%2520PROTACs%2520for%2520potential%2520treatment%2520of%2520ibrutinib-resistant%2520non-Hodgkin%2520lymphomas%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D2105%26epage%3D2110%26doi%3D10.1038%2Fs41375-019-0440-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bioorg.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30196207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=373-381&author=J.+Bianauthor=J.+Renauthor=Y.+Liauthor=J.+Wangauthor=X.+Xuauthor=Y.+Fengauthor=H.+Tangauthor=Y.+Wangauthor=Z.+Li&title=Discovery+of+Wogonin-based+PROTACs+against+CDK9+and+capable+of+achieving+antitumor+activity&doi=10.1016%2Fj.bioorg.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span></div><div class="casAuthors">Bian, Jinlei; Ren, Jie; Li, Yongren; Wang, Jubo; Xu, Xi; Feng, Yifan; Tang, Hui; Wang, Yajing; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-381</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved to be a potent and selective inhibitor of CDK9.  Using this scaffold, we designed and synthesized a series of proteolysis targeting chimeras (PROTACs) targeting CDK9 by recruiting ubiquitin E3 ligase cereblon (CRBN).  For constructing diverse Wogonin-based PROTACs, a "click chem." approach was employed for the synthesis of CDK9-targeting PROTACs.  The results of western blotting assays showed that compds. contg. triazole group in the linker could selectively downregulate the intracellular CDK9 level.  Among these compds., 11c could selectively degrade CDK9 in a concn.-dependent manner.  In addn., the application of the proteasome inhibitor MG132 and CRBN siRNA silencing confirmed that 11c could promote the proteasome-dependent and CRBN-dependent degrdn.  Consistent with the degrdn. of the CDK9 protein, 11c selectively inhibits proliferation of CDK9-overexpressed cancer cells.  Thus, our Wogonin-based PROTAC would be an efficient probe that induces the degrdn. of CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4sLAWq5vMrVg90H21EOLACvtfcHk0lhq-C8hd6VTVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE&md5=6a7158be1fce50296d6d0ec9160db0fc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Wogonin-based%2520PROTACs%2520against%2520CDK9%2520and%2520capable%2520of%2520achieving%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D373%26epage%3D381%26doi%3D10.1016%2Fj.bioorg.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.-R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0lhq-C8hd6VTVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.-R.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E.</span></span> <span> </span><span class="NLM_article-title">STATs: transcriptional control and biological impact</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1038/nrm909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrm909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12209125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=651-662&author=D.+E.+Levyauthor=J.+E.+Darnell&title=STATs%3A+transcriptional+control+and+biological+impact&doi=10.1038%2Fnrm909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Stats: transcriptional control and biological impact</span></div><div class="casAuthors">Levy, David E.; Darnell, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">651-662</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extracellular proteins bound to cell-surface receptors can change nuclear gene expression patterns in minutes, with far-reaching consequences for development, cell growth, and homeostasis.  The signal transducer and activator of transcription (STAT) proteins are among the most well studied of the latent cytoplasmic signal-dependent transcription factor pathways.  In addn. to several roles in normal cell decisions, dysregulation of STAT function contributes to human disease, making the study of these proteins an important topic of current research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGqYF32j262LVg90H21EOLACvtfcHk0lhENbnhgM5bYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D&md5=4a04359c59e54b12d8a67efb6ef42e4c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnrm909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm909%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATs%253A%2520transcriptional%2520control%2520and%2520biological%2520impact%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D651%26epage%3D662%26doi%3D10.1038%2Fnrm909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11280</span>– <span class="NLM_lpage">11300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01530</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01530" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11280-11300&author=H.+Zhouauthor=L.+Baiauthor=R.+Xuauthor=Y.+Zhaoauthor=J.+Chenauthor=D.+McEachernauthor=K.+Chinnaswamyauthor=B.+Wenauthor=L.+Daiauthor=P.+Kumarauthor=C.-Y.+Yangauthor=Z.+Liuauthor=M.+Wangauthor=L.+Liuauthor=J.+L.+Meagherauthor=H.+Yiauthor=D.+Sunauthor=J.+A.+Stuckeyauthor=S.+Wang&title=Structure-based+discovery+of+SD-36+as+a+potent%2C+selective%2C+and+efficacious+PROTAC+degrader+of+STAT3+protein&doi=10.1021%2Facs.jmedchem.9b01530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein</span></div><div class="casAuthors">Zhou, Haibin; Bai, Longchuan; Xu, Renqi; Zhao, Yujun; Chen, Jianyong; McEachern, Donna; Chinnaswamy, Krishnapriya; Wen, Bo; Dai, Lipeng; Kumar, Praveen; Yang, Chao-Yie; Liu, Zhaomin; Wang, Mi; Liu, Liu; Meagher, Jennifer L.; Yi, Han; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11280-11300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases.  Despite twenty-years of persistent research efforts, targeting STAT3 has been very challenging.  The authors report herein the structure-based discovery of potent small-mol. STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept.  The authors first designed SI-109 as a potent, small-mol. inhibitor of the STAT3 SH2 domain.  Employing ligands for cereblon/Cullin 4A E3 ligase and SI-109, the authors obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36.  SD-36 induces rapid STAT3 degrdn. at low nanomolar concns. in cells and fails to degrader other STAT proteins.  SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3.  A single dose of SD-36 results in complete STAT3 protein degrdn. in xenograft tumor tissue and normal mouse tissues.  SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules.  SD-36 is a potent, selective and efficacious STAT3 degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIAWd1hiuqy7Vg90H21EOLACvtfcHk0lhENbnhgM5bYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J&md5=7d0c656a2d96196a3b71829c9efe715a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01530%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-based%2520discovery%2520of%2520SD-36%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520PROTAC%2520degrader%2520of%2520STAT3%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11280%26epage%3D11300%26doi%3D10.1021%2Facs.jmedchem.9b01530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bioorg.2018.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30245235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=536-544&author=H.+Chenauthor=F.+Chenauthor=N.+Liuauthor=X.+Wangauthor=S.+Gou&title=Chemically+induced+degradation+of+CK2+by+proteolysis+targeting+chimeras+based+on+a+ubiquitin-proteasome+pathway&doi=10.1016%2Fj.bioorg.2018.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway</span></div><div class="casAuthors">Chen, Hong; Chen, Feihong; Liu, Nannan; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">536-544</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a ubiquitous, highly pleiotropic and constitutively active serine/threonine protein kinase, casein kinase 2 (CK2) is closely assocd. with tumorigenesis by its overexpression in cancer cells.  Here we report several proteolysis targeting chimeras (PROTACs) via "click reaction" to connect a CK2 inhibitor (CX-4945) and pomalidomide for degrdn. of CK2 protein.  Among them, compd. 2 degraded CK2 in a dose and time-dependent manner, and kept CK2 at a low basal level by recruiting ubiquitin-proteasome system (UPS).  The degrdn. of CK2 resulted in the reduced phosphorylation of Akt and the up-regulation of p53.  As a CK2 protein degrader, 2 showed the analogous cytotoxicity to CX-4945 but with a quite different mechanism of action from the CK2 inhibitor, hinting that degrdn. of CK2 proteins by PROTACs is a potential way for cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVzJ2UGozoLLVg90H21EOLACvtfcHk0lhCdG08wnINMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fJ&md5=d724e5c8420ae4e57916ac3000d9c408</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520CK2%2520by%2520proteolysis%2520targeting%2520chimeras%2520based%2520on%2520a%2520ubiquitin-proteasome%2520pathway%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D536%26epage%3D544%26doi%3D10.1016%2Fj.bioorg.2018.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7042</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7042-7057&author=H.+Wuauthor=K.+Yangauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=Z.+Liauthor=H.+Xieauthor=J.+Liuauthor=K.+A.+Smithauthor=Z.+Novakovaauthor=C.+Barinkaauthor=W.+Tang&title=Development+of+multifunctional+histone+deacetylase+6+degraders+with+potent+antimyeloma+activity&doi=10.1021%2Facs.jmedchem.9b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span></div><div class="casAuthors">Wu, Hao; Yang, Ka; Zhang, Zhongrui; Leisten, Eric D.; Li, Ziyuan; Xie, Haibo; Liu, Jin; Smith, Kerry A.; Novakova, Zora; Barinka, Cyril; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7042-7057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90.  HDAC6 is involved in multiple disease-relevant pathways.  Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand.  We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degrdn. for the antiproliferation of multiple myeloma (MM).  This new class of degraders exhibited improved potency and selectivity for the degrdn. of HDAC6.  After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb58zf04V2GLVg90H21EOLACvtfcHk0lhCdG08wnINMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO&md5=7aab402404a5fce732b4b68fd76395d4</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00516%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520multifunctional%2520histone%2520deacetylase%25206%2520degraders%2520with%2520potent%2520antimyeloma%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7042%26epage%3D7057%26doi%3D10.1021%2Facs.jmedchem.9b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of dual and selective degraders of cyclin-dependent kinases 4 and 6</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6326</span>, <span class="refDoi"> DOI: 10.1002/anie.201901336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fanie.201901336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6321-6326&author=B.+Jiangauthor=E.+S.+Wangauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Fischerauthor=T.+Zhangauthor=N.+S.+Gray&title=Development+of+dual+and+selective+degraders+of+cyclin-dependent+kinases+4+and+6&doi=10.1002%2Fanie.201901336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6</span></div><div class="casAuthors">Jiang, Baishan; Wang, Eric S.; Donovan, Katherine A.; Liang, Yanke; Fischer, Eric S.; Zhang, Tinghu; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6321-6326</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.  However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive.  Here, we report imide-based degrader mols. capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6.  We were also able to tune the activity of these mols. against Ikaros (IKZF1) and Aiolos (IKZF3), which are well-established targets of imide-based degraders.  We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degrdn. with dual CDK4/6 degrdn. produced enhanced anti-proliferative effects compared to CDK4/6 inhibition, CDK4/6 degrdn., or IKZF1/3 degrdn.  In summary, we report here the first compds. capable of inducing selective degrdn. of CDK4 and CDK6 as tools to pharmacol. dissect their distinct biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Vsqs-SM6hrVg90H21EOLACvtfcHk0lhC9-bsSQ8aFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D&md5=39a6937b24abad0940d359020e2b2f74</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fanie.201901336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201901336%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520dual%2520and%2520selective%2520degraders%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D6321%26epage%3D6326%26doi%3D10.1002%2Fanie.201901336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, Z. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillmore, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galwey, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddington, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parravicini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macmillan-Jones, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gongora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tough, D. F.</span></span> <span> </span><span class="NLM_article-title">Modulating PCAF/GCN5 immune cell function through a PROTAC approach</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2862</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00705</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00705" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OktL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2862-2867&author=Z.+I.+Bassiauthor=M.+C.+Fillmoreauthor=A.+H.+Miahauthor=T.+D.+Chapmanauthor=C.+Mallerauthor=E.+J.+Robertsauthor=L.+C.+Davisauthor=D.+E.+Lewisauthor=N.+W.+Galweyauthor=K.+E.+Waddingtonauthor=V.+Parraviciniauthor=A.+L.+Macmillan-Jonesauthor=C.+Gongoraauthor=P.+G.+Humphreysauthor=I.+Churcherauthor=R.+K.+Prinjhaauthor=D.+F.+Tough&title=Modulating+PCAF%2FGCN5+immune+cell+function+through+a+PROTAC+approach&doi=10.1021%2Facschembio.8b00705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach</span></div><div class="casAuthors">Bassi, Zuni I.; Fillmore, Martin C.; Miah, Afjal H.; Chapman, Trevor D.; Maller, Claire; Roberts, Emma J.; Davis, Lauren C.; Lewis, Darcy E.; Galwey, Nicholas W.; Waddington, Kirsty E.; Parravicini, Valentino; Macmillan-Jones, Abigail L.; Gongora, Celine; Humphreys, Philip G.; Churcher, Ian; Prinjha, Rab K.; Tough, David F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2862-2867</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P300/CBP-assocd. factor (PCAF) and general control nonderepressible 5 (GCN5) are closely related epigenetic proteins, each contg. an acetyltransferase domain and a bromodomain.  Consistent with reported roles for these proteins in immune function, we find that PCAF-deficient macrophages exhibit a markedly reduced ability to produce cytokines upon stimulation with lipopolysaccharide (LPS).  Investigating the potential to target this pathway pharmacol., we show that chem. inhibition of the PCAF/GCN5 bromodomains is insufficient to recapitulate the diminished inflammatory response of PCAF-deficient immune cells.  However, by generating the first PCAF/GCN5 proteolysis targeting chimera (PROTAC), we identify small mols. able to degrade PCAF/GCN5 and to potently modulate the expression of multiple inflammatory mediators in LPS-stimulated macrophages and dendritic cells.  Our data illustrate the power of the PROTAC approach in the context of multidomain proteins, revealing a novel anti-inflammatory therapeutic opportunity for targeting PCAF/GCN5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUuwZ6JZtCirVg90H21EOLACvtfcHk0lhC9-bsSQ8aFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OktL7I&md5=6783f39397381536ed40ac9e1b20fa5b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00705%26sid%3Dliteratum%253Aachs%26aulast%3DBassi%26aufirst%3DZ.%2BI.%26aulast%3DFillmore%26aufirst%3DM.%2BC.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DChapman%26aufirst%3DT.%2BD.%26aulast%3DMaller%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DE.%2BJ.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DLewis%26aufirst%3DD.%2BE.%26aulast%3DGalwey%26aufirst%3DN.%2BW.%26aulast%3DWaddington%26aufirst%3DK.%2BE.%26aulast%3DParravicini%26aufirst%3DV.%26aulast%3DMacmillan-Jones%26aufirst%3DA.%2BL.%26aulast%3DGongora%26aufirst%3DC.%26aulast%3DHumphreys%26aufirst%3DP.%2BG.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DTough%26aufirst%3DD.%2BF.%26atitle%3DModulating%2520PCAF%252FGCN5%2520immune%2520cell%2520function%2520through%2520a%2520PROTAC%2520approach%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D2862%26epage%3D2867%26doi%3D10.1021%2Facschembio.8b00705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurizi, M. R.</span></span> <span> </span><span class="NLM_article-title">Human mitochondrial ClpP is a stable heptamer that assembles into a tetradecamer in the presence of ClpX</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">35424</span>– <span class="NLM_lpage">35432</span>, <span class="refDoi"> DOI: 10.1074/jbc.M507240200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1074%2Fjbc.M507240200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16115876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWmurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=35424-35432&author=S.+G.+Kangauthor=M.+N.+Dimitrovaauthor=J.+Ortegaauthor=A.+Ginsburgauthor=M.+R.+Maurizi&title=Human+mitochondrial+ClpP+is+a+stable+heptamer+that+assembles+into+a+tetradecamer+in+the+presence+of+ClpX&doi=10.1074%2Fjbc.M507240200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Human Mitochondrial ClpP Is a Stable Heptamer That Assembles into a Tetradecamer in the Presence of ClpX</span></div><div class="casAuthors">Kang, Sung Gyun; Dimitrova, Mariana N.; Ortega, Joaquin; Ginsburg, Ann; Maurizi, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">35424-35432</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The functional form of ClpP, the proteolytic component of ATP-dependent Clp proteases, is a hollow-cored particle composed of two heptameric rings joined face-to-face forming an aq. chamber contg. the proteolytic active sites.  We have found that isolated human mitochondrial ClpP (hClpP) is stable as a heptamer and remains a monodisperse species (s20,w 7.0 S; Mapp 169, 200) at concns. ≥3 mg/mL.  Heptameric hClpP has no proteolytic activity and very low peptidase activity.  In the presence of ATP, hClpX interacts with hClpP forming a complex, which by equil. sedimentation measurements has a Mapp of 1 × 106.  Electron microscopy confirmed that the complex consisted of a double ring of hClpP with an hClpX ring axially aligned on each end.  The hClpXP complex has protease activity and greatly increased peptidase activity, indicating that interaction with hClpX affects the conformation of the hClpP catalytic active site.  A mutant of hClpP, in which a cysteine residue was introduced into the handle region at the interface between the two rings formed stable tetradecamers under oxidizing conditions but spontaneously dissocd. into two heptamers upon redn.  Thus, hClpP rings interact transiently but very weakly in soln., and hClpX must exert an allosteric effect on hClpP to promote a conformation that stabilizes the tetradecamer.  These data suggest that hClpX can regulate the appearance of hClpP peptidase activity in mitochondria and might affect the nature of the degrdn. products released during ATP-dependent proteolytic cycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsYy_dZvM84LVg90H21EOLACvtfcHk0lht64D1axCjbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWmurzI&md5=5f4265d7d51c7794eb92df5c4838132c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M507240200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M507240200%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BG.%26aulast%3DDimitrova%26aufirst%3DM.%2BN.%26aulast%3DOrtega%26aufirst%3DJ.%26aulast%3DGinsburg%26aufirst%3DA.%26aulast%3DMaurizi%26aufirst%3DM.%2BR.%26atitle%3DHuman%2520mitochondrial%2520ClpP%2520is%2520a%2520stable%2520heptamer%2520that%2520assembles%2520into%2520a%2520tetradecamer%2520in%2520the%2520presence%2520of%2520ClpX%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D35424%26epage%3D35432%26doi%3D10.1074%2Fjbc.M507240200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurizi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahvazi, B.</span></span> <span> </span><span class="NLM_article-title">Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2004.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.jsb.2004.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15522782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Squr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2004&pages=338-352&author=S.+G.+Kangauthor=M.+R.+Mauriziauthor=M.+Thompsonauthor=T.+Mueserauthor=B.+Ahvazi&title=Crystallography+and+mutagenesis+point+to+an+essential+role+for+the+N-terminus+of+human+mitochondrial+ClpP&doi=10.1016%2Fj.jsb.2004.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP</span></div><div class="casAuthors">Kang, Sung Gyun; Maurizi, Michael R.; Thompson, Mark; Mueser, Timothy; Ahvazi, Bijan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">338-352</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We have detd. a 2.1 Å crystal structure for human mitochondrial ClpP (hClpP), the proteolytic component of the ATP-dependent ClpXP protease.  HClpP has a structure similar to that of the bacterial enzyme, with the proteolytic active sites sequestered within an aq. chamber formed by face-to-face assembly of the two heptameric rings.  The hydrophobic N-terminal peptides of the subunits are bound within the narrow (12 Å) axial channel, positioned to interact with unfolded substrates translocated there by the assocd. ClpX chaperone.  Mutation or deletion of these residues causes a drastic decrease in ClpX-mediated protein and peptide degrdn.  Residues 8-16 form a mobile loop that extends above the ring surface and is also required for activity.  The 28 amino acid C-terminal domain, a unique feature of mammalian ClpP proteins, lies on the periphery of the ring, with its proximal portion forming a loop that extends out from the ring surface.  Residues at the start of the C-terminal domain impinge on subunit interfaces within the ring and affect heptamer assembly and stability.  We propose that the N-terminal peptide of ClpP is a structural component of the substrate translocation channel and may play an important functional role as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsX5RAG7dc7rVg90H21EOLACvtfcHk0lht64D1axCjbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Squr0%253D&md5=54ec88f302b433cc44e3109a1f9cb0f9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2004.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2004.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BG.%26aulast%3DMaurizi%26aufirst%3DM.%2BR.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DMueser%26aufirst%3DT.%26aulast%3DAhvazi%26aufirst%3DB.%26atitle%3DCrystallography%2520and%2520mutagenesis%2520point%2520to%2520an%2520essential%2520role%2520for%2520the%2520N-terminus%2520of%2520human%2520mitochondrial%2520ClpP%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2004%26volume%3D148%26spage%3D338%26epage%3D352%26doi%3D10.1016%2Fj.jsb.2004.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, R. T.</span></span> <span> </span><span class="NLM_article-title">Diverse pore loops of the AAA+ ClpX machine mediate unassisted and adaptor-dependent recognition of ssrA-tagged substrates</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2008.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.molcel.2008.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18313382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=441-450&author=A.+Martinauthor=T.+A.+Bakerauthor=R.+T.+Sauer&title=Diverse+pore+loops+of+the+AAA%2B+ClpX+machine+mediate+unassisted+and+adaptor-dependent+recognition+of+ssrA-tagged+substrates&doi=10.1016%2Fj.molcel.2008.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse pore loops of the AAA+ ClpX machine mediate unassisted and adaptor-dependent recognition of ssrA-tagged substrates</span></div><div class="casAuthors">Martin, Andreas; Baker, Tania A.; Sauer, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ClpX, an archetypal proteolytic AAA+ unfoldase, must engage the ssrA tags of appropriate substrates prior to ATP-dependent unfolding and translocation of the denatured polypeptide into ClpP for degrdn.  Here, specificity-transplant and disulfide-crosslinking expts. reveal that the ssrA tag interacts with different loops that form the top, middle, and lower portions of the central channel of the ClpX hexamer.  Our results support a two-step binding mechanism, in which the top loop serves as a specificity filter and the remaining loops form a binding site for the peptide tag relatively deep within the pore.  Crosslinking expts. suggest a staggered arrangement of pore loops in the hexamer and nucleotide-dependent changes in pore-loop conformations.  This mechanism of initial tag binding would allow ATP-dependent conformational changes in one or more pore loops to drive peptide translocation, force unfolding, and mediate threading of the denatured protein through the ClpX pore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWUaE9Yw5ywrVg90H21EOLACvtfcHk0lg3TzYhcV_fpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFCgsbc%253D&md5=e4c1d83f2c188ee90bbbe38886b5140a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DT.%2BA.%26aulast%3DSauer%26aufirst%3DR.%2BT.%26atitle%3DDiverse%2520pore%2520loops%2520of%2520the%2520AAA%252B%2520ClpX%2520machine%2520mediate%2520unassisted%2520and%2520adaptor-dependent%2520recognition%2520of%2520ssrA-tagged%2520substrates%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D29%26spage%3D441%26epage%3D450%26doi%3D10.1016%2Fj.molcel.2008.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ologbenla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W. A.</span></span> <span> </span><span class="NLM_article-title">Dynamics of the ClpP serine protease: a model for self-compartmentalized proteases</span>. <i>Crit. Rev. Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.3109/10409238.2014.925421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3109%2F10409238.2014.925421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=24915503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12kurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2014&pages=400-412&author=K.+Liuauthor=A.+Ologbenlaauthor=W.+A.+Houry&title=Dynamics+of+the+ClpP+serine+protease%3A+a+model+for+self-compartmentalized+proteases&doi=10.3109%2F10409238.2014.925421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamics of the ClpP serine protease: A model for self-compartmentalized proteases</span></div><div class="casAuthors">Liu, Kaiyin; Ologbenla, Adedeji; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">400-412</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  ClpP is a highly conserved serine protease present in most bacterial species and in the mitochondria of mammalian cells.  It forms a cylindrical tetradecameric complex arranged into two stacked heptamers.  The two heptameric rings of ClpP enclose a roughly spherical proteolytic chamber of about 51 Å in diam. with 14 Ser-His-Asp proteolytic active sites.  ClpP typically forms complexes with unfoldase chaperones of the AAA+ superfamily.  Chaperones dock on one or both ends of the ClpP double ring cylindrical structure.  Dynamics in the ClpP structure is crit. for its function.  Polypeptides targeted for degrdn. by ClpP are initially recognized by the AAA+ chaperones.  Polypeptides are unfolded by the chaperones and then translocated through the ClpP axial pores, present on both ends of the ClpP cylinder, into the ClpP catalytic chamber.  The axial pores of ClpP are gated by dynamic axial loops that restrict or allow substrate entry.  As a processive protease, ClpP degrades substrates to generate peptides of about 7-8 residues.  Based on structural, biochem. and theor. studies, the exit of these polypeptides from the proteolytic chamber is proposed to be mediated by the dynamics of the ClpP oligomer.  The ClpP cylinder has been found to exist in at least three conformations, extended, compact and compressed, that seem to represent different states of ClpP during its proteolytic functional cycle.  In this review, we discuss the link between ClpP dynamics and its activity.  We propose that such dynamics also exist in other cylindrical proteases such as HslV and the proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp95bFqjiaoI7Vg90H21EOLACvtfcHk0lg3TzYhcV_fpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12kurfI&md5=868f593942a12da6c9b9be2d46a17c93</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3109%2F10409238.2014.925421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2014.925421%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DOlogbenla%26aufirst%3DA.%26aulast%3DHoury%26aufirst%3DW.%2BA.%26atitle%3DDynamics%2520of%2520the%2520ClpP%2520serine%2520protease%253A%2520a%2520model%2520for%2520self-compartmentalized%2520proteases%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D49%26spage%3D400%26epage%3D412%26doi%3D10.3109%2F10409238.2014.925421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levichkin, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasinopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogenraad, N. J.</span></span> <span> </span><span class="NLM_article-title">A mitochondrial specific stress response in mammalian cells</span>. <i>EMBO journal</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4411</span>– <span class="NLM_lpage">4419</span>, <span class="refDoi"> DOI: 10.1093/emboj/cdf445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1093%2Femboj%2Fcdf445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Knu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=4411-4419&author=Q.+Zhaoauthor=J.+Wangauthor=I.+V.+Levichkinauthor=S.+Stasinopoulosauthor=M.+T.+Ryanauthor=N.+J.+Hoogenraad&title=A+mitochondrial+specific+stress+response+in+mammalian+cells&doi=10.1093%2Femboj%2Fcdf445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A mitochondrial specific stress response in mammalian cells</span></div><div class="casAuthors">Zhao, Quan; Wang, Jianghui; Levichkin, Ilya V.; Stasinopoulos, Stan; Ryan, Michael T.; Hoogenraad, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4411-4419</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cells respond to a wide variety of stresses through the transcriptional activation of genes that harbor stress elements within their promoters.  While many of these elements are shared by genes encoding proteins representative of all subcellular compartments, cells can also respond to stresses that are specific to individual organelles, such as the endoplasmic reticulum unfolded protein response.  Here the authors report on the discovery and characterization of a mitochondrial stress response in mammalian cells.  The authors find that the accumulation of unfolded protein within the mitochondrial matrix results in the transcriptional upregulation of nuclear genes encoding mitochondrial stress proteins such as chaperonin 60, chaperonin 10, mtDnaJ and ClpP, but not those encoding stress proteins of the endoplasmic reticulum.  Anal. of the chaperonin 60/10 bidirectional promoter identified a CHOP element as the mitochondrial stress response element.  Dominant-neg. mutant forms of CHOP and overexpression of CHOP revealed that this transcription factor, in assocn. with C/EBPβ, regulates expression of mitochondrial stress genes in response to the accumulation of unfolded proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKDp4TX9kK7Vg90H21EOLACvtfcHk0lgt1YUMvfO6dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Knu7w%253D&md5=53c22763d7e99abcb02ff364973ca71c</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1093%2Femboj%2Fcdf445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252Fcdf445%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLevichkin%26aufirst%3DI.%2BV.%26aulast%3DStasinopoulos%26aufirst%3DS.%26aulast%3DRyan%26aufirst%3DM.%2BT.%26aulast%3DHoogenraad%26aufirst%3DN.%2BJ.%26atitle%3DA%2520mitochondrial%2520specific%2520stress%2520response%2520in%2520mammalian%2520cells%26jtitle%3DEMBO%2520journal%26date%3D2002%26volume%3D21%26spage%3D4411%26epage%3D4419%26doi%3D10.1093%2Femboj%2Fcdf445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cormio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sardanelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadaleta, M. N.</span></span> <span> </span><span class="NLM_article-title">Increase in proteins involved in mitochondrial fission, mitophagy, proteolysis and antioxidant response in type I endometrial cancer as an adaptive response to respiratory complex I deficiency</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bbrc.2017.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28698145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFygt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2017&pages=85-90&author=A.+Cormioauthor=C.+Musiccoauthor=G.+Gasparreauthor=G.+Cormioauthor=V.+Pesceauthor=A.+M.+Sardanelliauthor=M.+N.+Gadaleta&title=Increase+in+proteins+involved+in+mitochondrial+fission%2C+mitophagy%2C+proteolysis+and+antioxidant+response+in+type+I+endometrial+cancer+as+an+adaptive+response+to+respiratory+complex+I+deficiency&doi=10.1016%2Fj.bbrc.2017.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Increase in proteins involved in mitochondrial fission, mitophagy, proteolysis and antioxidant response in type I endometrial cancer as an adaptive response to respiratory complex I deficiency</span></div><div class="casAuthors">Cormio, Antonella; Musicco, Clara; Gasparre, Giuseppe; Cormio, Gennaro; Pesce, Vito; Sardanelli, Anna Maria; Gadaleta, Maria Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-90</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pathogenic mtDNA mutations assocd. with alterations of respiratory complex I, mitochondrial proliferation (oncocytic-like phenotype) and increase in antioxidant response were previously reported in type I endometrial carcinoma (EC).  To evaluate whether in the presence of pathogenic mtDNA mutations other mitochondrial adaptive processes are triggered by cancer cells, the expression level of proteins involved in mitochondrial dynamics, mitophagy, proteolysis and apoptosis were evaluated in type I ECs harboring pathogenic mtDNA mutations and complex I deficiency.  An increase in the fission protein Drp1, in the mitophagy protein BNIP3, in the mitochondrial protease CLPP, in the antioxidant and anti-apoptotic protein ALR and in Bcl-2 as well as a decrease in the fusion protein Mfn2 were found in cancer compared to matched non malignant tissue.  Moreover, the level of these proteins was measured in type I EC, in hyperplastic (the premalignant form) and in non malignant tissues to verify whether the altered expression of these proteins is a common feature of endometrial cancer and of hyperplastic tissue.  This anal. confirmed in type I EC samples, but not in hyperplasia, an alteration of the expression level of these proteins.  These results suggest that in this cancer mitochondrial fission, antioxidant and anti-apoptotic response may be activated, as well as the discharge of damaged mitochondrial proteins as adaptation processes to mitochondrial dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9llNbpGOdv7Vg90H21EOLACvtfcHk0lgt1YUMvfO6dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFygt7jF&md5=dd8aefa8accec8546ed5c8ac3140ae5e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DCormio%26aufirst%3DA.%26aulast%3DMusicco%26aufirst%3DC.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DCormio%26aufirst%3DG.%26aulast%3DPesce%26aufirst%3DV.%26aulast%3DSardanelli%26aufirst%3DA.%2BM.%26aulast%3DGadaleta%26aufirst%3DM.%2BN.%26atitle%3DIncrease%2520in%2520proteins%2520involved%2520in%2520mitochondrial%2520fission%252C%2520mitophagy%252C%2520proteolysis%2520and%2520antioxidant%2520response%2520in%2520type%2520I%2520endometrial%2520cancer%2520as%2520an%2520adaptive%2520response%2520to%2520respiratory%2520complex%2520I%2520deficiency%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D491%26spage%3D85%26epage%3D90%26doi%3D10.1016%2Fj.bbrc.2017.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivadeneira, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaira, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palleschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Languino, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, D. C.</span></span> <span> </span><span class="NLM_article-title">The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1002507</span> <span class="refDoi"> DOI: 10.1371/journal.pbio.1002507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1371%2Fjournal.pbio.1002507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27389535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWgtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&author=J.+H.+Seoauthor=D.+B.+Rivadeneiraauthor=M.+C.+Cainoauthor=Y.+C.+Chaeauthor=D.+W.+Speicherauthor=H.+Y.+Tangauthor=V.+Vairaauthor=S.+Bosariauthor=A.+Palleschiauthor=P.+Rampiniauthor=A.+V.+Kossenkovauthor=L.+R.+Languinoauthor=D.+C.+Altieri&title=The+mitochondrial+unfoldase-peptidase+complex+ClpXP+controls+bioenergetics+stress+and+metastasis&doi=10.1371%2Fjournal.pbio.1002507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis</span></div><div class="casAuthors">Seo, Jae Ho; Rivadeneira, Dayana B.; Caino, M. Cecilia; Chae, Young Chan; Speicher, David W.; Tang, Hsin-Yao; Vaira, Valentina; Bosari, Silvano; Palleschi, Alessandro; Rampini, Paolo; Kossenkov, Andrew V.; Languino, Lucia R.; Altieri, Dario C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1002507/1-e1002507/21</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Mitochondria must buffer the risk of proteotoxic stress to preserve bioenergetics, but the role of these mechanisms in disease is poorly understood.  Using a proteomics screen, we now show that the mitochondrial unfoldase-peptidase complex ClpXP assocs. with the oncoprotein survivin and the respiratory chain Complex II subunit succinate dehydrogenase B (SDHB) in mitochondria of tumor cells.  Knockdown of ClpXP subunits ClpP or ClpX induces the accumulation of misfolded SDHB, impairing oxidative phosphorylation and ATP prodn. while activating "stress" signals of 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and autophagy.  Deregulated mitochondrial respiration induced by ClpXP targeting causes oxidative stress, which in turn reduces tumor cell proliferation, suppresses cell motility, and abolishes metastatic dissemination in vivo.  ClpP is universally overexpressed in primary and metastatic human cancer, correlating with shortened patient survival.  Therefore, tumors exploit ClpXP-directed proteostasis to maintain mitochondrial bioenergetics, buffer oxidative stress, and enable metastatic competence.  This pathway may provide a "drugable" therapeutic target in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVfOEi0b0tFbVg90H21EOLACvtfcHk0ljZHIY2_E2NeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWgtb3J&md5=52c9c4dff980aca286238f21e4e62191</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1002507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1002507%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DRivadeneira%26aufirst%3DD.%2BB.%26aulast%3DCaino%26aufirst%3DM.%2BC.%26aulast%3DChae%26aufirst%3DY.%2BC.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26aulast%3DTang%26aufirst%3DH.%2BY.%26aulast%3DVaira%26aufirst%3DV.%26aulast%3DBosari%26aufirst%3DS.%26aulast%3DPalleschi%26aufirst%3DA.%26aulast%3DRampini%26aufirst%3DP.%26aulast%3DKossenkov%26aufirst%3DA.%2BV.%26aulast%3DLanguino%26aufirst%3DL.%2BR.%26aulast%3DAltieri%26aufirst%3DD.%2BC.%26atitle%3DThe%2520mitochondrial%2520unfoldase-peptidase%2520complex%2520ClpXP%2520controls%2520bioenergetics%2520stress%2520and%2520metastasis%26jtitle%3DPLoS%2520Biol.%26date%3D2016%26volume%3D14%26doi%3D10.1371%2Fjournal.pbio.1002507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabharwal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacker, P. T.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel?</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1038/nrc3803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrc3803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25342630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=709-721&author=S.+S.+Sabharwalauthor=P.+T.+Schumacker&title=Mitochondrial+ROS+in+cancer%3A+initiators%2C+amplifiers+or+an+Achilles%E2%80%99+heel%3F&doi=10.1038%2Fnrc3803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?</span></div><div class="casAuthors">Sabharwal, Simran S.; Schumacker, Paul T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">709-721</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mitochondria cooperate with their host cells by contributing to bioenergetics, metab., biosynthesis, and cell death or survival functions.  Reactive oxygen species (ROS) generated by mitochondria participate in stress signalling in normal cells but also contribute to the initiation of nuclear or mitochondrial DNA mutations that promote neoplastic transformation.  In cancer cells, mitochondrial ROS amplify the tumorigenic phenotype and accelerate the accumulation of addnl. mutations that lead to metastatic behavior.  As mitochondria carry out important functions in normal cells, disabling their function is not a feasible therapy for cancer.  However, ROS signalling contributes to proliferation and survival in many cancers, so the targeted disruption of mitochondria-to-cell redox communication represents a promising avenue for future therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNrCJgdvCMg7Vg90H21EOLACvtfcHk0ljZHIY2_E2NeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLbO&md5=96707798e33043d755b569fd089d8617</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnrc3803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3803%26sid%3Dliteratum%253Aachs%26aulast%3DSabharwal%26aufirst%3DS.%2BS.%26aulast%3DSchumacker%26aufirst%3DP.%2BT.%26atitle%3DMitochondrial%2520ROS%2520in%2520cancer%253A%2520initiators%252C%2520amplifiers%2520or%2520an%2520Achilles%25E2%2580%2599%2520heel%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D709%26epage%3D721%26doi%3D10.1038%2Fnrc3803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeiler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz-Baath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">Development and characterization of improved β-lactone-based anti-virulence drugs targeting ClpP</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmc.2011.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21855356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=583-591&author=E.+Zeilerauthor=V.+S.+Korotkovauthor=K.+Lorenz-Baathauthor=T.+B%C3%B6ttcherauthor=S.+A.+Sieber&title=Development+and+characterization+of+improved+%CE%B2-lactone-based+anti-virulence+drugs+targeting+ClpP&doi=10.1016%2Fj.bmc.2011.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of improved β-lactone-based anti-virulence drugs targeting ClpP</span></div><div class="casAuthors">Zeiler, Evelyn; Korotkov, Vadim S.; Lorenz-Baath, Katrin; Boettcher, Thomas; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">583-591</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we report the synthesis and in depth characterization of a second generation β-lactone derived virulence inhibitors.  Based on initial results that emphasized the intriguing possibility to disarm bacteria in their virulence the present study develops this concept further and analyses the potential of this strategy for drug development.  We were able to expand the collection of bioactive compds. via an efficient synthetic route.  Testing of all compds. revealed several hits with anti-virulence activity.  Moreover, we demonstrated that these mols. act solely by reducing virulence but not killing bacteria which is an important prerequisite for preserving the useful microbiome.  Finally, incubation of lactones with eukaryotic cell lines indicated a tolerable cytotoxicity which is essential for entering animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlc86XDsGH9bVg90H21EOLACvtfcHk0ljkPF5sI5KXhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFShsQ%253D%253D&md5=e721d142315991665c2135dfe037dd4c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DZeiler%26aufirst%3DE.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DLorenz-Baath%26aufirst%3DK.%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DT.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520improved%2520%25CE%25B2-lactone-based%2520anti-virulence%2520drugs%2520targeting%2520ClpP%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D583%26epage%3D591%26doi%3D10.1016%2Fj.bmc.2011.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackl, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakemeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz-Baath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">phenyl esters are potent inhibitors of caseinolytic protease P and reveal a stereogenic switch for deoligomerization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">8475</span>– <span class="NLM_lpage">8483</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b03084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b03084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=8475-8483&author=M.+W.+Hacklauthor=M.+Lakemeyerauthor=M.+Dahmenauthor=M.+Glaserauthor=A.+Pahlauthor=K.+Lorenz-Baathauthor=T.+Menzelauthor=S.+Sieversauthor=T.+B%C3%B6ttcherauthor=I.+Antesauthor=H.+Waldmannauthor=S.+A.+Sieber&title=phenyl+esters+are+potent+inhibitors+of+caseinolytic+protease+P+and+reveal+a+stereogenic+switch+for+deoligomerization&doi=10.1021%2Fjacs.5b03084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyl Esters Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for Deoligomerization</span></div><div class="casAuthors">Hackl, Mathias W.; Lakemeyer, Markus; Dahmen, Maria; Glaser, Manuel; Pahl, Axel; Lorenz-Baath, Katrin; Menzel, Thomas; Sievers, Sonja; Boettcher, Thomas; Antes, Iris; Waldmann, Herbert; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">8475-8483</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Caseinolytic protease P (ClpP) represents a central bacterial degrdn. machinery that is involved in cell homeostasis and pathogenicity.  The functional role of ClpP has been studied by genetic knockouts and through the use of beta-lactones, which remain the only specific inhibitors of ClpP discovered to date.  Beta-lactones have served as chem. tools to manipulate ClpP in several organisms; however, their potency, selectivity and stability is limited.  Despite detailed structural insights into the compn. and conformational flexibility of the ClpP active site, no rational efforts to design specific non-beta-lactone inhibitors have been reported to date.  In this work, an unbiased screen of more than 137 000 compds. was used to identify five Ph ester compds. as highly potent ClpP inhibitors that were selective for bacterial, but not human ClpP.  The potency of Ph esters largely exceeded that of beta-lactones in ClpP peptidase and protease inhibition assays and displayed unique target selectivity in living S. aureus cells.  Anal. studies revealed that while Ph esters are cleaved like native peptide substrates, they remain covalently trapped as acyl-enzyme intermediates in the active site.  The synthesis of 36 derivs. and subsequent structure-activity relationship (SAR) studies provided insights into conserved structural elements that are important for inhibition potency and acylation reactivity.  Moreover, the stereochem. of a methyl-substituent at the alpha position to the ester, resembling amino acid side chains in peptide substrates, impacted ClpP complex stability, causing either dissocn. into heptamers or retention of the tetradecameric state.  Mechanistic insights into this intriguing stereo switch and the Ph ester binding mode were obtained by mol. docking expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxvq3gVIPaQLVg90H21EOLACvtfcHk0ljkPF5sI5KXhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rI&md5=5fb5e46ba6041a9530688cb0587bb50d</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b03084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b03084%26sid%3Dliteratum%253Aachs%26aulast%3DHackl%26aufirst%3DM.%2BW.%26aulast%3DLakemeyer%26aufirst%3DM.%26aulast%3DDahmen%26aufirst%3DM.%26aulast%3DGlaser%26aufirst%3DM.%26aulast%3DPahl%26aufirst%3DA.%26aulast%3DLorenz-Baath%26aufirst%3DK.%26aulast%3DMenzel%26aufirst%3DT.%26aulast%3DSievers%26aufirst%3DS.%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DT.%26aulast%3DAntes%26aufirst%3DI.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3Dphenyl%2520esters%2520are%2520potent%2520inhibitors%2520of%2520caseinolytic%2520protease%2520P%2520and%2520reveal%2520a%2520stereogenic%2520switch%2520for%2520deoligomerization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D8475%26epage%3D8483%26doi%3D10.1021%2Fjacs.5b03084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gronauer, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandl, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakemeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackl, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meßner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachmayr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tailored human caseinolytic protease P inhibitors</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">9833</span>– <span class="NLM_lpage">9836</span>, <span class="refDoi"> DOI: 10.1039/C8CC05265D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1039%2FC8CC05265D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30109319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=9833-9836&author=T.+F.+Gronauerauthor=M.+M.+Mandlauthor=M.+Lakemeyerauthor=M.+W.+Hacklauthor=M.+Me%C3%9Fnerauthor=V.+S.+Korotkovauthor=J.+Pachmayrauthor=S.+A.+Sieber&title=Design+and+synthesis+of+tailored+human+caseinolytic+protease+P+inhibitors&doi=10.1039%2FC8CC05265D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tailored human caseinolytic protease P inhibitors</span></div><div class="casAuthors">Gronauer, Thomas F.; Mandl, Melanie M.; Lakemeyer, Markus; Hackl, Mathias W.; Messner, Martina; Korotkov, Vadim S.; Pachmayr, Johanna; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">70</span>),
    <span class="NLM_cas:pages">9833-9836</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Human caseinolytic protease P (hClpP) is important for degrdn. of misfolded proteins in the mitochondrial unfolded protein response.  Here, we introduce tailored hClpP inhibitors that utilize a steric discrimination in their core naphthofuran scaffold to selectively address the human enzyme.  This novel inhibitor generation exhibited superior activity compared to previously introduced β-lactones, optimized for bacterial ClpP.  Further insights into the bioactivity and binding to cellular targets were obtained via chem. proteomics as well as proliferation and migration studies in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDnUZPmSEPWrVg90H21EOLACvtfcHk0lgzwmr7R4rmbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsL7M&md5=6ce8fca3b3907f80432364d92e3f5faa</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1039%2FC8CC05265D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC05265D%26sid%3Dliteratum%253Aachs%26aulast%3DGronauer%26aufirst%3DT.%2BF.%26aulast%3DMandl%26aufirst%3DM.%2BM.%26aulast%3DLakemeyer%26aufirst%3DM.%26aulast%3DHackl%26aufirst%3DM.%2BW.%26aulast%3DMe%25C3%259Fner%26aufirst%3DM.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DPachmayr%26aufirst%3DJ.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tailored%2520human%2520caseinolytic%2520protease%2520P%2520inhibitors%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2018%26volume%3D54%26spage%3D9833%26epage%3D9836%26doi%3D10.1039%2FC8CC05265D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishovitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W.</span></span> <span> </span><span class="NLM_article-title">N-Terminal peptidic boronic acids selectively inhibit human ClpXP</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3451</span>– <span class="NLM_lpage">3456</span>, <span class="refDoi"> DOI: 10.1039/c004247a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1039%2Fc004247a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20523950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=3451-3456&author=K.+Knottauthor=J.+Fishovitzauthor=S.+Thorpeauthor=I.+Leeauthor=W.+Santos&title=N-Terminal+peptidic+boronic+acids+selectively+inhibit+human+ClpXP&doi=10.1039%2Fc004247a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">N-Terminal peptidic boronic acids selectively inhibit human ClpXP</span></div><div class="casAuthors">Knott, Kenneth; Fishovitz, Jennifer; Thorpe, Steven B.; Lee, Irene; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3451-3456</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis and development of N-terminal peptidic boronic acids as protease inhibitors is reported.  N-Terminal peptidic boronic acids interrogate the S' sites of the target protein for selectivity and provide a new strategy that complements the currently known peptidic α-amino boronic acids (C-terminal boronic acids).  After screening a series of N-terminal peptidic boronic acids, the first selective inhibitor of human ClpXP, an ATP-dependent serine protease present in the mitochondrial matrix, was discovered.  This should facilitate the understanding of the physiol. function of this protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZA-P25YI47Vg90H21EOLACvtfcHk0lgzwmr7R4rmbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslylu7o%253D&md5=3b592584a9cc5fe49473e6de9349d7af</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1039%2Fc004247a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc004247a%26sid%3Dliteratum%253Aachs%26aulast%3DKnott%26aufirst%3DK.%26aulast%3DFishovitz%26aufirst%3DJ.%26aulast%3DThorpe%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DSantos%26aufirst%3DW.%26atitle%3DN-Terminal%2520peptidic%2520boronic%2520acids%2520selectively%2520inhibit%2520human%2520ClpXP%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D3451%26epage%3D3456%26doi%3D10.1039%2Fc004247a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grouleff, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanchikova, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yudin, A. K.</span></span> <span> </span><span class="NLM_article-title">De Novo design of boron-based peptidomimetics as potent inhibitors of human ClpP in the presence of human ClpX</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6377</span>– <span class="NLM_lpage">6390</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00878</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00878" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6377-6390&author=J.+Tanauthor=J.+J.+Grouleffauthor=Y.+Jitkovaauthor=D.+B.+Diazauthor=E.+C.+Griffithauthor=W.+Shaoauthor=A.+F.+Bogdanchikovaauthor=G.+Podaauthor=A.+D.+Schimmerauthor=R.+E.+Leeauthor=A.+K.+Yudin&title=De+Novo+design+of+boron-based+peptidomimetics+as+potent+inhibitors+of+human+ClpP+in+the+presence+of+human+ClpX&doi=10.1021%2Facs.jmedchem.9b00878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">De novo design of boron-based peptidomimetics as potent inhibitors of human ClpP in the presence of human ClpX</span></div><div class="casAuthors">Tan, Joanne; Grouleff, Julie J.; Jitkova, Yulia; Diaz, Diego B.; Griffith, Elizabeth C.; Shao, Wenjie; Bogdanchikova, Anastasia F.; Poda, Gennady; Schimmer, Aaron D.; Lee, Richard E.; Yudin, Andrei K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6377-6390</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron's ability to modulate enzyme function.  Recently, we demonstrated that boron-contg. amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids.  Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands.  This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degrdn. of misfolded proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4BMAt-T7WnbVg90H21EOLACvtfcHk0ljg9qeox7iIjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqsL7M&md5=699109813275d6e188390045040c112b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00878%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DGrouleff%26aufirst%3DJ.%2BJ.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DD.%2BB.%26aulast%3DGriffith%26aufirst%3DE.%2BC.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DBogdanchikova%26aufirst%3DA.%2BF.%26aulast%3DPoda%26aufirst%3DG.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DYudin%26aufirst%3DA.%2BK.%26atitle%3DDe%2520Novo%2520design%2520of%2520boron-based%2520peptidomimetics%2520as%2520potent%2520inhibitors%2520of%2520human%2520ClpP%2520in%2520the%2520presence%2520of%2520human%2520ClpX%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6377%26epage%3D6390%26doi%3D10.1021%2Facs.jmedchem.9b00878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodreid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakhamchik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bakkouri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray-Owen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span> <span> </span><span class="NLM_article-title">Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1167</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.chembiol.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21944755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eisr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1167-1178&author=E.+Leungauthor=A.+Dattiauthor=M.+Cossetteauthor=J.+Goodreidauthor=S.+McCawauthor=M.+Mahauthor=A.+Nakhamchikauthor=K.+Ogataauthor=M.+El+Bakkouriauthor=Y.+Chengauthor=S.+Wodakauthor=B.+Egerauthor=E.+Paiauthor=J.+Liuauthor=S.+Gray-Owenauthor=R.+Bateyauthor=W.+Houry&title=Activators+of+cylindrical+proteases+as+antimicrobials%3A+identification+and+development+of+small+molecule+activators+of+ClpP+protease&doi=10.1016%2Fj.chembiol.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Activators of cylindrical proteases as antimicrobials: Identification and development of small molecule activators of ClpP protease</span></div><div class="casAuthors">Leung, Elisa; Datti, Alessandro; Cossette, Michele; Goodreid, Jordan; McCaw, Shannon E.; Mah, Michelle; Nakhamchik, Alina; Ogata, Koji; El Bakkouri, Majida; Cheng, Yi-Qiang; Wodak, Shoshana J.; Eger, Bryan T.; Pai, Emil F.; Liu, Jun; Gray-Owen, Scott; Batey, Robert A.; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1167-1178</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ClpP is a cylindrical serine protease whose ability to degrade proteins is regulated by the unfoldase ATP-dependent chaperones.  ClpP on its own can only degrade small peptides.  Here, the authors used ClpP as a target in a high-throughput screen for compds., which activate the protease and allow it to degrade larger proteins, hence, abolishing the specificity arising from the ATP-dependent chaperones.  Their screen resulted in five distinct compds., which we designate as Activators of Self-Compartmentalizing Proteases 1 to 5 (ACP1 to 5).  The compds. are found to stabilize the ClpP double-ring structure.  The ACP1 chem. structure was considered to have drug-like characteristics and was further optimized to give analogs with bactericidal activity.  Hence, the ACPs represent classes of compds. that can activate ClpP and that can be developed as potential novel antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwrySw6SWPYLVg90H21EOLACvtfcHk0ljg9qeox7iIjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eisr7F&md5=719b0124b9cdeb56a6bc69e044d0fc88</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DCossette%26aufirst%3DM.%26aulast%3DGoodreid%26aufirst%3DJ.%26aulast%3DMcCaw%26aufirst%3DS.%26aulast%3DMah%26aufirst%3DM.%26aulast%3DNakhamchik%26aufirst%3DA.%26aulast%3DOgata%26aufirst%3DK.%26aulast%3DEl%2BBakkouri%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWodak%26aufirst%3DS.%26aulast%3DEger%26aufirst%3DB.%26aulast%3DPai%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGray-Owen%26aufirst%3DS.%26aulast%3DBatey%26aufirst%3DR.%26aulast%3DHoury%26aufirst%3DW.%26atitle%3DActivators%2520of%2520cylindrical%2520proteases%2520as%2520antimicrobials%253A%2520identification%2520and%2520development%2520of%2520small%2520molecule%2520activators%2520of%2520ClpP%2520protease%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D1167%26epage%3D1178%26doi%3D10.1016%2Fj.chembiol.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sello, J.</span></span> <span> </span><span class="NLM_article-title">Restriction of the conformational dynamics of the cyclic acyldepsipeptide antibiotics improves their antibacterial activity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">1922</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1021/ja410385c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja410385c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVGrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=1922-1929&author=D.+Carneyauthor=K.+Schmitzauthor=J.+Truongauthor=R.+Sauerauthor=J.+Sello&title=Restriction+of+the+conformational+dynamics+of+the+cyclic+acyldepsipeptide+antibiotics+improves+their+antibacterial+activity&doi=10.1021%2Fja410385c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Restriction of the Conformational Dynamics of the Cyclic Acyldepsipeptide Antibiotics Improves Their Antibacterial Activity</span></div><div class="casAuthors">Carney, Daniel W.; Schmitz, Karl R.; Truong, Jonathan V.; Sauer, Robert T.; Sello, Jason K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1922-1929</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cyclic acyldepsipeptide (ADEP) antibiotics are a new class of antibacterial agents that kill bacteria via a mechanism that is distinct from all clin. used drugs.  These mols. bind and dysregulate the activity of the ClpP peptidase.  The potential of these antibiotics as antibacterial drugs has been enhanced by the elimination of pharmacol. liabilities through medicinal chem. efforts.  Here, the authors demonstrate that the ADEP conformation obsd. in the ADEP-ClpP crystal structure is fortified by transannular hydrogen bonding and can be further stabilized by judicious replacement of constituent amino acids within the peptidolactone core structure with more conformationally constrained counterparts.  Evidence supporting constraint of the mol. into the bioactive conformer was obtained by measurements of deuterium-exchange kinetics of hydrogens that were proposed to be engaged in transannular hydrogen bonds.  The authors show that the rigidified ADEP analogs bind and activate ClpP at lower concns. in vitro.  Remarkably, these compds. have up to 1200-fold enhanced antibacterial activity when compared to those with the peptidolactone core structure common to two ADEP natural products.  This study compellingly demonstrates how rational modulation of conformational dynamics may be used to improve the bioactivities of natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF6ekCXYW2SbVg90H21EOLACvtfcHk0lhdXej4aERlJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVGrtQ%253D%253D&md5=47bc739241cda8935c81ffca6898564f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fja410385c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja410385c%26sid%3Dliteratum%253Aachs%26aulast%3DCarney%26aufirst%3DD.%26aulast%3DSchmitz%26aufirst%3DK.%26aulast%3DTruong%26aufirst%3DJ.%26aulast%3DSauer%26aufirst%3DR.%26aulast%3DSello%26aufirst%3DJ.%26atitle%3DRestriction%2520of%2520the%2520conformational%2520dynamics%2520of%2520the%2520cyclic%2520acyldepsipeptide%2520antibiotics%2520improves%2520their%2520antibacterial%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D1922%26epage%3D1929%26doi%3D10.1021%2Fja410385c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodreid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janetzko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santa Maria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray-Owen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R.</span></span> <span> </span><span class="NLM_article-title">Development and characterization of potent cyclic acyldepsipeptide analogues with Increased antimicrobial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01451</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01451" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=624-646&author=J.+Goodreidauthor=J.+Janetzkoauthor=J.+Santa+Mariaauthor=K.+Wongauthor=E.+Leungauthor=B.+Egerauthor=S.+Brysonauthor=E.+Paiauthor=S.+Gray-Owenauthor=S.+Walkerauthor=W.+Houryauthor=R.+Batey&title=Development+and+characterization+of+potent+cyclic+acyldepsipeptide+analogues+with+Increased+antimicrobial+activity&doi=10.1021%2Facs.jmedchem.5b01451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity</span></div><div class="casAuthors">Goodreid, Jordan D.; Janetzko, John; Santa Maria, John P.; Wong, Keith S.; Leung, Elisa; Eger, Bryan T.; Bryson, Steve; Pai, Emil F.; Gray-Owen, Scott D.; Walker, Suzanne; Houry, Walid A.; Batey, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">624-646</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The problem of antibiotic resistance has prompted the search for new antibiotics with novel mechanisms of action.  Analogs of the A54556 cyclic acyldepsipeptides (ADEPs) represent an attractive class of antimicrobial agents that act through dysregulation of caseinolytic protease (ClpP).  Previous studies have shown that ADEPs are active against Gram-pos. bacteria (e.g., MRSA, VRE, PRSP (penicillin-resistant Streptococcus pneumoniae)); however, there are currently few studies examg. Gram-neg. bacteria.  In this study, the synthesis and biol. evaluation of 14 novel ADEPs against a variety of pathogenic Gram-neg. and Gram-pos. organisms is outlined.  Optimization of the macrocyclic core residues and N-acyl side chain culminated in the development of 26, which shows potent activity against the Gram-neg. species Neisseria meningitidis and Neisseria gonorrheae and improved activity against the Gram-pos. organisms Staphylococcus aureus and Enterococcus faecalis in comparison with known analogs.  In addn., the co-crystal structure of an ADEP-ClpP complex derived from N. meningitidis was solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKYhvsX0MSbVg90H21EOLACvtfcHk0lhdXej4aERlJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGmsrk%253D&md5=fc27b90261ba245c9729570bc6694188</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01451%26sid%3Dliteratum%253Aachs%26aulast%3DGoodreid%26aufirst%3DJ.%26aulast%3DJanetzko%26aufirst%3DJ.%26aulast%3DSanta%2BMaria%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DEger%26aufirst%3DB.%26aulast%3DBryson%26aufirst%3DS.%26aulast%3DPai%26aufirst%3DE.%26aulast%3DGray-Owen%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DHoury%26aufirst%3DW.%26aulast%3DBatey%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520potent%2520cyclic%2520acyldepsipeptide%2520analogues%2520with%2520Increased%2520antimicrobial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D624%26epage%3D646%26doi%3D10.1021%2Facs.jmedchem.5b01451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gersch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famulla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göbl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sass, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rübsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brötz-Oesterhelt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6320</span>, <span class="refDoi"> DOI: 10.1038/ncomms7320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fncomms7320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25695750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFensLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6320&author=M.+Gerschauthor=K.+Famullaauthor=M.+Dahmenauthor=C.+G%C3%B6blauthor=I.+Malikauthor=K.+Richterauthor=V.+S.+Korotkovauthor=P.+Sassauthor=H.+R%C3%BCbsamen-Schaeffauthor=T.+Madlauthor=H.+Br%C3%B6tz-Oesterheltauthor=S.+A.+Sieber&title=AAA%2B+chaperones+and+acyldepsipeptides+activate+the+ClpP+protease+via+conformational+control&doi=10.1038%2Fncomms7320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control</span></div><div class="casAuthors">Gersch, Malte; Famulla, Kirsten; Dahmen, Maria; Goebl, Christoph; Malik, Imran; Richter, Klaus; Korotkov, Vadim S.; Sass, Peter; Ruebsamen-Schaeff, Helga; Madl, Tobias; Broetz-Oesterhelt, Heike; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6320</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Clp protease complex degrades a multitude of substrates, which are engaged by a AAA+ chaperone such as ClpX and subsequently digested by the dynamic, barrel-shaped ClpP protease.  Acyldepsipeptides (ADEPs) are natural product-derived antibiotics that activate ClpP for chaperone-independent protein digestion.  Here we show that both protein and small-mol. activators of ClpP allosterically control the ClpP barrel conformation.  We dissect the catalytic mechanism with chem. probes and show that ADEP in addn. to opening the axial pore directly stimulates ClpP activity through cooperative binding.  ClpP activation thus reaches beyond active site accessibility and also involves conformational control of the catalytic residues.  Moreover, we demonstrate that substoichiometric amts. of ADEP potently prevent binding of ClpX to ClpP and, at the same time, partially inhibit ClpP through conformational perturbance.  Collectively, our results establish the hydrophobic binding pocket as a major conformational regulatory site with implications for both ClpXP proteolysis and ADEP-based anti-bacterial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUgjQrOvvCT7Vg90H21EOLACvtfcHk0ljCGGkV36PCEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFensLw%253D&md5=0600e7339571a8b20983207c7bd87419</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fncomms7320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7320%26sid%3Dliteratum%253Aachs%26aulast%3DGersch%26aufirst%3DM.%26aulast%3DFamulla%26aufirst%3DK.%26aulast%3DDahmen%26aufirst%3DM.%26aulast%3DG%25C3%25B6bl%26aufirst%3DC.%26aulast%3DMalik%26aufirst%3DI.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DSass%26aufirst%3DP.%26aulast%3DR%25C3%25BCbsamen-Schaeff%26aufirst%3DH.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DBr%25C3%25B6tz-Oesterhelt%26aufirst%3DH.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DAAA%252B%2520chaperones%2520and%2520acyldepsipeptides%2520activate%2520the%2520ClpP%2520protease%2520via%2520conformational%2520control%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6320%26doi%3D10.1038%2Fncomms7320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabanglo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seraphim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moutaoufik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodreid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span> <span> </span><span class="NLM_article-title">Acyldepsipeptide analogs dysregulate human mitochondrial ClpP protease activity and cause apoptotic cell death</span>. <i>Cell chemical biology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.chembiol.2018.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30126533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Cis7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=1017-1030&author=K.+Wongauthor=M.+Mabangloauthor=T.+Seraphimauthor=A.+Mollicaauthor=Y.+Maoauthor=K.+Rizzoloauthor=E.+Leungauthor=M.+Moutaoufikauthor=L.+Hoellauthor=S.+Phanseauthor=J.+Goodreidauthor=L.+Barbosaauthor=C.+Ramosauthor=M.+Babuauthor=V.+Mennellaauthor=R.+Bateyauthor=A.+Schimmerauthor=W.+Houry&title=Acyldepsipeptide+analogs+dysregulate+human+mitochondrial+ClpP+protease+activity+and+cause+apoptotic+cell+death&doi=10.1016%2Fj.chembiol.2018.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Acyldepsipeptide Analogs Dysregulate Human Mitochondrial ClpP Protease Activity and Cause Apoptotic Cell Death</span></div><div class="casAuthors">Wong, Keith S.; Mabanglo, Mark F.; Seraphim, Thiago V.; Mollica, Antonio; Mao, Yu-Qian; Rizzolo, Kamran; Leung, Elisa; Moutaoufik, Mohamed T.; Hoell, Larissa; Phanse, Sadhna; Goodreid, Jordan; Barbosa, Leandro R. S.; Ramos, Carlos H. I.; Babu, Mohan; Mennella, Vito; Batey, Robert A.; Schimmer, Aaron D.; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1017-1030.e9</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Acyldepsipeptides (ADEPs) are potential antibiotics that dysregulate the activity of the highly conserved tetradecameric bacterial ClpP protease, leading to bacterial cell death.  Here, we identified ADEP analogs that are potent dysregulators of the human mitochondrial ClpP (HsClpP).  These ADEPs interact tightly with HsClpP, causing the protease to non-specifically degrade model substrates.  Dysregulation of HsClpP activity by ADEP was found to induce cytotoxic effects via activation of the intrinsic, caspase-dependent apoptosis.  ADEP-HsClpP co-crystal structure was solved for one of the analogs revealing a highly complementary binding interface formed by two HsClpP neighboring subunits but, unexpectedly, with HsClpP in the compact conformation.  Given that HsClpP is highly expressed in multiple cancers and has important roles in cell metastasis, our findings suggest a therapeutic potential for ADEPs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF835B8v9aubVg90H21EOLACvtfcHk0ljCGGkV36PCEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Cis7bO&md5=250f3a70350ba2f8196413c84f147121</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMabanglo%26aufirst%3DM.%26aulast%3DSeraphim%26aufirst%3DT.%26aulast%3DMollica%26aufirst%3DA.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DRizzolo%26aufirst%3DK.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DMoutaoufik%26aufirst%3DM.%26aulast%3DHoell%26aufirst%3DL.%26aulast%3DPhanse%26aufirst%3DS.%26aulast%3DGoodreid%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DL.%26aulast%3DRamos%26aufirst%3DC.%26aulast%3DBabu%26aufirst%3DM.%26aulast%3DMennella%26aufirst%3DV.%26aulast%3DBatey%26aufirst%3DR.%26aulast%3DSchimmer%26aufirst%3DA.%26aulast%3DHoury%26aufirst%3DW.%26atitle%3DAcyldepsipeptide%2520analogs%2520dysregulate%2520human%2520mitochondrial%2520ClpP%2520protease%2520activity%2520and%2520cause%2520apoptotic%2520cell%2520death%26jtitle%3DCell%2520chemical%2520biology%26date%3D2018%26volume%3D25%26spage%3D1017%26epage%3D1030%26doi%3D10.1016%2Fj.chembiol.2018.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balogh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kick, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kielkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">Selective activation of human caseinolytic protease P (ClpP)</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">14602</span>– <span class="NLM_lpage">14607</span>, <span class="refDoi"> DOI: 10.1002/anie.201808189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fanie.201808189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=14602-14607&author=M.+Stahlauthor=V.+S.+Korotkovauthor=D.+Baloghauthor=L.+M.+Kickauthor=M.+Gerschauthor=A.+Pahlauthor=P.+Kielkowskiauthor=K.+Richterauthor=S.+Schneiderauthor=S.+A.+Sieber&title=Selective+activation+of+human+caseinolytic+protease+P+%28ClpP%29&doi=10.1002%2Fanie.201808189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Activation of Human Caseinolytic Protease P (ClpP)</span></div><div class="casAuthors">Stahl, Matthias; Korotkov, Vadim S.; Balogh, Dora; Kick, Leonhard M.; Gersch, Malte; Pahl, Axel; Kielkowski, Pavel; Richter, Klaus; Schneider, Sabine; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14602-14607</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Caseinolytic protease P (ClpP) is the proteolytic component of the ClpXP protein degrdn. complex.  Eukaryotic ClpP was recently found to act within the mitochondria-specific unfolded protein response (UPRmt).  However, its detailed function and dedicated regulation remain largely unexplored.  A small mol. (D9) acts as a potent and species-selective activator of human ClpP (hClpP) by mimicking the natural chaperone ClpX.  Structure-activity relationship studies highlight the importance of a halogenated benzyl motif within D9 that interacts with a unique arom. amino acid network in hClpP.  Mutational and structural studies suggest that this YYW motif tightly controls hClpP activity and regulates substrate turnover by interaction with cognate ligands.  This signature motif is unique to ClpP from higher organisms and does not exist in tested bacterial homologues, allowing a species-selective anal.  Thus, D9 is a versatile tool to analyze mechanistic features of hClpP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJpXalhsHFdrVg90H21EOLACvtfcHk0lhYw-LZUFAhzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejurvI&md5=04d63d349df635d7965f974dda4f8632</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fanie.201808189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201808189%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DBalogh%26aufirst%3DD.%26aulast%3DKick%26aufirst%3DL.%2BM.%26aulast%3DGersch%26aufirst%3DM.%26aulast%3DPahl%26aufirst%3DA.%26aulast%3DKielkowski%26aufirst%3DP.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DSelective%2520activation%2520of%2520human%2520caseinolytic%2520protease%2520P%2520%2528ClpP%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D14602%26epage%3D14607%26doi%3D10.1002%2Fanie.201808189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarabi, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Germain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heese, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barghout, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabanglo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stogniew, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccell.2019.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=31056398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=721-737&author=J.+Ishizawaauthor=S.+F.+Zarabiauthor=R.+E.+Davisauthor=O.+Halgasauthor=T.+Niiauthor=Y.+Jitkovaauthor=R.+Zhaoauthor=J.+St-Germainauthor=L.+E.+Heeseauthor=G.+Eganauthor=V.+R.+Ruvoloauthor=S.+H.+Barghoutauthor=Y.+Nishidaauthor=R.+Hurrenauthor=W.+Maauthor=M.+Grondaauthor=T.+Linkauthor=K.+Wongauthor=M.+Mabangloauthor=K.+Kojimaauthor=G.+Borthakurauthor=N.+MacLeanauthor=M.+C.+J.+Maauthor=A.+B.+Leberauthor=M.+D.+Mindenauthor=W.+Houryauthor=H.+Kantarjianauthor=M.+Stogniewauthor=B.+Raughtauthor=E.+F.+Paiauthor=A.+D.+Schimmerauthor=M.+Andreeff&title=Mitochondrial+ClpP-mediated+proteolysis+induces+selective+cancer+cell+lethality&doi=10.1016%2Fj.ccell.2019.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality</span></div><div class="casAuthors">Ishizawa, Jo; Zarabi, Sarah F.; Davis, R. Eric; Halgas, Ondrej; Nii, Takenobu; Jitkova, Yulia; Zhao, Ran; St-Germain, Jonathan; Heese, Lauren E.; Egan, Grace; Ruvolo, Vivian R.; Barghout, Samir H.; Nishida, Yuki; Hurren, Rose; Ma, Wencai; Gronda, Marcela; Link, Todd; Wong, Keith; Mabanglo, Mark; Kojima, Kensuke; Borthakur, Gautam; MacLean, Neil; Ma, Man Chun John; Leber, Andrew B.; Minden, Mark D.; Houry, Walid; Kantarjian, Hagop; Stogniew, Martin; Raught, Brian; Pai, Emil F.; Schimmer, Aaron D.; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-737.e9</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins.  Using genetic and chem. approaches, we showed that hyperactivation of the protease selectively kills cancer cells, independently of p53 status, by selective degrdn. of its respiratory chain protein substrates and disrupts mitochondrial structure and function, while it does not affect non-malignant cells.  We identified imipridones as potent activators of ClpP.  Through biochem. studies and crystallog., we show that imipridones bind ClpP non-covalently and induce proteolysis by diverse structural changes.  Imipridones are presently in clin. trials.  Our findings suggest a general concept of inducing cancer cell lethality through activation of mitochondrial proteolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTd24nbBAMXrVg90H21EOLACvtfcHk0lhaWMfu-sORSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOmur0%253D&md5=b1a92c3cdf8f9f527563c798480c18e0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DIshizawa%26aufirst%3DJ.%26aulast%3DZarabi%26aufirst%3DS.%2BF.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DHalgas%26aufirst%3DO.%26aulast%3DNii%26aufirst%3DT.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSt-Germain%26aufirst%3DJ.%26aulast%3DHeese%26aufirst%3DL.%2BE.%26aulast%3DEgan%26aufirst%3DG.%26aulast%3DRuvolo%26aufirst%3DV.%2BR.%26aulast%3DBarghout%26aufirst%3DS.%2BH.%26aulast%3DNishida%26aufirst%3DY.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DLink%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMabanglo%26aufirst%3DM.%26aulast%3DKojima%26aufirst%3DK.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DMacLean%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DM.%2BC.%2BJ.%26aulast%3DLeber%26aufirst%3DA.%2BB.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DHoury%26aufirst%3DW.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DStogniew%26aufirst%3DM.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DPai%26aufirst%3DE.%2BF.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMitochondrial%2520ClpP-mediated%2520proteolysis%2520induces%2520selective%2520cancer%2520cell%2520lethality%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D35%26spage%3D721%26epage%3D737%26doi%3D10.1016%2Fj.ccell.2019.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Sloot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">C Huard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe-Huntington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertomeu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonneil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyers, M.</span></span> <span> </span><span class="NLM_article-title">Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1120</span>, <span class="refDoi"> DOI: 10.1534/genetics.119.302851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1534%2Fgenetics.119.302851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32094149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVarsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2020&pages=1103-1120&author=S.+Jacquesauthor=A.+van+der+Slootauthor=C.+C+Huardauthor=J.+Coulombe-Huntingtonauthor=S.+Tsaoauthor=S.+Tollisauthor=T.+Bertomeuauthor=E.+Culpauthor=D.+Pallantauthor=M.+Cookauthor=E.+Bonneilauthor=P.+Thibaultauthor=G.+Wrightauthor=M.+Tyers&title=Imipridone+anticancer+compounds+ectopically+activate+the+ClpP+protease+and+represent+a+new+scaffold+for+antibiotic+development&doi=10.1534%2Fgenetics.119.302851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Imipridone anticancer compounds ectopically activate the ClpP Protease and represent a new scaffold for antibiotic development</span></div><div class="casAuthors">Jacques, Samuel; van der Sloot, Almer M.; Huard, Caroline C.; Coulombe-Huntington, Jasmin; Tsao, Sarah; Tollis, Sylvain; Bertomeu, Thierry; Culp, Elizabeth J.; Pallant, Daniel; Cook, Michael A.; Bonneil, Eric; Thibault, Pierre; Wright, Gerard D.; Tyers, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Genetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1103-1120</span>CODEN:
                <span class="NLM_cas:coden">GENTAE</span>;
        ISSN:<span class="NLM_cas:issn">0016-6731</span>.
    
            (<span class="NLM_cas:orgname">Genetics Society of America</span>)
        </div><div class="casAbstract">Systematic genetic interaction profiles can reveal the mechanisms-of-action of bioactive compds.  The imipridone ONC201, which is currently in cancer clin. trials, has been ascribed a variety of different targets.  To investigate the genetic dependencies of imipridone action, we screened a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) knockout library in the presence of either ONC201 or its more potent analog ONC212.  Loss of the mitochondrial matrix protease CLPP or the mitochondrial intermediate peptidase MIPEP conferred strong resistance to both compds.  Biochem. and surrogate genetic assays showed that impridones directly activate CLPP and that MIPEP is necessary for proteolytic maturation of CLPP into a catalytically competent form.  Quant. proteomic anal. of cells treated with ONC212 revealed degrdn. of many mitochondrial as well as nonmitochondrial proteins.  Prompted by the conservation of ClpP from bacteria to humans, we found that the imipridones also activate ClpP from Escherichia coli, Bacillus subtilis, and Staphylococcus aureus in biochem. and genetic assays.  ONC212 and acyldepsipeptide-4 (ADEP4), a known activator of bacterial ClpP, caused similar proteome-wide degrdn. profiles in S. aureus.  ONC212 suppressed the proliferation of a no. of Gram-pos. (S. aureus, B. subtilis, and Enterococcus faecium) and Gramneg. species (E. coli and Neisseria gonorrhoeae).  Moreover, ONC212 enhanced the ability of rifampin to eradicate antibiotictolerant S. aureus persister cells.  These results reveal the genetic dependencies of imipridone action in human cells and identify the imipridone scaffold as a new entry point for antibiotic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYUg-FrUzprVg90H21EOLACvtfcHk0lhaWMfu-sORSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVarsrrM&md5=8fdc0ed3390fedfc57cd795ecf0d75c3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1534%2Fgenetics.119.302851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1534%252Fgenetics.119.302851%26sid%3Dliteratum%253Aachs%26aulast%3DJacques%26aufirst%3DS.%26aulast%3Dvan%2Bder%2BSloot%26aufirst%3DA.%26aulast%3DC%2BHuard%26aufirst%3DC.%26aulast%3DCoulombe-Huntington%26aufirst%3DJ.%26aulast%3DTsao%26aufirst%3DS.%26aulast%3DTollis%26aufirst%3DS.%26aulast%3DBertomeu%26aufirst%3DT.%26aulast%3DCulp%26aufirst%3DE.%26aulast%3DPallant%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DM.%26aulast%3DBonneil%26aufirst%3DE.%26aulast%3DThibault%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DTyers%26aufirst%3DM.%26atitle%3DImipridone%2520anticancer%2520compounds%2520ectopically%2520activate%2520the%2520ClpP%2520protease%2520and%2520represent%2520a%2520new%2520scaffold%2520for%2520antibiotic%2520development%26jtitle%3DGenetics%26date%3D2020%26volume%3D214%26spage%3D1103%26epage%3D1120%26doi%3D10.1534%2Fgenetics.119.302851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessenbrock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaks, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases: regulators of the tumor microenvironment</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.cell.2010.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20371345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=52-67&author=K.+Kessenbrockauthor=V.+Plaksauthor=Z.+Werb&title=Matrix+metalloproteinases%3A+regulators+of+the+tumor+microenvironment&doi=10.1016%2Fj.cell.2010.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases: regulators of the tumor microenvironment</span></div><div class="casAuthors">Kessenbrock, Kai; Plaks, Vicki; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-67</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Extracellular proteolysis mediates tissue homeostasis.  In cancer, altered proteolysis leads to unregulated tumor growth, tissue remodeling, inflammation, tissue invasion, and metastasis.  The matrix metalloproteinases (MMPs) represent the most prominent family of proteinases assocd. with tumorigenesis.  Recent technol. developments have markedly advanced our understanding of MMPs as modulators of the tumor microenvironment.  In addn. to their role in extracellular matrix turnover and cancer cell migration, MMPs regulate signaling pathways that control cell growth, inflammation, or angiogenesis and may even work in a nonproteolytic manner.  These aspects of MMP function are reorienting our approaches to cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAwNenyy027LVg90H21EOLACvtfcHk0liwTgOmJz4tFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtb4%253D&md5=fb7ee4c41ef31db0310b985e87bcdb94</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DKessenbrock%26aufirst%3DK.%26aulast%3DPlaks%26aufirst%3DV.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DMatrix%2520metalloproteinases%253A%2520regulators%2520of%2520the%2520tumor%2520microenvironment%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D52%26epage%3D67%26doi%3D10.1016%2Fj.cell.2010.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin Jensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrahmanyam, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandehari, H.</span></span> <span> </span><span class="NLM_article-title">Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>259</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2017.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.jconrel.2017.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28153760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2017&pages=62-75&author=K.+J.+Isaacsonauthor=M.+Martin+Jensenauthor=N.+B.+Subrahmanyamauthor=H.+Ghandehari&title=Matrix-metalloproteinases+as+targets+for+controlled+delivery+in+cancer%3A+An+analysis+of+upregulation+and+expression&doi=10.1016%2Fj.jconrel.2017.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression</span></div><div class="casAuthors">Isaacson, Kyle J.; Jensen, M. Martin; Subrahmanyam, Nithya B.; Ghandehari, Hamidreza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">259</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-75</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  While commonly known for degrdn. of the extracellular matrix, matrix metalloproteinases (MMPs) exhibit broad potential for use in targeting of bioactive and imaging agents in cancer treatment.  MMPs are upregulated at all stages of expression in cancers.  A comprehensive anal. of published literature on expression of all MMP subtypes at the genetic, protein, and activity levels in normal and diseased tissues indicate targeting applicability in a variety of cancers.  This expression significantly increases at advanced cancer stages, providing an improved opportunity for controlled release in higher-stage patients.  Since MMPs are integral at every stage of metastasis, MMP roles in cancer are discussed with a focus on MMP distribution and mobility within cells and tumors for cancer targeting applications.  Several strategies for MMP utilization in targeting - such as matrix degrdn., MMP cleavage, MMP binding, and MMP-induced environmental changes - are addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaU-TKJ4EKNbVg90H21EOLACvtfcHk0liwTgOmJz4tFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrurg%253D&md5=4e354ff9a251cc610d53fee86dcab23d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2017.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2017.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacson%26aufirst%3DK.%2BJ.%26aulast%3DMartin%2BJensen%26aufirst%3DM.%26aulast%3DSubrahmanyam%26aufirst%3DN.%2BB.%26aulast%3DGhandehari%26aufirst%3DH.%26atitle%3DMatrix-metalloproteinases%2520as%2520targets%2520for%2520controlled%2520delivery%2520in%2520cancer%253A%2520An%2520analysis%2520of%2520upregulation%2520and%2520expression%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2017%26volume%3D259%26spage%3D62%26epage%3D75%26doi%3D10.1016%2Fj.jconrel.2017.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000070112.80711.3D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1161%2F01.RES.0000070112.80711.3D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12730128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=827-839&author=R.+Visseauthor=H.+Nagase&title=Matrix+metalloproteinases+and+tissue+inhibitors+of+metalloproteinases%3A+structure%2C+function%2C+and+biochemistry&doi=10.1161%2F01.RES.0000070112.80711.3D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry</span></div><div class="casAuthors">Visse, Robert; Nagase, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-839</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs), also designated matrixins, hydrolyze components of the extracellular matrix.  These proteinases play a central role in many biol. processes, such as embryogenesis, normal tissue remodeling, wound healing, and angiogenesis, and in diseases such as atheroma, arthritis, cancer, and tissue ulceration.  Currently 23 MMP genes have been identified in humans, and most are multidomain proteins.  This review describes the members of the matrixin family and discusses substrate specificity, domain structure and function, the activation of proMMPs, the regulation of matrixin activity by tissue inhibitors of metalloproteinases (TIMPs), and their pathophysiol. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_QfsPFZtdjLVg90H21EOLACvtfcHk0lg-tciRAsI62w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7c%253D&md5=0fddee610a1b1defa7f60a14a11ae127</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000070112.80711.3D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000070112.80711.3D%26sid%3Dliteratum%253Aachs%26aulast%3DVisse%26aufirst%3DR.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DMatrix%2520metalloproteinases%2520and%2520tissue%2520inhibitors%2520of%2520metalloproteinases%253A%2520structure%252C%2520function%252C%2520and%2520biochemistry%26jtitle%3DCirc.%2520Res.%26date%3D2003%26volume%3D92%26spage%3D827%26epage%3D839%26doi%3D10.1161%2F01.RES.0000070112.80711.3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G.</span></span> <span> </span><span class="NLM_article-title">Structure and function of matrix metalloproteinases and TIMPs</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1016/j.cardiores.2005.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.cardiores.2005.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16405877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=562-573&author=H.+Nagaseauthor=R.+Visseauthor=G.+Murphy&title=Structure+and+function+of+matrix+metalloproteinases+and+TIMPs&doi=10.1016%2Fj.cardiores.2005.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of matrix metalloproteinases and TIMPs</span></div><div class="casAuthors">Nagase, Hideaki; Visse, Robert; Murphy, Gillian</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">562-573</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs), also called matrixins, function in the extracellular environment of cells and degrade both matrix and non-matrix proteins.  They play central roles in morphogenesis, wound healing, tissue repair and remodelling in response to injury, e.g. after myocardial infarction, and in progression of diseases such as atheroma, arthritis, cancer and chronic tissue ulcers.  They are multi-domain proteins and their activities are regulated by tissue inhibitors of metalloproteinases (TIMPs).  This review introduces the members of the MMP family and discusses their domain structure and function, proenyme activation, the mechanism of inhibition by TIMPs and their significance in physiol. and pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo77sy3-HPv0rVg90H21EOLACvtfcHk0lg-tciRAsI62w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVKitg%253D%253D&md5=2c9b99a424f3a604cc4dc899ddc41cd7</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2005.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2005.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DVisse%26aufirst%3DR.%26aulast%3DMurphy%26aufirst%3DG.%26atitle%3DStructure%2520and%2520function%2520of%2520matrix%2520metalloproteinases%2520and%2520TIMPs%26jtitle%3DCardiovasc.%2520Res.%26date%3D2006%26volume%3D69%26spage%3D562%26epage%3D573%26doi%3D10.1016%2Fj.cardiores.2005.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, R. A.</span></span> <span> </span><span class="NLM_article-title">Biochemical and biological attributes of matrix metalloproteinases</span>. <i>Progress in molecular biology and translational science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/bs.pmbts.2017.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fbs.pmbts.2017.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28413025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1yhs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2017&pages=1-73&author=N.+Cuiauthor=M.+Huauthor=R.+A.+Khalil&title=Biochemical+and+biological+attributes+of+matrix+metalloproteinases&doi=10.1016%2Fbs.pmbts.2017.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and biological attributes of matrix metalloproteinases</span></div><div class="casAuthors">Cui, Ning; Hu, Min; Khalil, Raouf A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Cardiovascular Remodeling</span>),
    <span class="NLM_cas:pages">1-73</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that are involved in the degrdn. of various proteins in the extracellular matrix (ECM).  Typically, MMPs have a propeptide sequence, a catalytic metalloproteinase domain with catalytic zinc, a hinge region or linker peptide, and a hemopexin domain.  MMPs are commonly classified on the basis of their substrates and the organization of their structural domains into collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT)-MMPs, and other MMPs.  MMPs are secreted by many cells including fibroblasts, vascular smooth muscle (VSM), and leukocytes.  MMPs are regulated at the level of mRNA expression and by activation of their latent zymogen form.  MMPs are often secreted as inactive pro-MMP form which is cleaved to the active form by various proteinases including other MMPs.  MMPs cause degrdn. of ECM proteins such as collagen and elastin, but could influence endothelial cell function as well as VSM cell migration, proliferation, Ca2+ signaling, and contraction.  MMPs play a role in tissue remodeling during various physiol. processes such as angiogenesis, embryogenesis, morphogenesis, and wound repair, as well as in pathol. conditions such as myocardial infarction, fibrotic disorders, osteoarthritis, and cancer.  Increases in specific MMPs could play a role in arterial remodeling, aneurysm formation, venous dilation, and lower extremity venous disorders.  MMPs also play a major role in leukocyte infiltration and tissue inflammation.  MMPs have been detected in cancer, and elevated MMP levels have been assocd. with tumor progression and invasiveness.  MMPs can be regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs), and the MMP/TIMP ratio often dets. the extent of ECM protein degrdn. and tissue remodeling.  MMPs have been proposed as biomarkers for numerous pathol. conditions and are being examd. as potential therapeutic targets in various cardiovascular and musculoskeletal disorders as well as cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFMGEWZ3Mm8LVg90H21EOLACvtfcHk0lg-tciRAsI62w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1yhs7vI&md5=2e660198c8cfd7f0f46df92b1ff1ff43</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmbts.2017.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmbts.2017.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DKhalil%26aufirst%3DR.%2BA.%26atitle%3DBiochemical%2520and%2520biological%2520attributes%2520of%2520matrix%2520metalloproteinases%26jtitle%3DProgress%2520in%2520molecular%2520biology%2520and%2520translational%2520science%26date%3D2017%26volume%3D147%26spage%3D1%26epage%3D73%26doi%3D10.1016%2Fbs.pmbts.2017.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollborn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, A.</span></span> <span> </span><span class="NLM_article-title">Positive feedback regulation between MMP-9 and VEGF in human RPE cells</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4360</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1167/iovs.06-1234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1167%2Fiovs.06-1234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17724228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BD2srgsVOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=4360-4367&author=M.+Hollbornauthor=C.+Stathopoulosauthor=A.+Steffenauthor=P.+Wiedemannauthor=L.+Kohenauthor=A.+Bringmann&title=Positive+feedback+regulation+between+MMP-9+and+VEGF+in+human+RPE+cells&doi=10.1167%2Fiovs.06-1234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Positive feedback regulation between MMP-9 and VEGF in human RPE cells</span></div><div class="casAuthors">Hollborn Margrit; Stathopoulos Christina; Steffen Anja; Wiedemann Peter; Kohen Leon; Bringmann Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4360-7</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  The proteolytic activity of matrix metalloproteinases (MMPs) is involved in pathologic angiogenesis in the eye.  However, it is unknown whether MMPs may stimulate the production of the major angiogenic factor, vascular endothelial growth factor (VEGF).  The authors investigated whether MMP-2 and MMP-9 alter the expression of VEGF by retinal pigment epithelial (RPE) cells.  They also sought to determine the effects of MMPs on cellular proliferation and migration and the effect of triamcinolone acetonide on MMP-9-evoked cellular responses.  METHODS:  Human RPE cell cultures were stimulated with MMP-2 or MMP-9.  The gene expression and secretion of MMP-9 and VEGF were determined by real-time RT-PCR and ELISA, respectively.  Cellular proliferation was investigated with a bromodeoxyuridine immunoassay, and chemotaxis was examined with a Boyden chamber assay.  RESULTS:  Under control conditions, RPE cells in vitro expressed a significantly higher amount of mRNA for MMP-2 than for MMP-9.  Chemical hypoxia caused upregulation of the gene expression of both MMPs, whereas VEGF increased the gene expression and secretion of MMP-9.  The hypoxic expression of MMP-9 was mediated by autocrine VEGF signaling.  Exogenous MMP-9 increased the gene expression and secretion of VEGF, whereas MMP-2 reduced the secretion of VEGF.  MMP-2 and MMP-9 did not alter the proliferation but stimulated the migration of RPE cells.  Triamcinolone fully inhibited the stimulatory effect of MMP-9 on the expression of VEGF and the VEGF-evoked increase in the expression of MMP-9.  However, triamcinolone had no effect on the motogenic effect of MMP-9.  CONCLUSIONS:  There is a positive feedback regulation between MMP-9 and VEGF in RPE cells.  The hypoxic expression of MMP-9 may stimulate the production and secretion of VEGF under pathologic conditions.  Triamcinolone inhibits the positive feedback regulation between MMP-9 and VEGF under hypoxic conditions through inhibition of the gene expression of MMP-9 and the secretion of VEGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPqea63gPcdFxYDaSSP8XfW6udTcc2eaFsVS1PAhqdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srgsVOitA%253D%253D&md5=8325e55b1b946e5dc7438c7fe3e1b448</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1167%2Fiovs.06-1234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.06-1234%26sid%3Dliteratum%253Aachs%26aulast%3DHollborn%26aufirst%3DM.%26aulast%3DStathopoulos%26aufirst%3DC.%26aulast%3DSteffen%26aufirst%3DA.%26aulast%3DWiedemann%26aufirst%3DP.%26aulast%3DKohen%26aufirst%3DL.%26aulast%3DBringmann%26aufirst%3DA.%26atitle%3DPositive%2520feedback%2520regulation%2520between%2520MMP-9%2520and%2520VEGF%2520in%2520human%2520RPE%2520cells%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2007%26volume%3D48%26spage%3D4360%26epage%3D4367%26doi%3D10.1167%2Fiovs.06-1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bornschein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wex, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selgrad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jechorek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird-Lieberman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfertheiner, P.</span></span> <span> </span><span class="NLM_article-title">MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression</span>. <i>Diagn. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">212</span>, <span class="refDoi"> DOI: 10.1186/s13000-015-0449-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs13000-015-0449-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26652716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKhurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=212&author=J.+Bornscheinauthor=T.+Seidelauthor=C.+Langnerauthor=A.+Linkauthor=T.+Wexauthor=M.+Selgradauthor=D.+Jechorekauthor=F.+Meyerauthor=E.+Bird-Liebermanauthor=M.+Viethauthor=P.+Malfertheiner&title=MMP2+and+MMP7+at+the+invasive+front+of+gastric+cancer+are+not+associated+with+mTOR+expression&doi=10.1186%2Fs13000-015-0449-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression</span></div><div class="casAuthors">Bornschein, Jan; Seidel, Tina; Langner, Cosima; Link, Alexander; Wex, Thomas; Selgrad, Michael; Jechorek, Doerthe; Meyer, Frank; Bird-Lieberman, Elizabeth; Vieth, Michael; Malfertheiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212/1-212/5</span>CODEN:
                <span class="NLM_cas:coden">DPIAAA</span>;
        ISSN:<span class="NLM_cas:issn">1746-1596</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Regulation of MMP expression by activation of mTOR signalling has been demonstrated for several tumor types, but has thus far not been confirmed in gastric cancer.  Findings: The study compromised 128 patients who underwent gastric resection for cancer (66.4 % male; 86 intestinal, 42 diffuse type).  Immunohistochem. staining of MMPs was performed to analyze the topog. pattern of MMP expression at the tumor center and the invasive front, resp.  MMP2 showed higher expression at the invasive front compared to the tumor center, whereas MMP7 staining scores were higher in the tumor center, and there was no difference for MMP9.  The expression of p-mTOR was higher in the tumor center than at the invasive front, with a similar trend for mTOR.  For intestinal type gastric cancer there was a weak correlation of MMP9 with expression of mTOR in the tumor center.  Otherwise, there was no correlation of the MMPs with mTOR.  By treatment of MKN45 gastric cancer cells with rapamycin, a redn. of p-mTOR in the Western blot was achieved; however, expression of MMPs remained unaffected.  Conclusions: Expression of MMP2 and MMP7 in gastric cancer is not assocd. with mTOR, MMP9 expression might be related to mTOR signalling in a subset of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqtQnHXIOxbLVg90H21EOLACvtfcHk0lh1o_YZN2o8Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKhurzJ&md5=f68943a12e1ba6e266e39080c266927b</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs13000-015-0449-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13000-015-0449-z%26sid%3Dliteratum%253Aachs%26aulast%3DBornschein%26aufirst%3DJ.%26aulast%3DSeidel%26aufirst%3DT.%26aulast%3DLangner%26aufirst%3DC.%26aulast%3DLink%26aufirst%3DA.%26aulast%3DWex%26aufirst%3DT.%26aulast%3DSelgrad%26aufirst%3DM.%26aulast%3DJechorek%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DF.%26aulast%3DBird-Lieberman%26aufirst%3DE.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DMalfertheiner%26aufirst%3DP.%26atitle%3DMMP2%2520and%2520MMP7%2520at%2520the%2520invasive%2520front%2520of%2520gastric%2520cancer%2520are%2520not%2520associated%2520with%2520mTOR%2520expression%26jtitle%3DDiagn.%2520Pathol.%26date%3D2015%26volume%3D10%26spage%3D212%26doi%3D10.1186%2Fs13000-015-0449-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Illemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majeed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehested, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laerum, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danø, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, B.</span></span> <span> </span><span class="NLM_article-title">MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-06-0003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1541-7786.MCR-06-0003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16687484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BD283mtlGhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=293-302&author=M.+Illemannauthor=N.+Birdauthor=A.+Majeedauthor=M.+Sehestedauthor=O.+Laerumauthor=L.+Lundauthor=K.+Dan%C3%B8author=B.+Nielsen&title=MMP-9+is+differentially+expressed+in+primary+human+colorectal+adenocarcinomas+and+their+metastases&doi=10.1158%2F1541-7786.MCR-06-0003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases</span></div><div class="casAuthors">Illemann Martin; Bird Nigel; Majeed Ali; Sehested Maxwell; Laerum Ole D; Lund Leif R; Dano Keld; Nielsen Boye Schnack</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer research : MCR</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">293-302</span>
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    </div><div class="casAbstract">Matrix metalloproteinase-9 (MMP-9) is up-regulated in macrophages in various human cancer types.  In human colon cancer, MMP-9 is expressed in a macrophage subpopulation located at the tumor edge, indicating a specific induction of MMP-9 in macrophages in direct association with cancer invasion.  To test whether MMP-9 is also induced in tumor edge macrophages in metastases from colorectal adenocarcinomas, we have compared the expression pattern of MMP-9 in primary colorectal adenocarcinomas (n = 15) with that in liver metastases (n = 15) and local lymph node metastases (n = 7) from the same patients by in situ hybridization and immunohistochemistry.  In all the colorectal adenocarcinomas, the expression of MMP-9 mRNA and immunoreactivity in macrophages was located at the invasive front.  In contrast, only 3 of the 15 liver metastases had MMP-9 mRNA and immunoreactivity at the periphery, and this expression was confined to small foci of macrophages located either among lymphocytes or in a dense desmoplastic stroma.  Expression of MMP-9 mRNA and immunoreactivity was in all liver metastases seen in macrophages located in the lumen of malignant glandular structures and in central necrotic tissue.  In all the 7 lymph node metastases, MMP-9 mRNA and immunoreactivity was seen in macrophages located in the stromal tissue surrounding the metastases.  We conclude that MMP-9 is not up-regulated in tumor edge macrophages in liver metastases like in their primary tumor and local lymph node metastases, suggesting that disseminating colorectal cancer cells can adopt alternative proteolytic mechanisms for invasion depending on the local microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIIw9rPqdfQYHWj6b1v8uTfW6udTcc2eb6eLHRmsG0K7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283mtlGhsg%253D%253D&md5=ebe587b4cf4cb62237e498ae078abaeb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-06-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-06-0003%26sid%3Dliteratum%253Aachs%26aulast%3DIllemann%26aufirst%3DM.%26aulast%3DBird%26aufirst%3DN.%26aulast%3DMajeed%26aufirst%3DA.%26aulast%3DSehested%26aufirst%3DM.%26aulast%3DLaerum%26aufirst%3DO.%26aulast%3DLund%26aufirst%3DL.%26aulast%3DDan%25C3%25B8%26aufirst%3DK.%26aulast%3DNielsen%26aufirst%3DB.%26atitle%3DMMP-9%2520is%2520differentially%2520expressed%2520in%2520primary%2520human%2520colorectal%2520adenocarcinomas%2520and%2520their%2520metastases%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2006%26volume%3D4%26spage%3D293%26epage%3D302%26doi%3D10.1158%2F1541-7786.MCR-06-0003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span> <span> </span><span class="NLM_article-title">Development of matrix metalloproteinase inhibitors in cancer therapy</span>. <i>Journal of the national cancer institute</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1093/jnci/93.3.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1093%2Fjnci%2F93.3.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11158186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlKiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=178-193&author=M.+Hidalgoauthor=S.+G.+Eckhardt&title=Development+of+matrix+metalloproteinase+inhibitors+in+cancer+therapy&doi=10.1093%2Fjnci%2F93.3.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Development of matrix metalloproteinase inhibitors in cancer therapy</span></div><div class="casAuthors">Hidalgo, Manuel; Eckhardt, S. Gail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">178-193</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 189 refs.  The matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degrdn. of the extracellular matrix.  The MMPs have been implicated in the processes of tumor growth, invasion, and metastasis; are frequently over-expressed in malignant tumors; and have been assocd. with an aggressive malignant phenotype and adverse prognosis in patients with cancer.  A no. of MMP inhibitors are being developed for the treatment of cancer.  The most extensively studied class of MMP inhibitors includes collagen peptidomimetics and nonpeptidomimetic inhibitors of the MMP active site, tetracycline derivs., and bisphosphonates.  The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analog marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail.  Marimastat is currently being studied in randomized clin. trials.  The nonpeptidic MMP inhibitors were synthesized in an attempt to improve the oral bioavailability and pharmaceutical properties of the peptidic inhibitors.  Several members of this class of compds. are undergoing evaluation in phase III clin. trials.  The tetracyclines and, particularly, the nonantibiotic chem. modified tetracyclines, interfere with several aspects of MMP expression and activation and inhibit tumor growth and metastases in preclin. models.  A representative agent of this class, Col-3, is currently undergoing phase I clin. trials.  The development of the MMP inhibitors, like that of other targeted and predominantly antiproliferative compds., poses a challenge because the paradigms that have governed the design of clin. oncol. trials may not be relevant to this new class of agents.  The anticipated need for long-term administration of these drugs, together with their cytostatic mechanism of action, will require novel clin. trial design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgnRed5mDw9LVg90H21EOLACvtfcHk0ljOGpxJ0QK_UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlKiurw%253D&md5=0094a1ba5e55ca5268f41eec2c8d8480</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.3.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.3.178%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DDevelopment%2520of%2520matrix%2520metalloproteinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJournal%2520of%2520the%2520national%2520cancer%2520institute%26date%3D2001%26volume%3D93%26spage%3D178%26epage%3D193%26doi%3D10.1093%2Fjnci%2F93.3.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braybrooke, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, D. C.</span></span> <span> </span><span class="NLM_article-title">Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10100701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXitVyisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=513-520&author=V.+M.+Macaulayauthor=K.+J.+O%E2%80%99Byrneauthor=M.+P.+Saundersauthor=J.+P.+Braybrookeauthor=L.+Longauthor=F.+Gleesonauthor=C.+S.+Masonauthor=A.+L.+Harrisauthor=P.+Brownauthor=D.+C.+Talbot&title=Phase+I+study+of+intrapleural+batimastat+%28BB-94%29%2C+a+matrix+metalloproteinase+inhibitor%2C+in+the+treatment+of+malignant+pleural+effusions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions</span></div><div class="casAuthors">Macaulay, Valentine M.; O'Byrne, Ken J.; Saunders, Mark P.; Braybrooke, Jeremy P.; Long, Louise; Gleeson, Fergus; Mason, Clare S.; Harris, Adrian L.; Brown, Peter; Talbot, Denis C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">513-520</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor cells and assocd. stromal cells secrete matrix metalloproteinases (MMPs), contributing to invasion, angiogenesis, and metastasis.  Batimastat (BB-94) is a broad-spectrum MMP inhibitor that causes resoln. of ascites and/or tumor growth delay in animal models of breast, ovarian, and colorectal cancer.  We recruited 18 patients with cytol. pos. malignant pleural effusions into a Phase I study of intrapleural BB-94.  Three patients received single doses of BB-94 at each dose level: 15, 30, 60, 105, 135, and 300 mg/m2.  Two patients were retreated with a second course at 60 and 105 mg/m2.  BB-94 was detectable in plasma 1 h after intrapleural administration, and peak levels of 20-200 ng/mL occurred after 4 h to 1 wk.  BB-94 persisted in the plasma for up to 12 wk, at levels exceeding the IC50s for target MMPs.  Peak values were higher, and persistence in the plasma was longer after higher doses of BB-94.  The treatment was well tolerated.  Toxic effects included low-grade fever for 24-48 h (6 of 18 patients, 33%) and reversible asymptomatic elevation of liver enzymes (8 patients, 44%).  Toxicity seemed unrelated to BB-94 dose or plasma levels.  Sixteen patients evaluable for response required significantly fewer pleural aspirations in the 3 mo after BB-94 compared with the 3 mo before.  Seven patients (44%) required no further pleural aspiration until death/last follow-up.  After 1 mo, patients treated with 60-300 mg/m2 BB-94 had significantly better dyspnea scores, indicating improved exercise tolerance, compared with baseline scores the day after BB-94.  The max. tolerated intrapleural dose remains to be defined, but it is clear that intrapleural BB-94 is well tolerated, with evidence of local activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHF-ZM_YECELVg90H21EOLACvtfcHk0li3d2Z132kCDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitVyisLg%253D&md5=075402235d2f2db88fa465ed33ece41c</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DSaunders%26aufirst%3DM.%2BP.%26aulast%3DBraybrooke%26aufirst%3DJ.%2BP.%26aulast%3DLong%26aufirst%3DL.%26aulast%3DGleeson%26aufirst%3DF.%26aulast%3DMason%26aufirst%3DC.%2BS.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26atitle%3DPhase%2520I%2520study%2520of%2520intrapleural%2520batimastat%2520%2528BB-94%2529%252C%2520a%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520malignant%2520pleural%2520effusions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26spage%3D513%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span> <span> </span><span class="NLM_article-title">Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects</span>. <i>Int. J. Biol. Markers</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.5301/JBM.5000026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.5301%2FJBM.5000026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23787494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=117-130&author=W.+Liauthor=S.+Sajiauthor=F.+Satoauthor=M.+Nodaauthor=M.+Toi&title=Potential+clinical+applications+of+matrix+metalloproteinase+inhibitors+and+their+future+prospects&doi=10.5301%2FJBM.5000026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects</span></div><div class="casAuthors">Li, Wenzhao; Saji, Shigehira; Sato, Fumiaki; Noda, Makoto; Toi, Masakazu</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Markers</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-130</span>CODEN:
                <span class="NLM_cas:coden">IBMAEP</span>;
        ISSN:<span class="NLM_cas:issn">1724-6008</span>.
    
            (<span class="NLM_cas:orgname">Wichtig Editore</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are endopeptidases that are involved in extracellular matrix degrdn.  They are also implicated in a no. of abnormal bioprocesses, such as tumor growth, invasion, and metastasis.  Therefore, controlling MMP activities has generated considerable interest as a possible therapeutic target.  The tissue inhibitors of metalloproteinases (TIMPs) are the major naturally occurring proteins that specifically inhibit MMPs and assist in maintaining the balance between extracellular matrix destruction and formation.  However, TIMPs are probably not suitable for pharmacol. applications due to their short half-lives in vivo.  During the last few decades, synthetic MMP inhibitors (MMPIs) have undergone rapid clin. development in attempts to control MMP enzymic activities in abnormal bioprocesses.  Although studies with these agents have met with limited clin. success, the field of MMPIs is still expanding, and generation of highly effective and selective MMPIs might be a promising direction of this research area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKXi8KW5kc6LVg90H21EOLACvtfcHk0li3d2Z132kCDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOgsL4%253D&md5=c59e328340b4ed7f09fdca50100d64fd</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.5301%2FJBM.5000026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5301%252FJBM.5000026%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSaji%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DF.%26aulast%3DNoda%26aufirst%3DM.%26aulast%3DToi%26aufirst%3DM.%26atitle%3DPotential%2520clinical%2520applications%2520of%2520matrix%2520metalloproteinase%2520inhibitors%2520and%2520their%2520future%2520prospects%26jtitle%3DInt.%2520J.%2520Biol.%2520Markers%26date%3D2013%26volume%3D28%26spage%3D117%26epage%3D130%26doi%3D10.5301%2FJBM.5000026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hugenberg, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrends, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szardenings, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haufe, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on gamma-fluorinated alpha-sulfonylaminohydroxamic acid</span>. <i>EJNMMI radiopharmacy and chemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1186/s41181-018-0045-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs41181-018-0045-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30101186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3c7nsVCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=10&author=V.+Hugenbergauthor=M.+Behrendsauthor=S.+Wagnerauthor=S.+Hermannauthor=M.+Schafersauthor=H.+C.+Kolbauthor=K.+Szardeningsauthor=J.+C.+Walshauthor=L.+F.+Gomezauthor=K.+Kopkaauthor=G.+Haufe&title=Synthesis%2C+radiosynthesis%2C+in+vitro+and+first+in+vivo+evaluation+of+a+new+matrix+metalloproteinase+inhibitor+based+on+gamma-fluorinated+alpha-sulfonylaminohydroxamic+acid&doi=10.1186%2Fs41181-018-0045-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid</span></div><div class="casAuthors">Hugenberg Verena; Hermann Sven; Schafers Michael; Haufe Gunter; Hugenberg Verena; Wagner Stefan; Schafers Michael; Kopka Klaus; Hugenberg Verena; Behrends Malte; Haufe Gunter; Hermann Sven; Schafers Michael; Haufe Gunter; Kolb Hartmuth C; Szardenings Katrin; Walsh Joseph C; Gomez Luis F; Kopka Klaus</div><div class="citationInfo"><span class="NLM_cas:title">EJNMMI radiopharmacy and chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  To study MMP activity in vivo in disease, several radiolabeled MMP inhibitors functioning as radiotracers have been evaluated by means of SPECT and PET.  Unfortunately, most of them suffer from metabolic instability, mainly hepatobiliary clearance and insufficient target binding.  The introduction of a fluorine atom into MMPIs could contribute to target binding, enhance the metabolic stability and might shift the clearance towards more renal elimination.  Recently developed α-sulfonylaminohydroxamic acid based γ-fluorinated inhibitors of MMP-2 and -9 provide promising fluorine interactions with the enzyme active site and high MMP inhibition potencies.  The aim of this study is the (radio)synthesis of a γ-fluorinated MMP-2 and -9 inhibitor to evaluate its potential as a radiotracer to image MMP activity in vivo.  Results:  Two new fluorine-containing, enantiomerically pure inhibitors for MMP-2 and -9 were synthesized in a six step sequence.  Both enantiomers exhibited equal inhibition potencies in the low nanomolar and subnanomolar range.  LogD value indicated better water solubility compared to the CGS 25966 based analog.  The most potent inhibitor was successfully radiofluorinated.  In vivo biodistribution in wild type mice revealed predominantly hepatobiliary clearance.  Two major radioactive metabolites were found in different organs.  Defluorination of the radiotracer was not observed.  Conclusion:  (Radio)synthesis of a CGS based γ-fluorinated MMP inhibitor was successfully accomplished.  The (S)-enantiomer, which normally shows no biological activity, also exhibited high MMP inhibition potencies, which may be attributed to additional interactions of fluorine with enzyme's active site.  Despite higher hydrophilicity no significant differences in the clearance characteristics compared to non-fluorinated MMPIs was observed.  Metabolically stabilizing effect of the fluorine was not monitored in vivo in wild type mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLZr8cnqmmoS-bLEOO4dYpfW6udTcc2eaArLPuySMuRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7nsVCktg%253D%253D&md5=d1bd7af79875a88ccf7ea19fd85d0f2c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1186%2Fs41181-018-0045-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41181-018-0045-0%26sid%3Dliteratum%253Aachs%26aulast%3DHugenberg%26aufirst%3DV.%26aulast%3DBehrends%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DHermann%26aufirst%3DS.%26aulast%3DSchafers%26aufirst%3DM.%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DSzardenings%26aufirst%3DK.%26aulast%3DWalsh%26aufirst%3DJ.%2BC.%26aulast%3DGomez%26aufirst%3DL.%2BF.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DHaufe%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520radiosynthesis%252C%2520in%2520vitro%2520and%2520first%2520in%2520vivo%2520evaluation%2520of%2520a%2520new%2520matrix%2520metalloproteinase%2520inhibitor%2520based%2520on%2520gamma-fluorinated%2520alpha-sulfonylaminohydroxamic%2520acid%26jtitle%3DEJNMMI%2520radiopharmacy%2520and%2520chemistry%26date%3D2018%26volume%3D3%26spage%3D10%26doi%3D10.1186%2Fs41181-018-0045-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matrisian, L. M.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases: biologic activity and clinical implications</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1135</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1200/JCO.2000.18.5.1135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2000.18.5.1135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10694567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVCgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=1135-1149&author=A.+R.+Nelsonauthor=B.+Fingletonauthor=M.+L.+Rothenbergauthor=L.+M.+Matrisian&title=Matrix+metalloproteinases%3A+biologic+activity+and+clinical+implications&doi=10.1200%2FJCO.2000.18.5.1135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases: biologic activity and clinical implications</span></div><div class="casAuthors">Nelson, Amy R.; Fingleton, Barbara; Rothenberg, Mace L.; Matrisian, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1135-1149</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 154 refs.  Abstr.: Tumor progression is a complex, multistage process by which a normal cell undergoes genetic changes that result in phenotypic alterations and the acquisition of the ability to spread and colonize distant sites in the body.  Although many factors regulate malignant tumor growth and spread, interactions between a tumor and its surrounding microenvironment result in the prodn. of important protein products that are crucial to each step of tumor progression.  The matrix metalloproteinases (MMPs) are a family of degradative enzymes with clear links to malignancy.  These enzymes are assocd. with tumor cell invasion of the basement membrane and stroma, blood vessel penetration, and metastasis.  They have more recently been implicated in primary and metastatic tumor growth and angiogenesis, and they may even have a role in tumor promotion.  This review outlines our current understanding of the MMP family, including the assocn. of particular MMPs with malignant phenotypes and the role of MMPs in specific steps of the metastatic cascade.  As scientific understanding of the MMPs has advanced, therapeutic strategies that capitalize on blocking the enzymes have rapidly developed.  The preclin. and clin. evolution of the synthetic MMP inhibitors (MMPIs) is also examd., with the discussion encompassing important methodol. issues assocd. with detg. clin. efficacy of MMPIs and other novel therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQhNHd2Oz8ErVg90H21EOLACvtfcHk0lgqKoVd4BL9IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVCgsbg%253D&md5=9a276fa4961253807cc7bd2bd253be0d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1200%2FJCO.2000.18.5.1135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2000.18.5.1135%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DA.%2BR.%26aulast%3DFingleton%26aufirst%3DB.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26atitle%3DMatrix%2520metalloproteinases%253A%2520biologic%2520activity%2520and%2520clinical%2520implications%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2000%26volume%3D18%26spage%3D1135%26epage%3D1149%26doi%3D10.1200%2FJCO.2000.18.5.1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cathcart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulkoski-Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Targeting matrix metalloproteinases in cancer: bringing new life to old ideas</span>. <i>Genes & diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.gendis.2014.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.gendis.2014.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26097889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC2srotlKmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=26-34&author=J.+Cathcartauthor=A.+Pulkoski-Grossauthor=J.+Cao&title=Targeting+matrix+metalloproteinases+in+cancer%3A+bringing+new+life+to+old+ideas&doi=10.1016%2Fj.gendis.2014.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas</span></div><div class="casAuthors">Cathcart Jillian; Pulkoski-Gross Ashleigh; Cao Jian</div><div class="citationInfo"><span class="NLM_cas:title">Genes & diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-34</span>
        ISSN:<span class="NLM_cas:issn">2352-4820</span>.
    </div><div class="casAbstract">Since the identification of matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, as being a driving factor for cancer progression and patient prognosis, MMPs have been studied extensively.  Although early programs targeting MMPs were largely unsuccessful in clinical trials, they remain a viable and highly desirable therapeutic target based on preclinical studies and their role in disease progression.  As information regarding the structure and function of these proteinases is compiled and biotechnology evolves, tools to develop better inhibitors is within our grasp.  Improved methods for high throughput screening and in silico drug design programs have identified compounds which are highly potent, have high binding affinities, and exhibit favorable pharmacokinetic profiles.  More recently, advances in drug delivery methods or compounds which bind outside the active site have brought new light to the field.  In this review, we highlight the role of MMPs in cancer, clinical trials for MMP inhibitors, and novel approaches to targeting MMPs in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEJ37PEUcnpYxhnOQkIHOxfW6udTcc2eYq5s_ThSfYobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srotlKmtw%253D%253D&md5=195802fe3f5c6881cdc9202d2ea3d957</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.gendis.2014.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gendis.2014.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DCathcart%26aufirst%3DJ.%26aulast%3DPulkoski-Gross%26aufirst%3DA.%26aulast%3DCao%26aufirst%3DJ.%26atitle%3DTargeting%2520matrix%2520metalloproteinases%2520in%2520cancer%253A%2520bringing%2520new%2520life%2520to%2520old%2520ideas%26jtitle%3DGenes%2520%2526%2520diseases%26date%3D2015%26volume%3D2%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.gendis.2014.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbroucke, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejonckheere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, C.</span></span> <span> </span><span class="NLM_article-title">A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1214</span>, <span class="refDoi"> DOI: 10.1183/09031936.00027411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1183%2F09031936.00027411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21659416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1agsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=1200-1214&author=R.+E.+Vandenbrouckeauthor=E.+Dejonckheereauthor=C.+Libert&title=A+therapeutic+role+for+matrix+metalloproteinase+inhibitors+in+lung+diseases%3F&doi=10.1183%2F09031936.00027411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?</span></div><div class="casAuthors">Vandenbroucke, R. E.; Dejonckheere, E.; Libert, C.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1200-1214</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Disruption of the balance between matrix metalloproteinases (MMPs) and their endogenous inhibitors is considered a key event in the development of pulmonary diseases such as chronic obstructive pulmonary disease, asthma, interstitial lung diseases and lung cancer.  This imbalance often results in elevated net MMP activity, making MMP inhibition an attractive therapeutic strategy.  Although promising results have been obtained, the lack of selective MMP inhibitors, together with limited knowledge regarding the exact functions of a particular MMP, hampers clin. application.  This review discusses the involvement of different MMPs in lung disorders and future opportunities and limitations of therapeutic MMP inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNPP3muS-QLVg90H21EOLACvtfcHk0ljyybW-wl4j6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1agsLw%253D&md5=a6246e4e64844afe46f7fcb99c2c4569</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1183%2F09031936.00027411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00027411%26sid%3Dliteratum%253Aachs%26aulast%3DVandenbroucke%26aufirst%3DR.%2BE.%26aulast%3DDejonckheere%26aufirst%3DE.%26aulast%3DLibert%26aufirst%3DC.%26atitle%3DA%2520therapeutic%2520role%2520for%2520matrix%2520metalloproteinase%2520inhibitors%2520in%2520lung%2520diseases%253F%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D38%26spage%3D1200%26epage%3D1214%26doi%3D10.1183%2F09031936.00027411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasatomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1002/ijc.21285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fijc.21285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16003755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BD2Mrot1GqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=215-221&author=Y.+Ogataauthor=K.+Matonoauthor=M.+Nakajimaauthor=T.+Sasatomiauthor=T.+Mizobeauthor=H.+Nagaseauthor=K.+Shirouzu&title=Efficacy+of+the+MMP+inhibitor+MMI270+against+lung+metastasis+following+removal+of+orthotopically+transplanted+human+colon+cancer+in+rat&doi=10.1002%2Fijc.21285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat</span></div><div class="casAuthors">Ogata Yutaka; Matono Keiko; Nakajima Motowo; Sasatomi Teruo; Mizobe Tomoaki; Nagase Hideaki; Shirouzu Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">215-21</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">We have investigated the antitumor effects of synthetic MMP inhibitor MMI270 against postoperative lung metastasis from colon cancer in nude rat.  The KM12SM human colon cancer cells were injected into the cecal wall, and at 5 weeks after the injection, the cecum was removed including the tumor.  Then, 30 mg/kg of MMI270 was administered perorally twice per day for 2 or 4 weeks, either immediately after removal or after week 2 after the removal.  At week 7 after the removal, lung metastasis was significantly inhibited by the early administration of MMI270 immediately after the tumor removal but not by the late administration.  The survival rates were significantly higher in the rats treated by early administration of MMI270 compared to the survival rate in untreated rats.  Moreover, no lung metastasis was detected in some rats with 24-weeks' survival treated by early administration.  Lower microvessel density, lower PCNA Index and higher Apoptotic Index in the lung metastases of the rats treated with MMI270 were found compared to those in untreated rats.  A beneficial effect of by early administration of MMI270 against postoperative lung metastases may be expected through inhibiting neovascularization of metastases in nude rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGphLXMHYYdz0O18WR3iAofW6udTcc2eYJNSQZDicKirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mrot1GqsA%253D%253D&md5=b246f3fbca38545dd4840e7724ed7fdb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fijc.21285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21285%26sid%3Dliteratum%253Aachs%26aulast%3DOgata%26aufirst%3DY.%26aulast%3DMatono%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DSasatomi%26aufirst%3DT.%26aulast%3DMizobe%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DShirouzu%26aufirst%3DK.%26atitle%3DEfficacy%2520of%2520the%2520MMP%2520inhibitor%2520MMI270%2520against%2520lung%2520metastasis%2520following%2520removal%2520of%2520orthotopically%2520transplanted%2520human%2520colon%2520cancer%2520in%2520rat%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D215%26epage%3D221%26doi%3D10.1002%2Fijc.21285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Propper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span> <span> </span><span class="NLM_article-title">Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11448904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslaltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1912-1922&author=N.+Levittauthor=F.+Eskensauthor=K.+O%E2%80%99Byrneauthor=D.+Propperauthor=L.+Denisauthor=S.+Owenauthor=L.+Choiauthor=J.+Foekensauthor=S.+Wilnerauthor=J.+Woodauthor=M.+Nakajimaauthor=D.+Talbotauthor=W.+Stewardauthor=A.+Harrisauthor=J.+Verweij&title=Phase+I+and+pharmacological+study+of+the+oral+matrix+metalloproteinase+inhibitor%2C+MMI270+%28CGS27023A%29%2C+in+patients+with+advanced+solid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer</span></div><div class="casAuthors">Levitt, Nicola C.; Eskens, Ferry A. L. M.; O'Byrne, Ken J.; Propper, David J.; Denis, Louis J.; Owen, Samantha J.; Choi, Les; Foekens, John A.; Wilner, Sue; Wood, Jeanette M.; Nakajima, Motowo; Talbot, Denis C.; Steward, William P.; Harris, Adrian L.; Verweij, Jaap</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1912-1922</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and investigated markers of biol. activity to recommend a dose for Phase II studies.  MMI270 was administered continuously at seven dose levels (50 mg once daily to 600 mg three times/day).  Patients were evaluated for toxicity and tumor response, and blood and urine samples were taken for pharmacokinetics, bone resorption markers, direct targets of the inhibitor [matrix metalloproteinase-2 (MMP-2), MMP-8, and MMP-9], indirect targets [tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, basic fibroblast growth factor, vascular endothelial growth factor, vascular cell adhesion mol.-1, sol. urokinase plasminogen activator receptor, and cathepsins B and H] and for a tumor necrosis factor-α cytokine release assay.  Ninety-two patients were entered.  There was no myelo-toxicity.  Eighteen patients developed a widespread maculopapular rash, which increased in frequency and severity at doses ≥300 mg bid.  Thirty nine patients developed musculoskeletal side effects, which were related to duration of treatment, not to dose level.  Pharmacokinetics were linear, and MMI270 was rapidly absorbed and eliminated with minimal accumulation on chronic dosing.  Sustained plasma concns. in excess of 4 × mean IC50 for the target enzymes were obsd. at dose levels ≥150 mg bid.  There were no tumor regressions; however, 19 patients had stable disease for ≥90 days.  There was a dose-response increase of MMP-2 and TIMP-1 with MMI270.  Transient effects on the bone resorption markers were detected.  MMI270 was generally well tolerated, with adequate plasma levels for target enzyme inhibition.  The two main toxicities were rash, resulting in a max. tolerated dose of 300 mg bid and musculoskeletal side effects.  Biol. marker data indicate drug effects.  The rise in TIMP-1 suggests that a reflex rise in inhibitors could modify the effects of MMI270.  The recommended Phase II dose is 300 mg bid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKRmnL75Gt2rVg90H21EOLACvtfcHk0liz_86cijSqKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslaltbY%253D&md5=275c688bd43c590141e8e652c73c779e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitt%26aufirst%3DN.%26aulast%3DEskens%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DPropper%26aufirst%3DD.%26aulast%3DDenis%26aufirst%3DL.%26aulast%3DOwen%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DL.%26aulast%3DFoekens%26aufirst%3DJ.%26aulast%3DWilner%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DD.%26aulast%3DSteward%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520and%2520pharmacological%2520study%2520of%2520the%2520oral%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520MMI270%2520%2528CGS27023A%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D1912%26epage%3D1922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignatti, P.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1155</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1535-7163.MCT-17-0646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29735645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1147-1155&author=A.+Winerauthor=S.+Adamsauthor=P.+Mignatti&title=Matrix+metalloproteinase+inhibitors+in+cancer+therapy%3A+Turning+past+failures+into+future+successes&doi=10.1158%2F1535-7163.MCT-17-0646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes</span></div><div class="casAuthors">Winer, Arthur; Adams, Sylvia; Mignatti, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1147-1155</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMP) are a family of proteolytic enzymes that degrade multiple components of the extracellular matrix.  A large body of exptl. and clin. evidence has implicated MMPs in tumor invasion, neoangiogenesis, and metastasis, and therefore they represent ideal pharmacol. targets for cancer therapy.  From the 1990s to early 2000s, synthetic inhibitors of MMPs (MMPI) were studied in various cancer types.  Unexpectedly, despite strongly promising preclin. data, all trials were unsuccessful in reducing tumor burden or improving overall survival; in addn., MMPIs had unforeseen, severe side effects.  Two main reasons can explain the failure of MMPIs in clin. trials.  It has now become apparent that some MMPs have antitumor effects; therefore, the broad-spectrum MMPIs used in the initial trials might block these MMPs and result in tumor progression.  In addn., although MMPs are involved in the early stages of tumor progression, MMPIs were tested in patients with advanced disease, beyond the stage when these compds. could be effective.  As more specific MMPIs are now available, MMP targeting could be reconsidered for cancer therapy; however, new trials should be designed to test their antimetastatic properties in early-stage tumors, and endpoints should focus on parameters other than decreasing metastatic tumor burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPKS7DzJJsbVg90H21EOLACvtfcHk0liECkkanJeJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3L&md5=cb10ac5dce9c30145e35c19b713a5ee4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0646%26sid%3Dliteratum%253Aachs%26aulast%3DWiner%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DMignatti%26aufirst%3DP.%26atitle%3DMatrix%2520metalloproteinase%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520Turning%2520past%2520failures%2520into%2520future%2520successes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1147%26epage%3D1155%26doi%3D10.1158%2F1535-7163.MCT-17-0646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, B. R.</span></span> <span> </span><span class="NLM_article-title">Abstract 35: Molecular optimization of phase III trial failed anticancer drugs using target affinity and toxicity-centered multiple properties reinforcement learning</span>. <i>Clinical cancer research</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">35</span>, <span class="refDoi"> DOI: 10.1158/1557-3265.ADVPRECMED20-35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1557-3265.ADVPRECMED20-35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=31597662" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=35&author=S.+Parkauthor=Y.+H.+Koauthor=B.+Leeauthor=B.+Shinauthor=B.+R.+Beck&title=Abstract+35%3A+Molecular+optimization+of+phase+III+trial+failed+anticancer+drugs+using+target+affinity+and+toxicity-centered+multiple+properties+reinforcement+learning&doi=10.1158%2F1557-3265.ADVPRECMED20-35"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1158%2F1557-3265.ADVPRECMED20-35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1557-3265.ADVPRECMED20-35%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DShin%26aufirst%3DB.%26aulast%3DBeck%26aufirst%3DB.%2BR.%26atitle%3DAbstract%252035%253A%2520Molecular%2520optimization%2520of%2520phase%2520III%2520trial%2520failed%2520anticancer%2520drugs%2520using%2520target%2520affinity%2520and%2520toxicity-centered%2520multiple%2520properties%2520reinforcement%2520learning%26jtitle%3DClinical%2520cancer%2520research%26date%3D2020%26volume%3D26%26spage%3D35%26doi%3D10.1158%2F1557-3265.ADVPRECMED20-35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shalinsky, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margosiak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varki, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelt, K.</span></span> <span> </span><span class="NLM_article-title">Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>878</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb07689.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1111%2Fj.1749-6632.1999.tb07689.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10415735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXkslems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=878&publication_year=1999&pages=236-270&author=D.+R.+Shalinskyauthor=J.+Brekkenauthor=H.+Zouauthor=C.+D.+McDermottauthor=P.+Forsythauthor=D.+Edwardsauthor=S.+Margosiakauthor=S.+Benderauthor=G.+Truittauthor=A.+Woodauthor=N.+M.+Varkiauthor=K.+Appelt&title=Broad+antitumor+and+antiangiogenic+activities+of+AG3340%2C+a+potent+and+selective+MMP+inhibitor+undergoing+advanced+oncology+clinical+trials&doi=10.1111%2Fj.1749-6632.1999.tb07689.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials</span></div><div class="casAuthors">Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">878</span>
        (<span class="NLM_cas:issue">Inhibition of Matrix Metalloproteinases</span>),
    <span class="NLM_cas:pages">236-270</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9), MT-MMP-1 (MMP-14), and collagenase-3 (MMP-13) in many tumor models.  AG3340 produced dose-dependent pharmacokinetics and was well tolerated after i.p. (i.p.) and oral dosing in mice.  Across human tumor models, AG3340 produced profound tumor growth delays when dosing began early or late after tumor implantation, although all established tumor types did not respond to AG3340.  A dose-response relationship was explored in three models: COLO-320DM colon, MV522 lung, and MDA-MB-435 breast.  Dose-dependent inhibitions of tumor growth (over 12.5-200 mg/kg given twice daily, b.i.d.) were obsd. in the colon and lung models; and in a third (breast), maximal inhibitions were produced by the lowest dose of AG3340 (50 mg/kg, b.i.d.) that was tested.  In another model, AG3340 (100 mg/kg, once daily, i.p.) markedly inhibited U87 glioma growth and increased animal survival.  AG3340 also inhibited tumor growth and increased the survival of nude mice bearing androgen-independent PC-3 prostatic tumors.  In a sixth model, KKLS gastric, AG3340 did not inhibit tumor growth but potentiated the efficacy of Taxol.  Importantly, AG3340 markedly decreased tumor angiogenesis (as assessed by CD-31 staining) and cell proliferation (as assessed by bromodeoxyuridine incorporation), and increased tumor necrosis and apoptosis (as assessed by hematoxylin and eosin and TUNEL staining).  These effects were model dependent, but angiogenesis was commonly inhibited.  AG3340 had a superior therapeutic index to the cytotoxic agents, carboplatin and Taxol, in the MV522 lung cancer model.  In combination, AG3340 enhanced the efficacy of these cytotoxic agents without altering drug tolerance.  Addnl., AG3340 decreased the no. of murine melanoma (B16-F10) lesions arising in the lung in an i.v. metastasis model when given in combination with carboplatin or Taxol.  These studies directly support the use of AG3340 in front-line combination chemotherapy in ongoing clin. trials in patients with advanced malignancies of the lung and prostate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1dLJ2G4J3vLVg90H21EOLACvtfcHk0lg4-EiJg41BVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslems78%253D&md5=bcd62f80fae17f4b8ce8a0fa34160ab5</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb07689.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb07689.x%26sid%3Dliteratum%253Aachs%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DMcDermott%26aufirst%3DC.%2BD.%26aulast%3DForsyth%26aufirst%3DP.%26aulast%3DEdwards%26aufirst%3DD.%26aulast%3DMargosiak%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DTruitt%26aufirst%3DG.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DVarki%26aufirst%3DN.%2BM.%26aulast%3DAppelt%26aufirst%3DK.%26atitle%3DBroad%2520antitumor%2520and%2520antiangiogenic%2520activities%2520of%2520AG3340%252C%2520a%2520potent%2520and%2520selective%2520MMP%2520inhibitor%2520undergoing%2520advanced%2520oncology%2520clinical%2520trials%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D878%26spage%3D236%26epage%3D270%26doi%3D10.1111%2Fj.1749-6632.1999.tb07689.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Pawel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatzemeier, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazabel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F.</span></span> <span> </span><span class="NLM_article-title">Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.03.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2005.03.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15681529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVKit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=842-849&author=D.+Bissettauthor=K.+O%E2%80%99Byrneauthor=J.+von+Pawelauthor=U.+Gatzemeierauthor=A.+Priceauthor=M.+Nicolsonauthor=R.+Mercierauthor=E.+Mazabelauthor=C.+Penningauthor=M.+Zhangauthor=M.+Collierauthor=F.+Shepherd&title=Phase+III+study+of+matrix+metalloproteinase+inhibitor+prinomastat+in+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2005.03.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer</span></div><div class="casAuthors">Bissett, Donald; O'Byrne, Ken J.; von Pawel, J.; Gatzemeier, Ulrich; Price, Allan; Nicolson, Marianne; Mercier, Richard; Mazabel, Elva; Penning, Carol; Zhang, Min H.; Collier, Mary A.; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-849</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs) degrade extracellular proteins and facilitate tumor growth, invasion, metastasis, and angiogenesis.  This trial was undertaken to det. the effect of prinomastat, an inhibitor of selected MMPs, on the survival of patients with advanced non-small-cell lung cancer (NSCLC), when given in combination with gemcitabine-cisplatin chemotherapy.  Chemotherapy-naive patients were randomly assigned to receive prinomastat 15 mg or placebo twice daily orally continuously, in combination with gemcitabine 1,250 mg/m2 days 1 and 8 plus cisplatin 75 mg/m2 day 1, every 21 days for up to six cycles.  The planned sample size was 420 patients.  Study results at an interim anal. and lack of efficacy in another phase III trial prompted early closure of this study.  There were 362 patients randomized (181 on prinomastat and 181 on placebo).  One hundred thirty-four patients had stage IIIB disease with T4 primary tumor, 193 had stage IV disease, and 34 had recurrent disease (one enrolled patient was ineligible with stage IIIA disease).  Overall response rates for the two treatment arms were similar (27% for prinomastat v 26% for placebo; P=.81).  There was no difference in overall survival or time to progression; for prinomastat vs. placebo patients, the median overall survival times were 11.5 vs. 10.8 mo (P =.82), 1-yr survival rates were 43% v 38% (P =.45), and progression-free survival times were 6.1 v 5.5 mo (P =.11), resp.  The toxicities of prinomastat were arthralgia, stiffness, and joint swelling.  Treatment interruption was required in 38% of prinomastat patients and 12% of placebo patients.  Prinomastat does not improve the outcome of chemotherapy in advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSpOytcWX7RLVg90H21EOLACvtfcHk0lg4-EiJg41BVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVKit7w%253D&md5=5f3b668b601b8bab0826f8bd52dc43df</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.170%26sid%3Dliteratum%253Aachs%26aulast%3DBissett%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGatzemeier%26aufirst%3DU.%26aulast%3DPrice%26aufirst%3DA.%26aulast%3DNicolson%26aufirst%3DM.%26aulast%3DMercier%26aufirst%3DR.%26aulast%3DMazabel%26aufirst%3DE.%26aulast%3DPenning%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DM.%26aulast%3DShepherd%26aufirst%3DF.%26atitle%3DPhase%2520III%2520study%2520of%2520matrix%2520metalloproteinase%2520inhibitor%2520prinomastat%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D842%26epage%3D849%26doi%3D10.1200%2FJCO.2005.03.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnachi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3096</span>– <span class="NLM_lpage">3100</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2006.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16632358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFertb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3096-3100&author=Y.+M.+Zhangauthor=X.+Fanauthor=B.+Xiangauthor=D.+Chakravartyauthor=R.+Scannevinauthor=S.+Burkeauthor=P.+Karnachiauthor=K.+Rhodesauthor=P.+Jackson&title=Synthesis+and+SAR+of+alpha-sulfonylcarboxylic+acids+as+potent+matrix+metalloproteinase+inhibitors&doi=10.1016%2Fj.bmcl.2006.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of α-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors</span></div><div class="casAuthors">Zhang, Yue-Mei; Fan, Xiaodong; Xiang, Bangping; Chakravarty, Devraj; Scannevin, Robert; Burke, Sharon; Karnachi, Prabha; Rhodes, Kenneth; Jackson, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3096-3100</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel carboxylic acid-based α-sulfone MMP inhibitors have been synthesized and the in vitro enzyme SAR is discussed.  A potential binding mode in the active site of the MMP-9 homol. model was highlighted.  These compds. are potent MMP-9 inhibitors and are selective over MMP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorWASoCppeULVg90H21EOLACvtfcHk0limVAV9SQsytQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFertb8%253D&md5=f1cebe7124a6ff398be78c23e9782a3d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DBurke%26aufirst%3DS.%26aulast%3DKarnachi%26aufirst%3DP.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520alpha-sulfonylcarboxylic%2520acids%2520as%2520potent%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3096%26epage%3D3100%26doi%3D10.1016%2Fj.bmcl.2006.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samartzis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stucki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imesch, P.</span></span> <span> </span><span class="NLM_article-title">Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and −9 activity in primary endometriotic stromal cells in vitro</span>. <i>Reprod. Biol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">38</span>, <span class="refDoi"> DOI: 10.1186/s12958-019-0481-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs12958-019-0481-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30981279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FltVKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=38&author=E.+P.+Samartzisauthor=D.+Finkauthor=M.+Stuckiauthor=P.+Imesch&title=Doxycycline+reduces+MMP-2+activity+and+inhibits+invasion+of+12Z+epithelial+endometriotic+cells+as+well+as+MMP-2+and+%E2%88%929+activity+in+primary+endometriotic+stromal+cells+in+vitro&doi=10.1186%2Fs12958-019-0481-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and -9 activity in primary endometriotic stromal cells in vitro</span></div><div class="casAuthors">Samartzis Eleftherios P; Fink Daniel; Stucki Manuel; Imesch Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Reproductive biology and endocrinology : RB&E</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Matrix metalloproteinases (MMPs), especially the gelatinases MMP-2 and MMP-9, play a crucial role in the pathogenesis of endometriosis by enabling invasion.  Doxycycline is a well-tolerated antibiotic and a potent MMP-inhibitor in subantimicrobial doses.  METHODS:  Gelatin zymography and activity assays were used to detect latent and active MMP-2 and -9 in cell culture supernatants of immortalized epithelial (12Z) and two isolates of primary endometriotic stromal cells treated with doxycycline.  The invasiveness of 12Z endometriotic cells treated with doxycycline was assessed in matrigel-coated invasion chambers.  The effect on latent and active MMP-2 expression of the combination of progesterone and doxycycline was tested in 12Z.  RESULTS:  Doxycycline significantly reduced the MMP-2 activity and pro-MMP-2 expression in 12Z and the MMP-2 and -9 activity as well as expression of pro-MMP-2 and -9 in primary endometriotic stromal cells.  The percentage of 12Z cells invading through a matrigel-coated membrane was reduced to 65 and 22% of the control after treatment with doxycycline at doses of 1 μg/ml and 10 μg/ml, respectively.  Furthermore, a combination of progesterone and doxycycline showed an additive effect in low doses on the reduction of MMP-2 activity and pro-MMP2 expression in 12Z endometriotic cells.  CONCLUSIONS:  In conclusion, the MMP-inhibiting features of subantimicrobial-dose doxycycline may be further evaluated as a well-tolerable additional therapeutic approach, e.g. in combination with progestins such as dienogest, in patients with infiltrative endometriosis with insufficient response to current medical treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsrewx-xl3iMzK395ZObgVfW6udTcc2eZpXnkS7GL4pLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FltVKmug%253D%253D&md5=723b1a24a9dd24bcedbf90c09cd57014</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1186%2Fs12958-019-0481-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12958-019-0481-z%26sid%3Dliteratum%253Aachs%26aulast%3DSamartzis%26aufirst%3DE.%2BP.%26aulast%3DFink%26aufirst%3DD.%26aulast%3DStucki%26aufirst%3DM.%26aulast%3DImesch%26aufirst%3DP.%26atitle%3DDoxycycline%2520reduces%2520MMP-2%2520activity%2520and%2520inhibits%2520invasion%2520of%252012Z%2520epithelial%2520endometriotic%2520cells%2520as%2520well%2520as%2520MMP-2%2520and%2520%25E2%2588%25929%2520activity%2520in%2520primary%2520endometriotic%2520stromal%2520cells%2520in%2520vitro%26jtitle%3DReprod.%2520Biol.%2520Endocrinol.%26date%3D2019%26volume%3D17%26spage%3D38%26doi%3D10.1186%2Fs12958-019-0481-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löffek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzke, C.</span></span> <span> </span><span class="NLM_article-title">Series “matrix metalloproteinases in lung health and disease“: Biological role of matrix metalloproteinases: a critical balance</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1183/09031936.00146510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1183%2F09031936.00146510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21177845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC3MnksF2ntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=191-208&author=S.+L%C3%B6ffekauthor=O.+Schillingauthor=C.+Franzke&title=Series+%E2%80%9Cmatrix+metalloproteinases+in+lung+health+and+disease%E2%80%9C%3A+Biological+role+of+matrix+metalloproteinases%3A+a+critical+balance&doi=10.1183%2F09031936.00146510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance</span></div><div class="casAuthors">Loffek S; Schilling O; Franzke C-W</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">191-208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Matrix metalloproteinases (MMPs) are members of the metzincin group of proteases which share the conserved zinc-binding motif in their catalytic active site.  It was originally thought that their main function is to degrade the various components of the extracellular matrix (ECM), yet recent studies have led us to appreciate their significance as regulators of extracellular tissue signalling networks.  Due to the broad spectrum of their substrate specificity, MMPs contribute to the homeostasis of many tissues and participate in several physiological processes, such as bone remodelling, angiogenesis, immunity and wound healing.  MMP activity is tightly controlled at the level of transcription, pro-peptide activation and inhibition by tissue inhibitors of MMPs.  Dysregulated MMP activity leads to pathological conditions such as arthritis, inflammation and cancer, thus highlighting MMPs as promising therapeutic targets.  Analysis of MMP mutant mice has proved to be an essential tool for the identification of novel functions and interactions of single MMP members.  Advancing our understanding of the MMP contribution to tissue homeostasis will lead us to identify causal relationships between their dysregulation and the development of disease pathologies, thus guiding us to successful MMP-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbRLIfsc9zKCXXDYhVZBdlfW6udTcc2eYH3pdHNSgIm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnksF2ntw%253D%253D&md5=4c4fd9a00410473421a7f942afd0ce38</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1183%2F09031936.00146510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00146510%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6ffek%26aufirst%3DS.%26aulast%3DSchilling%26aufirst%3DO.%26aulast%3DFranzke%26aufirst%3DC.%26atitle%3DSeries%2520%25E2%2580%259Cmatrix%2520metalloproteinases%2520in%2520lung%2520health%2520and%2520disease%25E2%2580%259C%253A%2520Biological%2520role%2520of%2520matrix%2520metalloproteinases%253A%2520a%2520critical%2520balance%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D38%26spage%3D191%26epage%3D208%26doi%3D10.1183%2F09031936.00146510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aelst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Steen, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proost, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liuzzi, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polverini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opdenakker, G.</span></span> <span> </span><span class="NLM_article-title">A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1770</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2006.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bbagen.2006.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17137715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1770&publication_year=2007&pages=178-186&author=E.+Martensauthor=A.+Leyssenauthor=I.+Van+Aelstauthor=P.+Fitenauthor=H.+Piccardauthor=J.+Huauthor=F.+J.+Descampsauthor=P.+E.+Van+den+Steenauthor=P.+Proostauthor=J.+Van+Dammeauthor=G.+M.+Liuzziauthor=P.+Riccioauthor=E.+Polveriniauthor=G.+Opdenakker&title=A+monoclonal+antibody+inhibits+gelatinase+B%2FMMP-9+by+selective+binding+to+part+of+the+catalytic+domain+and+not+to+the+fibronectin+or+zinc+binding+domains&doi=10.1016%2Fj.bbagen.2006.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains</span></div><div class="casAuthors">Martens, Erik; Leyssen, An; Van Aelst, Ilse; Fiten, Pierre; Piccard, Helene; Hu, Jialiang; Descamps, Francis J.; Van den Steen, Philippe E.; Proost, Paul; Van Damme, Jo; Liuzzi, Grazia Maria; Riccio, Paolo; Polverini, Eugenia; Opdenakker, Ghislain</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1770</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-186</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gelatinase B/matrix metalloproteinase-9 (MMP-9) is a multidomain enzyme functioning in acute and chronic inflammatory and neoplastic diseases.  It belongs to a family of more than 20 related zinc proteinases.  Therefore, the discovery and the definition of the action mechanism of selective MMP inhibitors form the basis for future therapeutics.  The monoclonal antibody REGA-3G12 is a most selective inhibitor of human gelatinase B.  REGA-3G12 was found to recognize the amino terminal part and not the carboxyterminal O-glycosylated and hemopexin protein domains.  A variant of gelatinase B, lacking the two carboxyterminal domains, was expressed in insect cells and fragmented with purified proteinases.  The fragments were probed by one- and two-dimensional Western blot and immunopptn. expts. with REGA-3G12 to map the interactions between the antibody and the enzyme.  The interaction unit was identified by Edman degrdn. anal. as the glycosylated segment from Trp116 to Lys214 of gelatinase B.  The sequence of this segment was analyzed by hydrophobicity/hydrophilicity, accessibility and flexibility profiling.  Four hydrophilic peptides were chem. synthesized and used in binding and competition assays.  The peptide Gly171-Leu187 in molar excess inhibited partially the binding of MMP-9 to REGA-3G12 and thus refines the structure of the conformational binding site.  These results define part of the catalytic domain of gelatinase B/MMP-9, and not the zinc-binding or fibronectin domains, as target for the development of selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBVg4Yn-PA8rVg90H21EOLACvtfcHk0liuvbccNtGeyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWnsg%253D%253D&md5=2972630d0bc24652d4c836ee1227ae1c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2006.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2006.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DMartens%26aufirst%3DE.%26aulast%3DLeyssen%26aufirst%3DA.%26aulast%3DVan%2BAelst%26aufirst%3DI.%26aulast%3DFiten%26aufirst%3DP.%26aulast%3DPiccard%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DDescamps%26aufirst%3DF.%2BJ.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DP.%2BE.%26aulast%3DProost%26aufirst%3DP.%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DLiuzzi%26aufirst%3DG.%2BM.%26aulast%3DRiccio%26aufirst%3DP.%26aulast%3DPolverini%26aufirst%3DE.%26aulast%3DOpdenakker%26aufirst%3DG.%26atitle%3DA%2520monoclonal%2520antibody%2520inhibits%2520gelatinase%2520B%252FMMP-9%2520by%2520selective%2520binding%2520to%2520part%2520of%2520the%2520catalytic%2520domain%2520and%2520not%2520to%2520the%2520fibronectin%2520or%2520zinc%2520binding%2520domains%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2007%26volume%3D1770%26spage%3D178%26epage%3D186%26doi%3D10.1016%2Fj.bbagen.2006.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pruijt, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fibbe, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laterveer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindley, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paemen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opdenakker, G.</span></span> <span> </span><span class="NLM_article-title">Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">10863</span>– <span class="NLM_lpage">10868</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.19.10863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1073%2Fpnas.96.19.10863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10485917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXmtFKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10863-10868&author=J.+F.+Pruijtauthor=W.+E.+Fibbeauthor=L.+Laterveerauthor=R.+A.+Pietersauthor=I.+J.+Lindleyauthor=L.+Paemenauthor=S.+Masureauthor=R.+Willemzeauthor=G.+Opdenakker&title=Prevention+of+interleukin-8-induced+mobilization+of+hematopoietic+progenitor+cells+in+rhesus+monkeys+by+inhibitory+antibodies+against+the+metalloproteinase+gelatinase+B+%28MMP-9%29&doi=10.1073%2Fpnas.96.19.10863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9)</span></div><div class="casAuthors">Pruijt, Johannes F. M.; Fibbe, Willem E.; Laterveer, Laurens; Pieters, Reagan A.; Lindley, Ivan J. D.; Paemen, Liesbet; Masure, Stefan; Willemze, Roel; Opdenakker, Ghislain</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10863-10868</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Previously, we demonstrated that IL-8 induces rapid mobilization of hematopoietic progenitor cells (HPC) from the bone marrow of rhesus monkeys.  Because activation of neutrophils by IL-8 induces the release of gelatinase B (MMP-9), which is involved in the degrdn. of extracellular matrix mols., we hypothesized that MMP-9 release might induce stem cell mobilization by cleaving matrix mols. to which stem cells are attached.  Rhesus monkeys were treated with a single i.v. injection of 0.1 mg/kg human IL-8, which resulted in a 10- to 100-fold increase in HPC within 30 min after injection.  Zymog. anal. revealed a dramatic instantaneous increase in the plasma levels of MMP-9, followed by the increase in circulating HPC.  Enzyme levels decreased at 2 h after injection of IL-8, simultaneously with the decrease in the nos. of circulating HPC.  To test the hypothesis that MMP-9 induction was involved in HPC mobilization, rhesus monkeys were treated with a highly specific inhibitory monoclonal anti-gelatinase B antibody.  Anti-gelatinase B at a dose of 1-2 mg/kg completely prevented the IL-8-induced mobilization of HPC, whereas a dose of 0.1 mg/kg had only a limited effect.  Preinjection of inhibitory antibodies did not preclude the IL-8-induced prodn. and secretion of MMP-9.  Pretreatment with an irrelevant control antibody did not affect IL-8-induced mobilization, showing that the inhibition by the anti-gelatinase B antibody was specific.  In summary, IL-8 induces the rapid systemic release of MMP-9 with concurrent mobilization of HPC that is prevented by pretreatment with an inhibitory anti-gelatinase B antibody, indicating that MMP-9 is involved as a mediator of the IL-8-induced mobilization of HPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKHBWUhLO77Vg90H21EOLACvtfcHk0lgjiZDCkRL45Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtFKjsb4%253D&md5=05f86402d1402f39b95f2ce8fcdc7ca3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.19.10863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.19.10863%26sid%3Dliteratum%253Aachs%26aulast%3DPruijt%26aufirst%3DJ.%2BF.%26aulast%3DFibbe%26aufirst%3DW.%2BE.%26aulast%3DLaterveer%26aufirst%3DL.%26aulast%3DPieters%26aufirst%3DR.%2BA.%26aulast%3DLindley%26aufirst%3DI.%2BJ.%26aulast%3DPaemen%26aufirst%3DL.%26aulast%3DMasure%26aufirst%3DS.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DOpdenakker%26aufirst%3DG.%26atitle%3DPrevention%2520of%2520interleukin-8-induced%2520mobilization%2520of%2520hematopoietic%2520progenitor%2520cells%2520in%2520rhesus%2520monkeys%2520by%2520inhibitory%2520antibodies%2520against%2520the%2520metalloproteinase%2520gelatinase%2520B%2520%2528MMP-9%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D10863%26epage%3D10868%26doi%3D10.1073%2Fpnas.96.19.10863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry-Hamilton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghermazien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels-Vigdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0127063</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0127063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1371%2Fjournal.pone.0127063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25961845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVakurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=D.+C.+Marshallauthor=S.+K.+Lymanauthor=S.+McCauleyauthor=M.+Kovalenkoauthor=R.+Spanglerauthor=C.+Liuauthor=M.+Leeauthor=C.+O%E2%80%99Sullivanauthor=V.+Barry-Hamiltonauthor=H.+Ghermazienauthor=A.+Mikels-Vigdalauthor=C.+A.+Garciaauthor=B.+Jorgensenauthor=A.+C.+Velayoauthor=R.+Wangauthor=J.+I.+Adamkewiczauthor=V.+Smith&title=Selective+allosteric+inhibition+of+MMP9+is+efficacious+in+preclinical+models+of+ulcerative+colitis+and+colorectal+cancer&doi=10.1371%2Fjournal.pone.0127063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Selective allosteric inhibition of MMP9 Is efficacious in preclinical models of ulcerative colitis and colorectal cancer</span></div><div class="casAuthors">Marshall, Derek C.; Lyman, Susan K.; McCauley, Scott; Kovalenko, Maria; Spangler, Rhyannon; Liu, Chian; Lee, Michael; O'Sullivan, Christopher; Barry-Hamilton, Vivian; Ghermazien, Haben; Mikels-Vigdal, Amanda; Garcia, Carlos A.; Jorgensen, Brett; Velayo, Arleene C.; Wang, Ruth; Adamkewicz, Joanne I.; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0127063/1-e0127063/26</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncol. indications, including ulcerative colitis and colorectal cancer.  MMP9 is a downstream effector and an upstream mediator of pathways involved in growth and inflammation, and has long been viewed as a promising therapeutic target.  However, previous efforts to target matrix metalloproteinases (MMPs), including MMP9, have utilized broad-spectrum or semi-selective inhibitors.  While some of these drugs showed signs of efficacy in patients, all MMP-targeted inhibitors have been hampered by dose-limiting toxicity or insufficient clin. benefit, likely due to their lack of specificity.  Here, we show that selective inhibition of MMP9 did not induce musculoskeletal syndrome (a characteristic toxicity of pan-MMP inhibitors) in a rat model, but did reduce disease severity in a dextran sodium sulfate-induced mouse model of ulcerative colitis.  We also found that MMP9 inhibition decreased tumor growth and metastases incidence in a surgical orthotopic xenograft model of colorectal carcinoma, and that inhibition of either tumor- or stroma-derived MMP9 was sufficient to reduce primary tumor growth.  Collectively, these data suggest that selective MMP9 inhibition is a promising therapeutic strategy for treatment of inflammatory and oncol. indications in which MMP9 is upregulated and is assocd. with disease pathol., such as ulcerative colitis and colorectal cancer.  In addn., we report the development of a potent and highly selective allosteric MMP9 inhibitor, the humanized monoclonal antibody GS-5745, which can be used to evaluate the therapeutic potential of MMP9 inhibition in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXAvk8jsdzUrVg90H21EOLACvtfcHk0lgjiZDCkRL45Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVakurrO&md5=43c6e647e653c2f1f8040460a9f8c6f0</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0127063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0127063%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DD.%2BC.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DKovalenko%26aufirst%3DM.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DMikels-Vigdal%26aufirst%3DA.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DSelective%2520allosteric%2520inhibition%2520of%2520MMP9%2520is%2520efficacious%2520in%2520preclinical%2520models%2520of%2520ulcerative%2520colitis%2520and%2520colorectal%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0127063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starodub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vosganian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltzman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span> <span> </span><span class="NLM_article-title">Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a Phase I study</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3829</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-17-2469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29691300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVahtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3829&author=M.+A.+Shahauthor=A.+Starodubauthor=S.+Sharmaauthor=J.+Berlinauthor=M.+Patelauthor=Z.+A.+Wainbergauthor=J.+Chavesauthor=M.+Gordonauthor=K.+Windsorauthor=C.+B.+Brachmannauthor=X.+Huangauthor=G.+Vosganianauthor=J.+D.+Maltzmanauthor=V.+Smithauthor=J.+A.+Silvermanauthor=H.-J.+Lenzauthor=J.+C.+Bendell&title=Andecaliximab%2FGS-5745+alone+and+combined+with+mFOLFOX6+in+advanced+gastric+and+gastroesophageal+junction+adenocarcinoma%3A+results+from+a+Phase+I+study&doi=10.1158%2F1078-0432.CCR-17-2469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study</span></div><div class="casAuthors">Shah, Manish A.; Starodub, Alexander; Sharma, Sunil; Berlin, Jordan; Patel, Manish; Wainberg, Zev A.; Chaves, Jorge; Gordon, Michael; Windsor, Kevin; Brachmann, Carrie Baker; Huang, Xi; Vosganian, Greg; Maltzman, Julia D.; Smith, Victoria; Silverman, Jeffrey A.; Lenz, Heinz-Josef; Bendell, Johanna C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3829-3837</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes.  Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6.  Three dosages of andecaliximab monotherapy [200, 600, and 1800 mg i.v. every 2 wk (q2w)] were investigated in patients with advanced solid tumors (n = 13 in a 3 + 3 design).  After detg. a recommended dose, patients with advanced HER2-neg. gastric/gastroesophageal junction (GEJ) adenocarcinoma (n = 40) received 800 mg andecaliximab + mFOLFOX6 q2w.  Pharmacokinetics, pharmacodynamics, safety, and efficacy were assessed.  Andecaliximab monotherapy demonstrated no dose-limiting toxicity (DLT) in any cohort, displaying target-mediated drug disposition at the lowest dose (200 mg) and linear pharmacokinetics at higher doses.  Based on target engagement, recommended doses for further study are 800 mg q2w or 1,200 mg q3w.  Maximal andecaliximab target binding, defined as undetectable andecaliximab-free MMP9 in plasma, was obsd. in the gastric/GEJ adenocarcinoma cohort.  We obsd. no unusual toxicity, although there were four deaths on study not attributed to andecaliximab treatment.  In first-line patients (n = 36), median progression-free survival (PFS) was 9.9 mo [95% confidence interval (CI), 5-13.9 mo], and the overall response rate (ORR) was 50%.  Among all patients (n = 40), median PFS was 7.8 (90% CI, 5.5-13.9) months, and ORR was 48%, with a median duration of response of 8.4 mo.  Andecaliximab monotherapy achieved target engagement without DLT.  Andecaliximab + mFOLFOX6 showed encouraging clin. activity without addnl. toxicity in patients with HER2-neg. gastric/GEJ adenocarcinoma.  A phase III study evaluating mFOLFOX6 ± andecaliximab in this setting is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri7aLCDnoeDbVg90H21EOLACvtfcHk0ljtaB_cQskuvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVahtrw%253D&md5=0f5d4809a3924fa1973eed981191ad74</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2469%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DM.%2BA.%26aulast%3DStarodub%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DWindsor%26aufirst%3DK.%26aulast%3DBrachmann%26aufirst%3DC.%2BB.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DVosganian%26aufirst%3DG.%26aulast%3DMaltzman%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DSilverman%26aufirst%3DJ.%2BA.%26aulast%3DLenz%26aufirst%3DH.-J.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26atitle%3DAndecaliximab%252FGS-5745%2520alone%2520and%2520combined%2520with%2520mFOLFOX6%2520in%2520advanced%2520gastric%2520and%2520gastroesophageal%2520junction%2520adenocarcinoma%253A%2520results%2520from%2520a%2520Phase%2520I%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3829%26doi%3D10.1158%2F1078-0432.CCR-17-2469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantelmo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camodeca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossello, A.</span></span> <span> </span><span class="NLM_article-title">N-O-Isopropyl sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors: hit selection and in vivo antiangiogenic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7224</span>– <span class="NLM_lpage">7240</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00367</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00367" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSmtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7224-7240&author=E.+Nutiauthor=A.+Cantelmoauthor=C.+Galloauthor=A.+Brunoauthor=B.+Bassaniauthor=C.+Camodecaauthor=T.+Tuccinardiauthor=L.+Veraauthor=E.+Orlandiniauthor=S.+Nencettiauthor=E.+Sturaauthor=A.+Martinelliauthor=V.+Diveauthor=A.+Albiniauthor=A.+Rossello&title=N-O-Isopropyl+sulfonamido-based+hydroxamates+as+matrix+metalloproteinase+inhibitors%3A+hit+selection+and+in+vivo+antiangiogenic+activity&doi=10.1021%2Facs.jmedchem.5b00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity</span></div><div class="casAuthors">Nuti, Elisa; Cantelmo, Anna Rita; Gallo, Cristina; Bruno, Antonino; Bassani, Barbara; Camodeca, Caterina; Tuccinardi, Tiziano; Vera, Laura; Orlandini, Elisabetta; Nencetti, Susanna; Stura, Enrico A.; Martinelli, Adriano; Dive, Vincent; Albini, Adriana; Rossello, Armando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7224-7240</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs) have been shown to be involved in tumor-induced angiogenesis.  In particular, MMP-2, MMP-9, and MMP-14 have been reported to be crucial for tumor angiogenesis and the formation of metastasis, thus becoming attractive targets in cancer therapy.  Here, the authors report the optimization effort to identify novel N-isopropoxy-arylsulfonamide hydroxamates with improved inhibitory activity toward MMP-2, MMP-9, and MMP-14 with respect to the previously discovered lead compd.  A new series of hydroxamates was designed, synthesized, and tested for their antiangiogenic activity using in vitro assays with human umbilical vein endothelial cells.  A nanomolar MMP-2, MMP-9, and MMP-14 inhibitor was identified, compd. I, able to potently inhibit angiogenesis in vitro and also in vivo in the matrigel sponge assay in mice.  Finally, x-ray crystallog. and docking studies were conducted for compd. I in order to investigate its binding mode to MMP-9 and MMP-14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkwrvJ2LNbVbVg90H21EOLACvtfcHk0lgl11qLmuoWTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSmtb3L&md5=e64e1150f5f2fe056185c2a0c2cf6881</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00367%26sid%3Dliteratum%253Aachs%26aulast%3DNuti%26aufirst%3DE.%26aulast%3DCantelmo%26aufirst%3DA.%26aulast%3DGallo%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DBassani%26aufirst%3DB.%26aulast%3DCamodeca%26aufirst%3DC.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DVera%26aufirst%3DL.%26aulast%3DOrlandini%26aufirst%3DE.%26aulast%3DNencetti%26aufirst%3DS.%26aulast%3DStura%26aufirst%3DE.%26aulast%3DMartinelli%26aufirst%3DA.%26aulast%3DDive%26aufirst%3DV.%26aulast%3DAlbini%26aufirst%3DA.%26aulast%3DRossello%26aufirst%3DA.%26atitle%3DN-O-Isopropyl%2520sulfonamido-based%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%253A%2520hit%2520selection%2520and%2520in%2520vivo%2520antiangiogenic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7224%26epage%3D7240%26doi%3D10.1021%2Facs.jmedchem.5b00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhogal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keily, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manallack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, R.</span></span> <span> </span><span class="NLM_article-title">Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1468</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00259-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0960-894X%2801%2900259-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11378378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVagtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1465-1468&author=A.+Baxterauthor=R.+Bhogalauthor=J.+Birdauthor=J.+Keilyauthor=D.+Manallackauthor=J.+Montanaauthor=D.+Owenauthor=W.+Pittauthor=R.+Watsonauthor=R.+Wills&title=Arylsulphonyl+hydroxamic+acids%3A+potent+and+selective+matrix+metalloproteinase+inhibitors&doi=10.1016%2FS0960-894X%2801%2900259-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors</span></div><div class="casAuthors">Baxter, A. D.; Bhogal, R.; Bird, J.; Keily, J. F.; Manallack, D. T.; Montana, J. G.; Owen, D. A.; Pitt, W. R.; Watson, R. J.; Wills, R. E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1465-1468</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkrTFiyeumrVg90H21EOLACvtfcHk0lgl11qLmuoWTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVagtrc%253D&md5=d013561f2a4d3eb4bb7898e837aec8f1</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900259-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900259-1%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DA.%26aulast%3DBhogal%26aufirst%3DR.%26aulast%3DBird%26aufirst%3DJ.%26aulast%3DKeily%26aufirst%3DJ.%26aulast%3DManallack%26aufirst%3DD.%26aulast%3DMontana%26aufirst%3DJ.%26aulast%3DOwen%26aufirst%3DD.%26aulast%3DPitt%26aufirst%3DW.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWills%26aufirst%3DR.%26atitle%3DArylsulphonyl%2520hydroxamic%2520acids%253A%2520potent%2520and%2520selective%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1465%26epage%3D1468%26doi%3D10.1016%2FS0960-894X%2801%2900259-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yodo, M.</span></span> <span> </span><span class="NLM_article-title">Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1738</span>, <span class="refDoi"> DOI: 10.1021/jm980514x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980514x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXisFGntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1723-1738&author=R.+Kiyamaauthor=Y.+Tamuraauthor=F.+Watanabeauthor=H.+Tsuzukiauthor=M.+Ohtaniauthor=M.+Yodo&title=Homology+modeling+of+gelatinase+catalytic+domains+and+docking+simulations+of+novel+sulfonamide+inhibitors&doi=10.1021%2Fjm980514x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Homology Modeling of Gelatinase Catalytic Domains and Docking Simulations of Novel Sulfonamide Inhibitors</span></div><div class="casAuthors">Kiyama, Ryuichi; Tamura, Yoshinori; Watanabe, Fumihiko; Tsuzuki, Hiroshige; Ohtani, Mitsuaki; Yodo, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1723-1738</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three-dimensional models for the catalytic domain of gelatinases (MMP-9 and -2) have been constructed based on the X-ray crystal structure of MMP-3.  Conformations of the loop segment which forms the bottom half of the S1' subsite but shows conformational diversity among the crystal structures of other MMPs have been explored by simulated annealing of each gelatinase model complexed with two highly potent "probe" inhibitors.  Representative catalytic domain models have been selected for each gelatinase from the set of generated conformations based on shape complementarity of the loop to the probe inhibitors.  The single model selected for MMP-9 was utilized to explain the structure-activity relationship of our novel sulfonamide inhibitors.  Mol. dynamics (MD) simulations of the complex models revealed important features of the binding mechanism of our inhibitors: (i) the ligand carboxylate group coordinating to the catalytic zinc ion and hydrogen bonding to the Glu219 side chain, (ii) one of the sulfonyl oxygens forming hydrogen bonds with the main chain NHs (Leu181 and Ala182), (iii) the sulfonyl substituent making extensive hydrophobic contact with the S1' subsite.  The gauche conformation exclusively adopted by the sulfonamide C-N-S-C torsion plays an important role in achieving the third binding feature by properly directing the substituent into the S1' subsite.  Improvement of the inhibitory activity according to straight elongation of the sulfonyl substituent was attributed to an increase of the hydrophobic contact between the substituent and the S1' subsite.  Structural modifications which alter the straight shape of the substituent lead to deterioration of the activity.  On the other hand, the two candidate models selected for MMP-2 differ in the bottom shape of the S1' subsite: one with a channel-like subsite and the other with a pocket-like subsite resembling that of the MMP-9 model.  The bottom shape was exptl. probed by chem. synthesis of inhibitors having elongated sulfonyl substituents whose terminal alkyl groups were shown by MD simulations to protrude from the S1' subsite bottom into the solvent.  Gelatinase assays of these inhibitors showed that elongation of the substituent significantly reduces activity against MMP-9 while retaining activity against MMP-2, consequently increasing the selectivity between MMP-2 and -9.  The results confirm that MMP-9 has a pocket-like S1' subsite with a floorboard and MMP-2 has a channel-like S1' subsite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMAdm5iXrSIbVg90H21EOLACvtfcHk0ljfE6dmAbGArg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisFGntrg%253D&md5=7e7041cce336dd66880689fa43c55a0e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Fjm980514x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980514x%26sid%3Dliteratum%253Aachs%26aulast%3DKiyama%26aufirst%3DR.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DF.%26aulast%3DTsuzuki%26aufirst%3DH.%26aulast%3DOhtani%26aufirst%3DM.%26aulast%3DYodo%26aufirst%3DM.%26atitle%3DHomology%2520modeling%2520of%2520gelatinase%2520catalytic%2520domains%2520and%2520docking%2520simulations%2520of%2520novel%2520sulfonamide%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1723%26epage%3D1738%26doi%3D10.1021%2Fjm980514x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, R.</span></span> <span> </span><span class="NLM_article-title">Antimetastatic activity of a novel mechanism-based gelatinase inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">3523</span>– <span class="NLM_lpage">3526</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-3570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-04-3570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15867341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3523-3526&author=A.+Kr%C3%BCgerauthor=M.+J.+Arltauthor=M.+Gergauthor=C.+Kopitzauthor=M.+M.+Bernardoauthor=M.+Changauthor=S.+Mobasheryauthor=R.+Fridman&title=Antimetastatic+activity+of+a+novel+mechanism-based+gelatinase+inhibitor&doi=10.1158%2F0008-5472.CAN-04-3570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Antimetastatic activity of a novel mechanism-based gelatinase inhibitor</span></div><div class="casAuthors">Krueger, Achim; Arlt, Matthias J. E.; Gerg, Michael; Kopitz, Charlotte; Bernardo, M. Margarida; Chang, Mayland; Mobashery, Shahriar; Fridman, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3523-3526</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs), and in particular gelatinases (MMP-2 and MMP-9), play a key role in cancer progression.  However, clin. trials in which MMP inhibitors were tested in cancer patients have been disappointing.  Whereas many reasons have been postulated to explain the failure of the clin. trials, lack of inhibitor selectivity was a major limitation.  Thus, despite the consensus opinion that MMP-mediated proteolysis is essential for cancer progression and that certain MMPs represent important targets for intervention, effective and selective inhibition of those MMPs remains a major challenge in drug development.  We previously reported the first mechanism-based MMP inhibitor, designated SB-3CT, which is a selective gelatinase inhibitor.  Here we report that SB-3CT (5-50 mg/kg/d) is a potent inhibitor of liver metastasis and increases survival in an aggressive mouse model of T-cell lymphoma.  This study shows that mechanism-based inhibition of gelatinases represents a novel approach to inhibitor design that promises to be a successful anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSJYWfMfofLVg90H21EOLACvtfcHk0lhbbX0PKocgZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGltb0%253D&md5=fe2a0c8c8cc6acd37123df24693bb179</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3570%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25BCger%26aufirst%3DA.%26aulast%3DArlt%26aufirst%3DM.%2BJ.%26aulast%3DGerg%26aufirst%3DM.%26aulast%3DKopitz%26aufirst%3DC.%26aulast%3DBernardo%26aufirst%3DM.%2BM.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DMobashery%26aufirst%3DS.%26aulast%3DFridman%26aufirst%3DR.%26atitle%3DAntimetastatic%2520activity%2520of%2520a%2520novel%2520mechanism-based%2520gelatinase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3523%26epage%3D3526%26doi%3D10.1158%2F0008-5472.CAN-04-3570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breyholz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabeneck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levkau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schober, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">3400</span>– <span class="NLM_lpage">3409</span>, <span class="refDoi"> DOI: 10.1021/jm049145x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049145x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFSjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=3400-3409&author=H.+J.+Breyholzauthor=M.+Schafersauthor=S.+Wagnerauthor=C.+Holtkeauthor=A.+Faustauthor=H.+Rabeneckauthor=B.+Levkauauthor=O.+Schoberauthor=K.+Kopka&title=C-5-disubstituted+barbiturates+as+potential+molecular+probes+for+noninvasive+matrix+metalloproteinase+imaging&doi=10.1021%2Fjm049145x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">C-5-Disubstituted Barbiturates as Potential Molecular Probes for Noninvasive Matrix Metalloproteinase Imaging</span></div><div class="casAuthors">Breyholz, Hans-Joerg; Schaefers, Michael; Wagner, Stefan; Hoeltke, Carsten; Faust, Andreas; Rabeneck, Helmut; Levkau, Bodo; Schober, Otmar; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3400-3409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Studies have demonstrated a pos. correlation between inflammation, metastasis, or atherosclerosis and the unbalanced or culminated expression of matrix metalloproteinases (MMPs).  The mol. imaging of locally upregulated MMP activity in vivo is a clin. challenge.  Actually, radioligands based on nonpeptidyl MMP inhibitors (MMPIs) are currently in development as putative radiopharmaceutical agents for the noninvasive in vivo assessment of activated MMPs.  Nonpeptidyl MMPIs bind to the zinc active site of the activated enzyme via mono- (e.g. carboxylate) or bidentate (e.g. hydroxamate) complexation thereby exhibiting a broad-spectrum MMP binding potency.  Thus, these mentioned endopeptidase inhibitors should be useable lead compds. for the redevelopment as diagnostic MMPI radiotracers.  Recently, the non-hydroxamate C-5-disubstituted pyrimidine-2,4,6-triones were disclosed as subgroup-selective MMP inhibitors.  We here describe a set of fine-tuned barbiturates as a new class of MMPI radiotracers for the noninvasive in vivo visualization of activated MMPs using scintigraphic techniques such as SPECT or PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYS_fgRnKuirVg90H21EOLACvtfcHk0lhbbX0PKocgZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFSjtbs%253D&md5=f574b4cffe59d35fdb6ec6ecbab9b000</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm049145x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049145x%26sid%3Dliteratum%253Aachs%26aulast%3DBreyholz%26aufirst%3DH.%2BJ.%26aulast%3DSchafers%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DHoltke%26aufirst%3DC.%26aulast%3DFaust%26aufirst%3DA.%26aulast%3DRabeneck%26aufirst%3DH.%26aulast%3DLevkau%26aufirst%3DB.%26aulast%3DSchober%26aufirst%3DO.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DC-5-disubstituted%2520barbiturates%2520as%2520potential%2520molecular%2520probes%2520for%2520noninvasive%2520matrix%2520metalloproteinase%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D3400%26epage%3D3409%26doi%3D10.1021%2Fjm049145x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Man, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, T.</span></span> <span> </span><span class="NLM_article-title">Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2504</span>– <span class="NLM_lpage">2505</span>, <span class="refDoi"> DOI: 10.1080/15548627.2016.1239679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1080%2F15548627.2016.1239679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27786577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKgsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=2504-2505&author=S.+Manauthor=T.+Kanneganti&title=Regulation+of+lysosomal+dynamics+and+autophagy+by+CTSB%2Fcathepsin+B&doi=10.1080%2F15548627.2016.1239679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B</span></div><div class="casAuthors">Man, Si Ming; Kanneganti, Thirumala-Devi</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2504-2505</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cysteine cathepsins are responsible for driving proteolytic degrdn. within the lysosome and in the extralysosomal milieu.  They also have an integral role in autophagy, antigen presentation, cellular stress signaling, metab. and lysosome-dependent cell death.  Here, we discuss our findings on the role of CTSB (cathepsin B), a member of the cysteine cathepsin family, in regulating the bioavailability of lysosomes and autophagosomes and consider how this regulatory response influences host susceptibility to infectious agents.  Our study demonstrates that under homeostatic conditions CTSB cleaves the calcium channel MCOLN1/TRPML1 in the lysosomes, maintaining suppression of the transcription factor TFEB and reducing expression of lysosomal and autophagy-related proteins.  This response controls the no. of lysosomes and autophagosomes in the cell.  However, the activity of CTSB is exploited by the cytosolic bacterium Francisella novicida, leading to enhanced survival of the pathogen and increased susceptibility of the host to infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqae_rpcL02mbVg90H21EOLACvtfcHk0lifrZYq0Bbr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKgsb3M&md5=ae74257ee31d822ade3a026c033adf45</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1080%2F15548627.2016.1239679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2016.1239679%26sid%3Dliteratum%253Aachs%26aulast%3DMan%26aufirst%3DS.%26aulast%3DKanneganti%26aufirst%3DT.%26atitle%3DRegulation%2520of%2520lysosomal%2520dynamics%2520and%2520autophagy%2520by%2520CTSB%252Fcathepsin%2520B%26jtitle%3DAutophagy%26date%3D2016%26volume%3D12%26spage%3D2504%26epage%3D2505%26doi%3D10.1080%2F15548627.2016.1239679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitrović, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirković, B.</span></span> <span> </span><span class="NLM_article-title">The current stage of cathepsin B inhibitors as potential anticancer agents</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.4155%2Ffmc.14.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25163003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVeisbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1355-1371&author=J.+Kosauthor=A.+Mitrovi%C4%87author=B.+Mirkovi%C4%87&title=The+current+stage+of+cathepsin+B+inhibitors+as+potential+anticancer+agents&doi=10.4155%2Ffmc.14.73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The current stage of cathepsin B inhibitors as potential anticancer agents</span></div><div class="casAuthors">Kos, Janko; Mitrovic, Ana; Mirkovic, Bojana</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1355-1371</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Cathepsin B is a lysosomal cysteine peptidase, with an important role in the development and progression of cancer.  It is involved in the degrdn. of extracellular matrix proteins, a process promoting invasion and metastasis of tumor cells and tumor angiogenesis.  Cathepsin B is unique among cathepsins in possessing both carboxypeptidase and endopeptidase activities.  While the former is assocd. with its physiol. role, the latter is involved in pathol. degrdn. of the extracellular matrix.  Its activities are regulated by different means, the most important being its endogenous inhibitors, the cystatins.  In cancer this peptidase/inhibitor balance is altered, leading to harmful cathepsin B activity.  The latter can be prevented by exogenous inhibitors.  They differ in modes of inhibition, size, structure, binding affinity, selectivity, toxicity and bioavailability.  In this article, we review the properties and function of endogenous and exogenous cathepsin B inhibitors and indicate their application as possible anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfpmptuVGlabVg90H21EOLACvtfcHk0lifrZYq0Bbr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVeisbjP&md5=98a16a3ebad41a8ca00d9fa5705bd10d</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.73%26sid%3Dliteratum%253Aachs%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DMitrovi%25C4%2587%26aufirst%3DA.%26aulast%3DMirkovi%25C4%2587%26aufirst%3DB.%26atitle%3DThe%2520current%2520stage%2520of%2520cathepsin%2520B%2520inhibitors%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1355%26epage%3D1371%26doi%3D10.4155%2Ffmc.14.73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span> <span> </span><span class="NLM_article-title">Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.3892/ol.2011.302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3892%2Fol.2011.302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22848251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslOiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=693-699&author=Q.+Chenauthor=J.+Feiauthor=L.+Wuauthor=Z.+Jiangauthor=Y.+Wuauthor=Y.+Zhengauthor=G.+Lu&title=Detection+of+cathepsin+B%2C+cathepsin+L%2C+cystatin+C%2C+urokinase+plasminogen+activator+and+urokinase+plasminogen+activator+receptor+in+the+sera+of+lung+cancer+patients&doi=10.3892%2Fol.2011.302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients</span></div><div class="casAuthors">Chen, Qingyong; Fei, Jun; Wu, Lijun; Jiang, Zhongyong; Wu, Yuquan; Zheng, Yun; Lu, Guohua</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">693-699</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The present study aimed to det. the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA.  Concomitantly, the relationship between the components and clinicopathol. prognosis was analyzed.  The study included 30 healthy volunteers and 105 lung cancer patients.  Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA.  Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls.  The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis.  There was no significance for other parameters.  Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C+/cath B- or with cystatin C+/cath B-.  Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival.  Furthermore, the univariate anal. revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival.  However, findings of the multivariate Cox anal. indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8uObw01MZrVg90H21EOLACvtfcHk0lhBdQ3bJTLMIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslOiurc%253D&md5=f2170f4806e216b773b1d058534a95fd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.3892%2Fol.2011.302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2011.302%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DFei%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DG.%26atitle%3DDetection%2520of%2520cathepsin%2520B%252C%2520cathepsin%2520L%252C%2520cystatin%2520C%252C%2520urokinase%2520plasminogen%2520activator%2520and%2520urokinase%2520plasminogen%2520activator%2520receptor%2520in%2520the%2520sera%2520of%2520lung%2520cancer%2520patients%26jtitle%3DOncol.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D693%26epage%3D699%26doi%3D10.3892%2Fol.2011.302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armeson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2034</span>– <span class="NLM_lpage">2043</span>, <span class="refDoi"> DOI: 10.1002/ijc.27480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fijc.27480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22322590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XksV2itbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=2034-2043&author=T.+H.+Beckhamauthor=P.+Luauthor=J.+C.+Chengauthor=D.+Zhaoauthor=L.+S.+Turnerauthor=X.+Zhangauthor=S.+Hoffmanauthor=K.+E.+Armesonauthor=A.+Liuauthor=T.+Marrisonauthor=Y.+A.+Hannunauthor=X.+Liu&title=Acid+ceramidase-mediated+production+of+sphingosine+1-phosphate+promotes+prostate+cancer+invasion+through+upregulation+of+cathepsin+B&doi=10.1002%2Fijc.27480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B</span></div><div class="casAuthors">Beckham, Thomas H.; Lu, Ping; Cheng, Joseph C.; Zhao, Dan; Turner, Lorianne S.; Zhang, Xiaoyi; Hoffman, Stanley; Armeson, Kent E.; Liu, Angen; Marrison, Tucker; Hannun, Yusuf A.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2034-2043</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Invasiveness is one of the key features of aggressive prostate cancer; however, our understanding of the precise mechanisms effecting invasion remains limited.  The ceramide hydrolyzing enzyme acid ceramidase (AC), overexpressed in most prostate tumors, causes an aggressive and invasive phenotype through downstream effectors that have not yet been well characterized.  Here, we demonstrate that AC, through generation of sphingosine-1-phosphate (S1P), promotes Ets1 nuclear expression and binding to the promoter region of matrix-degrading protease cathepsin B.  Through confocal microscopy and flow cytometry, we found that AC overexpression promotes pericellular localization of cathepsin B and its translocation to the outer leaflet of the cell membrane.  AC overexpressing cells have an increased abundance of cathepsin B-enriched invasive structures and enhanced ability to invade through a collagen matrix, but not in the presence of an inhibitor of cathepsin B.  In human prostate tissues, AC and cathepsin B overexpression were strongly assocd. and may relate to poor outcome.  These results demonstrate a novel pathway by which AC, through S1P, promotes an invasive phenotype in prostate cancer by causing overexpression and secretion of cathepsin B through activation and nuclear expression of Ets1.  As prostate cancer prognosis is dramatically worse when invasion has occurred, this study provides crit. insight into the progression toward lethal prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_675HsVz6bVg90H21EOLACvtfcHk0lhBdQ3bJTLMIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksV2itbs%253D&md5=2fce1a32e7e403e5e9032adb0c85550a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Fijc.27480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27480%26sid%3Dliteratum%253Aachs%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DS.%26aulast%3DArmeson%26aufirst%3DK.%2BE.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DMarrison%26aufirst%3DT.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAcid%2520ceramidase-mediated%2520production%2520of%2520sphingosine%25201-phosphate%2520promotes%2520prostate%2520cancer%2520invasion%2520through%2520upregulation%2520of%2520cathepsin%2520B%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D131%26spage%3D2034%26epage%3D2043%26doi%3D10.1002%2Fijc.27480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mijanović, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branković, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panin, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timashev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulasov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesniak, M. S.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B: a sellsword of cancer progression</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>449</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.canlet.2019.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30796968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslOrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2019&pages=207-214&author=O.+Mijanovi%C4%87author=A.+Brankovi%C4%87author=A.+N.+Paninauthor=S.+Savchukauthor=P.+Timashevauthor=I.+Ulasovauthor=M.+S.+Lesniak&title=Cathepsin+B%3A+a+sellsword+of+cancer+progression&doi=10.1016%2Fj.canlet.2019.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B: A sellsword of cancer progression</span></div><div class="casAuthors">Mijanovic, Olja; Brankovic, Ana; Panin, Alexander N.; Savchuk, Solomiia; Timashev, Peter; Ulasov, Ilya; Lesniak, Maciej S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">449</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-214</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Clin., biochem. and mol. biol. studies have identified lysosome-encapsulated cellular proteases as crit. risk factors for cancer progression.  Cathepsins represent a group of such proteases aimed at maintenance of cellular homeostasis.  Nevertheless, recent reports suggest that Cathepsin B executes other cellular programs such as controlling tumor growth, migration, invasion, angiogenesis, and metastases development.  In fact, elevated levels of Cathepsins are found under different pathol. conditions including inflammation, infection, neurodegenerative disease, and cancer.  Furthermore, the discovery of Cathepsin B secretion and function as an extracellular matrix protein has broadened our appreciation for the impact of Cathepsin B on cancer progression.  Underneath a fac[n.807]ade of an intracellular protease with limited therapeutic potential hides a central role of cathepsins in extracellular functions.  Moreover, this role is incredibly diverse from one condition to the next from driving caspase-dependent apoptosis to facilitating tumor neovascularization and metastasis.  Here we discuss the role of Cathepsin B in the oncogenic process and perspective the use of Cathepsin B for diagnostic and therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPYxjkNaUuybVg90H21EOLACvtfcHk0ljtVJSMQwSqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslOrsLk%253D&md5=6a85229e9df2c2e4009773480ba575e6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DMijanovi%25C4%2587%26aufirst%3DO.%26aulast%3DBrankovi%25C4%2587%26aufirst%3DA.%26aulast%3DPanin%26aufirst%3DA.%2BN.%26aulast%3DSavchuk%26aufirst%3DS.%26aulast%3DTimashev%26aufirst%3DP.%26aulast%3DUlasov%26aufirst%3DI.%26aulast%3DLesniak%26aufirst%3DM.%2BS.%26atitle%3DCathepsin%2520B%253A%2520a%2520sellsword%2520of%2520cancer%2520progression%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D449%26spage%3D207%26epage%3D214%26doi%3D10.1016%2Fj.canlet.2019.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal cysteine proteases: more than scavengers</span>. <i>Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1477</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/S0167-4838(99)00263-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0167-4838%2899%2900263-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10708852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsFGktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1477&publication_year=2000&pages=98-111&author=B.+Turkauthor=D.+Turkauthor=V.+Turk&title=Lysosomal+cysteine+proteases%3A+more+than+scavengers&doi=10.1016%2FS0167-4838%2899%2900263-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal cysteine proteases: more than scavengers</span></div><div class="casAuthors">Turk, B.; Turk, D.; Turk, V.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Protein Structure and Molecular Enzymology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1477</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">98-111</span>CODEN:
                <span class="NLM_cas:coden">BBAEDZ</span>;
        ISSN:<span class="NLM_cas:issn">0167-4838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 157 refs.  Lysosomal cysteine proteases were believed to be mainly involved in intracellular protein degrdn.  Under special conditions they have been found outside lysosomes resulting in pathol. conditions.  With the discovery of a series of new cathepsins with restricted tissue distributions, it has become evident that these enzymes must be involved in a range of specific cellular tasks much broader than as simple housekeeping enzymes.  It is therefore timely to review and discuss the various physiol. roles of mammalian lysosomal papain-like cysteine proteases as well as their mechanisms of action and the regulation of their activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKn0oFhrAq2LVg90H21EOLACvtfcHk0ljtVJSMQwSqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsFGktLo%253D&md5=4a477858e63d2373f3bd6359156eb2ba</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2FS0167-4838%2899%2900263-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-4838%252899%252900263-0%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26aulast%3DTurk%26aufirst%3DV.%26atitle%3DLysosomal%2520cysteine%2520proteases%253A%2520more%2520than%2520scavengers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Protein%2520Struct.%2520Mol.%2520Enzymol.%26date%3D2000%26volume%3D1477%26spage%3D98%26epage%3D111%26doi%3D10.1016%2FS0167-4838%2899%2900263-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Percival, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, J. A.</span></span> <span> </span><span class="NLM_article-title">Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">6311</span>– <span class="NLM_lpage">6318</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2000.01730.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1046%2Fj.1432-1327.2000.01730.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11012686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVygtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2000&pages=6311-6318&author=J.+Guayauthor=J.+P.+Falgueyretauthor=A.+Ducretauthor=M.+D.+Percivalauthor=J.+A.+Mancini&title=Potency+and+selectivity+of+inhibition+of+cathepsin+K%2C+L+and+S+by+their+respective+propeptides&doi=10.1046%2Fj.1432-1327.2000.01730.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides</span></div><div class="casAuthors">Guay, Jocelyne; Falgueyret, Jean-Pierre; Ducret, Axel; Percival, M. David; Mancini, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6311-6318</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The prodomains of several cysteine proteases of the papain family have been shown to be potent inhibitors of their parent enzymes.  An increased interest in cysteine proteases inhibitors has been generated with potential therapeutic targets such as cathepsin K for osteoporosis and cathepsin S for immune modulation.  The propeptides of cathepsin S, L and K were expressed as glutathione S-transferase-fusion proteins in Escherichia coli.  The proteins were purified on glutathione affinity columns and the glutathione S-transferase was removed by thrombin cleavage.  All three propeptides were tested for inhibitor potency and found to be selective within the cathepsin L subfamily (cathepsins K, L and S) compared with cathepsin B or papain.  Inhibition of cathepsin K by either procathepsin K, L or S was time-dependent and occurred by an apparent one-step mechanism.  The cathepsin K propeptide had a Ki of 3.6-6.3 nM for each of the three cathepsins K, L and S.  The cathepsin L propeptide was at least a 240-fold selective inhibitor of cathepsin K (Ki = 0.27 nM) and cathepsin L (Ki = 0.12 nM) compared with cathepsin S (Ki = 65 nM).  Interestingly, the cathepsin S propeptide was more selective for inhibition of cathepsin L (Ki = 0.46 nM) than cathepsin S (Ki = 7.6 nM) itself or cathepsin K (Ki = 7.0 nM).  This is in sharp contrast to previously published data demonstrating that the cathepsin S propeptide is equipotent for inhibition of human cathepsin S and rat and paramecium cathepsin L.  These results demonstrate that limited selectivity of inhibition can be measured for the procathepsins K, L and S vs. the parent enzymes, but selective inhibition vs. cathepsin B and papain was obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMcJhFn9vMorVg90H21EOLACvtfcHk0lgMNsiaAdIREg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVygtrk%253D&md5=17682fb392a0aa84e63d5216cd0c601e</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2000.01730.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2000.01730.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuay%26aufirst%3DJ.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DDucret%26aufirst%3DA.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DMancini%26aufirst%3DJ.%2BA.%26atitle%3DPotency%2520and%2520selectivity%2520of%2520inhibition%2520of%2520cathepsin%2520K%252C%2520L%2520and%2520S%2520by%2520their%2520respective%2520propeptides%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2000%26volume%3D267%26spage%3D6311%26epage%3D6318%26doi%3D10.1046%2Fj.1432-1327.2000.01730.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantes, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chagas, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faljoni-Alario, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersariol, I. L.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">944</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1074/jbc.M003820200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1074%2Fjbc.M003820200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11016923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtVymsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=944-951&author=P.+C.+Almeidaauthor=I.+L.+Nantesauthor=J.+R.+Chagasauthor=C.+C.+Rizziauthor=A.+Faljoni-Alarioauthor=E.+Carmonaauthor=L.+Julianoauthor=H.+B.+Naderauthor=I.+L.+Tersariol&title=Cathepsin+B+activity+regulation.+Heparin-like+glycosaminogylcans+protect+human+cathepsin+B+from+alkaline+pH-induced+inactivation&doi=10.1074%2Fjbc.M003820200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B activity regulation: heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation</span></div><div class="casAuthors">Almeida, Paulo C.; Nantes, Iseli L.; Chagas, Jair R.; Rizzi, Claudia C. A.; Faljoni-Alario, Adelaide; Carmona, Euridice; Juliano, Luiz; Nader, Helena B.; Tersariol, Ivarne L. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">944-951</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">It has been shown that lysosomal cysteine proteinases, specially cathepsin B, has been implicated in a variety of diseases involving tissue remodeling states, such as inflammation, parasite infection, and tumor metastasis, by degrdn. of extracellular matrix components.  Recently, we have shown that heparin and heparan sulfate bind to papain specifically; this interaction induces an increase of its α-helix content and stabilizes the enzyme structure even at alk. pH.  In the present work, a combination of CD anal., affinity chromatog., cathepsin B mutants, and fluorogenic substrate assays were used to characterize the interaction of human cathepsin B with glycosaminoglycans.  The nature of the cathepsin B-glycosaminoglycans interaction was sensitive to the charge and type of polysaccharide.  Like papain, heparin and heparan sulfate bind cathepsin B specifically, and this interaction reduces the loss of cathepsin B α-helix content at alk. pH.  Our data show that the coupling of cathepsin B with heparin or heparan sulfate can potentiate the endopeptidase activity of the cathepsin B, increasing 5-fold the half-life (t1/2) of the enzyme at alk. pH.  Most of these effects are related to the interaction of heparin and heparan sulfate with His111 residue of the cathepsin B occluding loop.  These results strongly suggest that heparan sulfate may be an important binding site for cathepsin B at cell surface, reporting a novel physiol. role for heparan sulfate proteoglycans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdhdcVd5khobVg90H21EOLACvtfcHk0lgMNsiaAdIREg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtVymsA%253D%253D&md5=a3cb3f77fba2d8fc8033fc1f0b48bb2e</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M003820200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M003820200%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%26aufirst%3DP.%2BC.%26aulast%3DNantes%26aufirst%3DI.%2BL.%26aulast%3DChagas%26aufirst%3DJ.%2BR.%26aulast%3DRizzi%26aufirst%3DC.%2BC.%26aulast%3DFaljoni-Alario%26aufirst%3DA.%26aulast%3DCarmona%26aufirst%3DE.%26aulast%3DJuliano%26aufirst%3DL.%26aulast%3DNader%26aufirst%3DH.%2BB.%26aulast%3DTersariol%26aufirst%3DI.%2BL.%26atitle%3DCathepsin%2520B%2520activity%2520regulation.%2520Heparin-like%2520glycosaminogylcans%2520protect%2520human%2520cathepsin%2520B%2520from%2520alkaline%2520pH-induced%2520inactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D944%26epage%3D951%26doi%3D10.1074%2Fjbc.M003820200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. K.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B expression and the correlation with clinical aspects of oral squamous cell carcinoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0152165</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0152165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1371%2Fjournal.pone.0152165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27031837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWms7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&author=W.+E.+Yangauthor=C.+C.+Hoauthor=S.+F.+Yangauthor=S.+H.+Linauthor=K.+T.+Yehauthor=C.+W.+Linauthor=M.+K.+Chen&title=Cathepsin+B+expression+and+the+correlation+with+clinical+aspects+of+oral+squamous+cell+carcinoma&doi=10.1371%2Fjournal.pone.0152165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B expression and the correlation with clinical aspects of oral squamous cell carcinoma</span></div><div class="casAuthors">Yang, Wei-En; Ho, Chuan-Chen; Yang, Shun-Fa; Lin, Shu-Hui; Yeh, Kun-Tu; Lin, Chiao-Wen; Chen, Mu-Kuan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0152165/1-e0152165/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Cathepsin B (CTSB), a member of the cathepsin family, is a cysteine protease that is widely distributed in the lysosomes of cells in various tissues.  It is overexpressed in several human cancers and may be related to tumorigenesis.  The main purpose of this study was to analyze CTSB expression in oral squamous cell carcinoma (OSCC) and its correlation with patient prognosis.  Methodol./Principal Findings Tissue microarrays were used to detect CTSB expression in 280 patients and to examine the assocn. between CTSB expression and clinicopathol. parameters.  In addn., the metastatic effects of the CTSB knockdown on two oral cancer cell lines were investigated by transwell migration assay.  Cytoplasmic CTSB expression was detected in 34.6% (97/280) of patients.  CTSB expression was correlated with pos. lymph node metastasis (p = 0.007) and higher tumor grade (p = 0.008) but not with tumor size and distant metastasis.  In addn., multivariate anal. using a Cox proportional hazards model revealed a higher hazard ratio, demonstrating that CTSB expression was an independent unfavorable prognostic factor in buccal mucosa carcinoma patients.  Furthermore, the Kaplan-Meier curve revealed that buccal mucosa OSCC patients with pos. CTSB expression had significantly shorter overall survival.  Moreover, treatment with the CTSB siRNA exerted an inhibitory effect on migration in OC2 and CAL27 oral cancer cells.  Conclusions We conclude that CTSB expression may be useful for detg. OSCC prognosis, particularly for patients with lymph node metastasis, and may function as a biomarker of the survival of OSCC patients in Taiwan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_H50NkY7CqrVg90H21EOLACvtfcHk0ljK0Ahb285e1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWms7nF&md5=27dfbbdd06699fd3a366b2ff755ce6b0</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0152165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0152165%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%2BE.%26aulast%3DHo%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DYeh%26aufirst%3DK.%2BT.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DM.%2BK.%26atitle%3DCathepsin%2520B%2520expression%2520and%2520the%2520correlation%2520with%2520clinical%2520aspects%2520of%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26doi%3D10.1371%2Fjournal.pone.0152165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lah, T. T.</span></span> <span> </span><span class="NLM_article-title">Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review)</span>. <i>Oncology reports</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1349</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.3892/or.5.6.1349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3892%2For.5.6.1349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=9769367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1cXntFSrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1998&pages=1349-1361&author=J.+Kosauthor=T.+T.+Lah&title=Cysteine+proteinases+and+their+endogenous+inhibitors%3A+target+proteins+for+prognosis%2C+diagnosis+and+therapy+in+cancer+%28review%29&doi=10.3892%2For.5.6.1349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review)</span></div><div class="casAuthors">Kos, Janko; Lah, Tamara T.</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1349-1361</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review with 145 refs.  Lysosomal cysteine proteinases, the cathepsins (Cats) belong to the papain family of proteinases, sharing a similar protein structure and mechanism of action.  Subtle structural differences between these enzymes give rise to important variations in substrate specificity and specificity of inhibition by their endogenous inhibitors, the cystatins, stefins and kininogens under physiol. and pathol. conditions.  Alterations in their expression, processing and localization have been obsd. at various levels in malignant human tumor tissue compared to normal and benign tissue counterparts.  The authors have proposed that an imbalance between cathepsins and cystatins, assocd. with metastatic tumor cell phenotype, may facilitate tumor cell invasion and metastasis.  The results of clin. investigations on cysteine cathepsins and their endogenous inhibitors in human breast, lung, brain and head and neck tumors, as well as in body fluids of ovarian, uterine, melanoma and colorectal carcinoma bearing patients, have shown that these mols. are highly predictive for the length of survival and may be used for assessment of risk of relapse and death for cancer patients.  Their application for diagnosis, follow-up and the anticancer therapy has also been proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfm_eMOSgpRbVg90H21EOLACvtfcHk0lh03PVK9a54Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFSrtrY%253D&md5=2ad38ca3b4a9cfae7270017bd68dc131</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.3892%2For.5.6.1349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.5.6.1349%26sid%3Dliteratum%253Aachs%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DLah%26aufirst%3DT.%2BT.%26atitle%3DCysteine%2520proteinases%2520and%2520their%2520endogenous%2520inhibitors%253A%2520target%2520proteins%2520for%2520prognosis%252C%2520diagnosis%2520and%2520therapy%2520in%2520cancer%2520%2528review%2529%26jtitle%3DOncology%2520reports%26date%3D1998%26volume%3D5%26spage%3D1349%26epage%3D1361%26doi%3D10.3892%2For.5.6.1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloane, B. F.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B: Multiple roles in cancer</span>. <i>Proteomics: Clin. Appl.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1002/prca.201300105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fprca.201300105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=24677670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVGrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=427-437&author=N.+Aggarwalauthor=B.+F.+Sloane&title=Cathepsin+B%3A+Multiple+roles+in+cancer&doi=10.1002%2Fprca.201300105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B: Multiple roles in cancer</span></div><div class="casAuthors">Aggarwal, Neha; Sloane, Bonnie F.</div><div class="citationInfo"><span class="NLM_cas:title">Proteomics: Clinical Applications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">427-437</span>CODEN:
                <span class="NLM_cas:coden">PCARCU</span>;
        ISSN:<span class="NLM_cas:issn">1862-8346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Proteases, including intracellular proteases, play roles at many different stages of malignant progression.  Our focus here is cathepsin B, a lysosomal cysteine cathepsin.  High levels of cathepsin B are found in a wide variety of human cancers, levels that often induce secretion and assocn. of cathepsin B with the tumor cell membrane.  In exptl. models, such as transgenic models of murine pancreatic and mammary carcinomas, causal roles for cathepsin B have been demonstrated in initiation, growth/tumor cell proliferation, angiogenesis, invasion, and metastasis.  Tumor growth in transgenic models is promoted by cathepsin B in tumor-assocd. cells, for example, tumor-assocd. macrophages, as well as in tumor cells.  In transgenic models, the absence of cathepsin B has been assocd. with enhanced apoptosis, yet cathepsin B also has been shown to contribute to apoptosis.  Cathepsin B is part of a proteolytic pathway identified in xenograft models of human glioma; targeting only cathepsin B in these tumors is less effective than targeting cathepsin B in combination with other proteases or protease receptors.  Understanding the mechanisms responsible for increased expression of cathepsin B in tumors and assocn. of cathepsin B with tumor cell membranes is needed to det. whether targeting cathepsin B could be of therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvW2jNDWUThbVg90H21EOLACvtfcHk0lh03PVK9a54Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVGrtLc%253D&md5=a305bd67d038b4f097abb1a7fb0d0082</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fprca.201300105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprca.201300105%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DN.%26aulast%3DSloane%26aufirst%3DB.%2BF.%26atitle%3DCathepsin%2520B%253A%2520Multiple%2520roles%2520in%2520cancer%26jtitle%3DProteomics%253A%2520Clin.%2520Appl.%26date%3D2014%26volume%3D8%26spage%3D427%26epage%3D437%26doi%3D10.1002%2Fprca.201300105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostoulas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baici, A.</span></span> <span> </span><span class="NLM_article-title">Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(99)00897-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0014-5793%2899%2900897-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10437790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXks1Olsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=1999&pages=286-290&author=G.+Kostoulasauthor=A.+Langauthor=H.+Nagaseauthor=A.+Baici&title=Stimulation+of+angiogenesis+through+cathepsin+B+inactivation+of+the+tissue+inhibitors+of+matrix+metalloproteinases&doi=10.1016%2FS0014-5793%2899%2900897-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases</span></div><div class="casAuthors">Kostoulas, Georgios; Lang, Angela; Nagase, Hideaki; Baici, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-290</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The tissue inhibitors of matrix metalloproteinases (MMPs), TIMP-1 and TIMP-2, are also angiogenesis inhibitors.  Cathepsin B and MMPs are found at sites of neovascularization in pathologies such as cancer and osteoarthritis.  Treatment of TIMP-1, TIMP-2, and of a mixt. of both inhibitors from human articular chondrocytes with cathepsin B resulted in their fragmentation, whereby they lost their MMP-inhibitory and anti-angiogenic activities.  The authors' data suggest that, besides directly participating in tissue destruction, cathepsin B can be harmful for two further reasons: it raises the activity of the MMPs also in the absence of mechanisms up-regulating these enzymes, and it stimulates angiogenesis.  This is a prerequisite for blood vessel invasion in a variety of pathol. situations of which cancer and osteoarthritis are prominent examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu06Wx6AjXbrVg90H21EOLACvtfcHk0ljpaSchq0BQxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXks1Olsbo%253D&md5=35e37ccb2c16fd0cb6024314269dc522</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2899%2900897-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252899%252900897-2%26sid%3Dliteratum%253Aachs%26aulast%3DKostoulas%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DBaici%26aufirst%3DA.%26atitle%3DStimulation%2520of%2520angiogenesis%2520through%2520cathepsin%2520B%2520inactivation%2520of%2520the%2520tissue%2520inhibitors%2520of%2520matrix%2520metalloproteinases%26jtitle%3DFEBS%2520Lett.%26date%3D1999%26volume%3D455%26spage%3D286%26epage%3D290%26doi%3D10.1016%2FS0014-5793%2899%2900897-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasiljeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span> <span> </span><span class="NLM_article-title">Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion</span>. <i>Biochimie</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/j.biochi.2007.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.biochi.2007.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17991442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2008&pages=380-386&author=O.+Vasiljevaauthor=B.+Turk&title=Dual+contrasting+roles+of+cysteine+cathepsins+in+cancer+progression%3A+apoptosis+versus+tumour+invasion&doi=10.1016%2Fj.biochi.2007.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Dual contrasting roles of cysteine cathepsins in cancer progression: Apoptosis versus tumor invasion</span></div><div class="casAuthors">Vasiljeva, Olga; Turk, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Biochimie</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">380-386</span>CODEN:
                <span class="NLM_cas:coden">BICMBE</span>;
        ISSN:<span class="NLM_cas:issn">0300-9084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cysteine cathepsins have been known for a long time to play an important role in cancer progression and metastasis.  Several studies have proposed the concept of anti-cathepsin therapy in cancer treatment.  On the other hand, cysteine cathepsins have been recently found to play a role in tumor cell death through mediation of apoptosis.  The purpose of this mini-review is therefore to provide an insight into the mechanisms by which cysteine cathepsins modulate apoptosis and/or participate in tumor invasion, and to evaluate the impact of these enzymes on both tumor progression and development of potential strategies for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkGN4RG3lghrVg90H21EOLACvtfcHk0ljpaSchq0BQxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGktbo%253D&md5=706bc27e09103d9c4384275b98232c49</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2007.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2007.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DVasiljeva%26aufirst%3DO.%26aulast%3DTurk%26aufirst%3DB.%26atitle%3DDual%2520contrasting%2520roles%2520of%2520cysteine%2520cathepsins%2520in%2520cancer%2520progression%253A%2520apoptosis%2520versus%2520tumour%2520invasion%26jtitle%3DBiochimie%26date%3D2008%26volume%3D90%26spage%3D380%26epage%3D386%26doi%3D10.1016%2Fj.biochi.2007.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katunuma, N.</span></span> <span> </span><span class="NLM_article-title">Structure-based development of specific inhibitors for individual cathepsins and their medical applications</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2183/pjab.87.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2183%2Fpjab.87.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2011&pages=29-39&author=N.+Katunuma&title=Structure-based+development+of+specific+inhibitors+for+individual+cathepsins+and+their+medical+applications&doi=10.2183%2Fpjab.87.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based development of specific inhibitors for individual cathepsins and their medical applications</span></div><div class="casAuthors">Katunuma, Nobuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  Specific inhibitors for individual cathepsins have been developed based on their tertiary structures of X-ray crystallog.  Cathepsin B-specific inhibitors, CA-074 and CA-030, and cathepsin L specific inhibitors, CLIK-148 and CLIK-195, were designed as the epoxysuccinate derivs.  Cathepsin S inhibitor, CLIK-060, and cathepsin K inhibitor, CLIK-166, were synthesized.  These inhibitors can use in vitro and also in vivo, and show no toxicity for exptl. animals by the amts. used as the cathepsin inhibitor.  Various cathepsins are used in the processing of antigenic proteins.  The CLIK-060 treatment to the autoimmune disease, Sjogren model mice, led to strongly suppress the expression of the pathol. symptoms.  Cathepsins L or K participates to the degrdn. of bone collagen.  The CLIK-148 protects osteoporosis in animals and also protects the bone metastasis of cancer cells.  Cathepsin L also enhances insulin-induced glucose uptake into 3T3-L1 adipocytes, suggesting cathepsin L plays the roles in adipogenesis and glucose tolerance in type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl9gYdvAtAJ7Vg90H21EOLACvtfcHk0li3oyykuSHhgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL8%253D&md5=75d9e6e6b75de8093775dd148b808d44</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.2183%2Fpjab.87.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.87.29%26sid%3Dliteratum%253Aachs%26aulast%3DKatunuma%26aufirst%3DN.%26atitle%3DStructure-based%2520development%2520of%2520specific%2520inhibitors%2520for%2520individual%2520cathepsins%2520and%2520their%2520medical%2520applications%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2011%26volume%3D87%26spage%3D29%26epage%3D39%26doi%3D10.2183%2Fpjab.87.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmeister, T.</span></span> <span> </span><span class="NLM_article-title">New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1021/jm981061z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm981061z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXht1Kjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=560-572&author=T.+Schirmeister&title=New+peptidic+cysteine+protease+inhibitors+derived+from+the+electrophilic+alpha-amino+acid+aziridine-2%2C3-dicarboxylic+acid&doi=10.1021%2Fjm981061z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">New Peptidic Cysteine Protease Inhibitors Derived from the Electrophilic α-Amino Acid Aziridine-2,3-dicarboxylic Acid</span></div><div class="casAuthors">Schirmeister, Tanja</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">560-572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three different types of peptides contg. aziridine-2,3-dicarboxylic acid (Azi) as an electrophilic α-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivs. of Azi) have been synthesized and tested as inhibitors of the cysteine proteases papain, cathepsins B, L, and H, and calpains I and II, as well as against several serine proteases, one aspartate, and one metalloprotease.  All aziridinyl peptides are specific cysteine protease inhibitors.  Papain and cathepsins B and L are inhibited irreversibly, whereas cathepsin H and calpains are inhibited in a non-time-dependent manner.  Some compds. turned out to be substrates for serine proteases and for the metalloprotease thermolysin.  Remarkable differences can be obsd. between the three different types of inhibitors concerning stereospecificity, pH dependency of inhibition, selectivity between different cysteine proteases, and the importance of a free carboxylic acid function at the aziridine ring for inhibition.  Above all type II inhibitors, aza analogs of the well-known epoxysuccinyl peptides, are potent cysteine protease inhibitors.  With the exception of BOC-Leu-Gly-(S,S+R,R)-Azi-(OEt)2 (28a+b), a highly selective and potent cathepsin L inhibitor, N-acylated aziridines of type I are weaker inhibitors than type II or type III compds.  The obsd. results can be explained by different binding modes of the three types of inhibitors with respect to their orientation in the S- and S'-binding sites of the enzymes. Furthermore, the presence of a protonated aziridine N modifies the binding mode of type II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojzrzdyt5ANLVg90H21EOLACvtfcHk0li3oyykuSHhgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1Kjs78%253D&md5=f427b27c59f4697baea11e457c656545</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fjm981061z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981061z%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmeister%26aufirst%3DT.%26atitle%3DNew%2520peptidic%2520cysteine%2520protease%2520inhibitors%2520derived%2520from%2520the%2520electrophilic%2520alpha-amino%2520acid%2520aziridine-2%252C3-dicarboxylic%2520acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D560%26epage%3D572%26doi%3D10.1021%2Fjm981061z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peric, M.</span></span> <span> </span><span class="NLM_article-title">Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(00)00058-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0968-0896%2800%2900058-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10896108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksFCrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=1281-1291&author=T.+Schirmeisterauthor=M.+Peric&title=Aziridinyl+peptides+as+inhibitors+of+cysteine+proteases%3A+effect+of+a+free+carboxylic+acid+function+on+inhibition&doi=10.1016%2FS0968-0896%2800%2900058-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Aziridinyl peptides as inhibitors of cysteine proteases: Effect of a free carboxylic acid function on inhibition</span></div><div class="casAuthors">Schirmeister, T.; Peric, M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1281-1291</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Peptides contg. aziridine-2,3-dicarboxylate (Azi) as electrophilic building block are evaluated as inhibitors of the cysteine proteases papain, cathepsin B, cathepsin L and clostripain.  The influence of a free carboxylic acid as functional group at different positions of the inhibitor mol. on inhibition is analyzed.  Structure-activity relationships and binding mode hypotheses are discussed.  In contrast to the bacterial enzyme clostripain, the papain like mammalian proteases (cathepsins) are irreversibly inactivated by aziridinyl peptides.  N-Unsubstituted aziridines are much more potent inhibitors of papain and cathepsins if they contain the free carboxylic acid attached to the aziridine ring (HOAzi-Leu-ProOBzl).  Two free carboxylic acid functions at the aziridine ring are necessary for good inhibition of these enzymes by N-acylated aziridinyl peptides (BOC-Phe-Azi(OH)2).  Chimeric bispeptidyl derivs. are selective cathepsin B inhibitors if the free acid is located at the C-terminus of the peptide (BOC-Phe-(EtO)Azi-Leu-ProOH).  Clostripain is only inhibited by aziridinyl peptide esters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy8B3EG21SYLVg90H21EOLACvtfcHk0liOSyhk2GO7ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksFCrsLs%253D&md5=2f4fa2bdeaad7a76f175665c9d512eda</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2800%2900058-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252800%252900058-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DPeric%26aufirst%3DM.%26atitle%3DAziridinyl%2520peptides%2520as%2520inhibitors%2520of%2520cysteine%2520proteases%253A%2520effect%2520of%2520a%2520free%2520carboxylic%2520acid%2520function%2520on%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2000%26volume%3D8%26spage%3D1281%26epage%3D1291%26doi%3D10.1016%2FS0968-0896%2800%2900058-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klockow, A.</span></span> <span> </span><span class="NLM_article-title">Cysteine protease inhibitors containing small rings</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.2174/1389557033487935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2174%2F1389557033487935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12871161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=585-596&author=T.+Schirmeisterauthor=A.+Klockow&title=Cysteine+protease+inhibitors+containing+small+rings&doi=10.2174%2F1389557033487935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine protease inhibitors containing small rings</span></div><div class="casAuthors">Schirmeister, T.; Klockow, A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-596</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the discovery of E-64 in 1978 as potent cysteine protease inhibitor a variety of inhibitors contg. small rings as electrophilic building blocks responsible for enzyme inhibition have been developed.  In this review we summarize new aspects concerning epoxysuccinyl peptides derived from E-64 and discuss inhibition potency, selectivity and mechanisms of peptidic and peptidomimetic inhibitors contg. epoxide, aziridine, thiirane, cyclopropane, β-lactam and β-lactone rings as electrophilic fragments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQbEljquTrLVg90H21EOLACvtfcHk0liOSyhk2GO7ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1WgsLc%253D&md5=d927db9cb884be32b6d96b0c316dcc2c</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.2174%2F1389557033487935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557033487935%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DKlockow%26aufirst%3DA.%26atitle%3DCysteine%2520protease%2520inhibitors%2520containing%2520small%2520rings%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26spage%3D585%26epage%3D596%26doi%3D10.2174%2F1389557033487935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siklos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BenAissa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R.</span></span> <span> </span><span class="NLM_article-title">Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.apsb.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26713267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC28rlslWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=506-519&author=M.+Siklosauthor=M.+BenAissaauthor=G.+R.+Thatcher&title=Cysteine+proteases+as+therapeutic+targets%3A+does+selectivity+matter%3F+A+systematic+review+of+calpain+and+cathepsin+inhibitors&doi=10.1016%2Fj.apsb.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors</span></div><div class="casAuthors">Siklos Marton; BenAissa Manel; Thatcher Gregory R J</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">506-19</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Cysteine proteases continue to provide validated targets for treatment of human diseases.  In neurodegenerative disorders, multiple cysteine proteases provide targets for enzyme inhibitors, notably caspases, calpains, and cathepsins.  The reactive, active-site cysteine provides specificity for many inhibitor designs over other families of proteases, such as aspartate and serine; however, a) inhibitor strategies often use covalent enzyme modification, and b) obtaining selectivity within families of cysteine proteases and their isozymes is problematic.  This review provides a general update on strategies for cysteine protease inhibitor design and a focus on cathepsin B and calpain 1 as drug targets for neurodegenerative disorders; the latter focus providing an interesting query for the contemporary assumptions that irreversible, covalent protein modification and low selectivity are anathema to therapeutic safety and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE6JaFL9P83mBAiYWy6n3SfW6udTcc2eYhZUFppq9bl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlslWjsg%253D%253D&md5=cbd246a39984c0d9e3a32fd26db8902d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DSiklos%26aufirst%3DM.%26aulast%3DBenAissa%26aufirst%3DM.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DCysteine%2520proteases%2520as%2520therapeutic%2520targets%253A%2520does%2520selectivity%2520matter%253F%2520A%2520systematic%2520review%2520of%2520calpain%2520and%2520cathepsin%2520inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D506%26epage%3D519%26doi%3D10.1016%2Fj.apsb.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfenden, R.</span></span> <span> </span><span class="NLM_article-title">Thiohemiacetal formation by inhibitory aldehydes at the active site of papain</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4890</span>– <span class="NLM_lpage">4895</span>, <span class="refDoi"> DOI: 10.1021/bi00641a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00641a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaE2sXlvFKgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1977&pages=4890-4895&author=C.+A.+Lewisauthor=R.+Wolfenden&title=Thiohemiacetal+formation+by+inhibitory+aldehydes+at+the+active+site+of+papain&doi=10.1021%2Fbi00641a023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Thiohemiacetal formation by inhibitory aldehydes at the active site of papain</span></div><div class="casAuthors">Lewis, Charles A., Jr.; Wolfenden, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4890-5</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Papain is strongly inhibited by aldehydes resembling carboxylic acids released by hydrolysis of specific substrates.  Inhibitory complexes might involve binding of the aldehyde intact or as a covalent hydrate, or the aldehyde might undergo covalent addn. of an active site SH group to form a thiohemiacetal deriv.  In an attempt to distinguish between these possibilities, benzamidoacetaldehyde-1-2H was synthesized, and its properties compared with those of the undeuterated inhibitor.  After correction for differences in hydration, the obsd. effect on inhibition is compatible with formation of a thiohemiacetal.  In keeping with this conclusion, benzamidoethanol (a partial analog of the covalent hydrate) and benzamide, N-methylbenzamide, and N-ethylbenzamide (somewhat similar to the free aldehyde in size and hydrophobic character) exhibit negligible affinity for the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQmR19Fk_65bVg90H21EOLACvtfcHk0lgq2qsqF-nDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXlvFKgsbY%253D&md5=f39c2cc892b7b70d32327b6b65f51c3f</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fbi00641a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00641a023%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DC.%2BA.%26aulast%3DWolfenden%26aufirst%3DR.%26atitle%3DThiohemiacetal%2520formation%2520by%2520inhibitory%2520aldehydes%2520at%2520the%2520active%2520site%2520of%2520papain%26jtitle%3DBiochemistry%26date%3D1977%26volume%3D16%26spage%3D4890%26epage%3D4895%26doi%3D10.1021%2Fbi00641a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, E.</span></span> <span> </span><span class="NLM_article-title">Cysteinyl proteinases and their selective inactivation</span>. <i>Advances in enzymology and related areas of molecular biology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1002/9780470123096.ch5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2F9780470123096.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=271-347&author=E.+Shaw&title=Cysteinyl+proteinases+and+their+selective+inactivation&doi=10.1002%2F9780470123096.ch5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2F9780470123096.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9780470123096.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DE.%26atitle%3DCysteinyl%2520proteinases%2520and%2520their%2520selective%2520inactivation%26jtitle%3DAdvances%2520in%2520enzymology%2520and%2520related%2520areas%2520of%2520molecular%2520biology%26date%3D2006%26volume%3D63%26spage%3D271%26epage%3D347%26doi%3D10.1002%2F9780470123096.ch5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, J. S.</span></span> <span> </span><span class="NLM_article-title">Chemistry of cyclopropenones</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1021/cr60288a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr60288a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaE2cXhtlart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1974&pages=189-213&author=K.+T.+Pottsauthor=J.+S.+Baum&title=Chemistry+of+cyclopropenones&doi=10.1021%2Fcr60288a003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry of cyclopropenones</span></div><div class="casAuthors">Potts, K. T.; Baum, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-213</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 175 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-ZbvJnR6FrVg90H21EOLACvtfcHk0liQ2bv3D1BFDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtlart7c%253D&md5=2ad661270e6f989d43d9556f2ff83b76</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fcr60288a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr60288a003%26sid%3Dliteratum%253Aachs%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DBaum%26aufirst%3DJ.%2BS.%26atitle%3DChemistry%2520of%2520cyclopropenones%26jtitle%3DChem.%2520Rev.%26date%3D1974%26volume%3D74%26spage%3D189%26epage%3D213%26doi%3D10.1021%2Fcr60288a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oballa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydzewski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riendeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodan, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Percival, M. D.</span></span> <span> </span><span class="NLM_article-title">Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/jm0003440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0003440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1ajs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=94-104&author=J.+P.+Falgueyretauthor=R.+M.+Oballaauthor=O.+Okamotoauthor=G.+Wesolowskiauthor=Y.+Aubinauthor=R.+M.+Rydzewskiauthor=P.+Prasitauthor=D.+Riendeauauthor=S.+B.+Rodanauthor=M.+D.+Percival&title=Novel%2C+nonpeptidic+cyanamides+as+potent+and+reversible+inhibitors+of+human+cathepsins+K+and+L&doi=10.1021%2Fjm0003440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L</span></div><div class="casAuthors">Falgueyret, Jean-Pierre; Oballa, Renata M.; Okamoto, Osamu; Wesolowski, Gregg; Aubin, Yves; Rydzewski, Robert M.; Prasit, Peppi; Riendeau, Denis; Rodan, Sevgi B.; Percival, M. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. contg. a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L.  The original lead compd. I inhibits cathepsins K and L with IC50 values of 0.37 and 0.45 μM, resp.  Modification of compd. I by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2).  Compd. II was found to be a potent inhibitor of cathepsins K and L with a Ki value of 50 nM for cathepsin K.  Replacement of the 1-cyanopyrrolidine of compd. II by a 1-cyanoazetidine increased the potency of the inhibitor by 10-fold.  This increase in potency is probably due to an enhanced chem. reactivity of the compd. toward the thiolate of the active site of the enzyme.  This is demonstrated when the assay is performed in the presence of glutathione at pH 7.0 which favors the formation of a GSH thiolate anion.  Under these assay conditions, there is a loss of potency in the 1-cyanoazetidine series due to the formation of an inactive complex between the GSH thiolate and the 1-cyanoazetidine inhibitors. 1-Cyanopyrrolidinyl inhibitors exhibited time-dependent inhibition which allowed us to det. the assocn. and dissocn. rate consts. with human cathepsin K.  The kinetic data obtained showed that the increase of potency obsd. between different 1-cyanopyrrolidinyl inhibitors is due to an increase of kon values and that the assocn. of the compd. with the enzyme fits an apparent one-step mechanism. 13C NMR expts. performed with the enzyme papain showed that compd. 2 forms a covalent isothiourea ester adduct with the enzyme.  As predicted by the kinetic anal., the addn. of the irreversible inhibitor E64 to the enzyme-cyanopyrrolidinyl complex totally abolished the signal of the isothiourea bond as obsd. by 13C NMR, thereby demonstrating that the formation of the covalent bond with the active site cysteine residue is reversible. Finally, compd. II inhibits bone resorption in an in vitro assay involving rabbit osteoclasts and bovine bone with an IC50 value of 0.7 μM. 1-Cyanopyrrolidine represents a new class of nonpeptidic compds. that inhibit cathepsin K and L activity and proteolysis of bone collagen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWnsb8us0GkrVg90H21EOLACvtfcHk0liQ2bv3D1BFDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1ajs7g%253D&md5=aed27c1353797e413890ea02d900095b</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm0003440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0003440%26sid%3Dliteratum%253Aachs%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DOkamoto%26aufirst%3DO.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DAubin%26aufirst%3DY.%26aulast%3DRydzewski%26aufirst%3DR.%2BM.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRodan%26aufirst%3DS.%2BB.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26atitle%3DNovel%252C%2520nonpeptidic%2520cyanamides%2520as%2520potent%2520and%2520reversible%2520inhibitors%2520of%2520human%2520cathepsins%2520K%2520and%2520L%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D94%26epage%3D104%26doi%3D10.1021%2Fjm0003440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung-Toung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodzinska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowrie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukreja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desilets, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, T. F.</span></span> <span> </span><span class="NLM_article-title">1,2,4-thiadiazole: A novel Cathepsin B inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5529</span>– <span class="NLM_lpage">5537</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2003.09.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmc.2003.09.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=14642597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1ens74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5529-5537&author=R.+Leung-Toungauthor=J.+Wodzinskaauthor=W.+Liauthor=J.+Lowrieauthor=R.+Kukrejaauthor=D.+Desiletsauthor=K.+Karimianauthor=T.+F.+Tam&title=1%2C2%2C4-thiadiazole%3A+A+novel+Cathepsin+B+inhibitor&doi=10.1016%2Fj.bmc.2003.09.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,4-Thiadiazole: A novel Cathepsin B inhibitor</span></div><div class="casAuthors">Leung-Toung, Regis; Wodzinska, Jolanta; Li, Wanren; Lowrie, Jayme; Kukreja, Rahul; Desilets, Denis; Karimian, Khashayar; Tam, Tim Fat</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5529-5537</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel class of Cathepsin B inhibitors has been developed with a 1,2,4-thiadiazole heterocycle as the thiol trapping pharmacophore.  Several compds. with different dipeptide recognition sequence (i.e., P1'-P2'=Leu-Pro-OH or P2-P1=Cbz-Phe-Ala) at the C5 position and with different substituents (i.e., OMe, Ph, or COOH) at the C3 position of the 1,2,4-thiadiazole ring have been synthesized and tested for their inhibitory activities.  The substituted thiadiazoles inhibit Cat B in a time dependent, irreversible manner.  A mechanism based on active-site directed inactivation of the enzyme by disulfide bond formation between the active site cysteine thiol and the sulfur atom of the heterocycle is proposed.  Compd. I (Ki=2.6 μM, kiKi=5630 M-1 s-1) with a C3 methoxy moiety and a Leu-Pro-OH dipeptide recognition sequence, is found to be the most potent inhibitor in this series.  The enhanced inhibitory potency of I is a consequence of its increased enzyme binding affinity (lower Ki) rather than its increased intrinsic reactivity (higher ki).  In addn., I is inactive against Cathepsin S, is a poor inhibitor of Cathepsin H and is >100-fold more selective for Cat B over papain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMeBoKxnLBT7Vg90H21EOLACvtfcHk0ljqi2XsX9HZxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1ens74%253D&md5=5faf35d17001a47f2d9734b4f7b25e1a</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.09.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.09.040%26sid%3Dliteratum%253Aachs%26aulast%3DLeung-Toung%26aufirst%3DR.%26aulast%3DWodzinska%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLowrie%26aufirst%3DJ.%26aulast%3DKukreja%26aufirst%3DR.%26aulast%3DDesilets%26aufirst%3DD.%26aulast%3DKarimian%26aufirst%3DK.%26aulast%3DTam%26aufirst%3DT.%2BF.%26atitle%3D1%252C2%252C4-thiadiazole%253A%2520A%2520novel%2520Cathepsin%2520B%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5529%26epage%3D5537%26doi%3D10.1016%2Fj.bmc.2003.09.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Withana, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sameni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidwell, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloane, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, B. S.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B inhibition limits bone metastasis in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-2759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-11-2759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22266111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1199-1209&author=N.+P.+Withanaauthor=G.+Blumauthor=M.+Sameniauthor=C.+Slaneyauthor=A.+Anbalaganauthor=M.+B.+Oliveauthor=B.+N.+Bidwellauthor=L.+Edgingtonauthor=L.+Wangauthor=K.+Moinauthor=B.+F.+Sloaneauthor=R.+L.+Andersonauthor=M.+S.+Bogyoauthor=B.+S.+Parker&title=Cathepsin+B+inhibition+limits+bone+metastasis+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-11-2759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer</span></div><div class="casAuthors">Withana, Nimali P.; Blum, Galia; Sameni, Mansoureh; Slaney, Clare; Anbalagan, Arulselvi; Olive, Mary B.; Bidwell, Bradley N.; Edgington, Laura; Wang, Ling; Moin, Kamiar; Sloane, Bonnie F.; Anderson, Robin L.; Bogyo, Matthew S.; Parker, Belinda S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1209</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying mol. drivers of bone metastasis for new therapeutic targets.  The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases.  In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease.  Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases.  RNA interference-mediated knockdown of cathepsin B in tumor cells reduced collagen I degrdn. in vitro and bone metastasis in vivo.  Similarly, i.p. administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a redn. that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt.  Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth.  Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo.  Cancer Res; 72(5); 1199-209.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaVtPHsMReRLVg90H21EOLACvtfcHk0ljqi2XsX9HZxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wis74%253D&md5=b66b32d65d9e9799412bb110b4c9d4e9</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-2759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-2759%26sid%3Dliteratum%253Aachs%26aulast%3DWithana%26aufirst%3DN.%2BP.%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DSameni%26aufirst%3DM.%26aulast%3DSlaney%26aufirst%3DC.%26aulast%3DAnbalagan%26aufirst%3DA.%26aulast%3DOlive%26aufirst%3DM.%2BB.%26aulast%3DBidwell%26aufirst%3DB.%2BN.%26aulast%3DEdgington%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMoin%26aufirst%3DK.%26aulast%3DSloane%26aufirst%3DB.%2BF.%26aulast%3DAnderson%26aufirst%3DR.%2BL.%26aulast%3DBogyo%26aufirst%3DM.%2BS.%26aulast%3DParker%26aufirst%3DB.%2BS.%26atitle%3DCathepsin%2520B%2520inhibition%2520limits%2520bone%2520metastasis%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1199%26epage%3D1209%26doi%3D10.1158%2F0008-5472.CAN-11-2759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satoyoshi, E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic trials on progressive muscular dystrophy</span>. <i>Intern. Med. (Tokyo, Jpn.)</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.2169/internalmedicine.31.841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2169%2Finternalmedicine.31.841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1450492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADyaK3s%252FotFyqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1992&pages=841-846&author=E.+Satoyoshi&title=Therapeutic+trials+on+progressive+muscular+dystrophy&doi=10.2169%2Finternalmedicine.31.841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic trials on progressive muscular dystrophy</span></div><div class="casAuthors">Satoyoshi E</div><div class="citationInfo"><span class="NLM_cas:title">Internal medicine (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">841-6</span>
        ISSN:<span class="NLM_cas:issn">0918-2918</span>.
    </div><div class="casAbstract">The special medical care in the National Sanatorium prolonged the life span of the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years.  Various new drug trials for muscular dystrophy have been implemented in the last 12 years in Japan.  Bestatin and Loxistatin, protease inhibitors, showed definite improvement on dystrophic mice or hamsters, animal models of muscular dystrophy.  However clinical application of these drugs failed to prove the effects on patients with Duchenne muscular dystrophy.  The difficulty of clinical evaluation and judgement of effects in progressive neurological diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyqhNezcuQ25VVjGoY74BafW6udTcc2eYfZHrn9yxbs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FotFyqsA%253D%253D&md5=e10067a63036f421b6bcd269450a0244</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.2169%2Finternalmedicine.31.841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2169%252Finternalmedicine.31.841%26sid%3Dliteratum%253Aachs%26aulast%3DSatoyoshi%26aufirst%3DE.%26atitle%3DTherapeutic%2520trials%2520on%2520progressive%2520muscular%2520dystrophy%26jtitle%3DIntern.%2520Med.%2520%2528Tokyo%252C%2520Jpn.%2529%26date%3D1992%26volume%3D31%26spage%3D841%26epage%3D846%26doi%3D10.2169%2Finternalmedicine.31.841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schurigt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Elverfeldt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinheckel, T.</span></span> <span> </span><span class="NLM_article-title">Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model</span>. <i>Biological chemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1515/BC.2008.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1515%2FBC.2008.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18710344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2008&pages=1067-1074&author=U.+Schurigtauthor=L.+Sevenichauthor=C.+Vannierauthor=M.+Gajdaauthor=A.+Schwindeauthor=F.+Wernerauthor=A.+Stahlauthor=D.+von+Elverfeldtauthor=A.+K.+Beckerauthor=M.+Bogyoauthor=C.+Petersauthor=T.+Reinheckel&title=Trial+of+the+cysteine+cathepsin+inhibitor+JPM-OEt+on+early+and+advanced+mammary+cancer+stages+in+the+MMTV-PyMT-transgenic+mouse+model&doi=10.1515%2FBC.2008.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model</span></div><div class="casAuthors">Schurigt, Uta; Sevenich, Lisa; Vannier, Corinne; Gajda, Mieczyslaw; Schwinde, Anne; Werner, Fee; Stahl, Andreas; von Elverfeldt, Dominik; Becker, Anne-Katrin; Bogyo, Matthew; Peters, Christoph; Reinheckel, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1067-1074</span>CODEN:
                <span class="NLM_cas:coden">BICHF3</span>;
        ISSN:<span class="NLM_cas:issn">1431-6730</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">Recent data suggest proteases of the papain-like cysteine cathepsin family as mol. targets for cancer therapy.  Here, we report the treatment of polyoma middle T oncogene-induced breast cancers in mice with the cell-permeable broad-spectrum cysteine cathepsin inhibitor JPM-OEt.  Up to 100 mg/kg inhibitor was i.p. injected once per day in two trials on early and advanced cancers.  In both trials, transient delays in tumor growth were obsd.  However, at the endpoint of both expts. no significant differences in tumor wts., histopathol. and lung metastasis were found between the inhibitor and the control group.  The invasive strand formation of collagen I-embedded tumor cell spheroids generated from primary tumors of inhibitor-treated mice in the early cancer trial could be inhibited in vitro by JPM-OEt; a result arguing against induction of resistance to the inhibitor.  Measurement of cysteine cathepsin activities in tissue exts. after i.p. injection of JPM-OEt revealed effective inhibition of cysteine cathepsins in pancreas, kidneys and liver, while activities in mammary cancers and in lungs were not significantly affected.  We conclude that the pharmacokinetic properties of JPM-OEt, which result in poor bioavailability, may prohibit its use for stand-alone treatment of solid mammary cancers and their lung metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxpOV_XtD27Vg90H21EOLACvtfcHk0ljl1NjBKrWIwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohurk%253D&md5=25ab2d52f96d301df3b993a7a2c01e61</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1515%2FBC.2008.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.2008.115%26sid%3Dliteratum%253Aachs%26aulast%3DSchurigt%26aufirst%3DU.%26aulast%3DSevenich%26aufirst%3DL.%26aulast%3DVannier%26aufirst%3DC.%26aulast%3DGajda%26aufirst%3DM.%26aulast%3DSchwinde%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DF.%26aulast%3DStahl%26aufirst%3DA.%26aulast%3Dvon%2BElverfeldt%26aufirst%3DD.%26aulast%3DBecker%26aufirst%3DA.%2BK.%26aulast%3DBogyo%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DC.%26aulast%3DReinheckel%26aufirst%3DT.%26atitle%3DTrial%2520of%2520the%2520cysteine%2520cathepsin%2520inhibitor%2520JPM-OEt%2520on%2520early%2520and%2520advanced%2520mammary%2520cancer%2520stages%2520in%2520the%2520MMTV-PyMT-transgenic%2520mouse%2520model%26jtitle%3DBiological%2520chemistry%26date%3D2008%26volume%3D389%26spage%3D1067%26epage%3D1074%26doi%3D10.1515%2FBC.2008.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eichhold, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hookfin, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiwo, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehmeyer, K. R.</span></span> <span> </span><span class="NLM_article-title">Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1016/S0731-7085(97)00102-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0731-7085%2897%2900102-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=9589405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=459-467&author=T.+H.+Eichholdauthor=E.+B.+Hookfinauthor=Y.+O.+Taiwoauthor=B.+Deauthor=K.+R.+Wehmeyer&title=Isolation+and+quantification+of+fluoroacetate+in+rat+tissues%2C+following+dosing+of+Z-Phe-Ala-CH2-F%2C+a+peptidyl+fluoromethyl+ketone+protease+inhibitor&doi=10.1016%2FS0731-7085%2897%2900102-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor</span></div><div class="casAuthors">Eichhold, Thomas H.; Hookfin, Erin B.; Taiwo, Yetunde O.; De, Biswanath; Wehmeyer, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-467</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Peptidyl fluoromethyl ketones (PFMK) are irreversible inhibitors of cathepsin B, a cysteine proteinase thought to be involved in the degrdn. of cartilage.  It has been speculated that PFMK inhibitors may metabolize in rodents to form fluoroacetate (FAC), an extremely toxic poison.  A highly selective and sensitive sepn. and detection scheme was developed to measure trace levels of FAC in rat tissues following PFMK dosing.  The procedure consisted of extg. FAC from tissue and spiking the ext. with [18O]2-fluoroacetate (18O-FAC) as an internal std.  FAC and 18O-FAC were further isolated from matrix components using ion-exchange, solid-phase extn.  The pentafluorobenzyl esters of FAC and 18O-FAC were formed to facilitate the chromatog. sepn.  Two-dimensional gas chromatog. coupled with selected-ion-monitoring detection provided the final measurement.  The assay had a limit of detection of 2 ng FAC per g tissue, and was capable of accurately quantitating as little as 10 ng FAC per g tissue with a S/N ratio of 40:1.  Linearity was established over two orders of magnitude, from 2-500 ng ml-1, with 5 μl injected on-column.  The method was used to demonstrate that FAC was formed in rats following dosing with Z-Phe-Ala-CH2-F, a PFMK cathepsin enzyme inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPmtRizUZf2bVg90H21EOLACvtfcHk0li4XRiPM9oEvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWqsL8%253D&md5=ea69dcdcaff325ed19d40e94c6f96760</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS0731-7085%2897%2900102-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0731-7085%252897%252900102-7%26sid%3Dliteratum%253Aachs%26aulast%3DEichhold%26aufirst%3DT.%2BH.%26aulast%3DHookfin%26aufirst%3DE.%2BB.%26aulast%3DTaiwo%26aufirst%3DY.%2BO.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DWehmeyer%26aufirst%3DK.%2BR.%26atitle%3DIsolation%2520and%2520quantification%2520of%2520fluoroacetate%2520in%2520rat%2520tissues%252C%2520following%2520dosing%2520of%2520Z-Phe-Ala-CH2-F%252C%2520a%2520peptidyl%2520fluoromethyl%2520ketone%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D1997%26volume%3D16%26spage%3D459%26epage%3D467%26doi%3D10.1016%2FS0731-7085%2897%2900102-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasnick, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/0003-2697(85)90598-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2F0003-2697%2885%2990598-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=4073501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaL2MXltlOmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=1985&pages=461-465&author=D.+Rasnick&title=Synthesis+of+peptide+fluoromethyl+ketones+and+the+inhibition+of+human+cathepsin+B&doi=10.1016%2F0003-2697%2885%2990598-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B</span></div><div class="casAuthors">Rasnick, David</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">461-5</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    </div><div class="casAbstract">Peptide fluoromethyl ketones were synthesized for the 1st time.  The inhibitor 3-(N-benzyloxycarbonylphenylalanylamido)-DL-1-fluoro-2-butanone (Z-Phe-AlaCH2F) was a 30-fold more potent inactivator of human cathepsin B than was 3-(N-benzyloxycarbonylphenylalanylamido)-L-1-diazo-2-butanone (Z-Phe-AlaCHN2), but less reactive than 3-(N-benzyloxycarbonylphenylalanylamido)-L-1-chloro-2-butanone (Z-Phe-AlaCH2Cl).  The fluoromethyl ketone's increased potency over the diazomethyl ketone is mainly due to its tighter binding to cathepsin B, with little difference between their resp. k3 values.  Both Z-Phe-AlaCHN2 and Z-Phe-AlaCH2F were quite stable to high concns. of dithiothreitol, whereas Z-Phe-AlaCH2Cl was rapidly destroyed by the thiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPFVuXW1TDrVg90H21EOLACvtfcHk0li4XRiPM9oEvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlOmu70%253D&md5=f53dcab5c3b1f33c472c1271c4ca2f6a</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2F0003-2697%2885%2990598-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-2697%252885%252990598-6%26sid%3Dliteratum%253Aachs%26aulast%3DRasnick%26aufirst%3DD.%26atitle%3DSynthesis%2520of%2520peptide%2520fluoromethyl%2520ketones%2520and%2520the%2520inhibition%2520of%2520human%2520cathepsin%2520B%26jtitle%3DAnal.%2520Biochem.%26date%3D1985%26volume%3D149%26spage%3D461%26epage%3D465%26doi%3D10.1016%2F0003-2697%2885%2990598-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shusuke  Tomoshige</span>, <span class="hlFld-ContribAuthor ">Minoru  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>41 </em>, 116221. <a href="https://doi.org/10.1016/j.bmc.2021.116221" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116221%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIn%252Bvivo%252Bsynthetic%252Bchemistry%252Bof%252Bproteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%26aulast%3DTomoshige%26aufirst%3DShusuke%26date%3D2021%26volume%3D41%26spage%3D116221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative proteases for proteostasis. The proteasomes are distributed in the cytoplasm and nucleus and participate in the UPS. hClpP located in the mitochondrial matrix maintains the mitochondria proteostasis. Cathepsin B participates in the ALS. MMPs mainly degrade ECM in the extracellular environment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) The proteasome structure consists of four rings, with each ring containing seven different subunits, and is capped by regulatory particles (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RYP">1RYP</a>). (B) Schematic of the UPS. The substrate protein is ubiquitinated through the activity of E1, E2, and E3 and subsequently hydrolyzed by the proteasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition mechanisms of proteasome inhibitors featuring different warheads. (A) Aldehydes. (B) Boronic acids. (C) Epoxyketones. (D) β-lactone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of some proteasome inhibitors and the β active site of the proteasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative proteasome inhibitors covalently bind at the active site of the proteasome: (A) MG132 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FGH">5FGH</a>); (B) Bortezomib (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16">2F16</a>); (C) Carfilzomib (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R67">4R67</a>); (D) Salinosporamide A (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FAK">2FAK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic of the PROTAC technology. A PROTAC molecule connects the target protein and an E3 ubiquitin ligase complex. The E3 ubiquitin ligase is recruited to the target protein by the PROTAC, and subsequently the ubiquitinated protein is recognized and degraded by the proteasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative E3 ubiquitin ligase ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Structures of MDM2-based PROTAC (<b>11</b> and <b>12</b>). (B) Structures of cIAP1-based PROTAC (<b>13</b> and <b>14</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of VHL-based PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of CRBN-based PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) The structure of hClpXP. hClpP is assembled into a double-ringed tetradecameric structure with its chaperone hClpX on each end. (B) Graphical representation of the hClpXP proteolytic process. The substrate protein binds to the hClpX, and subsequently hClpX unfolds the substrate and transfers it to the cavity of hClpP for proteolysis by an ATP-dependent pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Biological function of hClpP impaired by hClpP inhibitors. The hClpP inhibitors bind to the active site of hClpP to inhibit substrate protein hydrolysis (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TG6">1TG6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) Structure of β-lactone hClpP inhibitor A3-32-01. (B) Inhibition mechanism of β-lactone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Phenyl ester hClpP inhibitors. (B) Inhibition mechanism of phenyl ester.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) Inhibition mechanism of boronic acid inhibitors. (B) Boronic acid hClpP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Biological function of hClpP is dysregulated by hClpP agonists. The hClpP agonists physically displacing hClpX from hClpP cause dysregulation of substrate degradation (PDB ID:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TG6">1TG6</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of hClpP agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Imipridone hClpP agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Different structural domains of the MMP family members.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures of MMP inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of MMP-2/9 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Inhibition mechanism of cathepsin B inhibitors bearing various warheads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of cathepsin B inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/medium/jm0c01640_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Representative proteasome inhibitors covalently bind with Cys-29 of cathepsin B. (A) E-64c (an analogue of E-64d PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ITO">1ITO</a>) and (B) CA-074 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QDQ">1QDQ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01640/20210319/images/large/jm0c01640_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01640&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 172 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthiesen, R.</span></span> <span> </span><span class="NLM_article-title">Review and literature mining on proteostasis factors and cancer</span>. <i>Methods Mol. Biol. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1449</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-3756-1_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2F978-1-4939-3756-1_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVChtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1449&publication_year=2016&pages=71-84&author=A.+Carvalhoauthor=M.+Rodr%C3%ADguezauthor=R.+Matthiesen&title=Review+and+literature+mining+on+proteostasis+factors+and+cancer&doi=10.1007%2F978-1-4939-3756-1_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Review and literature mining on proteostasis factors and cancer</span></div><div class="casAuthors">Carvalho, Ana Sofia; Rodriguez, Manuel S.; Matthiesen, Rune</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1449</span>
        (<span class="NLM_cas:issue">Proteostasis</span>),
    <span class="NLM_cas:pages">71-84</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Automatic anal. of increasingly growing literature repositories including data integration to other databases is a powerful tool to propose hypothesis that can be used to plan expts. to validate or disprove the hypothesis.  Furthermore, it provides means to evaluate the redundancy of research line in comparison to the published literature.  This is potentially beneficial for those developing research in a specific disease which are interested in exploring a particular pathway or set of genes/proteins.  In the scope of the integrating book a case will be made addressing proteostasis factors in cancer.  The maintenance of proteome homeostasis, known as proteostasis, is a process by which cells regulate protein translation, degrdn., subcellular localization, and protein folding and consists of an integrated network of proteins.  The ubiquitin-proteasome system plays a key role in essential biol. processes such as cell cycle, DNA damage repair, membrane trafficking, and maintaining protein homeostasis.  Cells maintain proteostasis by regulating protein translation, degrdn., subcellular localization, and protein folding.  Aberrant proteostasis leads to loss-of-function diseases (cystic fibrosis) and gain-of-toxic-function diseases (Alzheimer's, Parkinson's, and Huntington's disease).  Cancer therapy on the other hand explores inhibition of proteostasis factors to trigger endoplasmic reticulum stress with subsequent apoptosis.  Alternatively therapies target deubiquitinases and thereby regulate tumor promoters or suppressors.  Furthermore, mutations in specific proteostasis factors are assocd. with higher risk for specific cancers, e.g., BRCA mutations in breast cancer.  This chapter discusses proteostasis protein factors' assocn. with cancer from a literature mining perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplumLjf9-unbVg90H21EOLACvtfcHk0liyQfGsFeuHDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVChtL%252FK&md5=f5c167f8079272f34ed12d1dfc29e6a9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3756-1_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3756-1_2%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DA.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%26aulast%3DMatthiesen%26aufirst%3DR.%26atitle%3DReview%2520and%2520literature%2520mining%2520on%2520proteostasis%2520factors%2520and%2520cancer%26jtitle%3DMethods%2520Mol.%2520Biol.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2016%26volume%3D1449%26spage%3D71%26epage%3D84%26doi%3D10.1007%2F978-1-4939-3756-1_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hipp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasturi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, F.</span></span> <span> </span><span class="NLM_article-title">The proteostasis network and its decline in ageing</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/s41580-019-0101-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fs41580-019-0101-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30733602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlWlt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=421-435&author=M.+Hippauthor=P.+Kasturiauthor=F.+Hartl&title=The+proteostasis+network+and+its+decline+in+ageing&doi=10.1038%2Fs41580-019-0101-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The proteostasis network and its decline in ageing</span></div><div class="casAuthors">Hipp, Mark S.; Kasturi, Prasad; Hartl, F. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">421-435</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Ageing is a major risk factor for the development of many diseases, prominently including neurodegenerative disorders such as Alzheimer disease and Parkinson disease.  A hallmark of many age-related diseases is the dysfunction in protein homeostasis (proteostasis), leading to the accumulation of protein aggregates.  In healthy cells, a complex proteostasis network, comprising mol. chaperones and proteolytic machineries and their regulators, operates to ensure the maintenance of proteostasis.  These factors coordinate protein synthesis with polypeptide folding, the conservation of protein conformation and protein degrdn.  However, sustaining proteome balance is a challenging task in the face of various external and endogenous stresses that accumulate during ageing.  These stresses lead to the decline of proteostasis network capacity and proteome integrity.  The resulting accumulation of misfolded and aggregated proteins affects, in particular, postmitotic cell types such as neurons, manifesting in disease.  Recent analyses of proteome-wide changes that occur during ageing inform strategies to improve proteostasis.  The possibilities of pharmacol. augmentation of the capacity of proteostasis networks hold great promise for delaying the onset of age-related pathologies assocd. with proteome deterioration and for extending healthspan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvfOtsme2IxLVg90H21EOLACvtfcHk0lgYfdoqK5V3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlWlt70%253D&md5=55132b34d115ea5ccaf9fd29ecff6b36</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41580-019-0101-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-019-0101-y%26sid%3Dliteratum%253Aachs%26aulast%3DHipp%26aufirst%3DM.%26aulast%3DKasturi%26aufirst%3DP.%26aulast%3DHartl%26aufirst%3DF.%26atitle%3DThe%2520proteostasis%2520network%2520and%2520its%2520decline%2520in%2520ageing%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26spage%3D421%26epage%3D435%26doi%3D10.1038%2Fs41580-019-0101-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span> <span> </span><span class="NLM_article-title">The autophagy-lysosomal pathways and their emerging roles in modulating proteostasis in tumors</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4</span>, <span class="refDoi"> DOI: 10.3390/cells8010004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3390%2Fcells8010004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKhtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=4&author=Z.+Dongauthor=H.+Cui&title=The+autophagy-lysosomal+pathways+and+their+emerging+roles+in+modulating+proteostasis+in+tumors&doi=10.3390%2Fcells8010004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The autophagy-lysosomal pathways and their emerging roles in modulating proteostasis in tumors</span></div><div class="casAuthors">Dong, Zhen; Cui, Hongjuan</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In normal physiol. condition, the maintenance of cellular proteostasis is a prerequisite for cell growth, functioning, adapting to changing micro-environments, and responding to extracellular stress.  Cellular proteostasis is maintained by specific proteostasis networks (PNs) to prevent protein misfolding, aggregating, and accumulating in subcellular compartments.  Commonly, the PNs are composed of protein synthesis, mol. chaperones, endoplasmic reticulum (ER), unfolded protein response (UPR), stress response pathways (SRPs), secretions, ubiquitin proteasome system (UPS), and autophagy-lysosomal pathways (ALPs).  Although great efforts have been made to explore the underlying detailed mechanisms of proteostasis, there are many questions remain to explore, esp. in proteostasis regulated by the ALPs.  Proteostasis out-off-balance is correlated with various human diseases such as diabetes, stroke, inflammation, hypertension, pulmonary fibrosis, and Alzheimer's disease.  Enhanced regulation of PNs is obsd. in tumors, thereby indicating that proteostasis may play a pivotal role in tumorigenesis and cancer development.  Recently, inhibitors targeting the UPS have shown to be failed in solid tumor treatment.  However, there is growing evidence showing that the ALPs play important roles in regulation of proteostasis alone or with a crosstalk with other PNs in tumors.  In this review, we provide insights into the proteostatic process and how it is regulated by the ALPs, such as macroautophagy, aggrephagy, chaperone-mediated autophagy, microautophagy, as well as mitophagy during tumor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFptUCsoPP7Vg90H21EOLACvtfcHk0lgYfdoqK5V3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKhtLfJ&md5=fb0d358d25e000a6e9bb5717dc21fb8b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fcells8010004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8010004%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DH.%26atitle%3DThe%2520autophagy-lysosomal%2520pathways%2520and%2520their%2520emerging%2520roles%2520in%2520modulating%2520proteostasis%2520in%2520tumors%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D4%26doi%3D10.3390%2Fcells8010004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskowitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzzy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor-Cortelli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubblefield, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portlock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumetrescu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trehu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A.</span></span> <span> </span><span class="NLM_article-title">Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2005.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15613699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVKisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=676-684&author=O.+O%E2%80%99Connorauthor=J.+Wrightauthor=C.+Moskowitzauthor=J.+Muzzyauthor=B.+MacGregor-Cortelliauthor=M.+Stubblefieldauthor=D.+Strausauthor=C.+Portlockauthor=P.+Hamlinauthor=E.+Choiauthor=O.+Dumetrescuauthor=D.+Esseltineauthor=E.+Trehuauthor=J.+Adamsauthor=D.+Schenkeinauthor=A.+Zelenetz&title=Phase+II+clinical+experience+with+the+novel+proteasome+inhibitor+bortezomib+in+patients+with+indolent+non-Hodgkin%E2%80%99s+lymphoma+and+mantle+cell+lymphoma&doi=10.1200%2FJCO.2005.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma</span></div><div class="casAuthors">O'Connor, Owen; Wright, John; Moskowitz, Craig; Muzzy, Jamie; MacGregor-Cortelli, Barbara; Stubblefield, Michael; Straus, David; Portlock, Carol; Hamlin, Paul; Choi, Elizabeth; Dumetrescu, Otila; Esseltine, Dixie; Trehu, Elizabeth; Adams, Julian; Schenkein, David; Zelenetz, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">676-684</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose was to det. the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL).  Patients with indolent and MCL were eligible.  Bortezomib was given at a dose of 1.5 mg/m2 on days 1, 4, 8, and 11.  Patients were required to have received no more than three prior chemotherapy regimens, with at least 1 mo since the prior treatment, 3 mo from prior rituximab, and 7 days from prior corticosteroids; abs. neutrophil count more than 1,500/μL (500/μL if documented bone marrow involvement); and platelet count more than 50,000/μL.  Twenty-six patients were registered, of whom 24 were assessable.  Ten patients had follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had marginal zone lymphoma.  The overall response rate was 58%, with one complete remission (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular non-Hodgkin's lymphoma (NHL).  All responses were durable, lasting from 3 to 24+ months.  One patient with MCL achieved a CRu, four achieved a PR, and four had stable disease.  One patient with MCL maintained his remission for 19 mo.  Both patients with marginal zone lymphoma achieved PR lasting 8+ and 11+ months, resp.  Patients with SLL or CLL have yet to respond.  Overall, the drug was well tolerated, with only one grade 4 toxicity (hyponatremia).  The most common grade 3 toxicities were lymphopenia (n = 14) and thrombocytopenia (n = 7).  These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvJzC-Q3QCWrVg90H21EOLACvtfcHk0lhFA7ju_5OHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVKisLg%253D&md5=9f60fb4da20f17036c070708f4cdf402</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DMoskowitz%26aufirst%3DC.%26aulast%3DMuzzy%26aufirst%3DJ.%26aulast%3DMacGregor-Cortelli%26aufirst%3DB.%26aulast%3DStubblefield%26aufirst%3DM.%26aulast%3DStraus%26aufirst%3DD.%26aulast%3DPortlock%26aufirst%3DC.%26aulast%3DHamlin%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DE.%26aulast%3DDumetrescu%26aufirst%3DO.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DTrehu%26aufirst%3DE.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DZelenetz%26aufirst%3DA.%26atitle%3DPhase%2520II%2520clinical%2520experience%2520with%2520the%2520novel%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520patients%2520with%2520indolent%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520and%2520mantle%2520cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D676%26epage%3D684%26doi%3D10.1200%2FJCO.2005.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiljeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span> <span> </span><span class="NLM_article-title">Cysteine cathepsins: from structure, function and regulation to new frontiers</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1824</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bbapap.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22024571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1824&publication_year=2012&pages=68-88&author=V.+Turkauthor=V.+Stokaauthor=O.+Vasiljevaauthor=M.+Renkoauthor=T.+Sunauthor=B.+Turkauthor=D.+Turk&title=Cysteine+cathepsins%3A+from+structure%2C+function+and+regulation+to+new+frontiers&doi=10.1016%2Fj.bbapap.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine cathepsins: From structure, function and regulation to new frontiers</span></div><div class="casAuthors">Turk, Vito; Stoka, Veronika; Vasiljeva, Olga; Renko, Miha; Sun, Tao; Turk, Boris; Turk, Dusan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1824</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-88</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  It is more than 50 years since the lysosome was discovered.  Since then its hydrolytic machinery, including proteases and other hydrolases, has been fairly well identified and characterized.  Among these are the cysteine cathepsins, members of the family of papain-like cysteine proteases.  They have unique reactive-site properties and an uneven tissue-specific expression pattern.  In living organisms, their activity is a delicate balance of expression, targeting, zymogen activation, inhibition by protein inhibitors and degrdn.  The specificity of their substrate binding sites, small-mol. inhibitor repertoire and crystal structures are providing new tools for research and development.  Their unique reactive-site properties have made it possible to confine the targets simply by the use of appropriate reactive groups.  The epoxysuccinyls still dominate the field, but now nitriles seem to be the most appropriate "warhead".  The view of cysteine cathepsins as lysosomal proteases is changing as there is now clear evidence of their localization in other cellular compartments.  Besides being involved in protein turnover, they build an important part of endosomal antigen presentation.  Together with the growing no. of non-endosomal roles of cysteine cathepsins is growing also the knowledge of their involvement in diseases such as cancer and rheumatoid arthritis, among others.  Finally, cysteine cathepsins are important regulators and signaling mols. of an unimaginable no. of biol. processes.  The current challenge is to identify their endogenous substrates, in order to gain an insight into the mechanisms of substrate degrdn. and processing.  In this review, some of the remarkable advances that have taken place in the past decade are presented.  This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEZ0u2P21D7Vg90H21EOLACvtfcHk0liQTiwx35QBKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI&md5=8615c1f0205d66b0fad932d6ff874390</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DStoka%26aufirst%3DV.%26aulast%3DVasiljeva%26aufirst%3DO.%26aulast%3DRenko%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26atitle%3DCysteine%2520cathepsins%253A%2520from%2520structure%252C%2520function%2520and%2520regulation%2520to%2520new%2520frontiers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2012%26volume%3D1824%26spage%3D68%26epage%3D88%26doi%3D10.1016%2Fj.bbapap.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabanglo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W. A.</span></span> <span> </span><span class="NLM_article-title">The role of ClpP protease in bacterial pathogenesis and human diseases</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1413</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00124</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00124" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps12lt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1413-1425&author=V.+Bhandariauthor=K.+S.+Wongauthor=J.+L.+Zhouauthor=M.+F.+Mabangloauthor=R.+A.+Bateyauthor=W.+A.+Houry&title=The+role+of+ClpP+protease+in+bacterial+pathogenesis+and+human+diseases&doi=10.1021%2Facschembio.8b00124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of ClpP Protease in Bacterial Pathogenesis and Human Diseases</span></div><div class="casAuthors">Bhandari, Vaibhav; Wong, Keith S.; Zhou, Jin Lin; Mabanglo, Mark F.; Batey, Robert A.; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1413-1425</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In prokaryotic cells and eukaryotic organelles, the ClpP protease plays an important role in proteostasis.  The disruption of ClpP function has been shown to influence the infectivity and virulence of a no. of bacterial pathogens.  More recently, ClpP has been found to be involved in various forms of carcinomas and in Perrault syndrome, which is an inherited condition characterized by hearing loss in males and females and by ovarian abnormalities in females.  Hence, targeting ClpP is a potentially viable, attractive option for the treatment of different ailments.  Herein, the biochem. and cellular activities of ClpP are discussed along with the mechanisms by which ClpP affects bacterial pathogenesis and various human diseases.  In addn., a comprehensive overview is given of the new classes of compds. in development that target ClpP.  Many of these compds. are currently primarily aimed at treating bacterial infections.  Some of these compds. inhibit ClpP activity, while others activate the protease and lead to its dysregulation.  The ClpP activators are remarkable examples of small mols. that inhibit protein-protein interactions but also result in a gain of function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiUm3tuolaabVg90H21EOLACvtfcHk0liQTiwx35QBKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps12lt7w%253D&md5=b7e2729aa3da2049740c7249a5f53d30</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00124%26sid%3Dliteratum%253Aachs%26aulast%3DBhandari%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BS.%26aulast%3DZhou%26aufirst%3DJ.%2BL.%26aulast%3DMabanglo%26aufirst%3DM.%2BF.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DHoury%26aufirst%3DW.%2BA.%26atitle%3DThe%2520role%2520of%2520ClpP%2520protease%2520in%2520bacterial%2520pathogenesis%2520and%2520human%2520diseases%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D1413%26epage%3D1425%26doi%3D10.1021%2Facschembio.8b00124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyaud, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraju, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qia, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketela, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienholds, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornblau, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human ccute myeloid leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccell.2015.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26058080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVejurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=864-876&author=A.+Coleauthor=Z.+Wangauthor=E.+Coyaudauthor=V.+Voisinauthor=M.+Grondaauthor=Y.+Jitkovaauthor=R.+Mattsonauthor=R.+Hurrenauthor=S.+Babovicauthor=N.+Macleanauthor=I.+Restallauthor=X.+Wangauthor=D.+V.+Jeyarajuauthor=M.+A.+Sukhaiauthor=S.+Prabhaauthor=S.+Bashirauthor=A.+Ramakrishnanauthor=E.+Leungauthor=Y.+H.+Qiaauthor=N.+Zhangauthor=K.+R.+Combesauthor=T.+Ketelaauthor=F.+Linauthor=W.+A.+Houryauthor=A.+Amanauthor=R.+Al-Awarauthor=W.+Zhengauthor=E.+Wienholdsauthor=C.+J.+Xuauthor=J.+Dickauthor=J.+C.+Wangauthor=J.+Moffatauthor=M.+D.+Mindenauthor=C.+J.+Eavesauthor=G.+D.+Baderauthor=Z.+Haoauthor=S.+M.+Kornblauauthor=B.+Raughtauthor=A.+D.+Schimmer&title=Inhibition+of+the+mitochondrial+protease+ClpP+as+a+therapeutic+strategy+for+human+ccute+myeloid+leukemia&doi=10.1016%2Fj.ccell.2015.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia</span></div><div class="casAuthors">Cole, Alicia; Wang, Zezhou; Coyaud, Etienne; Voisin, Veronique; Gronda, Marcela; Jitkova, Yulia; Mattson, Rachel; Hurren, Rose; Babovic, Sonja; MacLean, Neil; Restall, Ian; Wang, Xiaoming; Jeyaraju, Danny V.; Sukhai, Mahadeo A.; Prabha, Swayam; Bashir, Shaheena; Ramakrishnan, Ashwin; Leung, Elisa; Qia, Yi Hua; Zhang, Nianxian; Combes, Kevin R.; Ketela, Troy; Lin, Fengshu; Houry, Walid A.; Aman, Ahmed; Al-Awar, Rima; Zheng, Wei; Wienholds, Erno; Xu, Chang Jiang; Dick, John; Wang, Jean C. Y.; Moffat, Jason; Minden, Mark D.; Eaves, Connie J.; Bader, Gary D.; Hao, Zhenyue; Kornblau, Steven M.; Raught, Brian; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">864-876</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">From an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown reduced the viability of K562 leukemic cells.  Expression of this mitochondrial protease that has structural similarity to the cytoplasmic proteosome is increased in leukemic cells from approx. half of all patients with AML.  Genetic or chem. inhibition of ClpP killed cells from both human AML cell lines and primary samples in which the cells showed elevated ClpP expression but did not affect their normal counterparts.  Importantly, Clpp knockout mice were viable with normal hematopoiesis.  Mechanistically, we found that ClpP interacts with mitochondrial respiratory chain proteins and metabolic enzymes, and knockdown of ClpP in leukemic cells inhibited oxidative phosphorylation and mitochondrial metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PQElwRijsLVg90H21EOLACvtfcHk0ljWOJpSAwE1nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVejurnJ&md5=37380b21ff34c266a30288bb3915bf90</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DCoyaud%26aufirst%3DE.%26aulast%3DVoisin%26aufirst%3DV.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DMattson%26aufirst%3DR.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DBabovic%26aufirst%3DS.%26aulast%3DMaclean%26aufirst%3DN.%26aulast%3DRestall%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJeyaraju%26aufirst%3DD.%2BV.%26aulast%3DSukhai%26aufirst%3DM.%2BA.%26aulast%3DPrabha%26aufirst%3DS.%26aulast%3DBashir%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DQia%26aufirst%3DY.%2BH.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DCombes%26aufirst%3DK.%2BR.%26aulast%3DKetela%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DHoury%26aufirst%3DW.%2BA.%26aulast%3DAman%26aufirst%3DA.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DWienholds%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DC.%2BJ.%26aulast%3DDick%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DEaves%26aufirst%3DC.%2BJ.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DKornblau%26aufirst%3DS.%2BM.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DInhibition%2520of%2520the%2520mitochondrial%2520protease%2520ClpP%2520as%2520a%2520therapeutic%2520strategy%2520for%2520human%2520ccute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D864%26epage%3D876%26doi%3D10.1016%2Fj.ccell.2015.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">Remodelling the extracellular matrix in development and disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1038/nrm3904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrm3904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25415508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=786-801&author=C.+Bonnansauthor=J.+Chouauthor=Z.+Werb&title=Remodelling+the+extracellular+matrix+in+development+and+disease&doi=10.1038%2Fnrm3904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Remodelling the extracellular matrix in development and disease</span></div><div class="casAuthors">Bonnans, Caroline; Chou, Jonathan; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">786-801</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The extracellular matrix (ECM) is a highly dynamic structure that is present in all tissues and continuously undergoes controlled remodelling.  This process involves quant. and qual. changes in the ECM, mediated by specific enzymes that are responsible for ECM degrdn., such as metalloproteinases.  The ECM interacts with cells to regulate diverse functions, including proliferation, migration and differentiation.  ECM remodelling is crucial for regulating the morphogenesis of the intestine and lungs, as well as of the mammary and submandibular glands.  Dysregulation of ECM compn., structure, stiffness and abundance contributes to several pathol. conditions, such as fibrosis and invasive cancer.  A better understanding of how the ECM regulates organ structure and function and of how ECM remodelling affects disease progression will contribute to the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgvNjm5IvLgLVg90H21EOLACvtfcHk0ljWOJpSAwE1nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtbbF&md5=623492080876fee0ffa62b9f0dc1937c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrm3904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3904%26sid%3Dliteratum%253Aachs%26aulast%3DBonnans%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DJ.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DRemodelling%2520the%2520extracellular%2520matrix%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D786%26epage%3D801%26doi%3D10.1038%2Fnrm3904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. I.</span></span> <span> </span><span class="NLM_article-title">Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1002/path.5225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fpath.5225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30582157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3cnlt1OgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=2019&pages=629-640&author=G.+A.+Conlonauthor=G.+I.+Murray&title=Recent+advances+in+understanding+the+roles+of+matrix+metalloproteinases+in+tumour+invasion+and+metastasis&doi=10.1002%2Fpath.5225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis</span></div><div class="casAuthors">Conlon Guy A; Murray Graeme I</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-640</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review aims to provide an overview of recent developments regarding the roles of MMPs in tumour invasion and metastasis.  Much of the mortality burden belonging to cancer relates to its ability to invade adjacent tissue and form metastases at distant sites.  This would not be possible without remodelling of the ECM, a process which is enabled by the functions of MMPs.  Recent studies provide a better understanding of the importance of the biophysical nature of the ECM, how this influences cancer cell motility, and how MMPs act to modify matrix stiffness.  The regulation of MMPs and the role of immune cell generated MMPs has also become better understood.  All of this provides a framework for the therapeutic targeting of MMPs and recent advances in the development of selective MMPs inhibitors are also reviewed.  Copyright © 2018 Pathological Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiGXnJU5dcZrBItaL1WaVAfW6udTcc2eaADgSptZSeaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnlt1OgsA%253D%253D&md5=1780b99718cb6b8c031f18439b4b4096</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fpath.5225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5225%26sid%3Dliteratum%253Aachs%26aulast%3DConlon%26aufirst%3DG.%2BA.%26aulast%3DMurray%26aufirst%3DG.%2BI.%26atitle%3DRecent%2520advances%2520in%2520understanding%2520the%2520roles%2520of%2520matrix%2520metalloproteinases%2520in%2520tumour%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Pathol.%26date%3D2019%26volume%3D247%26spage%3D629%26epage%3D640%26doi%3D10.1002%2Fpath.5225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perantoni, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the ubiquitin-proteasome system for cancer therapy</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2008.01013.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1111%2Fj.1349-7006.2008.01013.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=19037995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2009&pages=24-28&author=Y.+Yangauthor=J.+Kitagakiauthor=H.+Wangauthor=D.+Houauthor=A.+Perantoni&title=Targeting+the+ubiquitin-proteasome+system+for+cancer+therapy&doi=10.1111%2Fj.1349-7006.2008.01013.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the ubiquitin-proteasome system for cancer therapy</span></div><div class="casAuthors">Yang, Yili; Kitagaki, Jirouta; Wang, Honghe; Hou, De-Xing; Perantoni, Alan O.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-28</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome system plays a crit. role in controlling the level, activity, and location of various cellular proteins.  Significant progress was made in investigating the mol. mechanisms of ubiquitination, particularly in understanding the structure of the ubiquitination machinery and identifying ubiquitin protein ligases, the primary specificity-detg. enzymes.  Therefore, it is now possible to target specific mols. involved in ubiquitination and proteasomal degrdn. to regulate many cellular processes such as signal transduction, proliferation, and apoptosis.  In particular, alterations in ubiquitination are obsd. in most, if not all, cancer cells.  This is manifested by destabilization of tumor suppressors, such as p53, and overexpression of oncogenes such as c-Myc and c-Jun.  In addn. to the development and clin. validation of proteasome inhibitor, bortezomib, in myeloma therapy, recent studies have demonstrated that it is possible to develop inhibitors for specific ubiquitination and deubiquitination enzymes.  With the help of structural studies, rational design, and chem. synthesis, it is conceivable that we will be able to use 'druggable' inhibitors of the ubiquitin system to evaluate their effects in animal tumor models in the not-so-distant future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_KciRHFSGhLVg90H21EOLACvtfcHk0liQQ4EjrUdNKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgurk%253D&md5=1e6fcbd11647d1bd370ea68a3cac96c7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.01013.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.01013.x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKitagaki%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DD.%26aulast%3DPerantoni%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520ubiquitin-proteasome%2520system%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Sci.%26date%3D2009%26volume%3D100%26spage%3D24%26epage%3D28%26doi%3D10.1111%2Fj.1349-7006.2008.01013.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">112260</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejmech.2020.112260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32224379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtVKgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2020&pages=112260&author=S.+Mondalauthor=N.+Adhikariauthor=S.+Banerjeeauthor=S.+A.+Aminauthor=T.+Jha&title=Matrix+metalloproteinase-9+%28MMP-9%29+and+its+inhibitors+in+cancer%3A+A+minireview&doi=10.1016%2Fj.ejmech.2020.112260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview</span></div><div class="casAuthors">Mondal, Subha; Adhikari, Nilanjan; Banerjee, Suvankar; Abdul Amin, Sk; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112260</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme.  MMP-9 is one of the most complex forms of matrix metalloproteinases.  MMP-9 has the ability to degrade the extracellular matrix (ECM) components and has important role in the pathophysiol. functions.  Overexpression and dysregulation of MMP-9 is assocd. with various diseases.  Thus, regulation and inhibition of MMP-9 is an important therapeutic approach for combating various diseases including cancer.  Inhibitors of MMP-9 can be used as anticancer agents.  Till date no selective MMP-9 inhibitors passed the clin. trials.  In this review the structure, activation, function and inhibitors of MMP-9 are mainly focused.  Some highly active and/or selective MMP-9 inhibitors have been discussed which may be helpful to explore the structural significance of MMP-9 inhibitors.  This study may be useful to design new potent and selective MMP-9 inhibitors against cancer in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKSwmQcbuNmbVg90H21EOLACvtfcHk0lgPcA7TfFUMJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtVKgs70%253D&md5=250e10deaacc265aa0a9af2b940d4e76</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112260%26sid%3Dliteratum%253Aachs%26aulast%3DMondal%26aufirst%3DS.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DMatrix%2520metalloproteinase-9%2520%2528MMP-9%2529%2520and%2520its%2520inhibitors%2520in%2520cancer%253A%2520A%2520minireview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D194%26spage%3D112260%26doi%3D10.1016%2Fj.ejmech.2020.112260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PROTACs: A novel strategy for cancer therapy</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2020.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.semcancer.2020.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32058059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2020&pages=171&author=J.+Liuauthor=J.+Maauthor=Y.+Liuauthor=J.+Xiaauthor=Y.+Liauthor=Z.+P.+Wangauthor=W.+Wei&title=PROTACs%3A+A+novel+strategy+for+cancer+therapy&doi=10.1016%2Fj.semcancer.2020.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: A novel strategy for cancer therapy</span></div><div class="casAuthors">Liu, Jing; Ma, Jia; Liu, Yi; Xia, Jun; Li, Yuyun; Wang, Z. Peter; Wei, Wenyi</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">Part_2</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time.  From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins.  The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chem. stability issues restrict their clin. application.  The second generation of small mol.-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied.  To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCR-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs.  The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role.  To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs.  The degrdn. of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKjhYqcuOobVg90H21EOLACvtfcHk0lgPcA7TfFUMJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D&md5=857bf22e06e986d57ad70fdd4a518953</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2020.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2020.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%2BP.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPROTACs%253A%2520A%2520novel%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D67%26spage%3D171%26doi%3D10.1016%2Fj.semcancer.2020.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graves, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aponte-Collazo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, E. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicheva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, T. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashamalla, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmuhamedov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1020</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1SntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1020-1029&author=P.+R.+Gravesauthor=L.+J.+Aponte-Collazoauthor=E.+M.+J.+Fennellauthor=A.+C.+Gravesauthor=A.+E.+Haleauthor=N.+Dichevaauthor=L.+E.+Herringauthor=T.+S.+K.+Gilbertauthor=M.+P.+Eastauthor=I.+M.+McDonaldauthor=M.+R.+Lockettauthor=H.+Ashamallaauthor=N.+J.+Moormanauthor=D.+S.+Karanewskyauthor=E.+J.+Iwanowiczauthor=E.+Holmuhamedovauthor=L.+M.+Graves&title=Mitochondrial+protease+ClpP+is+a+target+for+the+anticancer+compounds+ONC201+and+related+analogues&doi=10.1021%2Facschembio.9b00222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues</span></div><div class="casAuthors">Graves, Paul R.; Aponte-Collazo, Lucas J.; Fennell, Emily M. J.; Graves, Adam C.; Hale, Andrew E.; Dicheva, Nedyalka; Herring, Laura E.; Gilbert, Thomas S. K.; East, Michael P.; McDonald, Ian M.; Lockett, Matthew R.; Ashamalla, Hani; Moorman, Nathaniel J.; Karanewsky, Donald S.; Iwanowicz, Edwin J.; Holmuhamedov, Ekhson; Graves, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1020-1029</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ONC201 is a first-in-class imipridone mol. currently in clin. trials for the treatment of multiple cancers.  Despite enormous clin. potential, the mechanism of action is controversial.  To investigate the mechanism of ONC201 and identify compds. with improved potency, we tested a series of novel ONC201 analogs (TR compds.) for effects on cell viability and stress responses in breast and other cancer models.  The TR compds. were found to be ∼50-100 times more potent at inhibiting cell proliferation and inducing the integrated stress response protein ATF4 than ONC201.  Using immobilized TR compds., we identified the human mitochondrial caseinolytic protease P (ClpP) as a specific binding protein by mass spectrometry.  Affinity chromatog./drug competition assays showed that the TR compds. bound ClpP with ∼10-fold higher affinity compared to ONC201.  Importantly, we found that the peptidase activity of recombinant ClpP was strongly activated by ONC201 and the TR compds. in a dose- and time-dependent manner with the TR compds. displaying a ∼10-100 fold increase in potency over ONC201.  Finally, siRNA knockdown of ClpP in SUM159 cells reduced the response to ONC201 and the TR compds., including induction of CHOP, loss of the mitochondrial proteins (TFAM, TUFM), and the cytostatic effects of these compds.  Thus, we report that ClpP directly binds ONC201 and the related TR compds. and is an important biol. target for this class of mols.  Moreover, these studies provide, for the first time, a biochem. basis for the difference in efficacy between ONC201 and the TR compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ9b0PMFyCPbVg90H21EOLACvtfcHk0ljDb0s1UySkQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1SntLw%253D&md5=9291bc01f382a0b53ce059e30ecadfce</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00222%26sid%3Dliteratum%253Aachs%26aulast%3DGraves%26aufirst%3DP.%2BR.%26aulast%3DAponte-Collazo%26aufirst%3DL.%2BJ.%26aulast%3DFennell%26aufirst%3DE.%2BM.%2BJ.%26aulast%3DGraves%26aufirst%3DA.%2BC.%26aulast%3DHale%26aufirst%3DA.%2BE.%26aulast%3DDicheva%26aufirst%3DN.%26aulast%3DHerring%26aufirst%3DL.%2BE.%26aulast%3DGilbert%26aufirst%3DT.%2BS.%2BK.%26aulast%3DEast%26aufirst%3DM.%2BP.%26aulast%3DMcDonald%26aufirst%3DI.%2BM.%26aulast%3DLockett%26aufirst%3DM.%2BR.%26aulast%3DAshamalla%26aufirst%3DH.%26aulast%3DMoorman%26aufirst%3DN.%2BJ.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DIwanowicz%26aufirst%3DE.%2BJ.%26aulast%3DHolmuhamedov%26aufirst%3DE.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26atitle%3DMitochondrial%2520protease%2520ClpP%2520is%2520a%2520target%2520for%2520the%2520anticancer%2520compounds%2520ONC201%2520and%2520related%2520analogues%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D1020%26epage%3D1029%26doi%3D10.1021%2Facschembio.9b00222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span> <span> </span><span class="NLM_article-title">The proteasome: overview of structure and functions</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.2183/pjab.85.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2183%2Fpjab.85.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVyhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=12-36&author=K.+Tanaka&title=The+proteasome%3A+overview+of+structure+and+functions&doi=10.2183%2Fpjab.85.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: Overview of structure and functions</span></div><div class="casAuthors">Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-36</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  The proteasome is a highly sophisticated protease complex designed to carry out selective, efficient and processive hydrolysis of client proteins.  It is known to collaborate with ubiquitin, which polymerizes to form a marker for regulated proteolysis in eukaryotic cells.  The highly organized proteasome plays a prominent role in the control of a diverse array of basic cellular activities by rapidly and unidirectionally catalyzing biol. reactions.  Studies of the proteasome during the past quarter of a century have provided profound insights into its structure and functions, which has appreciably contributed to our understanding of cellular life.  Many questions, however, remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa5tUP87L9fLVg90H21EOLACvtfcHk0ljDb0s1UySkQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVyhu7o%253D&md5=e88b6a3d37c1fef34cdf9dce1657e88a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2183%2Fpjab.85.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.85.12%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DThe%2520proteasome%253A%2520overview%2520of%2520structure%2520and%2520functions%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2009%26volume%3D85%26spage%3D12%26epage%3D36%26doi%3D10.2183%2Fpjab.85.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, Y.</span></span> <span> </span><span class="NLM_article-title">The proteasome: molecular machinery and pathophysiological roles</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1515/hsz-2011-0285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1515%2Fhsz-2011-0285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23029643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFyrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2012&pages=217-234&author=K.+Tanakaauthor=T.+Mizushimaauthor=Y.+Saeki&title=The+proteasome%3A+molecular+machinery+and+pathophysiological+roles&doi=10.1515%2Fhsz-2011-0285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: molecular machinery and pathophysiological roles</span></div><div class="casAuthors">Tanaka, Keiji; Mizushima, Tsunehiro; Saeki, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-234</span>CODEN:
                <span class="NLM_cas:coden">BICHF3</span>;
        ISSN:<span class="NLM_cas:issn">1431-6730</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">A review.  The 26S proteasome, in collaboration with ubiquitin, operates the energy-dependent regulated proteolysis process in eukaryotic cells.  Over the past 30 years, several studies have comprehensively characterized the structure and mol./physiol. functions of the 26S proteasome.  It is a sophisticated 2.5-MDa protein degrdn. machine comprising a proteolytic core particle (CP) and one or two terminal regulatory particle(s) (RP).  The CP consists of two outer α rings and two inner β rings, which are made up of seven structurally similar α and β subunits, resp.  The CP contains catalytic threonine residues (β1, β2, and β5; caspase-like, trypsin-like, and chymotrypsin-like activities, resp.) on the inner surface of the chamber formed by two abutting β rings.  Intriguingly, the immunotype proteasomes, named "immunoproteasome" and "thymoproteasome", whose catalytic subunits are replaced by the related counterparts, were discovered lately.  Both unique isoenzymes essentially contribute to the acquisition of adaptive immunity in vertebrates.  The RP, which serves to recognize polyubiquitylated substrate proteins and plays a role in their deubiquitylating, unfolding, and translocation into the interior of the CP for destruction, forms two subcomplexes: the base and the lid.  On another front, the PA28 and PA200, alternative CP activator proteins discovered biochem., both play independent roles in proteolysis of the 26S proteasome.  Several studies have highlighted the importance of the proteasome in various intractable diseases that have been increasing in the aged society of the 21st century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9jQRtA_v8LbVg90H21EOLACvtfcHk0liWPwJVSLEdRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFyrsb8%253D&md5=ce2dac842b8a99205b517f660e26996e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1515%2Fhsz-2011-0285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhsz-2011-0285%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DMizushima%26aufirst%3DT.%26aulast%3DSaeki%26aufirst%3DY.%26atitle%3DThe%2520proteasome%253A%2520molecular%2520machinery%2520and%2520pathophysiological%2520roles%26jtitle%3DBiol.%2520Chem.%26date%3D2012%26volume%3D393%26spage%3D217%26epage%3D234%26doi%3D10.1515%2Fhsz-2011-0285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, L. D.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitor drugs</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010919-023603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1146%2Fannurev-pharmtox-010919-023603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=31479618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12qsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=457-476&author=L.+D.+Fricker&title=Proteasome+inhibitor+drugs&doi=10.1146%2Fannurev-pharmtox-010919-023603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibitor Drugs</span></div><div class="casAuthors">Fricker, Lloyd D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">457-476</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Proteasomes are large, multicatalytic protein complexes that cleave cellular proteins into peptides.  There are many distinct forms of proteasomes that differ in catalytically active subunits, regulatory subunits, and assocd. proteins.  Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and mantle cell lymphoma, and they are being investigated for other diseases.  Bortezomib (Velcade) was the first proteasome inhibitor to be approved by the US Food and Drug Administration.  Carfilzomib (Kyprolis) and ixazomib (Ninlaro) have recently been approved, and more drugs are in development.  While the primary mechanism of action is inhibition of the proteasome, the downstream events that lead to selective cell death are not entirely clear.  Proteasome inhibitors have been found to affect protein turnover but at concns. that are much higher than those achieved clin., raising the possibility that some of the effects of proteasome inhibitors are mediated by other mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlN6sX0x7nUrVg90H21EOLACvtfcHk0liWPwJVSLEdRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12qsrbK&md5=4c1413b510396792ca6a62b2b36cfaa5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010919-023603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010919-023603%26sid%3Dliteratum%253Aachs%26aulast%3DFricker%26aufirst%3DL.%2BD.%26atitle%3DProteasome%2520inhibitor%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2020%26volume%3D60%26spage%3D457%26epage%3D476%26doi%3D10.1146%2Fannurev-pharmtox-010919-023603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandolfi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span> <span> </span><span class="NLM_article-title">The proteasome and proteasome inhibitors in multiple myeloma</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1007/s10555-017-9707-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs10555-017-9707-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29196868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWmu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=561-584&author=S.+Gandolfiauthor=J.+P.+Laubachauthor=T.+Hideshimaauthor=D.+Chauhanauthor=K.+C.+Andersonauthor=P.+G.+Richardson&title=The+proteasome+and+proteasome+inhibitors+in+multiple+myeloma&doi=10.1007%2Fs10555-017-9707-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome and proteasome inhibitors in multiple myeloma</span></div><div class="casAuthors">Gandolfi, Sara; Laubach, Jacob P.; Hideshima, Teru; Chauhan, Dharminder; Anderson, Kenneth C.; Richardson, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">561-584</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Proteasome inhibitors are one of the most important classes of agents to have emerged for the treatment of multiple myeloma in the past two decades, and now form one of the backbones of treatment.  Three agents in this class have been approved by the United States Food and Drug Administration-the first-in-class compd. bortezomib, the second-generation agent carfilzomib, and the first oral proteasome inhibitor, ixazomib.  The success of this class of agents is due to the exquisite sensitivity of myeloma cells to the inhibition of the 26S proteasome, which plays a crit. role in the pathogenesis and proliferation of the disease.  Proteasome inhibition results in multiple downstream effects, including the inhibition of NF-κB signaling, the accumulation of misfolded and unfolded proteins, resulting in endoplasmic reticulum stress and leading to the unfolded protein response, the downregulation of growth factor receptors, suppression of adhesion mol. expression, and inhibition of angiogenesis; resistance to proteasome inhibition may arise through cellular responses mediating these downstream effects.  These multiple biol. consequences of proteasome inhibition result in synergistic or additive activity with other chemotherapeutic and targeted agents for myeloma, and proteasome inhibitor-based combination regimens have become established as a cornerstone of therapy throughout the myeloma treatment algorithm, incorporating agents from the other key classes of antimyeloma agents, including the immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors.  This review gives an overview of the crit. role of the proteasome in myeloma and the characteristics of the different proteasome inhibitors and provides a comprehensive summary of key clin. efficacy and safety data with the currently approved proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3y59EW8PTy7Vg90H21EOLACvtfcHk0lgB23qRB7qF8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWmu7nM&md5=9d2da9fe3c3571fb4c94c7a4886ddef3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs10555-017-9707-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-017-9707-8%26sid%3Dliteratum%253Aachs%26aulast%3DGandolfi%26aufirst%3DS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DThe%2520proteasome%2520and%2520proteasome%2520inhibitors%2520in%2520multiple%2520myeloma%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2017%26volume%3D36%26spage%3D561%26epage%3D584%26doi%3D10.1007%2Fs10555-017-9707-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borissenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">20S proteasome and its inhibitors: Crystallographic knowledge for drug development</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1021/cr0502504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0502504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=687-717&author=L.+Borissenkoauthor=M.+Groll&title=20S+proteasome+and+its+inhibitors%3A+Crystallographic+knowledge+for+drug+development&doi=10.1021%2Fcr0502504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development</span></div><div class="casAuthors">Borissenko, Ljudmila; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">687-717</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The aim of this review is to discuss the latest insights on the structure and function of the proteasome, highlighting the structural features that det. its activity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwElwBj8JBKrVg90H21EOLACvtfcHk0lgB23qRB7qF8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2kuro%253D&md5=af2e998e5443f598a46ffef71118a119</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fcr0502504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0502504%26sid%3Dliteratum%253Aachs%26aulast%3DBorissenko%26aufirst%3DL.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3D20S%2520proteasome%2520and%2520its%2520inhibitors%253A%2520Crystallographic%2520knowledge%2520for%2520drug%2520development%26jtitle%3DChem.%2520Rev.%26date%3D2007%26volume%3D107%26spage%3D687%26epage%3D717%26doi%3D10.1021%2Fcr0502504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturegli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span> <span> </span><span class="NLM_article-title">New insights into the function of the immunoproteasome in immune and nonimmune cells</span>. <i>Journal of immunology research</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">541984</span>, <span class="refDoi"> DOI: 10.1155/2015/541984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1155%2F2015%2F541984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26636107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC28vnvFCgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=541984&author=H.+Kimuraauthor=P.+Caturegliauthor=M.+Takahashiauthor=K.+Suzuki&title=New+insights+into+the+function+of+the+immunoproteasome+in+immune+and+nonimmune+cells&doi=10.1155%2F2015%2F541984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells</span></div><div class="casAuthors">Kimura Hiroaki; Takahashi Masafumi; Caturegli Patrizio; Suzuki Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">541984</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The immunoproteasome is a highly efficient proteolytic machinery derived from the constitutive proteasome and is abundantly expressed in immune cells.  The immunoproteasome plays a critical role in the immune system because it degrades intracellular proteins, for example, those of viral origin, into small proteins.  They are further digested into short peptides to be presented by major histocompatibility complex (MHC) class I molecules.  In addition, the immunoproteasome influences inflammatory disease pathogenesis through its ability to regulate T cell polarization.  The immunoproteasome is also expressed in nonimmune cell types during inflammation or neoplastic transformation, supporting a role in the pathogenesis of autoimmune diseases and neoplasms.  Following the success of inhibitors of the constitutive proteasome, which is now an established treatment modality for multiple myeloma, compounds that selectively inhibit the immunoproteasome are currently under active investigation.  This paper will review the functions of the immunoproteasome, highlighting areas where novel pharmacological treatments that regulate immunoproteasome activity could be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0syW_7fxhz2LFM_lbR1VmfW6udTcc2eYAV5IOEFckqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vnvFCgtw%253D%253D&md5=2908f35ddb6ce2386f1524c73c43d30f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1155%2F2015%2F541984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F541984%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DCaturegli%26aufirst%3DP.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DNew%2520insights%2520into%2520the%2520function%2520of%2520the%2520immunoproteasome%2520in%2520immune%2520and%2520nonimmune%2520cells%26jtitle%3DJournal%2520of%2520immunology%2520research%26date%3D2015%26volume%3D2015%26spage%3D541984%26doi%3D10.1155%2F2015%2F541984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Szanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K.</span></span> <span> </span><span class="NLM_article-title">Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2866</span>– <span class="NLM_lpage">2875</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1535-7163.MCT-08-0391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18790767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2866-2875&author=M.+Lioniauthor=K.+Nomaauthor=A.+Snyderauthor=A.+Klein-Szantoauthor=J.+Diehlauthor=A.+Rustgiauthor=M.+Herlynauthor=K.+Smalley&title=Bortezomib+induces+apoptosis+in+esophageal+squamous+cell+carcinoma+cells+through+activation+of+the+p38+mitogen-activated+protein+kinase+pathway&doi=10.1158%2F1535-7163.MCT-08-0391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway</span></div><div class="casAuthors">Lioni, Mercedes; Noma, Kazuhiro; Snyder, Andrew; Klein-Szanto, Andres; Diehl, J. Alan; Rustgi, Anil K.; Herlyn, Meenhard; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2866-2875</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Esophageal squamous cell carcinoma (ESCC) is an exceptionally drug-resistant tumor with a 5-yr survival rate <5%.  From an initial drug screen, we identified bortezomib as having robust activity in ESCC lines.  Mechanistically, bortezomib induced a G2-M-phase cell cycle arrest and p53-independent apoptosis assocd. with caspase cleavage and Noxa induction.  Bortezomib also showed excellent activity in organotypic culture and in vivo models of ESCC.  Biochem., bortezomib treatment activated the p38 and c-Jun NH2-terminal kinase stress-activated mitogen-activated protein kinase (MAPK) pathways and induced phospho-H2AX activity.  Although H2AX is known to cooperate with c-Jun NH2-terminal kinase to induce apoptosis following UV irradn., knockdown of H2AX did not abrogate bortezomib-induced apoptosis.  Instead, blockade of p38 MAPK signaling, using either small interfering RNA or a pharmacol. inhibitor, reversed bortezomib-induced apoptosis and the up-regulation of Noxa.  Radiation therapy is known to activate the p38 MAPK pathway and is a mainstay of ESCC treatment strategies.  In a final series of studies, we showed that the coadministration of bortezomib with irradn. led to enhanced p38 MAPK activity and a significant redn. in colony formation.  We therefore suggest that p38 MAPK pathway activation is an excellent potential therapeutic strategy in ESCC.  It is further suggested that bortezomib could be added to existing ESCC therapeutic regimens. [Mol Cancer Ther 2008;7(9):2866-75].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNLct8sjAx97Vg90H21EOLACvtfcHk0lhQ6nsc6Lp_Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7fP&md5=91c2a0fec8ebe9b7ccf505e68228f485</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0391%26sid%3Dliteratum%253Aachs%26aulast%3DLioni%26aufirst%3DM.%26aulast%3DNoma%26aufirst%3DK.%26aulast%3DSnyder%26aufirst%3DA.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DDiehl%26aufirst%3DJ.%26aulast%3DRustgi%26aufirst%3DA.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DSmalley%26aufirst%3DK.%26atitle%3DBortezomib%2520induces%2520apoptosis%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%2520cells%2520through%2520activation%2520of%2520the%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2866%26epage%3D2875%26doi%3D10.1158%2F1535-7163.MCT-08-0391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy-Thandavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaddar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenlein, P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.4161/auto.6.1.10323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.4161%2Fauto.6.1.10323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20110775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslCqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=19-35&author=S.+Periyasamy-Thandavanauthor=W.+Jacksonauthor=J.+Samaddarauthor=B.+Ericksonauthor=J.+Barrettauthor=L.+Raneyauthor=E.+Gopalauthor=V.+Ganapathyauthor=W.+Hillauthor=K.+Bhallaauthor=P.+Schoenlein&title=Bortezomib+blocks+the+catabolic+process+of+autophagy+via+a+cathepsin-dependent+mechanism%2C+affects+endoplasmic+reticulum+stress+and+induces+caspase-dependent+cell+death+in+antiestrogen-sensitive+and+resistant+ER%2B+breast+cancer+cells&doi=10.4161%2Fauto.6.1.10323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells</span></div><div class="casAuthors">Periyasamy-Thandavan, Sudharsan; Jackson, William H.; Samaddar, Julia S.; Erickson, Brian; Barrett, John R.; Raney, Lauren; Gopal, Elangovan; Ganapathy, Vadivel; Hill, William D.; Bhalla, Kapil N.; Schoenlein, Patricia V.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-35</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">In recent studies, we and others showed that autophagy is crit. to estrogen receptor pos. (ER+) breast cancer cell survival and the development of antiestrogen resistance.  Consequently, new approaches are warranted for targeting autophagy in breast cancer cells undergoing antiestrogen therapy.  Because crosstalk has been demonstrated between the autophagy- and proteasome-mediated pathways of protein degrdn., this study investigated how the proteasome inhibitor bortezomib affects autophagy and cell survival in antiestrogen-treated ER+ breast cancer cells.  Bortezomib, at clin. achievable doses, induced a robust death response in ER+, antiestrogen-sensitive and antiestrogen-resistant breast cancer cells undergoing hormonal therapy.  Cleavage of PARP and lamin A was detectable as a read-out of cell death, following bortezomib-induced mitochondrial dysfunction.  Prior to induction of cell death, bortezomib-treated cells showed high levels of light chain 3 (LC3) and p62, two protein markers for autophagy.  The accumulation of these proteins was due to bortezomib-mediated blockade of long-lived protein turnover during macroautophagy.  This novel action of bortezomib was linked to its blockade of cathepsin-L activity, which is required for autolysosomal-mediated protein turnover in ER+ breast cancer cells.  Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CHOP and GRP78.  Bortezomib also induced high levels of the pro-apoptotic protein BNIP3.  Knockdown of CHOP and/or BNIP3 expression via RNAi targeting significantly attenuated the death-promoting effects of bortezomib.  Thus, bortezomib inhibits prosurvival autophagy, in addn. to its known function in blocking the proteasome, and is cytotoxic to hormonally treated ER+ breast cancer cells.  These findings indicate that combining a proteasome inhibitor like bortezomib with antiestrogen therapy may have therapeutic advantage in the management of early-stage breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ0op4wl9kLLVg90H21EOLACvtfcHk0lhQ6nsc6Lp_Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslCqu7Y%253D&md5=98fb9a4a9685c593dcdc279f175dbf32</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4161%2Fauto.6.1.10323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.6.1.10323%26sid%3Dliteratum%253Aachs%26aulast%3DPeriyasamy-Thandavan%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DSamaddar%26aufirst%3DJ.%26aulast%3DErickson%26aufirst%3DB.%26aulast%3DBarrett%26aufirst%3DJ.%26aulast%3DRaney%26aufirst%3DL.%26aulast%3DGopal%26aufirst%3DE.%26aulast%3DGanapathy%26aufirst%3DV.%26aulast%3DHill%26aufirst%3DW.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DSchoenlein%26aufirst%3DP.%26atitle%3DBortezomib%2520blocks%2520the%2520catabolic%2520process%2520of%2520autophagy%2520via%2520a%2520cathepsin-dependent%2520mechanism%252C%2520affects%2520endoplasmic%2520reticulum%2520stress%2520and%2520induces%2520caspase-dependent%2520cell%2520death%2520in%2520antiestrogen-sensitive%2520and%2520resistant%2520ER%252B%2520breast%2520cancer%2520cells%26jtitle%3DAutophagy%26date%3D2010%26volume%3D6%26spage%3D19%26epage%3D35%26doi%3D10.4161%2Fauto.6.1.10323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velankar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuteboom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2005.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccr.2005.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16286248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=407-419&author=D.+Chauhanauthor=L.+Catleyauthor=G.+Liauthor=K.+Podarauthor=T.+Hideshimaauthor=M.+Velankarauthor=C.+Mitsiadesauthor=N.+Mitsiadesauthor=H.+Yasuiauthor=A.+Letaiauthor=H.+Ovaaauthor=C.+Berkersauthor=B.+Nicholsonauthor=T.+Chaoauthor=S.+Neuteboomauthor=P.+Richardsonauthor=M.+Palladinoauthor=K.+Anderson&title=A+novel+orally+active+proteasome+inhibitor+induces+apoptosis+in+multiple+myeloma+cells+with+mechanisms+distinct+from+Bortezomib&doi=10.1016%2Fj.ccr.2005.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib</span></div><div class="casAuthors">Chauhan, Dharminder; Catley, Laurence; Li, Guilan; Podar, Klaus; Hideshima, Teru; Velankar, Mugdha; Mitsiades, Constantine; Mitsiades, Nicolas; Yasui, Hiroshi; Letai, Anthony; Ovaa, Huib; Berkers, Celia; Nicholson, Benjamin; Chao, Ta-Hsiang; Neuteboom, Saskia T. C.; Richardson, Paul; Palladino, Michael A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); however, prolonged treatment is assocd. with toxicity and development of drug resistance.  Here, the authors show that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  NPI-0052 is distinct from bortezomib in its chem. structure, effects on proteasome activities, mechanisms of action, and toxicity profile against normal cells.  Moreover, NPI-0052 is orally bioactive.  In animal tumor model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumor recurrence.  Combining NPI-0052 and bortezomib induces synergistic anti-MM activity.  Our study therefore provides the rationale for clin. protocols evaluating NPI-0052, alone and together with bortezomib, to improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaYeiXJugULVg90H21EOLACvtfcHk0lhILk097sl_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12gsbvF&md5=7bce23ea2891fe8863835c589294b213</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DVelankar%26aufirst%3DM.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DBerkers%26aufirst%3DC.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DT.%26aulast%3DNeuteboom%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DA%2520novel%2520orally%2520active%2520proteasome%2520inhibitor%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520with%2520mechanisms%2520distinct%2520from%2520Bortezomib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D407%26epage%3D419%26doi%3D10.1016%2Fj.ccr.2005.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">The proteasome: a suitable antineoplastic target</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1038/nrc1361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrc1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15122206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=349-360&author=J.+Adams&title=The+proteasome%3A+a+suitable+antineoplastic+target&doi=10.1038%2Fnrc1361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: a suitable antineoplastic target</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-360</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The proteasome is an abundant multi-enzyme complex that provides the main pathway for degrdn. of intracellular proteins in eukaryotic cells.  As such, it controls the levels of proteins that are important for cell-cycle progression and apoptosis in normal and malignant cells; for example, cyclins, caspases, BCL2, and nuclear factor of κB.  A proteasome inhibitor - bortezomib - was developed that has shown efficacy as an anticancer agent in the clinic.  How can targeting such a universal, broadly active cellular component provide the selectivity and specificity that are required for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdI0j9dL6efrVg90H21EOLACvtfcHk0lhILk097sl_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D&md5=eeb2566e017e4aa1223b7bc8adb3b419</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1361%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520proteasome%253A%2520a%2520suitable%2520antineoplastic%2520target%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D349%26epage%3D360%26doi%3D10.1038%2Fnrc1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">The development of proteasome inhibitors as anticancer drugs</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(04)00120-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS1535-6108%2804%2900120-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15144949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=417-421&author=J.+Adams&title=The+development+of+proteasome+inhibitors+as+anticancer+drugs&doi=10.1016%2FS1535-6108%2804%2900120-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The development of proteasome inhibitors as anticancer drugs</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">417-421</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins.  Because these pathways are crit. for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy.  Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clin. trials.  Efficacy and safety results from a phase 2 clin. trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozXYZQ-zxJdbVg90H21EOLACvtfcHk0lhILk097sl_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D&md5=9a070d342533a3b6108150c40852834e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900120-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900120-5%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520development%2520of%2520proteasome%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D417%26epage%3D421%26doi%3D10.1016%2FS1535-6108%2804%2900120-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, A. K.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2217</span>– <span class="NLM_lpage">2229</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2004.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejca.2004.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15454246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2004&pages=2217-2229&author=A.+M.+Burgerauthor=A.+K.+Seth&title=The+ubiquitin-mediated+protein+degradation+pathway+in+cancer%3A+Therapeutic+implications&doi=10.1016%2Fj.ejca.2004.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications</span></div><div class="casAuthors">Burger, Angelika M.; Seth, Arun K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2217-2229</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The highly conserved eukaryotic ubiquitin-proteasome system (UP-S) plays a pivotal role in protein homeostasis and is crit. in regulating normal and cancer-related cellular processes.  The hierarchical nature of the UP-S provides a rich source of mol. targets for specific intervention and has therefore arisen as a promising approach to innovative anticancer therapies.  The first in class proteasome inhibitory agent Bortezomib (Velcade) has recently obtained regulatory approval for the treatment of multiple myeloma.  Ubiquitin-mediated degrdn. is a complex process that is comprised of well defined steps involving ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s).  Although a single E1 activates the ubiquitin conjugation machinery, a large no. of E2 conjugating enzymes and E3 ligases are now known to exist.  Proteins tagged with ubiquitin are subsequently recognized by the proteasome for digestion and fragmentation.  The enzymic nature, multitude of E3s and their specific substrate recognition predestines them as therapeutic targets.  This article will review known inhibitors of the proteasome and their mol. mechanisms as well as ongoing developments and promising avenues for targeting substrate-specific E3 ligases that are likely to yield a new class of therapeutics that will serve and complement the armamentarium of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE8GHAAD6JRbVg90H21EOLACvtfcHk0lhIxOqvyrrpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFWltL8%253D&md5=8303c779002b441396ebc3cd4c77b711</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2004.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2004.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%2BM.%26aulast%3DSeth%26aufirst%3DA.%2BK.%26atitle%3DThe%2520ubiquitin-mediated%2520protein%2520degradation%2520pathway%2520in%2520cancer%253A%2520Therapeutic%2520implications%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2004%26volume%3D40%26spage%3D2217%26epage%3D2229%26doi%3D10.1016%2Fj.ejca.2004.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiziltepe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">5228</span>– <span class="NLM_lpage">5236</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-06-161505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1182%2Fblood-2008-06-161505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=19270264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslalu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=5228-5236&author=T.+Hideshimaauthor=D.+Chauhanauthor=T.+Kiziltepeauthor=H.+Ikedaauthor=Y.+Okawaauthor=K.+Podarauthor=N.+Rajeauthor=A.+Protopopovauthor=N.+C.+Munshiauthor=P.+G.+Richardsonauthor=R.+D.+Carrascoauthor=K.+C.+Anderson&title=Biologic+sequelae+of+I%7Bkappa%7DB+kinase+%28IKK%29+inhibition+in+multiple+myeloma%3A+therapeutic+implications&doi=10.1182%2Fblood-2008-06-161505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications</span></div><div class="casAuthors">Hideshima, Teru; Chauhan, Dharminder; Kiziltepe, Tanyel; Ikeda, Hiroshi; Okawa, Yutaka; Podar, Klaus; Raje, Noopur; Protopopov, Alexei; Munshi, Nikhil C.; Richardson, Paul G.; Carrasco, Ruben D.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5228-5236</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Nuclear factor-κB (NF-κB) has an important role in multiple myeloma (MM) cell pathogenesis in the context of the bone marrow (BM) microenvironment.  In NF-κB signaling cascades, IκB kinase α (IKKα) and IKKβ are key mols. that predominantly mediate noncanonical and canonical pathways, resp.  In this study, we examd. the biol. sequelae of the inhibition of IKKα vs. IKKβ in MM cell lines.  All MM cell lines have constitutive canonical NF-κB activity, and a subset of MM cell lines shows noncanonical NF-κB activity.  Adhesion to BM stromal cells further activates both canonical and noncanonical NF-κB activity.  IKKβ inhibitor MLN120B blocks canonical pathway and growth of MM cell lines but does not inhibit the noncanonical NF-κB pathway.  Although IKKα knockdown induces significant growth inhibition in the cell lines with both canonical and noncanonical pathways, it does not inhibit NF-κB activation.  Importantly, IKKα down-regulation decreases expression of β-catenin and aurora-A, which are known to mediate MM cell growth and survival.  Finally, IKKβ inhibitor enhances the growth inhibition triggered by IKKα down-regulation in MM cells with both canonical and noncanonical NF-κB activity.  Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEvXZgJQso1rVg90H21EOLACvtfcHk0lhIxOqvyrrpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslalu78%253D&md5=4ab46ccabdf5852ee3a66eea1e5f6431</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-06-161505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-06-161505%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DProtopopov%26aufirst%3DA.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DBiologic%2520sequelae%2520of%2520I%257Bkappa%257DB%2520kinase%2520%2528IKK%2529%2520inhibition%2520in%2520multiple%2520myeloma%253A%2520therapeutic%2520implications%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D5228%26epage%3D5236%26doi%3D10.1182%2Fblood-2008-06-161505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manasanch, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitors in cancer therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrclinonc.2016.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28117417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=417-433&author=E.+E.+Manasanchauthor=R.+Z.+Orlowski&title=Proteasome+inhibitors+in+cancer+therapy&doi=10.1038%2Fnrclinonc.2016.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors in cancer therapy</span></div><div class="casAuthors">Manasanch, Elisabet E.; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-433</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degrdn. machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins.  Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit mechanisms of cell death.  This notion set the stage for preclin. testing of proteasome inhibitors as a means to shift this fine equil. towards cell death.  Since the late 1990s, clin. trials have been conducted for a variety of malignancies, leading to regulatory approvals of proteasome inhibitors to treat multiple myeloma and mantle-cell lymphoma.  First-generation and second-generation proteasome inhibitors can elicit deep initial responses in patients with myeloma, for whom these drugs have dramatically improved outcomes, but relapses are frequent and acquired resistance to treatment eventually emerges.  In addn., promising preclin. data obtained with proteasome inhibitors in models of solid tumors have not been confirmed in the clinic, indicating the importance of primary resistance.  Investigation of the mechanisms of resistance is, therefore, essential to further maximize the utility of this class of drugs in the era of personalized medicine.  Herein, we discuss the advances and challenges resulting from the introduction of proteasome inhibitors into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwd7_v_RFD8bVg90H21EOLACvtfcHk0lhIxOqvyrrpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGlsbg%253D&md5=7246069f357a4cc9449f822c57767811</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.206%26sid%3Dliteratum%253Aachs%26aulast%3DManasanch%26aufirst%3DE.%2BE.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DProteasome%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D417%26epage%3D433%26doi%3D10.1038%2Fnrclinonc.2016.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciechanover, A.</span></span> <span> </span><span class="NLM_article-title">Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1159/000334283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1159%2F000334283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22327508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVOnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=7-22&author=A.+Ciechanover&title=Intracellular+protein+degradation%3A+from+a+vague+idea+through+the+lysosome+and+the+ubiquitin-proteasome+system+and+onto+human+diseases+and+drug+targeting&doi=10.1159%2F000334283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting</span></div><div class="casAuthors">Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">7-22</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Between the 1950s and 1980s, scientists were focusing mostly on how the genetic code was transcribed to RNA and translated to proteins, but how proteins were degraded had remained a neglected research area.  With the discovery of the lysosome by Christian de Duve it was assumed that cellular proteins are degraded within this organelle.  Yet, several independent lines of exptl. evidence strongly suggested that intracellular proteolysis was largely nonlysosomal, but the mechanisms involved have remained obscure.  The discovery of the ubiquitin-proteasome system resolved the enigma.  We now recognize that degrdn. of intracellular proteins is involved in the regulation of a broad array of cellular processes, such as cell cycle and division, regulation of transcription factors, and assurance of the cellular quality control.  Not surprisingly, aberrations in the system have been implicated in the pathogenesis of human disease, such as malignancies and neurodegenerative disorders, which subsequently led to an increasing effort to develop mechanism-based drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFok37A034LVg90H21EOLACvtfcHk0ljl8HLwJqn6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVOnu7Y%253D&md5=6c9c3fd3fd2ece46f673d810569c0d16</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1159%2F000334283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000334283%26sid%3Dliteratum%253Aachs%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DIntracellular%2520protein%2520degradation%253A%2520from%2520a%2520vague%2520idea%2520through%2520the%2520lysosome%2520and%2520the%2520ubiquitin-proteasome%2520system%2520and%2520onto%2520human%2520diseases%2520and%2520drug%2520targeting%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2012%26volume%3D10%26spage%3D7%26epage%3D22%26doi%3D10.1159%2F000334283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1039/c3np20126k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1039%2Fc3np20126k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23575525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=600-604&author=K.+B.+Kimauthor=C.+M.+Crews&title=From+epoxomicin+to+carfilzomib%3A+chemistry%2C+biology%2C+and+medical+outcomes&doi=10.1039%2Fc3np20126k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span></div><div class="casAuthors">Kim, Kyung Bo; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">600-604</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: 1992 to 2012The initial enthusiasm following the discovery of a pharmacol. active natural product is often fleeting due to the poor prospects for its ultimate clin. application.  Despite this, the ever-changing landscape of modern biol. has a const. need for mol. probes that can aid in our understanding of biol. processes.  After its initial discovery by Bristol-Myers Squibb as a microbial anti-tumor natural product, epoxomicin was deemed unfit for development due to its peptide structure and potentially labile epoxyketone pharmacophore.  Despite its drawbacks, epoxomicin's pharmacophore was found to provide unprecedented selectivity for the proteasome.  Epoxomicin also served as a scaffold for the generation of a synthetic tetrapeptide epoxyketone with improved activity, YU-101, which became the parent lead compd. of carfilzomib (Kyprolis®), the recently approved therapeutic agent for multiple myeloma.  In this era of rational drug design and high-throughput screening, the prospects for turning an active natural product into an approved therapy are often slim.  However, by understanding the journey that began with the discovery of epoxomicin and ended with the successful use of carfilzomib in the clinic, we may find new insights into the keys for success in natural product-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ZmojYh4VybVg90H21EOLACvtfcHk0ljl8HLwJqn6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D&md5=fa9d90ac327e5383f6d80512ecec8db4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2Fc3np20126k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np20126k%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DFrom%2520epoxomicin%2520to%2520carfilzomib%253A%2520chemistry%252C%2520biology%252C%2520and%2520medical%2520outcomes%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2013%26volume%3D30%26spage%3D600%26epage%3D604%26doi%3D10.1039%2Fc3np20126k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10900</span>, <span class="refDoi"> DOI: 10.1038/ncomms10900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fncomms10900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26964885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFGru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10900&author=E.+M.+Huberauthor=W.+Heinemeyerauthor=X.+Liauthor=C.+S.+Arendtauthor=M.+Hochstrasserauthor=M.+Groll&title=A+unified+mechanism+for+proteolysis+and+autocatalytic+activation+in+the+20S+proteasome&doi=10.1038%2Fncomms10900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome</span></div><div class="casAuthors">Huber, Eva M.; Heinemeyer, Wolfgang; Li, Xia; Arendt, Cassandra S.; Hochstrasser, Mark; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10900</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biogenesis of the 20S proteasome is tightly regulated.  The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly.  However, the trigger for the self-activation and the reason for the strict conservation of threonine as the active site nucleophile remain enigmatic.  Here we use mutagenesis, X-ray crystallog. and biochem. assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.  Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.  Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavorable orientation of Ser1 towards incoming substrates.  This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy1w69NIOuAbVg90H21EOLACvtfcHk0ljl8HLwJqn6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFGru74%253D&md5=aa01e2449bf910aa488b50477bd6f0a3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fncomms10900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10900%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DArendt%26aufirst%3DC.%2BS.%26aulast%3DHochstrasser%26aufirst%3DM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DA%2520unified%2520mechanism%2520for%2520proteolysis%2520and%2520autocatalytic%2520activation%2520in%2520the%252020S%2520proteasome%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10900%26doi%3D10.1038%2Fncomms10900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">CCR 20th anniversary commentary: In the beginning, there was PS-341</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-14-2549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25733705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsF2iurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=939-941&author=B.+A.+Teicherauthor=K.+C.+Anderson&title=CCR+20th+anniversary+commentary%3A+In+the+beginning%2C+there+was+PS-341&doi=10.1158%2F1078-0432.CCR-14-2549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341</span></div><div class="casAuthors">Teicher, Beverly A.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">939-941</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Proteasome inhibitors have a 20-yr history in cancer therapy.  The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003.  Clin. Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708).  Clin Cancer Res; 21(5); 939-41. cpr2015 AACR.  See related article by Teicher et al., Clin Cancer Res 1999;5(9) Sept. 1999;2638-45.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoInDXnaUN_FbVg90H21EOLACvtfcHk0lho7KbNVoxp3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsF2iurk%253D&md5=ad2d2441f819a54925c7166d38443ffd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2549%26sid%3Dliteratum%253Aachs%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DCCR%252020th%2520anniversary%2520commentary%253A%2520In%2520the%2520beginning%252C%2520there%2520was%2520PS-341%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D939%26epage%3D941%26doi%3D10.1158%2F1078-0432.CCR-14-2549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the boronic acid-based proteasome inhibitor Bortezomib in complex with the yeast 20S proteasome</span>. <i>Structure (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/j.str.2005.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+structure+of+the+boronic+acid-based+proteasome+inhibitor+Bortezomib+in+complex+with+the+yeast+20S+proteasome&doi=10.1016%2Fj.str.2005.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lho7KbNVoxp3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520boronic%2520acid-based%2520proteasome%2520inhibitor%2520Bortezomib%2520in%2520complex%2520with%2520the%2520yeast%252020S%2520proteasome%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456%26doi%3D10.1016%2Fj.str.2005.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlogie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srkalovic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limentani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenkein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of bortezomib in relapsed, refractory myeloma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">2609</span>– <span class="NLM_lpage">2617</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa030288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1056%2FNEJMoa030288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12826635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2609-2617&author=P.+Richardsonauthor=B.+Barlogieauthor=J.+Berensonauthor=S.+Singhalauthor=S.+Jagannathauthor=D.+Irwinauthor=S.+Rajkumarauthor=G.+Srkalovicauthor=M.+Alsinaauthor=R.+Alexanianauthor=D.+Siegelauthor=R.+Orlowskiauthor=D.+Kuterauthor=S.+Limentaniauthor=S.+Leeauthor=T.+Hideshimaauthor=D.+Esseltineauthor=M.+Kauffmanauthor=J.+Adamsauthor=D.+Schenkeinauthor=K.+Anderson&title=A+phase+2+study+of+bortezomib+in+relapsed%2C+refractory+myeloma&doi=10.1056%2FNEJMoa030288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of bortezomib in relapsed, refractory myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Barlogie, Bart; Berenson, James; Singhal, Seema; Jagannath, Sundar; Irwin, David; Rajkumar, S. Vincent; Srkalovic, Gordan; Alsina, Melissa; Alexanian, Raymond; Siegel, David; Orlowski, Robert Z.; Kuter, David; Limentani, Steven A.; Lee, Stephanie; Hideshima, Teru; Esseltine, Dixie-Lee; Kauffman, Michael; Adams, Julian; Schenkein, David P.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2609-2617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclin. and phase 1 studies to have antimyeloma activity.  Methods: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently.  Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 wk, followed by 1 wk without treatment, for up to eight cycles (24 wk).  In patients with a suboptimal response, oral dexamethasone (20 mg daily, on the day of and the day after bortezomib administration) was added to the regimen.  The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee.  Results: Of 193 patients who could be evaluated, 92 % had been treated with three or more of the major classes of agents for myeloma, and in 91 %, the myeloma was refractory to the therapy received most recently.  The rate of response to bortezomib was 35 %, and those with a response included 7 patients in whom myeloma protein became undetectable and 12 in whom myeloma protein was detectable only by immunofixation.  The median overall survival was 16 mo, with a median duration of response of 12 mo.  Grade 3 adverse events included thrombocytopenia (in 28 % of patients), fatigue (in 12 %), peripheral neuropathy (in 12 %), and neutropenia (in 11 %).  Grade 4 events occurred in 14 % of patients.  Conclusions: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvlvB12o1xbVg90H21EOLACvtfcHk0lho7KbNVoxp3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVSksLs%253D&md5=7d7ef72077f270a421a538557b3bf9ca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa030288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa030288%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DBarlogie%26aufirst%3DB.%26aulast%3DBerenson%26aufirst%3DJ.%26aulast%3DSinghal%26aufirst%3DS.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DRajkumar%26aufirst%3DS.%26aulast%3DSrkalovic%26aufirst%3DG.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DAlexanian%26aufirst%3DR.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DKuter%26aufirst%3DD.%26aulast%3DLimentani%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DEsseltine%26aufirst%3DD.%26aulast%3DKauffman%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DA%2520phase%25202%2520study%2520of%2520bortezomib%2520in%2520relapsed%252C%2520refractory%2520myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2609%26epage%3D2617%26doi%3D10.1056%2FNEJMoa030288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rechsteiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. P.</span></span> <span> </span><span class="NLM_article-title">Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2004.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.tcb.2004.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15653075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=27-33&author=M.+Rechsteinerauthor=C.+P.+Hill&title=Mobilizing+the+proteolytic+machine%3A+cell+biological+roles+of+proteasome+activators+and+inhibitors&doi=10.1016%2Fj.tcb.2004.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors</span></div><div class="casAuthors">Rechsteiner, Martin; Hill, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-33</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Proteasomes perform the majority of proteolysis that occurs in the cytosol and nucleus of eukaryotic cells and, thereby, perform crucial roles in cellular regulation and homeostasis.  Isolated proteasomes are inactive because substrates cannot access the proteolytic sites.  PA28 and PA200 are activators that bind to proteasomes and stimulate the hydrolysis of peptides.  Several protein inhibitors of the proteasome have also been identified, and the properties of these activators and inhibitors have been characterized biochem.  By contrast, their physiol. roles, which have been reported to include prodn. of antigenic peptides, proteasome assembly and DNA repair, are controversial.  In this article, we briefly review the biochem. data and discuss the possible biol. roles of PA28, PA200 and proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg9BxR7OGV5LVg90H21EOLACvtfcHk0li26uv202uZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOrtw%253D%253D&md5=e6abdf92be6c0860cb852f98e3dcc81c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DRechsteiner%26aufirst%3DM.%26aulast%3DHill%26aufirst%3DC.%2BP.%26atitle%3DMobilizing%2520the%2520proteolytic%2520machine%253A%2520cell%2520biological%2520roles%2520of%2520proteasome%2520activators%2520and%2520inhibitors%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D27%26epage%3D33%26doi%3D10.1016%2Fj.tcb.2004.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Ixazomib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0548-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs40265-016-0548-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26846321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=405-411&author=M.+Shirley&title=Ixazomib%3A+first+global+approval&doi=10.1007%2Fs40265-016-0548-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ixazomib: First Global Approval</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ixazomib (Ninlaro) is an orally bioavailable, reversible proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. (now Takeda Oncol.).  Ixazomib acts by binding to and inhibiting the β5 subunit of the 20S proteasome.  In Nov. 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.  Ixazomib is under regulatory review for this indication in the EU.  Phase III development of ixazomib is underway worldwide for newly-diagnosed multiple myeloma (in patients who are not eligible for stem cell transplant, or as maintenance therapy) and for relapsed or refractory systemic light chain (AL) amyloidosis.  Ixazomib is also under phase I-II development for the treatment of several other haematol. and non-haematol. malignancies, graft-vs.-host disease and lupus nephritis.  This article summarizes the milestones in the development of ixazomib leading to this first approval for multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMK0Ud8_wMNrVg90H21EOLACvtfcHk0li26uv202uZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGksbg%253D&md5=a31e66cf68dce72be96fe8e8843919ac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0548-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0548-5%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DIxazomib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D405%26epage%3D411%26doi%3D10.1007%2Fs40265-016-0548-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kupperman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-09-2766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20160034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1970-1980&author=E.+Kuppermanauthor=E.+Leeauthor=Y.+Caoauthor=B.+Bannermanauthor=M.+Fitzgeraldauthor=A.+Bergerauthor=J.+Yuauthor=Y.+Yangauthor=P.+Halesauthor=F.+Bruzzeseauthor=J.+Liuauthor=J.+Blankauthor=K.+Garciaauthor=C.+Tsuauthor=L.+Dickauthor=P.+Flemingauthor=L.+Yuauthor=M.+Manfrediauthor=M.+Rolfeauthor=J.+Bolen&title=Evaluation+of+the+proteasome+inhibitor+MLN9708+in+preclinical+models+of+human+cancer&doi=10.1158%2F0008-5472.CAN-09-2766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span></div><div class="casAuthors">Kupperman, Erik; Lee, Edmund C.; Cao, Yueying; Bannerman, Bret; Fitzgerald, Michael; Berger, Allison; Yu, Jie; Yang, Yu; Bruzzese, Frank; Liu, Jane; Blank, Jonathan; Garcia, Khristofer; Tsu, Christopher; Dick, Larry; Fleming, Paul; Yu, Li; Manfredi, Mark; Rolfe, Mark; Bolen, Joe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1970-1980</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The proteasome was validated as an oncol. target following the clin. success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma.  Consequently, several groups are pursuing the development of addnl. small-mol. proteasome inhibitors for both hematol. and solid tumor indications.  Here, we describe MLN9708, a selective, orally bioavailable, second-generation proteasome inhibitor that is in phase I clin. development.  MLN9708 has a shorter proteasome dissocn. half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  MLN9708 has a larger blood vol. distribution at steady state, and anal. of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib.  MLN9708 showed activity in both solid tumor and hematol. preclin. xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity.  Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage.  Taken together, these data support the clin. development of MLN9708 for both hematol. and solid tumor indications.  Cancer Res; 70(5); 1970-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjauqAFEgDA7Vg90H21EOLACvtfcHk0li26uv202uZpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D&md5=45636404582fc0eb66581c6c19420458</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2766%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DBannerman%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520proteasome%2520inhibitor%2520MLN9708%2520in%2520preclinical%2520models%2520of%2520human%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1970%26epage%3D1980%26doi%3D10.1158%2F0008-5472.CAN-09-2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbiera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurlbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassnacht, M.</span></span> <span> </span><span class="NLM_article-title">Drug synergism of proteasome inhibitors and mitotane by complementary activation of ER Stress in adrenocortical carcinoma cells</span>. <i>Horm. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1007/s12672-016-0273-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs12672-016-0273-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27631436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSgtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=345-355&author=M.+Kroissauthor=S.+Sbieraauthor=S.+Kendlauthor=M.+Kurlbaumauthor=M.+Fassnacht&title=Drug+synergism+of+proteasome+inhibitors+and+mitotane+by+complementary+activation+of+ER+Stress+in+adrenocortical+carcinoma+cells&doi=10.1007%2Fs12672-016-0273-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells</span></div><div class="casAuthors">Kroiss, Matthias; Sbiera, Silviu; Kendl, Sabine; Kurlbaum, Max; Fassnacht, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Hormones & Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">345-355</span>CODEN:
                <span class="NLM_cas:coden">HCOABS</span>;
        ISSN:<span class="NLM_cas:issn">1868-8497</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clin. used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids.  Since mitotane has limited clin. activity as monotherapy, we here study the potential of activating ER-stress through alternative pathways.  The single reliable NCI-H295 cell culture model for ACC was used to study the impact MG132, bortezomib (BTZ) and carfilzomib (CFZ) on mRNA and protein expression of ER-stress markers, cell viability and steroid hormone secretion.  We found all proteasome inhibitors alone to trigger expression of mRNA (spliced X-box protein 1, XBP1) and protein markers indicative of the inositol-requiring enzyme 1 (IRE1) dependent pathway of ER-stress but not phosphorylation of eukaryotic initiation factor 2α (eIF2α), a marker of the PRKR-like endoplasmic reticulum kinase (PERK)-dependent pathway.  Whereas mitotane alone activated both pathways, combination of BTZ and CFZ with low-dose mitotane blocked mitotane-induced eIF2α phosphorylation but increased XBP1-mRNA splicing indicating that proteasome inhibitors can commit signalling towards a single ER-stress pathway in ACC cells.  By applying the median effect model of drug combinations using cell viability as a read out, we detd. significant drug synergism between mitotane and both BTZ and CFZ.  In conclusion, combination of mitotane with activators of ER-stress through the unfolded protein response is synergistic in an ACC cell culture model.  Since proteasome inhibitors are readily available clin., they are attractive candidates to study for ACC treatment in clin. trials in combination with mitotane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPLhlU503cLVg90H21EOLACvtfcHk0lh1OxMXGKOkbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSgtbvO&md5=b4db6d47e008073c5e9f05da0860acc1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs12672-016-0273-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12672-016-0273-2%26sid%3Dliteratum%253Aachs%26aulast%3DKroiss%26aufirst%3DM.%26aulast%3DSbiera%26aufirst%3DS.%26aulast%3DKendl%26aufirst%3DS.%26aulast%3DKurlbaum%26aufirst%3DM.%26aulast%3DFassnacht%26aufirst%3DM.%26atitle%3DDrug%2520synergism%2520of%2520proteasome%2520inhibitors%2520and%2520mitotane%2520by%2520complementary%2520activation%2520of%2520ER%2520Stress%2520in%2520adrenocortical%2520carcinoma%2520cells%26jtitle%3DHorm.%2520Cancer%26date%3D2016%26volume%3D7%26spage%3D345%26epage%3D355%26doi%3D10.1007%2Fs12672-016-0273-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallerani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberasco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cereda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span> <span> </span><span class="NLM_article-title">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2012.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejca.2012.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23058787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=290-296&author=E.+Galleraniauthor=M.+Zucchettiauthor=D.+Brunelliauthor=E.+Marangonauthor=C.+Noberascoauthor=D.+Hessauthor=A.+Delmonteauthor=G.+Martinelliauthor=S.+B%C3%B6hmauthor=C.+Driessenauthor=F.+De+Braudauthor=S.+Marsoniauthor=R.+Ceredaauthor=F.+Salaauthor=M.+D%E2%80%99Incalciauthor=C.+Sessa&title=A+first+in+human+phase+I+study+of+the+proteasome+inhibitor+CEP-18770+in+patients+with+advanced+solid+tumours+and+multiple+myeloma&doi=10.1016%2Fj.ejca.2012.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span></div><div class="casAuthors">Gallerani, Elisa; Zucchetti, Massimo; Brunelli, Dario; Marangon, Elena; Noberasco, Cristina; Hess, Dagmar; Delmonte, Angelo; Martinelli, Giovanni; Bohm, Steffen; Driessen, Christopher; De Braud, Filippo; Marsoni, Silvia; Cereda, Roberta; Sala, Federica; D'Incalci, Maurizio; Sessa, Cristiana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">290-296</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The safety, pharmacokinetics (PK) and pharmacodynamics of CEP-18770, a new peptide boronic acid proteasome inhibitor, have been investigated after i.v. administration on days 1, 4, 8 and 11 of every 21 d cycle in patients with solid tumors and multiple myeloma (MM).Thirty-eight patients were treated with CEP-18770 at escalating doses from 0.1 to 1.8 mg/m2 where 2 out of 5 patients showed dose limiting toxicities.  The max. tolerated/recommended dose (MTD/RD) of 1.5 mg/m2 was tested in 12 addnl. patients.  Skin rash was dose-limiting and occurred in 53% of patients; other frequent toxicities were asthenia (29%), stomatitis (21%) and pyrexia (16%).  No significant peripheral neuropathy was obsd.  PK in plasma was linear with a half-life of the elimination phase of 62.0 ± 43.5 h.  Proteasome inhibition in peripheral blood mononuclear cells was dose related in MM patients; it was of 45.4 ± 11.5% at the RD.CEP-18770 showed a favorable safety profile with lack of neurotoxicity and linear plasma PK.  The definition of the optimal biol. dose and schedule of treatment is actively pursued because of the high incidence of skin toxicity of the twice a week schedule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI8KtW1FW2LrVg90H21EOLACvtfcHk0lh1OxMXGKOkbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK&md5=29f393ac09aebfb7c0a4758fc9436af7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2012.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2012.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DGallerani%26aufirst%3DE.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DBrunelli%26aufirst%3DD.%26aulast%3DMarangon%26aufirst%3DE.%26aulast%3DNoberasco%26aufirst%3DC.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DB%25C3%25B6hm%26aufirst%3DS.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DMarsoni%26aufirst%3DS.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DSala%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DA%2520first%2520in%2520human%2520phase%2520I%2520study%2520of%2520the%2520proteasome%2520inhibitor%2520CEP-18770%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%2520and%2520multiple%2520myeloma%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D290%26epage%3D296%26doi%3D10.1016%2Fj.ejca.2012.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernareggi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassarà, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arasmo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Munari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allievi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strepponi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallamo, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1072</span>, <span class="refDoi"> DOI: 10.1021/jm7010589</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7010589" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1068-1072&author=B.+D.+Dorseyauthor=M.+Iqbalauthor=S.+Chatterjeeauthor=E.+Mentaauthor=R.+Bernardiniauthor=A.+Bernareggiauthor=P.+G.+Cassar%C3%A0author=G.+D%E2%80%99Arasmoauthor=E.+Ferrettiauthor=S.+De+Munariauthor=A.+Olivaauthor=G.+Pezzoniauthor=C.+Allieviauthor=I.+Strepponiauthor=B.+Ruggeriauthor=M.+A.+Atorauthor=M.+Williamsauthor=J.+P.+Mallamo&title=Discovery+of+a+potent%2C+selective%2C+and+orally+active+proteasome+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm7010589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Dorsey, Bruce D.; Iqbal, Mohamed; Chatterjee, Sankar; Menta, Ernesto; Bernardini, Raffaella; Bernareggi, Alberto; Cassara, Paolo G.; D'Arasmo, Germano; Ferretti, Edmondo; De Munari, Sergio; Oliva, Ambrogio; Pezzoni, Gabriella; Allievi, Cecilia; Strepponi, Ivan; Ruggeri, Bruce; Ator, Mark A.; Williams, Michael; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1068-1072</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome pathway plays a central role in regulation of the prodn. and destruction of cellular proteins.  These pathways mediate proliferation and cell survival, particularly in malignant cells.  The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy.  Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclin. development, [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid 20 (CEP-18770), is disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkNeu3d81vbVg90H21EOLACvtfcHk0lhI7ww_epEdDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D&md5=cfc22ee09c2a4f4d9c695010187c4693</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm7010589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010589%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DMenta%26aufirst%3DE.%26aulast%3DBernardini%26aufirst%3DR.%26aulast%3DBernareggi%26aufirst%3DA.%26aulast%3DCassar%25C3%25A0%26aufirst%3DP.%2BG.%26aulast%3DD%25E2%2580%2599Arasmo%26aufirst%3DG.%26aulast%3DFerretti%26aufirst%3DE.%26aulast%3DDe%2BMunari%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DA.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DAllievi%26aufirst%3DC.%26aulast%3DStrepponi%26aufirst%3DI.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520proteasome%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1068%26epage%3D1072%26doi%3D10.1021%2Fjm7010589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harshbarger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human 20S proteasome in complex with carfilzomib</span>. <i>Structure (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.str.2014.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25599644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=418-424&author=W.+Harshbargerauthor=C.+Millerauthor=C.+Diedrichauthor=J.+Sacchettini&title=Crystal+structure+of+the+human+20S+proteasome+in+complex+with+carfilzomib&doi=10.1016%2Fj.str.2014.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib</span></div><div class="casAuthors">Harshbarger, Wayne; Miller, Chase; Diedrich, Chandler; Sacchettini, James</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, resp.  Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites.  Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes.  In addn., comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes.  Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQfIgWQjhexbVg90H21EOLACvtfcHk0lhI7ww_epEdDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D&md5=0249966770dad6c25b7844fb1cea59b1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DHarshbarger%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DDiedrich%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%252020S%2520proteasome%2520in%2520complex%2520with%2520carfilzomib%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D23%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.str.2014.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delforge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparetto, C.</span></span> <span> </span><span class="NLM_article-title">Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1872</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1263842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1080%2F10428194.2016.1263842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28140719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1872-1879&author=D.+Voglauthor=T.+Martinauthor=R.+Vijauthor=P.+Hariauthor=J.+Mikhaelauthor=D.+Siegelauthor=K.+Wuauthor=M.+Delforgeauthor=C.+Gasparetto&title=Phase+I%2FII+study+of+the+novel+proteasome+inhibitor+delanzomib+%28CEP-18770%29+for+relapsed+and+refractory+multiple+myeloma&doi=10.1080%2F10428194.2016.1263842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma</span></div><div class="casAuthors">Vogl, Dan T.; Martin, Thomas G.; Vij, Ravi; Hari, Parameswaran; Mikhael, Joseph R.; Siegel, David; Wu, Ka Lung; Delforge, Michel; Gasparetto, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1872-1879</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Delanzomib (CEP-18770), a reversible P2 threonine boronic acid proteasome (β5/β1 subunits) inhibitor that showed promising anti-myeloma effects in preclin. studies, was investigated in a single-agent multicenter phase I/II study in patients with relapsed/refractory myeloma.  Sixty-one patients (17 during dose escalation; 44 in the expansion cohort) received delanzomib on days 1, 8, and 15 in 28-d cycles; 47 received the max. tolerated dose (MTD), 2.1 mg/m2.  Dose-limiting toxicities (DLTs) at 2.4 mg/m2 were rash and thrombocytopenia.  At the MTD, the most prominent adverse events were nausea, vomiting, anorexia, fatigue, and pyrexia; grade 3/4 thrombocytopenia and neutropenia occurred in 53 and 23% of patients, resp.  Peripheral neuropathy (21%) was limited to grades 1/2.  At the MTD, 26 patients (55%) had stable disease and four (9%) had a partial response (PR).  Median time to progression (TTP) was 2.5 mo across the cohort.  Based upon the efficacy results, development of delanzomib for myeloma was discontinued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrogIPOb5BLBLVg90H21EOLACvtfcHk0lhI7ww_epEdDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gt7k%253D&md5=a1abbcc8ecd992e0e63256302d6d3eb1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1263842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1263842%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DMikhael%26aufirst%3DJ.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DDelforge%26aufirst%3DM.%26aulast%3DGasparetto%26aufirst%3DC.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520the%2520novel%2520proteasome%2520inhibitor%2520delanzomib%2520%2528CEP-18770%2529%2520for%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1872%26epage%3D1879%26doi%3D10.1080%2F10428194.2016.1263842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harshbarger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human 20S proteasome in complex with carfilzomib</span>. <i>Structure (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.str.2014.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25599644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=418-424&author=W.+Harshbargerauthor=C.+Millerauthor=C.+Diedrichauthor=J.+Sacchettini&title=Crystal+structure+of+the+human+20S+proteasome+in+complex+with+carfilzomib&doi=10.1016%2Fj.str.2014.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib</span></div><div class="casAuthors">Harshbarger, Wayne; Miller, Chase; Diedrich, Chandler; Sacchettini, James</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, resp.  Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites.  Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes.  In addn., comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes.  Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQfIgWQjhexbVg90H21EOLACvtfcHk0ljkJQlowc-4yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D&md5=0249966770dad6c25b7844fb1cea59b1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DHarshbarger%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DDiedrich%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%252020S%2520proteasome%2520in%2520complex%2520with%2520carfilzomib%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D23%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.str.2014.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comenzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molineaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span> <span> </span><span class="NLM_article-title">A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4830</span>– <span class="NLM_lpage">4840</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-11-3007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22761464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4830-4840&author=M.+Alsinaauthor=S.+Trudelauthor=R.+Furmanauthor=P.+Rosenauthor=O.+O%E2%80%99Connorauthor=R.+Comenzoauthor=A.+Wongauthor=L.+Kunkelauthor=C.+Molineauxauthor=A.+Goy&title=A+phase+I+single-agent+study+of+twice-weekly+consecutive-day+dosing+of+the+proteasome+inhibitor+carfilzomib+in+patients+with+relapsed+or+refractory+multiple+myeloma+or+lymphoma&doi=10.1158%2F1078-0432.CCR-11-3007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma</span></div><div class="casAuthors">Alsina, Melissa; Trudel, Suzanne; Furman, Richard R.; Rosen, Peter J.; O'Connor, Owen A.; Comenzo, Raymond L.; Wong, Alvin; Kunkel, Lori A.; Molineaux, Christopher J.; Goy, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4830-4840</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Carfilzomib is a next-generation, selective, proteasome inhibitor with clin. activity in relapsed and/or refractory multiple myeloma.  The objectives of this phase I study were to establish the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of escalating doses of carfilzomib in patients with relapsed or refractory hematol. malignancies.  Exptl. design: Carfilzomib (doses ranging from 1.2-27 mg/m2) was administered i.v. on 2 consecutive days for 3 wk of a 4-wk cycle.  Single-agent dose escalation (n = 37) was followed by a dose-expansion phase (n = 11) that comprised 2 cohorts (carfilzomib or carfilzomib + dexamethasone).  During dose expansion, carfilzomib was administered starting with 20 mg/m2 during the first week (days 1, 2) and then escalated to 27 mg/m2 thereafter.  Results: A max. tolerated dose (MTD) was not reached during dose escalation.  Dosing in the expansion cohort was well tolerated.  Adverse events were manageable and primarily of grade I or II.  The main hematol. adverse events of ≥ grade III were anemia and thrombocytopenia.  Notably, there were no observations of grade III or more peripheral neuropathy.  Carfilzomib was cleared rapidly with an elimination half-life of less than 30 min but still induced dose-dependent inhibition of the 20S chymotrypsin-like proteasome activity.  At doses of 15 to 27 mg/m2, there was evidence of activity among patients with multiple myeloma and with non-Hodgkin lymphoma.  Conclusions: Escalated dosing of carfilzomib on a schedule of 2 consecutive days for 3 wk of a 4-wk cycle was tolerable and showed promising activity.  This dose regimen has been selected for ongoing and future clin. studies, including PX-171-003A1 and the pivotal trial ASPIRE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_a1xG-rD-LVg90H21EOLACvtfcHk0ljkJQlowc-4yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsbzE&md5=cb6a2086f5c90d9af01fb71884004762</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3007%26sid%3Dliteratum%253Aachs%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%26aulast%3DComenzo%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DKunkel%26aufirst%3DL.%26aulast%3DMolineaux%26aufirst%3DC.%26aulast%3DGoy%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%2520single-agent%2520study%2520of%2520twice-weekly%2520consecutive-day%2520dosing%2520of%2520the%2520proteasome%2520inhibitor%2520carfilzomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%2520or%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4830%26epage%3D4840%26doi%3D10.1158%2F1078-0432.CCR-11-3007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elofsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">10403</span>– <span class="NLM_lpage">10408</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.18.10403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1073%2Fpnas.96.18.10403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10468620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10403-10408&author=L.+Mengauthor=R.+Mohanauthor=B.+Kwokauthor=M.+Elofssonauthor=N.+Sinauthor=C.+Crews&title=Epoxomicin%2C+a+potent+and+selective+proteasome+inhibitor%2C+exhibits+in+vivo+antiinflammatory+activity&doi=10.1073%2Fpnas.96.18.10403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</span></div><div class="casAuthors">Meng, Lihao; Mohan, Royce; Kwok, Benjamin H. B.; Elofsson, Mikael; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10403-10408</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The proteasome (multicatalytic protease) regulates cellular processes as diverse as cell cycle progression and NF-κB activation.  The potent antitumor natural product epoxomicin specifically targets the proteasome.  Using biotinylated epoxomicin as a mol. probe showed that epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome.  Enzymic analyses with purified bovine erythrocyte proteasome revealed that epoxomicin potently inhibited primarily the chymotrypsin-like activity.  The trypsin-like and peptidyl-glutamyl peptide hydrolyzing catalytic activities were also inhibited at 100- and 1000-fold slower rates, resp.  In contrast to peptide aldehyde proteasome inhibitors, epoxomicin did not inhibit the nonproteasomal proteases, such as trypsin, chymotrypsin, papain, calpain, and cathepsin B, at concns. up to 50 μM.  Epoxomicin was a more potent inhibitor of the chymotrypsin-like activity than lactacystin and the peptide vinyl sulfone NLVS.  Epoxomicin also effectively inhibited the NF-κB activation in vitro and potently blocked the in vivo inflammation in the murine ear edema assay.  The results define epoxomicin as a novel proteasome inhibitor that may be useful in exploring the role of proteasome in various in vivo and in vitro systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXsPAKuQJ_LVg90H21EOLACvtfcHk0lh6eK4L-HB0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFentLk%253D&md5=df0b5cdcccf546d60dc4e01d885d554b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.10403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.10403%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKwok%26aufirst%3DB.%26aulast%3DElofsson%26aufirst%3DM.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DEpoxomicin%252C%2520a%2520potent%2520and%2520selective%2520proteasome%2520inhibitor%252C%2520exhibits%2520in%2520vivo%2520antiinflammatory%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D10403%26epage%3D10408%26doi%3D10.1073%2Fpnas.96.18.10403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strader, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanan-Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3281</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-01-065888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1182%2Fblood-2007-01-065888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17591945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yqur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3281-3290&author=D.+J.+Kuhnauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=J.+S.+Straderauthor=K.+D.+Shenkauthor=C.+M.+Sunauthor=S.+D.+Demoauthor=M.+K.+Bennettauthor=F.+W.+van+Leeuwenauthor=A.+A.+Chanan-Khanauthor=R.+Z.+Orlowski&title=Potent+activity+of+carfilzomib%2C+a+novel%2C+irreversible+inhibitor+of+the+ubiquitin-proteasome+pathway%2C+against+preclinical+models+of+multiple+myeloma&doi=10.1182%2Fblood-2007-01-065888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</span></div><div class="casAuthors">Kuhn, Deborah J.; Chen, Qing; Voorhees, Peter M.; Strader, John S.; Shenk, Kevin D.; Sun, Congcong M.; Demo, Susan D.; Bennett, Mark K.; van Leeuwen, Fijs W. B.; Chanan-Khan, Asher A.; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3281-3290</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a 1st-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM).  However, many patients have disease that does not respond to bortezomib, whereas others develop resistance, suggesting the need for other inhibitors with enhanced activity.  We therefore evaluated a novel, irreversible, epoxomicin-related proteasome inhibitor, carfilzomib.  In models of MM, this agent potently bound and specifically inhibited the chymotrypsin-like proteasome and immunoproteasome activities, resulting in accumulation of ubiquitinated substrates.  Carfilzomib induced a dose- and time-dependent inhibition of proliferation, ultimately leading to apoptosis.  Programmed cell death was assocd. with activation of c-Jun-N-terminal kinase, mitochondrial membrane depolarization, release of cytochrome c, and activation of both intrinsic and extrinsic caspase pathways.  This agent also inhibited proliferation and activated apoptosis in patient-derived MM cells and neoplastic cells from patients with other hematol. malignancies.  Importantly, carfilzomib showed increased efficacy compared with bortezomib and was active against bortezomib-resistant MM cell lines and samples from patients with clin. bortezomib resistance.  Carfilzomib also overcame resistance to other conventional agents and acted synergistically with dexamethasone to enhance cell death.  Taken together, these data provide a rationale for the clin. evaluation of carfilzomib in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96EI0UpzMFrVg90H21EOLACvtfcHk0lh6eK4L-HB0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yqur3L&md5=e8b3c1eff57c7613bebb921bdef8f87d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-01-065888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-01-065888%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DStrader%26aufirst%3DJ.%2BS.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DPotent%2520activity%2520of%2520carfilzomib%252C%2520a%2520novel%252C%2520irreversible%2520inhibitor%2520of%2520the%2520ubiquitin-proteasome%2520pathway%252C%2520against%2520preclinical%2520models%2520of%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3281%26epage%3D3290%26doi%3D10.1182%2Fblood-2007-01-065888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korde, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roschewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manasanch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tageja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazandjian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailankody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulquin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuchlinski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamping, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounden, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braylan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler-Stevenson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdziel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choyke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landgren, O.</span></span> <span> </span><span class="NLM_article-title">Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma</span>. <i>JAMA oncology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1001%2Fjamaoncol.2015.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26181891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=746-754&author=N.+Kordeauthor=M.+Roschewskiauthor=A.+Zingoneauthor=M.+Kwokauthor=E.+Manasanchauthor=M.+Bhutaniauthor=N.+Tagejaauthor=D.+Kazandjianauthor=S.+Mailankodyauthor=P.+Wuauthor=C.+Morrisonauthor=R.+Costelloauthor=Y.+Zhangauthor=D.+Burtonauthor=M.+Mulquinauthor=D.+Zuchlinskiauthor=L.+Lampingauthor=A.+Carpenterauthor=Y.+Wallauthor=G.+Carterauthor=S.+Cunninghamauthor=V.+Goundenauthor=T.+Sissungauthor=C.+Peerauthor=I.+Maricauthor=K.+Calvoauthor=R.+Braylanauthor=C.+Yuanauthor=M.+Stetler-Stevensonauthor=D.+Arthurauthor=K.+Kongauthor=L.+Wengauthor=M.+Fahamauthor=L.+Lindenbergauthor=K.+Kurdzielauthor=P.+Choykeauthor=S.+Steinbergauthor=W.+Figgauthor=O.+Landgren&title=Treatment+with+carfilzomib-lenalidomide-dexamethasone+with+lenalidomide+extension+in+patients+with+smoldering+or+newly+diagnosed+multiple+myeloma&doi=10.1001%2Fjamaoncol.2015.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma</span></div><div class="casAuthors">Korde Neha; Landgren Ola; Roschewski Mark; Zingone Adriana; Kwok Mary; Kazandjian Dickran; Wu Peter; Morrison Candis; Costello Rene; Zhang Yong; Burton Debra; Mulquin Marcia; Zuchlinski Diamond; Lamping Liz; Carpenter Ashley; Wall Yvonne; Carter George; Cunningham Schuyler C; Manasanch Elisabet E; Bhutani Manisha; Tageja Nishant; Mailankody Sham; Gounden Verena; Maric Irina; Calvo Katherine R; Braylan Raul; Sissung Tristan M; Peer Cody; Figg William; Yuan Constance; Stetler-Stevenson Maryalice; Arthur Diane C; Kong Katherine A; Weng Li; Faham Malek; Lindenberg Liza; Kurdziel Karen; Choyke Peter; Steinberg Seth M</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">746-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM).  It is important to gain an understanding of this combination's tolerability and impact on minimal residual disease (MRD) negativity because this end point has been associated with improved survival.  OBJECTIVE:  To assess the safety and efficacy of carfilzomib-lenalidomide-dexamethasone therapy in NDMM and high-risk smoldering multiple myeloma (SMM).  DESIGN, SETTING, AND PARTICIPANTS:  Clinical and correlative pilot study at the National Institutes of Health Clinical Center.  Patients with NDMM or high-risk SMM were enrolled between July 11, 2011, and October 9, 2013.  Median follow-up was 17.3 (NDMM) and 15.9 months (SMM).  INTERVENTIONS:  Eight 28-day cycles were composed of carfilzomib 20/36 mg/m2 on days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on days 1 through 21; and dexamethasone 20/10 mg (cycles 1-4/5-8) on days 1, 2, 8, 9, 15, 16, 22, and 23.  Patients who achieved at least stable disease subsequently received 24 cycles of lenalidomide extended dosing.  MAIN OUTCOMES AND MEASURES:  Primary end points were neuropathy of grade 3 or greater (NDMM) and at least very good partial response rates (SMM).  Minimal residual disease was also assessed.  RESULTS:  Of 45 patients with NDMM, none had neuropathy of grade 3 or greater.  Of 12 patients with high-risk SMM, the most common of any-grade adverse events were lymphopenia (12 [100%]) and gastrointestinal disorders (11 [92%]).  All patients with SMM achieved at least a very good partial response during the study period.  Among the 28 patients with NDMM and the 12 with SMM achieving at least a near-complete response, MRD negativity was found in 28 of 28 (100% [95% CI, 88%-100%]), 11 of 12 (92% [95% CI, 62%-100%]) (multiparametric flow cytometry), 14 of 21 (67% [95% CI, 43%-85%]), and 9 of 12 (75% [95% CI, 43%-94%]) (next-generation sequencing), respectively.  In patients with NDMM, 12-month progression-free survival for MRD-negative vs MRD-positive status by flow cytometry and next-generation sequencing was 100% vs 79% (95% CI, 47%-94%; P < .001) and 100% vs 95% (95% CI, 75%-99%; P = .02), respectively.  CONCLUSIONS AND RELEVANCE:  Carfilzomib-lenalidomide-dexamethasone therapy is tolerable and demonstrates high rates of MRD negativity in NDMM, translating into longer progression-free survival in patients achieving MRD negativity.  Carfilzomib-lenalidomide-dexamethasone therapy also demonstrates efficacy in high-risk SMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIQnEjFT74UmGmni0r9GoKfW6udTcc2ebLgh0jj1R4ULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVygtg%253D%253D&md5=f4c70f4a9eeaaccf7da444031d4a4479</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.2010%26sid%3Dliteratum%253Aachs%26aulast%3DKorde%26aufirst%3DN.%26aulast%3DRoschewski%26aufirst%3DM.%26aulast%3DZingone%26aufirst%3DA.%26aulast%3DKwok%26aufirst%3DM.%26aulast%3DManasanch%26aufirst%3DE.%26aulast%3DBhutani%26aufirst%3DM.%26aulast%3DTageja%26aufirst%3DN.%26aulast%3DKazandjian%26aufirst%3DD.%26aulast%3DMailankody%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMorrison%26aufirst%3DC.%26aulast%3DCostello%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DD.%26aulast%3DMulquin%26aufirst%3DM.%26aulast%3DZuchlinski%26aufirst%3DD.%26aulast%3DLamping%26aufirst%3DL.%26aulast%3DCarpenter%26aufirst%3DA.%26aulast%3DWall%26aufirst%3DY.%26aulast%3DCarter%26aufirst%3DG.%26aulast%3DCunningham%26aufirst%3DS.%26aulast%3DGounden%26aufirst%3DV.%26aulast%3DSissung%26aufirst%3DT.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DMaric%26aufirst%3DI.%26aulast%3DCalvo%26aufirst%3DK.%26aulast%3DBraylan%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DStetler-Stevenson%26aufirst%3DM.%26aulast%3DArthur%26aufirst%3DD.%26aulast%3DKong%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DL.%26aulast%3DFaham%26aufirst%3DM.%26aulast%3DLindenberg%26aufirst%3DL.%26aulast%3DKurdziel%26aufirst%3DK.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DFigg%26aufirst%3DW.%26aulast%3DLandgren%26aufirst%3DO.%26atitle%3DTreatment%2520with%2520carfilzomib-lenalidomide-dexamethasone%2520with%2520lenalidomide%2520extension%2520in%2520patients%2520with%2520smoldering%2520or%2520newly%2520diagnosed%2520multiple%2520myeloma%26jtitle%3DJAMA%2520oncology%26date%3D2015%26volume%3D1%26spage%3D746%26epage%3D754%26doi%3D10.1001%2Fjamaoncol.2015.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dajee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3038</span>, <span class="refDoi"> DOI: 10.1021/jm801329v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801329v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3028-3038&author=H.+Zhouauthor=M.+Aujayauthor=M.+Bennettauthor=M.+Dajeeauthor=S.+Demoauthor=Y.+Fangauthor=M.+Hoauthor=J.+Jiangauthor=C.+Kirkauthor=G.+Laidigauthor=E.+Lewisauthor=Y.+Luauthor=T.+Muchamuelauthor=F.+Parlatiauthor=E.+Ringauthor=K.+Shenkauthor=J.+Shieldsauthor=P.+Shwonekauthor=T.+Stantonauthor=C.+Sunauthor=C.+Sylvainauthor=T.+Wooauthor=J.+Yang&title=Design+and+synthesis+of+an+orally+bioavailable+and+selective+peptide+epoxyketone+proteasome+inhibitor+%28PR-047%29&doi=10.1021%2Fjm801329v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)</span></div><div class="casAuthors">Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; Lewis, Evan R.; Lu, Yan; Muchamuel, Tony; Parlati, Francesco; Ring, Eileen; Shenk, Kevin D.; Shields, Jamie; Shwonek, Peter J.; Stanton, Timothy; Sun, Congcong M.; Sylvain, Catherine; Woo, Tina M.; Yang, Jinfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epoxypeptides such as I are prepd. as carfilzomib analogs and proteasome inhibitors for use as antitumor agents; the inhibition of human 20S proteasomes and of the growth of multidrug-resistant and nonresistant cancer cells by selected compds. and their stabilities in simulated gastric and intestinal fluids and in liver microsomes are detd.  I selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrated an abs. bioavailability of up to 39% in rodents and dogs.  I is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equiv. to i.v. administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models.  I is prepd. in eight steps (longest linear sequence) from Cbz-L-phenylalanine, Boc-O-methyl-L-serine, 2-methyl-5-thiazolecarboxylic acid, and isopropenylmagnesium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNBIBwb8w47Vg90H21EOLACvtfcHk0lj_fiyKw6cG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D&md5=688c8d0942539bab2e50617d083bf89a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm801329v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801329v%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DLaidig%26aufirst%3DG.%26aulast%3DLewis%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRing%26aufirst%3DE.%26aulast%3DShenk%26aufirst%3DK.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DStanton%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520and%2520selective%2520peptide%2520epoxyketone%2520proteasome%2520inhibitor%2520%2528PR-047%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3028%26epage%3D3038%26doi%3D10.1021%2Fjm801329v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurchla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Gomez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica-Worms, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandiella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garayoa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weilbaecher, K.</span></span> <span> </span><span class="NLM_article-title">The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fleu.2012.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22763387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Gnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=430-440&author=M.+Hurchlaauthor=A.+Garcia-Gomezauthor=M.+Hornickauthor=E.+Ocioauthor=A.+Liauthor=J.+Blancoauthor=L.+Collinsauthor=C.+Kirkauthor=D.+Piwnica-Wormsauthor=R.+Vijauthor=M.+Tomassonauthor=A.+Pandiellaauthor=J.+San+Miguelauthor=M.+Garayoaauthor=K.+Weilbaecher&title=The+epoxyketone-based+proteasome+inhibitors+carfilzomib+and+orally+bioavailable+oprozomib+have+anti-resorptive+and+bone-anabolic+activity+in+addition+to+anti-myeloma+effects&doi=10.1038%2Fleu.2012.183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects</span></div><div class="casAuthors">Hurchla, M. A.; Garcia-Gomez, A.; Hornick, M. C.; Ocio, E. M.; Li, A.; Blanco, J. F.; Collins, L.; Kirk, C. J.; Piwnica-Worms, D.; Vij, R.; Tomasson, M. H.; Pandiella, A.; San Miguel, J. F.; Garayoa, M.; Weilbaecher, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting pathol. bone destruction.  In clin. trials, carfilzomib, a next generation epoxyketone-based irreversible PI, has exhibited potent anti-myeloma efficacy and decreased side effects compared with bortezomib.  Carfilzomib and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following continual or transient treatment mimicking in vivo pharmacokinetics.  Interactions between myeloma cells and the bone marrow (BM) microenvironment augment the no. and activity of bone-resorbing osteoclasts (OCs) while inhibiting bone-forming osteoblasts (OBs), resulting in increased tumor growth and osteolytic lesions.  At clin. relevant concns., carfilzomib and oprozomib directly inhibited OC formation and bone resorption in vitro, while enhancing osteogenic differentiation and matrix mineralization.  Accordingly, carfilzomib and oprozomib increased trabecular bone vol., decreased bone resorption and enhanced bone formation in non-tumor bearing mice.  Finally, in mouse models of disseminated MM, the epoxyketone-based PIs decreased murine 5TGM1 and human RPMI-8226 tumor burden and prevented bone loss.  These data demonstrate that, in addn. to anti-myeloma properties, carfilzomib and oprozomib effectively shift the bone microenvironment from a catabolic to an anabolic state and, similar to bortezomib, may decrease skeletal complications of MM.  Leukemia (2013) 27, 430-440; doi:10.1038/leu.2012.183; published online 27 July 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVyg3b1Z0_G7Vg90H21EOLACvtfcHk0lj_fiyKw6cG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Gnu7Y%253D&md5=00a1f6b061368a1e0c9b0ca3e6942ab3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.183%26sid%3Dliteratum%253Aachs%26aulast%3DHurchla%26aufirst%3DM.%26aulast%3DGarcia-Gomez%26aufirst%3DA.%26aulast%3DHornick%26aufirst%3DM.%26aulast%3DOcio%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DBlanco%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DL.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DPiwnica-Worms%26aufirst%3DD.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DTomasson%26aufirst%3DM.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%26aulast%3DGarayoa%26aufirst%3DM.%26aulast%3DWeilbaecher%26aufirst%3DK.%26atitle%3DThe%2520epoxyketone-based%2520proteasome%2520inhibitors%2520carfilzomib%2520and%2520orally%2520bioavailable%2520oprozomib%2520have%2520anti-resorptive%2520and%2520bone-anabolic%2520activity%2520in%2520addition%2520to%2520anti-myeloma%2520effects%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fleu.2012.183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillenwater, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1007/s10637-016-0327-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs10637-016-0327-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26924128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=216-224&author=J.+R.+Infanteauthor=D.+S.+Mendelsonauthor=H.+A.+Burrisauthor=J.+C.+Bendellauthor=A.+W.+Tolcherauthor=M.+S.+Gordonauthor=H.+H.+Gillenwaterauthor=S.+Arastu-Kapurauthor=H.+L.+Wongauthor=K.+P.+Papadopoulos&title=A+first-in-human+dose-escalation+study+of+the+oral+proteasome+inhibitor+oprozomib+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-016-0327-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span></div><div class="casAuthors">Infante, Jeffrey R.; Mendelson, David S.; Burris, Howard A., III; Bendell, Johanna C.; Tolcher, Anthony W.; Gordon, Michael S.; Gillenwater, Heidi H.; Arastu-Kapur, Shirin; Wong, Hansen L.; Papadopoulos, Kyriakos P.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To det. the dose-limiting toxicities (DLTs), max. tolerated dose (MTD), safety, and pharmacokinetic and pharmacodynamic profiles of the tripeptide epoxyketone proteasome inhibitor oprozomib in patients with advanced refractory or recurrent solid tumors.  Patients received escalating once daily (QD) or split doses of oprozomib on days 1-5 of 14-day cycles (C).  The split-dose arm was implemented and compared in fasted (C1) and fed (C2) states.  Pharmacokinetic samples were collected during C1 and C2.  Proteasome inhibition was evaluated in red blood cells and peripheral blood mononuclear cells.  Forty-four patients (QD, n = 25; split dose, n = 19) were enrolled.  The most common primary tumor types were non-small cell lung cancer (18 %) and colorectal cancer (16%).  In the 180-mg QD cohort, two patients experienced DLTs: grade 3 vomiting and dehydration; grade 3 hypophosphatemia (n = 1 each).  In the split-dose group, three DLTs were obsd. 180-mg cohort: grade 3 hypophosphatemia; 210-mg cohort: grade 5 gastrointestinal hemorrhage and grade 3 hallucinations (n = 1 each).  In the QD and split-dose groups, the MTD was 150 and 180 mg, resp.  Common adverse events (all grades) included nausea (91%), vomiting (86%), and diarrhea (61%).  Peak concns. and total exposure of oprozomib generally increased with the increasing dose.  Oprozomib induced dose-dependent proteasome inhibition.  Best response was stable disease.  While generally low-grade, clin. relevant gastrointestinal toxicities occurred frequently with this oprozomib formulation.  Despite dose-dependent increases in pharmacokinetics and pharmacodynamics, single-agent oprozomib had minimal antitumor activity in this patient population with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW2c034hrkubVg90H21EOLACvtfcHk0lh8jxdrHecBGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D&md5=e54838bb160c0886d08c5d0b8cb81a6a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0327-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0327-x%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMendelson%26aufirst%3DD.%2BS.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DGillenwater%26aufirst%3DH.%2BH.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%2BL.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26atitle%3DA%2520first-in-human%2520dose-escalation%2520study%2520of%2520the%2520oral%2520proteasome%2520inhibitor%2520oprozomib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26spage%3D216%26epage%3D224%26doi%3D10.1007%2Fs10637-016-0327-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funakoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, T.</span></span> <span> </span><span class="NLM_article-title">A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2003.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bcp.2003.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=14698035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvF2qs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2004&pages=227-234&author=A.+Asaiauthor=T.+Tsujitaauthor=S.+V.+Sharmaauthor=Y.+Yamashitaauthor=S.+Akinagaauthor=M.+Funakoshiauthor=H.+Kobayashiauthor=T.+Mizukami&title=A+new+structural+class+of+proteasome+inhibitors+identified+by+microbial+screening+using+yeast-based+assay&doi=10.1016%2Fj.bcp.2003.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay</span></div><div class="casAuthors">Asai, Akira; Tsujita, Tetsuya; Sharma, Sreenath V.; Yamashita, Yoshinori; Akinaga, Shiro; Funakoshi, Minoru; Kobayashi, Hideki; Mizukami, Tamio</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">227-234</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A yeast-based growth interference assay was developed utilizing a yeast strain in which expression of Xenopus cyclin A1 was induced to elevate cell division cycle 28 (Cdc28) kinase activity.  Since the hyperactivation of Cdc28 kinase in yeast results in a growth-arrest phenotype, compds. which could rescue the cyclin A1-induced growth arrest might be potential new, antitumor drug candidates acting on the cyclin-dependent, kinase-mediated, cell cycle regulation pathway.  In the course of our microbial screening program, the new Streptomyces metabolites, belactosins, were identified.  As reported previously, belactosin A induced cell cycle arrest at G2/M phase in human cancer cells.  However, the mol. mechanism of action was unknown.  We herein demonstrate the proteasome inhibition by belactosin A.  Belactosin A did not inhibit yeast Cdc28 kinase and human cyclin-dependent kinase in vitro.  On the other hand, it inhibited the chymotrypsin-like activity of the rabbit 20S proteasome.  From the initial SAR studies, we identified a hydrophobic belactosin A deriv., KF33955, which exhibited a 100-fold greater growth-inhibitory activity against HeLa S3 cells than belactosin A, presumably due to its higher cell permeability.  The biochem. anal. using KF33955 suggested that the proteasome inhibitory activity of KF33955 were irreversible and required the β-lactone moiety to inhibit the proteasome.  KF33955 increased the intracellular levels of protein ubiquitination in NIH3T3 cells.  In addn., KF33955 treatment resulted in the accumulation of known proteasome substrates in HeLa S3 cells.  These results identify belactosin A as a useful lead compd. to target proteasome for the treatment of disease whose etiol. is dependent on the unregulated ubiquitin-proteasome pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfEKiU4_45bVg90H21EOLACvtfcHk0lh8jxdrHecBGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvF2qs7c%253D&md5=54982fb9e94876de45d1cc2d6a8888a7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2003.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2003.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DTsujita%26aufirst%3DT.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DFunakoshi%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DMizukami%26aufirst%3DT.%26atitle%3DA%2520new%2520structural%2520class%2520of%2520proteasome%2520inhibitors%2520identified%2520by%2520microbial%2520screening%2520using%2520yeast-based%2520assay%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D67%26spage%3D227%26epage%3D234%26doi%3D10.1016%2Fj.bcp.2003.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, B. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">5136</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1021/ja058320b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja058320b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28XislOgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=5136-5141&author=M.+Grollauthor=R.+Huberauthor=B.+C.+Potts&title=Crystal+structures+of+salinosporamide+A+%28NPI-0052%29+and+B+%28NPI-0047%29+in+complex+with+the+20S+proteasome+reveal+important+consequences+of+beta-lactone+ring+opening+and+a+mechanism+for+irreversible+binding&doi=10.1021%2Fja058320b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of β-Lactone Ring Opening and a Mechanism for Irreversible Binding</span></div><div class="casAuthors">Groll, Michael; Huber, Robert; Potts, Barbara C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5136-5141</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The crystal structures of the yeast 20S proteasome core particle (CP) in complex with Salinosporamides A (NPI-0052; 1) and B (4) were solved at <3 Å resoln.  Each ligand is covalently bound to Thr1Oγ via an ester linkage to the carbonyl derived from the β-lactone ring of the inhibitor.  In the case of 1, nucleophilic addn. to the β-lactone ring is followed by addn. of C-3O to the chloroethyl group, giving rise to a cyclic ether.  The crystal structures were compared to that of the omuralide/CP structure solved previously, and the collective data provide new insights into the mechanism of inhibition and irreversible binding of 1.  Upon opening of the β-lactone ring, C-3O assumes the position occupied by a water mol. in the unligated enzyme and hinders deacylation of the enzyme-ligand complex.  Furthermore, the resulting protonation state of Thr1NH2 deactivates the catalytic N-terminus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbVM4Pd5jUeLVg90H21EOLACvtfcHk0lighin-5vrm-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislOgu70%253D&md5=66d24b5c6af2e0542b1682fe5c493253</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fja058320b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja058320b%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DPotts%26aufirst%3DB.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520salinosporamide%2520A%2520%2528NPI-0052%2529%2520and%2520B%2520%2528NPI-0047%2529%2520in%2520complex%2520with%2520the%252020S%2520proteasome%2520reveal%2520important%2520consequences%2520of%2520beta-lactone%2520ring%2520opening%2520and%2520a%2520mechanism%2520for%2520irreversible%2520binding%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D5136%26epage%3D5141%26doi%3D10.1021%2Fja058320b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainwaring, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underhill, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannell, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span> <span> </span><span class="NLM_article-title">Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052–102 final results</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4566</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-15-2616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27117181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCkurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4559-4566&author=S.+J.+Harrisonauthor=P.+Mainwaringauthor=T.+Priceauthor=M.+J.+Millwardauthor=P.+Padrikauthor=C.+R.+Underhillauthor=P.+K.+Cannellauthor=S.+D.+Reichauthor=M.+Trikhaauthor=A.+Spencer&title=Phase+I+clinical+trial+of+marizomib+%28NPI-0052%29+in+patients+with+advanced+malignancies+including+multiple+myeloma%3A+study+NPI-0052%E2%80%93102+final+results&doi=10.1158%2F1078-0432.CCR-15-2616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results</span></div><div class="casAuthors">Harrison, Simon J.; Mainwaring, Paul; Price, Timothy; Millward, Michael J.; Padrik, Peeter; Underhill, Craig R.; Cannell, Paul K.; Reich, Steven D.; Trikha, Mohit; Spencer, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4559-4566</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors.  Exptl. Design: Phase I study (NPI-0052-102) evaluated the MTD, pharmacokinetics, and pharmacodynamics of marizomib i.v. on two dosing schedules.  Results: Forty-two patients with advanced malignancies received Schedule A (0.1-0.9 mg/m2 over 1-10 min on days 1, 8, 15 in 4-wk cycles); 44 patients with relapsed and/or refractory multiple myeloma (RRMM) and other hematol. malignancies received Schedule B (0.075-0.6 mg/m2 over 1 min to 2 h on days 1, 4, 8, 11, in 3-wk cycles).  The Schedule A recommended phase II dose was 0.7 mg/m2 over 10 min; Schedule B was 0.5 mg/m2 over 2 h.  The most common (>25% of patients) related adverse events were fatigue, nausea, diarrhea, and infusion site pain (Schedule A); and fatigue (Schedule B).  Overall response rate of 11% was seen in 27 efficacy-evaluable RRMM Schedule B patients (1 very good partial response, 3 partial responses, 4 minimal responses, and 12 stable disease).  One Schedule A patient with transformed marginal zone lymphoma had complete response.  Marizomib has a short half-life (<30 min), with high vol. of distribution (∼15-416 L) and clearance (∼0.9-22 L/min).  Conclusions: Marizomib does not exhibit the severe peripheral neuropathy or hematol. toxicity obsd. with other proteasome inhibitors.  Marizomib was generally well tolerated with low-dose dexamethasone, demonstrated activity in heavily pretreated RRMM patients, and warrants further evaluation.  Clin Cancer Res; 22(18); 4559-66. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGIG3zJzG8qrVg90H21EOLACvtfcHk0lighin-5vrm-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCkurrN&md5=728da81129d49246b6d42e5aa7b2adfb</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2616%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DS.%2BJ.%26aulast%3DMainwaring%26aufirst%3DP.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DMillward%26aufirst%3DM.%2BJ.%26aulast%3DPadrik%26aufirst%3DP.%26aulast%3DUnderhill%26aufirst%3DC.%2BR.%26aulast%3DCannell%26aufirst%3DP.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BD.%26aulast%3DTrikha%26aufirst%3DM.%26aulast%3DSpencer%26aufirst%3DA.%26atitle%3DPhase%2520I%2520clinical%2520trial%2520of%2520marizomib%2520%2528NPI-0052%2529%2520in%2520patients%2520with%2520advanced%2520malignancies%2520including%2520multiple%2520myeloma%253A%2520study%2520NPI-0052%25E2%2580%2593102%2520final%2520results%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D4559%26epage%3D4566%26doi%3D10.1158%2F1078-0432.CCR-15-2616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span> <span> </span><span class="NLM_article-title">Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.1111/bjh.14113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1111%2Fbjh.14113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27161872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=711-720&author=N.+Levinauthor=A.+Spencerauthor=S.+Harrisonauthor=D.+Chauhanauthor=F.+Burrowsauthor=K.+Andersonauthor=S.+Reichauthor=P.+Richardsonauthor=M.+Trikha&title=Marizomib+irreversibly+inhibits+proteasome+to+overcome+compensatory+hyperactivation+in+multiple+myeloma+and+solid+tumour+patients&doi=10.1111%2Fbjh.14113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients</span></div><div class="casAuthors">Levin, Nancy; Spencer, Andrew; Harrison, Simon J.; Chauhan, Dharminder; Burrows, Francis J.; Anderson, Kenneth C.; Reich, Steven D.; Richardson, Paul G.; Trikha, Mohit</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">711-720</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly obsd.  All clin. stage PIs effectively inhibit chymotrypsin-like (CT-L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase-like (C-L) and trypsin-like (T-L) subunits, in response to CT-L blockade.  Marizomib (MRZ), an irreversible PI that potently inhibits all three 20S proteasome subunits with a specificity distinct from other PIs, is currently in development for treatment of MM and malignant glioma.  The pan-proteasome pharmacodynamic activity in packed whole blood and peripheral blood mononuclear cells was measured in two studies in patients with advanced solid tumors and haematol. malignancies.  Functional inhibition of all proteasome subunits was achieved with once- or twice-weekly MRZ dosing; 100% inhibition of CT-L was frequently achieved within one cycle at therapeutic doses.  Concomitantly, C-L and T-L activities were either unaffected or increased, suggesting compensatory hyperactivation of these subunits.  Importantly, this response was overcome by continued administration of MRZ, with robust inhibition of T-L and C-L (up to 80% and 50%, resp.) by the end of Cycle 2 and maintained thereafter.  This enhanced proteasome inhibition was independent of tumor type and may underlie the clin. activity of MRZ in patients resistant to other PIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGGdyJ_2yUYbVg90H21EOLACvtfcHk0lighin-5vrm-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrvL&md5=fc63e2622217b316eddf1245eabcac11</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14113%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DN.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DReich%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DTrikha%26aufirst%3DM.%26atitle%3DMarizomib%2520irreversibly%2520inhibits%2520proteasome%2520to%2520overcome%2520compensatory%2520hyperactivation%2520in%2520multiple%2520myeloma%2520and%2520solid%2520tumour%2520patients%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2016%26volume%3D174%26spage%3D711%26epage%3D720%26doi%3D10.1111%2Fbjh.14113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchier-Hayes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, J.</span></span> <span> </span><span class="NLM_article-title">Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">18953</span>, <span class="refDoi"> DOI: 10.1038/srep18953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fsrep18953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26804704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=18953&author=C.+Mantonauthor=B.+Johnsonauthor=M.+Singhauthor=C.+Baileyauthor=L.+Bouchier-Hayesauthor=J.+Chandra&title=Induction+of+cell+death+by+the+novel+proteasome+inhibitor+marizomib+in+glioblastoma+in+vitro+and+in+vivo&doi=10.1038%2Fsrep18953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo</span></div><div class="casAuthors">Manton, Christa A.; Johnson, Blake; Singh, Melissa; Bailey, Cavan P.; Bouchier-Hayes, Lisa; Chandra, Joya</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18953</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New therapies for glioblastoma (GBM) are needed, as five-year survival is <10%.  The proteasome inhibitor marizomib (MRZ) has inhibitory and death-inducing properties unique from previous inhibitors such as bortezomib (BTZ), and has not been well examd. in GBM.  We evaluated the mechanism of death and in vivo properties of MRZ in GBM.  The activation kinetics of initiator caspases 2, 8, and 9 were assessed using chem. and knockdown strategies to det. their contribution to cell death.  Blood brain barrier permeance and proteasome inhibition by MRZ and BTZ were examd. in an orthotopic GBM model.  Blockade of caspase 9, relative to other caspases, was most protective against both MRZ and BTZ.  Only MRZ increased the proteasome substrate p27 in orthotopic brain tumors after a single injection, while both MRZ and BTZ increased p21 levels after multiple treatments.  Cleavage of caspase substrate lamin A was increased in orthotopic brain tumors from mice treated with MRZ or BTZ and the histone deacetylase inhibitor vorinostat.  Our data indicate that MRZ induces caspase 9-dependent death in GBM, suggesting drug efficacy biomarkers and possible resistance mechanisms.  MRZ reaches orthotopic brain tumors where it inhibits proteasome function and increases death in combination with vorinostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_5LjCLYtgLVg90H21EOLACvtfcHk0li24F8_mFmYPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2lsbg%253D&md5=984760631c99714aad04805689eaac16</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fsrep18953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18953%26sid%3Dliteratum%253Aachs%26aulast%3DManton%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DBouchier-Hayes%26aufirst%3DL.%26aulast%3DChandra%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520cell%2520death%2520by%2520the%2520novel%2520proteasome%2520inhibitor%2520marizomib%2520in%2520glioblastoma%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D18953%26doi%3D10.1038%2Fsrep18953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLaren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bota, D.</span></span> <span> </span><span class="NLM_article-title">Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier</span>. <i>Neuro-oncology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nov299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1093%2Fneuonc%2Fnov299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26681765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=840-848&author=K.+Diauthor=G.+Lloydauthor=V.+Abrahamauthor=A.+MacLarenauthor=F.+Burrowsauthor=A.+Desjardinsauthor=M.+Trikhaauthor=D.+Bota&title=Marizomib+activity+as+a+single+agent+in+malignant+gliomas%3A+ability+to+cross+the+blood-brain+barrier&doi=10.1093%2Fneuonc%2Fnov299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier</span></div><div class="casAuthors">Di, Kaijun; Lloyd, G. Kenneth; Abraham, Vivek; MacLaren, Ann; Burrows, Francis J.; Desjardins, Annick; Trikha, Mohit; Bota, Daniela A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">840-848</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: The proteasome plays a vital role in the physiol. of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM.  Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential for penetrating the blood-brain barrier.  While bortezomib and carfilzomib, the 2 proteasome inhibitors approved for treatment of multiple myeloma, have little activity against malignant gliomas in vivo, marizomib could be a novel therapeutic strategy for primary brain tumors.  Methods: The in-vitro antitumor activity of marizomib was studied in glioma cell lines U-251 and D-54.  The ability of marizomib to cross the blood-brain barrier and regulate proteasome activities was evaluated in cynomolgus monkeys and rats.  The antitumor effect of marizomib in vivo was tested in an orthotopic xenograft model of human GBM.  Results: Marizomib inhibited the proteasome activity, proliferation, and invasion of glioma cells.  Meanwhile, free radical prodn. and apoptosis induced by marizomib could be blocked by antioxidant N-acetyl cysteine.  In animal studies, marizomib distributed into the brain at 30% of blood levels in rats and significantly inhibited (>30%) baseline chymotrypsin-like proteasome activity in brain tissue of monkeys.  Encouragingly, the immunocompromised mice, intracranially implanted with glioma xenografts, survived significantly longer than the control animals (P < .05) when treated with marizomib.  Conclusions: These preclin. studies demonstrated that marizomib can cross the blood-brain barrier and inhibit proteasome activity in rodent and nonhuman primate brain and elicit a significant antitumor effect in a rodent intracranial model of malignant glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ1xNVIW5NBbVg90H21EOLACvtfcHk0li24F8_mFmYPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFKnsg%253D%253D&md5=f65e8dec9a154fe5f3b9faff3163c49a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnov299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnov299%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DK.%26aulast%3DLloyd%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DV.%26aulast%3DMacLaren%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DTrikha%26aufirst%3DM.%26aulast%3DBota%26aufirst%3DD.%26atitle%3DMarizomib%2520activity%2520as%2520a%2520single%2520agent%2520in%2520malignant%2520gliomas%253A%2520ability%2520to%2520cross%2520the%2520blood-brain%2520barrier%26jtitle%3DNeuro-oncology%26date%3D2016%26volume%3D18%26spage%3D840%26epage%3D848%26doi%3D10.1093%2Fneuonc%2Fnov299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Prime time for PROTACs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnchembio.1887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26284668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKntrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=634-635&author=R.+J.+Deshaies&title=Prime+time+for+PROTACs&doi=10.1038%2Fnchembio.1887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Protein degradation. Prime time for PROTACs</span></div><div class="casAuthors">Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">634-635</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PROTACs (proteolysis-targeting chimeric mols.) are heterobifunctional small mols. that simultaneously bind a target protein and a ubiquitin ligase, enabling ubiquitination and degrdn. of the target.  Major progress in developing potent and specific PROTACs has recently been reported, invigorating prospects for novel PROTAC-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMM05VgBV07Vg90H21EOLACvtfcHk0li24F8_mFmYPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKntrvF&md5=cea6459c9e7a6911b8368c544af23a1f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1887%26sid%3Dliteratum%253Aachs%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DPrime%2520time%2520for%2520PROTACs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D634%26epage%3D635%26doi%3D10.1038%2Fnchembio.1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Degradation of proteins by PROTACs and other strategies</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.apsb.2019.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32082969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=207-238&author=Y.+Wangauthor=X.+Jiangauthor=F.+Fengauthor=W.+Liuauthor=H.+Sun&title=Degradation+of+proteins+by+PROTACs+and+other+strategies&doi=10.1016%2Fj.apsb.2019.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of proteins by PROTACs and other strategies</span></div><div class="casAuthors">Wang, Yang; Jiang, Xueyang; Feng, Feng; Liu, Wenyuan; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-238</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Abnormal protein expression or activities are assocd. with many diseases, esp. cancer.  Therefore, down-regulating the proteins involved in cancer cell survival proved to be an effective strategy for cancer treatment-a no. of drugs based on proteolysis-targeting chimaera (PROTAC) mechanism have demonstrated clin. efficacy.  Recent progress in the PROTAC strategy includes identification of the structure of the first ternary eutectic complex, extra-terminal domain-4-PROTAC-Von-Hippel-Lindau (BRD4-PROTAC-VHL), and PROTAC ARV-110 has entered clin. trials for the treatment of prostate cancer in 2019.  These discoveries strongly proved the value of the PROTAC strategy.  In this review, we summarize recent meaningful research of PROTACs, including the mol. design and optimization strategy as well as clin. application of candidate mols.  We hope to provide useful insights for rational design of PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqERwPjLbNodLVg90H21EOLACvtfcHk0li85DtLNKWT9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnslaisA%253D%253D&md5=5a7f617407bdd143a37cfac1e11201f1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DDegradation%2520of%2520proteins%2520by%2520PROTACs%2520and%2520other%2520strategies%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D207%26epage%3D238%26doi%3D10.1016%2Fj.apsb.2019.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC design for the degradation of oncogenic BCR-ABL</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1002/anie.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fanie.201507634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=807-810&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+design+for+the+degradation+of+oncogenic+BCR-ABL&doi=10.1002%2Fanie.201507634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span></div><div class="casAuthors">Lai, Ashton C.; Toure, Momar; Hellerschmied, Doris; Salami, Jemilat; Jaime-Figueroa, Saul; Ko, Eunhwa; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">807-810</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol. is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.  PROTAC technol. employs small mols. that recruit target proteins for ubiquitination and removal by the proteasome.  The synthesis of PROTAC compds. that mediate the degrdn. of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported.  During the course of their development, the authors discovered that the capacity of a PROTAC to induce degrdn. involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely det. the degrdn. profiles of the compds.; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degrdn. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcSTHt5WfILVg90H21EOLACvtfcHk0li85DtLNKWT9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN&md5=58a5d78f32bc8a21fd1a6e0c38b8979c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520design%2520for%2520the%2520degradation%2520of%2520oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D807%26epage%3D810%26doi%3D10.1002%2Fanie.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span> <span> </span><span class="NLM_article-title">Light-induced protein degradation with photocaged PROTACs</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">18370</span>– <span class="NLM_lpage">18374</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b06422</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b06422" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOmurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=18370-18374&author=G.+Xueauthor=K.+Wangauthor=D.+Zhouauthor=H.+Zhongauthor=Z.+Pan&title=Light-induced+protein+degradation+with+photocaged+PROTACs&doi=10.1021%2Fjacs.9b06422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Light-Induced Protein Degradation with Photocaged PROTACs</span></div><div class="casAuthors">Xue, Gang; Wang, Kun; Zhou, Danli; Zhong, Hanbing; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">18370-18374</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Induction of protein degrdn. is emerging as a powerful strategy to modulate protein functions and alter cellular signaling pathways.  Proteolysis-targeting chimeras (PROTACs) have been used to degrade a range of diverse proteins in vitro and in vivo.  Here we present a type of photo-caged PROTACs (pc-PROTACs) to induce degrdn. activity with light.  Photo-removable blocking groups were added to a degrader of Brd4, and the resulting mol. pc-PROTAC1 showed potent degrdn. activity in live cells only after light irradn.  Furthermore, this mol. efficiently degraded Brd4 and induced expected phenotypic changes in zebrafish.  Addnl., this approach was successfully applied to construct pc-PROTAC3 of BTK.  Thus, a general strategy to induce protein degrdn. with light was established to augment the chemists' toolbox to study disease-relevant protein targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYGnlMSsz2ubVg90H21EOLACvtfcHk0li85DtLNKWT9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOmurvJ&md5=75920669e7228755cfefb5650e4af6b0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b06422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b06422%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DLight-induced%2520protein%2520degradation%2520with%2520photocaged%2520PROTACs%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D18370%26epage%3D18374%26doi%3D10.1021%2Fjacs.9b06422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiters, A.</span></span> <span> </span><span class="NLM_article-title">Optical control of small molecule-induced protein degradation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">2193</span>– <span class="NLM_lpage">2197</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b12718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b12718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=2193-2197&author=Y.+Naroauthor=K.+Darrahauthor=A.+Deiters&title=Optical+control+of+small+molecule-induced+protein+degradation&doi=10.1021%2Fjacs.9b12718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Optical Control of Small Molecule-Induced Protein Degradation</span></div><div class="casAuthors">Naro, Yuta; Darrah, Kristie; Deiters, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2193-2197</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As an emerging approach to protein perturbation, small mol.-induced protein degrdn. has gained significant attention as both a chem. tool and a potential therapeutic.  To enable discrete control over its function, we have developed a broadly applicable approach for the optical activation of small mol.-induced protein degrdn.  By installing two different photolabile protecting groups, so-called caging groups, onto two different ligands recruiting Von Hippel-Lindau (VHL) and cereblon (CRBN) E3 ubiquitin ligases, our strategy enables light-triggered protein degrdn. for any small mol. warhead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7kp9dSOD7EbVg90H21EOLACvtfcHk0lgNsyqzoS77pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslOhsw%253D%253D&md5=ea8a4bfe78a8acd5fcb8d0bba85b2c02</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b12718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b12718%26sid%3Dliteratum%253Aachs%26aulast%3DNaro%26aufirst%3DY.%26aulast%3DDarrah%26aufirst%3DK.%26aulast%3DDeiters%26aufirst%3DA.%26atitle%3DOptical%2520control%2520of%2520small%2520molecule-induced%2520protein%2520degradation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D2193%26epage%3D2197%26doi%3D10.1021%2Fjacs.9b12718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinn, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faelth-Savitski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic in vivo protein knockdown by small-molecule PROTACs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnchembio.1858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26075522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=611-617&author=D.+P.+Bondesonauthor=A.+Maresauthor=I.+E.+D.+Smithauthor=E.+Koauthor=S.+Camposauthor=A.+H.+Miahauthor=K.+E.+Mulhollandauthor=N.+Routlyauthor=D.+L.+Buckleyauthor=J.+L.+Gustafsonauthor=N.+Zinnauthor=P.+Grandiauthor=S.+Shimamuraauthor=G.+Bergaminiauthor=M.+Faelth-Savitskiauthor=M.+Bantscheffauthor=C.+Coxauthor=D.+A.+Gordonauthor=R.+R.+Willardauthor=J.+J.+Flanaganauthor=L.+N.+Casillasauthor=B.+J.+Vottaauthor=W.+den+Bestenauthor=K.+Fammauthor=L.+Kruidenierauthor=P.+S.+Carterauthor=J.+D.+Harlingauthor=I.+Churcherauthor=C.+M.+Crews&title=Catalytic+in+vivo+protein+knockdown+by+small-molecule+PROTACs&doi=10.1038%2Fnchembio.1858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic in vivo protein knockdown by small-molecule PROTACs</span></div><div class="casAuthors">Bondeson, Daniel P.; Mares, Alina; Smith, Ian E. D.; Ko, Eunhwa; Campos, Sebastien; Miah, Afjal H.; Mulholland, Katie E.; Routly, Natasha; Buckley, Dennis L.; Gustafson, Jeffrey L.; Zinn, Nico; Grandi, Paola; Shimamura, Satoko; Bergamini, Giovanna; Faelth-Savitski, Maria; Bantscheff, Marcus; Cox, Carly; Gordon, Deborah A.; Willard, Ryan R.; Flanagan, John J.; Casillas, Linda N.; Votta, Bartholomew J.; den Besten, Willem; Famm, Kristoffer; Kruidenier, Laurens; Carter, Paul S.; Harling, John D.; Churcher, Ian; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">611-617</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clin. benefit.  This strategy, however, generally requires excessive drug concns. to ensure sufficient occupancy, often leading to adverse side effects.  Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chem. knockdown strategy in which a heterobifunctional mol. recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degrdn.  These compds. behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equil. occupancy.  We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concns.  In addn., mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts.  Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-mol. agents with the potent protein knockdown of RNAi and CRISPR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonhnajD3CxS7Vg90H21EOLACvtfcHk0lgNsyqzoS77pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP&md5=31eb8756c5661f78ab4527a50dc1e251</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1858%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DMares%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMulholland%26aufirst%3DK.%2BE.%26aulast%3DRoutly%26aufirst%3DN.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26aulast%3DZinn%26aufirst%3DN.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DShimamura%26aufirst%3DS.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DFaelth-Savitski%26aufirst%3DM.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DWillard%26aufirst%3DR.%2BR.%26aulast%3DFlanagan%26aufirst%3DJ.%2BJ.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DFamm%26aufirst%3DK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BS.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DCatalytic%2520in%2520vivo%2520protein%2520knockdown%2520by%2520small-molecule%2520PROTACs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D611%26epage%3D617%26doi%3D10.1038%2Fnchembio.1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ottis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2570</span>– <span class="NLM_lpage">2578</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Kisr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2570-2578&author=P.+Ottisauthor=M.+Toureauthor=P.+Crommauthor=E.+Koauthor=J.+Gustafsonauthor=C.+Crews&title=Assessing+different+E3+ligases+for+small+molecule+induced+protein+ubiquitination+and+degradation&doi=10.1021%2Facschembio.7b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation</span></div><div class="casAuthors">Ottis, Philipp; Toure, Momar; Cromm, Philipp M.; Ko, Eunhwa; Gustafson, Jeffrey L.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2570-2578</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol., the recruitment of E3 ubiquitin ligases to induce the degrdn. of a protein target, is rapidly impacting chem. biol., as well as modern drug development.  Here, we explore the breadth of this approach by evaluating different E3 ubiquitin ligases engineered in their substrate binding domains to accept a recruiting ligand.  Five out of six E3 ligases were found to be amenable to recruitment for target degrdn.  Taking advantage of the tight spatio-temporal control of inducing ubiquitination on a pre-selected target in living cells, we focused on two of the engineered E3 ligases, βTRCP and parkin, to characterize their ability to induce ubiquitination in comparison with the PROTAC-recruited endogenous E3 ligases VHL and cereblon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhBU1NFnjNbVg90H21EOLACvtfcHk0lgNsyqzoS77pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Kisr3O&md5=b643d34cb33b330a7658b8b7feb2c6cc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00485%26sid%3Dliteratum%253Aachs%26aulast%3DOttis%26aufirst%3DP.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DCromm%26aufirst%3DP.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DGustafson%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DAssessing%2520different%2520E3%2520ligases%2520for%2520small%2520molecule%2520induced%2520protein%2520ubiquitination%2520and%2520degradation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D2570%26epage%3D2578%26doi%3D10.1021%2Facschembio.7b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucheault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5904</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2008.07.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18752944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5904-5908&author=A.+Schneeklothauthor=M.+Pucheaultauthor=H.+Taeauthor=C.+Crews&title=Targeted+intracellular+protein+degradation+induced+by+a+small+molecule%3A+En+route+to+chemical+proteomics&doi=10.1016%2Fj.bmcl.2008.07.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span></div><div class="casAuthors">Schneekloth, Ashley R.; Pucheault, Mathieu; Tae, Hyun Seop; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5904-5908</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We have developed a heterobifunctional all-small mol. PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degrdn. of the androgen receptor.  This cell permeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker.  The SARM-nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase.  This leads to the ubiquitination of the androgen receptor, and its subsequent degrdn. by the proteasome.  Upon treatment of HeLa cells with 10 μM PROTAC for 7 h, we were able to observe a decrease in androgen receptor levels.  This degrdn. is proteasome dependent, as it is mitigated in cells pre-treated with 10 μM epoxomicin, a specific proteasome inhibitor.  These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZh1309EM47LVg90H21EOLACvtfcHk0ljpTylc2fJRtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL&md5=49f32203efc4b2f6f2cbc900df398a1a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.114%26sid%3Dliteratum%253Aachs%26aulast%3DSchneekloth%26aufirst%3DA.%26aulast%3DPucheault%26aufirst%3DM.%26aulast%3DTae%26aufirst%3DH.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DTargeted%2520intracellular%2520protein%2520degradation%2520induced%2520by%2520a%2520small%2520molecule%253A%2520En%2520route%2520to%2520chemical%2520proteomics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5904%26epage%3D5908%26doi%3D10.1016%2Fj.bmcl.2008.07.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernassola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciechanover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melino, G.</span></span> <span> </span><span class="NLM_article-title">The HECT family of E3 ubiquitin ligases: multiple players in cancer development</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccr.2008.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18598940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1ekt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=10-21&author=F.+Bernassolaauthor=M.+Karinauthor=A.+Ciechanoverauthor=G.+Melino&title=The+HECT+family+of+E3+ubiquitin+ligases%3A+multiple+players+in+cancer+development&doi=10.1016%2Fj.ccr.2008.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The HECT family of E3 ubiquitin ligases: multiple players in cancer development</span></div><div class="casAuthors">Bernassola, Francesca; Karin, Michael; Ciechanover, Aaron; Melino, Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-21</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest.  This review highlights recent discoveries on the ubiquitin-mediated degrdn. of crucial tumor suppressor mols. catalyzed by the HECT-type E3s.  By providing a portrait of their protein targets, we intend to link the substrate specificity of HECT-type E3s with their contribution to tumorigenesis.  Moreover, we discuss the relevance of targeting the HECT E3s, through the development of small-mol. inhibitors, as an anticancer therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS6JmekCvBZrVg90H21EOLACvtfcHk0ljpTylc2fJRtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1ekt7g%253D&md5=5322ca40bee58ac15c95ceec9beaeb0c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBernassola%26aufirst%3DF.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DCiechanover%26aufirst%3DA.%26aulast%3DMelino%26aufirst%3DG.%26atitle%3DThe%2520HECT%2520family%2520of%2520E3%2520ubiquitin%2520ligases%253A%2520multiple%2520players%2520in%2520cancer%2520development%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D14%26spage%3D10%26epage%3D21%26doi%3D10.1016%2Fj.ccr.2008.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, Y. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhanji, V.</span></span> <span> </span><span class="NLM_article-title">p53 inhibition by MDM2 in human pterygium</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2018.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.exer.2018.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29932882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2lu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=142-147&author=D.+Caoauthor=T.+K.+Ngauthor=Y.+W.+Y.+Yipauthor=A.+L.+Youngauthor=C.+P.+Pangauthor=W.+K.+Chuauthor=V.+Jhanji&title=p53+inhibition+by+MDM2+in+human+pterygium&doi=10.1016%2Fj.exer.2018.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">p53 inhibition by MDM2 in human pterygium</span></div><div class="casAuthors">Cao, Di; Ng, Tsz Kin; Yip, Yolanda W. Y.; Young, Alvin L.; Pang, Chi Pui; Chu, Wai Kit; Jhanji, Vishal</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">142-147</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To confirm that mouse double minute 2 (MDM2) could inhibit p53 activity in human pterygium.  And to show the disruption of MDM2-p53 interaction could reactive the functions of p53 in pterygium.  Pterygium and corresponding conjunctiva tissues were collected for establishment of primary cell lines.  Expression patterns of MDM2 and p53 were detected by immunofluorescence.  Protein localization of p53 and MDM2, and transcriptional activity of p53 in both untreated and MDM2 antagonist (Nutlin) treated pterygium cells were quantified.  In pterygium, p53 was highly expressed in cytoplasm and slightly expressed in the nuclei.  MDM2 was localized in the nuclei.  A p53 transcriptional regulated target gene, p21, was not expressed in pterygium tissues, suggesting the p53 transcriptional activity was not active in pterygium.  After treatment with Nutlin, increased nuclear localization of p53 (4.05%-80.56%) was obsd. in pterygium cells along with increasing Nutlin dosages (from 0 to 50 μM, p < 0.001).  The expression of p21 was increased after Nutlin treatments in pterygium cells (2.49 folds in 20 μM Nutlin treated cells compared to control treated cells, p = 0.012).  We discovered a novel mechanism in pterygium whereby MDM2 suppresses p53 transcriptional activity despite abundant p53 in pterygium.  Disruption of MDM2-p53 interaction by Nutlin could be a potential treatment for pterygium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTrKcuSDmAIrVg90H21EOLACvtfcHk0ljpTylc2fJRtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2lu7%252FN&md5=183bcb9a77f4ff97db7cefc19943c541</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2018.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2018.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DD.%26aulast%3DNg%26aufirst%3DT.%2BK.%26aulast%3DYip%26aufirst%3DY.%2BW.%2BY.%26aulast%3DYoung%26aufirst%3DA.%2BL.%26aulast%3DPang%26aufirst%3DC.%2BP.%26aulast%3DChu%26aufirst%3DW.%2BK.%26aulast%3DJhanji%26aufirst%3DV.%26atitle%3Dp53%2520inhibition%2520by%2520MDM2%2520in%2520human%2520pterygium%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2018%26volume%3D175%26spage%3D142%26epage%3D147%26doi%3D10.1016%2Fj.exer.2018.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucheault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5904</span>– <span class="NLM_lpage">5908</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2008.07.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18752944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5904-5908&author=A.+R.+Schneeklothauthor=M.+Pucheaultauthor=H.+S.+Taeauthor=C.+M.+Crews&title=Targeted+intracellular+protein+degradation+induced+by+a+small+molecule%3A+En+route+to+chemical+proteomics&doi=10.1016%2Fj.bmcl.2008.07.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics</span></div><div class="casAuthors">Schneekloth, Ashley R.; Pucheault, Mathieu; Tae, Hyun Seop; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5904-5908</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We have developed a heterobifunctional all-small mol. PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degrdn. of the androgen receptor.  This cell permeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker.  The SARM-nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase.  This leads to the ubiquitination of the androgen receptor, and its subsequent degrdn. by the proteasome.  Upon treatment of HeLa cells with 10 μM PROTAC for 7 h, we were able to observe a decrease in androgen receptor levels.  This degrdn. is proteasome dependent, as it is mitigated in cells pre-treated with 10 μM epoxomicin, a specific proteasome inhibitor.  These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZh1309EM47LVg90H21EOLACvtfcHk0lhQtxGkHgQTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7rL&md5=49f32203efc4b2f6f2cbc900df398a1a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.114%26sid%3Dliteratum%253Aachs%26aulast%3DSchneekloth%26aufirst%3DA.%2BR.%26aulast%3DPucheault%26aufirst%3DM.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520intracellular%2520protein%2520degradation%2520induced%2520by%2520a%2520small%2520molecule%253A%2520En%2520route%2520to%2520chemical%2520proteomics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5904%26epage%3D5908%26doi%3D10.1016%2Fj.bmcl.2008.07.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podlaski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammlott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span> <span> </span><span class="NLM_article-title">In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1126/science.1092472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1126%2Fscience.1092472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=14704432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2004&pages=844-848&author=L.+T.+Vassilevauthor=B.+T.+Vuauthor=B.+Gravesauthor=D.+Carvajalauthor=F.+Podlaskiauthor=Z.+Filipovicauthor=N.+Kongauthor=U.+Kammlottauthor=C.+Lukacsauthor=C.+Klein&title=In+vivo+activation+of+the+p53+pathway+by+small-molecule+antagonists+of+MDM2&doi=10.1126%2Fscience.1092472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2</span></div><div class="casAuthors">Vassilev, Lyubomir T.; Vu, Binh T.; Graves, Bradford; Carvajal, Daisy; Podlaski, Frank; Filipovic, Zoran; Kong, Norman; Kammlott, Ursula; Lukacs, Christine; Klein, Christian; Fotouhi, Nader; Liu, Emily A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">5659</span>),
    <span class="NLM_cas:pages">844-848</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">MDM2 binds the p53 tumor suppressor protein with high affinity and neg. modulates its transcriptional activity and stability.  Overexpression of MDM2, found in many human tumors, effectively impairs p53 function.  Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy.  Here, we identify potent and selective small-mol. antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes.  These compds. bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzumitGD6V4bVg90H21EOLACvtfcHk0lhQtxGkHgQTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKmtA%253D%253D&md5=cf80c399e8eca8766be1023cda438df3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1126%2Fscience.1092472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1092472%26sid%3Dliteratum%253Aachs%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26aulast%3DVu%26aufirst%3DB.%2BT.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DCarvajal%26aufirst%3DD.%26aulast%3DPodlaski%26aufirst%3DF.%26aulast%3DFilipovic%26aufirst%3DZ.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DKammlott%26aufirst%3DU.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DKlein%26aufirst%3DC.%26atitle%3DIn%2520vivo%2520activation%2520of%2520the%2520p53%2520pathway%2520by%2520small-molecule%2520antagonists%2520of%2520MDM2%26jtitle%3DScience%26date%3D2004%26volume%3D303%26spage%3D844%26epage%3D848%26doi%3D10.1126%2Fscience.1092472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lartigue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">251</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-18-2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=251&author=J.+Hinesauthor=S.+Lartigueauthor=H.+Dongauthor=Y.+Qianauthor=C.+M.+Crews&title=MDM2-recruiting+PROTAC+offers+superior%2C+synergistic+antiproliferative+activity+via+simultaneous+degradation+of+BRD4+and+stabilization+of+p53&doi=10.1158%2F0008-5472.CAN-18-2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53</span></div><div class="casAuthors">Hines, John; Lartigue, Schan; Dong, Hanqing; Qian, Yimin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Although the no. of proteins effectively targeted for posttranslational degrdn. by PROTAC has grown steadily, the no. of E3 ligases successfully exploited to accomplish this has been limited to the few for which small-mol. ligands have been discovered.  Although the E3 ligase MDM2 is bound by the nutlin class of small-mol. ligands, there are few nutlin-based PROTAC.  Because a nutlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53, we examd. the ability of such a PROTAC to decrease cancer cell viability.  A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency.  Given the complementary ability of A1874 to stabilize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of many cancer cell lines with wild-type p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4.  This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhead combine to exert a synergistic antiproliferative effect.  Our study highlights the untapped potential that may be unlocked by expanding the repertoire of E3 ligases that can be recruited by PROTAC.  Significance: These findings present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic biol. activities assocd. with both ends of this heterobifunctional mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UdOVtfCjPLVg90H21EOLACvtfcHk0lhQtxGkHgQTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFGnsr0%253D&md5=e5dbf80505bb32c232bce66b0445a1a9</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-2918%26sid%3Dliteratum%253Aachs%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DLartigue%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DMDM2-recruiting%2520PROTAC%2520offers%2520superior%252C%2520synergistic%2520antiproliferative%2520activity%2520via%2520simultaneous%2520degradation%2520of%2520BRD4%2520and%2520stabilization%2520of%2520p53%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D251%26doi%3D10.1158%2F0008-5472.CAN-18-2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">5820</span>– <span class="NLM_lpage">5826</span>, <span class="refDoi"> DOI: 10.1021/ja100691p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja100691p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1Gktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=5820-5826&author=Y.+Itohauthor=M.+Ishikawaauthor=M.+Naitoauthor=Y.+Hashimoto&title=Protein+knockdown+using+methyl+bestatin-ligand+hybrid+molecules%3A+design+and+synthesis+of+inducers+of+ubiquitination-mediated+degradation+of+cellular+retinoic+acid-binding+proteins&doi=10.1021%2Fja100691p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Knockdown Using Methyl Bestatin-Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins</span></div><div class="casAuthors">Itoh, Yukihiro; Ishikawa, Minoru; Naito, Mikihiko; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5820-5826</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Induction of selective degrdn. of target proteins by small mols. (protein knockdown) would be useful for biol. research and treatment of various diseases.  To achieve protein knockdown, we utilized the ubiquitin ligase activity of cellular inhibitor of apoptosis protein 1 (cIAP1), which is activated by Me bestatin (MeBS, 2).  We speculated that formation of an artificial (nonphysiol.) complex of cIAP1 and a target protein would be induced by a hybrid mol. consisting of MeBS (2) linked to a ligand of the target protein, and this would lead to cIAP1-mediated ubiquitination and subsequent proteasomal degrdn. of the target protein.  To verify this hypothesis, we focused on cellular retinoic acid-binding proteins (CRABP-I and -II) and designed hybrid mols. (compds. 4) consisting of MeBS (2) coupled via spacers of various lengths to all-trans retinoic acid (ATRA, 3), a ligand of CRABPs.  Compds. 4 induced selective loss of CRABP-I and -II proteins in cells.  We confirmed that 4b induced formation of a complex of cIAP1 and CRABP-II in vitro and induced proteasomal degrdn. of CRABP-II in cells.  When neuroblastoma IMR-32 cells were treated with 4b, the level of CRABP-II was reduced and cell migration was inhibited, suggesting potential value of CRABP-II-targeting therapy for controlling tumor metastasis.  Our results indicate that 4b possesses sufficient activity, permeability, and stability in cells to be employed in cellular assays.  Hybrid mols. such as 4 should be useful not only as chem. tools for studying the biol./physiol. functions of CRABPs but also as candidate therapeutic agents targeting CRABPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUZurgNT02VLVg90H21EOLACvtfcHk0lg5-yvdXrckOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1Gktb0%253D&md5=96c56bb081695a00b6fa6c269aaeef1b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fja100691p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja100691p%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DProtein%2520knockdown%2520using%2520methyl%2520bestatin-ligand%2520hybrid%2520molecules%253A%2520design%2520and%2520synthesis%2520of%2520inducers%2520of%2520ubiquitination-mediated%2520degradation%2520of%2520cellular%2520retinoic%2520acid-binding%2520proteins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D5820%26epage%3D5826%26doi%3D10.1021%2Fja100691p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitaguchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4453</span>– <span class="NLM_lpage">4457</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2012.04.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22658364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVeksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4453-4457&author=Y.+Itohauthor=M.+Ishikawaauthor=R.+Kitaguchiauthor=K.+Okuhiraauthor=M.+Naitoauthor=Y.+Hashimoto&title=Double+protein+knockdown+of+cIAP1+and+CRABP-II+using+a+hybrid+molecule+consisting+of+ATRA+and+IAPs+antagonist&doi=10.1016%2Fj.bmcl.2012.04.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist</span></div><div class="casAuthors">Itoh, Yukihiro; Ishikawa, Minoru; Kitaguchi, Risa; Okuhira, Keiichiro; Naito, Mikihiko; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4453-4457</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein knockdown can be achieved by the use of a small mol. that possesses affinity for both the target protein and ubiquitin ligase.  We have designed such a degrdn.-inducing mol. targeting cIAP1 and CRABP-II, which are involved in proliferation of several cancer cell lines and in neuroblastoma growth, resp.  As a CRABP-II-recognizing moiety, all-trans retinoic acid (ATRA, 3), a physiol. ligand of CRABP, was chosen.  As a cIAP1-recognizing moiety, MV1 (5), which is a cIAP1/cIAP2/XIAP pan-ligand, was chosen.  Although cIAP1 itself possesses ubiquitin ligase activity, we expected that its decompn. would be efficiently mediated by related mols., including cIAP2 and XIAP, which also possess ubiquitin ligase activity.  The designed degrdn. inducer 6, in which ATRA (3) and MV1 (5) moieties are connected via a linker, was synthesized and confirmed to induce efficient degrdn. of both cIAP1 and CRABP-II.  It showed potently inhibited the proliferation of IMR32 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5r5ZhuMqcy7Vg90H21EOLACvtfcHk0lg5-yvdXrckOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVeksrk%253D&md5=80ae0bc8df5b583ae01d7113558dc266</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.134%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DKitaguchi%26aufirst%3DR.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DDouble%2520protein%2520knockdown%2520of%2520cIAP1%2520and%2520CRABP-II%2520using%2520a%2520hybrid%2520molecule%2520consisting%2520of%2520ATRA%2520and%2520IAPs%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4453%26epage%3D4457%26doi%3D10.1016%2Fj.bmcl.2012.04.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sameshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohoka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1042</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2js7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1042-1047&author=K.+Shimokawaauthor=N.+Shibataauthor=T.+Sameshimaauthor=N.+Miyamotoauthor=O.+Ujikawaauthor=H.+Naraauthor=N.+Ohokaauthor=T.+Hattoriauthor=N.+Choauthor=M.+Naito&title=Targeting+the+allosteric+site+of+oncoprotein+BCR-ABL+as+an+alternative+strategy+for+effective+target+protein+degradation&doi=10.1021%2Facsmedchemlett.7b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation</span></div><div class="casAuthors">Shimokawa, Kenichiro; Shibata, Norihito; Sameshima, Tomoya; Miyamoto, Naoki; Ujikawa, Osamu; Nara, Hiroshi; Ohoka, Nobumichi; Hattori, Takayuki; Cho, Nobuo; Naito, Mikihiko</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1042-1047</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein degrdn. technol. based on hybrid small mols. is an emerging drug modality that has significant potential in drug discovery and as a unique method of post-translational protein knockdown in the field of chem. biol.  Here, we report the first example of a novel and potent protein degrdn. inducer that binds to an allosteric site of the oncogenic BCR-ABL protein.  BCR-ABL allosteric ligands were incorporated into the SNIPER (Specific and Nongenetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers) platform, and a series of in vitro biol. assays of binding affinity, target protein modulation, signal transduction, and growth inhibition were carried out.  One of the designed compds., I (SNIPER(ABL)-062), showed desirable binding affinities against ABL1, cIAP1/2, and XIAP and consequently caused potent BCR-ABL degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-F9T_RIbVbVg90H21EOLACvtfcHk0lg5-yvdXrckOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2js7fI&md5=2500e7d9129934033f969721141a8c1b</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00247%26sid%3Dliteratum%253Aachs%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DN.%26aulast%3DSameshima%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DUjikawa%26aufirst%3DO.%26aulast%3DNara%26aufirst%3DH.%26aulast%3DOhoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DT.%26aulast%3DCho%26aufirst%3DN.%26aulast%3DNaito%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520allosteric%2520site%2520of%2520oncoprotein%2520BCR-ABL%2520as%2520an%2520alternative%2520strategy%2520for%2520effective%2520target%2520protein%2520degradation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1042%26epage%3D1047%26doi%3D10.1021%2Facsmedchemlett.7b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span> <span> </span><span class="NLM_article-title">The expression of VHL (Von Hippel-Lindau) after traumatic spinal cord injury and its role in neuronal apoptosis</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2400</span>, <span class="refDoi"> DOI: 10.1007/s11064-016-1952-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1007%2Fs11064-016-1952-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27324785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCmtr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=2391-2400&author=J.+Haoauthor=X.+Chenauthor=T.+Fuauthor=J.+Liuauthor=M.+Yuauthor=W.+Hanauthor=S.+Heauthor=R.+Qianauthor=F.+Zhang&title=The+expression+of+VHL+%28Von+Hippel-Lindau%29+after+traumatic+spinal+cord+injury+and+its+role+in+neuronal+apoptosis&doi=10.1007%2Fs11064-016-1952-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The Expression of VHL (Von Hippel-Lindau) After Traumatic Spinal Cord Injury and Its Role in Neuronal Apoptosis</span></div><div class="casAuthors">Hao, Jie; Chen, Xiaoqing; Fu, Ting; Liu, Jie; Yu, Mingchen; Han, Wei; He, Shuang; Qian, Rong; Zhang, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2391-2400</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The VHL (Von Hippel-Lindau) gene is a tumor suppressor gene, which is best known as an E3 ubiquitin ligase that neg. regulates the hypoxia inducible factor.  The inactivation of VHL gene could result in the abnormal synthesis of VHL protein, which is in contact with the development and occurrence of renal clear cell carcinoma.  However, the expression and possible function of VHL in central nervous system (CNS) is still unclear.  To examine the function of VHL in CNS injury and repair, we used an acute spinal cord injury (SCI) model in adult rats.  Western blot anal. showed an important upregulation of VHL protein, reaching a peak at day 3 and then declined during the following days.  Double immunofluorescence staining showed that VHL was co-expressed with neurons, but not with astrocytes and microglia.  Moreover, we detected that active caspase-3 had co-localized with VHL in neurons after SCI.  Addnl. in vitro, VHL depletion, by short interfering RNA, significantly reduced neuronal apoptosis.  In conclusion, these data suggested that the change of VHL protein expression was related to neuronal apoptosis after SCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJzWNQks1A3LVg90H21EOLACvtfcHk0lgPbfWQhhppaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCmtr3E&md5=4b26d50baf1618df1a43f12f8079c4e0</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs11064-016-1952-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-016-1952-7%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DF.%26atitle%3DThe%2520expression%2520of%2520VHL%2520%2528Von%2520Hippel-Lindau%2529%2520after%2520traumatic%2520spinal%2520cord%2520injury%2520and%2520its%2520role%2520in%2520neuronal%2520apoptosis%26jtitle%3DNeurochem.%2520Res.%26date%3D2016%26volume%3D41%26spage%3D2391%26epage%3D2400%26doi%3D10.1007%2Fs11064-016-1952-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alabi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance</span>. <i>Communications biology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.1038/s42003-018-0105-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fs42003-018-0105-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30271980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3czksVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=100&author=J.+Salamiauthor=S.+Alabiauthor=R.+R.+Willardauthor=N.+J.+Vitaleauthor=J.+Wangauthor=H.+Dongauthor=M.+Jinauthor=D.+P.+McDonnellauthor=A.+P.+Crewauthor=T.+K.+Neklesaauthor=C.+M.+Crews&title=Androgen+receptor+degradation+by+the+proteolysis-targeting+chimera+ARCC-4+outperforms+enzalutamide+in+cellular+models+of+prostate+cancer+drug+resistance&doi=10.1038%2Fs42003-018-0105-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance</span></div><div class="casAuthors">Salami Jemilat; Crews Craig M; Alabi Shanique; Crews Craig M; Willard Ryan R; Vitale Nick J; Wang Jing; Dong Hanqing; Jin Meizhong; Crew Andrew P; Neklesa Taavi K; McDonnell Donald P; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The androgen receptor is a major driver of prostate cancer and inhibition of its transcriptional activity using competitive antagonists, such as enzalutamide remains a frontline therapy for prostate cancer management.  However, the majority of patients eventually develop drug resistance.  We propose that targeting the androgen receptor for degradation via Proteolysis Targeting Chimeras (PROTACs) will be a better therapeutic strategy for targeting androgen receptor signaling in prostate cancer cells.  Here we perform a head-to-head comparison between a currently approved androgen receptor antagonist enzalutamide, and its PROTAC derivative, ARCC-4, across different cellular models of prostate cancer drug resistance.  ARCC-4 is a low-nanomolar androgen receptor degrader able to degrade about 95% of cellular androgen receptors.  ARCC-4 inhibits prostate tumor cell proliferation, degrades clinically relevant androgen receptor point mutants and unlike enzalutamide, retains antiproliferative effect in a high androgen environment.  Thus, ARCC-4 exemplifies how protein degradation can address the drug resistance hurdles of enzalutamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQilKiHIro9_JI8NvIb08rbfW6udTcc2eYMqsmdN_MVBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czksVCksA%253D%253D&md5=b8b7a81226dcf37d9ff430244b21f952</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fs42003-018-0105-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-018-0105-8%26sid%3Dliteratum%253Aachs%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DAlabi%26aufirst%3DS.%26aulast%3DWillard%26aufirst%3DR.%2BR.%26aulast%3DVitale%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DAndrogen%2520receptor%2520degradation%2520by%2520the%2520proteolysis-targeting%2520chimera%2520ARCC-4%2520outperforms%2520enzalutamide%2520in%2520cellular%2520models%2520of%2520prostate%2520cancer%2520drug%2520resistance%26jtitle%3DCommunications%2520biology%26date%3D2018%26volume%3D1%26spage%3D100%26doi%3D10.1038%2Fs42003-018-0105-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs as potential therapeutic agents for cancer drug resistance</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00848</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00848" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=240-249&author=X.+Sunauthor=Y.+Rao&title=PROTACs+as+potential+therapeutic+agents+for+cancer+drug+resistance&doi=10.1021%2Facs.biochem.9b00848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance</span></div><div class="casAuthors">Sun, Xiuyun; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Cancer drug resistance has become the major problem facing current clin. treatment via different kinds of therapies.  Proteolysis targeting chimeras (PROTACs) as a novel and powerful strategy have attracted a great deal of attention both from academia and from industry for their sensitivity to drug-resistant targets relying on their unique characteristics compared to those of traditional inhibitors.  PROTACs exert their function by degrading the target protein instead of inhibiting targets.  Thus, different kinds of resistance could be conquered by PROTACs such as target mutation or overexpression.  Various resistant targets have been overcome by PROTACs, including AR, ER, BTK, BET, and BCR-ABL.  Though PROTACs have achieved some significant advances in combating drug resistance, more cases are needed to prove the efficiency of PROTACs in addressing the hurdle of resistance in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_hi9ENDVPLVg90H21EOLACvtfcHk0li_Y-9YG4GgPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCgs7rP&md5=bb7d34974dcb22f73ce9ce60665c391f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00848%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%2520as%2520potential%2520therapeutic%2520agents%2520for%2520cancer%2520drug%2520resistance%26jtitle%3DBiochemistry%26date%3D2020%26volume%3D59%26spage%3D240%26epage%3D249%26doi%3D10.1021%2Facs.biochem.9b00848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelzang, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan Moore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3500</span>– <span class="NLM_lpage">3500</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.3500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2020.38.15_suppl.3500" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=3500-3500&author=D.+P.+Petrylakauthor=X.+Gaoauthor=N.+J.+Vogelzangauthor=M.+H.+Garfieldauthor=I.+Taylorauthor=M.+Dougan+Mooreauthor=R.+A.+Peckauthor=H.+A.+Burris&title=First-in-human+phase+I+study+of+ARV-110%2C+an+androgen+receptor+%28AR%29+PROTAC+degrader+in+patients+%28pts%29+with+metastatic+castrate-resistant+prostate+cancer+%28mCRPC%29+following+enzalutamide+%28ENZ%29+and%2For+abiraterone+%28ABI%29&doi=10.1200%2FJCO.2020.38.15_suppl.3500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.3500%26sid%3Dliteratum%253Aachs%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DVogelzang%26aufirst%3DN.%2BJ.%26aulast%3DGarfield%26aufirst%3DM.%2BH.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DDougan%2BMoore%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DR.%2BA.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520ARV-110%252C%2520an%2520androgen%2520receptor%2520%2528AR%2529%2520PROTAC%2520degrader%2520in%2520patients%2520%2528pts%2529%2520with%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528mCRPC%2529%2520following%2520enzalutamide%2520%2528ENZ%2529%2520and%252For%2520abiraterone%2520%2528ABI%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D3500%26epage%3D3500%26doi%3D10.1200%2FJCO.2020.38.15_suppl.3500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span> <span> </span><span class="NLM_article-title">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">7124</span>– <span class="NLM_lpage">7129</span>, <span class="refDoi"> DOI: 10.1073/pnas.1521738113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1073%2Fpnas.1521738113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27274052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7124-7129&author=K.+Rainaauthor=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=D.+Gordonauthor=A.+Rossiauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=K.+Siuauthor=J.+Winklerauthor=A.+Crewauthor=C.+Crewsauthor=K.+Coleman&title=PROTAC-induced+BET+protein+degradation+as+a+therapy+for+castration-resistant+prostate+cancer&doi=10.1073%2Fpnas.1521738113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Raina, Kanak; Lu, Jing; Qian, Yimin; Altieri, Martha; Gordon, Deborah; Rossi, Ann Marie K.; Wang, Jing; Chen, Xin; Dong, Hanqing; Siu, Kam; Winkler, James D.; Crew, Andrew P.; Crews, Craig M.; Coleman, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States.  Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is assocd. with a poor prognosis.  Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed.  Recently, inhibitors of bromodomain and extra-terminal (BET) family proteins have shown growth-inhibitory activity in preclin. models of CRPC.  Here, we demonstrate that ARV-771, a small-mol. pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technol., demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.  Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.  This study is, to our knowledge, the first to demonstrate efficacy with a small-mol. BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD7QtYgZVig7Vg90H21EOLACvtfcHk0li_Y-9YG4GgPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptlyqs7s%253D&md5=34218e685ad72950f3eb85586110c43d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1521738113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1521738113%26sid%3Dliteratum%253Aachs%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DCrew%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DK.%26atitle%3DPROTAC-induced%2520BET%2520protein%2520degradation%2520as%2520a%2520therapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D7124%26epage%3D7129%26doi%3D10.1073%2Fpnas.1521738113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapakshe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coarfa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fleu.2017.207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28663582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=343-352&author=B.+Sunauthor=W.+Fiskusauthor=Y.+Qianauthor=K.+Rajapaksheauthor=K.+Rainaauthor=K.+Colemanauthor=A.+Crewauthor=A.+Shenauthor=D.+Saenzauthor=C.+Millauthor=A.+Nowakauthor=N.+Jainauthor=L.+Zhangauthor=M.+Wangauthor=J.+Khouryauthor=C.+Coarfaauthor=C.+Crewsauthor=K.+Bhalla&title=BET+protein+proteolysis+targeting+chimera+%28PROTAC%29+exerts+potent+lethal+activity+against+mantle+cell+lymphoma+cells&doi=10.1038%2Fleu.2017.207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Bet protein proteolysis targeting chimera (protac) exerts potent lethal activity against mantle cell lymphoma cells</span></div><div class="casAuthors">Sun, B.; Fiskus, W.; Qian, Y.; Rajapakshe, K.; Raina, K.; Coleman, K. G.; Crew, A. P.; Shen, A.; Saenz, D. T.; Mill, C. P.; Nowak, A. J.; Jain, N.; Zhang, L.; Wang, M.; Khoury, J. D.; Coarfa, C.; Crews, C. M.; Bhalla, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-352</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Bromodomain extraterminal protein (BETP) inhibitors transcriptionally repress oncoproteins and nuclear factor-κB (NF-κB) target genes that undermines the growth and survival of mantle cell lymphoma (MCL) cells.  However, BET bromodomain inhibitor (BETi) treatment causes accumulation of BETPs, assocd. with reversible binding and incomplete inhibition of BRD4 that potentially compromises the activity of BETi in MCL cells.  Unlike BETi, BET-PROTACs (proteolysis-targeting chimera) ARV-825 and ARV-771 (Arvinas, Inc.) recruit and utilize an E3-ubiquitin ligase to effectively degrade BETPs in MCL cells.  BET-PROTACs induce more apoptosis than BETi of MCL cells, including those resistant to ibrutinib.  BET-PROTAC treatment induced more perturbations in the mRNA and protein expressions than BETi, with depletion of c-Myc, CDK4, cyclin D1 and the NF-κB transcriptional targets Bcl-xL, XIAP and BTK, while inducing the levels of HEXIM1, NOXA and CDKN1A/p21.  Treatment with ARV-771, which possesses superior pharmacol. properties compared with ARV-825, inhibited the in vivo growth and induced greater survival improvement than the BETi OTX015 of immune-depleted mice engrafted with MCL cells.  Cotreatment of ARV-771 with ibrutinib or the BCL2 antagonist venetoclax or CDK4/6 inhibitor palbociclib synergistically induced apoptosis of MCL cells.  These studies highlight promising and superior preclin. activity of BET-PROTAC than BETi, requiring further in vivo evaluation of BET-PROTAC as a therapy for ibrutinib-sensitive or -resistant MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAZxihoDZILrVg90H21EOLACvtfcHk0lgyfCUHpY_rsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eqt77J&md5=f771eee574daf11546b93866ea314381</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.207%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DRajapakshe%26aufirst%3DK.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrew%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DSaenz%26aufirst%3DD.%26aulast%3DMill%26aufirst%3DC.%26aulast%3DNowak%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DKhoury%26aufirst%3DJ.%26aulast%3DCoarfa%26aufirst%3DC.%26aulast%3DCrews%26aufirst%3DC.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DBET%2520protein%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520exerts%2520potent%2520lethal%2520activity%2520against%2520mantle%2520cell%2520lymphoma%2520cells%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D343%26epage%3D352%26doi%3D10.1038%2Fleu.2017.207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span> <span> </span><span class="NLM_article-title">Small molecule KRAS agonist for mutant KRAS cancer therapy</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-1012-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs12943-019-1012-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30971271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FktVKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=85&author=K.+Xuauthor=D.+Parkauthor=A.+T.+Magisauthor=J.+Zhangauthor=W.+Zhouauthor=G.+L.+Sicaauthor=S.+S.+Ramalingamauthor=W.+J.+Curranauthor=X.+Deng&title=Small+molecule+KRAS+agonist+for+mutant+KRAS+cancer+therapy&doi=10.1186%2Fs12943-019-1012-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy</span></div><div class="casAuthors">Xu Ke; Park Dongkyoo; Curran Walter J; Deng Xingming; Magis Andrew T; Zhang Jun; Zhou Wei; Ramalingam Suresh S; Sica Gabriel L</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions.  Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatment of KRAS-mutant lung cancer.  RESULTS:  Here we identified a small molecule KRAS agonist, KRA-533, that binds the GTP/GDP-binding pocket of KRAS.  In vitro GDP/GTP exchange assay reveals that KRA-533 activates KRAS by preventing the cleavage of GTP into GDP, leading to the accumulation of GTP-KRAS, an active form of KRAS.  Treatment of human lung cancer cells with KRA-533 resulted in increased KRAS activity and suppression of cell growth.  Lung cancer cell lines with KRAS mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation.  Mutating one of the hydrogen-bonds among the KRA-533 binding amino acids in KRAS (mutant K117A) resulted in failure of KRAS to bind KRA-533.  KRA-533 had no effect on the activity of K117A mutant KRAS, suggesting that KRA-533 binding to K117 is required for KRA-533 to enhance KRAS activity.  Intriguingly, KRA-533-mediated KRAS activation not only promoted apoptosis but also autophagic cell death.  In mutant KRAS lung cancer xenografts and genetically engineered mutant KRAS-driven lung cancer models, KRA-533 suppressed malignant growth without significant toxicity to normal tissues.  CONCLUSIONS:  The development of this KRAS agonist as a new class of anticancer drug offers a potentially effective strategy for the treatment of lung cancer with KRAS mutation and/or mutant KRAS-driven lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQdRmF3d0rzcULxIEhxUjPfW6udTcc2eY37bLTtQdHE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FktVKlug%253D%253D&md5=78831531111b46153564c1c9ad23d6e8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1012-4%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DD.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSica%26aufirst%3DG.%2BL.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DCurran%26aufirst%3DW.%2BJ.%26aulast%3DDeng%26aufirst%3DX.%26atitle%3DSmall%2520molecule%2520KRAS%2520agonist%2520for%2520mutant%2520KRAS%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%26date%3D2019%26volume%3D18%26spage%3D85%26doi%3D10.1186%2Fs12943-019-1012-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bond, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalawansha, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1375</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.0c00411</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.0c00411" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlans7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=1367-1375&author=M.+J.+Bondauthor=L.+Chuauthor=D.+A.+Nalawanshaauthor=K.+Liauthor=C.+M.+Crews&title=Targeted+degradation+of+oncogenic+KRASG12C+by+VHL-recruiting+PROTACs&doi=10.1021%2Facscentsci.0c00411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs</span></div><div class="casAuthors">Bond, Michael J.; Chu, Ling; Nalawansha, Dhanusha A.; Li, Ke; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1367-1375</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRAS is mutated in ~ 20% of human cancers and is one of the most sought-after targets for pharmacol. modulation, despite having historically been considered "undruggable." The discovery of potent covalent inhibitors of the KRASG12C mutant in recent years has sparked a new wave of interest in small mols. targeting KRAS.  While these inhibitors have shown promise in the clinic, we wanted to explore PROTAC-mediated degrdn. as a complementary strategy to modulate mutant KRAS.  Herein, we report the development of LC-2(I), the first PROTAC capable of degrading endogenous KRASG12C.  LC-2 covalently binds KRASG12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRASG12C degrdn. leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines.  LC-2 demonstrates that PROTAC-mediated degrdn. is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.  KRAS is one of the most sought-after targets for cancer therapy.  Herein, we report the development of LC-2, the first PROTAC capable of inducing endogenous KRASG12C degrdn. by recruiting VHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra8EvL_8O3_rVg90H21EOLACvtfcHk0lgyfCUHpY_rsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlans7zM&md5=09dc3d55acd5ecd3e8e0e18740830263</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.0c00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.0c00411%26sid%3Dliteratum%253Aachs%26aulast%3DBond%26aufirst%3DM.%2BJ.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DNalawansha%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520degradation%2520of%2520oncogenic%2520KRASG12C%2520by%2520VHL-recruiting%2520PROTACs%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2020%26volume%3D6%26spage%3D1367%26epage%3D1375%26doi%3D10.1021%2Facscentsci.0c00411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase in B cell malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&author=R.+Hendriksauthor=S.+Yuvarajauthor=L.+Kil&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0lhIdVLIzJ1gCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C.</span></span> <span> </span><span class="NLM_article-title">Targeting the C481S Ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3564</span>– <span class="NLM_lpage">3575</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3564-3575&author=A.+Buhimschiauthor=H.+Armstrongauthor=M.+Toureauthor=S.+Jaime-Figueroaauthor=T.+Chenauthor=A.+Lehmanauthor=J.+Woyachauthor=A.+Johnsonauthor=J.+Byrdauthor=C.+Crews&title=Targeting+the+C481S+Ibrutinib-resistance+mutation+in+Bruton%E2%80%99s+tyrosine+kinase+using+PROTAC-mediated+degradation&doi=10.1021%2Facs.biochem.8b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation</span></div><div class="casAuthors">Buhimschi, Alexandru D.; Armstrong, Haley A.; Toure, Momar; Jaime-Figueroa, Saul; Chen, Timothy L.; Lehman, Amy M.; Woyach, Jennifer A.; Johnson, Amy J.; Byrd, John C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3564-3575</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies.  Yet, more than 80% of CLL patients develop resistance due to a cysteine to serine mutation at the site covalently bound by ibrutinib (C481S).  Currently, an effective treatment option for C481S patients exhibiting relapse to ibrutinib does not exist and these patients have poor outcomes.  To address this, we have developed a PROteolysis TArgeting Chimera (PROTAC) that induces degrdn. of both wild-type and C481S mutant BTK.  We selected a lead PROTAC, MT-802, from several candidates based on its potency to induce BTK knockdown.  MT-802 recruits BTK to the cereblon (CRBN) E3 ubiquitin ligase complex to trigger BTK ubiquitination and degrdn. via the proteasome.  MT-802 binds fewer off-target kinases than ibrutinib and retains equiv. potency (>99% degrdn. at nanomolar concns.) against wild-type and C481S BTK.  In cells isolated from CLL patients with the C481S mutation, MT-802 is able to reduce the pool of active, phosphorylated BTK whereas ibrutinib cannot.  Collectively, these data provide basis for further preclin. study of BTK PROTACs as a novel strategy for treatment of C481S mutant CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-ls5ps9FaLVg90H21EOLACvtfcHk0lhIdVLIzJ1gCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCgt7zO&md5=bd27f09d041413c7bacb6d61fcb9a327</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00391%26sid%3Dliteratum%253Aachs%26aulast%3DBuhimschi%26aufirst%3DA.%26aulast%3DArmstrong%26aufirst%3DH.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DByrd%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%26atitle%3DTargeting%2520the%2520C481S%2520Ibrutinib-resistance%2520mutation%2520in%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520using%2520PROTAC-mediated%2520degradation%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3564%26epage%3D3575%26doi%3D10.1021%2Facs.biochem.8b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2105</span>– <span class="NLM_lpage">2110</span>, <span class="refDoi"> DOI: 10.1038/s41375-019-0440-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fs41375-019-0440-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30858551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=2105-2110&author=Y.+Sunauthor=N.+Dingauthor=Y.+Songauthor=Z.+Yangauthor=W.+Liuauthor=J.+Zhuauthor=Y.+Rao&title=Degradation+of+Bruton%E2%80%99s+tyrosine+kinase+mutants+by+PROTACs+for+potential+treatment+of+ibrutinib-resistant+non-Hodgkin+lymphomas&doi=10.1038%2Fs41375-019-0440-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas</span></div><div class="casAuthors">Sun Yonghui; Yang Zimo; Rao Yu; Ding Ning; Song Yuqin; Zhu Jun; Liu Wanli</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2105-2110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF-dfST00W0BcfW6udTcc2eZqiEcfeUyE07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVKhtA%253D%253D&md5=9d58ea99a2e3c695ee226e78431fce91</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fs41375-019-0440-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-019-0440-x%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDegradation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520mutants%2520by%2520PROTACs%2520for%2520potential%2520treatment%2520of%2520ibrutinib-resistant%2520non-Hodgkin%2520lymphomas%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D2105%26epage%3D2110%26doi%3D10.1038%2Fs41375-019-0440-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bioorg.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30196207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=373-381&author=J.+Bianauthor=J.+Renauthor=Y.+Liauthor=J.+Wangauthor=X.+Xuauthor=Y.+Fengauthor=H.+Tangauthor=Y.+Wangauthor=Z.+Li&title=Discovery+of+Wogonin-based+PROTACs+against+CDK9+and+capable+of+achieving+antitumor+activity&doi=10.1016%2Fj.bioorg.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity</span></div><div class="casAuthors">Bian, Jinlei; Ren, Jie; Li, Yongren; Wang, Jubo; Xu, Xi; Feng, Yifan; Tang, Hui; Wang, Yajing; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-381</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved to be a potent and selective inhibitor of CDK9.  Using this scaffold, we designed and synthesized a series of proteolysis targeting chimeras (PROTACs) targeting CDK9 by recruiting ubiquitin E3 ligase cereblon (CRBN).  For constructing diverse Wogonin-based PROTACs, a "click chem." approach was employed for the synthesis of CDK9-targeting PROTACs.  The results of western blotting assays showed that compds. contg. triazole group in the linker could selectively downregulate the intracellular CDK9 level.  Among these compds., 11c could selectively degrade CDK9 in a concn.-dependent manner.  In addn., the application of the proteasome inhibitor MG132 and CRBN siRNA silencing confirmed that 11c could promote the proteasome-dependent and CRBN-dependent degrdn.  Consistent with the degrdn. of the CDK9 protein, 11c selectively inhibits proliferation of CDK9-overexpressed cancer cells.  Thus, our Wogonin-based PROTAC would be an efficient probe that induces the degrdn. of CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4sLAWq5vMrVg90H21EOLACvtfcHk0ljrQNXOqx_A1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7bE&md5=6a7158be1fce50296d6d0ec9160db0fc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Wogonin-based%2520PROTACs%2520against%2520CDK9%2520and%2520capable%2520of%2520achieving%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D373%26epage%3D381%26doi%3D10.1016%2Fj.bioorg.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.-R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0ljrQNXOqx_A1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.-R.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E.</span></span> <span> </span><span class="NLM_article-title">STATs: transcriptional control and biological impact</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1038/nrm909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrm909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12209125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=651-662&author=D.+E.+Levyauthor=J.+E.+Darnell&title=STATs%3A+transcriptional+control+and+biological+impact&doi=10.1038%2Fnrm909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Stats: transcriptional control and biological impact</span></div><div class="casAuthors">Levy, David E.; Darnell, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">651-662</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extracellular proteins bound to cell-surface receptors can change nuclear gene expression patterns in minutes, with far-reaching consequences for development, cell growth, and homeostasis.  The signal transducer and activator of transcription (STAT) proteins are among the most well studied of the latent cytoplasmic signal-dependent transcription factor pathways.  In addn. to several roles in normal cell decisions, dysregulation of STAT function contributes to human disease, making the study of these proteins an important topic of current research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGqYF32j262LVg90H21EOLACvtfcHk0ljrQNXOqx_A1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslansrw%253D&md5=4a04359c59e54b12d8a67efb6ef42e4c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnrm909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm909%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATs%253A%2520transcriptional%2520control%2520and%2520biological%2520impact%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D651%26epage%3D662%26doi%3D10.1038%2Fnrm909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11280</span>– <span class="NLM_lpage">11300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01530</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01530" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11280-11300&author=H.+Zhouauthor=L.+Baiauthor=R.+Xuauthor=Y.+Zhaoauthor=J.+Chenauthor=D.+McEachernauthor=K.+Chinnaswamyauthor=B.+Wenauthor=L.+Daiauthor=P.+Kumarauthor=C.-Y.+Yangauthor=Z.+Liuauthor=M.+Wangauthor=L.+Liuauthor=J.+L.+Meagherauthor=H.+Yiauthor=D.+Sunauthor=J.+A.+Stuckeyauthor=S.+Wang&title=Structure-based+discovery+of+SD-36+as+a+potent%2C+selective%2C+and+efficacious+PROTAC+degrader+of+STAT3+protein&doi=10.1021%2Facs.jmedchem.9b01530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein</span></div><div class="casAuthors">Zhou, Haibin; Bai, Longchuan; Xu, Renqi; Zhao, Yujun; Chen, Jianyong; McEachern, Donna; Chinnaswamy, Krishnapriya; Wen, Bo; Dai, Lipeng; Kumar, Praveen; Yang, Chao-Yie; Liu, Zhaomin; Wang, Mi; Liu, Liu; Meagher, Jennifer L.; Yi, Han; Sun, Duxin; Stuckey, Jeanne A.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11280-11300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases.  Despite twenty-years of persistent research efforts, targeting STAT3 has been very challenging.  The authors report herein the structure-based discovery of potent small-mol. STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept.  The authors first designed SI-109 as a potent, small-mol. inhibitor of the STAT3 SH2 domain.  Employing ligands for cereblon/Cullin 4A E3 ligase and SI-109, the authors obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36.  SD-36 induces rapid STAT3 degrdn. at low nanomolar concns. in cells and fails to degrader other STAT proteins.  SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3.  A single dose of SD-36 results in complete STAT3 protein degrdn. in xenograft tumor tissue and normal mouse tissues.  SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules.  SD-36 is a potent, selective and efficacious STAT3 degrader.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIAWd1hiuqy7Vg90H21EOLACvtfcHk0lgII0Pjt_swwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SnsL3J&md5=7d0c656a2d96196a3b71829c9efe715a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01530%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-based%2520discovery%2520of%2520SD-36%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520PROTAC%2520degrader%2520of%2520STAT3%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11280%26epage%3D11300%26doi%3D10.1021%2Facs.jmedchem.9b01530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bioorg.2018.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30245235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=536-544&author=H.+Chenauthor=F.+Chenauthor=N.+Liuauthor=X.+Wangauthor=S.+Gou&title=Chemically+induced+degradation+of+CK2+by+proteolysis+targeting+chimeras+based+on+a+ubiquitin-proteasome+pathway&doi=10.1016%2Fj.bioorg.2018.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway</span></div><div class="casAuthors">Chen, Hong; Chen, Feihong; Liu, Nannan; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">536-544</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a ubiquitous, highly pleiotropic and constitutively active serine/threonine protein kinase, casein kinase 2 (CK2) is closely assocd. with tumorigenesis by its overexpression in cancer cells.  Here we report several proteolysis targeting chimeras (PROTACs) via "click reaction" to connect a CK2 inhibitor (CX-4945) and pomalidomide for degrdn. of CK2 protein.  Among them, compd. 2 degraded CK2 in a dose and time-dependent manner, and kept CK2 at a low basal level by recruiting ubiquitin-proteasome system (UPS).  The degrdn. of CK2 resulted in the reduced phosphorylation of Akt and the up-regulation of p53.  As a CK2 protein degrader, 2 showed the analogous cytotoxicity to CX-4945 but with a quite different mechanism of action from the CK2 inhibitor, hinting that degrdn. of CK2 proteins by PROTACs is a potential way for cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVzJ2UGozoLLVg90H21EOLACvtfcHk0lgII0Pjt_swwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fJ&md5=d724e5c8420ae4e57916ac3000d9c408</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520CK2%2520by%2520proteolysis%2520targeting%2520chimeras%2520based%2520on%2520a%2520ubiquitin-proteasome%2520pathway%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D536%26epage%3D544%26doi%3D10.1016%2Fj.bioorg.2018.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7042</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7042-7057&author=H.+Wuauthor=K.+Yangauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=Z.+Liauthor=H.+Xieauthor=J.+Liuauthor=K.+A.+Smithauthor=Z.+Novakovaauthor=C.+Barinkaauthor=W.+Tang&title=Development+of+multifunctional+histone+deacetylase+6+degraders+with+potent+antimyeloma+activity&doi=10.1021%2Facs.jmedchem.9b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span></div><div class="casAuthors">Wu, Hao; Yang, Ka; Zhang, Zhongrui; Leisten, Eric D.; Li, Ziyuan; Xie, Haibo; Liu, Jin; Smith, Kerry A.; Novakova, Zora; Barinka, Cyril; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7042-7057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90.  HDAC6 is involved in multiple disease-relevant pathways.  Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand.  We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degrdn. for the antiproliferation of multiple myeloma (MM).  This new class of degraders exhibited improved potency and selectivity for the degrdn. of HDAC6.  After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb58zf04V2GLVg90H21EOLACvtfcHk0lgII0Pjt_swwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO&md5=7aab402404a5fce732b4b68fd76395d4</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00516%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520multifunctional%2520histone%2520deacetylase%25206%2520degraders%2520with%2520potent%2520antimyeloma%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7042%26epage%3D7057%26doi%3D10.1021%2Facs.jmedchem.9b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of dual and selective degraders of cyclin-dependent kinases 4 and 6</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6326</span>, <span class="refDoi"> DOI: 10.1002/anie.201901336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fanie.201901336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6321-6326&author=B.+Jiangauthor=E.+S.+Wangauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Fischerauthor=T.+Zhangauthor=N.+S.+Gray&title=Development+of+dual+and+selective+degraders+of+cyclin-dependent+kinases+4+and+6&doi=10.1002%2Fanie.201901336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6</span></div><div class="casAuthors">Jiang, Baishan; Wang, Eric S.; Donovan, Katherine A.; Liang, Yanke; Fischer, Eric S.; Zhang, Tinghu; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6321-6326</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.  However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive.  Here, we report imide-based degrader mols. capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6.  We were also able to tune the activity of these mols. against Ikaros (IKZF1) and Aiolos (IKZF3), which are well-established targets of imide-based degraders.  We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degrdn. with dual CDK4/6 degrdn. produced enhanced anti-proliferative effects compared to CDK4/6 inhibition, CDK4/6 degrdn., or IKZF1/3 degrdn.  In summary, we report here the first compds. capable of inducing selective degrdn. of CDK4 and CDK6 as tools to pharmacol. dissect their distinct biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Vsqs-SM6hrVg90H21EOLACvtfcHk0lg9KYsW75j7Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D&md5=39a6937b24abad0940d359020e2b2f74</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fanie.201901336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201901336%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520dual%2520and%2520selective%2520degraders%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D6321%26epage%3D6326%26doi%3D10.1002%2Fanie.201901336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bassi, Z. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillmore, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galwey, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddington, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parravicini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macmillan-Jones, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gongora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tough, D. F.</span></span> <span> </span><span class="NLM_article-title">Modulating PCAF/GCN5 immune cell function through a PROTAC approach</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2862</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00705</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00705" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OktL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2862-2867&author=Z.+I.+Bassiauthor=M.+C.+Fillmoreauthor=A.+H.+Miahauthor=T.+D.+Chapmanauthor=C.+Mallerauthor=E.+J.+Robertsauthor=L.+C.+Davisauthor=D.+E.+Lewisauthor=N.+W.+Galweyauthor=K.+E.+Waddingtonauthor=V.+Parraviciniauthor=A.+L.+Macmillan-Jonesauthor=C.+Gongoraauthor=P.+G.+Humphreysauthor=I.+Churcherauthor=R.+K.+Prinjhaauthor=D.+F.+Tough&title=Modulating+PCAF%2FGCN5+immune+cell+function+through+a+PROTAC+approach&doi=10.1021%2Facschembio.8b00705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach</span></div><div class="casAuthors">Bassi, Zuni I.; Fillmore, Martin C.; Miah, Afjal H.; Chapman, Trevor D.; Maller, Claire; Roberts, Emma J.; Davis, Lauren C.; Lewis, Darcy E.; Galwey, Nicholas W.; Waddington, Kirsty E.; Parravicini, Valentino; Macmillan-Jones, Abigail L.; Gongora, Celine; Humphreys, Philip G.; Churcher, Ian; Prinjha, Rab K.; Tough, David F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2862-2867</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P300/CBP-assocd. factor (PCAF) and general control nonderepressible 5 (GCN5) are closely related epigenetic proteins, each contg. an acetyltransferase domain and a bromodomain.  Consistent with reported roles for these proteins in immune function, we find that PCAF-deficient macrophages exhibit a markedly reduced ability to produce cytokines upon stimulation with lipopolysaccharide (LPS).  Investigating the potential to target this pathway pharmacol., we show that chem. inhibition of the PCAF/GCN5 bromodomains is insufficient to recapitulate the diminished inflammatory response of PCAF-deficient immune cells.  However, by generating the first PCAF/GCN5 proteolysis targeting chimera (PROTAC), we identify small mols. able to degrade PCAF/GCN5 and to potently modulate the expression of multiple inflammatory mediators in LPS-stimulated macrophages and dendritic cells.  Our data illustrate the power of the PROTAC approach in the context of multidomain proteins, revealing a novel anti-inflammatory therapeutic opportunity for targeting PCAF/GCN5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUuwZ6JZtCirVg90H21EOLACvtfcHk0lg9KYsW75j7Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OktL7I&md5=6783f39397381536ed40ac9e1b20fa5b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00705%26sid%3Dliteratum%253Aachs%26aulast%3DBassi%26aufirst%3DZ.%2BI.%26aulast%3DFillmore%26aufirst%3DM.%2BC.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DChapman%26aufirst%3DT.%2BD.%26aulast%3DMaller%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DE.%2BJ.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DLewis%26aufirst%3DD.%2BE.%26aulast%3DGalwey%26aufirst%3DN.%2BW.%26aulast%3DWaddington%26aufirst%3DK.%2BE.%26aulast%3DParravicini%26aufirst%3DV.%26aulast%3DMacmillan-Jones%26aufirst%3DA.%2BL.%26aulast%3DGongora%26aufirst%3DC.%26aulast%3DHumphreys%26aufirst%3DP.%2BG.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DTough%26aufirst%3DD.%2BF.%26atitle%3DModulating%2520PCAF%252FGCN5%2520immune%2520cell%2520function%2520through%2520a%2520PROTAC%2520approach%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D2862%26epage%3D2867%26doi%3D10.1021%2Facschembio.8b00705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurizi, M. R.</span></span> <span> </span><span class="NLM_article-title">Human mitochondrial ClpP is a stable heptamer that assembles into a tetradecamer in the presence of ClpX</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">35424</span>– <span class="NLM_lpage">35432</span>, <span class="refDoi"> DOI: 10.1074/jbc.M507240200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1074%2Fjbc.M507240200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16115876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWmurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=35424-35432&author=S.+G.+Kangauthor=M.+N.+Dimitrovaauthor=J.+Ortegaauthor=A.+Ginsburgauthor=M.+R.+Maurizi&title=Human+mitochondrial+ClpP+is+a+stable+heptamer+that+assembles+into+a+tetradecamer+in+the+presence+of+ClpX&doi=10.1074%2Fjbc.M507240200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Human Mitochondrial ClpP Is a Stable Heptamer That Assembles into a Tetradecamer in the Presence of ClpX</span></div><div class="casAuthors">Kang, Sung Gyun; Dimitrova, Mariana N.; Ortega, Joaquin; Ginsburg, Ann; Maurizi, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">35424-35432</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The functional form of ClpP, the proteolytic component of ATP-dependent Clp proteases, is a hollow-cored particle composed of two heptameric rings joined face-to-face forming an aq. chamber contg. the proteolytic active sites.  We have found that isolated human mitochondrial ClpP (hClpP) is stable as a heptamer and remains a monodisperse species (s20,w 7.0 S; Mapp 169, 200) at concns. ≥3 mg/mL.  Heptameric hClpP has no proteolytic activity and very low peptidase activity.  In the presence of ATP, hClpX interacts with hClpP forming a complex, which by equil. sedimentation measurements has a Mapp of 1 × 106.  Electron microscopy confirmed that the complex consisted of a double ring of hClpP with an hClpX ring axially aligned on each end.  The hClpXP complex has protease activity and greatly increased peptidase activity, indicating that interaction with hClpX affects the conformation of the hClpP catalytic active site.  A mutant of hClpP, in which a cysteine residue was introduced into the handle region at the interface between the two rings formed stable tetradecamers under oxidizing conditions but spontaneously dissocd. into two heptamers upon redn.  Thus, hClpP rings interact transiently but very weakly in soln., and hClpX must exert an allosteric effect on hClpP to promote a conformation that stabilizes the tetradecamer.  These data suggest that hClpX can regulate the appearance of hClpP peptidase activity in mitochondria and might affect the nature of the degrdn. products released during ATP-dependent proteolytic cycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsYy_dZvM84LVg90H21EOLACvtfcHk0li7CzvudOTDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWmurzI&md5=5f4265d7d51c7794eb92df5c4838132c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M507240200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M507240200%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BG.%26aulast%3DDimitrova%26aufirst%3DM.%2BN.%26aulast%3DOrtega%26aufirst%3DJ.%26aulast%3DGinsburg%26aufirst%3DA.%26aulast%3DMaurizi%26aufirst%3DM.%2BR.%26atitle%3DHuman%2520mitochondrial%2520ClpP%2520is%2520a%2520stable%2520heptamer%2520that%2520assembles%2520into%2520a%2520tetradecamer%2520in%2520the%2520presence%2520of%2520ClpX%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D35424%26epage%3D35432%26doi%3D10.1074%2Fjbc.M507240200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurizi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahvazi, B.</span></span> <span> </span><span class="NLM_article-title">Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2004.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.jsb.2004.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15522782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Squr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2004&pages=338-352&author=S.+G.+Kangauthor=M.+R.+Mauriziauthor=M.+Thompsonauthor=T.+Mueserauthor=B.+Ahvazi&title=Crystallography+and+mutagenesis+point+to+an+essential+role+for+the+N-terminus+of+human+mitochondrial+ClpP&doi=10.1016%2Fj.jsb.2004.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallography and mutagenesis point to an essential role for the N-terminus of human mitochondrial ClpP</span></div><div class="casAuthors">Kang, Sung Gyun; Maurizi, Michael R.; Thompson, Mark; Mueser, Timothy; Ahvazi, Bijan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">338-352</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We have detd. a 2.1 Å crystal structure for human mitochondrial ClpP (hClpP), the proteolytic component of the ATP-dependent ClpXP protease.  HClpP has a structure similar to that of the bacterial enzyme, with the proteolytic active sites sequestered within an aq. chamber formed by face-to-face assembly of the two heptameric rings.  The hydrophobic N-terminal peptides of the subunits are bound within the narrow (12 Å) axial channel, positioned to interact with unfolded substrates translocated there by the assocd. ClpX chaperone.  Mutation or deletion of these residues causes a drastic decrease in ClpX-mediated protein and peptide degrdn.  Residues 8-16 form a mobile loop that extends above the ring surface and is also required for activity.  The 28 amino acid C-terminal domain, a unique feature of mammalian ClpP proteins, lies on the periphery of the ring, with its proximal portion forming a loop that extends out from the ring surface.  Residues at the start of the C-terminal domain impinge on subunit interfaces within the ring and affect heptamer assembly and stability.  We propose that the N-terminal peptide of ClpP is a structural component of the substrate translocation channel and may play an important functional role as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsX5RAG7dc7rVg90H21EOLACvtfcHk0li7CzvudOTDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Squr0%253D&md5=54ec88f302b433cc44e3109a1f9cb0f9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2004.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2004.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BG.%26aulast%3DMaurizi%26aufirst%3DM.%2BR.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DMueser%26aufirst%3DT.%26aulast%3DAhvazi%26aufirst%3DB.%26atitle%3DCrystallography%2520and%2520mutagenesis%2520point%2520to%2520an%2520essential%2520role%2520for%2520the%2520N-terminus%2520of%2520human%2520mitochondrial%2520ClpP%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2004%26volume%3D148%26spage%3D338%26epage%3D352%26doi%3D10.1016%2Fj.jsb.2004.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, R. T.</span></span> <span> </span><span class="NLM_article-title">Diverse pore loops of the AAA+ ClpX machine mediate unassisted and adaptor-dependent recognition of ssrA-tagged substrates</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2008.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.molcel.2008.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18313382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=441-450&author=A.+Martinauthor=T.+A.+Bakerauthor=R.+T.+Sauer&title=Diverse+pore+loops+of+the+AAA%2B+ClpX+machine+mediate+unassisted+and+adaptor-dependent+recognition+of+ssrA-tagged+substrates&doi=10.1016%2Fj.molcel.2008.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse pore loops of the AAA+ ClpX machine mediate unassisted and adaptor-dependent recognition of ssrA-tagged substrates</span></div><div class="casAuthors">Martin, Andreas; Baker, Tania A.; Sauer, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ClpX, an archetypal proteolytic AAA+ unfoldase, must engage the ssrA tags of appropriate substrates prior to ATP-dependent unfolding and translocation of the denatured polypeptide into ClpP for degrdn.  Here, specificity-transplant and disulfide-crosslinking expts. reveal that the ssrA tag interacts with different loops that form the top, middle, and lower portions of the central channel of the ClpX hexamer.  Our results support a two-step binding mechanism, in which the top loop serves as a specificity filter and the remaining loops form a binding site for the peptide tag relatively deep within the pore.  Crosslinking expts. suggest a staggered arrangement of pore loops in the hexamer and nucleotide-dependent changes in pore-loop conformations.  This mechanism of initial tag binding would allow ATP-dependent conformational changes in one or more pore loops to drive peptide translocation, force unfolding, and mediate threading of the denatured protein through the ClpX pore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWUaE9Yw5ywrVg90H21EOLACvtfcHk0li7CzvudOTDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFCgsbc%253D&md5=e4c1d83f2c188ee90bbbe38886b5140a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DT.%2BA.%26aulast%3DSauer%26aufirst%3DR.%2BT.%26atitle%3DDiverse%2520pore%2520loops%2520of%2520the%2520AAA%252B%2520ClpX%2520machine%2520mediate%2520unassisted%2520and%2520adaptor-dependent%2520recognition%2520of%2520ssrA-tagged%2520substrates%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D29%26spage%3D441%26epage%3D450%26doi%3D10.1016%2Fj.molcel.2008.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ologbenla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W. A.</span></span> <span> </span><span class="NLM_article-title">Dynamics of the ClpP serine protease: a model for self-compartmentalized proteases</span>. <i>Crit. Rev. Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.3109/10409238.2014.925421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3109%2F10409238.2014.925421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=24915503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12kurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2014&pages=400-412&author=K.+Liuauthor=A.+Ologbenlaauthor=W.+A.+Houry&title=Dynamics+of+the+ClpP+serine+protease%3A+a+model+for+self-compartmentalized+proteases&doi=10.3109%2F10409238.2014.925421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamics of the ClpP serine protease: A model for self-compartmentalized proteases</span></div><div class="casAuthors">Liu, Kaiyin; Ologbenla, Adedeji; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">400-412</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  ClpP is a highly conserved serine protease present in most bacterial species and in the mitochondria of mammalian cells.  It forms a cylindrical tetradecameric complex arranged into two stacked heptamers.  The two heptameric rings of ClpP enclose a roughly spherical proteolytic chamber of about 51 Å in diam. with 14 Ser-His-Asp proteolytic active sites.  ClpP typically forms complexes with unfoldase chaperones of the AAA+ superfamily.  Chaperones dock on one or both ends of the ClpP double ring cylindrical structure.  Dynamics in the ClpP structure is crit. for its function.  Polypeptides targeted for degrdn. by ClpP are initially recognized by the AAA+ chaperones.  Polypeptides are unfolded by the chaperones and then translocated through the ClpP axial pores, present on both ends of the ClpP cylinder, into the ClpP catalytic chamber.  The axial pores of ClpP are gated by dynamic axial loops that restrict or allow substrate entry.  As a processive protease, ClpP degrades substrates to generate peptides of about 7-8 residues.  Based on structural, biochem. and theor. studies, the exit of these polypeptides from the proteolytic chamber is proposed to be mediated by the dynamics of the ClpP oligomer.  The ClpP cylinder has been found to exist in at least three conformations, extended, compact and compressed, that seem to represent different states of ClpP during its proteolytic functional cycle.  In this review, we discuss the link between ClpP dynamics and its activity.  We propose that such dynamics also exist in other cylindrical proteases such as HslV and the proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp95bFqjiaoI7Vg90H21EOLACvtfcHk0lgbPHlPjsq5IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12kurfI&md5=868f593942a12da6c9b9be2d46a17c93</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3109%2F10409238.2014.925421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2014.925421%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DOlogbenla%26aufirst%3DA.%26aulast%3DHoury%26aufirst%3DW.%2BA.%26atitle%3DDynamics%2520of%2520the%2520ClpP%2520serine%2520protease%253A%2520a%2520model%2520for%2520self-compartmentalized%2520proteases%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D49%26spage%3D400%26epage%3D412%26doi%3D10.3109%2F10409238.2014.925421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levichkin, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasinopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogenraad, N. J.</span></span> <span> </span><span class="NLM_article-title">A mitochondrial specific stress response in mammalian cells</span>. <i>EMBO journal</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4411</span>– <span class="NLM_lpage">4419</span>, <span class="refDoi"> DOI: 10.1093/emboj/cdf445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1093%2Femboj%2Fcdf445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Knu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=4411-4419&author=Q.+Zhaoauthor=J.+Wangauthor=I.+V.+Levichkinauthor=S.+Stasinopoulosauthor=M.+T.+Ryanauthor=N.+J.+Hoogenraad&title=A+mitochondrial+specific+stress+response+in+mammalian+cells&doi=10.1093%2Femboj%2Fcdf445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A mitochondrial specific stress response in mammalian cells</span></div><div class="casAuthors">Zhao, Quan; Wang, Jianghui; Levichkin, Ilya V.; Stasinopoulos, Stan; Ryan, Michael T.; Hoogenraad, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4411-4419</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cells respond to a wide variety of stresses through the transcriptional activation of genes that harbor stress elements within their promoters.  While many of these elements are shared by genes encoding proteins representative of all subcellular compartments, cells can also respond to stresses that are specific to individual organelles, such as the endoplasmic reticulum unfolded protein response.  Here the authors report on the discovery and characterization of a mitochondrial stress response in mammalian cells.  The authors find that the accumulation of unfolded protein within the mitochondrial matrix results in the transcriptional upregulation of nuclear genes encoding mitochondrial stress proteins such as chaperonin 60, chaperonin 10, mtDnaJ and ClpP, but not those encoding stress proteins of the endoplasmic reticulum.  Anal. of the chaperonin 60/10 bidirectional promoter identified a CHOP element as the mitochondrial stress response element.  Dominant-neg. mutant forms of CHOP and overexpression of CHOP revealed that this transcription factor, in assocn. with C/EBPβ, regulates expression of mitochondrial stress genes in response to the accumulation of unfolded proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKDp4TX9kK7Vg90H21EOLACvtfcHk0lgbPHlPjsq5IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Knu7w%253D&md5=53c22763d7e99abcb02ff364973ca71c</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1093%2Femboj%2Fcdf445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252Fcdf445%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLevichkin%26aufirst%3DI.%2BV.%26aulast%3DStasinopoulos%26aufirst%3DS.%26aulast%3DRyan%26aufirst%3DM.%2BT.%26aulast%3DHoogenraad%26aufirst%3DN.%2BJ.%26atitle%3DA%2520mitochondrial%2520specific%2520stress%2520response%2520in%2520mammalian%2520cells%26jtitle%3DEMBO%2520journal%26date%3D2002%26volume%3D21%26spage%3D4411%26epage%3D4419%26doi%3D10.1093%2Femboj%2Fcdf445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cormio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sardanelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadaleta, M. N.</span></span> <span> </span><span class="NLM_article-title">Increase in proteins involved in mitochondrial fission, mitophagy, proteolysis and antioxidant response in type I endometrial cancer as an adaptive response to respiratory complex I deficiency</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bbrc.2017.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28698145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFygt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2017&pages=85-90&author=A.+Cormioauthor=C.+Musiccoauthor=G.+Gasparreauthor=G.+Cormioauthor=V.+Pesceauthor=A.+M.+Sardanelliauthor=M.+N.+Gadaleta&title=Increase+in+proteins+involved+in+mitochondrial+fission%2C+mitophagy%2C+proteolysis+and+antioxidant+response+in+type+I+endometrial+cancer+as+an+adaptive+response+to+respiratory+complex+I+deficiency&doi=10.1016%2Fj.bbrc.2017.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Increase in proteins involved in mitochondrial fission, mitophagy, proteolysis and antioxidant response in type I endometrial cancer as an adaptive response to respiratory complex I deficiency</span></div><div class="casAuthors">Cormio, Antonella; Musicco, Clara; Gasparre, Giuseppe; Cormio, Gennaro; Pesce, Vito; Sardanelli, Anna Maria; Gadaleta, Maria Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-90</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pathogenic mtDNA mutations assocd. with alterations of respiratory complex I, mitochondrial proliferation (oncocytic-like phenotype) and increase in antioxidant response were previously reported in type I endometrial carcinoma (EC).  To evaluate whether in the presence of pathogenic mtDNA mutations other mitochondrial adaptive processes are triggered by cancer cells, the expression level of proteins involved in mitochondrial dynamics, mitophagy, proteolysis and apoptosis were evaluated in type I ECs harboring pathogenic mtDNA mutations and complex I deficiency.  An increase in the fission protein Drp1, in the mitophagy protein BNIP3, in the mitochondrial protease CLPP, in the antioxidant and anti-apoptotic protein ALR and in Bcl-2 as well as a decrease in the fusion protein Mfn2 were found in cancer compared to matched non malignant tissue.  Moreover, the level of these proteins was measured in type I EC, in hyperplastic (the premalignant form) and in non malignant tissues to verify whether the altered expression of these proteins is a common feature of endometrial cancer and of hyperplastic tissue.  This anal. confirmed in type I EC samples, but not in hyperplasia, an alteration of the expression level of these proteins.  These results suggest that in this cancer mitochondrial fission, antioxidant and anti-apoptotic response may be activated, as well as the discharge of damaged mitochondrial proteins as adaptation processes to mitochondrial dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9llNbpGOdv7Vg90H21EOLACvtfcHk0lgbPHlPjsq5IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFygt7jF&md5=dd8aefa8accec8546ed5c8ac3140ae5e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DCormio%26aufirst%3DA.%26aulast%3DMusicco%26aufirst%3DC.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DCormio%26aufirst%3DG.%26aulast%3DPesce%26aufirst%3DV.%26aulast%3DSardanelli%26aufirst%3DA.%2BM.%26aulast%3DGadaleta%26aufirst%3DM.%2BN.%26atitle%3DIncrease%2520in%2520proteins%2520involved%2520in%2520mitochondrial%2520fission%252C%2520mitophagy%252C%2520proteolysis%2520and%2520antioxidant%2520response%2520in%2520type%2520I%2520endometrial%2520cancer%2520as%2520an%2520adaptive%2520response%2520to%2520respiratory%2520complex%2520I%2520deficiency%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D491%26spage%3D85%26epage%3D90%26doi%3D10.1016%2Fj.bbrc.2017.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivadeneira, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaira, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palleschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Languino, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, D. C.</span></span> <span> </span><span class="NLM_article-title">The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1002507</span> <span class="refDoi"> DOI: 10.1371/journal.pbio.1002507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1371%2Fjournal.pbio.1002507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27389535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWgtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&author=J.+H.+Seoauthor=D.+B.+Rivadeneiraauthor=M.+C.+Cainoauthor=Y.+C.+Chaeauthor=D.+W.+Speicherauthor=H.+Y.+Tangauthor=V.+Vairaauthor=S.+Bosariauthor=A.+Palleschiauthor=P.+Rampiniauthor=A.+V.+Kossenkovauthor=L.+R.+Languinoauthor=D.+C.+Altieri&title=The+mitochondrial+unfoldase-peptidase+complex+ClpXP+controls+bioenergetics+stress+and+metastasis&doi=10.1371%2Fjournal.pbio.1002507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis</span></div><div class="casAuthors">Seo, Jae Ho; Rivadeneira, Dayana B.; Caino, M. Cecilia; Chae, Young Chan; Speicher, David W.; Tang, Hsin-Yao; Vaira, Valentina; Bosari, Silvano; Palleschi, Alessandro; Rampini, Paolo; Kossenkov, Andrew V.; Languino, Lucia R.; Altieri, Dario C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1002507/1-e1002507/21</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Mitochondria must buffer the risk of proteotoxic stress to preserve bioenergetics, but the role of these mechanisms in disease is poorly understood.  Using a proteomics screen, we now show that the mitochondrial unfoldase-peptidase complex ClpXP assocs. with the oncoprotein survivin and the respiratory chain Complex II subunit succinate dehydrogenase B (SDHB) in mitochondria of tumor cells.  Knockdown of ClpXP subunits ClpP or ClpX induces the accumulation of misfolded SDHB, impairing oxidative phosphorylation and ATP prodn. while activating "stress" signals of 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and autophagy.  Deregulated mitochondrial respiration induced by ClpXP targeting causes oxidative stress, which in turn reduces tumor cell proliferation, suppresses cell motility, and abolishes metastatic dissemination in vivo.  ClpP is universally overexpressed in primary and metastatic human cancer, correlating with shortened patient survival.  Therefore, tumors exploit ClpXP-directed proteostasis to maintain mitochondrial bioenergetics, buffer oxidative stress, and enable metastatic competence.  This pathway may provide a "drugable" therapeutic target in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVfOEi0b0tFbVg90H21EOLACvtfcHk0lhkftt4q3jsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWgtb3J&md5=52c9c4dff980aca286238f21e4e62191</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1002507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1002507%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DRivadeneira%26aufirst%3DD.%2BB.%26aulast%3DCaino%26aufirst%3DM.%2BC.%26aulast%3DChae%26aufirst%3DY.%2BC.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26aulast%3DTang%26aufirst%3DH.%2BY.%26aulast%3DVaira%26aufirst%3DV.%26aulast%3DBosari%26aufirst%3DS.%26aulast%3DPalleschi%26aufirst%3DA.%26aulast%3DRampini%26aufirst%3DP.%26aulast%3DKossenkov%26aufirst%3DA.%2BV.%26aulast%3DLanguino%26aufirst%3DL.%2BR.%26aulast%3DAltieri%26aufirst%3DD.%2BC.%26atitle%3DThe%2520mitochondrial%2520unfoldase-peptidase%2520complex%2520ClpXP%2520controls%2520bioenergetics%2520stress%2520and%2520metastasis%26jtitle%3DPLoS%2520Biol.%26date%3D2016%26volume%3D14%26doi%3D10.1371%2Fjournal.pbio.1002507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabharwal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacker, P. T.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel?</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1038/nrc3803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fnrc3803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25342630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=709-721&author=S.+S.+Sabharwalauthor=P.+T.+Schumacker&title=Mitochondrial+ROS+in+cancer%3A+initiators%2C+amplifiers+or+an+Achilles%E2%80%99+heel%3F&doi=10.1038%2Fnrc3803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?</span></div><div class="casAuthors">Sabharwal, Simran S.; Schumacker, Paul T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">709-721</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mitochondria cooperate with their host cells by contributing to bioenergetics, metab., biosynthesis, and cell death or survival functions.  Reactive oxygen species (ROS) generated by mitochondria participate in stress signalling in normal cells but also contribute to the initiation of nuclear or mitochondrial DNA mutations that promote neoplastic transformation.  In cancer cells, mitochondrial ROS amplify the tumorigenic phenotype and accelerate the accumulation of addnl. mutations that lead to metastatic behavior.  As mitochondria carry out important functions in normal cells, disabling their function is not a feasible therapy for cancer.  However, ROS signalling contributes to proliferation and survival in many cancers, so the targeted disruption of mitochondria-to-cell redox communication represents a promising avenue for future therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNrCJgdvCMg7Vg90H21EOLACvtfcHk0lhkftt4q3jsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLbO&md5=96707798e33043d755b569fd089d8617</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnrc3803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3803%26sid%3Dliteratum%253Aachs%26aulast%3DSabharwal%26aufirst%3DS.%2BS.%26aulast%3DSchumacker%26aufirst%3DP.%2BT.%26atitle%3DMitochondrial%2520ROS%2520in%2520cancer%253A%2520initiators%252C%2520amplifiers%2520or%2520an%2520Achilles%25E2%2580%2599%2520heel%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D709%26epage%3D721%26doi%3D10.1038%2Fnrc3803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeiler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz-Baath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">Development and characterization of improved β-lactone-based anti-virulence drugs targeting ClpP</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmc.2011.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21855356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=583-591&author=E.+Zeilerauthor=V.+S.+Korotkovauthor=K.+Lorenz-Baathauthor=T.+B%C3%B6ttcherauthor=S.+A.+Sieber&title=Development+and+characterization+of+improved+%CE%B2-lactone-based+anti-virulence+drugs+targeting+ClpP&doi=10.1016%2Fj.bmc.2011.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of improved β-lactone-based anti-virulence drugs targeting ClpP</span></div><div class="casAuthors">Zeiler, Evelyn; Korotkov, Vadim S.; Lorenz-Baath, Katrin; Boettcher, Thomas; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">583-591</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we report the synthesis and in depth characterization of a second generation β-lactone derived virulence inhibitors.  Based on initial results that emphasized the intriguing possibility to disarm bacteria in their virulence the present study develops this concept further and analyses the potential of this strategy for drug development.  We were able to expand the collection of bioactive compds. via an efficient synthetic route.  Testing of all compds. revealed several hits with anti-virulence activity.  Moreover, we demonstrated that these mols. act solely by reducing virulence but not killing bacteria which is an important prerequisite for preserving the useful microbiome.  Finally, incubation of lactones with eukaryotic cell lines indicated a tolerable cytotoxicity which is essential for entering animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlc86XDsGH9bVg90H21EOLACvtfcHk0lhkftt4q3jsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFShsQ%253D%253D&md5=e721d142315991665c2135dfe037dd4c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DZeiler%26aufirst%3DE.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DLorenz-Baath%26aufirst%3DK.%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DT.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520improved%2520%25CE%25B2-lactone-based%2520anti-virulence%2520drugs%2520targeting%2520ClpP%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D583%26epage%3D591%26doi%3D10.1016%2Fj.bmc.2011.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackl, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakemeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz-Baath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">phenyl esters are potent inhibitors of caseinolytic protease P and reveal a stereogenic switch for deoligomerization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">8475</span>– <span class="NLM_lpage">8483</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b03084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b03084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=8475-8483&author=M.+W.+Hacklauthor=M.+Lakemeyerauthor=M.+Dahmenauthor=M.+Glaserauthor=A.+Pahlauthor=K.+Lorenz-Baathauthor=T.+Menzelauthor=S.+Sieversauthor=T.+B%C3%B6ttcherauthor=I.+Antesauthor=H.+Waldmannauthor=S.+A.+Sieber&title=phenyl+esters+are+potent+inhibitors+of+caseinolytic+protease+P+and+reveal+a+stereogenic+switch+for+deoligomerization&doi=10.1021%2Fjacs.5b03084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyl Esters Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for Deoligomerization</span></div><div class="casAuthors">Hackl, Mathias W.; Lakemeyer, Markus; Dahmen, Maria; Glaser, Manuel; Pahl, Axel; Lorenz-Baath, Katrin; Menzel, Thomas; Sievers, Sonja; Boettcher, Thomas; Antes, Iris; Waldmann, Herbert; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">8475-8483</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Caseinolytic protease P (ClpP) represents a central bacterial degrdn. machinery that is involved in cell homeostasis and pathogenicity.  The functional role of ClpP has been studied by genetic knockouts and through the use of beta-lactones, which remain the only specific inhibitors of ClpP discovered to date.  Beta-lactones have served as chem. tools to manipulate ClpP in several organisms; however, their potency, selectivity and stability is limited.  Despite detailed structural insights into the compn. and conformational flexibility of the ClpP active site, no rational efforts to design specific non-beta-lactone inhibitors have been reported to date.  In this work, an unbiased screen of more than 137 000 compds. was used to identify five Ph ester compds. as highly potent ClpP inhibitors that were selective for bacterial, but not human ClpP.  The potency of Ph esters largely exceeded that of beta-lactones in ClpP peptidase and protease inhibition assays and displayed unique target selectivity in living S. aureus cells.  Anal. studies revealed that while Ph esters are cleaved like native peptide substrates, they remain covalently trapped as acyl-enzyme intermediates in the active site.  The synthesis of 36 derivs. and subsequent structure-activity relationship (SAR) studies provided insights into conserved structural elements that are important for inhibition potency and acylation reactivity.  Moreover, the stereochem. of a methyl-substituent at the alpha position to the ester, resembling amino acid side chains in peptide substrates, impacted ClpP complex stability, causing either dissocn. into heptamers or retention of the tetradecameric state.  Mechanistic insights into this intriguing stereo switch and the Ph ester binding mode were obtained by mol. docking expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxvq3gVIPaQLVg90H21EOLACvtfcHk0lheCnBCxQLuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rI&md5=5fb5e46ba6041a9530688cb0587bb50d</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b03084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b03084%26sid%3Dliteratum%253Aachs%26aulast%3DHackl%26aufirst%3DM.%2BW.%26aulast%3DLakemeyer%26aufirst%3DM.%26aulast%3DDahmen%26aufirst%3DM.%26aulast%3DGlaser%26aufirst%3DM.%26aulast%3DPahl%26aufirst%3DA.%26aulast%3DLorenz-Baath%26aufirst%3DK.%26aulast%3DMenzel%26aufirst%3DT.%26aulast%3DSievers%26aufirst%3DS.%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DT.%26aulast%3DAntes%26aufirst%3DI.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3Dphenyl%2520esters%2520are%2520potent%2520inhibitors%2520of%2520caseinolytic%2520protease%2520P%2520and%2520reveal%2520a%2520stereogenic%2520switch%2520for%2520deoligomerization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D8475%26epage%3D8483%26doi%3D10.1021%2Fjacs.5b03084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gronauer, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandl, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakemeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackl, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meßner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachmayr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tailored human caseinolytic protease P inhibitors</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">9833</span>– <span class="NLM_lpage">9836</span>, <span class="refDoi"> DOI: 10.1039/C8CC05265D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1039%2FC8CC05265D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30109319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=9833-9836&author=T.+F.+Gronauerauthor=M.+M.+Mandlauthor=M.+Lakemeyerauthor=M.+W.+Hacklauthor=M.+Me%C3%9Fnerauthor=V.+S.+Korotkovauthor=J.+Pachmayrauthor=S.+A.+Sieber&title=Design+and+synthesis+of+tailored+human+caseinolytic+protease+P+inhibitors&doi=10.1039%2FC8CC05265D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tailored human caseinolytic protease P inhibitors</span></div><div class="casAuthors">Gronauer, Thomas F.; Mandl, Melanie M.; Lakemeyer, Markus; Hackl, Mathias W.; Messner, Martina; Korotkov, Vadim S.; Pachmayr, Johanna; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">70</span>),
    <span class="NLM_cas:pages">9833-9836</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Human caseinolytic protease P (hClpP) is important for degrdn. of misfolded proteins in the mitochondrial unfolded protein response.  Here, we introduce tailored hClpP inhibitors that utilize a steric discrimination in their core naphthofuran scaffold to selectively address the human enzyme.  This novel inhibitor generation exhibited superior activity compared to previously introduced β-lactones, optimized for bacterial ClpP.  Further insights into the bioactivity and binding to cellular targets were obtained via chem. proteomics as well as proliferation and migration studies in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDnUZPmSEPWrVg90H21EOLACvtfcHk0lheCnBCxQLuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsL7M&md5=6ce8fca3b3907f80432364d92e3f5faa</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1039%2FC8CC05265D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC05265D%26sid%3Dliteratum%253Aachs%26aulast%3DGronauer%26aufirst%3DT.%2BF.%26aulast%3DMandl%26aufirst%3DM.%2BM.%26aulast%3DLakemeyer%26aufirst%3DM.%26aulast%3DHackl%26aufirst%3DM.%2BW.%26aulast%3DMe%25C3%259Fner%26aufirst%3DM.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DPachmayr%26aufirst%3DJ.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tailored%2520human%2520caseinolytic%2520protease%2520P%2520inhibitors%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2018%26volume%3D54%26spage%3D9833%26epage%3D9836%26doi%3D10.1039%2FC8CC05265D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishovitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W.</span></span> <span> </span><span class="NLM_article-title">N-Terminal peptidic boronic acids selectively inhibit human ClpXP</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3451</span>– <span class="NLM_lpage">3456</span>, <span class="refDoi"> DOI: 10.1039/c004247a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1039%2Fc004247a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20523950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=3451-3456&author=K.+Knottauthor=J.+Fishovitzauthor=S.+Thorpeauthor=I.+Leeauthor=W.+Santos&title=N-Terminal+peptidic+boronic+acids+selectively+inhibit+human+ClpXP&doi=10.1039%2Fc004247a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">N-Terminal peptidic boronic acids selectively inhibit human ClpXP</span></div><div class="casAuthors">Knott, Kenneth; Fishovitz, Jennifer; Thorpe, Steven B.; Lee, Irene; Santos, Webster L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3451-3456</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis and development of N-terminal peptidic boronic acids as protease inhibitors is reported.  N-Terminal peptidic boronic acids interrogate the S' sites of the target protein for selectivity and provide a new strategy that complements the currently known peptidic α-amino boronic acids (C-terminal boronic acids).  After screening a series of N-terminal peptidic boronic acids, the first selective inhibitor of human ClpXP, an ATP-dependent serine protease present in the mitochondrial matrix, was discovered.  This should facilitate the understanding of the physiol. function of this protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZA-P25YI47Vg90H21EOLACvtfcHk0lheCnBCxQLuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslylu7o%253D&md5=3b592584a9cc5fe49473e6de9349d7af</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1039%2Fc004247a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc004247a%26sid%3Dliteratum%253Aachs%26aulast%3DKnott%26aufirst%3DK.%26aulast%3DFishovitz%26aufirst%3DJ.%26aulast%3DThorpe%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DSantos%26aufirst%3DW.%26atitle%3DN-Terminal%2520peptidic%2520boronic%2520acids%2520selectively%2520inhibit%2520human%2520ClpXP%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D3451%26epage%3D3456%26doi%3D10.1039%2Fc004247a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grouleff, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanchikova, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yudin, A. K.</span></span> <span> </span><span class="NLM_article-title">De Novo design of boron-based peptidomimetics as potent inhibitors of human ClpP in the presence of human ClpX</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6377</span>– <span class="NLM_lpage">6390</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00878</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00878" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6377-6390&author=J.+Tanauthor=J.+J.+Grouleffauthor=Y.+Jitkovaauthor=D.+B.+Diazauthor=E.+C.+Griffithauthor=W.+Shaoauthor=A.+F.+Bogdanchikovaauthor=G.+Podaauthor=A.+D.+Schimmerauthor=R.+E.+Leeauthor=A.+K.+Yudin&title=De+Novo+design+of+boron-based+peptidomimetics+as+potent+inhibitors+of+human+ClpP+in+the+presence+of+human+ClpX&doi=10.1021%2Facs.jmedchem.9b00878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">De novo design of boron-based peptidomimetics as potent inhibitors of human ClpP in the presence of human ClpX</span></div><div class="casAuthors">Tan, Joanne; Grouleff, Julie J.; Jitkova, Yulia; Diaz, Diego B.; Griffith, Elizabeth C.; Shao, Wenjie; Bogdanchikova, Anastasia F.; Poda, Gennady; Schimmer, Aaron D.; Lee, Richard E.; Yudin, Andrei K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6377-6390</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron's ability to modulate enzyme function.  Recently, we demonstrated that boron-contg. amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids.  Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands.  This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degrdn. of misfolded proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4BMAt-T7WnbVg90H21EOLACvtfcHk0liCsea_4dLHlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqsL7M&md5=699109813275d6e188390045040c112b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00878%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DGrouleff%26aufirst%3DJ.%2BJ.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DD.%2BB.%26aulast%3DGriffith%26aufirst%3DE.%2BC.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DBogdanchikova%26aufirst%3DA.%2BF.%26aulast%3DPoda%26aufirst%3DG.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DYudin%26aufirst%3DA.%2BK.%26atitle%3DDe%2520Novo%2520design%2520of%2520boron-based%2520peptidomimetics%2520as%2520potent%2520inhibitors%2520of%2520human%2520ClpP%2520in%2520the%2520presence%2520of%2520human%2520ClpX%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6377%26epage%3D6390%26doi%3D10.1021%2Facs.jmedchem.9b00878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodreid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakhamchik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bakkouri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray-Owen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span> <span> </span><span class="NLM_article-title">Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1167</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.chembiol.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21944755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eisr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1167-1178&author=E.+Leungauthor=A.+Dattiauthor=M.+Cossetteauthor=J.+Goodreidauthor=S.+McCawauthor=M.+Mahauthor=A.+Nakhamchikauthor=K.+Ogataauthor=M.+El+Bakkouriauthor=Y.+Chengauthor=S.+Wodakauthor=B.+Egerauthor=E.+Paiauthor=J.+Liuauthor=S.+Gray-Owenauthor=R.+Bateyauthor=W.+Houry&title=Activators+of+cylindrical+proteases+as+antimicrobials%3A+identification+and+development+of+small+molecule+activators+of+ClpP+protease&doi=10.1016%2Fj.chembiol.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Activators of cylindrical proteases as antimicrobials: Identification and development of small molecule activators of ClpP protease</span></div><div class="casAuthors">Leung, Elisa; Datti, Alessandro; Cossette, Michele; Goodreid, Jordan; McCaw, Shannon E.; Mah, Michelle; Nakhamchik, Alina; Ogata, Koji; El Bakkouri, Majida; Cheng, Yi-Qiang; Wodak, Shoshana J.; Eger, Bryan T.; Pai, Emil F.; Liu, Jun; Gray-Owen, Scott; Batey, Robert A.; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1167-1178</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ClpP is a cylindrical serine protease whose ability to degrade proteins is regulated by the unfoldase ATP-dependent chaperones.  ClpP on its own can only degrade small peptides.  Here, the authors used ClpP as a target in a high-throughput screen for compds., which activate the protease and allow it to degrade larger proteins, hence, abolishing the specificity arising from the ATP-dependent chaperones.  Their screen resulted in five distinct compds., which we designate as Activators of Self-Compartmentalizing Proteases 1 to 5 (ACP1 to 5).  The compds. are found to stabilize the ClpP double-ring structure.  The ACP1 chem. structure was considered to have drug-like characteristics and was further optimized to give analogs with bactericidal activity.  Hence, the ACPs represent classes of compds. that can activate ClpP and that can be developed as potential novel antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwrySw6SWPYLVg90H21EOLACvtfcHk0liCsea_4dLHlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eisr7F&md5=719b0124b9cdeb56a6bc69e044d0fc88</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DCossette%26aufirst%3DM.%26aulast%3DGoodreid%26aufirst%3DJ.%26aulast%3DMcCaw%26aufirst%3DS.%26aulast%3DMah%26aufirst%3DM.%26aulast%3DNakhamchik%26aufirst%3DA.%26aulast%3DOgata%26aufirst%3DK.%26aulast%3DEl%2BBakkouri%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWodak%26aufirst%3DS.%26aulast%3DEger%26aufirst%3DB.%26aulast%3DPai%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGray-Owen%26aufirst%3DS.%26aulast%3DBatey%26aufirst%3DR.%26aulast%3DHoury%26aufirst%3DW.%26atitle%3DActivators%2520of%2520cylindrical%2520proteases%2520as%2520antimicrobials%253A%2520identification%2520and%2520development%2520of%2520small%2520molecule%2520activators%2520of%2520ClpP%2520protease%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D1167%26epage%3D1178%26doi%3D10.1016%2Fj.chembiol.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sello, J.</span></span> <span> </span><span class="NLM_article-title">Restriction of the conformational dynamics of the cyclic acyldepsipeptide antibiotics improves their antibacterial activity</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">1922</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1021/ja410385c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja410385c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVGrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=1922-1929&author=D.+Carneyauthor=K.+Schmitzauthor=J.+Truongauthor=R.+Sauerauthor=J.+Sello&title=Restriction+of+the+conformational+dynamics+of+the+cyclic+acyldepsipeptide+antibiotics+improves+their+antibacterial+activity&doi=10.1021%2Fja410385c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Restriction of the Conformational Dynamics of the Cyclic Acyldepsipeptide Antibiotics Improves Their Antibacterial Activity</span></div><div class="casAuthors">Carney, Daniel W.; Schmitz, Karl R.; Truong, Jonathan V.; Sauer, Robert T.; Sello, Jason K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1922-1929</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cyclic acyldepsipeptide (ADEP) antibiotics are a new class of antibacterial agents that kill bacteria via a mechanism that is distinct from all clin. used drugs.  These mols. bind and dysregulate the activity of the ClpP peptidase.  The potential of these antibiotics as antibacterial drugs has been enhanced by the elimination of pharmacol. liabilities through medicinal chem. efforts.  Here, the authors demonstrate that the ADEP conformation obsd. in the ADEP-ClpP crystal structure is fortified by transannular hydrogen bonding and can be further stabilized by judicious replacement of constituent amino acids within the peptidolactone core structure with more conformationally constrained counterparts.  Evidence supporting constraint of the mol. into the bioactive conformer was obtained by measurements of deuterium-exchange kinetics of hydrogens that were proposed to be engaged in transannular hydrogen bonds.  The authors show that the rigidified ADEP analogs bind and activate ClpP at lower concns. in vitro.  Remarkably, these compds. have up to 1200-fold enhanced antibacterial activity when compared to those with the peptidolactone core structure common to two ADEP natural products.  This study compellingly demonstrates how rational modulation of conformational dynamics may be used to improve the bioactivities of natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF6ekCXYW2SbVg90H21EOLACvtfcHk0liCsea_4dLHlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVGrtQ%253D%253D&md5=47bc739241cda8935c81ffca6898564f</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fja410385c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja410385c%26sid%3Dliteratum%253Aachs%26aulast%3DCarney%26aufirst%3DD.%26aulast%3DSchmitz%26aufirst%3DK.%26aulast%3DTruong%26aufirst%3DJ.%26aulast%3DSauer%26aufirst%3DR.%26aulast%3DSello%26aufirst%3DJ.%26atitle%3DRestriction%2520of%2520the%2520conformational%2520dynamics%2520of%2520the%2520cyclic%2520acyldepsipeptide%2520antibiotics%2520improves%2520their%2520antibacterial%2520activity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D1922%26epage%3D1929%26doi%3D10.1021%2Fja410385c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodreid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janetzko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santa Maria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray-Owen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R.</span></span> <span> </span><span class="NLM_article-title">Development and characterization of potent cyclic acyldepsipeptide analogues with Increased antimicrobial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01451</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01451" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=624-646&author=J.+Goodreidauthor=J.+Janetzkoauthor=J.+Santa+Mariaauthor=K.+Wongauthor=E.+Leungauthor=B.+Egerauthor=S.+Brysonauthor=E.+Paiauthor=S.+Gray-Owenauthor=S.+Walkerauthor=W.+Houryauthor=R.+Batey&title=Development+and+characterization+of+potent+cyclic+acyldepsipeptide+analogues+with+Increased+antimicrobial+activity&doi=10.1021%2Facs.jmedchem.5b01451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity</span></div><div class="casAuthors">Goodreid, Jordan D.; Janetzko, John; Santa Maria, John P.; Wong, Keith S.; Leung, Elisa; Eger, Bryan T.; Bryson, Steve; Pai, Emil F.; Gray-Owen, Scott D.; Walker, Suzanne; Houry, Walid A.; Batey, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">624-646</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The problem of antibiotic resistance has prompted the search for new antibiotics with novel mechanisms of action.  Analogs of the A54556 cyclic acyldepsipeptides (ADEPs) represent an attractive class of antimicrobial agents that act through dysregulation of caseinolytic protease (ClpP).  Previous studies have shown that ADEPs are active against Gram-pos. bacteria (e.g., MRSA, VRE, PRSP (penicillin-resistant Streptococcus pneumoniae)); however, there are currently few studies examg. Gram-neg. bacteria.  In this study, the synthesis and biol. evaluation of 14 novel ADEPs against a variety of pathogenic Gram-neg. and Gram-pos. organisms is outlined.  Optimization of the macrocyclic core residues and N-acyl side chain culminated in the development of 26, which shows potent activity against the Gram-neg. species Neisseria meningitidis and Neisseria gonorrheae and improved activity against the Gram-pos. organisms Staphylococcus aureus and Enterococcus faecalis in comparison with known analogs.  In addn., the co-crystal structure of an ADEP-ClpP complex derived from N. meningitidis was solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKYhvsX0MSbVg90H21EOLACvtfcHk0liRACmH35oFxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGmsrk%253D&md5=fc27b90261ba245c9729570bc6694188</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01451%26sid%3Dliteratum%253Aachs%26aulast%3DGoodreid%26aufirst%3DJ.%26aulast%3DJanetzko%26aufirst%3DJ.%26aulast%3DSanta%2BMaria%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DEger%26aufirst%3DB.%26aulast%3DBryson%26aufirst%3DS.%26aulast%3DPai%26aufirst%3DE.%26aulast%3DGray-Owen%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DHoury%26aufirst%3DW.%26aulast%3DBatey%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520potent%2520cyclic%2520acyldepsipeptide%2520analogues%2520with%2520Increased%2520antimicrobial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D624%26epage%3D646%26doi%3D10.1021%2Facs.jmedchem.5b01451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gersch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famulla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göbl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sass, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rübsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brötz-Oesterhelt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6320</span>, <span class="refDoi"> DOI: 10.1038/ncomms7320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1038%2Fncomms7320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25695750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFensLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6320&author=M.+Gerschauthor=K.+Famullaauthor=M.+Dahmenauthor=C.+G%C3%B6blauthor=I.+Malikauthor=K.+Richterauthor=V.+S.+Korotkovauthor=P.+Sassauthor=H.+R%C3%BCbsamen-Schaeffauthor=T.+Madlauthor=H.+Br%C3%B6tz-Oesterheltauthor=S.+A.+Sieber&title=AAA%2B+chaperones+and+acyldepsipeptides+activate+the+ClpP+protease+via+conformational+control&doi=10.1038%2Fncomms7320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control</span></div><div class="casAuthors">Gersch, Malte; Famulla, Kirsten; Dahmen, Maria; Goebl, Christoph; Malik, Imran; Richter, Klaus; Korotkov, Vadim S.; Sass, Peter; Ruebsamen-Schaeff, Helga; Madl, Tobias; Broetz-Oesterhelt, Heike; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6320</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Clp protease complex degrades a multitude of substrates, which are engaged by a AAA+ chaperone such as ClpX and subsequently digested by the dynamic, barrel-shaped ClpP protease.  Acyldepsipeptides (ADEPs) are natural product-derived antibiotics that activate ClpP for chaperone-independent protein digestion.  Here we show that both protein and small-mol. activators of ClpP allosterically control the ClpP barrel conformation.  We dissect the catalytic mechanism with chem. probes and show that ADEP in addn. to opening the axial pore directly stimulates ClpP activity through cooperative binding.  ClpP activation thus reaches beyond active site accessibility and also involves conformational control of the catalytic residues.  Moreover, we demonstrate that substoichiometric amts. of ADEP potently prevent binding of ClpX to ClpP and, at the same time, partially inhibit ClpP through conformational perturbance.  Collectively, our results establish the hydrophobic binding pocket as a major conformational regulatory site with implications for both ClpXP proteolysis and ADEP-based anti-bacterial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUgjQrOvvCT7Vg90H21EOLACvtfcHk0liRACmH35oFxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFensLw%253D&md5=0600e7339571a8b20983207c7bd87419</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fncomms7320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7320%26sid%3Dliteratum%253Aachs%26aulast%3DGersch%26aufirst%3DM.%26aulast%3DFamulla%26aufirst%3DK.%26aulast%3DDahmen%26aufirst%3DM.%26aulast%3DG%25C3%25B6bl%26aufirst%3DC.%26aulast%3DMalik%26aufirst%3DI.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DSass%26aufirst%3DP.%26aulast%3DR%25C3%25BCbsamen-Schaeff%26aufirst%3DH.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DBr%25C3%25B6tz-Oesterhelt%26aufirst%3DH.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DAAA%252B%2520chaperones%2520and%2520acyldepsipeptides%2520activate%2520the%2520ClpP%2520protease%2520via%2520conformational%2520control%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6320%26doi%3D10.1038%2Fncomms7320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabanglo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seraphim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moutaoufik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodreid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span> <span> </span><span class="NLM_article-title">Acyldepsipeptide analogs dysregulate human mitochondrial ClpP protease activity and cause apoptotic cell death</span>. <i>Cell chemical biology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.chembiol.2018.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30126533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Cis7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=1017-1030&author=K.+Wongauthor=M.+Mabangloauthor=T.+Seraphimauthor=A.+Mollicaauthor=Y.+Maoauthor=K.+Rizzoloauthor=E.+Leungauthor=M.+Moutaoufikauthor=L.+Hoellauthor=S.+Phanseauthor=J.+Goodreidauthor=L.+Barbosaauthor=C.+Ramosauthor=M.+Babuauthor=V.+Mennellaauthor=R.+Bateyauthor=A.+Schimmerauthor=W.+Houry&title=Acyldepsipeptide+analogs+dysregulate+human+mitochondrial+ClpP+protease+activity+and+cause+apoptotic+cell+death&doi=10.1016%2Fj.chembiol.2018.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Acyldepsipeptide Analogs Dysregulate Human Mitochondrial ClpP Protease Activity and Cause Apoptotic Cell Death</span></div><div class="casAuthors">Wong, Keith S.; Mabanglo, Mark F.; Seraphim, Thiago V.; Mollica, Antonio; Mao, Yu-Qian; Rizzolo, Kamran; Leung, Elisa; Moutaoufik, Mohamed T.; Hoell, Larissa; Phanse, Sadhna; Goodreid, Jordan; Barbosa, Leandro R. S.; Ramos, Carlos H. I.; Babu, Mohan; Mennella, Vito; Batey, Robert A.; Schimmer, Aaron D.; Houry, Walid A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1017-1030.e9</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Acyldepsipeptides (ADEPs) are potential antibiotics that dysregulate the activity of the highly conserved tetradecameric bacterial ClpP protease, leading to bacterial cell death.  Here, we identified ADEP analogs that are potent dysregulators of the human mitochondrial ClpP (HsClpP).  These ADEPs interact tightly with HsClpP, causing the protease to non-specifically degrade model substrates.  Dysregulation of HsClpP activity by ADEP was found to induce cytotoxic effects via activation of the intrinsic, caspase-dependent apoptosis.  ADEP-HsClpP co-crystal structure was solved for one of the analogs revealing a highly complementary binding interface formed by two HsClpP neighboring subunits but, unexpectedly, with HsClpP in the compact conformation.  Given that HsClpP is highly expressed in multiple cancers and has important roles in cell metastasis, our findings suggest a therapeutic potential for ADEPs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF835B8v9aubVg90H21EOLACvtfcHk0lhL5n0IhCnJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Cis7bO&md5=250f3a70350ba2f8196413c84f147121</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMabanglo%26aufirst%3DM.%26aulast%3DSeraphim%26aufirst%3DT.%26aulast%3DMollica%26aufirst%3DA.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DRizzolo%26aufirst%3DK.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DMoutaoufik%26aufirst%3DM.%26aulast%3DHoell%26aufirst%3DL.%26aulast%3DPhanse%26aufirst%3DS.%26aulast%3DGoodreid%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DL.%26aulast%3DRamos%26aufirst%3DC.%26aulast%3DBabu%26aufirst%3DM.%26aulast%3DMennella%26aufirst%3DV.%26aulast%3DBatey%26aufirst%3DR.%26aulast%3DSchimmer%26aufirst%3DA.%26aulast%3DHoury%26aufirst%3DW.%26atitle%3DAcyldepsipeptide%2520analogs%2520dysregulate%2520human%2520mitochondrial%2520ClpP%2520protease%2520activity%2520and%2520cause%2520apoptotic%2520cell%2520death%26jtitle%3DCell%2520chemical%2520biology%26date%3D2018%26volume%3D25%26spage%3D1017%26epage%3D1030%26doi%3D10.1016%2Fj.chembiol.2018.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korotkov, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balogh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kick, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kielkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span> <span> </span><span class="NLM_article-title">Selective activation of human caseinolytic protease P (ClpP)</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">14602</span>– <span class="NLM_lpage">14607</span>, <span class="refDoi"> DOI: 10.1002/anie.201808189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fanie.201808189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=14602-14607&author=M.+Stahlauthor=V.+S.+Korotkovauthor=D.+Baloghauthor=L.+M.+Kickauthor=M.+Gerschauthor=A.+Pahlauthor=P.+Kielkowskiauthor=K.+Richterauthor=S.+Schneiderauthor=S.+A.+Sieber&title=Selective+activation+of+human+caseinolytic+protease+P+%28ClpP%29&doi=10.1002%2Fanie.201808189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Activation of Human Caseinolytic Protease P (ClpP)</span></div><div class="casAuthors">Stahl, Matthias; Korotkov, Vadim S.; Balogh, Dora; Kick, Leonhard M.; Gersch, Malte; Pahl, Axel; Kielkowski, Pavel; Richter, Klaus; Schneider, Sabine; Sieber, Stephan A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14602-14607</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Caseinolytic protease P (ClpP) is the proteolytic component of the ClpXP protein degrdn. complex.  Eukaryotic ClpP was recently found to act within the mitochondria-specific unfolded protein response (UPRmt).  However, its detailed function and dedicated regulation remain largely unexplored.  A small mol. (D9) acts as a potent and species-selective activator of human ClpP (hClpP) by mimicking the natural chaperone ClpX.  Structure-activity relationship studies highlight the importance of a halogenated benzyl motif within D9 that interacts with a unique arom. amino acid network in hClpP.  Mutational and structural studies suggest that this YYW motif tightly controls hClpP activity and regulates substrate turnover by interaction with cognate ligands.  This signature motif is unique to ClpP from higher organisms and does not exist in tested bacterial homologues, allowing a species-selective anal.  Thus, D9 is a versatile tool to analyze mechanistic features of hClpP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJpXalhsHFdrVg90H21EOLACvtfcHk0lhL5n0IhCnJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejurvI&md5=04d63d349df635d7965f974dda4f8632</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fanie.201808189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201808189%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DKorotkov%26aufirst%3DV.%2BS.%26aulast%3DBalogh%26aufirst%3DD.%26aulast%3DKick%26aufirst%3DL.%2BM.%26aulast%3DGersch%26aufirst%3DM.%26aulast%3DPahl%26aufirst%3DA.%26aulast%3DKielkowski%26aufirst%3DP.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26atitle%3DSelective%2520activation%2520of%2520human%2520caseinolytic%2520protease%2520P%2520%2528ClpP%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D14602%26epage%3D14607%26doi%3D10.1002%2Fanie.201808189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarabi, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jitkova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Germain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heese, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barghout, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurren, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabanglo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houry, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stogniew, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raught, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.ccell.2019.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=31056398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=721-737&author=J.+Ishizawaauthor=S.+F.+Zarabiauthor=R.+E.+Davisauthor=O.+Halgasauthor=T.+Niiauthor=Y.+Jitkovaauthor=R.+Zhaoauthor=J.+St-Germainauthor=L.+E.+Heeseauthor=G.+Eganauthor=V.+R.+Ruvoloauthor=S.+H.+Barghoutauthor=Y.+Nishidaauthor=R.+Hurrenauthor=W.+Maauthor=M.+Grondaauthor=T.+Linkauthor=K.+Wongauthor=M.+Mabangloauthor=K.+Kojimaauthor=G.+Borthakurauthor=N.+MacLeanauthor=M.+C.+J.+Maauthor=A.+B.+Leberauthor=M.+D.+Mindenauthor=W.+Houryauthor=H.+Kantarjianauthor=M.+Stogniewauthor=B.+Raughtauthor=E.+F.+Paiauthor=A.+D.+Schimmerauthor=M.+Andreeff&title=Mitochondrial+ClpP-mediated+proteolysis+induces+selective+cancer+cell+lethality&doi=10.1016%2Fj.ccell.2019.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality</span></div><div class="casAuthors">Ishizawa, Jo; Zarabi, Sarah F.; Davis, R. Eric; Halgas, Ondrej; Nii, Takenobu; Jitkova, Yulia; Zhao, Ran; St-Germain, Jonathan; Heese, Lauren E.; Egan, Grace; Ruvolo, Vivian R.; Barghout, Samir H.; Nishida, Yuki; Hurren, Rose; Ma, Wencai; Gronda, Marcela; Link, Todd; Wong, Keith; Mabanglo, Mark; Kojima, Kensuke; Borthakur, Gautam; MacLean, Neil; Ma, Man Chun John; Leber, Andrew B.; Minden, Mark D.; Houry, Walid; Kantarjian, Hagop; Stogniew, Martin; Raught, Brian; Pai, Emil F.; Schimmer, Aaron D.; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-737.e9</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins.  Using genetic and chem. approaches, we showed that hyperactivation of the protease selectively kills cancer cells, independently of p53 status, by selective degrdn. of its respiratory chain protein substrates and disrupts mitochondrial structure and function, while it does not affect non-malignant cells.  We identified imipridones as potent activators of ClpP.  Through biochem. studies and crystallog., we show that imipridones bind ClpP non-covalently and induce proteolysis by diverse structural changes.  Imipridones are presently in clin. trials.  Our findings suggest a general concept of inducing cancer cell lethality through activation of mitochondrial proteolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTd24nbBAMXrVg90H21EOLACvtfcHk0litmC9gB7Ug_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOmur0%253D&md5=b1a92c3cdf8f9f527563c798480c18e0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DIshizawa%26aufirst%3DJ.%26aulast%3DZarabi%26aufirst%3DS.%2BF.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DHalgas%26aufirst%3DO.%26aulast%3DNii%26aufirst%3DT.%26aulast%3DJitkova%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSt-Germain%26aufirst%3DJ.%26aulast%3DHeese%26aufirst%3DL.%2BE.%26aulast%3DEgan%26aufirst%3DG.%26aulast%3DRuvolo%26aufirst%3DV.%2BR.%26aulast%3DBarghout%26aufirst%3DS.%2BH.%26aulast%3DNishida%26aufirst%3DY.%26aulast%3DHurren%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DGronda%26aufirst%3DM.%26aulast%3DLink%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMabanglo%26aufirst%3DM.%26aulast%3DKojima%26aufirst%3DK.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DMacLean%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DM.%2BC.%2BJ.%26aulast%3DLeber%26aufirst%3DA.%2BB.%26aulast%3DMinden%26aufirst%3DM.%2BD.%26aulast%3DHoury%26aufirst%3DW.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DStogniew%26aufirst%3DM.%26aulast%3DRaught%26aufirst%3DB.%26aulast%3DPai%26aufirst%3DE.%2BF.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMitochondrial%2520ClpP-mediated%2520proteolysis%2520induces%2520selective%2520cancer%2520cell%2520lethality%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D35%26spage%3D721%26epage%3D737%26doi%3D10.1016%2Fj.ccell.2019.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Sloot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">C Huard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe-Huntington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertomeu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonneil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyers, M.</span></span> <span> </span><span class="NLM_article-title">Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1120</span>, <span class="refDoi"> DOI: 10.1534/genetics.119.302851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1534%2Fgenetics.119.302851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=32094149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVarsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2020&pages=1103-1120&author=S.+Jacquesauthor=A.+van+der+Slootauthor=C.+C+Huardauthor=J.+Coulombe-Huntingtonauthor=S.+Tsaoauthor=S.+Tollisauthor=T.+Bertomeuauthor=E.+Culpauthor=D.+Pallantauthor=M.+Cookauthor=E.+Bonneilauthor=P.+Thibaultauthor=G.+Wrightauthor=M.+Tyers&title=Imipridone+anticancer+compounds+ectopically+activate+the+ClpP+protease+and+represent+a+new+scaffold+for+antibiotic+development&doi=10.1534%2Fgenetics.119.302851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Imipridone anticancer compounds ectopically activate the ClpP Protease and represent a new scaffold for antibiotic development</span></div><div class="casAuthors">Jacques, Samuel; van der Sloot, Almer M.; Huard, Caroline C.; Coulombe-Huntington, Jasmin; Tsao, Sarah; Tollis, Sylvain; Bertomeu, Thierry; Culp, Elizabeth J.; Pallant, Daniel; Cook, Michael A.; Bonneil, Eric; Thibault, Pierre; Wright, Gerard D.; Tyers, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Genetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1103-1120</span>CODEN:
                <span class="NLM_cas:coden">GENTAE</span>;
        ISSN:<span class="NLM_cas:issn">0016-6731</span>.
    
            (<span class="NLM_cas:orgname">Genetics Society of America</span>)
        </div><div class="casAbstract">Systematic genetic interaction profiles can reveal the mechanisms-of-action of bioactive compds.  The imipridone ONC201, which is currently in cancer clin. trials, has been ascribed a variety of different targets.  To investigate the genetic dependencies of imipridone action, we screened a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) knockout library in the presence of either ONC201 or its more potent analog ONC212.  Loss of the mitochondrial matrix protease CLPP or the mitochondrial intermediate peptidase MIPEP conferred strong resistance to both compds.  Biochem. and surrogate genetic assays showed that impridones directly activate CLPP and that MIPEP is necessary for proteolytic maturation of CLPP into a catalytically competent form.  Quant. proteomic anal. of cells treated with ONC212 revealed degrdn. of many mitochondrial as well as nonmitochondrial proteins.  Prompted by the conservation of ClpP from bacteria to humans, we found that the imipridones also activate ClpP from Escherichia coli, Bacillus subtilis, and Staphylococcus aureus in biochem. and genetic assays.  ONC212 and acyldepsipeptide-4 (ADEP4), a known activator of bacterial ClpP, caused similar proteome-wide degrdn. profiles in S. aureus.  ONC212 suppressed the proliferation of a no. of Gram-pos. (S. aureus, B. subtilis, and Enterococcus faecium) and Gramneg. species (E. coli and Neisseria gonorrhoeae).  Moreover, ONC212 enhanced the ability of rifampin to eradicate antibiotictolerant S. aureus persister cells.  These results reveal the genetic dependencies of imipridone action in human cells and identify the imipridone scaffold as a new entry point for antibiotic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYUg-FrUzprVg90H21EOLACvtfcHk0litmC9gB7Ug_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVarsrrM&md5=8fdc0ed3390fedfc57cd795ecf0d75c3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1534%2Fgenetics.119.302851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1534%252Fgenetics.119.302851%26sid%3Dliteratum%253Aachs%26aulast%3DJacques%26aufirst%3DS.%26aulast%3Dvan%2Bder%2BSloot%26aufirst%3DA.%26aulast%3DC%2BHuard%26aufirst%3DC.%26aulast%3DCoulombe-Huntington%26aufirst%3DJ.%26aulast%3DTsao%26aufirst%3DS.%26aulast%3DTollis%26aufirst%3DS.%26aulast%3DBertomeu%26aufirst%3DT.%26aulast%3DCulp%26aufirst%3DE.%26aulast%3DPallant%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DM.%26aulast%3DBonneil%26aufirst%3DE.%26aulast%3DThibault%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DTyers%26aufirst%3DM.%26atitle%3DImipridone%2520anticancer%2520compounds%2520ectopically%2520activate%2520the%2520ClpP%2520protease%2520and%2520represent%2520a%2520new%2520scaffold%2520for%2520antibiotic%2520development%26jtitle%3DGenetics%26date%3D2020%26volume%3D214%26spage%3D1103%26epage%3D1120%26doi%3D10.1534%2Fgenetics.119.302851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessenbrock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaks, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases: regulators of the tumor microenvironment</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.cell.2010.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=20371345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=52-67&author=K.+Kessenbrockauthor=V.+Plaksauthor=Z.+Werb&title=Matrix+metalloproteinases%3A+regulators+of+the+tumor+microenvironment&doi=10.1016%2Fj.cell.2010.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases: regulators of the tumor microenvironment</span></div><div class="casAuthors">Kessenbrock, Kai; Plaks, Vicki; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-67</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Extracellular proteolysis mediates tissue homeostasis.  In cancer, altered proteolysis leads to unregulated tumor growth, tissue remodeling, inflammation, tissue invasion, and metastasis.  The matrix metalloproteinases (MMPs) represent the most prominent family of proteinases assocd. with tumorigenesis.  Recent technol. developments have markedly advanced our understanding of MMPs as modulators of the tumor microenvironment.  In addn. to their role in extracellular matrix turnover and cancer cell migration, MMPs regulate signaling pathways that control cell growth, inflammation, or angiogenesis and may even work in a nonproteolytic manner.  These aspects of MMP function are reorienting our approaches to cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAwNenyy027LVg90H21EOLACvtfcHk0litmC9gB7Ug_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtb4%253D&md5=fb7ee4c41ef31db0310b985e87bcdb94</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DKessenbrock%26aufirst%3DK.%26aulast%3DPlaks%26aufirst%3DV.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DMatrix%2520metalloproteinases%253A%2520regulators%2520of%2520the%2520tumor%2520microenvironment%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D52%26epage%3D67%26doi%3D10.1016%2Fj.cell.2010.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin Jensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrahmanyam, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandehari, H.</span></span> <span> </span><span class="NLM_article-title">Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>259</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2017.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.jconrel.2017.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28153760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2017&pages=62-75&author=K.+J.+Isaacsonauthor=M.+Martin+Jensenauthor=N.+B.+Subrahmanyamauthor=H.+Ghandehari&title=Matrix-metalloproteinases+as+targets+for+controlled+delivery+in+cancer%3A+An+analysis+of+upregulation+and+expression&doi=10.1016%2Fj.jconrel.2017.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression</span></div><div class="casAuthors">Isaacson, Kyle J.; Jensen, M. Martin; Subrahmanyam, Nithya B.; Ghandehari, Hamidreza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">259</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-75</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  While commonly known for degrdn. of the extracellular matrix, matrix metalloproteinases (MMPs) exhibit broad potential for use in targeting of bioactive and imaging agents in cancer treatment.  MMPs are upregulated at all stages of expression in cancers.  A comprehensive anal. of published literature on expression of all MMP subtypes at the genetic, protein, and activity levels in normal and diseased tissues indicate targeting applicability in a variety of cancers.  This expression significantly increases at advanced cancer stages, providing an improved opportunity for controlled release in higher-stage patients.  Since MMPs are integral at every stage of metastasis, MMP roles in cancer are discussed with a focus on MMP distribution and mobility within cells and tumors for cancer targeting applications.  Several strategies for MMP utilization in targeting - such as matrix degrdn., MMP cleavage, MMP binding, and MMP-induced environmental changes - are addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaU-TKJ4EKNbVg90H21EOLACvtfcHk0lgOznskaG4Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrurg%253D&md5=4e354ff9a251cc610d53fee86dcab23d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2017.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2017.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacson%26aufirst%3DK.%2BJ.%26aulast%3DMartin%2BJensen%26aufirst%3DM.%26aulast%3DSubrahmanyam%26aufirst%3DN.%2BB.%26aulast%3DGhandehari%26aufirst%3DH.%26atitle%3DMatrix-metalloproteinases%2520as%2520targets%2520for%2520controlled%2520delivery%2520in%2520cancer%253A%2520An%2520analysis%2520of%2520upregulation%2520and%2520expression%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2017%26volume%3D259%26spage%3D62%26epage%3D75%26doi%3D10.1016%2Fj.jconrel.2017.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000070112.80711.3D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1161%2F01.RES.0000070112.80711.3D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12730128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=827-839&author=R.+Visseauthor=H.+Nagase&title=Matrix+metalloproteinases+and+tissue+inhibitors+of+metalloproteinases%3A+structure%2C+function%2C+and+biochemistry&doi=10.1161%2F01.RES.0000070112.80711.3D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry</span></div><div class="casAuthors">Visse, Robert; Nagase, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-839</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs), also designated matrixins, hydrolyze components of the extracellular matrix.  These proteinases play a central role in many biol. processes, such as embryogenesis, normal tissue remodeling, wound healing, and angiogenesis, and in diseases such as atheroma, arthritis, cancer, and tissue ulceration.  Currently 23 MMP genes have been identified in humans, and most are multidomain proteins.  This review describes the members of the matrixin family and discusses substrate specificity, domain structure and function, the activation of proMMPs, the regulation of matrixin activity by tissue inhibitors of metalloproteinases (TIMPs), and their pathophysiol. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_QfsPFZtdjLVg90H21EOLACvtfcHk0lgOznskaG4Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7c%253D&md5=0fddee610a1b1defa7f60a14a11ae127</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000070112.80711.3D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000070112.80711.3D%26sid%3Dliteratum%253Aachs%26aulast%3DVisse%26aufirst%3DR.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DMatrix%2520metalloproteinases%2520and%2520tissue%2520inhibitors%2520of%2520metalloproteinases%253A%2520structure%252C%2520function%252C%2520and%2520biochemistry%26jtitle%3DCirc.%2520Res.%26date%3D2003%26volume%3D92%26spage%3D827%26epage%3D839%26doi%3D10.1161%2F01.RES.0000070112.80711.3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G.</span></span> <span> </span><span class="NLM_article-title">Structure and function of matrix metalloproteinases and TIMPs</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1016/j.cardiores.2005.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.cardiores.2005.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16405877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=562-573&author=H.+Nagaseauthor=R.+Visseauthor=G.+Murphy&title=Structure+and+function+of+matrix+metalloproteinases+and+TIMPs&doi=10.1016%2Fj.cardiores.2005.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of matrix metalloproteinases and TIMPs</span></div><div class="casAuthors">Nagase, Hideaki; Visse, Robert; Murphy, Gillian</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">562-573</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs), also called matrixins, function in the extracellular environment of cells and degrade both matrix and non-matrix proteins.  They play central roles in morphogenesis, wound healing, tissue repair and remodelling in response to injury, e.g. after myocardial infarction, and in progression of diseases such as atheroma, arthritis, cancer and chronic tissue ulcers.  They are multi-domain proteins and their activities are regulated by tissue inhibitors of metalloproteinases (TIMPs).  This review introduces the members of the MMP family and discusses their domain structure and function, proenyme activation, the mechanism of inhibition by TIMPs and their significance in physiol. and pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo77sy3-HPv0rVg90H21EOLACvtfcHk0lgOznskaG4Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVKitg%253D%253D&md5=2c9b99a424f3a604cc4dc899ddc41cd7</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2005.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2005.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DVisse%26aufirst%3DR.%26aulast%3DMurphy%26aufirst%3DG.%26atitle%3DStructure%2520and%2520function%2520of%2520matrix%2520metalloproteinases%2520and%2520TIMPs%26jtitle%3DCardiovasc.%2520Res.%26date%3D2006%26volume%3D69%26spage%3D562%26epage%3D573%26doi%3D10.1016%2Fj.cardiores.2005.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, R. A.</span></span> <span> </span><span class="NLM_article-title">Biochemical and biological attributes of matrix metalloproteinases</span>. <i>Progress in molecular biology and translational science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/bs.pmbts.2017.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fbs.pmbts.2017.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=28413025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1yhs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2017&pages=1-73&author=N.+Cuiauthor=M.+Huauthor=R.+A.+Khalil&title=Biochemical+and+biological+attributes+of+matrix+metalloproteinases&doi=10.1016%2Fbs.pmbts.2017.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and biological attributes of matrix metalloproteinases</span></div><div class="casAuthors">Cui, Ning; Hu, Min; Khalil, Raouf A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Cardiovascular Remodeling</span>),
    <span class="NLM_cas:pages">1-73</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that are involved in the degrdn. of various proteins in the extracellular matrix (ECM).  Typically, MMPs have a propeptide sequence, a catalytic metalloproteinase domain with catalytic zinc, a hinge region or linker peptide, and a hemopexin domain.  MMPs are commonly classified on the basis of their substrates and the organization of their structural domains into collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT)-MMPs, and other MMPs.  MMPs are secreted by many cells including fibroblasts, vascular smooth muscle (VSM), and leukocytes.  MMPs are regulated at the level of mRNA expression and by activation of their latent zymogen form.  MMPs are often secreted as inactive pro-MMP form which is cleaved to the active form by various proteinases including other MMPs.  MMPs cause degrdn. of ECM proteins such as collagen and elastin, but could influence endothelial cell function as well as VSM cell migration, proliferation, Ca2+ signaling, and contraction.  MMPs play a role in tissue remodeling during various physiol. processes such as angiogenesis, embryogenesis, morphogenesis, and wound repair, as well as in pathol. conditions such as myocardial infarction, fibrotic disorders, osteoarthritis, and cancer.  Increases in specific MMPs could play a role in arterial remodeling, aneurysm formation, venous dilation, and lower extremity venous disorders.  MMPs also play a major role in leukocyte infiltration and tissue inflammation.  MMPs have been detected in cancer, and elevated MMP levels have been assocd. with tumor progression and invasiveness.  MMPs can be regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs), and the MMP/TIMP ratio often dets. the extent of ECM protein degrdn. and tissue remodeling.  MMPs have been proposed as biomarkers for numerous pathol. conditions and are being examd. as potential therapeutic targets in various cardiovascular and musculoskeletal disorders as well as cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFMGEWZ3Mm8LVg90H21EOLACvtfcHk0lgOznskaG4Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1yhs7vI&md5=2e660198c8cfd7f0f46df92b1ff1ff43</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmbts.2017.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmbts.2017.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DKhalil%26aufirst%3DR.%2BA.%26atitle%3DBiochemical%2520and%2520biological%2520attributes%2520of%2520matrix%2520metalloproteinases%26jtitle%3DProgress%2520in%2520molecular%2520biology%2520and%2520translational%2520science%26date%3D2017%26volume%3D147%26spage%3D1%26epage%3D73%26doi%3D10.1016%2Fbs.pmbts.2017.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollborn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, A.</span></span> <span> </span><span class="NLM_article-title">Positive feedback regulation between MMP-9 and VEGF in human RPE cells</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4360</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1167/iovs.06-1234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1167%2Fiovs.06-1234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17724228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BD2srgsVOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=4360-4367&author=M.+Hollbornauthor=C.+Stathopoulosauthor=A.+Steffenauthor=P.+Wiedemannauthor=L.+Kohenauthor=A.+Bringmann&title=Positive+feedback+regulation+between+MMP-9+and+VEGF+in+human+RPE+cells&doi=10.1167%2Fiovs.06-1234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Positive feedback regulation between MMP-9 and VEGF in human RPE cells</span></div><div class="casAuthors">Hollborn Margrit; Stathopoulos Christina; Steffen Anja; Wiedemann Peter; Kohen Leon; Bringmann Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4360-7</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  The proteolytic activity of matrix metalloproteinases (MMPs) is involved in pathologic angiogenesis in the eye.  However, it is unknown whether MMPs may stimulate the production of the major angiogenic factor, vascular endothelial growth factor (VEGF).  The authors investigated whether MMP-2 and MMP-9 alter the expression of VEGF by retinal pigment epithelial (RPE) cells.  They also sought to determine the effects of MMPs on cellular proliferation and migration and the effect of triamcinolone acetonide on MMP-9-evoked cellular responses.  METHODS:  Human RPE cell cultures were stimulated with MMP-2 or MMP-9.  The gene expression and secretion of MMP-9 and VEGF were determined by real-time RT-PCR and ELISA, respectively.  Cellular proliferation was investigated with a bromodeoxyuridine immunoassay, and chemotaxis was examined with a Boyden chamber assay.  RESULTS:  Under control conditions, RPE cells in vitro expressed a significantly higher amount of mRNA for MMP-2 than for MMP-9.  Chemical hypoxia caused upregulation of the gene expression of both MMPs, whereas VEGF increased the gene expression and secretion of MMP-9.  The hypoxic expression of MMP-9 was mediated by autocrine VEGF signaling.  Exogenous MMP-9 increased the gene expression and secretion of VEGF, whereas MMP-2 reduced the secretion of VEGF.  MMP-2 and MMP-9 did not alter the proliferation but stimulated the migration of RPE cells.  Triamcinolone fully inhibited the stimulatory effect of MMP-9 on the expression of VEGF and the VEGF-evoked increase in the expression of MMP-9.  However, triamcinolone had no effect on the motogenic effect of MMP-9.  CONCLUSIONS:  There is a positive feedback regulation between MMP-9 and VEGF in RPE cells.  The hypoxic expression of MMP-9 may stimulate the production and secretion of VEGF under pathologic conditions.  Triamcinolone inhibits the positive feedback regulation between MMP-9 and VEGF under hypoxic conditions through inhibition of the gene expression of MMP-9 and the secretion of VEGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPqea63gPcdFxYDaSSP8XfW6udTcc2eYKZHUTI4Nsnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srgsVOitA%253D%253D&md5=8325e55b1b946e5dc7438c7fe3e1b448</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1167%2Fiovs.06-1234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.06-1234%26sid%3Dliteratum%253Aachs%26aulast%3DHollborn%26aufirst%3DM.%26aulast%3DStathopoulos%26aufirst%3DC.%26aulast%3DSteffen%26aufirst%3DA.%26aulast%3DWiedemann%26aufirst%3DP.%26aulast%3DKohen%26aufirst%3DL.%26aulast%3DBringmann%26aufirst%3DA.%26atitle%3DPositive%2520feedback%2520regulation%2520between%2520MMP-9%2520and%2520VEGF%2520in%2520human%2520RPE%2520cells%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2007%26volume%3D48%26spage%3D4360%26epage%3D4367%26doi%3D10.1167%2Fiovs.06-1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bornschein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wex, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selgrad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jechorek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird-Lieberman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfertheiner, P.</span></span> <span> </span><span class="NLM_article-title">MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression</span>. <i>Diagn. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">212</span>, <span class="refDoi"> DOI: 10.1186/s13000-015-0449-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs13000-015-0449-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26652716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKhurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=212&author=J.+Bornscheinauthor=T.+Seidelauthor=C.+Langnerauthor=A.+Linkauthor=T.+Wexauthor=M.+Selgradauthor=D.+Jechorekauthor=F.+Meyerauthor=E.+Bird-Liebermanauthor=M.+Viethauthor=P.+Malfertheiner&title=MMP2+and+MMP7+at+the+invasive+front+of+gastric+cancer+are+not+associated+with+mTOR+expression&doi=10.1186%2Fs13000-015-0449-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression</span></div><div class="casAuthors">Bornschein, Jan; Seidel, Tina; Langner, Cosima; Link, Alexander; Wex, Thomas; Selgrad, Michael; Jechorek, Doerthe; Meyer, Frank; Bird-Lieberman, Elizabeth; Vieth, Michael; Malfertheiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212/1-212/5</span>CODEN:
                <span class="NLM_cas:coden">DPIAAA</span>;
        ISSN:<span class="NLM_cas:issn">1746-1596</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Regulation of MMP expression by activation of mTOR signalling has been demonstrated for several tumor types, but has thus far not been confirmed in gastric cancer.  Findings: The study compromised 128 patients who underwent gastric resection for cancer (66.4 % male; 86 intestinal, 42 diffuse type).  Immunohistochem. staining of MMPs was performed to analyze the topog. pattern of MMP expression at the tumor center and the invasive front, resp.  MMP2 showed higher expression at the invasive front compared to the tumor center, whereas MMP7 staining scores were higher in the tumor center, and there was no difference for MMP9.  The expression of p-mTOR was higher in the tumor center than at the invasive front, with a similar trend for mTOR.  For intestinal type gastric cancer there was a weak correlation of MMP9 with expression of mTOR in the tumor center.  Otherwise, there was no correlation of the MMPs with mTOR.  By treatment of MKN45 gastric cancer cells with rapamycin, a redn. of p-mTOR in the Western blot was achieved; however, expression of MMPs remained unaffected.  Conclusions: Expression of MMP2 and MMP7 in gastric cancer is not assocd. with mTOR, MMP9 expression might be related to mTOR signalling in a subset of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqtQnHXIOxbLVg90H21EOLACvtfcHk0liwBnVKCs-QQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKhurzJ&md5=f68943a12e1ba6e266e39080c266927b</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs13000-015-0449-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13000-015-0449-z%26sid%3Dliteratum%253Aachs%26aulast%3DBornschein%26aufirst%3DJ.%26aulast%3DSeidel%26aufirst%3DT.%26aulast%3DLangner%26aufirst%3DC.%26aulast%3DLink%26aufirst%3DA.%26aulast%3DWex%26aufirst%3DT.%26aulast%3DSelgrad%26aufirst%3DM.%26aulast%3DJechorek%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DF.%26aulast%3DBird-Lieberman%26aufirst%3DE.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DMalfertheiner%26aufirst%3DP.%26atitle%3DMMP2%2520and%2520MMP7%2520at%2520the%2520invasive%2520front%2520of%2520gastric%2520cancer%2520are%2520not%2520associated%2520with%2520mTOR%2520expression%26jtitle%3DDiagn.%2520Pathol.%26date%3D2015%26volume%3D10%26spage%3D212%26doi%3D10.1186%2Fs13000-015-0449-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Illemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majeed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehested, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laerum, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danø, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, B.</span></span> <span> </span><span class="NLM_article-title">MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-06-0003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1541-7786.MCR-06-0003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16687484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BD283mtlGhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=293-302&author=M.+Illemannauthor=N.+Birdauthor=A.+Majeedauthor=M.+Sehestedauthor=O.+Laerumauthor=L.+Lundauthor=K.+Dan%C3%B8author=B.+Nielsen&title=MMP-9+is+differentially+expressed+in+primary+human+colorectal+adenocarcinomas+and+their+metastases&doi=10.1158%2F1541-7786.MCR-06-0003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases</span></div><div class="casAuthors">Illemann Martin; Bird Nigel; Majeed Ali; Sehested Maxwell; Laerum Ole D; Lund Leif R; Dano Keld; Nielsen Boye Schnack</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer research : MCR</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">293-302</span>
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    </div><div class="casAbstract">Matrix metalloproteinase-9 (MMP-9) is up-regulated in macrophages in various human cancer types.  In human colon cancer, MMP-9 is expressed in a macrophage subpopulation located at the tumor edge, indicating a specific induction of MMP-9 in macrophages in direct association with cancer invasion.  To test whether MMP-9 is also induced in tumor edge macrophages in metastases from colorectal adenocarcinomas, we have compared the expression pattern of MMP-9 in primary colorectal adenocarcinomas (n = 15) with that in liver metastases (n = 15) and local lymph node metastases (n = 7) from the same patients by in situ hybridization and immunohistochemistry.  In all the colorectal adenocarcinomas, the expression of MMP-9 mRNA and immunoreactivity in macrophages was located at the invasive front.  In contrast, only 3 of the 15 liver metastases had MMP-9 mRNA and immunoreactivity at the periphery, and this expression was confined to small foci of macrophages located either among lymphocytes or in a dense desmoplastic stroma.  Expression of MMP-9 mRNA and immunoreactivity was in all liver metastases seen in macrophages located in the lumen of malignant glandular structures and in central necrotic tissue.  In all the 7 lymph node metastases, MMP-9 mRNA and immunoreactivity was seen in macrophages located in the stromal tissue surrounding the metastases.  We conclude that MMP-9 is not up-regulated in tumor edge macrophages in liver metastases like in their primary tumor and local lymph node metastases, suggesting that disseminating colorectal cancer cells can adopt alternative proteolytic mechanisms for invasion depending on the local microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIIw9rPqdfQYHWj6b1v8uTfW6udTcc2eYqiY7c5YltAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283mtlGhsg%253D%253D&md5=ebe587b4cf4cb62237e498ae078abaeb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-06-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-06-0003%26sid%3Dliteratum%253Aachs%26aulast%3DIllemann%26aufirst%3DM.%26aulast%3DBird%26aufirst%3DN.%26aulast%3DMajeed%26aufirst%3DA.%26aulast%3DSehested%26aufirst%3DM.%26aulast%3DLaerum%26aufirst%3DO.%26aulast%3DLund%26aufirst%3DL.%26aulast%3DDan%25C3%25B8%26aufirst%3DK.%26aulast%3DNielsen%26aufirst%3DB.%26atitle%3DMMP-9%2520is%2520differentially%2520expressed%2520in%2520primary%2520human%2520colorectal%2520adenocarcinomas%2520and%2520their%2520metastases%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2006%26volume%3D4%26spage%3D293%26epage%3D302%26doi%3D10.1158%2F1541-7786.MCR-06-0003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, S. G.</span></span> <span> </span><span class="NLM_article-title">Development of matrix metalloproteinase inhibitors in cancer therapy</span>. <i>Journal of the national cancer institute</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1093/jnci/93.3.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1093%2Fjnci%2F93.3.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11158186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlKiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=178-193&author=M.+Hidalgoauthor=S.+G.+Eckhardt&title=Development+of+matrix+metalloproteinase+inhibitors+in+cancer+therapy&doi=10.1093%2Fjnci%2F93.3.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Development of matrix metalloproteinase inhibitors in cancer therapy</span></div><div class="casAuthors">Hidalgo, Manuel; Eckhardt, S. Gail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">178-193</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 189 refs.  The matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degrdn. of the extracellular matrix.  The MMPs have been implicated in the processes of tumor growth, invasion, and metastasis; are frequently over-expressed in malignant tumors; and have been assocd. with an aggressive malignant phenotype and adverse prognosis in patients with cancer.  A no. of MMP inhibitors are being developed for the treatment of cancer.  The most extensively studied class of MMP inhibitors includes collagen peptidomimetics and nonpeptidomimetic inhibitors of the MMP active site, tetracycline derivs., and bisphosphonates.  The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analog marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail.  Marimastat is currently being studied in randomized clin. trials.  The nonpeptidic MMP inhibitors were synthesized in an attempt to improve the oral bioavailability and pharmaceutical properties of the peptidic inhibitors.  Several members of this class of compds. are undergoing evaluation in phase III clin. trials.  The tetracyclines and, particularly, the nonantibiotic chem. modified tetracyclines, interfere with several aspects of MMP expression and activation and inhibit tumor growth and metastases in preclin. models.  A representative agent of this class, Col-3, is currently undergoing phase I clin. trials.  The development of the MMP inhibitors, like that of other targeted and predominantly antiproliferative compds., poses a challenge because the paradigms that have governed the design of clin. oncol. trials may not be relevant to this new class of agents.  The anticipated need for long-term administration of these drugs, together with their cytostatic mechanism of action, will require novel clin. trial design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgnRed5mDw9LVg90H21EOLACvtfcHk0lhcQmtqsdxAZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlKiurw%253D&md5=0094a1ba5e55ca5268f41eec2c8d8480</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.3.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.3.178%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DDevelopment%2520of%2520matrix%2520metalloproteinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJournal%2520of%2520the%2520national%2520cancer%2520institute%26date%3D2001%26volume%3D93%26spage%3D178%26epage%3D193%26doi%3D10.1093%2Fjnci%2F93.3.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braybrooke, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, D. C.</span></span> <span> </span><span class="NLM_article-title">Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10100701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXitVyisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=513-520&author=V.+M.+Macaulayauthor=K.+J.+O%E2%80%99Byrneauthor=M.+P.+Saundersauthor=J.+P.+Braybrookeauthor=L.+Longauthor=F.+Gleesonauthor=C.+S.+Masonauthor=A.+L.+Harrisauthor=P.+Brownauthor=D.+C.+Talbot&title=Phase+I+study+of+intrapleural+batimastat+%28BB-94%29%2C+a+matrix+metalloproteinase+inhibitor%2C+in+the+treatment+of+malignant+pleural+effusions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions</span></div><div class="casAuthors">Macaulay, Valentine M.; O'Byrne, Ken J.; Saunders, Mark P.; Braybrooke, Jeremy P.; Long, Louise; Gleeson, Fergus; Mason, Clare S.; Harris, Adrian L.; Brown, Peter; Talbot, Denis C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">513-520</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor cells and assocd. stromal cells secrete matrix metalloproteinases (MMPs), contributing to invasion, angiogenesis, and metastasis.  Batimastat (BB-94) is a broad-spectrum MMP inhibitor that causes resoln. of ascites and/or tumor growth delay in animal models of breast, ovarian, and colorectal cancer.  We recruited 18 patients with cytol. pos. malignant pleural effusions into a Phase I study of intrapleural BB-94.  Three patients received single doses of BB-94 at each dose level: 15, 30, 60, 105, 135, and 300 mg/m2.  Two patients were retreated with a second course at 60 and 105 mg/m2.  BB-94 was detectable in plasma 1 h after intrapleural administration, and peak levels of 20-200 ng/mL occurred after 4 h to 1 wk.  BB-94 persisted in the plasma for up to 12 wk, at levels exceeding the IC50s for target MMPs.  Peak values were higher, and persistence in the plasma was longer after higher doses of BB-94.  The treatment was well tolerated.  Toxic effects included low-grade fever for 24-48 h (6 of 18 patients, 33%) and reversible asymptomatic elevation of liver enzymes (8 patients, 44%).  Toxicity seemed unrelated to BB-94 dose or plasma levels.  Sixteen patients evaluable for response required significantly fewer pleural aspirations in the 3 mo after BB-94 compared with the 3 mo before.  Seven patients (44%) required no further pleural aspiration until death/last follow-up.  After 1 mo, patients treated with 60-300 mg/m2 BB-94 had significantly better dyspnea scores, indicating improved exercise tolerance, compared with baseline scores the day after BB-94.  The max. tolerated intrapleural dose remains to be defined, but it is clear that intrapleural BB-94 is well tolerated, with evidence of local activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHF-ZM_YECELVg90H21EOLACvtfcHk0lhcQmtqsdxAZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitVyisLg%253D&md5=075402235d2f2db88fa465ed33ece41c</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DSaunders%26aufirst%3DM.%2BP.%26aulast%3DBraybrooke%26aufirst%3DJ.%2BP.%26aulast%3DLong%26aufirst%3DL.%26aulast%3DGleeson%26aufirst%3DF.%26aulast%3DMason%26aufirst%3DC.%2BS.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26atitle%3DPhase%2520I%2520study%2520of%2520intrapleural%2520batimastat%2520%2528BB-94%2529%252C%2520a%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520malignant%2520pleural%2520effusions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26spage%3D513%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span> <span> </span><span class="NLM_article-title">Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects</span>. <i>Int. J. Biol. Markers</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.5301/JBM.5000026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.5301%2FJBM.5000026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=23787494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=117-130&author=W.+Liauthor=S.+Sajiauthor=F.+Satoauthor=M.+Nodaauthor=M.+Toi&title=Potential+clinical+applications+of+matrix+metalloproteinase+inhibitors+and+their+future+prospects&doi=10.5301%2FJBM.5000026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects</span></div><div class="casAuthors">Li, Wenzhao; Saji, Shigehira; Sato, Fumiaki; Noda, Makoto; Toi, Masakazu</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Markers</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-130</span>CODEN:
                <span class="NLM_cas:coden">IBMAEP</span>;
        ISSN:<span class="NLM_cas:issn">1724-6008</span>.
    
            (<span class="NLM_cas:orgname">Wichtig Editore</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are endopeptidases that are involved in extracellular matrix degrdn.  They are also implicated in a no. of abnormal bioprocesses, such as tumor growth, invasion, and metastasis.  Therefore, controlling MMP activities has generated considerable interest as a possible therapeutic target.  The tissue inhibitors of metalloproteinases (TIMPs) are the major naturally occurring proteins that specifically inhibit MMPs and assist in maintaining the balance between extracellular matrix destruction and formation.  However, TIMPs are probably not suitable for pharmacol. applications due to their short half-lives in vivo.  During the last few decades, synthetic MMP inhibitors (MMPIs) have undergone rapid clin. development in attempts to control MMP enzymic activities in abnormal bioprocesses.  Although studies with these agents have met with limited clin. success, the field of MMPIs is still expanding, and generation of highly effective and selective MMPIs might be a promising direction of this research area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKXi8KW5kc6LVg90H21EOLACvtfcHk0lhcQmtqsdxAZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOgsL4%253D&md5=c59e328340b4ed7f09fdca50100d64fd</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.5301%2FJBM.5000026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5301%252FJBM.5000026%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSaji%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DF.%26aulast%3DNoda%26aufirst%3DM.%26aulast%3DToi%26aufirst%3DM.%26atitle%3DPotential%2520clinical%2520applications%2520of%2520matrix%2520metalloproteinase%2520inhibitors%2520and%2520their%2520future%2520prospects%26jtitle%3DInt.%2520J.%2520Biol.%2520Markers%26date%3D2013%26volume%3D28%26spage%3D117%26epage%3D130%26doi%3D10.5301%2FJBM.5000026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hugenberg, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrends, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szardenings, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haufe, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on gamma-fluorinated alpha-sulfonylaminohydroxamic acid</span>. <i>EJNMMI radiopharmacy and chemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1186/s41181-018-0045-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs41181-018-0045-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30101186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3c7nsVCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=10&author=V.+Hugenbergauthor=M.+Behrendsauthor=S.+Wagnerauthor=S.+Hermannauthor=M.+Schafersauthor=H.+C.+Kolbauthor=K.+Szardeningsauthor=J.+C.+Walshauthor=L.+F.+Gomezauthor=K.+Kopkaauthor=G.+Haufe&title=Synthesis%2C+radiosynthesis%2C+in+vitro+and+first+in+vivo+evaluation+of+a+new+matrix+metalloproteinase+inhibitor+based+on+gamma-fluorinated+alpha-sulfonylaminohydroxamic+acid&doi=10.1186%2Fs41181-018-0045-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid</span></div><div class="casAuthors">Hugenberg Verena; Hermann Sven; Schafers Michael; Haufe Gunter; Hugenberg Verena; Wagner Stefan; Schafers Michael; Kopka Klaus; Hugenberg Verena; Behrends Malte; Haufe Gunter; Hermann Sven; Schafers Michael; Haufe Gunter; Kolb Hartmuth C; Szardenings Katrin; Walsh Joseph C; Gomez Luis F; Kopka Klaus</div><div class="citationInfo"><span class="NLM_cas:title">EJNMMI radiopharmacy and chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  To study MMP activity in vivo in disease, several radiolabeled MMP inhibitors functioning as radiotracers have been evaluated by means of SPECT and PET.  Unfortunately, most of them suffer from metabolic instability, mainly hepatobiliary clearance and insufficient target binding.  The introduction of a fluorine atom into MMPIs could contribute to target binding, enhance the metabolic stability and might shift the clearance towards more renal elimination.  Recently developed α-sulfonylaminohydroxamic acid based γ-fluorinated inhibitors of MMP-2 and -9 provide promising fluorine interactions with the enzyme active site and high MMP inhibition potencies.  The aim of this study is the (radio)synthesis of a γ-fluorinated MMP-2 and -9 inhibitor to evaluate its potential as a radiotracer to image MMP activity in vivo.  Results:  Two new fluorine-containing, enantiomerically pure inhibitors for MMP-2 and -9 were synthesized in a six step sequence.  Both enantiomers exhibited equal inhibition potencies in the low nanomolar and subnanomolar range.  LogD value indicated better water solubility compared to the CGS 25966 based analog.  The most potent inhibitor was successfully radiofluorinated.  In vivo biodistribution in wild type mice revealed predominantly hepatobiliary clearance.  Two major radioactive metabolites were found in different organs.  Defluorination of the radiotracer was not observed.  Conclusion:  (Radio)synthesis of a CGS based γ-fluorinated MMP inhibitor was successfully accomplished.  The (S)-enantiomer, which normally shows no biological activity, also exhibited high MMP inhibition potencies, which may be attributed to additional interactions of fluorine with enzyme's active site.  Despite higher hydrophilicity no significant differences in the clearance characteristics compared to non-fluorinated MMPIs was observed.  Metabolically stabilizing effect of the fluorine was not monitored in vivo in wild type mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLZr8cnqmmoS-bLEOO4dYpfW6udTcc2eZaUI-KkZqnHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7nsVCktg%253D%253D&md5=d1bd7af79875a88ccf7ea19fd85d0f2c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1186%2Fs41181-018-0045-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41181-018-0045-0%26sid%3Dliteratum%253Aachs%26aulast%3DHugenberg%26aufirst%3DV.%26aulast%3DBehrends%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DHermann%26aufirst%3DS.%26aulast%3DSchafers%26aufirst%3DM.%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DSzardenings%26aufirst%3DK.%26aulast%3DWalsh%26aufirst%3DJ.%2BC.%26aulast%3DGomez%26aufirst%3DL.%2BF.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DHaufe%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520radiosynthesis%252C%2520in%2520vitro%2520and%2520first%2520in%2520vivo%2520evaluation%2520of%2520a%2520new%2520matrix%2520metalloproteinase%2520inhibitor%2520based%2520on%2520gamma-fluorinated%2520alpha-sulfonylaminohydroxamic%2520acid%26jtitle%3DEJNMMI%2520radiopharmacy%2520and%2520chemistry%26date%3D2018%26volume%3D3%26spage%3D10%26doi%3D10.1186%2Fs41181-018-0045-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matrisian, L. M.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinases: biologic activity and clinical implications</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1135</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1200/JCO.2000.18.5.1135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2000.18.5.1135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10694567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVCgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=1135-1149&author=A.+R.+Nelsonauthor=B.+Fingletonauthor=M.+L.+Rothenbergauthor=L.+M.+Matrisian&title=Matrix+metalloproteinases%3A+biologic+activity+and+clinical+implications&doi=10.1200%2FJCO.2000.18.5.1135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases: biologic activity and clinical implications</span></div><div class="casAuthors">Nelson, Amy R.; Fingleton, Barbara; Rothenberg, Mace L.; Matrisian, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1135-1149</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 154 refs.  Abstr.: Tumor progression is a complex, multistage process by which a normal cell undergoes genetic changes that result in phenotypic alterations and the acquisition of the ability to spread and colonize distant sites in the body.  Although many factors regulate malignant tumor growth and spread, interactions between a tumor and its surrounding microenvironment result in the prodn. of important protein products that are crucial to each step of tumor progression.  The matrix metalloproteinases (MMPs) are a family of degradative enzymes with clear links to malignancy.  These enzymes are assocd. with tumor cell invasion of the basement membrane and stroma, blood vessel penetration, and metastasis.  They have more recently been implicated in primary and metastatic tumor growth and angiogenesis, and they may even have a role in tumor promotion.  This review outlines our current understanding of the MMP family, including the assocn. of particular MMPs with malignant phenotypes and the role of MMPs in specific steps of the metastatic cascade.  As scientific understanding of the MMPs has advanced, therapeutic strategies that capitalize on blocking the enzymes have rapidly developed.  The preclin. and clin. evolution of the synthetic MMP inhibitors (MMPIs) is also examd., with the discussion encompassing important methodol. issues assocd. with detg. clin. efficacy of MMPIs and other novel therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQhNHd2Oz8ErVg90H21EOLACvtfcHk0lgff2avpmdDWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVCgsbg%253D&md5=9a276fa4961253807cc7bd2bd253be0d</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1200%2FJCO.2000.18.5.1135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2000.18.5.1135%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DA.%2BR.%26aulast%3DFingleton%26aufirst%3DB.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26atitle%3DMatrix%2520metalloproteinases%253A%2520biologic%2520activity%2520and%2520clinical%2520implications%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2000%26volume%3D18%26spage%3D1135%26epage%3D1149%26doi%3D10.1200%2FJCO.2000.18.5.1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cathcart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulkoski-Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Targeting matrix metalloproteinases in cancer: bringing new life to old ideas</span>. <i>Genes & diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.gendis.2014.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.gendis.2014.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26097889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC2srotlKmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=26-34&author=J.+Cathcartauthor=A.+Pulkoski-Grossauthor=J.+Cao&title=Targeting+matrix+metalloproteinases+in+cancer%3A+bringing+new+life+to+old+ideas&doi=10.1016%2Fj.gendis.2014.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas</span></div><div class="casAuthors">Cathcart Jillian; Pulkoski-Gross Ashleigh; Cao Jian</div><div class="citationInfo"><span class="NLM_cas:title">Genes & diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-34</span>
        ISSN:<span class="NLM_cas:issn">2352-4820</span>.
    </div><div class="casAbstract">Since the identification of matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, as being a driving factor for cancer progression and patient prognosis, MMPs have been studied extensively.  Although early programs targeting MMPs were largely unsuccessful in clinical trials, they remain a viable and highly desirable therapeutic target based on preclinical studies and their role in disease progression.  As information regarding the structure and function of these proteinases is compiled and biotechnology evolves, tools to develop better inhibitors is within our grasp.  Improved methods for high throughput screening and in silico drug design programs have identified compounds which are highly potent, have high binding affinities, and exhibit favorable pharmacokinetic profiles.  More recently, advances in drug delivery methods or compounds which bind outside the active site have brought new light to the field.  In this review, we highlight the role of MMPs in cancer, clinical trials for MMP inhibitors, and novel approaches to targeting MMPs in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEJ37PEUcnpYxhnOQkIHOxfW6udTcc2ea6bsQ0q3lYUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srotlKmtw%253D%253D&md5=195802fe3f5c6881cdc9202d2ea3d957</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.gendis.2014.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gendis.2014.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DCathcart%26aufirst%3DJ.%26aulast%3DPulkoski-Gross%26aufirst%3DA.%26aulast%3DCao%26aufirst%3DJ.%26atitle%3DTargeting%2520matrix%2520metalloproteinases%2520in%2520cancer%253A%2520bringing%2520new%2520life%2520to%2520old%2520ideas%26jtitle%3DGenes%2520%2526%2520diseases%26date%3D2015%26volume%3D2%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.gendis.2014.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbroucke, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejonckheere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, C.</span></span> <span> </span><span class="NLM_article-title">A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1214</span>, <span class="refDoi"> DOI: 10.1183/09031936.00027411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1183%2F09031936.00027411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21659416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1agsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=1200-1214&author=R.+E.+Vandenbrouckeauthor=E.+Dejonckheereauthor=C.+Libert&title=A+therapeutic+role+for+matrix+metalloproteinase+inhibitors+in+lung+diseases%3F&doi=10.1183%2F09031936.00027411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?</span></div><div class="casAuthors">Vandenbroucke, R. E.; Dejonckheere, E.; Libert, C.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1200-1214</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Disruption of the balance between matrix metalloproteinases (MMPs) and their endogenous inhibitors is considered a key event in the development of pulmonary diseases such as chronic obstructive pulmonary disease, asthma, interstitial lung diseases and lung cancer.  This imbalance often results in elevated net MMP activity, making MMP inhibition an attractive therapeutic strategy.  Although promising results have been obtained, the lack of selective MMP inhibitors, together with limited knowledge regarding the exact functions of a particular MMP, hampers clin. application.  This review discusses the involvement of different MMPs in lung disorders and future opportunities and limitations of therapeutic MMP inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNPP3muS-QLVg90H21EOLACvtfcHk0ljLGSgBwwIPHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1agsLw%253D&md5=a6246e4e64844afe46f7fcb99c2c4569</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1183%2F09031936.00027411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00027411%26sid%3Dliteratum%253Aachs%26aulast%3DVandenbroucke%26aufirst%3DR.%2BE.%26aulast%3DDejonckheere%26aufirst%3DE.%26aulast%3DLibert%26aufirst%3DC.%26atitle%3DA%2520therapeutic%2520role%2520for%2520matrix%2520metalloproteinase%2520inhibitors%2520in%2520lung%2520diseases%253F%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D38%26spage%3D1200%26epage%3D1214%26doi%3D10.1183%2F09031936.00027411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasatomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1002/ijc.21285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fijc.21285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16003755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BD2Mrot1GqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=215-221&author=Y.+Ogataauthor=K.+Matonoauthor=M.+Nakajimaauthor=T.+Sasatomiauthor=T.+Mizobeauthor=H.+Nagaseauthor=K.+Shirouzu&title=Efficacy+of+the+MMP+inhibitor+MMI270+against+lung+metastasis+following+removal+of+orthotopically+transplanted+human+colon+cancer+in+rat&doi=10.1002%2Fijc.21285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat</span></div><div class="casAuthors">Ogata Yutaka; Matono Keiko; Nakajima Motowo; Sasatomi Teruo; Mizobe Tomoaki; Nagase Hideaki; Shirouzu Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">215-21</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">We have investigated the antitumor effects of synthetic MMP inhibitor MMI270 against postoperative lung metastasis from colon cancer in nude rat.  The KM12SM human colon cancer cells were injected into the cecal wall, and at 5 weeks after the injection, the cecum was removed including the tumor.  Then, 30 mg/kg of MMI270 was administered perorally twice per day for 2 or 4 weeks, either immediately after removal or after week 2 after the removal.  At week 7 after the removal, lung metastasis was significantly inhibited by the early administration of MMI270 immediately after the tumor removal but not by the late administration.  The survival rates were significantly higher in the rats treated by early administration of MMI270 compared to the survival rate in untreated rats.  Moreover, no lung metastasis was detected in some rats with 24-weeks' survival treated by early administration.  Lower microvessel density, lower PCNA Index and higher Apoptotic Index in the lung metastases of the rats treated with MMI270 were found compared to those in untreated rats.  A beneficial effect of by early administration of MMI270 against postoperative lung metastases may be expected through inhibiting neovascularization of metastases in nude rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGphLXMHYYdz0O18WR3iAofW6udTcc2ea6bsQ0q3lYUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mrot1GqsA%253D%253D&md5=b246f3fbca38545dd4840e7724ed7fdb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fijc.21285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21285%26sid%3Dliteratum%253Aachs%26aulast%3DOgata%26aufirst%3DY.%26aulast%3DMatono%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DSasatomi%26aufirst%3DT.%26aulast%3DMizobe%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DShirouzu%26aufirst%3DK.%26atitle%3DEfficacy%2520of%2520the%2520MMP%2520inhibitor%2520MMI270%2520against%2520lung%2520metastasis%2520following%2520removal%2520of%2520orthotopically%2520transplanted%2520human%2520colon%2520cancer%2520in%2520rat%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D215%26epage%3D221%26doi%3D10.1002%2Fijc.21285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Propper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span> <span> </span><span class="NLM_article-title">Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11448904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslaltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1912-1922&author=N.+Levittauthor=F.+Eskensauthor=K.+O%E2%80%99Byrneauthor=D.+Propperauthor=L.+Denisauthor=S.+Owenauthor=L.+Choiauthor=J.+Foekensauthor=S.+Wilnerauthor=J.+Woodauthor=M.+Nakajimaauthor=D.+Talbotauthor=W.+Stewardauthor=A.+Harrisauthor=J.+Verweij&title=Phase+I+and+pharmacological+study+of+the+oral+matrix+metalloproteinase+inhibitor%2C+MMI270+%28CGS27023A%29%2C+in+patients+with+advanced+solid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer</span></div><div class="casAuthors">Levitt, Nicola C.; Eskens, Ferry A. L. M.; O'Byrne, Ken J.; Propper, David J.; Denis, Louis J.; Owen, Samantha J.; Choi, Les; Foekens, John A.; Wilner, Sue; Wood, Jeanette M.; Nakajima, Motowo; Talbot, Denis C.; Steward, William P.; Harris, Adrian L.; Verweij, Jaap</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1912-1922</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and investigated markers of biol. activity to recommend a dose for Phase II studies.  MMI270 was administered continuously at seven dose levels (50 mg once daily to 600 mg three times/day).  Patients were evaluated for toxicity and tumor response, and blood and urine samples were taken for pharmacokinetics, bone resorption markers, direct targets of the inhibitor [matrix metalloproteinase-2 (MMP-2), MMP-8, and MMP-9], indirect targets [tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, basic fibroblast growth factor, vascular endothelial growth factor, vascular cell adhesion mol.-1, sol. urokinase plasminogen activator receptor, and cathepsins B and H] and for a tumor necrosis factor-α cytokine release assay.  Ninety-two patients were entered.  There was no myelo-toxicity.  Eighteen patients developed a widespread maculopapular rash, which increased in frequency and severity at doses ≥300 mg bid.  Thirty nine patients developed musculoskeletal side effects, which were related to duration of treatment, not to dose level.  Pharmacokinetics were linear, and MMI270 was rapidly absorbed and eliminated with minimal accumulation on chronic dosing.  Sustained plasma concns. in excess of 4 × mean IC50 for the target enzymes were obsd. at dose levels ≥150 mg bid.  There were no tumor regressions; however, 19 patients had stable disease for ≥90 days.  There was a dose-response increase of MMP-2 and TIMP-1 with MMI270.  Transient effects on the bone resorption markers were detected.  MMI270 was generally well tolerated, with adequate plasma levels for target enzyme inhibition.  The two main toxicities were rash, resulting in a max. tolerated dose of 300 mg bid and musculoskeletal side effects.  Biol. marker data indicate drug effects.  The rise in TIMP-1 suggests that a reflex rise in inhibitors could modify the effects of MMI270.  The recommended Phase II dose is 300 mg bid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKRmnL75Gt2rVg90H21EOLACvtfcHk0ljGM1GYwc5R1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslaltbY%253D&md5=275c688bd43c590141e8e652c73c779e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitt%26aufirst%3DN.%26aulast%3DEskens%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DPropper%26aufirst%3DD.%26aulast%3DDenis%26aufirst%3DL.%26aulast%3DOwen%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DL.%26aulast%3DFoekens%26aufirst%3DJ.%26aulast%3DWilner%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DD.%26aulast%3DSteward%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520and%2520pharmacological%2520study%2520of%2520the%2520oral%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520MMI270%2520%2528CGS27023A%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D1912%26epage%3D1922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignatti, P.</span></span> <span> </span><span class="NLM_article-title">Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1155</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1535-7163.MCT-17-0646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29735645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1147-1155&author=A.+Winerauthor=S.+Adamsauthor=P.+Mignatti&title=Matrix+metalloproteinase+inhibitors+in+cancer+therapy%3A+Turning+past+failures+into+future+successes&doi=10.1158%2F1535-7163.MCT-17-0646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes</span></div><div class="casAuthors">Winer, Arthur; Adams, Sylvia; Mignatti, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1147-1155</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMP) are a family of proteolytic enzymes that degrade multiple components of the extracellular matrix.  A large body of exptl. and clin. evidence has implicated MMPs in tumor invasion, neoangiogenesis, and metastasis, and therefore they represent ideal pharmacol. targets for cancer therapy.  From the 1990s to early 2000s, synthetic inhibitors of MMPs (MMPI) were studied in various cancer types.  Unexpectedly, despite strongly promising preclin. data, all trials were unsuccessful in reducing tumor burden or improving overall survival; in addn., MMPIs had unforeseen, severe side effects.  Two main reasons can explain the failure of MMPIs in clin. trials.  It has now become apparent that some MMPs have antitumor effects; therefore, the broad-spectrum MMPIs used in the initial trials might block these MMPs and result in tumor progression.  In addn., although MMPs are involved in the early stages of tumor progression, MMPIs were tested in patients with advanced disease, beyond the stage when these compds. could be effective.  As more specific MMPIs are now available, MMP targeting could be reconsidered for cancer therapy; however, new trials should be designed to test their antimetastatic properties in early-stage tumors, and endpoints should focus on parameters other than decreasing metastatic tumor burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPKS7DzJJsbVg90H21EOLACvtfcHk0ljGM1GYwc5R1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3L&md5=cb10ac5dce9c30145e35c19b713a5ee4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0646%26sid%3Dliteratum%253Aachs%26aulast%3DWiner%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DMignatti%26aufirst%3DP.%26atitle%3DMatrix%2520metalloproteinase%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520Turning%2520past%2520failures%2520into%2520future%2520successes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1147%26epage%3D1155%26doi%3D10.1158%2F1535-7163.MCT-17-0646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, B. R.</span></span> <span> </span><span class="NLM_article-title">Abstract 35: Molecular optimization of phase III trial failed anticancer drugs using target affinity and toxicity-centered multiple properties reinforcement learning</span>. <i>Clinical cancer research</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">35</span>, <span class="refDoi"> DOI: 10.1158/1557-3265.ADVPRECMED20-35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1557-3265.ADVPRECMED20-35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=31597662" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=35&author=S.+Parkauthor=Y.+H.+Koauthor=B.+Leeauthor=B.+Shinauthor=B.+R.+Beck&title=Abstract+35%3A+Molecular+optimization+of+phase+III+trial+failed+anticancer+drugs+using+target+affinity+and+toxicity-centered+multiple+properties+reinforcement+learning&doi=10.1158%2F1557-3265.ADVPRECMED20-35"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1158%2F1557-3265.ADVPRECMED20-35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1557-3265.ADVPRECMED20-35%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DShin%26aufirst%3DB.%26aulast%3DBeck%26aufirst%3DB.%2BR.%26atitle%3DAbstract%252035%253A%2520Molecular%2520optimization%2520of%2520phase%2520III%2520trial%2520failed%2520anticancer%2520drugs%2520using%2520target%2520affinity%2520and%2520toxicity-centered%2520multiple%2520properties%2520reinforcement%2520learning%26jtitle%3DClinical%2520cancer%2520research%26date%3D2020%26volume%3D26%26spage%3D35%26doi%3D10.1158%2F1557-3265.ADVPRECMED20-35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shalinsky, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margosiak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varki, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelt, K.</span></span> <span> </span><span class="NLM_article-title">Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>878</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1999.tb07689.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1111%2Fj.1749-6632.1999.tb07689.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10415735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXkslems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=878&publication_year=1999&pages=236-270&author=D.+R.+Shalinskyauthor=J.+Brekkenauthor=H.+Zouauthor=C.+D.+McDermottauthor=P.+Forsythauthor=D.+Edwardsauthor=S.+Margosiakauthor=S.+Benderauthor=G.+Truittauthor=A.+Woodauthor=N.+M.+Varkiauthor=K.+Appelt&title=Broad+antitumor+and+antiangiogenic+activities+of+AG3340%2C+a+potent+and+selective+MMP+inhibitor+undergoing+advanced+oncology+clinical+trials&doi=10.1111%2Fj.1749-6632.1999.tb07689.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials</span></div><div class="casAuthors">Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">878</span>
        (<span class="NLM_cas:issue">Inhibition of Matrix Metalloproteinases</span>),
    <span class="NLM_cas:pages">236-270</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9), MT-MMP-1 (MMP-14), and collagenase-3 (MMP-13) in many tumor models.  AG3340 produced dose-dependent pharmacokinetics and was well tolerated after i.p. (i.p.) and oral dosing in mice.  Across human tumor models, AG3340 produced profound tumor growth delays when dosing began early or late after tumor implantation, although all established tumor types did not respond to AG3340.  A dose-response relationship was explored in three models: COLO-320DM colon, MV522 lung, and MDA-MB-435 breast.  Dose-dependent inhibitions of tumor growth (over 12.5-200 mg/kg given twice daily, b.i.d.) were obsd. in the colon and lung models; and in a third (breast), maximal inhibitions were produced by the lowest dose of AG3340 (50 mg/kg, b.i.d.) that was tested.  In another model, AG3340 (100 mg/kg, once daily, i.p.) markedly inhibited U87 glioma growth and increased animal survival.  AG3340 also inhibited tumor growth and increased the survival of nude mice bearing androgen-independent PC-3 prostatic tumors.  In a sixth model, KKLS gastric, AG3340 did not inhibit tumor growth but potentiated the efficacy of Taxol.  Importantly, AG3340 markedly decreased tumor angiogenesis (as assessed by CD-31 staining) and cell proliferation (as assessed by bromodeoxyuridine incorporation), and increased tumor necrosis and apoptosis (as assessed by hematoxylin and eosin and TUNEL staining).  These effects were model dependent, but angiogenesis was commonly inhibited.  AG3340 had a superior therapeutic index to the cytotoxic agents, carboplatin and Taxol, in the MV522 lung cancer model.  In combination, AG3340 enhanced the efficacy of these cytotoxic agents without altering drug tolerance.  Addnl., AG3340 decreased the no. of murine melanoma (B16-F10) lesions arising in the lung in an i.v. metastasis model when given in combination with carboplatin or Taxol.  These studies directly support the use of AG3340 in front-line combination chemotherapy in ongoing clin. trials in patients with advanced malignancies of the lung and prostate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1dLJ2G4J3vLVg90H21EOLACvtfcHk0lihzWP1kbsQRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslems78%253D&md5=bcd62f80fae17f4b8ce8a0fa34160ab5</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1999.tb07689.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1999.tb07689.x%26sid%3Dliteratum%253Aachs%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DMcDermott%26aufirst%3DC.%2BD.%26aulast%3DForsyth%26aufirst%3DP.%26aulast%3DEdwards%26aufirst%3DD.%26aulast%3DMargosiak%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DTruitt%26aufirst%3DG.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DVarki%26aufirst%3DN.%2BM.%26aulast%3DAppelt%26aufirst%3DK.%26atitle%3DBroad%2520antitumor%2520and%2520antiangiogenic%2520activities%2520of%2520AG3340%252C%2520a%2520potent%2520and%2520selective%2520MMP%2520inhibitor%2520undergoing%2520advanced%2520oncology%2520clinical%2520trials%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D878%26spage%3D236%26epage%3D270%26doi%3D10.1111%2Fj.1749-6632.1999.tb07689.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Pawel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatzemeier, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazabel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F.</span></span> <span> </span><span class="NLM_article-title">Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.03.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1200%2FJCO.2005.03.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15681529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVKit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=842-849&author=D.+Bissettauthor=K.+O%E2%80%99Byrneauthor=J.+von+Pawelauthor=U.+Gatzemeierauthor=A.+Priceauthor=M.+Nicolsonauthor=R.+Mercierauthor=E.+Mazabelauthor=C.+Penningauthor=M.+Zhangauthor=M.+Collierauthor=F.+Shepherd&title=Phase+III+study+of+matrix+metalloproteinase+inhibitor+prinomastat+in+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2005.03.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer</span></div><div class="casAuthors">Bissett, Donald; O'Byrne, Ken J.; von Pawel, J.; Gatzemeier, Ulrich; Price, Allan; Nicolson, Marianne; Mercier, Richard; Mazabel, Elva; Penning, Carol; Zhang, Min H.; Collier, Mary A.; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-849</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs) degrade extracellular proteins and facilitate tumor growth, invasion, metastasis, and angiogenesis.  This trial was undertaken to det. the effect of prinomastat, an inhibitor of selected MMPs, on the survival of patients with advanced non-small-cell lung cancer (NSCLC), when given in combination with gemcitabine-cisplatin chemotherapy.  Chemotherapy-naive patients were randomly assigned to receive prinomastat 15 mg or placebo twice daily orally continuously, in combination with gemcitabine 1,250 mg/m2 days 1 and 8 plus cisplatin 75 mg/m2 day 1, every 21 days for up to six cycles.  The planned sample size was 420 patients.  Study results at an interim anal. and lack of efficacy in another phase III trial prompted early closure of this study.  There were 362 patients randomized (181 on prinomastat and 181 on placebo).  One hundred thirty-four patients had stage IIIB disease with T4 primary tumor, 193 had stage IV disease, and 34 had recurrent disease (one enrolled patient was ineligible with stage IIIA disease).  Overall response rates for the two treatment arms were similar (27% for prinomastat v 26% for placebo; P=.81).  There was no difference in overall survival or time to progression; for prinomastat vs. placebo patients, the median overall survival times were 11.5 vs. 10.8 mo (P =.82), 1-yr survival rates were 43% v 38% (P =.45), and progression-free survival times were 6.1 v 5.5 mo (P =.11), resp.  The toxicities of prinomastat were arthralgia, stiffness, and joint swelling.  Treatment interruption was required in 38% of prinomastat patients and 12% of placebo patients.  Prinomastat does not improve the outcome of chemotherapy in advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSpOytcWX7RLVg90H21EOLACvtfcHk0lihzWP1kbsQRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVKit7w%253D&md5=5f3b668b601b8bab0826f8bd52dc43df</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.170%26sid%3Dliteratum%253Aachs%26aulast%3DBissett%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGatzemeier%26aufirst%3DU.%26aulast%3DPrice%26aufirst%3DA.%26aulast%3DNicolson%26aufirst%3DM.%26aulast%3DMercier%26aufirst%3DR.%26aulast%3DMazabel%26aufirst%3DE.%26aulast%3DPenning%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DM.%26aulast%3DShepherd%26aufirst%3DF.%26atitle%3DPhase%2520III%2520study%2520of%2520matrix%2520metalloproteinase%2520inhibitor%2520prinomastat%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D842%26epage%3D849%26doi%3D10.1200%2FJCO.2005.03.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnachi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3096</span>– <span class="NLM_lpage">3100</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmcl.2006.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=16632358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFertb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3096-3100&author=Y.+M.+Zhangauthor=X.+Fanauthor=B.+Xiangauthor=D.+Chakravartyauthor=R.+Scannevinauthor=S.+Burkeauthor=P.+Karnachiauthor=K.+Rhodesauthor=P.+Jackson&title=Synthesis+and+SAR+of+alpha-sulfonylcarboxylic+acids+as+potent+matrix+metalloproteinase+inhibitors&doi=10.1016%2Fj.bmcl.2006.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of α-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors</span></div><div class="casAuthors">Zhang, Yue-Mei; Fan, Xiaodong; Xiang, Bangping; Chakravarty, Devraj; Scannevin, Robert; Burke, Sharon; Karnachi, Prabha; Rhodes, Kenneth; Jackson, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3096-3100</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of novel carboxylic acid-based α-sulfone MMP inhibitors have been synthesized and the in vitro enzyme SAR is discussed.  A potential binding mode in the active site of the MMP-9 homol. model was highlighted.  These compds. are potent MMP-9 inhibitors and are selective over MMP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorWASoCppeULVg90H21EOLACvtfcHk0lihzWP1kbsQRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFertb8%253D&md5=f1cebe7124a6ff398be78c23e9782a3d</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DBurke%26aufirst%3DS.%26aulast%3DKarnachi%26aufirst%3DP.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520alpha-sulfonylcarboxylic%2520acids%2520as%2520potent%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3096%26epage%3D3100%26doi%3D10.1016%2Fj.bmcl.2006.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samartzis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stucki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imesch, P.</span></span> <span> </span><span class="NLM_article-title">Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and −9 activity in primary endometriotic stromal cells in vitro</span>. <i>Reprod. Biol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">38</span>, <span class="refDoi"> DOI: 10.1186/s12958-019-0481-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1186%2Fs12958-019-0481-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30981279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FltVKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=38&author=E.+P.+Samartzisauthor=D.+Finkauthor=M.+Stuckiauthor=P.+Imesch&title=Doxycycline+reduces+MMP-2+activity+and+inhibits+invasion+of+12Z+epithelial+endometriotic+cells+as+well+as+MMP-2+and+%E2%88%929+activity+in+primary+endometriotic+stromal+cells+in+vitro&doi=10.1186%2Fs12958-019-0481-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and -9 activity in primary endometriotic stromal cells in vitro</span></div><div class="casAuthors">Samartzis Eleftherios P; Fink Daniel; Stucki Manuel; Imesch Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Reproductive biology and endocrinology : RB&E</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Matrix metalloproteinases (MMPs), especially the gelatinases MMP-2 and MMP-9, play a crucial role in the pathogenesis of endometriosis by enabling invasion.  Doxycycline is a well-tolerated antibiotic and a potent MMP-inhibitor in subantimicrobial doses.  METHODS:  Gelatin zymography and activity assays were used to detect latent and active MMP-2 and -9 in cell culture supernatants of immortalized epithelial (12Z) and two isolates of primary endometriotic stromal cells treated with doxycycline.  The invasiveness of 12Z endometriotic cells treated with doxycycline was assessed in matrigel-coated invasion chambers.  The effect on latent and active MMP-2 expression of the combination of progesterone and doxycycline was tested in 12Z.  RESULTS:  Doxycycline significantly reduced the MMP-2 activity and pro-MMP-2 expression in 12Z and the MMP-2 and -9 activity as well as expression of pro-MMP-2 and -9 in primary endometriotic stromal cells.  The percentage of 12Z cells invading through a matrigel-coated membrane was reduced to 65 and 22% of the control after treatment with doxycycline at doses of 1 μg/ml and 10 μg/ml, respectively.  Furthermore, a combination of progesterone and doxycycline showed an additive effect in low doses on the reduction of MMP-2 activity and pro-MMP2 expression in 12Z endometriotic cells.  CONCLUSIONS:  In conclusion, the MMP-inhibiting features of subantimicrobial-dose doxycycline may be further evaluated as a well-tolerable additional therapeutic approach, e.g. in combination with progestins such as dienogest, in patients with infiltrative endometriosis with insufficient response to current medical treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsrewx-xl3iMzK395ZObgVfW6udTcc2eZ3OV8jp8FsDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FltVKmug%253D%253D&md5=723b1a24a9dd24bcedbf90c09cd57014</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1186%2Fs12958-019-0481-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12958-019-0481-z%26sid%3Dliteratum%253Aachs%26aulast%3DSamartzis%26aufirst%3DE.%2BP.%26aulast%3DFink%26aufirst%3DD.%26aulast%3DStucki%26aufirst%3DM.%26aulast%3DImesch%26aufirst%3DP.%26atitle%3DDoxycycline%2520reduces%2520MMP-2%2520activity%2520and%2520inhibits%2520invasion%2520of%252012Z%2520epithelial%2520endometriotic%2520cells%2520as%2520well%2520as%2520MMP-2%2520and%2520%25E2%2588%25929%2520activity%2520in%2520primary%2520endometriotic%2520stromal%2520cells%2520in%2520vitro%26jtitle%3DReprod.%2520Biol.%2520Endocrinol.%26date%3D2019%26volume%3D17%26spage%3D38%26doi%3D10.1186%2Fs12958-019-0481-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löffek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzke, C.</span></span> <span> </span><span class="NLM_article-title">Series “matrix metalloproteinases in lung health and disease“: Biological role of matrix metalloproteinases: a critical balance</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1183/09031936.00146510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1183%2F09031936.00146510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=21177845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC3MnksF2ntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=191-208&author=S.+L%C3%B6ffekauthor=O.+Schillingauthor=C.+Franzke&title=Series+%E2%80%9Cmatrix+metalloproteinases+in+lung+health+and+disease%E2%80%9C%3A+Biological+role+of+matrix+metalloproteinases%3A+a+critical+balance&doi=10.1183%2F09031936.00146510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance</span></div><div class="casAuthors">Loffek S; Schilling O; Franzke C-W</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">191-208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Matrix metalloproteinases (MMPs) are members of the metzincin group of proteases which share the conserved zinc-binding motif in their catalytic active site.  It was originally thought that their main function is to degrade the various components of the extracellular matrix (ECM), yet recent studies have led us to appreciate their significance as regulators of extracellular tissue signalling networks.  Due to the broad spectrum of their substrate specificity, MMPs contribute to the homeostasis of many tissues and participate in several physiological processes, such as bone remodelling, angiogenesis, immunity and wound healing.  MMP activity is tightly controlled at the level of transcription, pro-peptide activation and inhibition by tissue inhibitors of MMPs.  Dysregulated MMP activity leads to pathological conditions such as arthritis, inflammation and cancer, thus highlighting MMPs as promising therapeutic targets.  Analysis of MMP mutant mice has proved to be an essential tool for the identification of novel functions and interactions of single MMP members.  Advancing our understanding of the MMP contribution to tissue homeostasis will lead us to identify causal relationships between their dysregulation and the development of disease pathologies, thus guiding us to successful MMP-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbRLIfsc9zKCXXDYhVZBdlfW6udTcc2eZ3OV8jp8FsDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnksF2ntw%253D%253D&md5=4c4fd9a00410473421a7f942afd0ce38</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1183%2F09031936.00146510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00146510%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6ffek%26aufirst%3DS.%26aulast%3DSchilling%26aufirst%3DO.%26aulast%3DFranzke%26aufirst%3DC.%26atitle%3DSeries%2520%25E2%2580%259Cmatrix%2520metalloproteinases%2520in%2520lung%2520health%2520and%2520disease%25E2%2580%259C%253A%2520Biological%2520role%2520of%2520matrix%2520metalloproteinases%253A%2520a%2520critical%2520balance%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D38%26spage%3D191%26epage%3D208%26doi%3D10.1183%2F09031936.00146510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aelst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Steen, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proost, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liuzzi, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polverini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opdenakker, G.</span></span> <span> </span><span class="NLM_article-title">A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1770</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2006.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bbagen.2006.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17137715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1770&publication_year=2007&pages=178-186&author=E.+Martensauthor=A.+Leyssenauthor=I.+Van+Aelstauthor=P.+Fitenauthor=H.+Piccardauthor=J.+Huauthor=F.+J.+Descampsauthor=P.+E.+Van+den+Steenauthor=P.+Proostauthor=J.+Van+Dammeauthor=G.+M.+Liuzziauthor=P.+Riccioauthor=E.+Polveriniauthor=G.+Opdenakker&title=A+monoclonal+antibody+inhibits+gelatinase+B%2FMMP-9+by+selective+binding+to+part+of+the+catalytic+domain+and+not+to+the+fibronectin+or+zinc+binding+domains&doi=10.1016%2Fj.bbagen.2006.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains</span></div><div class="casAuthors">Martens, Erik; Leyssen, An; Van Aelst, Ilse; Fiten, Pierre; Piccard, Helene; Hu, Jialiang; Descamps, Francis J.; Van den Steen, Philippe E.; Proost, Paul; Van Damme, Jo; Liuzzi, Grazia Maria; Riccio, Paolo; Polverini, Eugenia; Opdenakker, Ghislain</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1770</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-186</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gelatinase B/matrix metalloproteinase-9 (MMP-9) is a multidomain enzyme functioning in acute and chronic inflammatory and neoplastic diseases.  It belongs to a family of more than 20 related zinc proteinases.  Therefore, the discovery and the definition of the action mechanism of selective MMP inhibitors form the basis for future therapeutics.  The monoclonal antibody REGA-3G12 is a most selective inhibitor of human gelatinase B.  REGA-3G12 was found to recognize the amino terminal part and not the carboxyterminal O-glycosylated and hemopexin protein domains.  A variant of gelatinase B, lacking the two carboxyterminal domains, was expressed in insect cells and fragmented with purified proteinases.  The fragments were probed by one- and two-dimensional Western blot and immunopptn. expts. with REGA-3G12 to map the interactions between the antibody and the enzyme.  The interaction unit was identified by Edman degrdn. anal. as the glycosylated segment from Trp116 to Lys214 of gelatinase B.  The sequence of this segment was analyzed by hydrophobicity/hydrophilicity, accessibility and flexibility profiling.  Four hydrophilic peptides were chem. synthesized and used in binding and competition assays.  The peptide Gly171-Leu187 in molar excess inhibited partially the binding of MMP-9 to REGA-3G12 and thus refines the structure of the conformational binding site.  These results define part of the catalytic domain of gelatinase B/MMP-9, and not the zinc-binding or fibronectin domains, as target for the development of selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBVg4Yn-PA8rVg90H21EOLACvtfcHk0ljncPPW2Qfzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWnsg%253D%253D&md5=2972630d0bc24652d4c836ee1227ae1c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2006.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2006.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DMartens%26aufirst%3DE.%26aulast%3DLeyssen%26aufirst%3DA.%26aulast%3DVan%2BAelst%26aufirst%3DI.%26aulast%3DFiten%26aufirst%3DP.%26aulast%3DPiccard%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DDescamps%26aufirst%3DF.%2BJ.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DP.%2BE.%26aulast%3DProost%26aufirst%3DP.%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DLiuzzi%26aufirst%3DG.%2BM.%26aulast%3DRiccio%26aufirst%3DP.%26aulast%3DPolverini%26aufirst%3DE.%26aulast%3DOpdenakker%26aufirst%3DG.%26atitle%3DA%2520monoclonal%2520antibody%2520inhibits%2520gelatinase%2520B%252FMMP-9%2520by%2520selective%2520binding%2520to%2520part%2520of%2520the%2520catalytic%2520domain%2520and%2520not%2520to%2520the%2520fibronectin%2520or%2520zinc%2520binding%2520domains%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2007%26volume%3D1770%26spage%3D178%26epage%3D186%26doi%3D10.1016%2Fj.bbagen.2006.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pruijt, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fibbe, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laterveer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindley, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paemen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opdenakker, G.</span></span> <span> </span><span class="NLM_article-title">Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">10863</span>– <span class="NLM_lpage">10868</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.19.10863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1073%2Fpnas.96.19.10863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10485917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXmtFKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10863-10868&author=J.+F.+Pruijtauthor=W.+E.+Fibbeauthor=L.+Laterveerauthor=R.+A.+Pietersauthor=I.+J.+Lindleyauthor=L.+Paemenauthor=S.+Masureauthor=R.+Willemzeauthor=G.+Opdenakker&title=Prevention+of+interleukin-8-induced+mobilization+of+hematopoietic+progenitor+cells+in+rhesus+monkeys+by+inhibitory+antibodies+against+the+metalloproteinase+gelatinase+B+%28MMP-9%29&doi=10.1073%2Fpnas.96.19.10863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9)</span></div><div class="casAuthors">Pruijt, Johannes F. M.; Fibbe, Willem E.; Laterveer, Laurens; Pieters, Reagan A.; Lindley, Ivan J. D.; Paemen, Liesbet; Masure, Stefan; Willemze, Roel; Opdenakker, Ghislain</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10863-10868</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Previously, we demonstrated that IL-8 induces rapid mobilization of hematopoietic progenitor cells (HPC) from the bone marrow of rhesus monkeys.  Because activation of neutrophils by IL-8 induces the release of gelatinase B (MMP-9), which is involved in the degrdn. of extracellular matrix mols., we hypothesized that MMP-9 release might induce stem cell mobilization by cleaving matrix mols. to which stem cells are attached.  Rhesus monkeys were treated with a single i.v. injection of 0.1 mg/kg human IL-8, which resulted in a 10- to 100-fold increase in HPC within 30 min after injection.  Zymog. anal. revealed a dramatic instantaneous increase in the plasma levels of MMP-9, followed by the increase in circulating HPC.  Enzyme levels decreased at 2 h after injection of IL-8, simultaneously with the decrease in the nos. of circulating HPC.  To test the hypothesis that MMP-9 induction was involved in HPC mobilization, rhesus monkeys were treated with a highly specific inhibitory monoclonal anti-gelatinase B antibody.  Anti-gelatinase B at a dose of 1-2 mg/kg completely prevented the IL-8-induced mobilization of HPC, whereas a dose of 0.1 mg/kg had only a limited effect.  Preinjection of inhibitory antibodies did not preclude the IL-8-induced prodn. and secretion of MMP-9.  Pretreatment with an irrelevant control antibody did not affect IL-8-induced mobilization, showing that the inhibition by the anti-gelatinase B antibody was specific.  In summary, IL-8 induces the rapid systemic release of MMP-9 with concurrent mobilization of HPC that is prevented by pretreatment with an inhibitory anti-gelatinase B antibody, indicating that MMP-9 is involved as a mediator of the IL-8-induced mobilization of HPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKHBWUhLO77Vg90H21EOLACvtfcHk0ljrH4YiCvonXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtFKjsb4%253D&md5=05f86402d1402f39b95f2ce8fcdc7ca3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.19.10863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.19.10863%26sid%3Dliteratum%253Aachs%26aulast%3DPruijt%26aufirst%3DJ.%2BF.%26aulast%3DFibbe%26aufirst%3DW.%2BE.%26aulast%3DLaterveer%26aufirst%3DL.%26aulast%3DPieters%26aufirst%3DR.%2BA.%26aulast%3DLindley%26aufirst%3DI.%2BJ.%26aulast%3DPaemen%26aufirst%3DL.%26aulast%3DMasure%26aufirst%3DS.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DOpdenakker%26aufirst%3DG.%26atitle%3DPrevention%2520of%2520interleukin-8-induced%2520mobilization%2520of%2520hematopoietic%2520progenitor%2520cells%2520in%2520rhesus%2520monkeys%2520by%2520inhibitory%2520antibodies%2520against%2520the%2520metalloproteinase%2520gelatinase%2520B%2520%2528MMP-9%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D10863%26epage%3D10868%26doi%3D10.1073%2Fpnas.96.19.10863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry-Hamilton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghermazien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels-Vigdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0127063</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0127063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1371%2Fjournal.pone.0127063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25961845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVakurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=D.+C.+Marshallauthor=S.+K.+Lymanauthor=S.+McCauleyauthor=M.+Kovalenkoauthor=R.+Spanglerauthor=C.+Liuauthor=M.+Leeauthor=C.+O%E2%80%99Sullivanauthor=V.+Barry-Hamiltonauthor=H.+Ghermazienauthor=A.+Mikels-Vigdalauthor=C.+A.+Garciaauthor=B.+Jorgensenauthor=A.+C.+Velayoauthor=R.+Wangauthor=J.+I.+Adamkewiczauthor=V.+Smith&title=Selective+allosteric+inhibition+of+MMP9+is+efficacious+in+preclinical+models+of+ulcerative+colitis+and+colorectal+cancer&doi=10.1371%2Fjournal.pone.0127063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Selective allosteric inhibition of MMP9 Is efficacious in preclinical models of ulcerative colitis and colorectal cancer</span></div><div class="casAuthors">Marshall, Derek C.; Lyman, Susan K.; McCauley, Scott; Kovalenko, Maria; Spangler, Rhyannon; Liu, Chian; Lee, Michael; O'Sullivan, Christopher; Barry-Hamilton, Vivian; Ghermazien, Haben; Mikels-Vigdal, Amanda; Garcia, Carlos A.; Jorgensen, Brett; Velayo, Arleene C.; Wang, Ruth; Adamkewicz, Joanne I.; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0127063/1-e0127063/26</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncol. indications, including ulcerative colitis and colorectal cancer.  MMP9 is a downstream effector and an upstream mediator of pathways involved in growth and inflammation, and has long been viewed as a promising therapeutic target.  However, previous efforts to target matrix metalloproteinases (MMPs), including MMP9, have utilized broad-spectrum or semi-selective inhibitors.  While some of these drugs showed signs of efficacy in patients, all MMP-targeted inhibitors have been hampered by dose-limiting toxicity or insufficient clin. benefit, likely due to their lack of specificity.  Here, we show that selective inhibition of MMP9 did not induce musculoskeletal syndrome (a characteristic toxicity of pan-MMP inhibitors) in a rat model, but did reduce disease severity in a dextran sodium sulfate-induced mouse model of ulcerative colitis.  We also found that MMP9 inhibition decreased tumor growth and metastases incidence in a surgical orthotopic xenograft model of colorectal carcinoma, and that inhibition of either tumor- or stroma-derived MMP9 was sufficient to reduce primary tumor growth.  Collectively, these data suggest that selective MMP9 inhibition is a promising therapeutic strategy for treatment of inflammatory and oncol. indications in which MMP9 is upregulated and is assocd. with disease pathol., such as ulcerative colitis and colorectal cancer.  In addn., we report the development of a potent and highly selective allosteric MMP9 inhibitor, the humanized monoclonal antibody GS-5745, which can be used to evaluate the therapeutic potential of MMP9 inhibition in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXAvk8jsdzUrVg90H21EOLACvtfcHk0ljrH4YiCvonXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVakurrO&md5=43c6e647e653c2f1f8040460a9f8c6f0</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0127063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0127063%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DD.%2BC.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DKovalenko%26aufirst%3DM.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DMikels-Vigdal%26aufirst%3DA.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DSelective%2520allosteric%2520inhibition%2520of%2520MMP9%2520is%2520efficacious%2520in%2520preclinical%2520models%2520of%2520ulcerative%2520colitis%2520and%2520colorectal%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0127063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starodub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vosganian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltzman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span> <span> </span><span class="NLM_article-title">Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a Phase I study</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3829</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F1078-0432.CCR-17-2469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=29691300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVahtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3829&author=M.+A.+Shahauthor=A.+Starodubauthor=S.+Sharmaauthor=J.+Berlinauthor=M.+Patelauthor=Z.+A.+Wainbergauthor=J.+Chavesauthor=M.+Gordonauthor=K.+Windsorauthor=C.+B.+Brachmannauthor=X.+Huangauthor=G.+Vosganianauthor=J.+D.+Maltzmanauthor=V.+Smithauthor=J.+A.+Silvermanauthor=H.-J.+Lenzauthor=J.+C.+Bendell&title=Andecaliximab%2FGS-5745+alone+and+combined+with+mFOLFOX6+in+advanced+gastric+and+gastroesophageal+junction+adenocarcinoma%3A+results+from+a+Phase+I+study&doi=10.1158%2F1078-0432.CCR-17-2469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study</span></div><div class="casAuthors">Shah, Manish A.; Starodub, Alexander; Sharma, Sunil; Berlin, Jordan; Patel, Manish; Wainberg, Zev A.; Chaves, Jorge; Gordon, Michael; Windsor, Kevin; Brachmann, Carrie Baker; Huang, Xi; Vosganian, Greg; Maltzman, Julia D.; Smith, Victoria; Silverman, Jeffrey A.; Lenz, Heinz-Josef; Bendell, Johanna C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3829-3837</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes.  Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6.  Three dosages of andecaliximab monotherapy [200, 600, and 1800 mg i.v. every 2 wk (q2w)] were investigated in patients with advanced solid tumors (n = 13 in a 3 + 3 design).  After detg. a recommended dose, patients with advanced HER2-neg. gastric/gastroesophageal junction (GEJ) adenocarcinoma (n = 40) received 800 mg andecaliximab + mFOLFOX6 q2w.  Pharmacokinetics, pharmacodynamics, safety, and efficacy were assessed.  Andecaliximab monotherapy demonstrated no dose-limiting toxicity (DLT) in any cohort, displaying target-mediated drug disposition at the lowest dose (200 mg) and linear pharmacokinetics at higher doses.  Based on target engagement, recommended doses for further study are 800 mg q2w or 1,200 mg q3w.  Maximal andecaliximab target binding, defined as undetectable andecaliximab-free MMP9 in plasma, was obsd. in the gastric/GEJ adenocarcinoma cohort.  We obsd. no unusual toxicity, although there were four deaths on study not attributed to andecaliximab treatment.  In first-line patients (n = 36), median progression-free survival (PFS) was 9.9 mo [95% confidence interval (CI), 5-13.9 mo], and the overall response rate (ORR) was 50%.  Among all patients (n = 40), median PFS was 7.8 (90% CI, 5.5-13.9) months, and ORR was 48%, with a median duration of response of 8.4 mo.  Andecaliximab monotherapy achieved target engagement without DLT.  Andecaliximab + mFOLFOX6 showed encouraging clin. activity without addnl. toxicity in patients with HER2-neg. gastric/GEJ adenocarcinoma.  A phase III study evaluating mFOLFOX6 ± andecaliximab in this setting is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri7aLCDnoeDbVg90H21EOLACvtfcHk0ljJ5WzgURUFIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVahtrw%253D&md5=0f5d4809a3924fa1973eed981191ad74</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2469%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DM.%2BA.%26aulast%3DStarodub%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DWindsor%26aufirst%3DK.%26aulast%3DBrachmann%26aufirst%3DC.%2BB.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DVosganian%26aufirst%3DG.%26aulast%3DMaltzman%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DSilverman%26aufirst%3DJ.%2BA.%26aulast%3DLenz%26aufirst%3DH.-J.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26atitle%3DAndecaliximab%252FGS-5745%2520alone%2520and%2520combined%2520with%2520mFOLFOX6%2520in%2520advanced%2520gastric%2520and%2520gastroesophageal%2520junction%2520adenocarcinoma%253A%2520results%2520from%2520a%2520Phase%2520I%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3829%26doi%3D10.1158%2F1078-0432.CCR-17-2469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantelmo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camodeca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossello, A.</span></span> <span> </span><span class="NLM_article-title">N-O-Isopropyl sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors: hit selection and in vivo antiangiogenic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7224</span>– <span class="NLM_lpage">7240</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00367</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00367" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSmtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7224-7240&author=E.+Nutiauthor=A.+Cantelmoauthor=C.+Galloauthor=A.+Brunoauthor=B.+Bassaniauthor=C.+Camodecaauthor=T.+Tuccinardiauthor=L.+Veraauthor=E.+Orlandiniauthor=S.+Nencettiauthor=E.+Sturaauthor=A.+Martinelliauthor=V.+Diveauthor=A.+Albiniauthor=A.+Rossello&title=N-O-Isopropyl+sulfonamido-based+hydroxamates+as+matrix+metalloproteinase+inhibitors%3A+hit+selection+and+in+vivo+antiangiogenic+activity&doi=10.1021%2Facs.jmedchem.5b00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity</span></div><div class="casAuthors">Nuti, Elisa; Cantelmo, Anna Rita; Gallo, Cristina; Bruno, Antonino; Bassani, Barbara; Camodeca, Caterina; Tuccinardi, Tiziano; Vera, Laura; Orlandini, Elisabetta; Nencetti, Susanna; Stura, Enrico A.; Martinelli, Adriano; Dive, Vincent; Albini, Adriana; Rossello, Armando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7224-7240</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs) have been shown to be involved in tumor-induced angiogenesis.  In particular, MMP-2, MMP-9, and MMP-14 have been reported to be crucial for tumor angiogenesis and the formation of metastasis, thus becoming attractive targets in cancer therapy.  Here, the authors report the optimization effort to identify novel N-isopropoxy-arylsulfonamide hydroxamates with improved inhibitory activity toward MMP-2, MMP-9, and MMP-14 with respect to the previously discovered lead compd.  A new series of hydroxamates was designed, synthesized, and tested for their antiangiogenic activity using in vitro assays with human umbilical vein endothelial cells.  A nanomolar MMP-2, MMP-9, and MMP-14 inhibitor was identified, compd. I, able to potently inhibit angiogenesis in vitro and also in vivo in the matrigel sponge assay in mice.  Finally, x-ray crystallog. and docking studies were conducted for compd. I in order to investigate its binding mode to MMP-9 and MMP-14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkwrvJ2LNbVbVg90H21EOLACvtfcHk0ljJ5WzgURUFIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSmtb3L&md5=e64e1150f5f2fe056185c2a0c2cf6881</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00367%26sid%3Dliteratum%253Aachs%26aulast%3DNuti%26aufirst%3DE.%26aulast%3DCantelmo%26aufirst%3DA.%26aulast%3DGallo%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DBassani%26aufirst%3DB.%26aulast%3DCamodeca%26aufirst%3DC.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DVera%26aufirst%3DL.%26aulast%3DOrlandini%26aufirst%3DE.%26aulast%3DNencetti%26aufirst%3DS.%26aulast%3DStura%26aufirst%3DE.%26aulast%3DMartinelli%26aufirst%3DA.%26aulast%3DDive%26aufirst%3DV.%26aulast%3DAlbini%26aufirst%3DA.%26aulast%3DRossello%26aufirst%3DA.%26atitle%3DN-O-Isopropyl%2520sulfonamido-based%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%253A%2520hit%2520selection%2520and%2520in%2520vivo%2520antiangiogenic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7224%26epage%3D7240%26doi%3D10.1021%2Facs.jmedchem.5b00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhogal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keily, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manallack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, R.</span></span> <span> </span><span class="NLM_article-title">Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1468</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00259-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0960-894X%2801%2900259-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11378378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVagtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1465-1468&author=A.+Baxterauthor=R.+Bhogalauthor=J.+Birdauthor=J.+Keilyauthor=D.+Manallackauthor=J.+Montanaauthor=D.+Owenauthor=W.+Pittauthor=R.+Watsonauthor=R.+Wills&title=Arylsulphonyl+hydroxamic+acids%3A+potent+and+selective+matrix+metalloproteinase+inhibitors&doi=10.1016%2FS0960-894X%2801%2900259-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors</span></div><div class="casAuthors">Baxter, A. D.; Bhogal, R.; Bird, J.; Keily, J. F.; Manallack, D. T.; Montana, J. G.; Owen, D. A.; Pitt, W. R.; Watson, R. J.; Wills, R. E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1465-1468</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkrTFiyeumrVg90H21EOLACvtfcHk0ljJ5WzgURUFIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVagtrc%253D&md5=d013561f2a4d3eb4bb7898e837aec8f1</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900259-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900259-1%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DA.%26aulast%3DBhogal%26aufirst%3DR.%26aulast%3DBird%26aufirst%3DJ.%26aulast%3DKeily%26aufirst%3DJ.%26aulast%3DManallack%26aufirst%3DD.%26aulast%3DMontana%26aufirst%3DJ.%26aulast%3DOwen%26aufirst%3DD.%26aulast%3DPitt%26aufirst%3DW.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWills%26aufirst%3DR.%26atitle%3DArylsulphonyl%2520hydroxamic%2520acids%253A%2520potent%2520and%2520selective%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1465%26epage%3D1468%26doi%3D10.1016%2FS0960-894X%2801%2900259-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yodo, M.</span></span> <span> </span><span class="NLM_article-title">Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1738</span>, <span class="refDoi"> DOI: 10.1021/jm980514x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980514x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXisFGntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1723-1738&author=R.+Kiyamaauthor=Y.+Tamuraauthor=F.+Watanabeauthor=H.+Tsuzukiauthor=M.+Ohtaniauthor=M.+Yodo&title=Homology+modeling+of+gelatinase+catalytic+domains+and+docking+simulations+of+novel+sulfonamide+inhibitors&doi=10.1021%2Fjm980514x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Homology Modeling of Gelatinase Catalytic Domains and Docking Simulations of Novel Sulfonamide Inhibitors</span></div><div class="casAuthors">Kiyama, Ryuichi; Tamura, Yoshinori; Watanabe, Fumihiko; Tsuzuki, Hiroshige; Ohtani, Mitsuaki; Yodo, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1723-1738</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three-dimensional models for the catalytic domain of gelatinases (MMP-9 and -2) have been constructed based on the X-ray crystal structure of MMP-3.  Conformations of the loop segment which forms the bottom half of the S1' subsite but shows conformational diversity among the crystal structures of other MMPs have been explored by simulated annealing of each gelatinase model complexed with two highly potent "probe" inhibitors.  Representative catalytic domain models have been selected for each gelatinase from the set of generated conformations based on shape complementarity of the loop to the probe inhibitors.  The single model selected for MMP-9 was utilized to explain the structure-activity relationship of our novel sulfonamide inhibitors.  Mol. dynamics (MD) simulations of the complex models revealed important features of the binding mechanism of our inhibitors: (i) the ligand carboxylate group coordinating to the catalytic zinc ion and hydrogen bonding to the Glu219 side chain, (ii) one of the sulfonyl oxygens forming hydrogen bonds with the main chain NHs (Leu181 and Ala182), (iii) the sulfonyl substituent making extensive hydrophobic contact with the S1' subsite.  The gauche conformation exclusively adopted by the sulfonamide C-N-S-C torsion plays an important role in achieving the third binding feature by properly directing the substituent into the S1' subsite.  Improvement of the inhibitory activity according to straight elongation of the sulfonyl substituent was attributed to an increase of the hydrophobic contact between the substituent and the S1' subsite.  Structural modifications which alter the straight shape of the substituent lead to deterioration of the activity.  On the other hand, the two candidate models selected for MMP-2 differ in the bottom shape of the S1' subsite: one with a channel-like subsite and the other with a pocket-like subsite resembling that of the MMP-9 model.  The bottom shape was exptl. probed by chem. synthesis of inhibitors having elongated sulfonyl substituents whose terminal alkyl groups were shown by MD simulations to protrude from the S1' subsite bottom into the solvent.  Gelatinase assays of these inhibitors showed that elongation of the substituent significantly reduces activity against MMP-9 while retaining activity against MMP-2, consequently increasing the selectivity between MMP-2 and -9.  The results confirm that MMP-9 has a pocket-like S1' subsite with a floorboard and MMP-2 has a channel-like S1' subsite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMAdm5iXrSIbVg90H21EOLACvtfcHk0lgjtGmPMWbfQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXisFGntrg%253D&md5=7e7041cce336dd66880689fa43c55a0e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Fjm980514x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980514x%26sid%3Dliteratum%253Aachs%26aulast%3DKiyama%26aufirst%3DR.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DF.%26aulast%3DTsuzuki%26aufirst%3DH.%26aulast%3DOhtani%26aufirst%3DM.%26aulast%3DYodo%26aufirst%3DM.%26atitle%3DHomology%2520modeling%2520of%2520gelatinase%2520catalytic%2520domains%2520and%2520docking%2520simulations%2520of%2520novel%2520sulfonamide%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1723%26epage%3D1738%26doi%3D10.1021%2Fjm980514x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, R.</span></span> <span> </span><span class="NLM_article-title">Antimetastatic activity of a novel mechanism-based gelatinase inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">3523</span>– <span class="NLM_lpage">3526</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-3570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-04-3570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=15867341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3523-3526&author=A.+Kr%C3%BCgerauthor=M.+J.+Arltauthor=M.+Gergauthor=C.+Kopitzauthor=M.+M.+Bernardoauthor=M.+Changauthor=S.+Mobasheryauthor=R.+Fridman&title=Antimetastatic+activity+of+a+novel+mechanism-based+gelatinase+inhibitor&doi=10.1158%2F0008-5472.CAN-04-3570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Antimetastatic activity of a novel mechanism-based gelatinase inhibitor</span></div><div class="casAuthors">Krueger, Achim; Arlt, Matthias J. E.; Gerg, Michael; Kopitz, Charlotte; Bernardo, M. Margarida; Chang, Mayland; Mobashery, Shahriar; Fridman, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3523-3526</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Matrix metalloproteinases (MMPs), and in particular gelatinases (MMP-2 and MMP-9), play a key role in cancer progression.  However, clin. trials in which MMP inhibitors were tested in cancer patients have been disappointing.  Whereas many reasons have been postulated to explain the failure of the clin. trials, lack of inhibitor selectivity was a major limitation.  Thus, despite the consensus opinion that MMP-mediated proteolysis is essential for cancer progression and that certain MMPs represent important targets for intervention, effective and selective inhibition of those MMPs remains a major challenge in drug development.  We previously reported the first mechanism-based MMP inhibitor, designated SB-3CT, which is a selective gelatinase inhibitor.  Here we report that SB-3CT (5-50 mg/kg/d) is a potent inhibitor of liver metastasis and increases survival in an aggressive mouse model of T-cell lymphoma.  This study shows that mechanism-based inhibition of gelatinases represents a novel approach to inhibitor design that promises to be a successful anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSJYWfMfofLVg90H21EOLACvtfcHk0lgjtGmPMWbfQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGltb0%253D&md5=fe2a0c8c8cc6acd37123df24693bb179</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3570%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25BCger%26aufirst%3DA.%26aulast%3DArlt%26aufirst%3DM.%2BJ.%26aulast%3DGerg%26aufirst%3DM.%26aulast%3DKopitz%26aufirst%3DC.%26aulast%3DBernardo%26aufirst%3DM.%2BM.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DMobashery%26aufirst%3DS.%26aulast%3DFridman%26aufirst%3DR.%26atitle%3DAntimetastatic%2520activity%2520of%2520a%2520novel%2520mechanism-based%2520gelatinase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3523%26epage%3D3526%26doi%3D10.1158%2F0008-5472.CAN-04-3570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breyholz, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabeneck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levkau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schober, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">3400</span>– <span class="NLM_lpage">3409</span>, <span class="refDoi"> DOI: 10.1021/jm049145x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049145x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFSjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=3400-3409&author=H.+J.+Breyholzauthor=M.+Schafersauthor=S.+Wagnerauthor=C.+Holtkeauthor=A.+Faustauthor=H.+Rabeneckauthor=B.+Levkauauthor=O.+Schoberauthor=K.+Kopka&title=C-5-disubstituted+barbiturates+as+potential+molecular+probes+for+noninvasive+matrix+metalloproteinase+imaging&doi=10.1021%2Fjm049145x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">C-5-Disubstituted Barbiturates as Potential Molecular Probes for Noninvasive Matrix Metalloproteinase Imaging</span></div><div class="casAuthors">Breyholz, Hans-Joerg; Schaefers, Michael; Wagner, Stefan; Hoeltke, Carsten; Faust, Andreas; Rabeneck, Helmut; Levkau, Bodo; Schober, Otmar; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3400-3409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Studies have demonstrated a pos. correlation between inflammation, metastasis, or atherosclerosis and the unbalanced or culminated expression of matrix metalloproteinases (MMPs).  The mol. imaging of locally upregulated MMP activity in vivo is a clin. challenge.  Actually, radioligands based on nonpeptidyl MMP inhibitors (MMPIs) are currently in development as putative radiopharmaceutical agents for the noninvasive in vivo assessment of activated MMPs.  Nonpeptidyl MMPIs bind to the zinc active site of the activated enzyme via mono- (e.g. carboxylate) or bidentate (e.g. hydroxamate) complexation thereby exhibiting a broad-spectrum MMP binding potency.  Thus, these mentioned endopeptidase inhibitors should be useable lead compds. for the redevelopment as diagnostic MMPI radiotracers.  Recently, the non-hydroxamate C-5-disubstituted pyrimidine-2,4,6-triones were disclosed as subgroup-selective MMP inhibitors.  We here describe a set of fine-tuned barbiturates as a new class of MMPI radiotracers for the noninvasive in vivo visualization of activated MMPs using scintigraphic techniques such as SPECT or PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYS_fgRnKuirVg90H21EOLACvtfcHk0lgjtGmPMWbfQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFSjtbs%253D&md5=f574b4cffe59d35fdb6ec6ecbab9b000</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm049145x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049145x%26sid%3Dliteratum%253Aachs%26aulast%3DBreyholz%26aufirst%3DH.%2BJ.%26aulast%3DSchafers%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DHoltke%26aufirst%3DC.%26aulast%3DFaust%26aufirst%3DA.%26aulast%3DRabeneck%26aufirst%3DH.%26aulast%3DLevkau%26aufirst%3DB.%26aulast%3DSchober%26aufirst%3DO.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DC-5-disubstituted%2520barbiturates%2520as%2520potential%2520molecular%2520probes%2520for%2520noninvasive%2520matrix%2520metalloproteinase%2520imaging%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D3400%26epage%3D3409%26doi%3D10.1021%2Fjm049145x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Man, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, T.</span></span> <span> </span><span class="NLM_article-title">Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2504</span>– <span class="NLM_lpage">2505</span>, <span class="refDoi"> DOI: 10.1080/15548627.2016.1239679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1080%2F15548627.2016.1239679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27786577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKgsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=2504-2505&author=S.+Manauthor=T.+Kanneganti&title=Regulation+of+lysosomal+dynamics+and+autophagy+by+CTSB%2Fcathepsin+B&doi=10.1080%2F15548627.2016.1239679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B</span></div><div class="casAuthors">Man, Si Ming; Kanneganti, Thirumala-Devi</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2504-2505</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cysteine cathepsins are responsible for driving proteolytic degrdn. within the lysosome and in the extralysosomal milieu.  They also have an integral role in autophagy, antigen presentation, cellular stress signaling, metab. and lysosome-dependent cell death.  Here, we discuss our findings on the role of CTSB (cathepsin B), a member of the cysteine cathepsin family, in regulating the bioavailability of lysosomes and autophagosomes and consider how this regulatory response influences host susceptibility to infectious agents.  Our study demonstrates that under homeostatic conditions CTSB cleaves the calcium channel MCOLN1/TRPML1 in the lysosomes, maintaining suppression of the transcription factor TFEB and reducing expression of lysosomal and autophagy-related proteins.  This response controls the no. of lysosomes and autophagosomes in the cell.  However, the activity of CTSB is exploited by the cytosolic bacterium Francisella novicida, leading to enhanced survival of the pathogen and increased susceptibility of the host to infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqae_rpcL02mbVg90H21EOLACvtfcHk0ljXis42whC-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKgsb3M&md5=ae74257ee31d822ade3a026c033adf45</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1080%2F15548627.2016.1239679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2016.1239679%26sid%3Dliteratum%253Aachs%26aulast%3DMan%26aufirst%3DS.%26aulast%3DKanneganti%26aufirst%3DT.%26atitle%3DRegulation%2520of%2520lysosomal%2520dynamics%2520and%2520autophagy%2520by%2520CTSB%252Fcathepsin%2520B%26jtitle%3DAutophagy%26date%3D2016%26volume%3D12%26spage%3D2504%26epage%3D2505%26doi%3D10.1080%2F15548627.2016.1239679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitrović, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirković, B.</span></span> <span> </span><span class="NLM_article-title">The current stage of cathepsin B inhibitors as potential anticancer agents</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.4155%2Ffmc.14.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=25163003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVeisbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1355-1371&author=J.+Kosauthor=A.+Mitrovi%C4%87author=B.+Mirkovi%C4%87&title=The+current+stage+of+cathepsin+B+inhibitors+as+potential+anticancer+agents&doi=10.4155%2Ffmc.14.73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The current stage of cathepsin B inhibitors as potential anticancer agents</span></div><div class="casAuthors">Kos, Janko; Mitrovic, Ana; Mirkovic, Bojana</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1355-1371</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Cathepsin B is a lysosomal cysteine peptidase, with an important role in the development and progression of cancer.  It is involved in the degrdn. of extracellular matrix proteins, a process promoting invasion and metastasis of tumor cells and tumor angiogenesis.  Cathepsin B is unique among cathepsins in possessing both carboxypeptidase and endopeptidase activities.  While the former is assocd. with its physiol. role, the latter is involved in pathol. degrdn. of the extracellular matrix.  Its activities are regulated by different means, the most important being its endogenous inhibitors, the cystatins.  In cancer this peptidase/inhibitor balance is altered, leading to harmful cathepsin B activity.  The latter can be prevented by exogenous inhibitors.  They differ in modes of inhibition, size, structure, binding affinity, selectivity, toxicity and bioavailability.  In this article, we review the properties and function of endogenous and exogenous cathepsin B inhibitors and indicate their application as possible anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfpmptuVGlabVg90H21EOLACvtfcHk0ljXis42whC-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVeisbjP&md5=98a16a3ebad41a8ca00d9fa5705bd10d</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.73%26sid%3Dliteratum%253Aachs%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DMitrovi%25C4%2587%26aufirst%3DA.%26aulast%3DMirkovi%25C4%2587%26aufirst%3DB.%26atitle%3DThe%2520current%2520stage%2520of%2520cathepsin%2520B%2520inhibitors%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1355%26epage%3D1371%26doi%3D10.4155%2Ffmc.14.73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span> <span> </span><span class="NLM_article-title">Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.3892/ol.2011.302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3892%2Fol.2011.302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22848251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslOiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=693-699&author=Q.+Chenauthor=J.+Feiauthor=L.+Wuauthor=Z.+Jiangauthor=Y.+Wuauthor=Y.+Zhengauthor=G.+Lu&title=Detection+of+cathepsin+B%2C+cathepsin+L%2C+cystatin+C%2C+urokinase+plasminogen+activator+and+urokinase+plasminogen+activator+receptor+in+the+sera+of+lung+cancer+patients&doi=10.3892%2Fol.2011.302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients</span></div><div class="casAuthors">Chen, Qingyong; Fei, Jun; Wu, Lijun; Jiang, Zhongyong; Wu, Yuquan; Zheng, Yun; Lu, Guohua</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">693-699</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The present study aimed to det. the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA.  Concomitantly, the relationship between the components and clinicopathol. prognosis was analyzed.  The study included 30 healthy volunteers and 105 lung cancer patients.  Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA.  Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls.  The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis.  There was no significance for other parameters.  Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C+/cath B- or with cystatin C+/cath B-.  Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival.  Furthermore, the univariate anal. revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival.  However, findings of the multivariate Cox anal. indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8uObw01MZrVg90H21EOLACvtfcHk0ljXis42whC-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslOiurc%253D&md5=f2170f4806e216b773b1d058534a95fd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.3892%2Fol.2011.302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2011.302%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DFei%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DG.%26atitle%3DDetection%2520of%2520cathepsin%2520B%252C%2520cathepsin%2520L%252C%2520cystatin%2520C%252C%2520urokinase%2520plasminogen%2520activator%2520and%2520urokinase%2520plasminogen%2520activator%2520receptor%2520in%2520the%2520sera%2520of%2520lung%2520cancer%2520patients%26jtitle%3DOncol.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D693%26epage%3D699%26doi%3D10.3892%2Fol.2011.302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armeson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2034</span>– <span class="NLM_lpage">2043</span>, <span class="refDoi"> DOI: 10.1002/ijc.27480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fijc.27480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22322590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38XksV2itbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=2034-2043&author=T.+H.+Beckhamauthor=P.+Luauthor=J.+C.+Chengauthor=D.+Zhaoauthor=L.+S.+Turnerauthor=X.+Zhangauthor=S.+Hoffmanauthor=K.+E.+Armesonauthor=A.+Liuauthor=T.+Marrisonauthor=Y.+A.+Hannunauthor=X.+Liu&title=Acid+ceramidase-mediated+production+of+sphingosine+1-phosphate+promotes+prostate+cancer+invasion+through+upregulation+of+cathepsin+B&doi=10.1002%2Fijc.27480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B</span></div><div class="casAuthors">Beckham, Thomas H.; Lu, Ping; Cheng, Joseph C.; Zhao, Dan; Turner, Lorianne S.; Zhang, Xiaoyi; Hoffman, Stanley; Armeson, Kent E.; Liu, Angen; Marrison, Tucker; Hannun, Yusuf A.; Liu, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2034-2043</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Invasiveness is one of the key features of aggressive prostate cancer; however, our understanding of the precise mechanisms effecting invasion remains limited.  The ceramide hydrolyzing enzyme acid ceramidase (AC), overexpressed in most prostate tumors, causes an aggressive and invasive phenotype through downstream effectors that have not yet been well characterized.  Here, we demonstrate that AC, through generation of sphingosine-1-phosphate (S1P), promotes Ets1 nuclear expression and binding to the promoter region of matrix-degrading protease cathepsin B.  Through confocal microscopy and flow cytometry, we found that AC overexpression promotes pericellular localization of cathepsin B and its translocation to the outer leaflet of the cell membrane.  AC overexpressing cells have an increased abundance of cathepsin B-enriched invasive structures and enhanced ability to invade through a collagen matrix, but not in the presence of an inhibitor of cathepsin B.  In human prostate tissues, AC and cathepsin B overexpression were strongly assocd. and may relate to poor outcome.  These results demonstrate a novel pathway by which AC, through S1P, promotes an invasive phenotype in prostate cancer by causing overexpression and secretion of cathepsin B through activation and nuclear expression of Ets1.  As prostate cancer prognosis is dramatically worse when invasion has occurred, this study provides crit. insight into the progression toward lethal prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_675HsVz6bVg90H21EOLACvtfcHk0lgcqDa8m03rUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksV2itbs%253D&md5=2fce1a32e7e403e5e9032adb0c85550a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Fijc.27480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27480%26sid%3Dliteratum%253Aachs%26aulast%3DBeckham%26aufirst%3DT.%2BH.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DTurner%26aufirst%3DL.%2BS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DS.%26aulast%3DArmeson%26aufirst%3DK.%2BE.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DMarrison%26aufirst%3DT.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAcid%2520ceramidase-mediated%2520production%2520of%2520sphingosine%25201-phosphate%2520promotes%2520prostate%2520cancer%2520invasion%2520through%2520upregulation%2520of%2520cathepsin%2520B%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D131%26spage%3D2034%26epage%3D2043%26doi%3D10.1002%2Fijc.27480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mijanović, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branković, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panin, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timashev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulasov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesniak, M. S.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B: a sellsword of cancer progression</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>449</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.canlet.2019.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=30796968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslOrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2019&pages=207-214&author=O.+Mijanovi%C4%87author=A.+Brankovi%C4%87author=A.+N.+Paninauthor=S.+Savchukauthor=P.+Timashevauthor=I.+Ulasovauthor=M.+S.+Lesniak&title=Cathepsin+B%3A+a+sellsword+of+cancer+progression&doi=10.1016%2Fj.canlet.2019.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B: A sellsword of cancer progression</span></div><div class="casAuthors">Mijanovic, Olja; Brankovic, Ana; Panin, Alexander N.; Savchuk, Solomiia; Timashev, Peter; Ulasov, Ilya; Lesniak, Maciej S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">449</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-214</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Clin., biochem. and mol. biol. studies have identified lysosome-encapsulated cellular proteases as crit. risk factors for cancer progression.  Cathepsins represent a group of such proteases aimed at maintenance of cellular homeostasis.  Nevertheless, recent reports suggest that Cathepsin B executes other cellular programs such as controlling tumor growth, migration, invasion, angiogenesis, and metastases development.  In fact, elevated levels of Cathepsins are found under different pathol. conditions including inflammation, infection, neurodegenerative disease, and cancer.  Furthermore, the discovery of Cathepsin B secretion and function as an extracellular matrix protein has broadened our appreciation for the impact of Cathepsin B on cancer progression.  Underneath a fac[n.807]ade of an intracellular protease with limited therapeutic potential hides a central role of cathepsins in extracellular functions.  Moreover, this role is incredibly diverse from one condition to the next from driving caspase-dependent apoptosis to facilitating tumor neovascularization and metastasis.  Here we discuss the role of Cathepsin B in the oncogenic process and perspective the use of Cathepsin B for diagnostic and therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPYxjkNaUuybVg90H21EOLACvtfcHk0lgcqDa8m03rUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslOrsLk%253D&md5=6a85229e9df2c2e4009773480ba575e6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DMijanovi%25C4%2587%26aufirst%3DO.%26aulast%3DBrankovi%25C4%2587%26aufirst%3DA.%26aulast%3DPanin%26aufirst%3DA.%2BN.%26aulast%3DSavchuk%26aufirst%3DS.%26aulast%3DTimashev%26aufirst%3DP.%26aulast%3DUlasov%26aufirst%3DI.%26aulast%3DLesniak%26aufirst%3DM.%2BS.%26atitle%3DCathepsin%2520B%253A%2520a%2520sellsword%2520of%2520cancer%2520progression%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D449%26spage%3D207%26epage%3D214%26doi%3D10.1016%2Fj.canlet.2019.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal cysteine proteases: more than scavengers</span>. <i>Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1477</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/S0167-4838(99)00263-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0167-4838%2899%2900263-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10708852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsFGktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1477&publication_year=2000&pages=98-111&author=B.+Turkauthor=D.+Turkauthor=V.+Turk&title=Lysosomal+cysteine+proteases%3A+more+than+scavengers&doi=10.1016%2FS0167-4838%2899%2900263-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal cysteine proteases: more than scavengers</span></div><div class="casAuthors">Turk, B.; Turk, D.; Turk, V.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Protein Structure and Molecular Enzymology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1477</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">98-111</span>CODEN:
                <span class="NLM_cas:coden">BBAEDZ</span>;
        ISSN:<span class="NLM_cas:issn">0167-4838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 157 refs.  Lysosomal cysteine proteases were believed to be mainly involved in intracellular protein degrdn.  Under special conditions they have been found outside lysosomes resulting in pathol. conditions.  With the discovery of a series of new cathepsins with restricted tissue distributions, it has become evident that these enzymes must be involved in a range of specific cellular tasks much broader than as simple housekeeping enzymes.  It is therefore timely to review and discuss the various physiol. roles of mammalian lysosomal papain-like cysteine proteases as well as their mechanisms of action and the regulation of their activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKn0oFhrAq2LVg90H21EOLACvtfcHk0ljdeop65KWcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsFGktLo%253D&md5=4a477858e63d2373f3bd6359156eb2ba</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2FS0167-4838%2899%2900263-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-4838%252899%252900263-0%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26aulast%3DTurk%26aufirst%3DV.%26atitle%3DLysosomal%2520cysteine%2520proteases%253A%2520more%2520than%2520scavengers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Protein%2520Struct.%2520Mol.%2520Enzymol.%26date%3D2000%26volume%3D1477%26spage%3D98%26epage%3D111%26doi%3D10.1016%2FS0167-4838%2899%2900263-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducret, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Percival, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, J. A.</span></span> <span> </span><span class="NLM_article-title">Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">6311</span>– <span class="NLM_lpage">6318</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2000.01730.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1046%2Fj.1432-1327.2000.01730.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11012686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnsVygtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2000&pages=6311-6318&author=J.+Guayauthor=J.+P.+Falgueyretauthor=A.+Ducretauthor=M.+D.+Percivalauthor=J.+A.+Mancini&title=Potency+and+selectivity+of+inhibition+of+cathepsin+K%2C+L+and+S+by+their+respective+propeptides&doi=10.1046%2Fj.1432-1327.2000.01730.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides</span></div><div class="casAuthors">Guay, Jocelyne; Falgueyret, Jean-Pierre; Ducret, Axel; Percival, M. David; Mancini, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6311-6318</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The prodomains of several cysteine proteases of the papain family have been shown to be potent inhibitors of their parent enzymes.  An increased interest in cysteine proteases inhibitors has been generated with potential therapeutic targets such as cathepsin K for osteoporosis and cathepsin S for immune modulation.  The propeptides of cathepsin S, L and K were expressed as glutathione S-transferase-fusion proteins in Escherichia coli.  The proteins were purified on glutathione affinity columns and the glutathione S-transferase was removed by thrombin cleavage.  All three propeptides were tested for inhibitor potency and found to be selective within the cathepsin L subfamily (cathepsins K, L and S) compared with cathepsin B or papain.  Inhibition of cathepsin K by either procathepsin K, L or S was time-dependent and occurred by an apparent one-step mechanism.  The cathepsin K propeptide had a Ki of 3.6-6.3 nM for each of the three cathepsins K, L and S.  The cathepsin L propeptide was at least a 240-fold selective inhibitor of cathepsin K (Ki = 0.27 nM) and cathepsin L (Ki = 0.12 nM) compared with cathepsin S (Ki = 65 nM).  Interestingly, the cathepsin S propeptide was more selective for inhibition of cathepsin L (Ki = 0.46 nM) than cathepsin S (Ki = 7.6 nM) itself or cathepsin K (Ki = 7.0 nM).  This is in sharp contrast to previously published data demonstrating that the cathepsin S propeptide is equipotent for inhibition of human cathepsin S and rat and paramecium cathepsin L.  These results demonstrate that limited selectivity of inhibition can be measured for the procathepsins K, L and S vs. the parent enzymes, but selective inhibition vs. cathepsin B and papain was obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMcJhFn9vMorVg90H21EOLACvtfcHk0ljdeop65KWcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnsVygtrk%253D&md5=17682fb392a0aa84e63d5216cd0c601e</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2000.01730.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2000.01730.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuay%26aufirst%3DJ.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DDucret%26aufirst%3DA.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DMancini%26aufirst%3DJ.%2BA.%26atitle%3DPotency%2520and%2520selectivity%2520of%2520inhibition%2520of%2520cathepsin%2520K%252C%2520L%2520and%2520S%2520by%2520their%2520respective%2520propeptides%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2000%26volume%3D267%26spage%3D6311%26epage%3D6318%26doi%3D10.1046%2Fj.1432-1327.2000.01730.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantes, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chagas, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faljoni-Alario, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersariol, I. L.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">944</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1074/jbc.M003820200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1074%2Fjbc.M003820200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=11016923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtVymsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=944-951&author=P.+C.+Almeidaauthor=I.+L.+Nantesauthor=J.+R.+Chagasauthor=C.+C.+Rizziauthor=A.+Faljoni-Alarioauthor=E.+Carmonaauthor=L.+Julianoauthor=H.+B.+Naderauthor=I.+L.+Tersariol&title=Cathepsin+B+activity+regulation.+Heparin-like+glycosaminogylcans+protect+human+cathepsin+B+from+alkaline+pH-induced+inactivation&doi=10.1074%2Fjbc.M003820200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B activity regulation: heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation</span></div><div class="casAuthors">Almeida, Paulo C.; Nantes, Iseli L.; Chagas, Jair R.; Rizzi, Claudia C. A.; Faljoni-Alario, Adelaide; Carmona, Euridice; Juliano, Luiz; Nader, Helena B.; Tersariol, Ivarne L. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">944-951</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">It has been shown that lysosomal cysteine proteinases, specially cathepsin B, has been implicated in a variety of diseases involving tissue remodeling states, such as inflammation, parasite infection, and tumor metastasis, by degrdn. of extracellular matrix components.  Recently, we have shown that heparin and heparan sulfate bind to papain specifically; this interaction induces an increase of its α-helix content and stabilizes the enzyme structure even at alk. pH.  In the present work, a combination of CD anal., affinity chromatog., cathepsin B mutants, and fluorogenic substrate assays were used to characterize the interaction of human cathepsin B with glycosaminoglycans.  The nature of the cathepsin B-glycosaminoglycans interaction was sensitive to the charge and type of polysaccharide.  Like papain, heparin and heparan sulfate bind cathepsin B specifically, and this interaction reduces the loss of cathepsin B α-helix content at alk. pH.  Our data show that the coupling of cathepsin B with heparin or heparan sulfate can potentiate the endopeptidase activity of the cathepsin B, increasing 5-fold the half-life (t1/2) of the enzyme at alk. pH.  Most of these effects are related to the interaction of heparin and heparan sulfate with His111 residue of the cathepsin B occluding loop.  These results strongly suggest that heparan sulfate may be an important binding site for cathepsin B at cell surface, reporting a novel physiol. role for heparan sulfate proteoglycans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdhdcVd5khobVg90H21EOLACvtfcHk0ljdeop65KWcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtVymsA%253D%253D&md5=a3cb3f77fba2d8fc8033fc1f0b48bb2e</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M003820200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M003820200%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%26aufirst%3DP.%2BC.%26aulast%3DNantes%26aufirst%3DI.%2BL.%26aulast%3DChagas%26aufirst%3DJ.%2BR.%26aulast%3DRizzi%26aufirst%3DC.%2BC.%26aulast%3DFaljoni-Alario%26aufirst%3DA.%26aulast%3DCarmona%26aufirst%3DE.%26aulast%3DJuliano%26aufirst%3DL.%26aulast%3DNader%26aufirst%3DH.%2BB.%26aulast%3DTersariol%26aufirst%3DI.%2BL.%26atitle%3DCathepsin%2520B%2520activity%2520regulation.%2520Heparin-like%2520glycosaminogylcans%2520protect%2520human%2520cathepsin%2520B%2520from%2520alkaline%2520pH-induced%2520inactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D944%26epage%3D951%26doi%3D10.1074%2Fjbc.M003820200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. K.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B expression and the correlation with clinical aspects of oral squamous cell carcinoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0152165</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0152165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1371%2Fjournal.pone.0152165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=27031837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWms7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&author=W.+E.+Yangauthor=C.+C.+Hoauthor=S.+F.+Yangauthor=S.+H.+Linauthor=K.+T.+Yehauthor=C.+W.+Linauthor=M.+K.+Chen&title=Cathepsin+B+expression+and+the+correlation+with+clinical+aspects+of+oral+squamous+cell+carcinoma&doi=10.1371%2Fjournal.pone.0152165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B expression and the correlation with clinical aspects of oral squamous cell carcinoma</span></div><div class="casAuthors">Yang, Wei-En; Ho, Chuan-Chen; Yang, Shun-Fa; Lin, Shu-Hui; Yeh, Kun-Tu; Lin, Chiao-Wen; Chen, Mu-Kuan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0152165/1-e0152165/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Cathepsin B (CTSB), a member of the cathepsin family, is a cysteine protease that is widely distributed in the lysosomes of cells in various tissues.  It is overexpressed in several human cancers and may be related to tumorigenesis.  The main purpose of this study was to analyze CTSB expression in oral squamous cell carcinoma (OSCC) and its correlation with patient prognosis.  Methodol./Principal Findings Tissue microarrays were used to detect CTSB expression in 280 patients and to examine the assocn. between CTSB expression and clinicopathol. parameters.  In addn., the metastatic effects of the CTSB knockdown on two oral cancer cell lines were investigated by transwell migration assay.  Cytoplasmic CTSB expression was detected in 34.6% (97/280) of patients.  CTSB expression was correlated with pos. lymph node metastasis (p = 0.007) and higher tumor grade (p = 0.008) but not with tumor size and distant metastasis.  In addn., multivariate anal. using a Cox proportional hazards model revealed a higher hazard ratio, demonstrating that CTSB expression was an independent unfavorable prognostic factor in buccal mucosa carcinoma patients.  Furthermore, the Kaplan-Meier curve revealed that buccal mucosa OSCC patients with pos. CTSB expression had significantly shorter overall survival.  Moreover, treatment with the CTSB siRNA exerted an inhibitory effect on migration in OC2 and CAL27 oral cancer cells.  Conclusions We conclude that CTSB expression may be useful for detg. OSCC prognosis, particularly for patients with lymph node metastasis, and may function as a biomarker of the survival of OSCC patients in Taiwan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_H50NkY7CqrVg90H21EOLACvtfcHk0ljM43HEOWw2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWms7nF&md5=27dfbbdd06699fd3a366b2ff755ce6b0</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0152165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0152165%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%2BE.%26aulast%3DHo%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DYeh%26aufirst%3DK.%2BT.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DM.%2BK.%26atitle%3DCathepsin%2520B%2520expression%2520and%2520the%2520correlation%2520with%2520clinical%2520aspects%2520of%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26doi%3D10.1371%2Fjournal.pone.0152165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lah, T. T.</span></span> <span> </span><span class="NLM_article-title">Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review)</span>. <i>Oncology reports</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1349</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.3892/or.5.6.1349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.3892%2For.5.6.1349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=9769367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1cXntFSrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1998&pages=1349-1361&author=J.+Kosauthor=T.+T.+Lah&title=Cysteine+proteinases+and+their+endogenous+inhibitors%3A+target+proteins+for+prognosis%2C+diagnosis+and+therapy+in+cancer+%28review%29&doi=10.3892%2For.5.6.1349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review)</span></div><div class="casAuthors">Kos, Janko; Lah, Tamara T.</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1349-1361</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review with 145 refs.  Lysosomal cysteine proteinases, the cathepsins (Cats) belong to the papain family of proteinases, sharing a similar protein structure and mechanism of action.  Subtle structural differences between these enzymes give rise to important variations in substrate specificity and specificity of inhibition by their endogenous inhibitors, the cystatins, stefins and kininogens under physiol. and pathol. conditions.  Alterations in their expression, processing and localization have been obsd. at various levels in malignant human tumor tissue compared to normal and benign tissue counterparts.  The authors have proposed that an imbalance between cathepsins and cystatins, assocd. with metastatic tumor cell phenotype, may facilitate tumor cell invasion and metastasis.  The results of clin. investigations on cysteine cathepsins and their endogenous inhibitors in human breast, lung, brain and head and neck tumors, as well as in body fluids of ovarian, uterine, melanoma and colorectal carcinoma bearing patients, have shown that these mols. are highly predictive for the length of survival and may be used for assessment of risk of relapse and death for cancer patients.  Their application for diagnosis, follow-up and the anticancer therapy has also been proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfm_eMOSgpRbVg90H21EOLACvtfcHk0ljM43HEOWw2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFSrtrY%253D&md5=2ad38ca3b4a9cfae7270017bd68dc131</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.3892%2For.5.6.1349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.5.6.1349%26sid%3Dliteratum%253Aachs%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DLah%26aufirst%3DT.%2BT.%26atitle%3DCysteine%2520proteinases%2520and%2520their%2520endogenous%2520inhibitors%253A%2520target%2520proteins%2520for%2520prognosis%252C%2520diagnosis%2520and%2520therapy%2520in%2520cancer%2520%2528review%2529%26jtitle%3DOncology%2520reports%26date%3D1998%26volume%3D5%26spage%3D1349%26epage%3D1361%26doi%3D10.3892%2For.5.6.1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloane, B. F.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B: Multiple roles in cancer</span>. <i>Proteomics: Clin. Appl.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1002/prca.201300105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2Fprca.201300105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=24677670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVGrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=427-437&author=N.+Aggarwalauthor=B.+F.+Sloane&title=Cathepsin+B%3A+Multiple+roles+in+cancer&doi=10.1002%2Fprca.201300105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B: Multiple roles in cancer</span></div><div class="casAuthors">Aggarwal, Neha; Sloane, Bonnie F.</div><div class="citationInfo"><span class="NLM_cas:title">Proteomics: Clinical Applications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">427-437</span>CODEN:
                <span class="NLM_cas:coden">PCARCU</span>;
        ISSN:<span class="NLM_cas:issn">1862-8346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Proteases, including intracellular proteases, play roles at many different stages of malignant progression.  Our focus here is cathepsin B, a lysosomal cysteine cathepsin.  High levels of cathepsin B are found in a wide variety of human cancers, levels that often induce secretion and assocn. of cathepsin B with the tumor cell membrane.  In exptl. models, such as transgenic models of murine pancreatic and mammary carcinomas, causal roles for cathepsin B have been demonstrated in initiation, growth/tumor cell proliferation, angiogenesis, invasion, and metastasis.  Tumor growth in transgenic models is promoted by cathepsin B in tumor-assocd. cells, for example, tumor-assocd. macrophages, as well as in tumor cells.  In transgenic models, the absence of cathepsin B has been assocd. with enhanced apoptosis, yet cathepsin B also has been shown to contribute to apoptosis.  Cathepsin B is part of a proteolytic pathway identified in xenograft models of human glioma; targeting only cathepsin B in these tumors is less effective than targeting cathepsin B in combination with other proteases or protease receptors.  Understanding the mechanisms responsible for increased expression of cathepsin B in tumors and assocn. of cathepsin B with tumor cell membranes is needed to det. whether targeting cathepsin B could be of therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvW2jNDWUThbVg90H21EOLACvtfcHk0ljM43HEOWw2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVGrtLc%253D&md5=a305bd67d038b4f097abb1a7fb0d0082</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fprca.201300105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprca.201300105%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DN.%26aulast%3DSloane%26aufirst%3DB.%2BF.%26atitle%3DCathepsin%2520B%253A%2520Multiple%2520roles%2520in%2520cancer%26jtitle%3DProteomics%253A%2520Clin.%2520Appl.%26date%3D2014%26volume%3D8%26spage%3D427%26epage%3D437%26doi%3D10.1002%2Fprca.201300105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostoulas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baici, A.</span></span> <span> </span><span class="NLM_article-title">Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(99)00897-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0014-5793%2899%2900897-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10437790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXks1Olsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=1999&pages=286-290&author=G.+Kostoulasauthor=A.+Langauthor=H.+Nagaseauthor=A.+Baici&title=Stimulation+of+angiogenesis+through+cathepsin+B+inactivation+of+the+tissue+inhibitors+of+matrix+metalloproteinases&doi=10.1016%2FS0014-5793%2899%2900897-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases</span></div><div class="casAuthors">Kostoulas, Georgios; Lang, Angela; Nagase, Hideaki; Baici, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-290</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The tissue inhibitors of matrix metalloproteinases (MMPs), TIMP-1 and TIMP-2, are also angiogenesis inhibitors.  Cathepsin B and MMPs are found at sites of neovascularization in pathologies such as cancer and osteoarthritis.  Treatment of TIMP-1, TIMP-2, and of a mixt. of both inhibitors from human articular chondrocytes with cathepsin B resulted in their fragmentation, whereby they lost their MMP-inhibitory and anti-angiogenic activities.  The authors' data suggest that, besides directly participating in tissue destruction, cathepsin B can be harmful for two further reasons: it raises the activity of the MMPs also in the absence of mechanisms up-regulating these enzymes, and it stimulates angiogenesis.  This is a prerequisite for blood vessel invasion in a variety of pathol. situations of which cancer and osteoarthritis are prominent examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu06Wx6AjXbrVg90H21EOLACvtfcHk0ljM43HEOWw2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXks1Olsbo%253D&md5=35e37ccb2c16fd0cb6024314269dc522</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2899%2900897-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252899%252900897-2%26sid%3Dliteratum%253Aachs%26aulast%3DKostoulas%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DBaici%26aufirst%3DA.%26atitle%3DStimulation%2520of%2520angiogenesis%2520through%2520cathepsin%2520B%2520inactivation%2520of%2520the%2520tissue%2520inhibitors%2520of%2520matrix%2520metalloproteinases%26jtitle%3DFEBS%2520Lett.%26date%3D1999%26volume%3D455%26spage%3D286%26epage%3D290%26doi%3D10.1016%2FS0014-5793%2899%2900897-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasiljeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span> <span> </span><span class="NLM_article-title">Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion</span>. <i>Biochimie</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/j.biochi.2007.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.biochi.2007.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=17991442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2008&pages=380-386&author=O.+Vasiljevaauthor=B.+Turk&title=Dual+contrasting+roles+of+cysteine+cathepsins+in+cancer+progression%3A+apoptosis+versus+tumour+invasion&doi=10.1016%2Fj.biochi.2007.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Dual contrasting roles of cysteine cathepsins in cancer progression: Apoptosis versus tumor invasion</span></div><div class="casAuthors">Vasiljeva, Olga; Turk, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Biochimie</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">380-386</span>CODEN:
                <span class="NLM_cas:coden">BICMBE</span>;
        ISSN:<span class="NLM_cas:issn">0300-9084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cysteine cathepsins have been known for a long time to play an important role in cancer progression and metastasis.  Several studies have proposed the concept of anti-cathepsin therapy in cancer treatment.  On the other hand, cysteine cathepsins have been recently found to play a role in tumor cell death through mediation of apoptosis.  The purpose of this mini-review is therefore to provide an insight into the mechanisms by which cysteine cathepsins modulate apoptosis and/or participate in tumor invasion, and to evaluate the impact of these enzymes on both tumor progression and development of potential strategies for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkGN4RG3lghrVg90H21EOLACvtfcHk0lgpU3EA-IFAtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGktbo%253D&md5=706bc27e09103d9c4384275b98232c49</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2007.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2007.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DVasiljeva%26aufirst%3DO.%26aulast%3DTurk%26aufirst%3DB.%26atitle%3DDual%2520contrasting%2520roles%2520of%2520cysteine%2520cathepsins%2520in%2520cancer%2520progression%253A%2520apoptosis%2520versus%2520tumour%2520invasion%26jtitle%3DBiochimie%26date%3D2008%26volume%3D90%26spage%3D380%26epage%3D386%26doi%3D10.1016%2Fj.biochi.2007.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katunuma, N.</span></span> <span> </span><span class="NLM_article-title">Structure-based development of specific inhibitors for individual cathepsins and their medical applications</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2183/pjab.87.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2183%2Fpjab.87.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2011&pages=29-39&author=N.+Katunuma&title=Structure-based+development+of+specific+inhibitors+for+individual+cathepsins+and+their+medical+applications&doi=10.2183%2Fpjab.87.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based development of specific inhibitors for individual cathepsins and their medical applications</span></div><div class="casAuthors">Katunuma, Nobuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  Specific inhibitors for individual cathepsins have been developed based on their tertiary structures of X-ray crystallog.  Cathepsin B-specific inhibitors, CA-074 and CA-030, and cathepsin L specific inhibitors, CLIK-148 and CLIK-195, were designed as the epoxysuccinate derivs.  Cathepsin S inhibitor, CLIK-060, and cathepsin K inhibitor, CLIK-166, were synthesized.  These inhibitors can use in vitro and also in vivo, and show no toxicity for exptl. animals by the amts. used as the cathepsin inhibitor.  Various cathepsins are used in the processing of antigenic proteins.  The CLIK-060 treatment to the autoimmune disease, Sjogren model mice, led to strongly suppress the expression of the pathol. symptoms.  Cathepsins L or K participates to the degrdn. of bone collagen.  The CLIK-148 protects osteoporosis in animals and also protects the bone metastasis of cancer cells.  Cathepsin L also enhances insulin-induced glucose uptake into 3T3-L1 adipocytes, suggesting cathepsin L plays the roles in adipogenesis and glucose tolerance in type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl9gYdvAtAJ7Vg90H21EOLACvtfcHk0lgpU3EA-IFAtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL8%253D&md5=75d9e6e6b75de8093775dd148b808d44</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.2183%2Fpjab.87.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.87.29%26sid%3Dliteratum%253Aachs%26aulast%3DKatunuma%26aufirst%3DN.%26atitle%3DStructure-based%2520development%2520of%2520specific%2520inhibitors%2520for%2520individual%2520cathepsins%2520and%2520their%2520medical%2520applications%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2011%26volume%3D87%26spage%3D29%26epage%3D39%26doi%3D10.2183%2Fpjab.87.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmeister, T.</span></span> <span> </span><span class="NLM_article-title">New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1021/jm981061z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm981061z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK1MXht1Kjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=560-572&author=T.+Schirmeister&title=New+peptidic+cysteine+protease+inhibitors+derived+from+the+electrophilic+alpha-amino+acid+aziridine-2%2C3-dicarboxylic+acid&doi=10.1021%2Fjm981061z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">New Peptidic Cysteine Protease Inhibitors Derived from the Electrophilic α-Amino Acid Aziridine-2,3-dicarboxylic Acid</span></div><div class="casAuthors">Schirmeister, Tanja</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">560-572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three different types of peptides contg. aziridine-2,3-dicarboxylic acid (Azi) as an electrophilic α-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivs. of Azi) have been synthesized and tested as inhibitors of the cysteine proteases papain, cathepsins B, L, and H, and calpains I and II, as well as against several serine proteases, one aspartate, and one metalloprotease.  All aziridinyl peptides are specific cysteine protease inhibitors.  Papain and cathepsins B and L are inhibited irreversibly, whereas cathepsin H and calpains are inhibited in a non-time-dependent manner.  Some compds. turned out to be substrates for serine proteases and for the metalloprotease thermolysin.  Remarkable differences can be obsd. between the three different types of inhibitors concerning stereospecificity, pH dependency of inhibition, selectivity between different cysteine proteases, and the importance of a free carboxylic acid function at the aziridine ring for inhibition.  Above all type II inhibitors, aza analogs of the well-known epoxysuccinyl peptides, are potent cysteine protease inhibitors.  With the exception of BOC-Leu-Gly-(S,S+R,R)-Azi-(OEt)2 (28a+b), a highly selective and potent cathepsin L inhibitor, N-acylated aziridines of type I are weaker inhibitors than type II or type III compds.  The obsd. results can be explained by different binding modes of the three types of inhibitors with respect to their orientation in the S- and S'-binding sites of the enzymes. Furthermore, the presence of a protonated aziridine N modifies the binding mode of type II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojzrzdyt5ANLVg90H21EOLACvtfcHk0lgpU3EA-IFAtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1Kjs78%253D&md5=f427b27c59f4697baea11e457c656545</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fjm981061z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981061z%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmeister%26aufirst%3DT.%26atitle%3DNew%2520peptidic%2520cysteine%2520protease%2520inhibitors%2520derived%2520from%2520the%2520electrophilic%2520alpha-amino%2520acid%2520aziridine-2%252C3-dicarboxylic%2520acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D560%26epage%3D572%26doi%3D10.1021%2Fjm981061z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peric, M.</span></span> <span> </span><span class="NLM_article-title">Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(00)00058-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0968-0896%2800%2900058-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10896108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksFCrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=1281-1291&author=T.+Schirmeisterauthor=M.+Peric&title=Aziridinyl+peptides+as+inhibitors+of+cysteine+proteases%3A+effect+of+a+free+carboxylic+acid+function+on+inhibition&doi=10.1016%2FS0968-0896%2800%2900058-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Aziridinyl peptides as inhibitors of cysteine proteases: Effect of a free carboxylic acid function on inhibition</span></div><div class="casAuthors">Schirmeister, T.; Peric, M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1281-1291</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Peptides contg. aziridine-2,3-dicarboxylate (Azi) as electrophilic building block are evaluated as inhibitors of the cysteine proteases papain, cathepsin B, cathepsin L and clostripain.  The influence of a free carboxylic acid as functional group at different positions of the inhibitor mol. on inhibition is analyzed.  Structure-activity relationships and binding mode hypotheses are discussed.  In contrast to the bacterial enzyme clostripain, the papain like mammalian proteases (cathepsins) are irreversibly inactivated by aziridinyl peptides.  N-Unsubstituted aziridines are much more potent inhibitors of papain and cathepsins if they contain the free carboxylic acid attached to the aziridine ring (HOAzi-Leu-ProOBzl).  Two free carboxylic acid functions at the aziridine ring are necessary for good inhibition of these enzymes by N-acylated aziridinyl peptides (BOC-Phe-Azi(OH)2).  Chimeric bispeptidyl derivs. are selective cathepsin B inhibitors if the free acid is located at the C-terminus of the peptide (BOC-Phe-(EtO)Azi-Leu-ProOH).  Clostripain is only inhibited by aziridinyl peptide esters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy8B3EG21SYLVg90H21EOLACvtfcHk0lgDL0kp2cZ7ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksFCrsLs%253D&md5=2f4fa2bdeaad7a76f175665c9d512eda</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2800%2900058-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252800%252900058-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DPeric%26aufirst%3DM.%26atitle%3DAziridinyl%2520peptides%2520as%2520inhibitors%2520of%2520cysteine%2520proteases%253A%2520effect%2520of%2520a%2520free%2520carboxylic%2520acid%2520function%2520on%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2000%26volume%3D8%26spage%3D1281%26epage%3D1291%26doi%3D10.1016%2FS0968-0896%2800%2900058-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klockow, A.</span></span> <span> </span><span class="NLM_article-title">Cysteine protease inhibitors containing small rings</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.2174/1389557033487935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2174%2F1389557033487935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=12871161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=585-596&author=T.+Schirmeisterauthor=A.+Klockow&title=Cysteine+protease+inhibitors+containing+small+rings&doi=10.2174%2F1389557033487935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine protease inhibitors containing small rings</span></div><div class="casAuthors">Schirmeister, T.; Klockow, A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-596</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the discovery of E-64 in 1978 as potent cysteine protease inhibitor a variety of inhibitors contg. small rings as electrophilic building blocks responsible for enzyme inhibition have been developed.  In this review we summarize new aspects concerning epoxysuccinyl peptides derived from E-64 and discuss inhibition potency, selectivity and mechanisms of peptidic and peptidomimetic inhibitors contg. epoxide, aziridine, thiirane, cyclopropane, β-lactam and β-lactone rings as electrophilic fragments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQbEljquTrLVg90H21EOLACvtfcHk0lgDL0kp2cZ7ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1WgsLc%253D&md5=d927db9cb884be32b6d96b0c316dcc2c</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.2174%2F1389557033487935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557033487935%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DKlockow%26aufirst%3DA.%26atitle%3DCysteine%2520protease%2520inhibitors%2520containing%2520small%2520rings%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26spage%3D585%26epage%3D596%26doi%3D10.2174%2F1389557033487935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siklos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BenAissa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R.</span></span> <span> </span><span class="NLM_article-title">Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.apsb.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=26713267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADC%252BC28rlslWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=506-519&author=M.+Siklosauthor=M.+BenAissaauthor=G.+R.+Thatcher&title=Cysteine+proteases+as+therapeutic+targets%3A+does+selectivity+matter%3F+A+systematic+review+of+calpain+and+cathepsin+inhibitors&doi=10.1016%2Fj.apsb.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors</span></div><div class="casAuthors">Siklos Marton; BenAissa Manel; Thatcher Gregory R J</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">506-19</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Cysteine proteases continue to provide validated targets for treatment of human diseases.  In neurodegenerative disorders, multiple cysteine proteases provide targets for enzyme inhibitors, notably caspases, calpains, and cathepsins.  The reactive, active-site cysteine provides specificity for many inhibitor designs over other families of proteases, such as aspartate and serine; however, a) inhibitor strategies often use covalent enzyme modification, and b) obtaining selectivity within families of cysteine proteases and their isozymes is problematic.  This review provides a general update on strategies for cysteine protease inhibitor design and a focus on cathepsin B and calpain 1 as drug targets for neurodegenerative disorders; the latter focus providing an interesting query for the contemporary assumptions that irreversible, covalent protein modification and low selectivity are anathema to therapeutic safety and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE6JaFL9P83mBAiYWy6n3SfW6udTcc2eZMiATQRAszfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlslWjsg%253D%253D&md5=cbd246a39984c0d9e3a32fd26db8902d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DSiklos%26aufirst%3DM.%26aulast%3DBenAissa%26aufirst%3DM.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DCysteine%2520proteases%2520as%2520therapeutic%2520targets%253A%2520does%2520selectivity%2520matter%253F%2520A%2520systematic%2520review%2520of%2520calpain%2520and%2520cathepsin%2520inhibitors%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2015%26volume%3D5%26spage%3D506%26epage%3D519%26doi%3D10.1016%2Fj.apsb.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfenden, R.</span></span> <span> </span><span class="NLM_article-title">Thiohemiacetal formation by inhibitory aldehydes at the active site of papain</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4890</span>– <span class="NLM_lpage">4895</span>, <span class="refDoi"> DOI: 10.1021/bi00641a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00641a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaE2sXlvFKgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1977&pages=4890-4895&author=C.+A.+Lewisauthor=R.+Wolfenden&title=Thiohemiacetal+formation+by+inhibitory+aldehydes+at+the+active+site+of+papain&doi=10.1021%2Fbi00641a023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Thiohemiacetal formation by inhibitory aldehydes at the active site of papain</span></div><div class="casAuthors">Lewis, Charles A., Jr.; Wolfenden, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4890-5</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Papain is strongly inhibited by aldehydes resembling carboxylic acids released by hydrolysis of specific substrates.  Inhibitory complexes might involve binding of the aldehyde intact or as a covalent hydrate, or the aldehyde might undergo covalent addn. of an active site SH group to form a thiohemiacetal deriv.  In an attempt to distinguish between these possibilities, benzamidoacetaldehyde-1-2H was synthesized, and its properties compared with those of the undeuterated inhibitor.  After correction for differences in hydration, the obsd. effect on inhibition is compatible with formation of a thiohemiacetal.  In keeping with this conclusion, benzamidoethanol (a partial analog of the covalent hydrate) and benzamide, N-methylbenzamide, and N-ethylbenzamide (somewhat similar to the free aldehyde in size and hydrophobic character) exhibit negligible affinity for the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQmR19Fk_65bVg90H21EOLACvtfcHk0lj2rLmeCf65Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXlvFKgsbY%253D&md5=f39c2cc892b7b70d32327b6b65f51c3f</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fbi00641a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00641a023%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DC.%2BA.%26aulast%3DWolfenden%26aufirst%3DR.%26atitle%3DThiohemiacetal%2520formation%2520by%2520inhibitory%2520aldehydes%2520at%2520the%2520active%2520site%2520of%2520papain%26jtitle%3DBiochemistry%26date%3D1977%26volume%3D16%26spage%3D4890%26epage%3D4895%26doi%3D10.1021%2Fbi00641a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, E.</span></span> <span> </span><span class="NLM_article-title">Cysteinyl proteinases and their selective inactivation</span>. <i>Advances in enzymology and related areas of molecular biology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1002/9780470123096.ch5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1002%2F9780470123096.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=271-347&author=E.+Shaw&title=Cysteinyl+proteinases+and+their+selective+inactivation&doi=10.1002%2F9780470123096.ch5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2F9780470123096.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9780470123096.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DE.%26atitle%3DCysteinyl%2520proteinases%2520and%2520their%2520selective%2520inactivation%26jtitle%3DAdvances%2520in%2520enzymology%2520and%2520related%2520areas%2520of%2520molecular%2520biology%26date%3D2006%26volume%3D63%26spage%3D271%26epage%3D347%26doi%3D10.1002%2F9780470123096.ch5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, J. S.</span></span> <span> </span><span class="NLM_article-title">Chemistry of cyclopropenones</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1021/cr60288a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr60288a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaE2cXhtlart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1974&pages=189-213&author=K.+T.+Pottsauthor=J.+S.+Baum&title=Chemistry+of+cyclopropenones&doi=10.1021%2Fcr60288a003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry of cyclopropenones</span></div><div class="casAuthors">Potts, K. T.; Baum, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-213</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 175 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-ZbvJnR6FrVg90H21EOLACvtfcHk0lj5GoUDutcbzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtlart7c%253D&md5=2ad661270e6f989d43d9556f2ff83b76</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fcr60288a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr60288a003%26sid%3Dliteratum%253Aachs%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DBaum%26aufirst%3DJ.%2BS.%26atitle%3DChemistry%2520of%2520cyclopropenones%26jtitle%3DChem.%2520Rev.%26date%3D1974%26volume%3D74%26spage%3D189%26epage%3D213%26doi%3D10.1021%2Fcr60288a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oballa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydzewski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riendeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodan, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Percival, M. D.</span></span> <span> </span><span class="NLM_article-title">Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/jm0003440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0003440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1ajs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=94-104&author=J.+P.+Falgueyretauthor=R.+M.+Oballaauthor=O.+Okamotoauthor=G.+Wesolowskiauthor=Y.+Aubinauthor=R.+M.+Rydzewskiauthor=P.+Prasitauthor=D.+Riendeauauthor=S.+B.+Rodanauthor=M.+D.+Percival&title=Novel%2C+nonpeptidic+cyanamides+as+potent+and+reversible+inhibitors+of+human+cathepsins+K+and+L&doi=10.1021%2Fjm0003440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L</span></div><div class="casAuthors">Falgueyret, Jean-Pierre; Oballa, Renata M.; Okamoto, Osamu; Wesolowski, Gregg; Aubin, Yves; Rydzewski, Robert M.; Prasit, Peppi; Riendeau, Denis; Rodan, Sevgi B.; Percival, M. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. contg. a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L.  The original lead compd. I inhibits cathepsins K and L with IC50 values of 0.37 and 0.45 μM, resp.  Modification of compd. I by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2).  Compd. II was found to be a potent inhibitor of cathepsins K and L with a Ki value of 50 nM for cathepsin K.  Replacement of the 1-cyanopyrrolidine of compd. II by a 1-cyanoazetidine increased the potency of the inhibitor by 10-fold.  This increase in potency is probably due to an enhanced chem. reactivity of the compd. toward the thiolate of the active site of the enzyme.  This is demonstrated when the assay is performed in the presence of glutathione at pH 7.0 which favors the formation of a GSH thiolate anion.  Under these assay conditions, there is a loss of potency in the 1-cyanoazetidine series due to the formation of an inactive complex between the GSH thiolate and the 1-cyanoazetidine inhibitors. 1-Cyanopyrrolidinyl inhibitors exhibited time-dependent inhibition which allowed us to det. the assocn. and dissocn. rate consts. with human cathepsin K.  The kinetic data obtained showed that the increase of potency obsd. between different 1-cyanopyrrolidinyl inhibitors is due to an increase of kon values and that the assocn. of the compd. with the enzyme fits an apparent one-step mechanism. 13C NMR expts. performed with the enzyme papain showed that compd. 2 forms a covalent isothiourea ester adduct with the enzyme.  As predicted by the kinetic anal., the addn. of the irreversible inhibitor E64 to the enzyme-cyanopyrrolidinyl complex totally abolished the signal of the isothiourea bond as obsd. by 13C NMR, thereby demonstrating that the formation of the covalent bond with the active site cysteine residue is reversible. Finally, compd. II inhibits bone resorption in an in vitro assay involving rabbit osteoclasts and bovine bone with an IC50 value of 0.7 μM. 1-Cyanopyrrolidine represents a new class of nonpeptidic compds. that inhibit cathepsin K and L activity and proteolysis of bone collagen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWnsb8us0GkrVg90H21EOLACvtfcHk0lj5GoUDutcbzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1ajs7g%253D&md5=aed27c1353797e413890ea02d900095b</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm0003440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0003440%26sid%3Dliteratum%253Aachs%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DOkamoto%26aufirst%3DO.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DAubin%26aufirst%3DY.%26aulast%3DRydzewski%26aufirst%3DR.%2BM.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRodan%26aufirst%3DS.%2BB.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26atitle%3DNovel%252C%2520nonpeptidic%2520cyanamides%2520as%2520potent%2520and%2520reversible%2520inhibitors%2520of%2520human%2520cathepsins%2520K%2520and%2520L%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D94%26epage%3D104%26doi%3D10.1021%2Fjm0003440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung-Toung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodzinska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowrie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukreja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desilets, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, T. F.</span></span> <span> </span><span class="NLM_article-title">1,2,4-thiadiazole: A novel Cathepsin B inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5529</span>– <span class="NLM_lpage">5537</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2003.09.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2Fj.bmc.2003.09.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=14642597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1ens74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5529-5537&author=R.+Leung-Toungauthor=J.+Wodzinskaauthor=W.+Liauthor=J.+Lowrieauthor=R.+Kukrejaauthor=D.+Desiletsauthor=K.+Karimianauthor=T.+F.+Tam&title=1%2C2%2C4-thiadiazole%3A+A+novel+Cathepsin+B+inhibitor&doi=10.1016%2Fj.bmc.2003.09.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,4-Thiadiazole: A novel Cathepsin B inhibitor</span></div><div class="casAuthors">Leung-Toung, Regis; Wodzinska, Jolanta; Li, Wanren; Lowrie, Jayme; Kukreja, Rahul; Desilets, Denis; Karimian, Khashayar; Tam, Tim Fat</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5529-5537</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel class of Cathepsin B inhibitors has been developed with a 1,2,4-thiadiazole heterocycle as the thiol trapping pharmacophore.  Several compds. with different dipeptide recognition sequence (i.e., P1'-P2'=Leu-Pro-OH or P2-P1=Cbz-Phe-Ala) at the C5 position and with different substituents (i.e., OMe, Ph, or COOH) at the C3 position of the 1,2,4-thiadiazole ring have been synthesized and tested for their inhibitory activities.  The substituted thiadiazoles inhibit Cat B in a time dependent, irreversible manner.  A mechanism based on active-site directed inactivation of the enzyme by disulfide bond formation between the active site cysteine thiol and the sulfur atom of the heterocycle is proposed.  Compd. I (Ki=2.6 μM, kiKi=5630 M-1 s-1) with a C3 methoxy moiety and a Leu-Pro-OH dipeptide recognition sequence, is found to be the most potent inhibitor in this series.  The enhanced inhibitory potency of I is a consequence of its increased enzyme binding affinity (lower Ki) rather than its increased intrinsic reactivity (higher ki).  In addn., I is inactive against Cathepsin S, is a poor inhibitor of Cathepsin H and is >100-fold more selective for Cat B over papain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMeBoKxnLBT7Vg90H21EOLACvtfcHk0liMt7sIWoJm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1ens74%253D&md5=5faf35d17001a47f2d9734b4f7b25e1a</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.09.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.09.040%26sid%3Dliteratum%253Aachs%26aulast%3DLeung-Toung%26aufirst%3DR.%26aulast%3DWodzinska%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLowrie%26aufirst%3DJ.%26aulast%3DKukreja%26aufirst%3DR.%26aulast%3DDesilets%26aufirst%3DD.%26aulast%3DKarimian%26aufirst%3DK.%26aulast%3DTam%26aufirst%3DT.%2BF.%26atitle%3D1%252C2%252C4-thiadiazole%253A%2520A%2520novel%2520Cathepsin%2520B%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5529%26epage%3D5537%26doi%3D10.1016%2Fj.bmc.2003.09.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Withana, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sameni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidwell, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloane, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, B. S.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B inhibition limits bone metastasis in breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-2759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1158%2F0008-5472.CAN-11-2759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=22266111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1199-1209&author=N.+P.+Withanaauthor=G.+Blumauthor=M.+Sameniauthor=C.+Slaneyauthor=A.+Anbalaganauthor=M.+B.+Oliveauthor=B.+N.+Bidwellauthor=L.+Edgingtonauthor=L.+Wangauthor=K.+Moinauthor=B.+F.+Sloaneauthor=R.+L.+Andersonauthor=M.+S.+Bogyoauthor=B.+S.+Parker&title=Cathepsin+B+inhibition+limits+bone+metastasis+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-11-2759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer</span></div><div class="casAuthors">Withana, Nimali P.; Blum, Galia; Sameni, Mansoureh; Slaney, Clare; Anbalagan, Arulselvi; Olive, Mary B.; Bidwell, Bradley N.; Edgington, Laura; Wang, Ling; Moin, Kamiar; Sloane, Bonnie F.; Anderson, Robin L.; Bogyo, Matthew S.; Parker, Belinda S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1209</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying mol. drivers of bone metastasis for new therapeutic targets.  The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases.  In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease.  Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases.  RNA interference-mediated knockdown of cathepsin B in tumor cells reduced collagen I degrdn. in vitro and bone metastasis in vivo.  Similarly, i.p. administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a redn. that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt.  Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth.  Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo.  Cancer Res; 72(5); 1199-209.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaVtPHsMReRLVg90H21EOLACvtfcHk0liMt7sIWoJm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wis74%253D&md5=b66b32d65d9e9799412bb110b4c9d4e9</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-2759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-2759%26sid%3Dliteratum%253Aachs%26aulast%3DWithana%26aufirst%3DN.%2BP.%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DSameni%26aufirst%3DM.%26aulast%3DSlaney%26aufirst%3DC.%26aulast%3DAnbalagan%26aufirst%3DA.%26aulast%3DOlive%26aufirst%3DM.%2BB.%26aulast%3DBidwell%26aufirst%3DB.%2BN.%26aulast%3DEdgington%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMoin%26aufirst%3DK.%26aulast%3DSloane%26aufirst%3DB.%2BF.%26aulast%3DAnderson%26aufirst%3DR.%2BL.%26aulast%3DBogyo%26aufirst%3DM.%2BS.%26aulast%3DParker%26aufirst%3DB.%2BS.%26atitle%3DCathepsin%2520B%2520inhibition%2520limits%2520bone%2520metastasis%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1199%26epage%3D1209%26doi%3D10.1158%2F0008-5472.CAN-11-2759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satoyoshi, E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic trials on progressive muscular dystrophy</span>. <i>Intern. Med. (Tokyo, Jpn.)</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.2169/internalmedicine.31.841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.2169%2Finternalmedicine.31.841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1450492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A280%3ADyaK3s%252FotFyqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1992&pages=841-846&author=E.+Satoyoshi&title=Therapeutic+trials+on+progressive+muscular+dystrophy&doi=10.2169%2Finternalmedicine.31.841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic trials on progressive muscular dystrophy</span></div><div class="casAuthors">Satoyoshi E</div><div class="citationInfo"><span class="NLM_cas:title">Internal medicine (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">841-6</span>
        ISSN:<span class="NLM_cas:issn">0918-2918</span>.
    </div><div class="casAbstract">The special medical care in the National Sanatorium prolonged the life span of the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years.  Various new drug trials for muscular dystrophy have been implemented in the last 12 years in Japan.  Bestatin and Loxistatin, protease inhibitors, showed definite improvement on dystrophic mice or hamsters, animal models of muscular dystrophy.  However clinical application of these drugs failed to prove the effects on patients with Duchenne muscular dystrophy.  The difficulty of clinical evaluation and judgement of effects in progressive neurological diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyqhNezcuQ25VVjGoY74BafW6udTcc2eYADegt09vbALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FotFyqsA%253D%253D&md5=e10067a63036f421b6bcd269450a0244</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.2169%2Finternalmedicine.31.841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2169%252Finternalmedicine.31.841%26sid%3Dliteratum%253Aachs%26aulast%3DSatoyoshi%26aufirst%3DE.%26atitle%3DTherapeutic%2520trials%2520on%2520progressive%2520muscular%2520dystrophy%26jtitle%3DIntern.%2520Med.%2520%2528Tokyo%252C%2520Jpn.%2529%26date%3D1992%26volume%3D31%26spage%3D841%26epage%3D846%26doi%3D10.2169%2Finternalmedicine.31.841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schurigt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Elverfeldt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinheckel, T.</span></span> <span> </span><span class="NLM_article-title">Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model</span>. <i>Biological chemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1515/BC.2008.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1515%2FBC.2008.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=18710344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2008&pages=1067-1074&author=U.+Schurigtauthor=L.+Sevenichauthor=C.+Vannierauthor=M.+Gajdaauthor=A.+Schwindeauthor=F.+Wernerauthor=A.+Stahlauthor=D.+von+Elverfeldtauthor=A.+K.+Beckerauthor=M.+Bogyoauthor=C.+Petersauthor=T.+Reinheckel&title=Trial+of+the+cysteine+cathepsin+inhibitor+JPM-OEt+on+early+and+advanced+mammary+cancer+stages+in+the+MMTV-PyMT-transgenic+mouse+model&doi=10.1515%2FBC.2008.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model</span></div><div class="casAuthors">Schurigt, Uta; Sevenich, Lisa; Vannier, Corinne; Gajda, Mieczyslaw; Schwinde, Anne; Werner, Fee; Stahl, Andreas; von Elverfeldt, Dominik; Becker, Anne-Katrin; Bogyo, Matthew; Peters, Christoph; Reinheckel, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1067-1074</span>CODEN:
                <span class="NLM_cas:coden">BICHF3</span>;
        ISSN:<span class="NLM_cas:issn">1431-6730</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">Recent data suggest proteases of the papain-like cysteine cathepsin family as mol. targets for cancer therapy.  Here, we report the treatment of polyoma middle T oncogene-induced breast cancers in mice with the cell-permeable broad-spectrum cysteine cathepsin inhibitor JPM-OEt.  Up to 100 mg/kg inhibitor was i.p. injected once per day in two trials on early and advanced cancers.  In both trials, transient delays in tumor growth were obsd.  However, at the endpoint of both expts. no significant differences in tumor wts., histopathol. and lung metastasis were found between the inhibitor and the control group.  The invasive strand formation of collagen I-embedded tumor cell spheroids generated from primary tumors of inhibitor-treated mice in the early cancer trial could be inhibited in vitro by JPM-OEt; a result arguing against induction of resistance to the inhibitor.  Measurement of cysteine cathepsin activities in tissue exts. after i.p. injection of JPM-OEt revealed effective inhibition of cysteine cathepsins in pancreas, kidneys and liver, while activities in mammary cancers and in lungs were not significantly affected.  We conclude that the pharmacokinetic properties of JPM-OEt, which result in poor bioavailability, may prohibit its use for stand-alone treatment of solid mammary cancers and their lung metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxpOV_XtD27Vg90H21EOLACvtfcHk0lgDU-hJLwuwZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohurk%253D&md5=25ab2d52f96d301df3b993a7a2c01e61</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1515%2FBC.2008.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.2008.115%26sid%3Dliteratum%253Aachs%26aulast%3DSchurigt%26aufirst%3DU.%26aulast%3DSevenich%26aufirst%3DL.%26aulast%3DVannier%26aufirst%3DC.%26aulast%3DGajda%26aufirst%3DM.%26aulast%3DSchwinde%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DF.%26aulast%3DStahl%26aufirst%3DA.%26aulast%3Dvon%2BElverfeldt%26aufirst%3DD.%26aulast%3DBecker%26aufirst%3DA.%2BK.%26aulast%3DBogyo%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DC.%26aulast%3DReinheckel%26aufirst%3DT.%26atitle%3DTrial%2520of%2520the%2520cysteine%2520cathepsin%2520inhibitor%2520JPM-OEt%2520on%2520early%2520and%2520advanced%2520mammary%2520cancer%2520stages%2520in%2520the%2520MMTV-PyMT-transgenic%2520mouse%2520model%26jtitle%3DBiological%2520chemistry%26date%3D2008%26volume%3D389%26spage%3D1067%26epage%3D1074%26doi%3D10.1515%2FBC.2008.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eichhold, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hookfin, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiwo, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehmeyer, K. R.</span></span> <span> </span><span class="NLM_article-title">Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1016/S0731-7085(97)00102-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2FS0731-7085%2897%2900102-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=9589405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=459-467&author=T.+H.+Eichholdauthor=E.+B.+Hookfinauthor=Y.+O.+Taiwoauthor=B.+Deauthor=K.+R.+Wehmeyer&title=Isolation+and+quantification+of+fluoroacetate+in+rat+tissues%2C+following+dosing+of+Z-Phe-Ala-CH2-F%2C+a+peptidyl+fluoromethyl+ketone+protease+inhibitor&doi=10.1016%2FS0731-7085%2897%2900102-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor</span></div><div class="casAuthors">Eichhold, Thomas H.; Hookfin, Erin B.; Taiwo, Yetunde O.; De, Biswanath; Wehmeyer, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-467</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Peptidyl fluoromethyl ketones (PFMK) are irreversible inhibitors of cathepsin B, a cysteine proteinase thought to be involved in the degrdn. of cartilage.  It has been speculated that PFMK inhibitors may metabolize in rodents to form fluoroacetate (FAC), an extremely toxic poison.  A highly selective and sensitive sepn. and detection scheme was developed to measure trace levels of FAC in rat tissues following PFMK dosing.  The procedure consisted of extg. FAC from tissue and spiking the ext. with [18O]2-fluoroacetate (18O-FAC) as an internal std.  FAC and 18O-FAC were further isolated from matrix components using ion-exchange, solid-phase extn.  The pentafluorobenzyl esters of FAC and 18O-FAC were formed to facilitate the chromatog. sepn.  Two-dimensional gas chromatog. coupled with selected-ion-monitoring detection provided the final measurement.  The assay had a limit of detection of 2 ng FAC per g tissue, and was capable of accurately quantitating as little as 10 ng FAC per g tissue with a S/N ratio of 40:1.  Linearity was established over two orders of magnitude, from 2-500 ng ml-1, with 5 μl injected on-column.  The method was used to demonstrate that FAC was formed in rats following dosing with Z-Phe-Ala-CH2-F, a PFMK cathepsin enzyme inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPmtRizUZf2bVg90H21EOLACvtfcHk0lgDU-hJLwuwZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWqsL8%253D&md5=ea69dcdcaff325ed19d40e94c6f96760</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS0731-7085%2897%2900102-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0731-7085%252897%252900102-7%26sid%3Dliteratum%253Aachs%26aulast%3DEichhold%26aufirst%3DT.%2BH.%26aulast%3DHookfin%26aufirst%3DE.%2BB.%26aulast%3DTaiwo%26aufirst%3DY.%2BO.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DWehmeyer%26aufirst%3DK.%2BR.%26atitle%3DIsolation%2520and%2520quantification%2520of%2520fluoroacetate%2520in%2520rat%2520tissues%252C%2520following%2520dosing%2520of%2520Z-Phe-Ala-CH2-F%252C%2520a%2520peptidyl%2520fluoromethyl%2520ketone%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D1997%26volume%3D16%26spage%3D459%26epage%3D467%26doi%3D10.1016%2FS0731-7085%2897%2900102-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasnick, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/0003-2697(85)90598-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=10.1016%2F0003-2697%2885%2990598-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=4073501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;key=1%3ACAS%3A528%3ADyaL2MXltlOmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=1985&pages=461-465&author=D.+Rasnick&title=Synthesis+of+peptide+fluoromethyl+ketones+and+the+inhibition+of+human+cathepsin+B&doi=10.1016%2F0003-2697%2885%2990598-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B</span></div><div class="casAuthors">Rasnick, David</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">461-5</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    </div><div class="casAbstract">Peptide fluoromethyl ketones were synthesized for the 1st time.  The inhibitor 3-(N-benzyloxycarbonylphenylalanylamido)-DL-1-fluoro-2-butanone (Z-Phe-AlaCH2F) was a 30-fold more potent inactivator of human cathepsin B than was 3-(N-benzyloxycarbonylphenylalanylamido)-L-1-diazo-2-butanone (Z-Phe-AlaCHN2), but less reactive than 3-(N-benzyloxycarbonylphenylalanylamido)-L-1-chloro-2-butanone (Z-Phe-AlaCH2Cl).  The fluoromethyl ketone's increased potency over the diazomethyl ketone is mainly due to its tighter binding to cathepsin B, with little difference between their resp. k3 values.  Both Z-Phe-AlaCHN2 and Z-Phe-AlaCH2F were quite stable to high concns. of dithiothreitol, whereas Z-Phe-AlaCH2Cl was rapidly destroyed by the thiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPFVuXW1TDrVg90H21EOLACvtfcHk0lhAbguK9Jzd-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlOmu70%253D&md5=f53dcab5c3b1f33c472c1271c4ca2f6a</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2F0003-2697%2885%2990598-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-2697%252885%252990598-6%26sid%3Dliteratum%253Aachs%26aulast%3DRasnick%26aufirst%3DD.%26atitle%3DSynthesis%2520of%2520peptide%2520fluoromethyl%2520ketones%2520and%2520the%2520inhibition%2520of%2520human%2520cathepsin%2520B%26jtitle%3DAnal.%2520Biochem.%26date%3D1985%26volume%3D149%26spage%3D461%26epage%3D465%26doi%3D10.1016%2F0003-2697%2885%2990598-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RYP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RYP','PDB','1RYP'); return false;">PDB: 1RYP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FGH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FGH','PDB','5FGH'); return false;">PDB: 5FGH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F16','PDB','2F16'); return false;">PDB: 2F16</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R67" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4R67','PDB','4R67'); return false;">PDB: 4R67</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FAK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FAK','PDB','2FAK'); return false;">PDB: 2FAK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TG6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TG6','PDB','1TG6'); return false;">PDB: 1TG6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ITO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ITO','PDB','1ITO'); return false;">PDB: 1ITO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QDQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QDQ','PDB','1QDQ'); return false;">PDB: 1QDQ</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01640&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01640%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-6%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01640" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a9f84ceb03cca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
